<SEC-DOCUMENT>0000882095-22-000013.txt : 20220504
<SEC-HEADER>0000882095-22-000013.hdr.sgml : 20220504
<ACCEPTANCE-DATETIME>20220504162613
ACCESSION NUMBER:		0000882095-22-000013
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220504
DATE AS OF CHANGE:		20220504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		22891928

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gild-20220331.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:047062f8-b3c9-4367-911c-0f45b6df8713,g:679ab3c4-b282-4926-9aaf-46591661bf28,d:b054ed57a41746f6adeff83e9a6e8cad--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:gild="http://www.gilead.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl80LTEtMS0xLTEwNDUyMg_a57fdc67-ae99-4ea1-b8ba-b089b7c23717">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl81LTEtMS0xLTEwNDUyMg_1f908578-2053-4701-a300-c8e06b63fcea">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl85LTEtMS0xLTEwNDUyMg_946c0a9a-f380-4a2f-aaa2-9d0b46b201f7">2022</ix:nonNumeric><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl8xMC0xLTEtMS0xMDQ1MjI_5c34101f-1a4b-444d-b2f9-6d94d4aa6734">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl8xMy0xLTEtMS0xMDQ1MjI_09a9d0f0-d90e-4e40-a000-eadd22787fa8">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1850f3306cd34634bedc7f64be32424a_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if150cff9011c4cb8865c7d010dea19b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad8a561a83946e2be71c0773364df03_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6adca2cb2df45159579306959cd9182_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f491d481954bfb91bb63808792a107_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0589a869ef75463baf4882764f90b836_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69dcda8ca004abb9ed728a2c520c160_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97be958f8ea44f6bf64ec6b93653cd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaede3fb2344847fea92949ea16a03f84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bbba3bf8d68467f8171054b804a1ac9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if538f3fabd96439a81d45376a26388ff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cea6550adf3442f91f94178b881760a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9781941f584349a74927f787b7e812_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31c7f678df04d0dac0d6728662443f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id993c220a3874424a2e4ebabbf6841f5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042afe2516664edcbb58b11b031f07c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e28083e946c46d38dd4c1bbf423acfb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9f66d43a49486cb27df9c7ce53de4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004764dee0dd403db285a0bdf557180f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8beedc1ba15342129f01b711293f2310_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4874edd47334bd394e3a3ea1da5ca86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1673112d964a58a17fc93e7d35ff26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if27321762d2f4ae8a9a783e43673fccc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice22d99dfaaf407181dfa92cad25c12d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib900b75bb57c4248b64d9bdcf700306e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0889fbcdb67f4509b5f885c5a7468633_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997fc483bf224ea9a20e7b632dfba8b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72674008e77942a3986c777c8aab4eb4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d7f1d99b11464eb7135895f195aaa9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eec7f2c8c1a4636ba925954742eba86_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9796d93b2414e28a30a1b8602920120_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>gild:segment</xbrli:measure></xbrli:unit><xbrli:context id="ied51c768bed843aea34aaed4b945684f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f1dd54de90447294f3c861a9ee3e1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3a3af70db64f0f978246427bb3f9d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf8c7affd72e42ca9f179e85ebb2f9d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i783425dee7ca4e6694dbf5913283547c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb25c59c64f544eea1c86c507469316f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i656b35f1983b428c8545aed7327ea2c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f1409918fc427bb29d5b500a1321e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8346dabbdc9f40229cb19c819e8c69f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d8e2e5477841eaa52ff3b838cba27f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1ba0c7461d47268493fb140371a2e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d0cd2f382340f197f0214e199101db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ceb4bbcd084712bfcf12627e4a8876_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fee41710daf4f27b3133b3886edbf83_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3afddfa05b845c7b30a26d393a73e1b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9938c6a4da9146d99d8b8dd9069cfcd6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee884799ae424e94b23704c602366eee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aae21f9faa440b8b79c88263d1f048f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537a84e24dc24f9d9f384863ce96bd8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2dad0f86f1e46f4882d989fb19a2630_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i073c91ae4254439ab6ef2904a9afe007_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff23fb99e7024ad4aa2ad12bcfbf8f61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib607ac8cf58544f0ba59e08838b4c390_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i890c16b438d54cc18fc29556f4322577_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c6687c2bfa42828d22e4837dbb5dea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3ea5627de74bc29c321695fbae0bb9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84542ccfad574a82827956f97ca98665_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e989af964740d3828ca89bb31ed8c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636c5da3398c47caa2887765bc8fb4c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776ae62f154a426aa156b5d44009a287_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id360b7a80ef8475ba2077b3d656c6b26_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8e37ffa86f41faa81072218b874e20_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i318393636e2047c38e33f9a92263613f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff5e11317cc34eee936bb532fbcc45b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f008fe0e88941f2ba5d03745e0d1c14_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513c8fd2c5fc4a58bff490e075395991_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e711dc3d84406db6c1a10ada56e5c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0154ed0d254253a0dc7d64c5706bc1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia918f81a777249f2bfcf4b1d5bbc499e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3deebc7b364524b98fef879ed25401_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850f290111644c449e9a3a3812c4622f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0286c60ccf4c62918cb03477641fe6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cddc469a4df4ece9423e33e5c08e8de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1e75cd345542ebbf1359781e3b4ce3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289d747c6aa447e1b03b39c79c030884_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774c61105333410bb42045f3a93ac5d4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i981cb25bb09f433d8815cfd0cac49e61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie612932f7fc7413bb9340d0712dddb5d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i520f60d941974d6582ab8ff03d2bb9f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac86cc9d45a445d1b66e5d3b1328b298_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20f6a7498f24890ba6109800b4579f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic364bf5827b344f9b7277fa3059e41b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib80f4c1c06954aecbea13eb8c57c84cb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f542fe236ba49be97003a22c3952e2f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b924aff33144adbbdbe4b55024bc966_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8df5b8207746d79c0457bf4ecf84e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0309aadc6ff4ac2b67d133870ecfc21_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f78bff3afeb44fabb11776d7ffc143b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad40f3526c94d2a8d401c53ce69ea1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7716776c36cb4bd491d74086bfb7ecb2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if12564811a9e4bdca5202382aefc69f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c956ed6342b42718cec14ac863bdb58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bb10d32aec44247a4f5d7cd6e811377_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5f964326e14b269641c03739405c1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7a3b05ecdb94c10ab42d41aa1405831_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c6a13f318f24325a71e2857063f5848_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82e4d1739634b57a20ede2010592159_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibefee3ae93504f46a2d372c49fdf40ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic97f28b8981248dbad7137dfc8e3f6db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a54006651944977a0f2ea299b135a39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900a3386106549a885dd226281746116_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbbdd491da34ec79838d8ba4a860828_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640cb048ad564d1eb126e98c3f9dd4cb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice89761ab066473ebe252ea4efa20c75_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d27e27d65994e5c99f272ab08bdca75_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972d712715ae466db4de275f56044425_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92246dae9bf04aeda16066d6e5e604ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic905d65961ca41f2a16684c08c4b1170_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f3508e4df94ef2aa9af3131d031ebf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a89c780806d4aaf9d6742d4500a8692_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9080da0fd2da4f02a87f7d29708792ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b77ced81c9d459e8714ab97c49ac8e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ec7cb46bf4485eb4111720cefb6f25_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dcfee614954446f890fad6e3acec329_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc5bd1f95304695811a90a3fb77aa6c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e4003abdc8446fb15dd00423d76bfe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6ba86f84d04fbbbe732f5893719820_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a987fb1a2345cf9feca51b56f3002e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1151230a7249eba5e92c53b6c99591_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3886fecdb734baca592defec1da8854_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab0e630afcb4839815382487e6d7a71_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990036800e314c019d9924b8c48d9a69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654b56035ac5429299e0bf0750f7c159_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912899de9e384b4991388b77ab326802_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a0eb3a98cb45b6a547ce971f34baae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbcc4494362d4aeb9f8d78936bd67dea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3fc4821b2594c9bb862fc7dfbd1c7e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9bd2c916494ddfa644ed66486ffa3c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ca5a367cbb4823bbb2ddbaa8ba1531_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2191fce5382f493f98627963be2fd34f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d13d672db4940049677cdc0bedae177_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5736172bd8c74fa9b0b84ecba12b6da4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia072a52bdb734592ad37964a3ef65749_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ac5763bfd14785880a550fa2c4b4a7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362e3866a26a48cd8450a9aed1b9c71a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b64a5280a334b8d87dd853cc7b50fb2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1247c9718f48619c3461a53ade8241_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38923dc977ec4c608fd74bd8d1002b89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce473a465f24a4587c7b09d8571a2e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd98d98b9029490083e145d555397c64_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49d9927d07794d42b9acd485d0be4ccc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28cc147626d342f18fa203f1fffaeda0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45dd1b2780dc41fb9de50648b1af8b36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b0273edd1d40f39c13f63cfaa3039f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib343c66d342c48b188ec538e601a802f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331f92fda21545a788d654fdc98d17fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id370a2241bdc4d15986cd6b2356a1be4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a17bd8d6a14480b89ee581a835b1a4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5e3587978b4fad9196cbbc06ce3e95_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7bc0ebe5e34348a81d50bcaaf131cc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ef9863b06448f19486cc46a20126f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe7dfedae9e4ea69012d15a904e0bed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc8c47023174a3ca739f65aee4d80be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc10b00ada44fdc804e51838f1acfc3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ffa5ec1dd4840c3b41240ec44fb1a8d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3c2ed8de2c45ed8ea22f65a1300661_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b98d9083b942118db200dec1a903da_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf0b2687f723400eb3f2b51560d5627e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7bb17eb8edf4095affa55b5c94b7511_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e82886013e34e8cb5b040660f8b2134_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62e1f4cdbc94d6496e8d6e303892aea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3a26232e49487cb08e72e73e05cd8f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601e9f250eff46568a11f08fe9496e7f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f013c8b8554acdb3ac0e4cb83b0826_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ade0cdccab94dbcad52ed0019f0c921_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae0e683ad6b40c2a698b3d311bc01d7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88dee8c0fd39453297ea8ac9fead6e30_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ab69156b914bd9a8d4a4bf92a01786_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac685a4449e4a41827017a39c195f98_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9317885eae4f5e974a6c62a56a7eca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9e05a885fd437c97e145bf9ebb7f92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8982d5cbae8145d4a736780033c94930_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258f51e659e04edd969980eb593baee3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab12b495137c43e6886d664932ca0d4e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6427ea1ce218423483ed2d165863e48f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c48e2dcd6644766923dc0cb2bf31d07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ce309faae5419f8ed78774354b4a97_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38350f5e76ed41d99e350a0226a0b299_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3578cd64764c43b28d8596a841916105_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b523e88394b42e49bca13934b5204c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b50daaafcf4acdb978f2b3cbc02a69_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4df11eb0e9c46829ee856f8acd0ac01_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b9973fb9aa4626ae5ac04a936c01e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a95859331e4ac19317036e0daf101a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f5a7f19d504c2ba7ff905f67f4d127_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c624c206e4400e9df42232adf50e0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1322e9bf1b8348f6aa69afe538a30158_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife80ece44c874be5a32808230e9cd4aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if82cf194379246a1859100c8bba11cca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6781ab9027f460c9cf7dcef1a2581ab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5f0d1cad9a4d5c88b552349bd0e426_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1092026c503d4c2caf06ab450b1a56e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d9cb25ede7b47f58962912789bb85f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f208e609ef24694949d9d18a38323a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6282aee3fc5402ba404682fb65354b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39dd6b3aa4eb4ccc9b8976c09c4c815c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1077536f948c4d599ca3de2b9fa0caf0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591623e8a2444a6294da53ce3e3564dd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7a0afec35c4ec89e02da19e66297a3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e1f408f244494e83312207a23684ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id370f64f9232406da268e72edab2bb89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a1637a55bc47ce876af3c9b975c36b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i004d4d1e19524166b98a5650d0a3d5b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4868996536f41c395fd9eb7bf456345_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9510dc0a1cb48a09b7cf7cee5127926_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14f21e46dfd54c5088e33fe80e268c5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506b80edb1094a058227180fe89d36be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc2da0fa42e9465fa82e367afd29d07d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d45fdbebfa497793e9c785c45cd171_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd6c25925024d0ca5e62c2eb0d94599_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie575076324b442bb96747058f585fc96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab947b2302b41098d510e78eec884f9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e1c13afe4c4b36b0e56bcf32399b38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e85eb47143437996c24d62ee7a5072_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e4818a6e7548a7bbf17c683d46095a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f6ecb369e549f69bab7f9d26c72c13_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc546c6f7ee04e13856084c40921bee6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc670dab94b43efac0330f320d308ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d67453bf2b4b61b493a79e64689edf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedf0dddfad54c6d83baf2098d0cce00_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636b58243bec406486f70783ac586b07_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceea7510047144d48d7b55394af029e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fee66d032984dd9a95ce2b80bdc73e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab28717012a4316be156607025ebbee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1e16a6586047f7aa6d8cdf0cc52aee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i707cbcb9a5dd45609f9783347b2969a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd56e62b9064dbfa19723ea33df5f2d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28abe53df7b94be6bd5527b6651854c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i883d4917ebfd4efa968bd072df8d5d90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611a9bb6162246d68e854f3e608a8ba8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f69128a6d940b0969c29eb905e9e01_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72629c36c3ac4b5c90339697d9b5841c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aab0d0a8a054b2191999850619d3215_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f81b41c6ab4c1a8172650fc81804cb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b35be1f6524162a052f75f2c305f1d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9470361de7e54728a05b1c0b65a767b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb419930edcc478c9416d2a9cb5ddb57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36489d020f7443788b3cbd0ccfb9d0f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c4299b47fa4635908637e78b2e1670_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e9c418833d40b2b818caa3cd26b3b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c739ead4a5e450393f03a09963c462d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ca722e30584518aa14b0e7bf67600b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd10541ce9cb4f0baa1c775e04fcff49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i842cc6151e23445faaa596d0f12d6d10_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d0c4f130c9455faf16cf800852d2a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133f797d043a461884b3be51d030f6bd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b794129571f4c3d90efb49ef01d3118_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d4742d49c541aaaa995cdc86772e9d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6352cfc350f64fb58df0dbdcb47f284a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac215de11e334702b29490e622de1ee9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee61ad8ad9b4ceeafdbe187f3ac6b18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9db6c1894c24e5c940af32de705648b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f41643b44694636b95fbedee07cb74a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b4c37dbec149e580bc98a08db8a779_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562545855775425380ef8229edbcd63c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie425b655a72c4978a3a152d215d89082_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e961357d334fe1868904f1cf61fe7f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f038b7cb5048789472b556cec62a76_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450e90b0899c413f9adda90b2983c33f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e918b0999104da8bcafade720bc9b31_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3686af1f019f450eb7208b0baaafb092_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574f697fada244ed8d5d02623914c1e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0734cb68049494fafe29592fc4b53af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e181e2c5404c43aaf1a8e699cb5ecc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176dd2b5900a430a8769d523c75624e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i95bedcc32b2b473584af9e33a7e1d845_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb49adc0c914214b0cf681200d4116f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9ccec8490648f89cb63618723a451e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328a5479a2be4ecabc38b95ddd05d567_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4739475a7bf45baa7a16fc49ba98df2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76465e7067f243bca6ad8e5ab38fa633_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140c790345dd4179834f4c8b07bfb8b8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ce8aecccf3444880c9cbaeee334a73_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8429eedb67b4e29966dd05758722f62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f66a5967db44f1b832d3882c44a50ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74725ac875c8489088c9e3ce59925700_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98f3a5ba27de450689d4df428849595e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ef3595a00743e5a7af8c76c459e14b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01ae90f5f764dcda9f3b84fb3c0c54b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88cec99f19b4e1aba4ef2f6127972fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d68f81dce946ce9958065f41c11dd2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i200e82b6162646ee8c54e3be1e9b651b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia86049893a634ee3bb28b8e42ec50e44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i862defdf94944941b57660ed32b562fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a7c5c399874ea6acc5ea1cb2da6ec1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ebbebfdaf14b6faa9cf2fe95f1a416_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c3072371fb40e1a27e1c3eedd45a42_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5096915ac2409d8fc7cf00977aa468_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e40aa5ee08404a8b9fba38e9c1d51f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d00e372db14beba5926893075d82e6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057d3b67bbe0417c9f5751710eecc36e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b8f69f452145d684659547efc6183b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf9472d8837472bb72056071e3bcc2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a947129bd0b4128a5b74a946315b11d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb035999fbde4492a61824d97546fcf6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e163c502c3149529b2710b48e018b35_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a70f62d258b4e2a84bcf2d184731151_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021f337b4cdf48d7921f51bc2532b923_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6bc8a9e6e2c4acd97a125ed75216ff4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bc95c69093435488202bb8c647ad08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided8687dc3744e439646e8257fdd793f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad5c5562a7eb4824ac24cfd6ad279dd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c103262dfb4e5284221d8be36cba80_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39db5b06f794fb18a7032c5fc0bc7ad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i270271b7414b4aee9f1a3da9ce2b7382_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b2f24271294a2eb663d0975ebee946_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a0d52cd14ad4c7580e4dec70cc96976_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ccd9e592044f67803b6e2b75ca4260_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efd8fc300e2405d8b1f4a654504ec05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idae51e28be204725a4f236b9b15f9524_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cb7a08d6804ff499cfb7252fb8d9fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ccd377ef1345a6926dc2a8fa826850_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i205b417c4c654633a4bbb6e38d915d6a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6351d7d85d4ec18acf7c5279c0884a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee9028ea70334edabc968f604261d6af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e3897facac41f1a56e386be016d76c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f063731fee4046908c3a1a1e0053e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3f51c3344b4ed2b2fab26b0aa77412_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99305aacdd484354bade2301930b1542_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857c66ec002c4aa9adc11ff5a2424048_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e34a0b5b1545cda6d7fa644e9297c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2525c2cad7949b99b59099149545ad3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb98e1a8d414c63a4f91b8642e4d776_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4c6d7874ba4f5fa0cd030ee16e21e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib298944c5a5b499fbefa89414cfbc34f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f568032fe6c4908a1cc54d8e025aeaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b04d9ed9c25401c862faf9f0dfe47e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14683cfbcb854f06a1133e77aa8126c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf1e7edcd4c402a93bfc7b9231c5eda_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if272f16215814e408fee0ea6c0c68918_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf49983739c4f4a92b0acd7196c9d45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5214efc2a7ec4769aefb4a504c5a9fa7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c97fddb35a4c2fbd8c78085e1dd095_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib84f70f7509f4f20b5f383de8dfd0a74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba3a5f1c0fd04bc09a8d036709d8b1f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b37e4f1d2046feaafd8f5615f12122_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a71d4ce57724fd3ac83a73b7bbef78c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50020f5f6954fe0a1e6658494e5a775_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a5f1893f3547fa829f8586420e43d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7331130ff6d8406cb228958b17149855_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1008a176c6de4b40a6a73b757acc7f70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabf4e0443f74462a97365b827ffa008_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358f4a3297e542349a9a568ed3b11df3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id569202dda104d39a7a750670b0d84bb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d750d13d4f649cab754bb9764317fb5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf1acc9c421458f93a3f08a21c062ba_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d6618cd7c4444e8afb57f3ae24ade4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a0bbba08f347d193e2b1828a35d52d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i309bbd4aa703457b9a31d2fde9c76235_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb39a7d3f58491b9ccb76970fd032bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e18d952c0446c1ad43e7467144a8d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5c242b674b44679c627a7248ef2819_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ffe45070124a318e73e7a6e504352a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e3eeefe5c946fba06a0bee7b36d266_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae857828574b4a668d913b270f8b36f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d49299020542a392c3db192ea63db8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43e2337e11144df5a90e99b5c638a73c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70726c081bb4947af4189a219572868_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f3a3d42167442d9bea77b4bb2f39e6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f1eba71d184d8ca513113104bff510_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b1cdaa3e0f34234bf362b822775dec5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8204c7a6c9e14f10be68903951892472_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf92a809cfe4430bf1591de1f172efd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0e2e41b80c40d189eb508b9f0e5d8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4692d33efa2e4c1a903bbfa6eb1bf652_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9a9dc69fb240d1812e5cdbb79f5bf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e426ceed16d4ea0b50c79b82c4ac9ed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie023e3f9d84842d5b43ecca161e36545_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc443f74d743469fa8a5404cb1d7b20d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9276731dd9df4019aaff0654ed7ba115_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf82d3635af4b94b02308fda06d4aaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7023a532dbca4fdcb35a761a941711f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if019e7ba00f744d384b6d00260c70676_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic736f3c433054ecab5e86925ad5cd22e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d2ad95a1744b048be0fefbdfa02051_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibafcf9464f63422d9fb63a2de8d93d48_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f5465ec02d4a35b998d802608fff25_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874752c3de8541159a7aed9141a3553e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide78159bcbbd42a48bbbcc894680d340_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a54e53274284e9ea52e289b3ec3aaee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d6fced1e674a6a8d953ff5bc008fef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb992b77b3444d00b7b2813dab4e0089_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd69502271af4d6eb175d2a6ec3ec8ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90dc5662383a49e5addf18ac3694d3f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia58d2c0a64564683a5f1a7c8f578f7a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ca803e36054d509ef339b251361ad7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c0710e6642417481cd192d1e448da3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7300d904ed1b4713acd2ddc7fb40833f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78d4bd4a4574be68dce08afe8061e93_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120e85817179476683841797ae988eef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0978b5f9be8f41cb89b77a87ab36cfa2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9c20940c1043059e2558cfbd912517_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b177f8e4b4d4b6080d2cf0a7bb6b531_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a57fe489af45e99b1deeafae96476c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a35912508b74867862fe94d3155d586_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6297966b092c4f5a888d0ccf4cd376a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d44fdf6091a441db520ad3f8f024aa5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib456b5dd5eba41d78d922d73a09bf090_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id130f892b445421ba418a4ff87945c26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic528c221d89a4614bb571ddc51d780fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be735be6bd241ddb4bb0c132722eb91_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd6c25aa9ef435ca2a940cd82ec2eab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76e15d8f3034561bc0f77901e95f300_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734040fec2ae4fefa9ac801de7c29378_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972796d2c85047ffae7e45d4d942a4ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f8d6f5408d437593d6ed14249728b1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366bb0c4a80d436dab4d980a44b57763_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>gild:position</xbrli:measure></xbrli:unit><xbrli:context id="i54513ac7f8334fc5b465981879a0f801_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1a320253be4fd0b8481aa6a57537c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0589c2ad7eb480b8da2a801c4d25063_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4120862280544540a63c21d7e97b6c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a456fff65c843b6a626df4ea2ce55e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed49fdba2a147c4b79505826a478d36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6ff6cc00ff41f8b7ec36a69139238b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b085d7670ea434382d8a85edb3d068e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc2166d764d47b790982ea8d24ca4c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb3d84561ec4098843a2d085b4a0ca6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f2d07dee1c49d6beb026214523051a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7427f7cf7f37493d9bdc7a0ae323cc7b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ff03aad47143d2886a6c27847acb8c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f27f012480540869dfec449f56f64fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541ecc08f5ab4ef1b08aa8faf2073803_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c84a15b4f764e02becb348c2b986e0e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e169fb1551b4471ac0f7b68e6ded3af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i755866e871aa435bbe8cc99ea9405032_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3654deba3ec8484aa044f0318ffe9226_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590c1dfde3d24201beae31f590843dfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4108efc629d9462db4043d3b73894ef6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9099c763634be097da7c2e31d5b983_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2c11db705040bb991212a1df88c126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcd9ccfcbe9446eb6f087a60e2891fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3a437f7d5e4a888f6943960ee7df17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="icbff931ce23a4b7fbc85927c27dcbb38_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82997a4df3f84a3ea62a3b4b42b70d35_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282910930ada4568b9f7fbf7401e7ebe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa635ad0e1a44f7b6c2b98f4ad871c7_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e131229c44421889bd64bd4ca11a35_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>gild:program</xbrli:measure></xbrli:unit><xbrli:context id="i13a9e3a52328474db24a8e8398a645e2_D20211221-20211221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-21</xbrli:startDate><xbrli:endDate>2021-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86cf8f539a93434791137d23f91be357_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840ba75e346d4681849daddb6e34dc67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4196245fb7d144eb9adbee95335379ec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb2cc7630cdb422387b0f6b01196b3cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8151e3893ea4621a6b91e28a0a81267_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8335947a672a4bf581dd7173d631b531_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d2e499098c4f4ba1e2564a683b808a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff62af4097e04403ac73d0cac08de46b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf48242a25a48a49a44e99af42e2e75_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414779d0bb44463e89fae77dc259101a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ea8eac0938446ea3ef964301fddeea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b791ce935c423893acbd1d5237a6a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80486df441b94309bf7388e71d0392a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257ea51d20324ca09177cd0d150f10e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f249c798e6480c85ff4095cc8ec9fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5248381b9f4abebf4c2f5778f80f05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia203cc43338e4b63a44ff1ec45bc1a31_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7de9e17b244038bf3bc1cff4883ce2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d50a2523c6d40889f73a7fabfab2e49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea02e471b61436f9c0ec424b611b358_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53a5ab8e03f4ffb92c7f39803b6595b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e70a13105b4454e9983b755cf5e801b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia375ee6d18984f8cb58cbf41605a3a02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d36da1631914269907cd58f8afe4bac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ffac061a264104a18929d13674c19e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b34c3a4e3a3433c96acaa5ecaa28b50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec48a6ac3ce4cb08310b8ee51083fde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778b869054c9463e8cd09ca793264290_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a458700e8ab46c588af1e244ecdd413_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e1179fb9c24e2fa4872abe26299e32_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80beed14e70493c85b0036c04e5e1b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1898e2ef2bd41e092d17dd630de1f86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766605ef96f74675add6345046f2ff5f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c33c2ee7674cc6a7f7187ddd22ac13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849968d6d54e42b7a4440de8cb2b01f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60bc99a828e44a87aeb970348be95119_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52d4ee07275499f9e21b3b419e65345_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2259043e9523429d8166efc5e113295f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406c686943914b65a05b788e6714fa04_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35dedb6bce1648f5aacca48840848457_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3ff054de0246f682af95f77b83ccd9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8297424984554341a6cf87b296e9e43d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27643ccf07b464b925ac68cbdb116cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dc99172f8b246e88d87b181a2923978_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i498ffcf1be474bd3918aef4609196972_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb76d2db3b804d9dababcc6f82e2d016_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa725b2b3e84d07b775bc9eaa5463c8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd14cdab0be64d6aabc8c30d9b047909_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06221e90836348968d49234dbf14d1bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbeb6c7348bb4b8aaa56ac4ec2c04a5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a2802dbbc844e2858b672dfcde8038_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd02b491e1a447e7bed36e4655ecccb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6813bb08ecdd4b31892315a2074efcc6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388fe16439ae47f3b185a0de4b4ddf82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5317908672c2495db89fbaa4d6ab0754_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02ab28eb41e345ada758ce1aab74170a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c0fa504fd846aabc3b372785f24c97_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6007d0be2b424a0c8e7fc133a041c624_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacaf1b5ba1374bdbbdfce05c8d032bab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic477d5bf6c90403e856da095ce607bef_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d9c9741d4e4098bcc97e45010d58c3_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03333a449154cb7b8232d024d98f8f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c1bf3df91d4e6db4587e1096299bf0_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ccebc28b844e218656b87fdf4c2179_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0018ba912b0047809cae45058f13a571_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i185d5cd8a06a4180acfc1cbdbf6ae18f_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gild:patent</xbrli:measure></xbrli:unit><xbrli:context id="iaf92539a830e4f129492e4de6932612b_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df3344fe2684c4db01931149342fe76_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc02333637e24bd4ab2f7235cb6e6be5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2024ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="opposingparty"><xbrli:measure>gild:opposingParty</xbrli:measure></xbrli:unit><xbrli:context id="i3a3b1fcfcfcf4d1288de350903d04105_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2026ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6a4c4eb7dd45e19e3d027acae2a40c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie253cd11e2894e2eb71ca1ebfd05ee3a_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="party"><xbrli:measure>gild:party</xbrli:measure></xbrli:unit><xbrli:context id="if2e36e12155d43ce870b52c07b49d3b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480272d3e47746109dccd3cc3b185332_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>gild:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i8a21d016ed3f4fef846e7281366b96ba_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28098faeeb64ff9abedb2ceb8db8e9b_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic645773c025f4573b8df34872cf19436_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2b570214ba4b4380a34ff9a40f2812_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f95a618e4294659ad494cd557c4c835_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218acb5be9394b00a1883e43cf92536c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8302b75564a54dd8a549d442749edb52_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d01a7b28f14000ac327b84cdbf6de2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6073554deb9e48ac9edef34f381a133d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb3a8cc8d58460b859489810a00ad9d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba93b576592245e8aad3a67ae9a4d33a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i363d24e7ddb249f281fc0dcd63f42999_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaddf54d089b4e758cb7bcdc7898e276_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8a7d072c434eef82e6df74c248a6fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77b97648262458092baafbed5c40ad1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6704da2f166c4ccaba27a2d1ce1023bc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6451f2f16f341a48298ff3195581dc3_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8577a82d764a7eb6649aba6ff99894_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_1"></div><div style="min-height:33.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl84OA_a0da87a8-9069-4f51-9aa2-f95d04cf9b34">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YzgzZjMwYjVmYWQ5NDdjMzk1N2E4OTE1YzA3NjM2YjcvdGFibGVyYW5nZTpjODNmMzBiNWZhZDk0N2MzOTU3YTg5MTVjMDc2MzZiN18wLTAtMS0xLTEwNDUyMg_3ff49d67-08f3-4296-bf20-e93e3755e976">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8xMDY_b3b71db3-9ae5-4390-8429-0aeaf75ad398">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6ODc1NTRmMGUxNWQ1NGRkZTg1NzdmNzBkZDRiNjQyODMvdGFibGVyYW5nZTo4NzU1NGYwZTE1ZDU0ZGRlODU3N2Y3MGRkNGI2NDI4M18wLTAtMS0xLTEwNDUyMg_37d8e4e8-e88a-499a-ba51-6bed305e8cd8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">     For the transition period from ________ to ________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8xOTM_2a1ba557-f461-4f8c-947c-7b928999e097">0-19731</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDE_493068dc-91ca-40be-9814-7314d018a864">GILEAD SCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6MDgyNWQ2NGQ4OWZjNDEwYmJmNGVlYzg5ZjE4ZTk0YzMvdGFibGVyYW5nZTowODI1ZDY0ZDg5ZmM0MTBiYmY0ZWVjODlmMThlOTRjM18wLTAtMS0xLTEwNDUyMg_c8c0c1b8-ea5d-4521-b099-6a9956f2562d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6MDgyNWQ2NGQ4OWZjNDEwYmJmNGVlYzg5ZjE4ZTk0YzMvdGFibGVyYW5nZTowODI1ZDY0ZDg5ZmM0MTBiYmY0ZWVjODlmMThlOTRjM18wLTEtMS0xLTEwNDUyMg_5ffdd222-e932-41c9-9b3a-0eddf90da0ee">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNjU_eb9879fd-6c98-4ac6-8013-9aba027cc81c">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNjk_563f4af8-2bf9-43c2-8569-75d8aff31c1d">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNzM_68de628b-297a-4f34-921e-4aaf013df786">California</ix:nonNumeric> <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNzY_de0dac20-0fee-4640-8bee-319e50421e4c">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8zMzI_f0946c9b-b61b-4791-b6d7-6b8c9af3d83d">650</ix:nonNumeric>-<ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8zMzU_93cc0e60-4fa9-4905-8781-f967e3606eb9">574-3000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YThmZGE3NjEyNzZkNDRiYjg4N2NmYmIxNjdmZDM1YjMvdGFibGVyYW5nZTphOGZkYTc2MTI3NmQ0NGJiODg3Y2ZiYjE2N2ZkMzViM18xLTAtMS0xLTEwNDUyMg_0ddcc3d3-8d98-472a-93e5-660b0152a2b7">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YThmZGE3NjEyNzZkNDRiYjg4N2NmYmIxNjdmZDM1YjMvdGFibGVyYW5nZTphOGZkYTc2MTI3NmQ0NGJiODg3Y2ZiYjE2N2ZkMzViM18xLTItMS0xLTEwNDUyMg_987680af-55a7-4778-a3de-d55f2a897637">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YThmZGE3NjEyNzZkNDRiYjg4N2NmYmIxNjdmZDM1YjMvdGFibGVyYW5nZTphOGZkYTc2MTI3NmQ0NGJiODg3Y2ZiYjE2N2ZkMzViM18xLTQtMS0xLTEwNDUyMg_03c19f47-4420-41c6-9d13-f5d1f2a5f346">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl84MDM_5143d08b-c0ab-4c79-8b43-6d8c34d98675">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant&#160;has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8xMTIy_7164e4f3-608c-4dc8-9d3c-80b0d1b35fb6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDg1_61306d24-ac9d-4a5f-80f2-3bb066522c8c">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDg2_20b1680a-6459-40f7-9285-1a3bf22326c8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDgz_01330df0-9c8f-4e3b-9420-e692c22e0652">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDg5MDcyMDkyOTgzNQ_2fa8ec8a-a241-4256-93be-e0aa8b759c0a">x</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock, par value $0.001 per share, as of April&#160;29, 2022: <ix:nonFraction unitRef="shares" contextRef="i1850f3306cd34634bedc7f64be32424a_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDgw_be2e1b4b-aac4-4893-9902-c282fff55357">1,254,313,448</ix:nonFraction></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_10">PART&#160;I.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_10">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_13">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_13">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_16">Condensed Consolidated Balance Sheets at March 31, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_16">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_19">Condensed Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_19">Income</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_19"> for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_19">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_22">Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_22">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_28">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_28">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_31">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_76">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_100">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_103">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_106">PART&#160;II.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_106">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_106">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_109">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_109">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_112">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_112">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_115">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_115">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_115">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_118">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_118">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_118">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_121">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_121">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_121">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_124">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_124">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_124">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_127">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_127">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_127">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_133">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib054ed57a41746f6adeff83e9a6e8cad_133">52</a></span></div></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or have rights to various trademarks and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BULEVIRTIDE), HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(FILGOTINIB), LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. This report also refers to trademarks, service marks and trade names of other companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_13"></div><div style="margin-top:16.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_16"></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMy0yLTEtMS0xMDQ1MjI_735ef562-ff3c-4767-b5fa-6d1da4aaac72">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMy00LTEtMS0xMDQ1MjI_05ad5963-bfe8-4d62-805d-3b1d3ddf17c7">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNC0yLTEtMS0xMDQ1MjI_1991c886-3ccd-4ba0-8a7d-2708350cccc9">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNC00LTEtMS0xMDQ1MjI_af2a2070-93b5-4cbd-8a60-b4cd7bcc00fb">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNS0yLTEtMS0xMDQ1MjI_bea1a8d6-928f-455e-9b53-b49a61fe7cb7">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNS00LTEtMS0xMDQ1MjI_7912dec3-06f7-437b-a3a8-fad7fc6fd141">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNi0yLTEtMS0xMDQ1MjI_00679a2d-12cf-48bc-99e1-5e7993960a9d">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNi00LTEtMS0xMDQ1MjI_e8e0b34b-abac-4fdb-8aad-081f9e201638">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNy0yLTEtMS0xMDQ1MjI_2271bb40-8514-4b3b-a9ff-371d8f227eda">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNy00LTEtMS0xMDQ1MjI_a0e28587-3dc7-4b18-acfb-161865417613">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOC0yLTEtMS0xMDQ1MjI_29bdc680-de11-4d98-857c-9993d9fb65e5">12,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOC00LTEtMS0xMDQ1MjI_b86f9c80-9c0c-441c-8efa-ce272ed6e115">14,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOS0yLTEtMS0xMDQ1MjI_ae4524fa-727d-4407-9112-2232195c900e">5,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOS00LTEtMS0xMDQ1MjI_08648e77-b1bb-4747-94b1-3f2dbbe05605">5,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTAtMi0xLTEtMTA0NTIy_11604ae4-3225-4c65-9d89-61cbd0a709d7">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTAtNC0xLTEtMTA0NTIy_658a68c1-9705-4d84-bf6b-326720d94e54">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTEtMi0xLTEtMTA0NTIy_a51c3554-c900-4535-bd8c-d876c06cdb04">30,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTEtNC0xLTEtMTA0NTIy_5d85c9b8-fef3-4a94-8d5c-ab7781ef392a">33,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTItMi0xLTEtMTA0NTIy_8b93488b-1182-4631-8699-a0605fbdfd1b">8,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTItNC0xLTEtMTA0NTIy_cd58db2a-2d11-4d0d-829a-974ddb8ee5be">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTMtMi0xLTEtMTA0NTIy_e5cb5701-fd8f-4fee-9a4e-5750537139bc">5,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTMtNC0xLTEtMTA0NTIy_87365ec1-755c-427a-9d4b-0f5bba22cb94">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTQtMi0xLTEtMTA0NTIy_01d5fcfd-3178-43b2-9e4b-a2f929071544">63,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTQtNC0xLTEtMTA0NTIy_03a48bb0-f34e-4ef3-865a-c170f21af8e8">67,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTctMi0xLTEtMTA0NTIy_a329859f-3c65-4b51-92eb-09e6273925fe">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTctNC0xLTEtMTA0NTIy_9ce1c08f-eaa1-4417-80f5-d70221fa6d15">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued government and other rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTgtMi0xLTEtMTA0NTIy_2eb7cd1f-7040-4e54-9ab3-965c455d6f11">3,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTgtNC0xLTEtMTA0NTIy_5ebdf5dc-a62e-404b-a636-a98449b24897">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTktMi0xLTEtMTA0NTIy_7118b1eb-9040-4fa8-9e87-d57f25559f39">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTktNC0xLTEtMTA0NTIy_a09f489f-e0fb-4e9e-9441-897e89d5fa49">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjAtMi0xLTEtMTA0NTIy_1e7a26b3-4570-4fcf-930d-cf8125da15e2">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjAtNC0xLTEtMTA0NTIy_c6f62a59-7b26-41c4-89fe-77297510e3ae">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjEtMi0xLTEtMTA0NTIy_63589b7b-7f73-4d8a-a424-a347be43a96f">8,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjEtNC0xLTEtMTA0NTIy_556ad3f6-444d-4c4e-b16f-60748e1f114e">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjItMi0xLTEtMTA0NTIy_90a79d34-8baa-4be3-9097-9158a0d30053">25,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjItNC0xLTEtMTA0NTIy_660ebe06-62fc-4698-afb7-a23f083d88bf">25,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjMtMi0xLTEtMTA0NTIy_2ef2526f-aa17-4f1e-aada-90637997894f">4,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjMtNC0xLTEtMTA0NTIy_2d35848a-a7f6-4b7e-81eb-3a86ebbe56c9">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjQtMi0xLTEtMTA0NTIy_1d9604cf-cc42-44c3-9af0-57d1515712bc">3,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjQtNC0xLTEtMTA0NTIy_d8221b86-d883-41b9-acb3-7c4a35ad7268">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjUtMi0xLTEtMTA0NTIy_e8b29536-d05f-4c3b-8275-4b938144dd8d">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjUtNC0xLTEtMTA0NTIy_2bca657a-26f7-44e5-8edd-d99cc1fdc496">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjYtMi0xLTEtMTA0NTIy_9ab2b02a-4dce-4d0a-8517-f9168d5c03d4"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjYtNC0xLTEtMTA0NTIy_57cec06a-383b-418e-adf5-1243097ee1b6"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfMzE_7b48b453-5da2-4025-b68e-33040ad11907"><ix:nonFraction unitRef="usdPerShare" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfMzE_8f5bfd80-2516-4c3f-935c-642d630ca46c">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNDU_2b7c7ad7-22bc-4e0c-8c32-18071a44bc9f"><ix:nonFraction unitRef="shares" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNDU_9d776e26-7d8a-4869-97ac-88f9a31056ca">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNjc_8d38b8bd-36e3-4da1-907d-9c1494eb2ca4"><ix:nonFraction unitRef="shares" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNjc_d63e1023-8f8b-4c7e-adab-6dbce0fba980">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMi0xLTEtMTA0NTIy_f91cc731-ea28-43b8-92cb-afc47b54fb03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtNC0xLTEtMTA0NTIy_c620dc73-1036-4085-a2fd-105a8e65e3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfMjg_3919b854-aa78-4f0a-a8b3-67d1a2971f9a"><ix:nonFraction unitRef="usdPerShare" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfMjg_765e7e0f-2b3b-4d3c-999e-a6d495498189">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNDI_142d348e-a067-4a28-b22f-a74fdfe4cc2d"><ix:nonFraction unitRef="shares" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNDI_b57bfb96-22da-4311-b3d3-698d73487a43">5,600</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNjQ_8626fc89-0dd7-4877-93e0-611d73d04d50"><ix:nonFraction unitRef="shares" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNjQ_e0ea9558-0bc8-4750-bc48-88f6e005c942">1,255</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNzE_0832e308-3add-43ff-952e-21b705a181fa"><ix:nonFraction unitRef="shares" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNzE_bf6ae982-4e91-48ae-a882-d3a040bd2274">1,254</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMi0xLTEtMTA0NTIy_fbf4b77c-43c0-47d6-9b1e-683708fb257d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktNC0xLTEtMTA0NTIy_d021fda9-b0ec-4c92-a63f-1a6cdd93a1bb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzAtMi0xLTEtMTA0NTIy_363018a8-8d5e-4f4c-a8da-5b8827e155c8">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzAtNC0xLTEtMTA0NTIy_3bcf0057-99b1-4802-858b-eb83c89754fb">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzEtMi0xLTEtMTA0NTIy_cd429d66-3220-48f1-8aec-f6667c348ea2">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzEtNC0xLTEtMTA0NTIy_d67126ba-c766-4afd-8901-002590e08c78">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzItMi0xLTEtMTA0NTIy_4c43eb12-a317-4e47-9053-a3618055d88c">14,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzItNC0xLTEtMTA0NTIy_07c64403-a7b5-47bb-b080-00ca1b56e413">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzMtMi0xLTEtMTA0NTIy_60e18d5c-e402-465a-bba6-2f4ffecbacc7">19,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzMtNC0xLTEtMTA0NTIy_e9eb9507-48c6-44ac-bc6f-04ab76172ed7">21,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzQtMi0xLTEtMTA0NTIy_127b5028-1409-4b5f-b47c-721f92265d5e">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzQtNC0xLTEtMTA0NTIy_681fae63-1de4-4fe3-9485-6ee02dc6a756">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzUtMi0xLTEtMTA0NTIy_09bbd724-9498-4d98-964f-afea34fdf288">19,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzUtNC0xLTEtMTA0NTIy_b2dc4ad1-9086-4994-9077-2d2e5f721f06">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzYtMi0xLTEtMTA0NTIy_5a929e4b-59eb-4143-9f55-4d0bf18baab9">63,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzYtNC0xLTEtMTA0NTIy_549c761b-d9f9-4dff-8245-373d3e19b0fb">67,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if150cff9011c4cb8865c7d010dea19b6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNC0yLTEtMS0xMDQ1MjI_36fd48ff-92bf-468c-9fd6-1758b8d13295">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad8a561a83946e2be71c0773364df03_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNC00LTEtMS0xMDQ1MjI_78286d4b-5174-408e-b931-dc461e9c8f95">6,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6adca2cb2df45159579306959cd9182_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNS0yLTEtMS0xMDQ1MjI_b4833e94-8be6-48fe-b38f-20b85ef820e1">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f491d481954bfb91bb63808792a107_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNS00LTEtMS0xMDQ1MjI_4fc95d75-fec4-4485-a990-4c84c0f86d50">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNi0yLTEtMS0xMDQ1MjI_f22a2d3c-77da-49d6-a01f-da7dbc248d0f">6,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNi00LTEtMS0xMDQ1MjI_35b88e90-8a37-4fb2-ba8a-05675b8e4f1d">6,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOC0yLTEtMS0xMDQ1MjI_1c4d87a1-bb91-4f52-9022-eec55446f363">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOC00LTEtMS0xMDQ1MjI_5c13f043-3129-4803-b61c-24cf7e889446">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOS0yLTEtMS0xMDQ1MjI_8d7dd6fa-29af-41a8-982d-d9305e6cd15e">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOS00LTEtMS0xMDQ1MjI_f0247cc3-cd30-47fc-a001-ef235da531e8">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtMi0xLTEtMTIzOTc5_46794cdf-40dd-4287-b03f-5d8a6e60ea82">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtNC0xLTEtMTIzOTc5_b2b3ae34-ebbb-424e-9ec6-d2baf4a38d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtMi0xLTEtMTA0NTIy_f72c8812-143c-456b-aa17-962506c48dbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtNC0xLTEtMTA0NTIy_dc944efd-0d2a-47f0-b3cd-fa80b62658e8">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTEtMi0xLTEtMTA0NTIy_6551cf3b-802a-4ebf-aa96-227776e6b03b">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTEtNC0xLTEtMTA0NTIy_67d82ce0-cc56-40a0-91bd-ba7cf1406543">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTItMi0xLTEtMTA0NTIy_77b29eb1-b118-4b48-9857-5101006383df">6,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTItNC0xLTEtMTA0NTIy_64ddd63b-fc40-40ee-9599-0c9d5887269d">3,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTMtMi0xLTEtMTA0NTIy_3b70b8c8-c050-4212-9c75-d6b6eb0b4283">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTMtNC0xLTEtMTA0NTIy_ebd12bbf-ca9a-4bcd-877b-5032bb8967b8">2,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTQtMi0xLTEtMTA0NTIy_c2c5e09f-8f3c-4ce3-ade9-db5b7e6171df">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTQtNC0xLTEtMTA0NTIy_92de9d04-8e86-403d-9cc9-1b2642ffc131">257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTUtMi0xLTEtMTA0NTIy_1881bee4-c18c-43f4-aed8-a1d97e3dfbb5">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTUtNC0xLTEtMTA0NTIy_d3e31954-f9d7-4ab6-8db3-b3b817200a1a">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTYtMi0xLTEtMTA0NTIy_5f236620-4567-403e-9017-a2aa392030a9">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTYtNC0xLTEtMTA0NTIy_1ab812a5-c30a-4006-adea-cabd5cde7545">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTctMi0xLTEtMTA0NTIy_5a97b446-71bc-4362-b146-f8fe88154238">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTctNC0xLTEtMTA0NTIy_8870ad5f-aab6-4ae7-a929-03555a21558d">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTgtMi0xLTEtMTA0NTIy_a22177c9-ded7-4f52-a8a4-7657a5bd0b0a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTgtNC0xLTEtMTA0NTIy_3123fb9f-4d08-4c43-af17-fde82165959e">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTktMi0xLTEtMTA0NTIy_7c7c7b91-00e5-43a3-a6b7-30177e6d00d1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTktNC0xLTEtMTA0NTIy_dd680e55-06a9-4469-9919-52de7f882a04">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjAtMi0xLTEtMTA0NTIy_fb286ff2-b784-4579-a514-5576d3c0dbbb">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjAtNC0xLTEtMTA0NTIy_ad52e8f3-b082-491d-836e-47985326a3fb">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjEtMi0xLTEtMTA0NTIy_32dac2d5-da9d-494d-b34c-b69a71ae2e9d">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjEtNC0xLTEtMTA0NTIy_256981ea-fda5-474c-a0d9-cdd467941983">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjItMi0xLTEtMTA0NTIy_419536d3-4fc8-4a28-b272-97c17ae57ff0">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjItNC0xLTEtMTA0NTIy_aac54c2d-3d56-470b-a0ab-e7ca00b12e97">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjMtMi0xLTEtMTA0NTIy_f34f5233-9615-4557-8bfb-dbcd119b2604">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjMtNC0xLTEtMTA0NTIy_5db5e269-394e-4c33-8f7b-56bb87d2588a">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjQtMi0xLTEtMTA0NTIy_de8b67c9-4f49-45bc-a66e-4846a251d9b5">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjQtNC0xLTEtMTA0NTIy_18a34b22-8210-4b63-b509-39baedaf1ff3">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMy0yLTEtMS0xMDQ1MjI_a22177c9-ded7-4f52-a8a4-7657a5bd0b0a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMy00LTEtMS0xMDQ1MjI_3123fb9f-4d08-4c43-af17-fde82165959e">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNS0yLTEtMS0xMDQ1MjI_f507674a-c761-42b9-a55a-712cd18f0e85">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNS00LTEtMS0xMDQ1MjI_2b0c17ff-169f-449d-b442-5f431c6295d2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNy0yLTEtMS0xMDQ1MjI_072b5e69-16d3-479d-91f9-2eaeb8863dbd">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNy00LTEtMS0xMDQ1MjI_edff0a3d-284a-4d18-8dc1-ba1556fb84a7">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOC0yLTEtMS0xMDQ1MjI_4597db75-700e-46aa-88de-d830a693313a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOC00LTEtMS0xMDQ1MjI_f7741b1b-8262-4887-bec8-d9e579b1d32d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOS0yLTEtMS0xMDQ1MjI_d0acdd68-3ba1-4532-804f-9768af8a2540">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOS00LTEtMS0xMDQ1MjI_6824b71f-2552-4b23-b62b-39aa74fbd928">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain, net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTEtMi0xLTEtMTA0NTIy_ffe88c4f-b9f3-4d4c-baae-80aa22202b3a">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTEtNC0xLTEtMTA0NTIy_00f77eaf-fd57-495b-ba92-ba9db848f6df">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTItMi0xLTEtMTA0NTIy_b0e52aef-f0f5-4dc3-80cf-1451534ba211">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTItNC0xLTEtMTA0NTIy_bface712-92b1-4caa-9ba2-e7bd20abe3f3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTMtMi0xLTEtMTA0NTIy_e6475c58-c576-4267-96b0-4db66eee3738">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTMtNC0xLTEtMTA0NTIy_5fdbc021-2638-4687-a6c4-0fea28c60333">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTQtMi0xLTEtMTA0NTIy_5a974c46-cd14-46a1-8558-9571dfa49848">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTQtNC0xLTEtMTA0NTIy_03d63158-4e22-44de-a19b-5530aa30e750">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTUtMi0xLTEtMTA0NTIy_73816bb8-b596-4320-82a2-a7c799957190">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTUtNC0xLTEtMTA0NTIy_69605c84-78a6-4dc5-8019-8d2693791132">1,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTYtMi0xLTEtMTA0NTIy_f37fd5a7-f9ed-420e-a9eb-3249e3f50c2c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTYtNC0xLTEtMTA0NTIy_c76e105f-0329-4893-a937-04c6170cc600">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTctMi0xLTEtMTA0NTIy_94bcc5e5-b1eb-4cc1-ad12-2b953dd7a403">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTctNC0xLTEtMTA0NTIy_68063788-70aa-41d7-8461-31cf4e852ceb">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0589a869ef75463baf4882764f90b836_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0yLTEtMS0xMDQ1MjI_d2a4aee9-de1e-4af4-b124-b6beb6791de0">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0589a869ef75463baf4882764f90b836_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC00LTEtMS0xMDQ1MjI_568f13d7-a6a5-4e84-85f4-17714f77b02e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic69dcda8ca004abb9ed728a2c520c160_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC02LTEtMS0xMDQ1MjI_21abcc15-f70d-4c6c-b6aa-81f8c2e91d56">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97be958f8ea44f6bf64ec6b93653cd0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC04LTEtMS0xMDQ1MjI_8d048280-8336-4b12-bc4f-9325980b169f">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaede3fb2344847fea92949ea16a03f84_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0xMC0xLTEtMTA0NTIy_6c5ea87f-15a2-4b4a-9fb8-3c4620a75602">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bbba3bf8d68467f8171054b804a1ac9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0xMi0xLTEtMTA0NTIy_14d2f7d7-9aa3-45e0-85d2-4076ac311bef">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0xNC0xLTEtMTA0NTIy_7ec09e93-faa3-463e-9fb5-a4af3522717c">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNS0xMC0xLTEtMTA0NTIy_68abb57d-aa9f-4d0c-a2d3-a1223dda25e7">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if538f3fabd96439a81d45376a26388ff_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNS0xMi0xLTEtMTA0NTIy_fa21408f-fdb0-414c-bd35-c34fc9b2326b">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNS0xNC0xLTEtMTA0NTIy_0db58815-d682-4597-99e7-d4570cb223b5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cea6550adf3442f91f94178b881760a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNi04LTEtMS0xMDQ1MjI_ea0ecc0e-5789-483d-b64d-bd0c24f940fc">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNi0xNC0xLTEtMTA0NTIy_96957240-28b0-41e9-b1db-667df43addf5">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNy0yLTEtMS0xMDQ1MjI_5f7a6555-492f-490e-98ae-0899708e1f2c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNy02LTEtMS0xMDQ1MjI_11f2c8e8-fdcd-4dac-838f-3d3a1687d0b5">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNy0xNC0xLTEtMTA0NTIy_27e036b6-1f6c-48cd-a06a-d31c0cb05089">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOC0yLTEtMS0xMDQ1MjI_f52488a3-9d2e-451a-8bd5-ddec0fbe0880">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOC02LTEtMS0xMDQ1MjI_624dee4b-7663-4a20-ae6a-54c210e6a80d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOC0xNC0xLTEtMTA0NTIy_fd25671b-580b-4134-8de3-95cddd9a2733">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOS02LTEtMS0xMDQ1MjI_3988e8da-8b31-4a0d-b8e4-74f785afc489">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOS0xNC0xLTEtMTA0NTIy_7fe7a778-3b79-4b7a-b80c-0fe5c6c41c26">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtMi0xLTEtMTA0NTIy_f5161a96-68fb-442c-ba7b-b59346c5f367">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtNi0xLTEtMTA0NTIy_c9353846-b7f2-44fb-8b07-8e5d6b665bad">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtMTAtMS0xLTEwNDUyMg_fe94d630-f0f3-4726-b5ca-19f5b9c3b601">425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtMTQtMS0xLTEwNDUyMg_b85939cd-0e39-417d-933d-f25e2979f701">444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTEtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246Y2U4OTcyYjA0MWM5NDMyNjk0NTQxOWNhMDIyOWU3MTBfMTA5OTUxMTYyNzgyMQ_ae82a30a-1d3c-4416-b4b2-d8af5e493073">0.73</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTEtMTAtMS0xLTEwNDUyMg_cab2db12-9e68-48e3-b81a-28633a8a5476">932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTEtMTQtMS0xLTEwNDUyMg_d654fad7-67b1-4724-939d-d54e24f1d1ac">932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e9781941f584349a74927f787b7e812_I20220331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMi0xLTEtMTA0NTIy_02899246-19a8-4c9a-8d24-19a813dd741b">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9781941f584349a74927f787b7e812_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItNC0xLTEtMTA0NTIy_29354d4a-6206-4a52-9d48-69ae4ec228d1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31c7f678df04d0dac0d6728662443f9_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItNi0xLTEtMTA0NTIy_cce74a97-320a-4c3c-ad66-b6b48f323fba">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id993c220a3874424a2e4ebabbf6841f5_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItOC0xLTEtMTA0NTIy_32231eb3-89d3-46bd-8df8-59447ad48599">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042afe2516664edcbb58b11b031f07c0_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMTAtMS0xLTEwNDUyMg_0f68371e-a488-470e-81bb-fdf397235205">14,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e28083e946c46d38dd4c1bbf423acfb_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMTItMS0xLTEwNDUyMg_42f68c38-7876-4e6b-9845-4d8b5105a94f">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMTQtMS0xLTEwNDUyMg_9a14a0a3-eacf-4462-ab4a-d651ee226541">19,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e9f66d43a49486cb27df9c7ce53de4c_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0yLTEtMS0xMDQ1MjI_251a483c-ca13-4739-8ecf-d333c610939c">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9f66d43a49486cb27df9c7ce53de4c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC00LTEtMS0xMDQ1MjI_f67c8de6-71d8-4ed0-9930-601f1484d79b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004764dee0dd403db285a0bdf557180f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC02LTEtMS0xMDQ1MjI_97dc97e7-62bf-48d2-a24d-229a1e10b0f5">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8beedc1ba15342129f01b711293f2310_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC04LTEtMS0xMDQ1MjI_2b1489ea-88eb-4e26-bcf7-c86127967da2">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4874edd47334bd394e3a3ea1da5ca86_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0xMC0xLTEtMTA0NTIy_9d9eee94-0a27-4c49-b42c-c4978ff531cd">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1673112d964a58a17fc93e7d35ff26_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0xMi0xLTEtMTA0NTIy_4c39e0a1-db31-485e-bf38-b3996b263b34">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27321762d2f4ae8a9a783e43673fccc_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0xNC0xLTEtMTA0NTIy_358f81b4-c232-4248-86cd-ef2627247467">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNS0xMC0xLTEtMTA0NTIy_7ff10f32-bb7a-4820-ae04-5bbb32976a3b">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice22d99dfaaf407181dfa92cad25c12d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNS0xMi0xLTEtMTA0NTIy_17b8c732-3621-4add-bba0-0e95e92230ea">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNS0xNC0xLTEtMTA0NTIy_bcb65df7-f985-4673-b1af-f2bf67b29721">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib900b75bb57c4248b64d9bdcf700306e_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNi04LTEtMS0xMDQ1MjI_3bf57514-8dc4-45fa-959c-f8a429c0edd3">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNi0xNC0xLTEtMTA0NTIy_dfa221be-8bff-4d6f-af0f-c03f82efdcd9">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNy0yLTEtMS0xMDQ1MjI_80af0e16-934e-4440-9ac8-1616637292d4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNy02LTEtMS0xMDQ1MjI_5025f455-b286-47eb-8dae-7c4f4881a94b">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNy0xNC0xLTEtMTA0NTIy_49652d2a-d3fa-42e5-94f5-6414b432180c">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOC0yLTEtMS0xMDQ1MjI_d4af0c5c-5214-47f8-85a8-0e3b998c7f77">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOC02LTEtMS0xMDQ1MjI_aa50ff9e-78ff-4263-9fb1-4e14b9b5ce56">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOC0xNC0xLTEtMTA0NTIy_baa44d0f-032f-4685-9d5d-50fb15fb7ebf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOS02LTEtMS0xMDQ1MjI_dcb001b2-4788-4991-ac30-21115caf9757">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOS0xNC0xLTEtMTA0NTIy_05089c52-9023-48b0-9cb9-553ec3e2381a">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtMi0xLTEtMTA0NTIy_0a4f5742-2cab-40a4-bf8f-17dd1a520736">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtNi0xLTEtMTA0NTIy_945ae89f-4a5f-41a5-b7b4-9b0fe9ea2708">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtMTAtMS0xLTEwNDUyMg_628d5d9a-6cf3-4800-8386-7db141172b9c">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtMTQtMS0xLTEwNDUyMg_60223773-8f92-4195-88a8-0ff0bb548abf">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTEtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246MzczOGEyZTkzNTkzNDRkMWI4MzYzYzQxNWM5ZWU1MTRfMTA5OTUxMTYyNzgyMQ_49fce0ed-e2b5-495b-bf1a-3067454ce1f4">0.71</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTEtMTAtMS0xLTEwNDUyMg_482169b5-d86e-4300-8c47-6639eae55c37">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTEtMTQtMS0xLTEwNDUyMg_1c62098f-91a1-40b4-b6e7-83b5fee072b5">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0889fbcdb67f4509b5f885c5a7468633_I20210331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMi0xLTEtMTA0NTIy_f2ac76d4-d786-4593-8a9b-03b6d7806ec1">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0889fbcdb67f4509b5f885c5a7468633_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItNC0xLTEtMTA0NTIy_8175715f-4392-4d39-81fa-852647a644a8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997fc483bf224ea9a20e7b632dfba8b9_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItNi0xLTEtMTA0NTIy_ca50d0a7-2ddb-445a-b5de-585806ebf936">4,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72674008e77942a3986c777c8aab4eb4_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItOC0xLTEtMTA0NTIy_80c963a5-0e3b-414d-9977-5353f699b95b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d7f1d99b11464eb7135895f195aaa9_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMTAtMS0xLTEwNDUyMg_8fa7452c-77fd-42bf-94e9-a28b4662f52f">14,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eec7f2c8c1a4636ba925954742eba86_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMTItMS0xLTEwNDUyMg_11550991-24cc-46a0-a9c4-cfc8fe66e370">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9796d93b2414e28a30a1b8602920120_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMTQtMS0xLTEwNDUyMg_372b2cf8-5d14-4962-8f1b-08f5bfa305aa">18,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNC0yLTEtMS0xMDQ1MjI_ca37b482-a380-49eb-9c50-39b1ea59d08e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNC00LTEtMS0xMDQ1MjI_9063375b-3ee4-4dfa-a880-2103a3df83c0">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNi0yLTEtMS0xMDQ1MjI_04dcd89a-6a0a-4fd9-adf4-c56209dd0639">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNi00LTEtMS0xMDQ1MjI_853ad9bb-df23-4632-9717-12402969c082">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNy0yLTEtMS0xMDQ1MjI_2b31ef96-6377-4a38-8ae3-81b8b5b2d72e">445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNy00LTEtMS0xMDQ1MjI_c4304c50-5a16-43c8-8bb9-0ab411128635">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOC0yLTEtMS0xMDQ1MjI_5d8d56b8-fd2e-470d-8d62-60d22217f726">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOC00LTEtMS0xMDQ1MjI_6635ee44-02a2-4136-a34c-ddbccd13962e">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOS0yLTEtMS0xMDQ1MjI_29444af9-9719-40c3-9811-b9bb608cdd54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOS00LTEtMS0xMDQ1MjI_176886c1-373b-4438-a736-c5905d17356d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtMi0xLTEtMTIzMDAx_f679b262-f360-41ae-a7eb-93e7c7604eb9">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtNC0xLTEtMTIzMDAx_5ef35fd5-8710-4d3d-92e0-9d536a861162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtMi0xLTEtMTA0NTIy_7a854fa1-8cf2-4b79-96cb-991b03bba0ed">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtNC0xLTEtMTA0NTIy_f7c75432-b762-4a71-a31f-8f0f689b8525">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss from equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTEtMi0xLTEtMTA0NTIy_719f931c-ac45-4ce8-b558-a599c1efab40">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTEtNC0xLTEtMTA0NTIy_46ef0e37-0c53-48db-b10d-9729b59faf8b">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTItMi0xLTEtMTA0NTIy_67130a77-568f-4df5-a91b-e276793fce23">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTItNC0xLTEtMTA0NTIy_b6ac6d16-e6a3-4478-b589-909d24517abe">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTQtMi0xLTEtMTA0NTIy_a660f6a9-7f45-4f3e-9958-0b326c1c8ce7">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTQtNC0xLTEtMTA0NTIy_32179264-9f41-470f-a86b-bc1d607ffa82">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTUtMi0xLTEtMTA0NTIy_d080a5ff-8959-4318-b5cd-8a650336c0b3">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTUtNC0xLTEtMTA0NTIy_fc56d569-c95a-422e-b9a9-8e20551fa83d">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTYtMi0xLTEtMTA0NTIy_482a041c-1b7b-472d-bf73-51fd25e117ee">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTYtNC0xLTEtMTA0NTIy_c2535cfb-6447-4198-a6a0-6d60271d6b36">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTctMi0xLTEtMTA0NTIy_4bc64fdb-2641-4a08-a174-e556b8305294">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTctNC0xLTEtMTA0NTIy_e689bc8b-d788-4fcf-bce9-b75056fe69c9">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTgtMi0xLTEtMTA0NTIy_c6017fd2-889a-43ad-a004-a28b9e9a618f">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTgtNC0xLTEtMTA0NTIy_778c3b60-a364-45ee-88b6-87273ef49ff2">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTktMi0xLTEtMTA0NTIy_a8f30868-ad71-455b-879e-0479dc932e0c">1,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTktNC0xLTEtMTA0NTIy_5d6754de-a129-47b9-8f61-b0f8ac64715a">738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjAtMi0xLTEtMTA0NTIy_8bfe47e8-3b3d-46cb-a942-65d2ccee4977">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjAtNC0xLTEtMTA0NTIy_2bfd40f2-d64a-45c2-bd19-e25d2087e1e5">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjItMi0xLTEtMTA0NTIy_6b69f051-aa3e-4db0-b76d-f66fbd41bb97">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjItNC0xLTEtMTA0NTIy_3fad441b-e8f8-48f2-9db3-b7bf77564e56">931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjMtMi0xLTEtMTA0NTIy_8ce68965-8877-472b-a6cc-1ecda07325fb">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjMtNC0xLTEtMTA0NTIy_7c24402e-da85-43f0-9707-e7bb56e2309e">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjQtMi0xLTEtMTA0NTIy_b92a66c0-2e64-4c11-bbd0-d6fb01ae724d">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjQtNC0xLTEtMTA0NTIy_11b0d7d6-d713-4f83-8290-51073eee6c44">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjUtMi0xLTEtMTA0NTIy_d27ba6a7-a5bc-40a5-ae5d-f6267c3cba6d">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjUtNC0xLTEtMTA0NTIy_047b37f2-821f-4734-9b1c-24a9f0d23c1d">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjYtMi0xLTEtMTA0NTIy_9e51fd6c-f3bc-4ea0-bf64-479c1c290438">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjYtNC0xLTEtMTA0NTIy_38d807dd-d22d-4416-a9c2-7b31cb9df6dc">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjctMi0xLTEtMTA0NTIy_6f5d5c08-267c-4c56-a866-ae0fc584cf50">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjctNC0xLTEtMTA0NTIy_85e96549-8ae5-4b69-b123-60099ce2981c">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjgtMi0xLTEtMTA0NTIy_070282ca-c1b4-44fa-b302-1d33416967a7">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjgtNC0xLTEtMTA0NTIy_2c0bc68b-e9c8-42d3-8286-29dba9d3054c">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjktMi0xLTEtMTA0NTIy_8b70eb32-67fb-4972-9270-97e481da9791">1,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjktNC0xLTEtMTA0NTIy_4851ef68-0b23-4432-9364-a6fb15caae26">2,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzItMi0xLTEtMTA0NTIy_8ff0dcc5-4aed-4c83-8813-43abed9768a5">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzItNC0xLTEtMTA0NTIy_2929958a-4196-4806-950c-d57edd9eefc1">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzMtMi0xLTEtMTA0NTIy_eed935eb-fbb6-4187-8543-19c9c3af44e3">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzMtNC0xLTEtMTA0NTIy_ab486f07-689d-456b-bc46-3f084f9ca0d0">309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzQtMi0xLTEtMTA0NTIy_aa0f1cc3-7261-4ced-b8f9-0d2596f4d857">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzQtNC0xLTEtMTA0NTIy_32cf001a-5995-4f8a-bd39-c8d27833e613">1,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments of dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzUtMi0xLTEtMTA0NTIy_8669225d-0785-44a1-8faa-9711e4ef795d">945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzUtNC0xLTEtMTA0NTIy_60d7f656-6950-45c6-8418-f385e44f4ff2">917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzYtMi0xLTEtMTA0NTIy_1da3b77e-be47-4c7a-9066-d4e61459014a">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzYtNC0xLTEtMTA0NTIy_1a756906-d8eb-420c-860b-c3432c6855ff">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzctMi0xLTEtMTA0NTIy_c4a884b8-8436-405c-a74c-76c305e05923">1,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzctNC0xLTEtMTA0NTIy_b6f17ade-1318-46ea-8a78-0bfb5d2b49fb">2,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzgtMi0xLTEtMTA0NTIy_043095b0-0b9e-4435-90fd-4b8070bedb3d">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzgtNC0xLTEtMTA0NTIy_d8abf082-7466-4deb-bd5e-95da66a42395">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzktMi0xLTEtMTA0NTIy_f530ce85-dab9-4ecd-b357-a1767fc61661">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzktNC0xLTEtMTA0NTIy_26abe5d0-2e30-4483-b0c5-d986db05dbf7">1,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDAtMi0xLTEtMTA0NTIy_099d6582-ad24-4fb2-a962-fc5d9340c62e">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27321762d2f4ae8a9a783e43673fccc_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDAtNC0xLTEtMTA0NTIy_22a1a535-fcd5-4a73-a9ac-e98e166525de">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDEtMi0xLTEtMTA0NTIy_982a2c2d-8a0b-4368-8818-4d4eb4b0fc7a">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9796d93b2414e28a30a1b8602920120_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDEtNC0xLTEtMTA0NTIy_d5cf6f79-3893-460e-8ff5-42f8f0cfb296">4,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_34"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE3NQ_83adaebc-8bcd-44c0-9b20-b3e33cf24a01" continuedAt="i423e034affd048ea864622b9a9b1bcf0" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i423e034affd048ea864622b9a9b1bcf0" continuedAt="i632c760259aa41beb3a6c0b1512d3b97"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE2NA_7fd03f93-dbe4-4fea-ad67-645283a1b459" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess at the inception of an arrangement with another entity whether the relationship results in it being a variable interest entity (&#8220;VIE&#8221;) and, if so, whether we are the primary beneficiary of the VIE. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of March&#160;31, 2022.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE1NA_5e68a445-7ba2-42bd-97b0-df63648dbe07" escape="true">We have <ix:nonFraction unitRef="segment" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfMTgyNw_be08046e-83c9-43bc-918b-d5dc6b72fe6c">one</ix:nonFraction> operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.</ix:nonNumeric> See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE3Nw_db4240cc-9c24-4b9c-b510-75fe5576d516" escape="true">The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE1OA_ab1fea19-99d4-4f1d-8c01-486850805834" continuedAt="iafe88d91160d489ab5dd8d86d378a61a" escape="true">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i632c760259aa41beb3a6c0b1512d3b97"><ix:continuation id="iafe88d91160d489ab5dd8d86d378a61a">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.</ix:continuation></ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjU0MA_c64b5c36-48e8-4c64-98bd-2fd2dcd9081f" continuedAt="i48cf10c87c994208a333862f5b650efc" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i48cf10c87c994208a333862f5b650efc" continuedAt="i8770343034e74d38a710a0b6550ceccd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjUzNA_f76a3c4a-bb69-418e-8a1b-3faf78e1745c" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied51c768bed843aea34aaed4b945684f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0yLTEtMS0xMDQ1MjI_a17d27ea-42be-4f15-91ed-4acb277c071b">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f1dd54de90447294f3c861a9ee3e1b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS00LTEtMS0xMDQ1MjI_a1dd5d4d-3c1b-4f7a-bebb-b68eb0243487">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3a3af70db64f0f978246427bb3f9d4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS02LTEtMS0xMDQ1MjI_e669ac90-103e-478d-994c-d3e01a81fd0a">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8c7affd72e42ca9f179e85ebb2f9d3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS04LTEtMS0xMDQ1MjI_1a2b54b7-c76a-4aad-a962-36a60257939c">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783425dee7ca4e6694dbf5913283547c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xMC0xLTEtMTA0NTIy_41487c19-81b4-4cb8-a723-597ea052a307">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb25c59c64f544eea1c86c507469316f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xMi0xLTEtMTA0NTIy_0d54fb54-7a0a-4bd6-a9e9-a47880088a46">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b35f1983b428c8545aed7327ea2c2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xNC0xLTEtMTA0NTIy_7bbb1ff8-be76-4201-afab-4c2179da99cc">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f1409918fc427bb29d5b500a1321e4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xNi0xLTEtMTA0NTIy_c4a234e4-9ca5-4949-b3e6-3df418fff3d4">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8346dabbdc9f40229cb19c819e8c69f7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0yLTEtMS0xMDQ1MjI_ef775b91-fcce-450f-8522-91789427db05">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1d8e2e5477841eaa52ff3b838cba27f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi00LTEtMS0xMDQ1MjI_f6a6ef1f-1c06-4055-8b7a-e797bf108a80">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1ba0c7461d47268493fb140371a2e3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi02LTEtMS0xMDQ1MjI_8c3fb8af-6b8a-43c2-b059-45e21080de42">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d0cd2f382340f197f0214e199101db_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi04LTEtMS0xMDQ1MjI_0a043a6b-6da8-4d86-9680-97d5e90a31b7">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ceb4bbcd084712bfcf12627e4a8876_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xMC0xLTEtMTA0NTIy_51244b5f-8791-46a5-bae4-c19360cae2e5">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fee41710daf4f27b3133b3886edbf83_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xMi0xLTEtMTA0NTIy_6b25744e-93bb-4f96-8703-c44382ba899a">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3afddfa05b845c7b30a26d393a73e1b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xNC0xLTEtMTA0NTIy_e46551a7-85e2-4125-8577-be01b3bb41ec">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9938c6a4da9146d99d8b8dd9069cfcd6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xNi0xLTEtMTA0NTIy_3561aaf7-c9db-40ef-a20c-07f57dbe49f8">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee884799ae424e94b23704c602366eee_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0yLTEtMS0xMDQ1MjI_1f945c5e-8f33-4a40-bc48-b9b308e9d35a">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aae21f9faa440b8b79c88263d1f048f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy00LTEtMS0xMDQ1MjI_5770f2c4-c810-4d21-a971-859fcf00ac52">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537a84e24dc24f9d9f384863ce96bd8a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy02LTEtMS0xMDQ1MjI_5db95ad3-1e4e-4aff-ab7b-41d62f9eef82">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2dad0f86f1e46f4882d989fb19a2630_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy04LTEtMS0xMDQ1MjI_d6d6e74e-2b7b-46d0-a6b9-259621a1d4b5">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073c91ae4254439ab6ef2904a9afe007_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xMC0xLTEtMTA0NTIy_a7ee4ddb-547a-4b10-9c94-6617b2c3047b">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff23fb99e7024ad4aa2ad12bcfbf8f61_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xMi0xLTEtMTA0NTIy_e4d442c6-04d8-4d45-93a3-26ed7c9c5fce">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib607ac8cf58544f0ba59e08838b4c390_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xNC0xLTEtMTA0NTIy_b6156df5-ffd8-4290-8016-fe722aa7de96">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890c16b438d54cc18fc29556f4322577_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xNi0xLTEtMTA0NTIy_b4349eba-2bfa-4f6b-b49e-cf8671e0687c">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c6687c2bfa42828d22e4837dbb5dea_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0yLTEtMS0xMDQ1MjI_ec750cea-94cc-4ad3-92cd-5936ba15fb14">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3ea5627de74bc29c321695fbae0bb9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC00LTEtMS0xMDQ1MjI_b85ae090-2c9f-47d5-b4a6-6e751d17fe62">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84542ccfad574a82827956f97ca98665_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC02LTEtMS0xMDQ1MjI_65a61f63-8190-4212-b5f9-912ffe8c9489">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e989af964740d3828ca89bb31ed8c4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC04LTEtMS0xMDQ1MjI_a99c6e92-648d-4553-a9c7-cce7ff3369f4">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636c5da3398c47caa2887765bc8fb4c4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xMC0xLTEtMTA0NTIy_64e59c3f-f95c-4a7c-9183-90192ff15f4c">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776ae62f154a426aa156b5d44009a287_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xMi0xLTEtMTA0NTIy_ab04a5d9-89ef-4e32-b873-9c64e261431f">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id360b7a80ef8475ba2077b3d656c6b26_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xNC0xLTEtMTA0NTIy_492d7693-c5e2-4173-960e-cfeacadadcde">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8e37ffa86f41faa81072218b874e20_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xNi0xLTEtMTA0NTIy_89b97ba4-bc8a-494c-be73-b10489885792">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318393636e2047c38e33f9a92263613f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0yLTEtMS0xMDQ1MjI_942adb79-4e27-4ac4-b809-7dc27ab53c18">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5e11317cc34eee936bb532fbcc45b3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS00LTEtMS0xMDQ1MjI_593f6969-45a4-43bb-9ee3-897b34c252e9">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f008fe0e88941f2ba5d03745e0d1c14_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS02LTEtMS0xMDQ1MjI_66ec35aa-3ab9-4828-803d-aeadbc4bf3ee">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513c8fd2c5fc4a58bff490e075395991_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS04LTEtMS0xMDQ1MjI_86555663-c462-4d2b-a0b7-4fe75a295d6f">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e711dc3d84406db6c1a10ada56e5c3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xMC0xLTEtMTA0NTIy_ac17b4d1-5d0f-4157-b32f-f3fb22a709eb">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0154ed0d254253a0dc7d64c5706bc1_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xMi0xLTEtMTA0NTIy_e2975af1-ce34-4add-ae34-1e4f1f5f4e9f">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia918f81a777249f2bfcf4b1d5bbc499e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xNC0xLTEtMTA0NTIy_0d699bc1-59f5-4a0a-99c6-ae230bb51175">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c3deebc7b364524b98fef879ed25401_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xNi0xLTEtMTA0NTIy_c353e7bd-5514-4923-beff-664ac273de87">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i850f290111644c449e9a3a3812c4622f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMi0xLTEtMTA0NTIy_229f9a90-c41d-4646-a0f1-a20bd4329615">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f0286c60ccf4c62918cb03477641fe6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtNC0xLTEtMTA0NTIy_e2f86984-908d-49b2-bb4f-d6bc16fe73d5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cddc469a4df4ece9423e33e5c08e8de_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtNi0xLTEtMTA0NTIy_95fb31f0-8689-4ec5-b3bb-6fdd0304bd36">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1e75cd345542ebbf1359781e3b4ce3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtOC0xLTEtMTA0NTIy_c80869d1-4a26-4f8d-b02d-abc53dc4dd47">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289d747c6aa447e1b03b39c79c030884_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTAtMS0xLTEwNDUyMg_ed281e2c-ef01-4ded-a1d1-3d943af3793c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774c61105333410bb42045f3a93ac5d4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTItMS0xLTEwNDUyMg_fda54870-f993-4021-84d2-2f814f935b6a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981cb25bb09f433d8815cfd0cac49e61_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTQtMS0xLTEwNDUyMg_764e14cf-351e-4e91-aa4f-91ca0a4ea547">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie612932f7fc7413bb9340d0712dddb5d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTYtMS0xLTEwNDUyMg_8025f18e-22ed-4966-98ca-b6225f3735cb">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520f60d941974d6582ab8ff03d2bb9f6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMi0xLTEtMTA0NTIy_f81b1ee0-254e-435b-9078-931a0fa3d626">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac86cc9d45a445d1b66e5d3b1328b298_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtNC0xLTEtMTA0NTIy_c6fcd4ac-2846-4f32-83e8-1be466d9fb0a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20f6a7498f24890ba6109800b4579f9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtNi0xLTEtMTA0NTIy_e838f406-f043-422c-b6bd-abbcefc13bd0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic364bf5827b344f9b7277fa3059e41b9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtOC0xLTEtMTA0NTIy_5d977a94-4579-4c86-bf3c-62af59a789c6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80f4c1c06954aecbea13eb8c57c84cb_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTAtMS0xLTEwNDUyMg_d4fdb3db-aa0e-4d72-a547-b6141dcb35d9">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f542fe236ba49be97003a22c3952e2f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTItMS0xLTEwNDUyMg_774d7263-b0ab-48e4-a054-5f43f3fdcb2f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b924aff33144adbbdbe4b55024bc966_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTQtMS0xLTEwNDUyMg_22a8413f-887b-4ffa-9008-2751e9ae9b68">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8df5b8207746d79c0457bf4ecf84e4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTYtMS0xLTEwNDUyMg_6180070c-c6fe-42a6-b6a2-6e9f4cff6fb7">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0309aadc6ff4ac2b67d133870ecfc21_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMi0xLTEtMTA0NTIy_0761ec7b-5054-420f-a896-cf0889412d17">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f78bff3afeb44fabb11776d7ffc143b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItNC0xLTEtMTA0NTIy_c620771f-2cfd-4661-95b6-e3e0a4aa2cfa">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad40f3526c94d2a8d401c53ce69ea1a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItNi0xLTEtMTA0NTIy_5d81cbdd-d543-47d1-9b04-586bc4f40169">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7716776c36cb4bd491d74086bfb7ecb2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItOC0xLTEtMTA0NTIy_0e948c73-9965-454b-990a-593b64198d15">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12564811a9e4bdca5202382aefc69f6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTAtMS0xLTEwNDUyMg_34cca6ce-3ea3-4fb0-a671-498d2136479f">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c956ed6342b42718cec14ac863bdb58_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTItMS0xLTEwNDUyMg_dd671c37-9a65-4085-a787-f677050c9dde">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb10d32aec44247a4f5d7cd6e811377_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTQtMS0xLTEwNDUyMg_1f0b8a63-ea90-4051-bc81-3ab0ce3e7e6c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5f964326e14b269641c03739405c1e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTYtMS0xLTEwNDUyMg_469189c3-76a8-41e2-ad65-fee21116ea64">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a3b05ecdb94c10ab42d41aa1405831_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMi0xLTEtMTA0NTIy_ef9d3a40-9fba-441a-b010-e1e7514b8641">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6a13f318f24325a71e2857063f5848_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtNC0xLTEtMTA0NTIy_1e626381-ee8d-4bfa-8f49-0121ade342e1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie82e4d1739634b57a20ede2010592159_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtNi0xLTEtMTA0NTIy_21a7084e-e6a5-4266-b1f3-db0640a31905">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefee3ae93504f46a2d372c49fdf40ab_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtOC0xLTEtMTA0NTIy_54bd0fe9-fe77-494f-b649-f5c9ec24b0ed">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97f28b8981248dbad7137dfc8e3f6db_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTAtMS0xLTEwNDUyMg_bd51ec28-4a56-4c43-b959-007322c0bc04">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a54006651944977a0f2ea299b135a39_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTItMS0xLTEwNDUyMg_9e1b4f7a-897b-45b3-9a39-52d60a10615a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900a3386106549a885dd226281746116_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTQtMS0xLTEwNDUyMg_9555ad2a-267c-4d98-9d08-6d5e46795528">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dbbdd491da34ec79838d8ba4a860828_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTYtMS0xLTEwNDUyMg_6026b5a2-5570-453c-be6b-81193964e9fd">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640cb048ad564d1eb126e98c3f9dd4cb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMi0xLTEtMTA0NTIy_897b10e8-af23-4331-9e4b-5122ccabb001">2,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice89761ab066473ebe252ea4efa20c75_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtNC0xLTEtMTA0NTIy_ba4ffb8f-4e79-4f68-8d44-e164359baf3f">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d27e27d65994e5c99f272ab08bdca75_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtNi0xLTEtMTA0NTIy_23536fa9-15cf-42df-a52a-f9d8d7317fb1">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972d712715ae466db4de275f56044425_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtOC0xLTEtMTA0NTIy_7e25cd8d-a6bc-483f-8342-b7c6104c07e9">3,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92246dae9bf04aeda16066d6e5e604ca_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTAtMS0xLTEwNDUyMg_1464ada2-8502-4aca-83dd-38eab5209e36">2,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic905d65961ca41f2a16684c08c4b1170_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTItMS0xLTEwNDUyMg_6c301e44-8412-4798-8c15-a8bb826618f8">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f3508e4df94ef2aa9af3131d031ebf_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTQtMS0xLTEwNDUyMg_951c091a-13a4-4a52-acd7-12c2bb944d37">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a89c780806d4aaf9d6742d4500a8692_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTYtMS0xLTEwNDUyMg_5e433278-1092-4e0b-86cd-48cd69fabeb1">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9080da0fd2da4f02a87f7d29708792ae_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMi0xLTEtMTE4NjA5_2b769192-f54c-4348-8cf0-26fec5888bb8">801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b77ced81c9d459e8714ab97c49ac8e6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNC0xLTEtMTE4NjA5_317e7e5d-3ead-4841-a34a-e3309e18402f">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ec7cb46bf4485eb4111720cefb6f25_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNi0xLTEtMTE4NjA5_8f8967dd-37b2-48e4-b648-3fa075b2518d">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcfee614954446f890fad6e3acec329_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtOC0xLTEtMTE4NjA5_400f2083-1337-4c27-99df-59c15baad836">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc5bd1f95304695811a90a3fb77aa6c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTAtMS0xLTExODYwOQ_bcc5d86d-f8f0-4238-9317-a0f0051ae055">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e4003abdc8446fb15dd00423d76bfe_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTItMS0xLTExODYwOQ_fe6e7b54-16da-4f30-b4f4-fea7d22773b6">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6ba86f84d04fbbbe732f5893719820_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTQtMS0xLTExODYwOQ_9687e8bc-bfcf-4d1c-937e-421fde7c0035">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a987fb1a2345cf9feca51b56f3002e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTYtMS0xLTExODYwOQ_60622f47-6095-4e9c-9fd6-2b02c3450098">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1151230a7249eba5e92c53b6c99591_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMi0xLTEtMTA0NTIy_55b2e086-3673-45f1-9736-dd9a0c4ea891">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3886fecdb734baca592defec1da8854_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNC0xLTEtMTA0NTIy_faaa9da2-3a68-49d3-95ea-4dc1e03b9b12">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab0e630afcb4839815382487e6d7a71_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNi0xLTEtMTA0NTIy_c1a287c4-ec15-4273-9ff7-9680737420d7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i990036800e314c019d9924b8c48d9a69_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtOC0xLTEtMTA0NTIy_8a6404ac-6ced-4e31-95b3-72336f6b79df">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654b56035ac5429299e0bf0750f7c159_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTAtMS0xLTEwNDUyMg_9645c601-f8aa-41db-8730-3ef5fb9c95ad">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912899de9e384b4991388b77ab326802_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTItMS0xLTEwNDUyMg_7b25b99f-6f1f-4021-9894-362aea3aea29">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a0eb3a98cb45b6a547ce971f34baae_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTQtMS0xLTEwNDUyMg_161182ec-d075-4c12-9264-a9e41123132a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbcc4494362d4aeb9f8d78936bd67dea_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTYtMS0xLTEwNDUyMg_2d525dcd-5e81-4776-8a74-ff1b337ee40e">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fc4821b2594c9bb862fc7dfbd1c7e6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMi0xLTEtMTA0NTIy_b2b97fd5-4a17-4f3a-99f4-59b7a68bf262">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9bd2c916494ddfa644ed66486ffa3c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctNC0xLTEtMTA0NTIy_a5b52cae-3a69-42c6-8df8-b5d41d6be585">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ca5a367cbb4823bbb2ddbaa8ba1531_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctNi0xLTEtMTA0NTIy_322300d0-e2b1-4f14-bfff-6f757119728f">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2191fce5382f493f98627963be2fd34f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctOC0xLTEtMTA0NTIy_f69d8c1b-3dc7-4b61-8ac7-125fed2a648c">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d13d672db4940049677cdc0bedae177_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTAtMS0xLTEwNDUyMg_37bc8827-1fec-43a3-94ef-be5b17ed68b0">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5736172bd8c74fa9b0b84ecba12b6da4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTItMS0xLTEwNDUyMg_e4388a7d-724e-4578-81e1-2a60bde8be09">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a52bdb734592ad37964a3ef65749_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTQtMS0xLTEwNDUyMg_aaee60aa-c5cf-469c-83a7-f38ccbc1f27c">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ac5763bfd14785880a550fa2c4b4a7_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTYtMS0xLTEwNDUyMg_fcc1ee76-e05e-4360-9db7-53991c6255ba">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362e3866a26a48cd8450a9aed1b9c71a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMi0xLTEtMTA0NTIy_ad1df343-4c04-498b-bf24-cc296258b682">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b64a5280a334b8d87dd853cc7b50fb2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtNC0xLTEtMTA0NTIy_2b3c0894-b18d-479d-a18a-694fa8b9d64e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1247c9718f48619c3461a53ade8241_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtNi0xLTEtMTA0NTIy_30d19e47-1efe-4b71-b634-00b217d4f796">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38923dc977ec4c608fd74bd8d1002b89_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtOC0xLTEtMTA0NTIy_d230fc59-b270-42c4-83d5-02cbbe3799a8">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce473a465f24a4587c7b09d8571a2e7_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTAtMS0xLTEwNDUyMg_53619a59-b718-4a49-b2d7-554fc4846b09">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd98d98b9029490083e145d555397c64_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTItMS0xLTEwNDUyMg_267d07c6-acba-44cc-ae8c-123a2bca7091">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49d9927d07794d42b9acd485d0be4ccc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTQtMS0xLTEwNDUyMg_70db9f1d-7482-4ab3-97b4-3ca6edf15f85">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28cc147626d342f18fa203f1fffaeda0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTYtMS0xLTEwNDUyMg_793d24fa-f1c9-412b-b55c-a7103759e5bb">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dd1b2780dc41fb9de50648b1af8b36_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMi0xLTEtMTA0NTIy_7c4fc935-c5ec-4b94-aa9e-7d17b0fc8998">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b0273edd1d40f39c13f63cfaa3039f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktNC0xLTEtMTA0NTIy_592bbb2e-bc24-48bb-9895-3907c4b4c31a">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib343c66d342c48b188ec538e601a802f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktNi0xLTEtMTA0NTIy_062e1c8f-b479-49bd-bd77-289e9a84543d">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331f92fda21545a788d654fdc98d17fe_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktOC0xLTEtMTA0NTIy_10e30a90-1294-4a60-b78f-553e3c6707a9">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id370a2241bdc4d15986cd6b2356a1be4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTAtMS0xLTEwNDUyMg_7483f75a-1f6d-4dee-ad54-de12947713ce">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24a17bd8d6a14480b89ee581a835b1a4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTItMS0xLTEwNDUyMg_01b54fb7-82d1-4e04-90e2-c4cb37dcc97a">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5e3587978b4fad9196cbbc06ce3e95_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTQtMS0xLTEwNDUyMg_6c894881-967c-4a29-ad61-bb31d55d6d56">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7bc0ebe5e34348a81d50bcaaf131cc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTYtMS0xLTEwNDUyMg_cdf41d97-f84c-4fa5-9aed-5333f01876cd">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ef9863b06448f19486cc46a20126f6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMi0xLTEtMTA0NTIy_8b97c10c-5fe1-4d3f-8e49-30db6586ec6e">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe7dfedae9e4ea69012d15a904e0bed_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtNC0xLTEtMTA0NTIy_8648669b-5a38-478b-bfcb-a12ca12493e8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc8c47023174a3ca739f65aee4d80be_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtNi0xLTEtMTA0NTIy_28936303-8261-4b1f-8939-5d364f2494c5">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc10b00ada44fdc804e51838f1acfc3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtOC0xLTEtMTA0NTIy_e8e54fb3-026b-41b0-8511-19ac968c2f7b">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ffa5ec1dd4840c3b41240ec44fb1a8d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTAtMS0xLTEwNDUyMg_586aefb9-10fe-4de0-b394-8af1e963c0b5">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3c2ed8de2c45ed8ea22f65a1300661_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTItMS0xLTEwNDUyMg_900ef2f2-5d77-4f32-b42b-2611d4fc9cd6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b98d9083b942118db200dec1a903da_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTQtMS0xLTEwNDUyMg_ebee309e-e00b-4792-8670-1f1d0cf6a0bd">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf0b2687f723400eb3f2b51560d5627e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTYtMS0xLTEwNDUyMg_7f9af099-49ee-4187-9c94-3c10e431c15f">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bb17eb8edf4095affa55b5c94b7511_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMi0xLTEtMTA0NTIy_cc14e041-9891-49ad-94c4-e38bbc4f1183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e82886013e34e8cb5b040660f8b2134_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItNC0xLTEtMTA0NTIy_a3ea7e2e-56eb-49bc-824b-42e030d1b28f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62e1f4cdbc94d6496e8d6e303892aea_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItNi0xLTEtMTA0NTIy_36644848-913c-4e66-8cf3-d068bb4fe796">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3a26232e49487cb08e72e73e05cd8f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItOC0xLTEtMTA0NTIy_3e8c0a94-7752-4700-9d07-b51283857725">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601e9f250eff46568a11f08fe9496e7f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTAtMS0xLTEwNDUyMg_972fc4d7-d91d-42e4-bafa-8e581c40704a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f013c8b8554acdb3ac0e4cb83b0826_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTItMS0xLTEwNDUyMg_892fe2a8-69c6-4699-b1c6-f866bdb7a29e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ade0cdccab94dbcad52ed0019f0c921_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTQtMS0xLTEwNDUyMg_83492df6-882f-4d93-8c7f-849a59012e77">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae0e683ad6b40c2a698b3d311bc01d7_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTYtMS0xLTEwNDUyMg_629a8e54-6a4f-49a7-a70c-ab497a9c79bc">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88dee8c0fd39453297ea8ac9fead6e30_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMi0xLTEtMTA0NTIy_094a5e4a-3e57-4d37-a4b8-778a67aac255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ab69156b914bd9a8d4a4bf92a01786_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtNC0xLTEtMTA0NTIy_de821fc5-d51b-4875-a41f-aaff811e8d99">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac685a4449e4a41827017a39c195f98_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtNi0xLTEtMTA0NTIy_276e6e73-851a-4153-9a86-5632b4d9eb12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9317885eae4f5e974a6c62a56a7eca_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtOC0xLTEtMTA0NTIy_c4c30d79-37f3-453e-96d3-b96e5c9236b4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9e05a885fd437c97e145bf9ebb7f92_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTAtMS0xLTEwNDUyMg_208a3e3b-89f0-4b83-bb2b-a9215ac32d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8982d5cbae8145d4a736780033c94930_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTItMS0xLTEwNDUyMg_91983b3f-4946-4e12-9a92-e5f0393562c3">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258f51e659e04edd969980eb593baee3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTQtMS0xLTEwNDUyMg_38ffc887-9b0c-4edf-b03d-a8751d0588dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab12b495137c43e6886d664932ca0d4e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTYtMS0xLTEwNDUyMg_bc3ada64-f828-4b8e-946b-367f6ccce55e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6427ea1ce218423483ed2d165863e48f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMi0xLTEtMTA0NTIy_57b0ea39-ccde-4d1f-a59a-e02217eb34db">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c48e2dcd6644766923dc0cb2bf31d07_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtNC0xLTEtMTA0NTIy_3821b083-d4c9-400f-9afb-4ae36e5c6fa9">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ce309faae5419f8ed78774354b4a97_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtNi0xLTEtMTA0NTIy_975b968f-1a03-4741-93ff-0ba00a2258e5">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38350f5e76ed41d99e350a0226a0b299_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtOC0xLTEtMTA0NTIy_92e1fdf4-6436-433d-8218-bf2f1e2127b1">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3578cd64764c43b28d8596a841916105_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTAtMS0xLTEwNDUyMg_0c74087e-e562-456b-a9d2-83df9174cc38">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b523e88394b42e49bca13934b5204c0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTItMS0xLTEwNDUyMg_9d879529-01ba-493c-8208-f779e00b7cc0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b50daaafcf4acdb978f2b3cbc02a69_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTQtMS0xLTEwNDUyMg_489f8a67-9f4f-4e84-a185-835651053264">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4df11eb0e9c46829ee856f8acd0ac01_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTYtMS0xLTEwNDUyMg_b2f572f8-eaeb-4341-b174-0297cc0d095d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cell therapy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b9973fb9aa4626ae5ac04a936c01e4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMi0xLTEtMTA0NTIy_2aeb7a58-a21b-402e-96bd-9e2a79896c6d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a95859331e4ac19317036e0daf101a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktNC0xLTEtMTA0NTIy_5d178b4d-97da-4e24-ad5c-fa6a9934d512">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f5a7f19d504c2ba7ff905f67f4d127_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktNi0xLTEtMTA0NTIy_1250c031-441f-407b-b523-ae41311f1ca3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c624c206e4400e9df42232adf50e0d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktOC0xLTEtMTA0NTIy_85b90de9-46ba-489a-bdee-2bff084d91b3">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1322e9bf1b8348f6aa69afe538a30158_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTAtMS0xLTEwNDUyMg_2fe79d6c-1e3c-4613-b133-36463cad7236">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife80ece44c874be5a32808230e9cd4aa_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTItMS0xLTEwNDUyMg_23655d1b-c642-4522-9f4f-e213ef38b25d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if82cf194379246a1859100c8bba11cca_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTQtMS0xLTEwNDUyMg_9c16c8a3-308a-4451-9f1a-86aea1e4c784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6781ab9027f460c9cf7dcef1a2581ab_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTYtMS0xLTEwNDUyMg_e24ba681-2ecd-49b0-81f6-7afc41ecfa12">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5f0d1cad9a4d5c88b552349bd0e426_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMi0xLTEtMTA0NTIy_1cf9dc55-489f-40cf-ab2c-3007ca8627eb">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1092026c503d4c2caf06ab450b1a56e6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtNC0xLTEtMTA0NTIy_21f1110c-4c38-4f19-919e-f0db2dcfeda4">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9cb25ede7b47f58962912789bb85f0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtNi0xLTEtMTA0NTIy_12f83c5f-97f7-448a-be94-58c3d4482c0d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f208e609ef24694949d9d18a38323a4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtOC0xLTEtMTA0NTIy_5e517fee-7f16-4337-97b4-c70b636d71e5">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6282aee3fc5402ba404682fb65354b3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTAtMS0xLTEwNDUyMg_44716598-b840-4f87-923b-e4d970b15981">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39dd6b3aa4eb4ccc9b8976c09c4c815c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTItMS0xLTEwNDUyMg_1024249c-6d90-4852-8c43-feedb1ce2263">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1077536f948c4d599ca3de2b9fa0caf0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTQtMS0xLTEwNDUyMg_ec9205df-64c3-4969-a1a9-27f7e9c1ba96">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591623e8a2444a6294da53ce3e3564dd_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTYtMS0xLTEwNDUyMg_6aa711f7-e2de-4ae2-b20f-1b17e344751f">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cell therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7a0afec35c4ec89e02da19e66297a3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMi0xLTEtMTA0NTIy_520afb66-0914-4765-acce-933dfc909d3d">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e1f408f244494e83312207a23684ae_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtNC0xLTEtMTA0NTIy_4e9540e7-cbed-40f3-a28d-c164598e979c">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id370f64f9232406da268e72edab2bb89_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtNi0xLTEtMTA0NTIy_b01c9049-00c6-4008-931a-28e88e31c8a8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a1637a55bc47ce876af3c9b975c36b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtOC0xLTEtMTA0NTIy_a8529be9-b63d-41cd-9f15-b14fad41d368">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004d4d1e19524166b98a5650d0a3d5b0_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTAtMS0xLTEwNDUyMg_c9bb368c-986d-4ca0-b487-c1d0608ca0c2">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4868996536f41c395fd9eb7bf456345_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTItMS0xLTEwNDUyMg_237153d6-a18d-4152-9d1b-4cce5ac0a406">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9510dc0a1cb48a09b7cf7cee5127926_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTQtMS0xLTEwNDUyMg_5ab4d3d9-4164-4fca-8246-51c0a307e5b0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f21e46dfd54c5088e33fe80e268c5e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTYtMS0xLTEwNDUyMg_af428052-df34-45f8-a384-802a70836401">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506b80edb1094a058227180fe89d36be_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMi0xLTEtMTA0NTIy_48681040-e565-47bd-b845-101302898360">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2da0fa42e9465fa82e367afd29d07d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtNC0xLTEtMTA0NTIy_30b06da0-e366-419d-9d8d-ed680915300e">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d45fdbebfa497793e9c785c45cd171_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtNi0xLTEtMTA0NTIy_a58b6118-5edd-4ccf-af2e-e7243fb0b43b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd6c25925024d0ca5e62c2eb0d94599_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtOC0xLTEtMTA0NTIy_814dbc2f-f37e-4bcc-b012-734e602bf819">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie575076324b442bb96747058f585fc96_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTAtMS0xLTEwNDUyMg_2de44423-7a0a-4510-a9cf-4104c3a91c31">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab947b2302b41098d510e78eec884f9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTItMS0xLTEwNDUyMg_e033237b-e7de-4872-9bf8-d67264f24d4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e1c13afe4c4b36b0e56bcf32399b38_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTQtMS0xLTEwNDUyMg_f25e8f10-9afc-4f1b-9c19-a0f7c18058f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e85eb47143437996c24d62ee7a5072_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTYtMS0xLTEwNDUyMg_5b0980bb-27be-418c-bc2b-dba016ab7262">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e4818a6e7548a7bbf17c683d46095a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMi0xLTEtMTA0NTIy_eb22d7df-4258-40e0-9840-4efc0b92c1d1">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f6ecb369e549f69bab7f9d26c72c13_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtNC0xLTEtMTA0NTIy_d61d8521-a620-4630-ab6e-2656ba22a7cb">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc546c6f7ee04e13856084c40921bee6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtNi0xLTEtMTA0NTIy_bb74e02c-c399-4216-8fba-0505e24318f7">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc670dab94b43efac0330f320d308ab_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtOC0xLTEtMTA0NTIy_36d396ff-b4ff-4ebe-8a07-51fbb6704d25">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d67453bf2b4b61b493a79e64689edf_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTAtMS0xLTEwNDUyMg_68c68a09-3aa8-43b8-a4b7-9527bac183ea">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedf0dddfad54c6d83baf2098d0cce00_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTItMS0xLTEwNDUyMg_4be2de65-03aa-43aa-8ed2-4b99bb6eeb69">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636b58243bec406486f70783ac586b07_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTQtMS0xLTEwNDUyMg_a5583074-4859-4dab-ae08-9d7794ad5caf">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceea7510047144d48d7b55394af029e5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTYtMS0xLTEwNDUyMg_db4e1ea2-a887-48ba-901e-06f9d5de35c3">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fee66d032984dd9a95ce2b80bdc73e4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMi0xLTEtMTA0NTIy_c605960c-ce2f-456f-8f3d-7e20c7767801">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab28717012a4316be156607025ebbee_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctNC0xLTEtMTA0NTIy_d5010182-0c96-4766-af44-28cdf35d2540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1e16a6586047f7aa6d8cdf0cc52aee_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctNi0xLTEtMTA0NTIy_7d78f743-fab8-43b5-97c5-9be1f114b42b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707cbcb9a5dd45609f9783347b2969a7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctOC0xLTEtMTA0NTIy_aef4f39b-3ccc-4769-bc52-94f2c8441137">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd56e62b9064dbfa19723ea33df5f2d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTAtMS0xLTEwNDUyMg_335cfbe5-dc7d-4395-b25a-380f26cd4f2a">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28abe53df7b94be6bd5527b6651854c4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTItMS0xLTEwNDUyMg_250d349e-303b-41ac-8323-8a0e1f7bfe19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883d4917ebfd4efa968bd072df8d5d90_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTQtMS0xLTEwNDUyMg_950a563e-68c5-4708-98fd-c4558fc80644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611a9bb6162246d68e854f3e608a8ba8_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTYtMS0xLTEwNDUyMg_ec5fe45b-85c6-476c-b912-0af17cbed9a9">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f69128a6d940b0969c29eb905e9e01_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMi0xLTEtMTA0NTIy_956a460e-fb65-4b0f-93ce-3d0075e3de70">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72629c36c3ac4b5c90339697d9b5841c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktNC0xLTEtMTA0NTIy_40e4ab87-76df-4579-a989-48572688e0f3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aab0d0a8a054b2191999850619d3215_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktNi0xLTEtMTA0NTIy_cbaaa799-ee24-4129-bb69-173a4c3b74e2">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f81b41c6ab4c1a8172650fc81804cb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktOC0xLTEtMTA0NTIy_d1b25bc5-c6be-4986-b300-3054e0be03b5">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b35be1f6524162a052f75f2c305f1d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTAtMS0xLTEwNDUyMg_02a37201-082e-4124-85ce-37f2649b1304">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9470361de7e54728a05b1c0b65a767b4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTItMS0xLTEwNDUyMg_1d9376fc-86a4-4098-86b5-61c4febf2ec3">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb419930edcc478c9416d2a9cb5ddb57_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTQtMS0xLTEwNDUyMg_1c97d320-a0f3-495f-a034-82217d411756">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36489d020f7443788b3cbd0ccfb9d0f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTYtMS0xLTEwNDUyMg_1d004b20-46cb-45e1-a377-ebf526b02ced">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c4299b47fa4635908637e78b2e1670_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMi0xLTEtMTA0NTIy_276ae63a-c49c-45ed-9738-57673f0795f4">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e9c418833d40b2b818caa3cd26b3b4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtNC0xLTEtMTA0NTIy_f010686a-a839-411a-9979-58c323acb347">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c739ead4a5e450393f03a09963c462d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtNi0xLTEtMTA0NTIy_073b8266-80cd-431d-bcd0-85b215a72413">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ca722e30584518aa14b0e7bf67600b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtOC0xLTEtMTA0NTIy_77438d70-1fb6-4960-9ac9-330f01b48e04">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd10541ce9cb4f0baa1c775e04fcff49_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTAtMS0xLTEwNDUyMg_abbfa0c9-5faf-4af1-893d-bac3415b720e">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842cc6151e23445faaa596d0f12d6d10_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTItMS0xLTEwNDUyMg_2498db20-554e-47bf-9152-68d4935514fe">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d0c4f130c9455faf16cf800852d2a2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTQtMS0xLTEwNDUyMg_b77c3d21-1c82-4204-874c-12cbfa17ba17">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133f797d043a461884b3be51d030f6bd_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTYtMS0xLTEwNDUyMg_a293ecf4-891f-4a7a-9601-88900887bcf6">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b794129571f4c3d90efb49ef01d3118_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMi0xLTEtMTA0NTIy_70e8457b-2b39-4557-9c50-7f68ca4142fa">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82d4742d49c541aaaa995cdc86772e9d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtNC0xLTEtMTA0NTIy_81c6c79b-083a-427d-b903-ea10c650fddc">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6352cfc350f64fb58df0dbdcb47f284a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtNi0xLTEtMTA0NTIy_d998fe15-967f-40b1-b0e3-b126c3a2062a">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if150cff9011c4cb8865c7d010dea19b6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtOC0xLTEtMTA0NTIy_31e271b0-a00c-44b5-bcb9-3f7d8c8461da">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac215de11e334702b29490e622de1ee9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTAtMS0xLTEwNDUyMg_0a764d9c-bd11-4cbc-95cf-0bb32d0e5711">4,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee61ad8ad9b4ceeafdbe187f3ac6b18_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTItMS0xLTEwNDUyMg_57aad22b-f4b8-48f4-9003-3262e9d3dd0e">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9db6c1894c24e5c940af32de705648b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTQtMS0xLTEwNDUyMg_7c377f5f-0382-4d0c-913a-90e3d33e174a">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad8a561a83946e2be71c0773364df03_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTYtMS0xLTEwNDUyMg_ad3afcf4-4f6b-4fa4-bbc8-b945af52a9a1">6,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f41643b44694636b95fbedee07cb74a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMi0xLTEtMTA0NTIy_ecb1baa8-6f79-46d6-b8df-bba81ef2c918">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b4c37dbec149e580bc98a08db8a779_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItNC0xLTEtMTA0NTIy_4f08d92c-3034-4293-a803-6b793aaa595e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562545855775425380ef8229edbcd63c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItNi0xLTEtMTA0NTIy_696ce9dc-554b-4351-a849-9f14ecfee51a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6adca2cb2df45159579306959cd9182_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItOC0xLTEtMTA0NTIy_146ba18d-356f-4418-86f3-7acce6e15be3">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie425b655a72c4978a3a152d215d89082_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTAtMS0xLTEwNDUyMg_a2e7e4a3-74f9-4b42-a3c9-16e889ef7e30">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e961357d334fe1868904f1cf61fe7f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTItMS0xLTEwNDUyMg_42dbb1d0-1238-4a13-8186-82fa9472ff2f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f038b7cb5048789472b556cec62a76_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTQtMS0xLTEwNDUyMg_e3137f8e-44ab-4440-b610-4a1f053bb968">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f491d481954bfb91bb63808792a107_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTYtMS0xLTEwNDUyMg_4164a112-8648-408f-b635-59f5a9cc26a2">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450e90b0899c413f9adda90b2983c33f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMi0xLTEtMTA0NTIy_27538656-cfdb-44cf-b6f1-30f15107bcaf">4,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e918b0999104da8bcafade720bc9b31_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtNC0xLTEtMTA0NTIy_4fdb3889-789d-4cea-9089-794273f1a245">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3686af1f019f450eb7208b0baaafb092_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtNi0xLTEtMTA0NTIy_c932841c-21ad-4446-8b47-8a0c7fc16d39">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtOC0xLTEtMTA0NTIy_b990cd25-8f13-42c8-bade-128173cc456d">6,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574f697fada244ed8d5d02623914c1e9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTAtMS0xLTEwNDUyMg_632099fb-a12e-4453-95d9-c9a0facdec94">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0734cb68049494fafe29592fc4b53af_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTItMS0xLTEwNDUyMg_c47b289c-5604-4f18-a063-5661ed8f813e">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e181e2c5404c43aaf1a8e699cb5ecc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTQtMS0xLTEwNDUyMg_5039f048-89ad-4b2e-af72-16c3a106556e">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTYtMS0xLTEwNDUyMg_a98077ae-6d73-471c-9457-395abdd4da19">6,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Atripla, Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i8770343034e74d38a710a0b6550ceccd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues from Major Customers</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjU0NA_34f428a2-294e-4e8f-8c50-d0b9b6d20d63" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176dd2b5900a430a8769d523c75624e5_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfMy0yLTEtMS0xMDQ1MjI_7c6b7085-c4ed-4afe-a94f-52934fe68bd8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95bedcc32b2b473584af9e33a7e1d845_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfMy00LTEtMS0xMDQ1MjI_ced3f01f-a6ed-4913-9582-1cfa3f67f093">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bb49adc0c914214b0cf681200d4116f_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNC0yLTEtMS0xMDQ1MjI_318d6acf-eacd-44a4-b551-9817a6c42625">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d9ccec8490648f89cb63618723a451e_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNC00LTEtMS0xMDQ1MjI_3cc4c446-dcdd-4965-bd21-d58204c1c7a8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i328a5479a2be4ecabc38b95ddd05d567_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNS0yLTEtMS0xMDQ1MjI_e35bcd78-41ed-4aca-95df-b5058d84b98a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4739475a7bf45baa7a16fc49ba98df2_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNS00LTEtMS0xMDQ1MjI_85fbab75-12f6-49e6-a646-2ac7fac14dc6">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods </span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfOTM0NTg0ODg0MzIzNw_b77b7b76-b1d2-4b28-a519-79e59906b1bb" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen and royalties for licenses of intellectual property</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMS0yLTEtMS0xMzIyMzA_9bc9391b-eb09-4077-92b5-69e07be9feba">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMS00LTEtMS0xMzIyMzA_4a0d01a1-bc2f-4862-ab4b-bdd80a0b0770">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMi0yLTEtMS0xMzIyMzA_502f9a4a-d3fa-4420-bf30-45c249135ff1">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMi00LTEtMS0xMzIyMzA_23a45783-d8d1-406c-800a-d619b0ab75cf">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMTk5Nw_db95270b-b93c-487e-979e-046e8f5600d3">160</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjAwNA_9137152f-52b7-4e85-9224-f0ff9b6476dd">174</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfNTQ5NzU1ODE0NDkzNA_47dd9695-03fc-45e1-9333-7d73ced1c5a1">117</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfNTQ5NzU1ODE0NTAwNA_f74cdc79-9f42-4fc9-ab3f-afd14cd1c84e">79</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div id="ib054ed57a41746f6adeff83e9a6e8cad_40"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNzg1Mg_1f3def52-7658-4d01-b53f-69256cbf197f" continuedAt="ibdbc55757ece4729a3d2af88961ecb8f" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ibdbc55757ece4729a3d2af88961ecb8f" continuedAt="ia3e211ed18a846ad864d048042123b96"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfOTM0NTg0ODg2NDczNw_4f4dad93-6e98-4ec5-83a5-30fcd029bbfa" continuedAt="i040d93facc294d43a303fccf37323186" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia3e211ed18a846ad864d048042123b96" continuedAt="iaa09da3c0f0e4807832644269fd4aec2"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNzg2Ng_193ee416-3d8a-4efa-bb34-b4b704e9341d" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76465e7067f243bca6ad8e5ab38fa633_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0yLTEtMS0xMDQ1MjI_6afa7e92-8261-42e4-87fc-a99288bc1473">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140c790345dd4179834f4c8b07bfb8b8_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC00LTEtMS0xMDQ1MjI_3b4df6ce-b7fa-4bb3-8a1d-707172d9f32d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ce8aecccf3444880c9cbaeee334a73_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC02LTEtMS0xMDQ1MjI_102e46fe-c2cd-4d50-8914-7b05b36416d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8429eedb67b4e29966dd05758722f62_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC04LTEtMS0xMDQ1MjI_22853ae3-2032-4ee5-8600-09e59ad742ba">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f66a5967db44f1b832d3882c44a50ee_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xMC0xLTEtMTA0NTIy_52eba0db-6e78-47e8-9e8c-fbebd7cacc7d">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74725ac875c8489088c9e3ce59925700_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xMi0xLTEtMTA0NTIy_0ac9fed2-69cc-45db-ac46-52ab79b285ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f3a5ba27de450689d4df428849595e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xNC0xLTEtMTA0NTIy_1c0cc295-37c6-4768-8d13-fc8fbf1a9fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ef3595a00743e5a7af8c76c459e14b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xNi0xLTEtMTA0NTIy_570c39fa-232b-4360-a786-1c068c6265af">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01ae90f5f764dcda9f3b84fb3c0c54b_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0yLTEtMS0xMDQ1MjI_d3cffdf5-dced-4813-a80e-da854a4c2afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88cec99f19b4e1aba4ef2f6127972fe_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS00LTEtMS0xMDQ1MjI_04af66b2-040c-47ba-82ae-a588b0637643">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d68f81dce946ce9958065f41c11dd2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS02LTEtMS0xMDQ1MjI_671c7c47-b038-4c04-8e4f-33568623e9a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200e82b6162646ee8c54e3be1e9b651b_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS04LTEtMS0xMDQ1MjI_a0125fe0-82b4-4f04-925b-7c20b18367b3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86049893a634ee3bb28b8e42ec50e44_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xMC0xLTEtMTA0NTIy_f0a57e9a-b1b7-4f54-a543-2be4f5827da1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862defdf94944941b57660ed32b562fc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xMi0xLTEtMTA0NTIy_74d33b3a-54df-4167-bdf6-502736a6a689">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a7c5c399874ea6acc5ea1cb2da6ec1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xNC0xLTEtMTA0NTIy_2c058a8f-642c-484e-b9f1-6d69610193b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ebbebfdaf14b6faa9cf2fe95f1a416_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xNi0xLTEtMTA0NTIy_641b022b-1e92-4e82-aca3-772b121749fa">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c3072371fb40e1a27e1c3eedd45a42_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0yLTEtMS0xMDQ1MjI_a0cd7045-e498-40ed-a314-bccef88f4185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5096915ac2409d8fc7cf00977aa468_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi00LTEtMS0xMDQ1MjI_fa7a00f4-0b10-42b7-8691-a8cef5bb775d">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e40aa5ee08404a8b9fba38e9c1d51f_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi02LTEtMS0xMDQ1MjI_ad6b78d1-604b-4cd5-b789-5c9934397e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d00e372db14beba5926893075d82e6_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi04LTEtMS0xMDQ1MjI_fa2a92b0-33d1-4c5e-89eb-87c49d9a868e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057d3b67bbe0417c9f5751710eecc36e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xMC0xLTEtMTA0NTIy_9ef018df-3677-4a68-a98c-edae7163b71e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b8f69f452145d684659547efc6183b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xMi0xLTEtMTA0NTIy_ce7b6913-8843-4656-b015-f04d1e4cda48">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf9472d8837472bb72056071e3bcc2b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xNC0xLTEtMTA0NTIy_e1c873c4-6733-47ed-b0cf-129bdf523015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a947129bd0b4128a5b74a946315b11d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xNi0xLTEtMTA0NTIy_6c747dd6-ff45-415d-b7db-fc8ad4818ce2">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb035999fbde4492a61824d97546fcf6_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0yLTEtMS0xMDQ1MjI_11ac28ed-10b7-45cb-8fdc-43b8e4c336b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e163c502c3149529b2710b48e018b35_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy00LTEtMS0xMDQ1MjI_c517f0f7-4f77-4e13-9915-d8eb940e4615">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a70f62d258b4e2a84bcf2d184731151_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy02LTEtMS0xMDQ1MjI_12e3475b-7882-449f-a944-9a8403e85c0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021f337b4cdf48d7921f51bc2532b923_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy04LTEtMS0xMDQ1MjI_eef92ec1-5875-45a6-89c2-11742e80a7a2">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6bc8a9e6e2c4acd97a125ed75216ff4_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xMC0xLTEtMTA0NTIy_1876567e-94c2-488c-81f9-e28fb21433b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bc95c69093435488202bb8c647ad08_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xMi0xLTEtMTA0NTIy_9e8e60ab-761d-4176-831e-b74c873c840d">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided8687dc3744e439646e8257fdd793f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xNC0xLTEtMTA0NTIy_e874f288-d217-4d7a-ad1f-5a23a380f9c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5c5562a7eb4824ac24cfd6ad279dd2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xNi0xLTEtMTA0NTIy_96c41785-143e-4ec8-a247-4c741d8961c9">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c103262dfb4e5284221d8be36cba80_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0yLTEtMS0xMDQ1MjI_813de5b0-cf11-45ef-9be5-1855b797523d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39db5b06f794fb18a7032c5fc0bc7ad_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC00LTEtMS0xMDQ1MjI_7b7b36d9-5c9b-4693-a64c-3fe9efef89de">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270271b7414b4aee9f1a3da9ce2b7382_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC02LTEtMS0xMDQ1MjI_fd4ddab3-656a-4da6-900f-4581496c1e20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b2f24271294a2eb663d0975ebee946_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC04LTEtMS0xMDQ1MjI_e7b122ff-42d6-42f8-826e-8e71bb250d28">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0d52cd14ad4c7580e4dec70cc96976_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xMC0xLTEtMTA0NTIy_04ed836d-a2f8-472e-bdc7-e96c45ce73e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ccd9e592044f67803b6e2b75ca4260_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xMi0xLTEtMTA0NTIy_750bd55a-9e72-474d-8be3-f9d3ac4b305f">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efd8fc300e2405d8b1f4a654504ec05_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xNC0xLTEtMTA0NTIy_2dca1958-5b75-4ebc-8486-e901cb04910c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae51e28be204725a4f236b9b15f9524_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xNi0xLTEtMTA0NTIy_ab5c78bc-b5de-49b5-8e9b-0017c44037aa">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65cb7a08d6804ff499cfb7252fb8d9fe_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0yLTEtMS0xMDQ1MjI_bd3d5f92-a2a6-4b3d-bbc9-49184a63e305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ccd377ef1345a6926dc2a8fa826850_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS00LTEtMS0xMDQ1MjI_19e72150-6e76-4d5c-bc71-d422b4e1a230">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205b417c4c654633a4bbb6e38d915d6a_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS02LTEtMS0xMDQ1MjI_153676c3-072d-47a4-aec8-90a726493b21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6351d7d85d4ec18acf7c5279c0884a_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS04LTEtMS0xMDQ1MjI_21524f6c-2576-40e9-bff7-ab4798f66051">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9028ea70334edabc968f604261d6af_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xMC0xLTEtMTA0NTIy_425e30ba-6735-477f-8fff-4e23b33ea336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e3897facac41f1a56e386be016d76c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xMi0xLTEtMTA0NTIy_0f1ebd85-0bae-45b6-98aa-90ac904d7104">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f063731fee4046908c3a1a1e0053e1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xNC0xLTEtMTA0NTIy_e0ea33b8-faa4-4b98-b342-b28f7140341b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3f51c3344b4ed2b2fab26b0aa77412_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xNi0xLTEtMTA0NTIy_8f5b40d4-4fe2-422d-8009-1e09417b5e53">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99305aacdd484354bade2301930b1542_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMi0xLTEtMTA0NTIy_ff99d8f1-3119-4d63-be44-b966e210f225">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857c66ec002c4aa9adc11ff5a2424048_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtNC0xLTEtMTA0NTIy_597d294f-ce40-4579-905a-75f8c070af2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e34a0b5b1545cda6d7fa644e9297c0_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtNi0xLTEtMTA0NTIy_0da6fefb-2e4a-4e53-a33d-eaf94d9ce6b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2525c2cad7949b99b59099149545ad3_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtOC0xLTEtMTA0NTIy_f862c001-e1a3-40a5-9966-c1ed35f88daf">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb98e1a8d414c63a4f91b8642e4d776_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTAtMS0xLTEwNDUyMg_9de527b5-1203-4990-bba3-7e224ae83b58">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4c6d7874ba4f5fa0cd030ee16e21e1_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTItMS0xLTEwNDUyMg_37ca43f2-8790-4cea-bc1d-0763cce37b36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib298944c5a5b499fbefa89414cfbc34f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTQtMS0xLTEwNDUyMg_9715c5fa-3203-4661-9a89-d0630d37ca57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f568032fe6c4908a1cc54d8e025aeaa_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTYtMS0xLTEwNDUyMg_01cfa4b5-1a16-4cec-a691-1b8354966912">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b04d9ed9c25401c862faf9f0dfe47e0_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMi0xLTEtMTA0NTIy_05b4d098-dac8-430a-955c-216750d5a025">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14683cfbcb854f06a1133e77aa8126c6_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItNC0xLTEtMTA0NTIy_2adc4a39-0627-47d0-9afb-5525a9cb5b82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf1e7edcd4c402a93bfc7b9231c5eda_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItNi0xLTEtMTA0NTIy_a69fd48f-0d4b-43d7-a490-d5b09023d827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if272f16215814e408fee0ea6c0c68918_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItOC0xLTEtMTA0NTIy_8b2a72a8-ecd1-4b81-9e9f-62e599e1e662">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf49983739c4f4a92b0acd7196c9d45_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTAtMS0xLTEwNDUyMg_98890c10-0e42-4a67-8626-30ba5b2edcbb">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5214efc2a7ec4769aefb4a504c5a9fa7_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTItMS0xLTEwNDUyMg_3bf2801d-0ea9-4ef1-8ee3-36861ebef94a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c97fddb35a4c2fbd8c78085e1dd095_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTQtMS0xLTEwNDUyMg_c82672ca-1120-4f49-afda-8867d2efec69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84f70f7509f4f20b5f383de8dfd0a74_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTYtMS0xLTEwNDUyMg_e569df50-bcf9-4a30-a852-1e52d2b1d403">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3a5f1c0fd04bc09a8d036709d8b1f9_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMi0xLTEtMTEzOTYz_207b40c1-d6a7-4d2f-a0fb-513b04c7ca09">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b37e4f1d2046feaafd8f5615f12122_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNC0xLTEtMTEzOTYz_d7b5f1be-cf63-4cf6-843d-9bf3cdb40493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a71d4ce57724fd3ac83a73b7bbef78c_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNi0xLTEtMTEzOTYz_3eacc498-b064-40ef-a200-4936038ec747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50020f5f6954fe0a1e6658494e5a775_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtOC0xLTEtMTEzOTYz_cab68d2f-39f3-4a85-a018-474eaa9ad9ff">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a5f1893f3547fa829f8586420e43d2_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTAtMS0xLTExMzk2Mw_8e0b4707-7402-44d1-8b80-6cfe8381d87b">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7331130ff6d8406cb228958b17149855_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTItMS0xLTExMzk2Mw_62e5fbe8-cf24-43ec-ad0b-dae6158ea1d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1008a176c6de4b40a6a73b757acc7f70_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTQtMS0xLTExMzk2Mw_82df13b6-ccb3-424c-bca1-a3cec317e3b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabf4e0443f74462a97365b827ffa008_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTYtMS0xLTExMzk2Mw_4b9b17bb-2e82-4fcf-8d9c-4f2f6a921bc5">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358f4a3297e542349a9a568ed3b11df3_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMi0xLTEtMTA0NTIy_6dcd0032-d794-4418-9c42-8c68e76a5e34">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id569202dda104d39a7a750670b0d84bb_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNC0xLTEtMTA0NTIy_3a81f245-84a6-49b5-8397-3f8a007eba09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d750d13d4f649cab754bb9764317fb5_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNi0xLTEtMTA0NTIy_30fd8aa2-a6c0-415a-9c38-d2c479fd6bae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf1acc9c421458f93a3f08a21c062ba_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtOC0xLTEtMTA0NTIy_d7aa1f80-c0d5-497b-ad62-0c6ff3a6d193">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d6618cd7c4444e8afb57f3ae24ade4_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTAtMS0xLTEwNDUyMg_b32f7c1e-2acf-43cb-b2af-592288ea80a4">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a0bbba08f347d193e2b1828a35d52d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTItMS0xLTEwNDUyMg_b0a8da61-94d8-450f-b159-abfe8527c6b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309bbd4aa703457b9a31d2fde9c76235_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTQtMS0xLTEwNDUyMg_eb06394d-e5c4-415c-88f3-dcb2ef7eb57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb39a7d3f58491b9ccb76970fd032bc_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTYtMS0xLTEwNDUyMg_406926d1-0a7e-484b-8add-f8392b8fa605">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e18d952c0446c1ad43e7467144a8d1_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMi0xLTEtMTA0NTIy_dd2ac758-12ae-448c-bb70-8fda8e51c1eb">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5c242b674b44679c627a7248ef2819_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtNC0xLTEtMTA0NTIy_5cbfc957-4264-46a3-8450-80c7d2739c9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ffe45070124a318e73e7a6e504352a_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtNi0xLTEtMTA0NTIy_de8f2201-ca8e-437e-a5d2-547fd0f7dbb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e3eeefe5c946fba06a0bee7b36d266_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtOC0xLTEtMTA0NTIy_ef636fc9-422a-4bee-9477-cc4b465bbbd3">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae857828574b4a668d913b270f8b36f5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTAtMS0xLTEwNDUyMg_7f9cd8fd-7155-4edc-84da-c94e5148864f">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d49299020542a392c3db192ea63db8_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTItMS0xLTEwNDUyMg_23048ace-a546-4e8c-8ffc-ff39c06fae1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43e2337e11144df5a90e99b5c638a73c_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTQtMS0xLTEwNDUyMg_27c4fe09-ef4e-4703-8c1e-1e3aabc1879a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70726c081bb4947af4189a219572868_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTYtMS0xLTEwNDUyMg_b45f6a94-bcf2-461e-9f07-273565e19b54">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f3a3d42167442d9bea77b4bb2f39e6_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMi0xLTEtMTA0NTIy_5cb65a50-73ea-41d9-b7bc-8c5ff5491c9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f1eba71d184d8ca513113104bff510_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtNC0xLTEtMTA0NTIy_71c8ca05-5ee7-46a5-8dab-0e885e8ea65c">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1cdaa3e0f34234bf362b822775dec5_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtNi0xLTEtMTA0NTIy_d66d46ff-0278-4874-86e7-b73a0e98aa5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8204c7a6c9e14f10be68903951892472_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtOC0xLTEtMTA0NTIy_98c2b828-7330-42ae-b97c-e0832aca3c57">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf92a809cfe4430bf1591de1f172efd_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTAtMS0xLTEwNDUyMg_2aebf6f1-a56d-4fd0-86a5-3ebd66dc811a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0e2e41b80c40d189eb508b9f0e5d8b_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTItMS0xLTEwNDUyMg_11be32f4-5b72-4fc2-a9d4-2025d569606f">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4692d33efa2e4c1a903bbfa6eb1bf652_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTQtMS0xLTEwNDUyMg_69018aef-c86c-4a6c-b090-eb692973b895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9a9dc69fb240d1812e5cdbb79f5bf4_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTYtMS0xLTEwNDUyMg_b415bd4b-045a-4b6e-8fe1-30b81ba9a85f">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e426ceed16d4ea0b50c79b82c4ac9ed_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMi0xLTEtMTA0NTIy_87652bc7-a92c-48c9-925b-ff69e8898c17">4,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie023e3f9d84842d5b43ecca161e36545_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtNC0xLTEtMTA0NTIy_e510db05-2b5b-4395-ae53-5cec4550063a">2,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc443f74d743469fa8a5404cb1d7b20d_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtNi0xLTEtMTA0NTIy_2c58b954-1c52-4828-a1c5-5ad62aedbce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtOC0xLTEtMTA0NTIy_2e684bba-0df1-47c6-bd69-21d6eed21243">6,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9276731dd9df4019aaff0654ed7ba115_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTAtMS0xLTEwNDUyMg_6cd0e985-2a91-457e-a64a-cdb5842cd429">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf82d3635af4b94b02308fda06d4aaf_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTItMS0xLTEwNDUyMg_50e09fde-c529-4f13-8190-28784eaa6db2">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7023a532dbca4fdcb35a761a941711f5_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTQtMS0xLTEwNDUyMg_d76b2a3e-b889-4dcd-b7d6-1d9a3cd67f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if019e7ba00f744d384b6d00260c70676_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTYtMS0xLTEwNDUyMg_a53823a3-60a3-4577-ab65-bf7005fa8a4a">8,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic736f3c433054ecab5e86925ad5cd22e_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMi0xLTEtMTA0NTIy_76ce4c25-f6fe-4926-bdc3-ad81a286b6ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d2ad95a1744b048be0fefbdfa02051_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtNC0xLTEtMTA0NTIy_76b9a7b7-6a24-4020-bbe0-4adda2e8c3da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibafcf9464f63422d9fb63a2de8d93d48_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtNi0xLTEtMTA0NTIy_a0aadfc1-356c-44d1-bf1e-63f4de548e8c">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f5465ec02d4a35b998d802608fff25_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtOC0xLTEtMTA0NTIy_d5b8c1ac-747c-4063-8880-c73d8621e950">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874752c3de8541159a7aed9141a3553e_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTAtMS0xLTEwNDUyMg_447da145-505b-49d3-bb1e-4fd049d9b29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide78159bcbbd42a48bbbcc894680d340_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTItMS0xLTEwNDUyMg_0114fb90-9f3f-4b0d-8e75-8a383c647041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54e53274284e9ea52e289b3ec3aaee_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTQtMS0xLTEwNDUyMg_4ca3a327-900a-469f-be2d-a8a5db5d974d">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d6fced1e674a6a8d953ff5bc008fef_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTYtMS0xLTEwNDUyMg_26a28418-9956-4255-bae8-bca7c392d766">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e18d952c0446c1ad43e7467144a8d1_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMi0xLTEtMTA0NTIy_c356a5c4-3a38-47ab-8965-c2fc5cfc34b0">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5c242b674b44679c627a7248ef2819_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktNC0xLTEtMTA0NTIy_e350aab3-427f-4aea-8730-544d2f412cfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ffe45070124a318e73e7a6e504352a_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktNi0xLTEtMTA0NTIy_312c1b7c-84cc-4a85-b2da-1bde2e3ce221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e3eeefe5c946fba06a0bee7b36d266_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktOC0xLTEtMTA0NTIy_dfaeb27f-f761-46c2-9eff-d848e3f12d50">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae857828574b4a668d913b270f8b36f5_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTAtMS0xLTEwNDUyMg_30fe1229-e3f8-4c20-a156-c97c5d12edf2">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d49299020542a392c3db192ea63db8_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTItMS0xLTEwNDUyMg_ac526e49-1712-4b1d-a5b7-242fc96eaeb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43e2337e11144df5a90e99b5c638a73c_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTQtMS0xLTEwNDUyMg_94f55190-54f5-4313-b887-8f5e76f98a29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70726c081bb4947af4189a219572868_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTYtMS0xLTEwNDUyMg_d529ab00-fdca-4f09-a779-ad886cd5149a">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f3a3d42167442d9bea77b4bb2f39e6_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMi0xLTEtMTA0NTIy_969f2120-cbb4-49f0-b928-e24189936ecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f1eba71d184d8ca513113104bff510_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtNC0xLTEtMTA0NTIy_584076b8-d661-4db9-affb-80951ff8ad5f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1cdaa3e0f34234bf362b822775dec5_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtNi0xLTEtMTA0NTIy_11004db1-bb93-48d2-8cca-040038f33a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8204c7a6c9e14f10be68903951892472_I20220331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtOC0xLTEtMTA0NTIy_8aaf67cf-6eec-4155-a3b6-ff212065ea4b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf92a809cfe4430bf1591de1f172efd_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTAtMS0xLTEwNDUyMg_5ee06c0a-f510-4c94-a54e-e750771d395d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0e2e41b80c40d189eb508b9f0e5d8b_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTItMS0xLTEwNDUyMg_922b4836-b334-49ac-89f4-940db1aa47d8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4692d33efa2e4c1a903bbfa6eb1bf652_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTQtMS0xLTEwNDUyMg_47f00c0b-5df8-47e7-8a36-4ee4851ac5f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9a9dc69fb240d1812e5cdbb79f5bf4_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTYtMS0xLTEwNDUyMg_532b82b7-3bd2-4bd7-9190-ba36accc7f7e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e426ceed16d4ea0b50c79b82c4ac9ed_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMi0xLTEtMTA0NTIy_2ba67594-d34b-42e2-8820-3f6ecfc6bf96">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie023e3f9d84842d5b43ecca161e36545_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtNC0xLTEtMTA0NTIy_938f4a4a-c839-4f75-8b59-052011e489fc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc443f74d743469fa8a5404cb1d7b20d_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtNi0xLTEtMTA0NTIy_44f3092d-4cc7-4feb-8408-aae05db21c7e">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtOC0xLTEtMTA0NTIy_092bda81-d3eb-4df5-af0d-becac7942546">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9276731dd9df4019aaff0654ed7ba115_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTAtMS0xLTEwNDUyMg_c08e0215-8474-4638-9483-c4c718b5af97">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf82d3635af4b94b02308fda06d4aaf_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTItMS0xLTEwNDUyMg_fede4433-960f-4624-bbe9-eab50fbf1fef">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7023a532dbca4fdcb35a761a941711f5_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTQtMS0xLTEwNDUyMg_0a201571-0157-4aa4-bfe3-67ce1fdf97f3">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if019e7ba00f744d384b6d00260c70676_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTYtMS0xLTEwNDUyMg_33ac6f3b-cba4-4b43-90ae-f89955043969">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i040d93facc294d43a303fccf37323186" continuedAt="i2e10751867ea46348d5e54ba33616ce2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (&#8220;SOFR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div></ix:continuation><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="idb992b77b3444d00b7b2813dab4e0089_I20220331" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNjY0MA_7ba0c1b8-f3ed-4cb2-bf7a-74b6558e2a71">25.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="idd69502271af4d6eb175d2a6ec3ec8ee_I20211231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNjY0Nw_94b99952-6ed9-49de-84ed-6e97b2ee6f44">28.6</ix:nonFraction> billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i90dc5662383a49e5addf18ac3694d3f8_I20220331" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNTQ5NzU1ODE2MzMwNg_379682b0-fbbe-4b91-83bf-cab96e4e524a">25.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ia58d2c0a64564683a5f1a7c8f578f7a2_I20211231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNjcxNw_cb442fc6-8dae-41fd-a1b8-ac276d2d29c8">25.6</ix:nonFraction> billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaa09da3c0f0e4807832644269fd4aec2"><ix:continuation id="i2e10751867ea46348d5e54ba33616ce2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex.</span></div></ix:continuation><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfOTM0NTg0ODg2MzU2Mw_19eee1a2-f1fb-4ae7-b45f-a4144aaca370" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the change in fair value of our contingent consideration: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ca803e36054d509ef339b251361ad7_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfMS0yLTEtMS0xMjExNDE_3c3c8daf-2d31-4079-8e0e-fc6c8624b663">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0710e6642417481cd192d1e448da3_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNC00LTEtMS0xMzMxNjk_d4284e56-4a3a-4b91-95f3-729efb7b7ed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNS0yLTEtMS0xMzMxNDM_7798920b-5e64-4893-a364-f30dd2fc95f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNS00LTEtMS0xMzMxMzc_b67de630-94b0-4d48-b93b-46684d6d113b">341</ix:nonFraction></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfMi0yLTEtMS0xMjY3MjY_0eabc17f-1302-4e27-aef0-7c7ca2984e58">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNi00LTEtMS0xMzMxNTc_af7aff58-d495-40bd-98bb-392ba0752982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331" decimals="-6" sign="-" name="gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfMy0yLTEtMS0xMjY3MjY_ce368028-965c-4f0c-8678-4dcd6df03f57">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331" decimals="-6" name="gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNy00LTEtMS0xMzMxNTc_4a83d9d8-f734-4ecc-9dc6-8e67f3573b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7300d904ed1b4713acd2ddc7fb40833f_I20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNC0yLTEtMS0xMjY3MjY_8b5fe326-bb72-46c4-ba13-8688d96697ec">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78d4bd4a4574be68dce08afe8061e93_I20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfOC00LTEtMS0xMzMxNjQ_da2a297f-8874-460f-865d-dc9c5ae8a59e">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in valuation assumptions were primarily related to updated probability rate estimates. The changes in the fair value of this contingent consideration were included in Research and development expenses on our Condensed Consolidated Statements of Income.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a liability related to the sale of future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $<ix:nonFraction unitRef="usd" contextRef="i120e85817179476683841797ae988eef_I20220331" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODExNA_6471393f-b3b8-4db4-b473-cfe38a83e042">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i0978b5f9be8f41cb89b77a87ab36cfa2_I20211231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODEyNw_3bf19d37-cb75-4476-891d-89bb5d63cdc6">1.3</ix:nonFraction>&#160;billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and the carrying value was $<ix:nonFraction unitRef="usd" contextRef="i7d9c20940c1043059e2558cfbd912517_I20220331" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODE0MA_60cf6268-0a56-4ff8-87ad-fd086c6566f2"><ix:nonFraction unitRef="usd" contextRef="i7b177f8e4b4d4b6080d2cf0a7bb6b531_I20211231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODE0MA_bf2b74a1-0288-41f4-acc5-34ddf1503845">1.1</ix:nonFraction></ix:nonFraction>&#160;billion as of March&#160;31, 2022 and December&#160;31, 2021. See Note 9. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Level Transfers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we recorded a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNTQ5NzU1ODE1OTU4OQ_eeb492c2-0a0a-4ff0-80fa-022d9e506532">2.7</ix:nonFraction>&#160;billion related to certain in-process research and development (&#8220;IPR&amp;D&#8221;) assets. See Note 7. Goodwill and Intangible Assets for additional information.</span></div></ix:continuation><div id="ib054ed57a41746f6adeff83e9a6e8cad_43"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjU2_538242db-f09e-47cf-a1e9-3f198549d6e7" continuedAt="i7d93daa4bd7f4da6af5c6e2d2194604b" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i7d93daa4bd7f4da6af5c6e2d2194604b" continuedAt="ib993d6aa0ce8498191ebc198170465f0"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjI2_7dde92f4-899d-4ee6-abb3-8f90fb9506df" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0yLTEtMS0xMDQ1MjI_c09b8002-63f1-4b66-b2a9-6d0317c4ae37">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi00LTEtMS0xMDQ1MjI_e9b266b8-40d3-4d26-acf6-6a6012a58c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi02LTEtMS0xMDQ1MjI_0c6b4ef5-abf8-43aa-a102-560284e2bf44">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi04LTEtMS0xMDQ1MjI_aaf91f3c-3840-4b7f-a1d6-c783ef75405e">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xMC0xLTEtMTA0NTIy_3a405dd4-dea4-4105-a6f0-4cacdfe22560">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xMi0xLTEtMTA0NTIy_1beca765-587c-4564-a1c9-1e3ff2df4f2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xNC0xLTEtMTA0NTIy_cffc3563-128e-4242-81a8-8b31323395c5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xNi0xLTEtMTA0NTIy_e4a9a921-20cf-403a-b528-47ee9134ed88">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a35912508b74867862fe94d3155d586_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0yLTEtMS0xMDQ1MjI_00592bf5-3668-4fcc-a9dc-86d4da52d496">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a35912508b74867862fe94d3155d586_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy00LTEtMS0xMDQ1MjI_3f26beb4-a4d5-4aab-acbc-cedaed8f7d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a35912508b74867862fe94d3155d586_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy02LTEtMS0xMDQ1MjI_5bc96538-bbf6-469d-8d9c-9d9aca2ec613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a35912508b74867862fe94d3155d586_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy04LTEtMS0xMDQ1MjI_03081edd-d091-49ea-b8c8-33e765294019">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xMC0xLTEtMTA0NTIy_837a8157-2e23-4f50-a3d6-8b1063ffdfdc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xMi0xLTEtMTA0NTIy_42978181-cb9c-4d51-89c2-0d5247030cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xNC0xLTEtMTA0NTIy_dc747f42-b663-425d-b4dd-1f89643ba541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xNi0xLTEtMTA0NTIy_4e990d67-c4c4-44e9-be20-4e83a6870de9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0yLTEtMS0xMDQ1MjI_658d0b98-e266-4218-a4d0-84aa0545cef4">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC00LTEtMS0xMDQ1MjI_c127478a-e9aa-45c5-9cd2-5629cc8644d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC02LTEtMS0xMDQ1MjI_7f09d1af-1bfd-4a8a-9e92-efc22dfaeaef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC04LTEtMS0xMDQ1MjI_0a2978ef-a75f-4f16-a2a3-211fb9249ac0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xMC0xLTEtMTA0NTIy_9a06a7d5-7200-4c9a-a742-6e98bf8302ad">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xMi0xLTEtMTA0NTIy_be0794c9-36ef-4d62-99e6-3274c7c8e7b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xNC0xLTEtMTA0NTIy_e21c0eac-6b1b-4c33-b50f-e70af214b99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xNi0xLTEtMTA0NTIy_238c511a-1222-4cee-9118-50f2a3da2f72">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0yLTEtMS0xMDQ1MjI_65c1f7b5-e971-4729-a7dd-55caf5200217">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS00LTEtMS0xMDQ1MjI_baa0aa14-b504-4432-9c11-0f63e501081d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS02LTEtMS0xMDQ1MjI_b4cc3fa3-cede-4db1-a446-ea4ad8b4ef5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS04LTEtMS0xMDQ1MjI_940634bf-52ff-4cb0-8c01-2d23919733eb">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id130f892b445421ba418a4ff87945c26_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xMC0xLTEtMTA0NTIy_8ceb2f10-0b82-4ed7-8154-16240160cddf">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id130f892b445421ba418a4ff87945c26_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xMi0xLTEtMTA0NTIy_dc1d3509-0207-4012-b82c-57197eb19e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id130f892b445421ba418a4ff87945c26_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xNC0xLTEtMTA0NTIy_d5440f97-733e-4713-826a-4a5c0d7fecf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id130f892b445421ba418a4ff87945c26_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xNi0xLTEtMTA0NTIy_804a55cb-e50d-4230-b243-269641b0ca1f">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0yLTEtMS0xMDQ1MjI_ef4bd06a-15a5-476e-8014-26ac954aab03">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi00LTEtMS0xMDQ1MjI_0188e06f-52d1-42c2-bbb9-99c4eacbc979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi02LTEtMS0xMDQ1MjI_97839ab1-2a6a-4378-b39e-1cf06d7c4dd0">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi04LTEtMS0xMDQ1MjI_0ed47ca5-fef3-4240-a45a-ac60c7f61c2e">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xMC0xLTEtMTA0NTIy_7e1e4d94-a400-4ba9-b3a7-81d2f39feefe">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xMi0xLTEtMTA0NTIy_cf94801f-8b2d-49e6-9637-8e3e909c5c82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xNC0xLTEtMTA0NTIy_325db30e-30a4-47d2-a8fb-268900747bba">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xNi0xLTEtMTA0NTIy_a4a6c09c-a5eb-4402-8324-60691cda5038">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0yLTEtMS0xMDQ1MjI_6d61034a-9bd1-4651-9866-dba369924997">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy00LTEtMS0xMDQ1MjI_4e36bf6d-f6b5-44ae-b5b1-93327a39ff9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy02LTEtMS0xMDQ1MjI_a439af9a-9b58-4bc1-aa4a-4f5d7aff25b3">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy04LTEtMS0xMDQ1MjI_a0f3c5a9-9eb6-4e9b-89d7-fef033258729">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xMC0xLTEtMTA0NTIy_f5a45adc-1dc9-4794-8400-b4591e7c1a55">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xMi0xLTEtMTA0NTIy_a7360677-07ee-4004-9314-eddaf0ec4b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xNC0xLTEtMTA0NTIy_8c2f3d89-435b-4328-9496-6e184106ac2b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xNi0xLTEtMTA0NTIy_b3d0568e-c879-4d1e-8a43-0db0216f8999">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0yLTEtMS0xMDQ1MjI_da07a98e-60ce-4df2-9227-808fac733fee">2,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC00LTEtMS0xMDQ1MjI_ffe733a8-6893-49b3-b9b7-b237babb6499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC02LTEtMS0xMDQ1MjI_0a6c0352-cd5f-48cf-a70b-c40efa8365bf">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC04LTEtMS0xMDQ1MjI_9588f326-d8d7-41b6-9388-0e522e817b06">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xMC0xLTEtMTA0NTIy_0cb23c22-4d65-4f8c-91b9-4b4336684bbe">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xMi0xLTEtMTA0NTIy_4d1d7f9f-680e-4582-b584-f0b417280bbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xNC0xLTEtMTA0NTIy_b661883e-7ff3-437c-9233-22819b605809">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xNi0xLTEtMTA0NTIy_3e537204-8bfc-40c6-ac4c-de645b63a645">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib993d6aa0ce8498191ebc198170465f0"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjIz_bc347487-aa18-4c34-96e7-8d2ca623e745" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd6c25aa9ef435ca2a940cd82ec2eab_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMS0yLTEtMS0xMDQ1MjI_55812d08-84b2-4498-8133-9a6bf8c62d8c">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76e15d8f3034561bc0f77901e95f300_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMS00LTEtMS0xMDQ1MjI_d844262b-fec5-4bca-bfca-2c16e6b702fe">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734040fec2ae4fefa9ac801de7c29378_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMi0yLTEtMS0xMDQ1MjI_325832b7-0cb5-477e-a886-513c9e17ed6b">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972796d2c85047ffae7e45d4d942a4ff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMi00LTEtMS0xMDQ1MjI_cc7b602a-c283-4e06-98fa-907436ec2c8b">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f8d6f5408d437593d6ed14249728b1_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMy0yLTEtMS0xMDQ1MjI_fc0c8e8e-0c5b-4153-8a62-f7cdb6d3c2eb">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366bb0c4a80d436dab4d980a44b57763_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMy00LTEtMS0xMDQ1MjI_05666835-c93b-46e9-acb3-a61fbce3a57f">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfNC0yLTEtMS0xMDQ1MjI_2be23c89-35e9-4350-a032-89975adff1e8">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfNC00LTEtMS0xMDQ1MjI_15e255bc-0ce2-48ca-962c-1afd4e55a8f4">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjI0_5fc12776-4345-4e29-b9dc-009fd2405024" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMi0yLTEtMS0xMDQ1MjI_59347e90-7c7e-4e10-b37e-0ab92db9bd42">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMi00LTEtMS0xMDQ1MjI_2e7dbf9b-1ef0-4aa5-8d2a-bcb9571f4aa3">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMy0yLTEtMS0xMDQ1MjI_7ef98d84-6169-469b-b3ca-f15db9f6b99c">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMy00LTEtMS0xMDQ1MjI_ba563ad0-15f6-4c5e-bc32-cb61dd0cfd0a">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNC0yLTEtMS0xMDQ1MjI_7a4b8f06-40a8-4f22-8deb-bb881695c49d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNC00LTEtMS0xMDQ1MjI_9ed63bc8-3a3b-4e51-b9ca-892f69d3b7e1">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNS0yLTEtMS0xMDQ1MjI_beddf1db-c81b-4a86-9437-f9579d106b33">2,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNS00LTEtMS0xMDQ1MjI_95ad106f-ecd8-4936-99fe-c7df7be97a39">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a total of <ix:nonFraction unitRef="position" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMzA3_c641800a-2c18-4149-bc96-fb916956d67a">618</ix:nonFraction> and <ix:nonFraction unitRef="position" contextRef="ia9796d93b2414e28a30a1b8602920120_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMzE0_e695f8d0-a8c3-4af2-930c-4d08ad10708c">203</ix:nonFraction> positions which were in unrealized loss positions as of March&#160;31, 2022 and 2021, respectively. <ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTc3_0b300bc4-cc9b-45bf-8a83-b2136605f3ff"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTc3_18a1be71-cb73-47ae-a57d-b1c66356adbe">No</ix:nonFraction></ix:nonFraction> impairment was recognized for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities Measured at Fair Value</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfOTM0NTg0ODgzODU3OA_d187c464-0f2b-4610-8cd6-6795ec03e7ce" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54513ac7f8334fc5b465981879a0f801_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMS0yLTEtMS0xMjIwMzM_0d9bd69e-d136-43dc-af25-c7902ff703c8">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1a320253be4fd0b8481aa6a57537c1_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMS00LTEtMS0xMjIwMzM_e400a970-3de1-4f4a-9834-98225e95e964">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0589c2ad7eb480b8da2a801c4d25063_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMi0yLTEtMS0xMjIwMzM_a1904df2-8b00-4938-9c87-f91702a3523e">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4120862280544540a63c21d7e97b6c0f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMi00LTEtMS0xMjIwMzM_ec828040-246e-42e9-a09f-ea454ed06982">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a456fff65c843b6a626df4ea2ce55e3_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMy0yLTEtMS0xMjIwMzM_23c59880-9d53-4992-b7c1-1c2c3e8d1fbf">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed49fdba2a147c4b79505826a478d36_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMy00LTEtMS0xMjIwMzM_a6d47e4c-d4f0-44fd-81d5-43572a13d92f">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6ff6cc00ff41f8b7ec36a69139238b_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfNC0yLTEtMS0xMjIwMzM_079f1f46-c672-434d-b00b-eca83e43e95f">4,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b085d7670ea434382d8a85edb3d068e_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfNC00LTEtMS0xMjIwMzM_0e6f3a44-6e3d-4582-8539-c5408c4c5bb6">5,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Equity Securities</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMTA5OTUxMTYyOTUwOQ_26fae77b-5968-4fa8-b613-8a2ce1e59687">375</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMTA5OTUxMTYyOTUxOA_14e47a32-721c-42c7-86a0-78a32cb5d4ec">338</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized Gains and Losses </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized on equity securities were $<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTQ5NzU1ODE0MDkwMg_8cb72680-e217-4cce-8d3d-6899cf6d1562">96</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTQ5NzU1ODE0MDkxMA_a43c324f-ff40-45c4-bf4d-b65f6a2d2397">351</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzM0Ng_62e5252e-521b-4ed8-a84e-7379a9497261" continuedAt="iee169b83769b434aa3c85b85b660788c" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="iee169b83769b434aa3c85b85b660788c" continuedAt="ia175b7534b014ef1967d2fcb9d1fe2b2"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="ibdc2166d764d47b790982ea8d24ca4c5_D20220101-20220331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMTg3NQ_f632e393-8ce6-4c39-9a71-4e3e22796ec3">18</ix:nonNumeric> months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses on these hedges are recorded in Accumulated other comprehensive income (&#8220;AOCI&#8221;) and are reclassified into Product sales on our Condensed Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of March&#160;31, 2022 are expected to be reclassified to Product sales within <ix:nonNumeric contextRef="ibdc2166d764d47b790982ea8d24ca4c5_D20220101-20220331" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMjM0MA_0635a688-42b2-4eb3-89c7-01566138d163">12</ix:nonNumeric> months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the three months ended March 31, 2022 and 2021 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts of foreign currency exchange contracts outstanding of $<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMjU2NA_0c894d40-17e1-4fc6-9eb8-ddee9ba3e94b">3.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMjU3MQ_acd16a4c-2f0d-4b96-81b4-9cd614d2d244">2.9</ix:nonFraction> billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. <ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzMzMg_beb4c27d-33ee-484c-9fe1-051782e30b1d" continuedAt="i5bfe7fcb7e354575863ef151474394e8" escape="true">The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets:</ix:nonNumeric></span></div><div style="margin-top:4.5pt"><ix:continuation id="i5bfe7fcb7e354575863ef151474394e8" continuedAt="i3539cb2188dd4909a16a766260c5228d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb3d84561ec4098843a2d085b4a0ca6_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNC00LTEtMS0xMDQ1MjI_643cebbc-6967-4dc7-998c-df39965260db">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f2d07dee1c49d6beb026214523051a_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNC04LTEtMS0xMDQ1MjI_14ac9bb3-6d2d-4504-a5a6-827589772bff">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7427f7cf7f37493d9bdc7a0ae323cc7b_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNS00LTEtMS0xMDQ1MjI_4c18f4ac-8424-4ee3-9bf8-4f78b0c35a88">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ff03aad47143d2886a6c27847acb8c_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNS04LTEtMS0xMDQ1MjI_5103ca1a-14ac-4e2f-bdef-9001de5ac2cc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f27f012480540869dfec449f56f64fc_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNi00LTEtMS0xMDQ1MjI_5b7c76a9-165f-4719-b8db-cf91d3d33a09">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f27f012480540869dfec449f56f64fc_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNi04LTEtMS0xMDQ1MjI_5138aa54-668b-4a03-8b09-6a7f49bcdc7a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541ecc08f5ab4ef1b08aa8faf2073803_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOC00LTEtMS0xMDQ1MjI_a8c4a4fd-1ad3-4e19-985b-d37249e34ba6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c84a15b4f764e02becb348c2b986e0e_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOC04LTEtMS0xMDQ1MjI_20d8e00c-94d8-4d5f-b930-f166690a923e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e169fb1551b4471ac0f7b68e6ded3af_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOS00LTEtMS0xMDQ1MjI_e705ecef-6fd6-440e-8ffb-69d170aa8d7a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e169fb1551b4471ac0f7b68e6ded3af_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOS04LTEtMS0xMDQ1MjI_d0b0f9f7-2c46-41c7-b441-1525a50680d2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfMTAtNC0xLTEtMTA0NTIy_726abf6d-8247-40e1-b658-e7d1df3666fc">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfMTAtOC0xLTEtMTA0NTIy_87dde558-2366-4821-9027-46a70175f15a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia175b7534b014ef1967d2fcb9d1fe2b2"><div style="margin-top:4.5pt"><ix:continuation id="i3539cb2188dd4909a16a766260c5228d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755866e871aa435bbe8cc99ea9405032_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNC00LTEtMS0xMDQ1MjI_92cac24a-e736-491f-956b-69a8d22bb579">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3654deba3ec8484aa044f0318ffe9226_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNC04LTEtMS0xMDQ1MjI_4819732f-621b-4746-94d8-f432a41a3e2c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590c1dfde3d24201beae31f590843dfe_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNS00LTEtMS0xMDQ1MjI_4c51ac4d-66fc-46a1-b720-7ac7cfd91f93">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4108efc629d9462db4043d3b73894ef6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNS04LTEtMS0xMDQ1MjI_4247feab-6f74-46da-b455-6c7b1898e616">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9099c763634be097da7c2e31d5b983_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNi00LTEtMS0xMDQ1MjI_d9c604eb-6284-4f20-806e-2d3b7ee463ec">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9099c763634be097da7c2e31d5b983_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNi04LTEtMS0xMDQ1MjI_5afdcff8-9f3d-45c0-b13f-2c47be0a2133">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2c11db705040bb991212a1df88c126_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOC00LTEtMS0xMDQ1MjI_bd50753e-5465-4874-8387-3da25e752d6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcd9ccfcbe9446eb6f087a60e2891fe_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOC04LTEtMS0xMDQ1MjI_315be5fc-f080-4cf9-9e53-519ed6283618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3a437f7d5e4a888f6943960ee7df17_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOS00LTEtMS0xMDQ1MjI_3d049ac3-7ef3-41c8-8f55-1dd087882d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3a437f7d5e4a888f6943960ee7df17_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOS04LTEtMS0xMDQ1MjI_36d9c909-91d6-4099-bff8-ebd12a95e54a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfMTAtNC0xLTEtMTA0NTIy_abf95f74-4993-4009-b863-42c141f3881d">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfMTAtOC0xLTEtMTA0NTIy_1181c0cb-1f00-436a-b625-62a26211e36d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzM0Nw_dd77960a-92f1-45c7-9d14-68cda927a37d" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNC0yLTEtMS0xMDQ1MjI_7c831260-acd6-4654-805b-853be267c475">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNC00LTEtMS0xMDQ1MjI_71f4e7b5-3bfb-43b4-a0dc-eff339e1f89b">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNS0yLTEtMS0xMDQ1MjI_ee08c880-8bd2-4727-ba73-d9d0292f10bb">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNS00LTEtMS0xMDQ1MjI_4bf13e22-2653-4ed1-a803-71492a0b4054">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNy0yLTEtMS0xMDQ1MjI_8b5de066-7d99-4aee-8f92-dcc60a0d4b96">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNy00LTEtMS0xMDQ1MjI_c5fe2626-8a52-4d0c-9e65-bbd5841269c6">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were <ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="INF" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzA2OA_b7962f18-1a0f-4138-9b79-0a97793d9a55"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="INF" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzA2OA_ef4ebf62-5e12-426a-a65b-a42ed9662169">no</ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the three months ended March 31, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzM0OA_e44268ce-bfc3-48ee-af13-a851a8e20fed" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy02LTEtMS0xMTkxMDk_06e10464-700c-431c-a142-664473687af1">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy04LTEtMS0xMTkxMDk_85a12ce2-ff41-406c-a5f8-5dc06065451d">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy01LTEtMS0xMzczMjM_478c814f-b691-4be5-a83d-d2e692b6f5a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy0xMi0xLTEtMTE5MTA5_b3e70197-2ed7-46ae-8833-9fb3c00ef4d1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC02LTEtMS0xMTkxMDk_8af1389e-9172-4a6e-9c11-cfae6ac5b3f4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC04LTEtMS0xMTkxMDk_ddd0f663-cd12-42c0-ac79-1157dbb2865a">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC01LTEtMS0xMzczMjM_402c5970-2364-4c0e-a0a5-d04a59da33cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC0xMi0xLTEtMTE5MTA5_436cfd94-bf65-4869-b6ad-a52d409b4a76">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi02LTEtMS0xMTkxMDQ_b1328c73-aaff-4f73-b19a-d8a240614af1">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi04LTEtMS0xMTkxMDQ_3026bd7a-075a-4b86-8c8d-99af81344d55">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi01LTEtMS0xMzA3MTQ_dafd2963-e976-4b0b-8474-9685e131a9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi0xMi0xLTEtMTE5MTA0_93fbe3dd-1457-4920-acd0-098244f38535">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy02LTEtMS0xMTkxMDQ_c19e8d30-ab5f-4ced-9c96-f0e3c70a1ae4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy04LTEtMS0xMTkxMDQ_ab445809-2df3-4d86-8bf8-d87ae08d0018">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy01LTEtMS0xMzA3MTQ_2b319a83-b910-4c0b-9fc1-9b80207dfafa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy0xMi0xLTEtMTE5MTA0_584b6c83-2eda-43a9-8f11-6ca666512463">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfNzQ0MA_97090999-8b25-48d7-a386-90db37b1f03a" continuedAt="i7b775878b0df42caab91687b328587ec" escape="true">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i7b775878b0df42caab91687b328587ec" continuedAt="i58ddd79be09e4a7e91008efd65668091"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments. We also have equity investments in third parties focused on the development and commercialization of products and product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. MYR is a wholly-owned subsidiary of Gilead.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;<ix:nonFraction unitRef="eur" contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjAzMg_400a1238-fd53-44d8-95f1-2da8986dd600">1.3</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjAzOQ_3c7aebd4-9869-4dde-9b88-5275eb184a4c">1.6</ix:nonFraction> billion) primarily consisted of &#8364;<ix:nonFraction unitRef="eur" contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjA2NQ_c9f656cf-519c-4d9e-ade9-d923184d74eb">1.0</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjA3Mg_03b5912a-3eb4-49b9-9f59-6871887d4ac8">1.2</ix:nonFraction> billion) paid upon closing and contingent consideration of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="icbff931ce23a4b7fbc85927c27dcbb38_I20210304" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjEzMg_2361930b-5e34-4f72-a106-1106507d8447">300</ix:nonFraction> million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $<ix:nonFraction unitRef="usd" contextRef="i82997a4df3f84a3ea62a3b4b42b70d35_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjM2Ng_6dd48e2e-a4c7-45be-98d6-bb676159f88b">341</ix:nonFraction> million as of the acquisition date. The estimated fair value of the contingent liability was $<ix:nonFraction unitRef="usd" contextRef="i282910930ada4568b9f7fbf7401e7ebe_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfODc5NjA5MzA2NjYyOQ_05c58772-dd88-444a-a9e5-7260f51bd19a">322</ix:nonFraction> million as of March&#160;31, 2022. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. Measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three months ended March 31, 2022 amounted to $<ix:nonFraction unitRef="usd" contextRef="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTA5OTUxMTY3NzY5Mw_b96b18d7-3290-46d5-a7c3-94f304af6ea9">18</ix:nonFraction> million. See Note 7. Goodwill and Intangible Assets for additional information. The fair value estimates for the assets acquired and liabilities assumed have been completed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arcus</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i58ddd79be09e4a7e91008efd65668091">In 2020, we entered into an option, license and collaboration agreement with Arcus (the &#8220;Arcus Collaboration Agreement&#8221;), which granted us the right to opt in to all current and future clinical-stage product candidates for up to <ix:nonNumeric contextRef="i2aa635ad0e1a44f7b6c2b98f4ad871c7_D20200527-20200527" name="gild:CollaborativeAgreementOptInTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTIyMw_15f56c4f-7e8c-4c86-9744-776abe8e5e8f">ten years</ix:nonNumeric> following the closing of the transaction. In November 2021, we exercised our options to <ix:nonFraction unitRef="program" contextRef="i84e131229c44421889bd64bd4ca11a35_I20211118" decimals="INF" name="gild:NumberOfClinicalStageProgramsWithExercisedOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTIzMw_39417c83-8cac-429b-9b1b-849dd9a23ce8">three</ix:nonFraction> of the clinical-stage programs and amended the Arcus Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $<ix:nonFraction unitRef="usd" contextRef="i13a9e3a52328474db24a8e8398a645e2_D20211221-20211221" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTI0OQ_109cec9c-1934-468d-96f7-37a6efb920ec"><ix:nonFraction unitRef="usd" contextRef="i86cf8f539a93434791137d23f91be357_D20220101-20220131" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTI0OQ_e9a4684b-6d80-40c1-b3b5-48f6192e3883">725</ix:nonFraction></ix:nonFraction> million and waiving a $<ix:nonFraction unitRef="usd" contextRef="i840ba75e346d4681849daddb6e34dc67_I20211231" decimals="-6" name="gild:EquitySecuritiesFVNIAdditionalOptionPaymentWaived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTI2NQ_d4dcd988-3552-442d-b301-c247314daf8f">100</ix:nonFraction> million option continuation payment which would have been due to Arcus in the third quarter of 2022. The collaboration opt-in payments of $<ix:nonFraction unitRef="usd" contextRef="i13a9e3a52328474db24a8e8398a645e2_D20211221-20211221" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTMwMQ_109cec9c-1934-468d-96f7-37a6efb920ec"><ix:nonFraction unitRef="usd" contextRef="i86cf8f539a93434791137d23f91be357_D20220101-20220131" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTMwMQ_e9a4684b-6d80-40c1-b3b5-48f6192e3883">725</ix:nonFraction></ix:nonFraction> million were recorded in Accrued and other current liabilities on our Consolidated Balance Sheets as of December 31, 2021 and paid to Arcus in January 2022. Our payments to Arcus were included in Other in investing activities on our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022.</ix:continuation> </span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_52"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYyNA_abfc1af9-8109-4286-919c-2f1786e48aa5" continuedAt="idc87622fbcd948a395a770262d122aea" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="idc87622fbcd948a395a770262d122aea" continuedAt="i7614833b81024aeb921d575897a34997"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYxMg_8ad97607-eb8a-46a6-89a9-1b77c401b10a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjI1MWRlZTA2NjhiYzQ3Mjc4ZTEwNzIzMjRlN2FjMDMzL3RhYmxlcmFuZ2U6MjUxZGVlMDY2OGJjNDcyNzhlMTA3MjMyNGU3YWMwMzNfMS0yLTEtMS0xMDQ1MjI_7eef9a78-44d3-4134-95c8-05dcf838b7a6">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjI1MWRlZTA2NjhiYzQ3Mjc4ZTEwNzIzMjRlN2FjMDMzL3RhYmxlcmFuZ2U6MjUxZGVlMDY2OGJjNDcyNzhlMTA3MjMyNGU3YWMwMzNfMy0yLTEtMS0xMDQ1MjI_1a8cf234-d1cc-4b75-b00f-925b9ee83063">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjI1MWRlZTA2NjhiYzQ3Mjc4ZTEwNzIzMjRlN2FjMDMzL3RhYmxlcmFuZ2U6MjUxZGVlMDY2OGJjNDcyNzhlMTA3MjMyNGU3YWMwMzNfNC0yLTEtMS0xMDQ1MjI_6782fbfe-93bd-4c3d-b3a6-5644735f7836">8,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, goodwill decreased by $<ix:nonFraction unitRef="usd" contextRef="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTA5MDA3Mg_1a8cf234-d1cc-4b75-b00f-925b9ee83063">18</ix:nonFraction>&#160;million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7614833b81024aeb921d575897a34997"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYzMw_42b089ae-514e-40e4-b82d-e7712bf918ba" escape="true"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYzNA_8a85700a-116e-4412-8f91-efabca5a7b7b" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0yLTEtMS0xMDQ1MjI_136a4c78-8d40-41fc-a6d7-b98b008b2ba4">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy00LTEtMS0xMDQ1MjI_30e2a803-1438-4151-867e-c96fb1ae46d9">5,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy02LTEtMS0xMDQ1MjI_8929da05-c3f6-4b9d-9d98-7877baf52c0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy04LTEtMS0xMDQ1MjI_bacb9720-e7a2-4732-98db-42ab98cc819e">4,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xMC0xLTEtMTA0NTIy_180aa90d-6a7b-4b15-8eab-cd5527162a4d">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xMi0xLTEtMTA0NTIy_f48f9e98-caa1-476a-a355-8ebaf6e9d9c0">5,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xNC0xLTEtMTA0NTIy_c9ac563e-304d-466b-9001-3b5110e3aa52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xNi0xLTEtMTA0NTIy_dee09282-9419-47df-968e-7bf910a2cead">5,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0yLTEtMS0xMDQ1MjI_a27e7709-eb8c-491a-90be-ee9c0b915155">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC00LTEtMS0xMDQ1MjI_cfe0c6d6-f5ac-4304-96fd-a497afc0d0f0">1,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC02LTEtMS0xMDQ1MjI_d6816c67-a6fd-43cd-a606-9c7ee9b8e6a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC04LTEtMS0xMDQ1MjI_6d9490d6-0034-48fc-8e54-12bdb97fbc4b">5,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8335947a672a4bf581dd7173d631b531_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xMC0xLTEtMTA0NTIy_52d8c01a-7def-4025-ac95-3ceed042de64">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8335947a672a4bf581dd7173d631b531_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xMi0xLTEtMTA0NTIy_671bc77f-b1a0-4531-9c21-72e59bb197fe">1,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8335947a672a4bf581dd7173d631b531_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xNC0xLTEtMTA0NTIy_b9a09898-7967-403b-b590-36cf6bb29b76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8335947a672a4bf581dd7173d631b531_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xNi0xLTEtMTA0NTIy_0393cefb-ac9d-4cf5-8a09-5da193158a8f">5,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0yLTEtMS0xMDQ1MjI_3d1a926b-e5a5-48af-a954-933a1b34f08d">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS00LTEtMS0xMDQ1MjI_2fd2671c-817b-4a32-b8a6-e52bef1e5d55">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS02LTEtMS0xMDQ1MjI_6993ee46-edb1-42de-9621-f6a721288ff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS04LTEtMS0xMDQ1MjI_458619ec-1767-4599-836c-44122815b752">5,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xMC0xLTEtMTA0NTIy_0dc6f3a1-7c71-4c80-a996-ff50b9d56f4d">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xMi0xLTEtMTA0NTIy_79f3f754-a5e6-410f-a664-4729de2501b1">507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xNC0xLTEtMTA0NTIy_02bb0af0-fbd2-491c-b8fb-f0da31a29251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xNi0xLTEtMTA0NTIy_09d52da8-3612-4f03-ba47-68a738b91431">5,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0yLTEtMS0xMDQ1MjI_0e63277e-de89-43f3-acd4-180f1c026325">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi00LTEtMS0xMDQ1MjI_70139600-4b04-44de-9698-8899f2714e80">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi02LTEtMS0xMDQ1MjI_f0d8887e-29dc-44df-b3cb-7e92b5bca831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi04LTEtMS0xMDQ1MjI_f94834b7-cbe4-47ad-9c39-392cc1f0c3f3">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414779d0bb44463e89fae77dc259101a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xMC0xLTEtMTA0NTIy_b6e21d23-fa88-4615-89ff-96018c0b736b">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i414779d0bb44463e89fae77dc259101a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xMi0xLTEtMTA0NTIy_f5d3cf47-be93-4626-9283-777668604e88">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414779d0bb44463e89fae77dc259101a_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xNC0xLTEtMTA0NTIy_f4eb8c14-79ce-422f-bb15-0e41aece1f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414779d0bb44463e89fae77dc259101a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xNi0xLTEtMTA0NTIy_3ff64e9f-7c94-470e-9e62-4306ce6f2bb7">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0yLTEtMS0xMDQ1MjI_1066c0f1-fd70-40f1-abf4-024ff43a07aa">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy00LTEtMS0xMDQ1MjI_adad9af6-bccc-40f2-82bf-6bc7c30ebf74">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy02LTEtMS0xMDQ1MjI_5d747bce-26eb-488e-8d81-2215297fd14b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy04LTEtMS0xMDQ1MjI_dbdf918c-90a9-401d-8235-12e5dedb61fe">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xMC0xLTEtMTA0NTIy_83c82bf1-c98c-403e-b40d-8fb862d980e0">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xMi0xLTEtMTA0NTIy_13be700d-63ec-4245-ac05-2cb6ceb7e0a1">650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xNC0xLTEtMTA0NTIy_7a5dd10c-b99c-43fa-a468-b211970e9b02">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xNi0xLTEtMTA0NTIy_145d7f17-17ed-476a-8d0a-bec3d5ef1b62">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0yLTEtMS0xMDQ1MjI_51290464-0f49-477e-95ba-a53f19735b4b">25,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC00LTEtMS0xMDQ1MjI_66ccf2f2-97bf-4bec-b01f-28db0e40c0fb">8,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC02LTEtMS0xMDQ1MjI_60dfa8d6-fc8c-499b-8c59-8337e22bc9d5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC04LTEtMS0xMDQ1MjI_0150b8f8-fd02-47f3-91dc-e9e217499712">17,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xMC0xLTEtMTA0NTIy_54ab095e-3653-4f15-a341-118e743bf9ae">25,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xMi0xLTEtMTA0NTIy_fec1346c-d3a0-4e47-91d5-a9fe352e50b2">8,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xNC0xLTEtMTA0NTIy_50c940c4-8024-4971-b192-73b86d32ba85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xNi0xLTEtMTA0NTIy_b2493840-ba32-43e1-9f52-aeb6cf3db45c">17,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0yLTEtMS0xMDQ1MjI_8e9dbf7d-894a-4cae-b477-952ced4b2d52">13,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS02LTEtMS0xMDQ1MjI_18f8cb83-7443-4bbf-a977-4c6af3f8e434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS04LTEtMS0xMDQ1MjI_76cee353-ec53-4272-b3a1-676528da821f">13,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0xMC0xLTEtMTA0NTIy_38f779ce-f64e-4bc6-aee3-4b4c27d0975f">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0xNC0xLTEtMTA0NTIy_de7a11e7-41c4-496b-9679-346283163760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0xNi0xLTEtMTA0NTIy_238b6fdf-1b2a-43ff-8a39-afd6a691f5a3">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMi0xLTEtMTA0NTIy_f27b0ecb-14c7-4fd3-ae3f-ff6f66f5979c">39,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtNC0xLTEtMTA0NTIy_257aebfb-7bde-45bd-90de-d52e94c29b4e">8,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtNi0xLTEtMTA0NTIy_20f6312b-e62f-4acb-a5eb-798708644040">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtOC0xLTEtMTA0NTIy_1bbd5d8d-4e4f-47d2-92a4-f7b0e38b5881">30,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTAtMS0xLTEwNDUyMg_a3aeeb08-d679-465f-8257-c91ec9f4c9fc">41,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTItMS0xLTEwNDUyMg_ce335b03-e3b1-4f9d-95ab-b77d2266b92a">8,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTQtMS0xLTEwNDUyMg_c3f63d63-c0ba-45ee-b464-26dee7c54bea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTYtMS0xLTEwNDUyMg_84757b10-5357-44aa-89c0-a616494647a7">33,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTM0OA_8bab340e-fb2d-4437-95d6-c95f8b3781b0">445</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTM3Mw_1944bdbf-58ac-4617-95f2-ae51a9572ab7">395</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively, and is primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYyMg_9ee6911f-b6ac-4ae4-a7bd-b3cf2dfb2472" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2022:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfMS0yLTEtMS0xMDQ1MjI_598a6051-c427-49dc-825a-34f52ada2152">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfMi0yLTEtMS0xMDQ1MjI_c7b7cee4-6efe-42a0-a456-a4ef74e6dd91">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfMy0yLTEtMS0xMDQ1MjI_4e30c9f4-db16-4b74-b8cd-05089957c18c">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNC0yLTEtMS0xMDQ1MjI_f6f9634c-81be-45cc-bc6f-97cd9b1f9f34">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNS0yLTEtMS0xMDQ1MjI_6f4b03c3-8278-462a-903f-f35fc49901df">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNi0yLTEtMS0xMDQ1MjI_699eaa8e-7554-4880-8f58-ddbd93364aa1">8,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNy0yLTEtMS0xMDQ1MjI_f974136c-e6a8-4e96-860e-6a82ef096325">17,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $<ix:nonFraction unitRef="usd" contextRef="i80486df441b94309bf7388e71d0392a0_I20201231" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDk2MA_4a5cc3a6-db78-486b-b291-1b50f815b206">8.8</ix:nonFraction>&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) metastatic breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $<ix:nonFraction unitRef="usd" contextRef="i257ea51d20324ca09177cd0d150f10e5_I20220331" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDkyMw_e87bee1a-773b-412a-8f23-84ee11cf099a">6.1</ix:nonFraction>&#160;billion as of March&#160;31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. There were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of <ix:nonFraction unitRef="number" contextRef="i18f249c798e6480c85ff4095cc8ec9fc_I20220331" decimals="4" name="gild:IndefiniteLivedIntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDcyMg_a238bb05-2bd1-41ce-a21a-82806a581030">6.75</ix:nonFraction>% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDczNw_eeb492c2-0a0a-4ff0-80fa-022d9e506532">2.7</ix:nonFraction>&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjM4_c0612450-8713-418c-b37b-ada23a619719" continuedAt="i7aa1ad5bdf444a69a11b25904cd12051" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i7aa1ad5bdf444a69a11b25904cd12051"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjUw_77990da2-a634-4b0f-871a-ea85de401e61" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMS0yLTEtMS0xMDQ1MjI_11b8d3da-058d-41f1-8bf3-af3cf7360f80">4,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMS00LTEtMS0xMDQ1MjI_6eb0f796-91b5-44e3-b7f2-81e5c3780679">5,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMi0yLTEtMS0xMDQ1MjI_437a3629-616d-4690-8a8e-83433d1b5d9f">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMi00LTEtMS0xMDQ1MjI_ec4fb4dc-0e91-464c-8cc0-74fc87937b98">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMy0yLTEtMS0xMDQ1MjI_d47cf350-bff1-4948-b553-0b214ad13754">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMy00LTEtMS0xMDQ1MjI_052192a6-058b-4e20-a908-0cabb02c34e5">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNC0yLTEtMS0xMDQ1MjI_71c9b8b5-d434-4a0f-87fa-2cc09e878db0">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNC00LTEtMS0xMDQ1MjI_d17b072d-6cdf-4964-9c4c-c32ac133ed0a">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNS0yLTEtMS0xMDQ1MjI_2c7cb104-0847-4a0a-b151-4a5d153f20be">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNS00LTEtMS0xMDQ1MjI_1559abae-c9bc-483c-87ea-396b26514ef2">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjM5_617789b0-635e-42bb-b79f-8744f89648d9" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMS0yLTEtMS0xMDQ1MjI_9b3ac5cf-6f4e-4304-9d8b-6ca6598e6760">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMS00LTEtMS0xMDQ1MjI_e28a71c8-de42-4949-8eb5-ffcaf561e373">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMi0yLTEtMS0xMDQ1MjI_d6bd358f-997c-4d67-910e-c3e932d768d1">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMi00LTEtMS0xMDQ1MjI_2e51b486-90bc-4808-af91-aeeb114b1c71">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMy0yLTEtMS0xMDQ1MjI_42cf67a0-2bc8-403d-9096-d1c400c5132f">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMy00LTEtMS0xMDQ1MjI_8bdc78b0-f652-4694-a40d-22eed795abcf">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNC0yLTEtMS0xMDQ1MjI_bd26194a-33f9-4fef-95df-099da2a1a3a3">2,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNC00LTEtMS0xMDQ1MjI_3feaada8-e1ca-4346-b5d2-d298066e2d75">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNy0yLTEtMS0xMDQ1MjI_00679a2d-12cf-48bc-99e1-5e7993960a9d">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNy00LTEtMS0xMDQ1MjI_e8e0b34b-abac-4fdb-8aad-081f9e201638">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOC0yLTEtMS0xMDQ1MjI_d3022016-0f6e-4283-8311-e8f3615a63f9">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOC00LTEtMS0xMDQ1MjI_ae76079f-7d26-4279-8a8c-40475b07cc28">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOS0yLTEtMS0xMDQ1MjI_1d7cf2f0-69ce-478b-9f7d-d039d1fd708f">2,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOS00LTEtMS0xMDQ1MjI_1fe435b7-6424-4cb9-9ddb-7792e8fdfbd4">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities </span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjQy_afd21017-2513-497f-998d-fde768d27cac" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMS0yLTEtMS0xMDQ1MjI_b3fb5da4-3f2a-45d2-abb7-7af9160c65df">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMS00LTEtMS0xMDQ1MjI_58e1d7e2-d89f-4e2e-bd7e-f3bcf52907f8">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMi0yLTEtMS0xMDQ1MjI_d02102b7-478f-4ebc-ab92-e26e4f2f6832">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMi00LTEtMS0xMDQ1MjI_7d50cad7-7f8c-420f-bb43-3df9c322a162">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMy0yLTEtMS0xMDQ1MjI_491efb3f-f79e-4dd0-bae6-46b3d4fbd872">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMy00LTEtMS0xMDQ1MjI_ca88d0f2-4c10-47ab-8596-2c39125d2371">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC0yLTEtMS0xMTU0ODA_26f8b207-6ee2-49e5-af94-c76b304f4771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC00LTEtMS0xMTU0ODA_14eb030f-246c-4d83-a05c-8178168efc17">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC0yLTEtMS0xMDQ1MjI_f41357c6-436d-4bff-8757-7bb04bcc22fb">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC00LTEtMS0xMDQ1MjI_07700d52-e791-4fc6-ad72-42e733ebd6e8">2,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNS0yLTEtMS0xMDQ1MjI_50618106-0113-4ee5-83f5-34c9d307ec6b">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNS00LTEtMS0xMDQ1MjI_609216c9-01fd-4320-880e-ebcc947b5eab">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 10. Commitments and Contingencies for additional information.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTEzNQ_8e22c535-dd5d-4c0b-a7bd-7e2ee3d2a372" continuedAt="i360f583fae434f399c25428dd3063f32" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="i360f583fae434f399c25428dd3063f32"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTE1OA_fb772bde-f4df-4826-8c7d-2a63dffe0d62" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf5248381b9f4abebf4c2f5778f80f05_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNS02LTEtMS0xMDQ1MjI_d00a91d2-9eb8-41cf-ad46-1879e8d81e2c">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia203cc43338e4b63a44ff1ec45bc1a31_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNS04LTEtMS0xMDQ1MjI_2c7fe632-57d8-4295-abb5-df15bd08d45e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5248381b9f4abebf4c2f5778f80f05_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNS0xMC0xLTEtMTA0NTIy_4f85ec3a-9661-46ce-b5dc-ec708499d0f3">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf7de9e17b244038bf3bc1cff4883ce2_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNi02LTEtMS0xMDQ1MjI_ef702c5a-9d1d-46e1-b5fd-6736752475c5">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7de9e17b244038bf3bc1cff4883ce2_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNi04LTEtMS0xMDQ1MjI_5d9f6b09-708f-4c1d-9694-08599ac2cbc2">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d50a2523c6d40889f73a7fabfab2e49_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNi0xMC0xLTEtMTA0NTIy_11abda29-d2a6-44ee-9b15-758bd083f243">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ea02e471b61436f9c0ec424b611b358_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNy02LTEtMS0xMDQ1MjI_60fc98e5-2e1c-43eb-91d6-d9805923ec7d">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea02e471b61436f9c0ec424b611b358_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNy04LTEtMS0xMDQ1MjI_779d6fd6-b485-4e41-a589-7ab664d51452">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53a5ab8e03f4ffb92c7f39803b6595b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNy0xMC0xLTEtMTA0NTIy_f14d7849-a0b9-4f91-a132-da60fab3e326">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e70a13105b4454e9983b755cf5e801b_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS02LTEtMS0xMDQ1MjI_d8f3c793-bc1b-402f-836e-ab0b09a48a6e"><ix:nonFraction unitRef="number" contextRef="i8e70a13105b4454e9983b755cf5e801b_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS02LTEtMS0xMDQ1MjI_da52f47e-16b6-4588-b487-8c4feae8d9d8">0.75</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e70a13105b4454e9983b755cf5e801b_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS04LTEtMS0xMDQ1MjI_9a8d9383-73a9-40a0-8ec6-928354601702">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia375ee6d18984f8cb58cbf41605a3a02_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS0xMC0xLTEtMTA0NTIy_c96670b1-273e-44af-bd0a-15583242f928">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d36da1631914269907cd58f8afe4bac_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTEtNi0xLTEtMTA0NTIy_198bd4cf-69ba-4544-b836-d696f095394f">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d36da1631914269907cd58f8afe4bac_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTEtOC0xLTEtMTA0NTIy_91e94741-1cf7-4b21-8de3-93783d59af42">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ffac061a264104a18929d13674c19e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTEtMTAtMS0xLTEwNDUyMg_f545cfbc-ed0e-41b0-8c50-1ca5eaeff7ba">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b34c3a4e3a3433c96acaa5ecaa28b50_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTItNi0xLTEtMTA0NTIy_53006091-9f14-4c39-84b8-7ad90d9438d9">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b34c3a4e3a3433c96acaa5ecaa28b50_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTItOC0xLTEtMTA0NTIy_8cf6ef11-4f25-4b48-bc14-932fef7a3c70">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec48a6ac3ce4cb08310b8ee51083fde_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTItMTAtMS0xLTEwNDUyMg_f8a7eb1a-bce3-490d-9502-437104ded069">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i778b869054c9463e8cd09ca793264290_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTMtNi0xLTEtMTA0NTIy_eb199303-1b9d-430a-a1c6-f7d032b47cc2">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778b869054c9463e8cd09ca793264290_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTMtOC0xLTEtMTA0NTIy_9cc4d77a-beb1-4d2d-8c0e-55eb3e729ecd">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a458700e8ab46c588af1e244ecdd413_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTMtMTAtMS0xLTEwNDUyMg_0b301436-64dc-44d0-948a-4c8978789d7b">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86e1179fb9c24e2fa4872abe26299e32_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTQtNi0xLTEtMTA0NTIy_81975d5a-c0d9-4ab8-9a4f-40099b020542">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e1179fb9c24e2fa4872abe26299e32_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTQtOC0xLTEtMTA0NTIy_f745dea1-92b0-486f-ba00-14e694e2a1c0">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80beed14e70493c85b0036c04e5e1b5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTQtMTAtMS0xLTEwNDUyMg_cee91ce7-4b99-42a2-b50e-15f0f5b7bddd">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtNi0xLTEtMTA0NTIy_86457f94-adac-4f6f-be53-74db6050b8f2"><ix:nonFraction unitRef="number" contextRef="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtNi0xLTEtMTA0NTIy_ba25e006-3eec-4227-aea6-216baca24fc7">1.20</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtOC0xLTEtMTA0NTIy_febe1f00-6812-4356-a046-3598ebc1ee19">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1898e2ef2bd41e092d17dd630de1f86_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtMTAtMS0xLTEwNDUyMg_ca52a6a9-1d3d-4740-ab34-bacc1e2da634">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i766605ef96f74675add6345046f2ff5f_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtNi0xLTEtMTA0NTIy_1605785d-e84a-4f84-abd6-8aa6c90ae6b0"><ix:nonFraction unitRef="number" contextRef="i766605ef96f74675add6345046f2ff5f_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtNi0xLTEtMTA0NTIy_a29a2f7c-0fec-42fb-bab8-333e4e44c27c">1.65</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766605ef96f74675add6345046f2ff5f_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtOC0xLTEtMTA0NTIy_e7aad822-6802-4aa5-94cd-74076f0e4f91">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c33c2ee7674cc6a7f7187ddd22ac13_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtMTAtMS0xLTEwNDUyMg_6598d399-1f30-47ba-9ac2-7ede3c719406">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i849968d6d54e42b7a4440de8cb2b01f9_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTctNi0xLTEtMTA0NTIy_3badde69-ce8a-4db2-ae4b-becfbad91e29">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849968d6d54e42b7a4440de8cb2b01f9_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTctOC0xLTEtMTA0NTIy_521d3134-0453-40d4-ab17-deda47c5eb45">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bc99a828e44a87aeb970348be95119_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTctMTAtMS0xLTEwNDUyMg_23e9500a-d682-48ee-ba8b-3c78e709d088">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if52d4ee07275499f9e21b3b419e65345_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTgtNi0xLTEtMTA0NTIy_13cb720f-4b78-4855-8982-815d174a3ecb">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d4ee07275499f9e21b3b419e65345_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTgtOC0xLTEtMTA0NTIy_26a5e004-657d-4eb7-b93c-a0a59f8d7df9">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2259043e9523429d8166efc5e113295f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTgtMTAtMS0xLTEwNDUyMg_22c92d0a-7626-4f71-8c3f-5c9e98141929">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i406c686943914b65a05b788e6714fa04_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktNi0xLTEtMTA0NTIy_6dc8ccd2-e340-468d-acf7-5544d40ce260"><ix:nonFraction unitRef="number" contextRef="i406c686943914b65a05b788e6714fa04_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktNi0xLTEtMTA0NTIy_7ccec520-2b2b-47e9-bae3-caa8e8903e3f">2.60</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406c686943914b65a05b788e6714fa04_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktOC0xLTEtMTA0NTIy_2329332b-431a-4f19-9fc9-a3430fd01eaa">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35dedb6bce1648f5aacca48840848457_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktMTAtMS0xLTEwNDUyMg_5809f794-233c-41cc-90f3-f91813fb1a83">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb3ff054de0246f682af95f77b83ccd9_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjAtNi0xLTEtMTA0NTIy_cdea2f30-5580-412b-87ef-fa42424574a1">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3ff054de0246f682af95f77b83ccd9_I20220331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjAtOC0xLTEtMTA0NTIy_4577686d-4f7c-469f-9206-c1c40924710f">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8297424984554341a6cf87b296e9e43d_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjAtMTAtMS0xLTEwNDUyMg_c21a25e9-2fcd-40e0-86f9-4aba6c0976d2">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic27643ccf07b464b925ac68cbdb116cb_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjEtNi0xLTEtMTA0NTIy_92d018c0-c953-4608-8088-9a5a955af6b8">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27643ccf07b464b925ac68cbdb116cb_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjEtOC0xLTEtMTA0NTIy_9aaf4294-7435-43a2-ac43-cf01c7616815">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dc99172f8b246e88d87b181a2923978_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjEtMTAtMS0xLTEwNDUyMg_ed1a710a-bd17-46e6-ba8c-f1b3ead1ab47">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i498ffcf1be474bd3918aef4609196972_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjItNi0xLTEtMTA0NTIy_d40ca763-7d2e-42d4-a88e-3c71c07d5f1b">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498ffcf1be474bd3918aef4609196972_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjItOC0xLTEtMTA0NTIy_e960ab61-be80-41a6-9964-e07679a4d91f">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb76d2db3b804d9dababcc6f82e2d016_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjItMTAtMS0xLTEwNDUyMg_7e5698b6-93d6-46db-acaa-c24ab4db2d00">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fa725b2b3e84d07b775bc9eaa5463c8_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjMtNi0xLTEtMTA0NTIy_9844a121-cfc8-4a0a-be86-cd8fad02b6d8">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa725b2b3e84d07b775bc9eaa5463c8_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjMtOC0xLTEtMTA0NTIy_721f0856-7c6b-44cd-8556-b290d3a734d3">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd14cdab0be64d6aabc8c30d9b047909_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjMtMTAtMS0xLTEwNDUyMg_41459526-ed17-4c97-afdd-54dcf46f3117">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06221e90836348968d49234dbf14d1bd_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjQtNi0xLTEtMTA0NTIy_63fab4f4-b295-4339-a88d-beda350d3bea">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06221e90836348968d49234dbf14d1bd_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjQtOC0xLTEtMTA0NTIy_116278c2-a617-4d24-bf36-94d98fbaad08">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbeb6c7348bb4b8aaa56ac4ec2c04a5f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjQtMTAtMS0xLTEwNDUyMg_5409bbca-8f87-4bf2-83bc-e76124e47b64">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9a2802dbbc844e2858b672dfcde8038_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtNi0xLTEtMTA0NTIy_64318f78-79cb-49dc-8ef3-a3a5d1f77a31"><ix:nonFraction unitRef="number" contextRef="ib9a2802dbbc844e2858b672dfcde8038_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtNi0xLTEtMTA0NTIy_eeeb4636-9c49-47c7-ab63-7e8c028bf7d0">2.80</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a2802dbbc844e2858b672dfcde8038_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtOC0xLTEtMTA0NTIy_6e1e4919-547f-4da2-b840-b0ad2fc720da">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd02b491e1a447e7bed36e4655ecccb3_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtMTAtMS0xLTEwNDUyMg_aa69731d-db2f-4d16-a3b2-367afb53a5dd">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6813bb08ecdd4b31892315a2074efcc6_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjYtOC0xLTEtMTA0NTIy_8d03ef06-2945-4ef8-8816-c50c40de43f1">25,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388fe16439ae47f3b185a0de4b4ddf82_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjYtMTAtMS0xLTEwNDUyMg_2511dc45-6340-49ea-a33d-b2de4f48d053">25,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5317908672c2495db89fbaa4d6ab0754_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjctOC0xLTEtMTA0NTIy_47760f34-2ffa-4386-a45b-c2b626a31d68">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ab28eb41e345ada758ce1aab74170a_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjctMTAtMS0xLTEwNDUyMg_a22e7042-1ef4-4fef-82cb-e3b3b9e80de1">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjgtOC0xLTEtMTA0NTIy_ac59922a-b8dc-4106-9de0-c96220882499">26,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjgtMTAtMS0xLTEwNDUyMg_855a5a71-019a-40a9-8726-969f8cc5c16b">26,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjktOC0xLTEtMTA0NTIy_8d02d380-45a8-4a83-86f7-2440a3162273">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjktMTAtMS0xLTEwNDUyMg_9ab1bb18-3390-43b8-94ce-d6e8a14face3">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMzAtOC0xLTEtMTA0NTIy_ca5bda9c-46bd-4f5f-bd4b-d85499a015c4">25,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMzAtMTAtMS0xLTEwNDUyMg_7f1c260e-b8c8-4354-b987-dcd23072d656">25,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we repaid $<ix:nonFraction unitRef="usd" contextRef="ib9c0fa504fd846aabc3b372785f24c97_D20220201-20220228" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTY0OTI2NzQ0MjgzMw_c5684219-d71a-4f7c-920f-7ea3be7ee86e">500</ix:nonFraction> million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. <ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="INF" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfNzU4_9045e1c7-8d0a-4545-96d8-7ff62c10bd86">No</ix:nonFraction> new debt was issued during the three months ended March 31, 2022. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2022, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i6007d0be2b424a0c8e7fc133a041c624_I20211231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMzI5ODUzNDg4NTM3OQ_20814aad-2095-46d1-95fd-6ea5b50a0732"><ix:nonFraction unitRef="usd" contextRef="iacaf1b5ba1374bdbbdfce05c8d032bab_I20220331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMzI5ODUzNDg4NTM3OQ_e972c575-2ed6-48d9-9728-333409c9a7b5">no</ix:nonFraction></ix:nonFraction> amounts outstanding under our $<ix:nonFraction unitRef="usd" contextRef="iacaf1b5ba1374bdbbdfce05c8d032bab_I20220331" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTAzOA_0c1335d5-8a0b-4a65-97fe-8f3848cbd9e8">2.5</ix:nonFraction> billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjQ4OTA_26492f7e-290c-4556-bd55-6e6f904d4271" continuedAt="i88c20f8965b243da8883290b1b98a25a" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i88c20f8965b243da8883290b1b98a25a" continuedAt="ia6f479c51e7645d48279f3ef0c7c39ae"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did <ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="INF" name="us-gaap:LitigationReserve" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfOTM0NTg0ODk4MjQ1OA_8154a752-c0f1-4b19-bb52-4c0ccffcb347">no</ix:nonFraction>t have any material accruals for the matters described below as of March&#160;31, 2022. As of December&#160;31, 2021, we recorded an accrual of $<ix:nonFraction unitRef="usd" contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTc3ODMzOA_b6db48a0-8535-4a8b-b2b7-aea3143a66b9">1.25</ix:nonFraction> billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation described below, which we paid during the three months ended March 31, 2022.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. In April 2022, we filed a motion for grant of a compulsory license before the Federal Patent Court in Germany. The hearing date for the German NuCana infringement case has been scheduled for May 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hearing date for the UK NuCana case has been scheduled for January 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia6f479c51e7645d48279f3ef0c7c39ae" continuedAt="i3343dd5a7d814486afaa2ec65a1f8ec9"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $<ix:nonFraction unitRef="usd" contextRef="ic477d5bf6c90403e856da095ce607bef_D20191201-20191231" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI4MA_55cd25f4-d4b3-40da-afed-07c4098436cc">585</ix:nonFraction> million in an upfront payment and a <ix:nonFraction unitRef="number" contextRef="ic477d5bf6c90403e856da095ce607bef_D20191201-20191231" decimals="3" name="gild:JudgmentRoyaltyRateFromOctober2017" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI4NA_3f02f5a7-5673-4c88-bc7b-749f94f243a0">27.6</ix:nonFraction>% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by <ix:nonFraction unitRef="number" contextRef="ie9d9c9741d4e4098bcc97e45010d58c3_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesOnPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI4OA_3b590672-3654-48ba-b140-812f5f98cb12">50</ix:nonFraction>% and maintained the royalties on future Yescarta sales at <ix:nonFraction unitRef="number" contextRef="ie9d9c9741d4e4098bcc97e45010d58c3_I20200430" decimals="3" name="gild:JudgmentRoyaltyRateOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI5Mg_b608af32-cb74-4b77-94d5-44004007463f">27.6</ix:nonFraction>%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict, finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#8217;s petition for rehearing. We believe that the likelihood of a material adverse outcome in this matter is remote.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;VHC&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes VHC&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering VHC&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. In its lawsuit, VHC was seeking billions of dollars for alleged damages comprised of VHC&#8217;s lost profits and a royalty on U.S. sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we also expected VHC to seek a royalty on U.S. sales after the trial.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, VHC also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound infringes VHC&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and VHC. The &#8217;282 patent is the compound patent covering VHC&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In November and December 2019, VHC filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206; in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 and 1363875. These patents all relate to molecules that VHC claims would act as integrase inhibitors. We believe that bictegravir does not infringe any valid claims of VHC&#8217;s patents and have prevailed in court proceedings to date in Canada and Germany. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, Gilead reached an agreement (the &#8220;Settlement&#8221;) with VHC, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi &amp; Co., Ltd. and GlaxoSmithKline Mercury Limited (collectively, &#8220;ViiV&#8221;) for a global resolution of all pending or potential claims related to Gilead&#8217;s sales of Biktarvy, including the litigation pending in the U.S. District Court of Delaware and other jurisdictions outside the United States as described above. In February 2022, the lawsuit pending in the United States was dismissed as well as the lawsuits in Canada, France, Germany, Ireland, the UK, Australia, Japan and Korea.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir. In connection with the Settlement, Gilead (1) made a one-time payment to ViiV of $<ix:nonFraction unitRef="usd" contextRef="ic03333a449154cb7b8232d024d98f8f8_D20220101-20220331" decimals="-7" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTc3ODc5Mw_96a93e7d-3103-44c0-9c3e-11d8d6791364">1.25</ix:nonFraction> billion in the first quarter of 2022, and (2) will provide ViiV an ongoing royalty at a rate of <ix:nonFraction unitRef="number" contextRef="id1c1bf3df91d4e6db4587e1096299bf0_D20220201-20220201" decimals="2" name="gild:LossContingencyRoyaltyPercentageOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM2OA_9fbed281-4276-47db-8c35-f7f535981753">3</ix:nonFraction>% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027. In connection with the Settlement, Gilead recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i80ccebc28b844e218656b87fdf4c2179_D20210101-20211231" decimals="-7" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM3Mg_49e62d64-3dac-433d-9936-14b5562464e3">1.25</ix:nonFraction> billion to Cost of goods sold on our Consolidated Financial Statements in our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3343dd5a7d814486afaa2ec65a1f8ec9" continuedAt="i7b710f3e02a94931bebbf03ebf9e5740"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or tenofovir alafenamide (&#8220;TAF&#8221;) prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of <ix:nonFraction unitRef="agreement" contextRef="i0018ba912b0047809cae45058f13a571_I20200430" decimals="INF" name="gild:LossContingencyMaterialTransferAgreementsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM3OA_ba90ff45-aea7-48d0-b8c7-3ebba0c6bb13">four</ix:nonFraction> material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd. (&#8220;Lupin&#8221;), Apotex Inc., Shilpa Medicare Ltd. (&#8220;Shilpa&#8221;), Sunshine Lake Pharma Co. Ltd. (&#8220;Sunshine Lake&#8221;), Laurus Labs (&#8220;Laurus&#8221;), Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (&#8220;Cipla&#8221;) (collectively, &#8220;Generic Manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our TAF-containing products. Between them, these Generic Manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. The Generic Manufacturers have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="i185d5cd8a06a4180acfc1cbdbf6ae18f_D20191201-20191231" decimals="INF" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM5MA_dbf1881a-05a0-44c6-aace-5babcd4fe967">two</ix:nonFraction> to <ix:nonFraction unitRef="patent" contextRef="i185d5cd8a06a4180acfc1cbdbf6ae18f_D20191201-20191231" decimals="INF" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM4NA_e159044d-3ef6-4b8d-b3a5-04e01d9a757d">four</ix:nonFraction> patents listed on the Orange Book and associated with TAF. We filed lawsuits against the Generic Manufacturers, and we intend to enforce and defend our intellectual property. In November 2021, we reached an agreement with Shilpa to resolve the lawsuit against Shilpa. In addition, in January 2022, we reached an agreement with Sunshine Lake to resolve the lawsuit against Sunshine Lake. The settlement agreements have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law. In April 2022, the case against Laurus was dismissed after Laurus agreed not to challenge any of the Orange Book-listed patents associated with TAF.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen, filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of <ix:nonFraction unitRef="patent" contextRef="iaf92539a830e4f129492e4de6932612b_D20211001-20211031" decimals="INF" name="gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM5OA_7aa68011-35fa-406a-a431-1c83f5d56eb6">two</ix:nonFraction> additional patents in the same court. This second case has been stayed pending resolution of the generic litigation regarding our TAF-containing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2022, we received letters from Lupin, Laurus and Cipla indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="i9df3344fe2684c4db01931149342fe76_D20220301-20220331" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTY0OTI2NzU4OTQzNA_a9278cef-9efe-422f-b827-8c365a35924b">three</ix:nonFraction> of the <ix:nonFraction unitRef="patent" contextRef="i9df3344fe2684c4db01931149342fe76_D20220301-20220331" decimals="INF" name="gild:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTY0OTI2NzU4OTQ0MQ_74d9bbca-9383-4cc4-81e0-b670b41c281b">five</ix:nonFraction> patents listed in the Orange Book as associated with Biktarvy. We intend to enforce and defend our intellectual property. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7b710f3e02a94931bebbf03ebf9e5740" continuedAt="i7cb47ad4a4cd48ebb5d1e413b05c40ac"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. <ix:nonFraction unitRef="opposingparty" contextRef="ibc02333637e24bd4ab2f7235cb6e6be5_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3MzcyOA_7255a7ed-0133-4e5f-9fd0-1fd226988a85">Two</ix:nonFraction> of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. <ix:nonFraction unitRef="opposingparty" contextRef="i3a3b1fcfcfcf4d1288de350903d04105_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3MzczNQ_833b4fa1-a9cf-499b-87d5-fc8713728725">Three</ix:nonFraction> parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. <ix:nonFraction unitRef="opposingparty" contextRef="ifc6a4c4eb7dd45e19e3d027acae2a40c_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3Mzc0Nw_5df183b8-7996-4cc0-91b5-200334074d68">Three</ix:nonFraction> parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, <ix:nonFraction unitRef="party" contextRef="ie253cd11e2894e2eb71ca1ebfd05ee3a_D20160101-20161231" decimals="INF" name="gild:LossContingencyPartiesFilingOppositionNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3Mzc1NA_e454447f-ad85-47ed-a477-3b3120cca87b">three</ix:nonFraction> parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2028. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. <ix:nonFraction unitRef="opposingparty" contextRef="if2e36e12155d43ce870b52c07b49d3b0_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3Mzc2MA_16245a28-53e0-4999-8a9e-67dfb1fbeb15">Two</ix:nonFraction> parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes&#8212;one of direct purchasers consisting largely of wholesalers, and another of indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the fall of 2021, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have been coordinated with the class actions. Trial is set for March 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#8220;Cipla Defendants&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and Teva Pharmaceutical Industries Ltd. were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i480272d3e47746109dccd3cc3b185332_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDQzOQ_864ac7c5-0cc6-414c-b427-395e98cdc268">one</ix:nonFraction> class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Missouri and New Jersey, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="i480272d3e47746109dccd3cc3b185332_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDQ1Mg_08ba85a5-8573-40f1-9370-7531df5c485c">27,000</ix:nonFraction> plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7cb47ad4a4cd48ebb5d1e413b05c40ac"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="plaintiff" contextRef="i8a21d016ed3f4fef846e7281366b96ba_D20200401-20200430" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDQ1Ng_7a2136b0-567b-4b85-bb09-88dcd7180284">Two</ix:nonFraction> former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8220;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA. In December 2021, Gilead and relators executed a settlement agreement to resolve the lawsuit, and in February 2022, the court issued an order dismissing the lawsuit with prejudice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement does not have a material impact to our Consolidated Financial Statements. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div></ix:continuation><div id="ib054ed57a41746f6adeff83e9a6e8cad_67"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTU5Nw_46ddee76-9e0c-42a2-8a28-2fe9fd3d98b6" continuedAt="i39c9f6d52d6948468d08ccbd905a04e0" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i39c9f6d52d6948468d08ccbd905a04e0" continuedAt="if760501b9c5b48d38091979c14681cc9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="ie28098faeeb64ff9abedb2ceb8db8e9b_I20160331" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTA0_f4713ec4-e351-4db6-9c60-82e50928654f">12.0</ix:nonFraction> billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="ic645773c025f4573b8df34872cf19436_I20200331" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMzU3_3e1326aa-7858-49ec-be32-a2ea5150a93b">5.0</ix:nonFraction> billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the remaining authorized repurchase amount under both programs was $<ix:nonFraction unitRef="usd" contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTA5OTUxMTYzMDIxMA_df3c29d6-e3e8-47d6-9993-40ea7cd62568">5.9</ix:nonFraction> billion</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if760501b9c5b48d38091979c14681cc9"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfOTM0NTg0ODgzOTU1Mg_3bdc6b9c-6c8e-4651-9628-257503f86364" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases through open market transactions under the 2016 Program:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMi0yLTEtMS0xMjE2NzU_3a2106e7-3517-4816-aa54-82176048b829">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMi00LTEtMS0xMjE2NzU_21357535-a99d-47b3-9d32-69a03b02750b">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMy0yLTEtMS0xMjE2NzU_90f6c05d-5b8a-4dfa-9aa7-90982856928a">352</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMy00LTEtMS0xMjE2NzU_860ba81e-c673-4e54-8a87-a588b6f8745c">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTYwNQ_de417cb6-672a-462c-82ee-9fda2bb91bef" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2b570214ba4b4380a34ff9a40f2812_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS0yLTEtMS0xMDQ1MjI_228c45b1-1ee4-4b2a-b084-d3a199050c2d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f95a618e4294659ad494cd557c4c835_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS00LTEtMS0xMDQ1MjI_b00bab2b-633f-46b7-876e-09c932fb0eea">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218acb5be9394b00a1883e43cf92536c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS02LTEtMS0xMDQ1MjI_01c2fc93-b3b5-4514-a16a-19a66d3b51b4">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97be958f8ea44f6bf64ec6b93653cd0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS04LTEtMS0xMDQ1MjI_05124ec1-7bb8-4350-aa72-11d3a390229e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8302b75564a54dd8a549d442749edb52_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi0yLTEtMS0xMDQ1MjI_ac4b8464-5217-45dc-ac4e-cf19e5590f7b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi00LTEtMS0xMDQ1MjI_996d34bc-28f5-458a-a6e0-e0a4bbdd9a7d">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi02LTEtMS0xMDQ1MjI_5468a2fb-3670-4b51-9e1c-0897b09c9b86">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi04LTEtMS0xMDQ1MjI_9cb86c9c-31f7-48a0-a93f-e75e563f1b3f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8302b75564a54dd8a549d442749edb52_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy0yLTEtMS0xMDQ1MjI_476d88bd-1f07-4ee2-978d-b537e49d547b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy00LTEtMS0xMDQ1MjI_bb3ef6c9-67b3-46e1-9769-86abed2fd116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy02LTEtMS0xMDQ1MjI_8b875328-5dcf-4a04-9d0c-14717761bc6e">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy04LTEtMS0xMDQ1MjI_15ab2faf-ccd0-47c5-b983-6cb145067512">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8302b75564a54dd8a549d442749edb52_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC0yLTEtMS0xMDQ1MjI_c43351ef-2a6a-4492-a0f5-6601e814f692">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC00LTEtMS0xMDQ1MjI_9727ec53-6594-4f86-88fc-02bb71b4d4cb">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC02LTEtMS0xMDQ1MjI_0bf270ff-031a-41c7-b406-e1427242099b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC04LTEtMS0xMDQ1MjI_353cdfe5-a9b9-4828-b66a-337c090244c5">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d01a7b28f14000ac327b84cdbf6de2_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS0yLTEtMS0xMDQ1MjI_3455511e-d88e-4638-a787-3e18f6be047b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6073554deb9e48ac9edef34f381a133d_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS00LTEtMS0xMDQ1MjI_e98f5852-6d94-4245-a3d9-be0b19f1dce3">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb3a8cc8d58460b859489810a00ad9d_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS02LTEtMS0xMDQ1MjI_cc2daea3-57c5-4d07-a6c1-5c391579c35c">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id993c220a3874424a2e4ebabbf6841f5_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS04LTEtMS0xMDQ1MjI_735a1c82-1a2b-4e58-bbfd-e609b8c0d7da">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba93b576592245e8aad3a67ae9a4d33a_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS0yLTEtMS0xMDQ1MjI_bec5d15c-a76b-4888-93d1-e882e31b6055">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363d24e7ddb249f281fc0dcd63f42999_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS00LTEtMS0xMDQ1MjI_f3a6d15f-f7ea-4a25-8b52-ec22f4fff887">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaddf54d089b4e758cb7bcdc7898e276_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS02LTEtMS0xMDQ1MjI_e8a7ce5f-2f2b-4863-8074-120b18786f77">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8beedc1ba15342129f01b711293f2310_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS04LTEtMS0xMDQ1MjI_9b4f5508-5113-4190-bc7e-6b3a367dace5">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi0yLTEtMS0xMDQ1MjI_606edf6b-bff4-41a3-852a-92a1cd603391">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi00LTEtMS0xMDQ1MjI_3d99dc7b-b06c-44cd-8949-bb2e4c90646e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi02LTEtMS0xMDQ1MjI_0c4946cb-b239-4672-a8fd-b8a696c8d538">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi04LTEtMS0xMDQ1MjI_06a12a0d-87ef-4503-85aa-c41c8e310ca3">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy0yLTEtMS0xMDQ1MjI_2f1bc658-0e03-4844-a4f5-6a82aa8608f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy00LTEtMS0xMDQ1MjI_1550b538-8188-4724-87c5-aef737246a1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy02LTEtMS0xMDQ1MjI_fbf8bd10-d104-4a56-9d51-0efbf3c9a889">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy04LTEtMS0xMDQ1MjI_d8cf8e0a-c585-4e58-abd2-19cdaa4e55a1">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC0yLTEtMS0xMDQ1MjI_d93fecf6-2ba3-45c5-85b1-bbcf3cd562f3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC00LTEtMS0xMDQ1MjI_3815a840-345b-45b7-b7b3-7a111b1de038">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC02LTEtMS0xMDQ1MjI_42d26565-852f-494b-a071-941088d3449e">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC04LTEtMS0xMDQ1MjI_de54345b-b4e1-476f-8e1f-9fd5ff1001d2">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida8a7d072c434eef82e6df74c248a6fc_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS0yLTEtMS0xMDQ1MjI_eb536b1b-55d3-4cf5-8917-df63f782f0fd">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77b97648262458092baafbed5c40ad1_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS00LTEtMS0xMDQ1MjI_4bf37e4c-f7b9-407e-abe8-ab0c13651728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6704da2f166c4ccaba27a2d1ce1023bc_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS02LTEtMS0xMDQ1MjI_372d5f29-4865-412e-bf09-bacf3735e740">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72674008e77942a3986c777c8aab4eb4_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS04LTEtMS0xMDQ1MjI_14466c51-2ee8-4738-b88e-03a98d4f64d5">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to Net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to Net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div id="ib054ed57a41746f6adeff83e9a6e8cad_70"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfMTAyMQ_640a1cc6-fb37-4974-b326-9c812a5a5125" continuedAt="i42fb462ffe574b2583c0f060b2869d25" escape="true">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ix:nonNumeric></span></div><ix:continuation id="i42fb462ffe574b2583c0f060b2869d25" continuedAt="i522ea88e53c94222ae21d248e19ee969"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfODA1_267833ae-1628-4b0e-ab41-7037d0f30428">16</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfODI0NjMzNzIwOTU0NA_d02be4a9-b21b-4629-a382-cea73b82a925">15</ix:nonFraction> million, for the three months ended March 31, 2022 and 2021 respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i522ea88e53c94222ae21d248e19ee969"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfMTAyOA_6f8d0be4-c451-433c-84f8-2bf2f4c95023" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfMy0yLTEtMS0xMDQ1MjI_fb286ff2-b784-4579-a514-5576d3c0dbbb">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfMy00LTEtMS0xMDQ1MjI_ad52e8f3-b082-491d-836e-47985326a3fb">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNC0yLTEtMS0xMDQ1MjI_e6ad8943-0e20-49f9-aced-3dcefee05aa1">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNC00LTEtMS0xMDQ1MjI_cd892dc1-062b-4bd4-b422-775655bc6904">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNS0yLTEtMS0xMDQ1MjI_b246a18a-700b-4ae9-a82c-63770ac01b56">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNS00LTEtMS0xMDQ1MjI_048fc301-692c-4713-af66-a4a52fd6417a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNi0yLTEtMS0xMDQ1MjI_3145d47a-1fbc-4bcd-8b9e-186d6d1b71d2">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNi00LTEtMS0xMDQ1MjI_ae4bc811-c232-4f13-bfa3-57f86f1ac8c7">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOC0yLTEtMS0xMDQ1MjI_32dac2d5-da9d-494d-b34c-b69a71ae2e9d">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOC00LTEtMS0xMDQ1MjI_256981ea-fda5-474c-a0d9-cdd467941983">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOS0yLTEtMS0xMDQ1MjI_f34f5233-9615-4557-8bfb-dbcd119b2604">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOS00LTEtMS0xMDQ1MjI_5db5e269-394e-4c33-8f7b-56bb87d2588a">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib054ed57a41746f6adeff83e9a6e8cad_73"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMjEyOA_884a348e-f6a3-450b-b010-59e3859e3ab9" continuedAt="i6d0c9ce80ae54838892ed499eab277f6" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i6d0c9ce80ae54838892ed499eab277f6"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMjEyOQ_0034281d-4e31-4b90-b6b2-b7f7d9410225" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfMy0yLTEtMS0xMDQ1MjI_5f236620-4567-403e-9017-a2aa392030a9">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfMy00LTEtMS0xMDQ1MjI_1ab812a5-c30a-4006-adea-cabd5cde7545">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNC0yLTEtMS0xMDQ1MjI_5a97b446-71bc-4362-b146-f8fe88154238">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNC00LTEtMS0xMDQ1MjI_8870ad5f-aab6-4ae7-a929-03555a21558d">542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNS0yLTEtMS0xMDQ1MjI_a428dd98-0dc9-440d-a626-a43ddc272937">107.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNS00LTEtMS0xMDQ1MjI_bdd1fa89-77da-44fe-a74f-de775de124d5">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMTAy_a428dd98-0dc9-440d-a626-a43ddc272937">107.9</ix:nonFraction>% for the three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in state deferred tax liabilities associated with a partial IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMTA5OTUxMTYzNDg1NQ_eeb492c2-0a0a-4ff0-80fa-022d9e506532">2.7</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMjE5OTAyMzI1NzcwMA_8ce31cdf-0a6b-4f52-9d94-54ccbb04d04b">23.9</ix:nonFraction>% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to settlements with taxing authorities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span></div></ix:continuation><div id="ib054ed57a41746f6adeff83e9a6e8cad_1216"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xMjE2L2ZyYWc6ZmFiMTM1NzY2MmYwNGVkOThiYTVlNmJkZTVkMzFlMTgvdGV4dHJlZ2lvbjpmYWIxMzU3NjYyZjA0ZWQ5OGJhNWU2YmRlNWQzMWUxOF85MzQ1ODQ4ODQxMDg5_90f9c976-d2ba-4fe6-9170-3d806be25e37" continuedAt="i854b034184324d79be788736ebdab347" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i854b034184324d79be788736ebdab347">In April 2022, we entered into a strategic research collaboration agreement with Dragonfly Therapeutics, Inc. (&#8220;Dragonfly&#8221;) (the &#8220;Dragonfly Collaboration Agreement&#8221;) to develop natural killer (&#8220;NK&#8221;) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we will make a $<ix:nonFraction unitRef="usd" contextRef="ib6451f2f16f341a48298ff3195581dc3_D20220401-20220430" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xMjE2L2ZyYWc6ZmFiMTM1NzY2MmYwNGVkOThiYTVlNmJkZTVkMzFlMTgvdGV4dHJlZ2lvbjpmYWIxMzU3NjYyZjA0ZWQ5OGJhNWU2YmRlNWQzMWUxOF8xMDk5NTExNjMyNzU2_37838568-03c4-4736-a00d-0dadc9723560">300</ix:nonFraction> million upfront payment to Dragonfly. In addition, Dragonfly is eligible to receive potential opt-in payments and performance-based development, regulatory and commercial milestone payments. Dragonfly will also be eligible to receive royalties of up to <ix:nonFraction unitRef="number" contextRef="ife8577a82d764a7eb6649aba6ff99894_I20220430" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltiesPercentageMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xMjE2L2ZyYWc6ZmFiMTM1NzY2MmYwNGVkOThiYTVlNmJkZTVkMzFlMTgvdGV4dHJlZ2lvbjpmYWIxMzU3NjYyZjA0ZWQ5OGJhNWU2YmRlNWQzMWUxOF8xMDk5NTExNjMyNzYz_30454161-0626-4428-8301-286b67ae38d5">20</ix:nonFraction>% on worldwide net sales. The closing of the Dragonfly Collaboration Agreement is subject to antitrust clearances required by the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The forward-looking statements are contained principally in this section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors.&#8221; Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends, operating cost and revenue trends, liquidity and capital needs, collaboration and licensing arrangements, ongoing litigation and investigation matters, statements regarding the anticipated future impact on our business of the ongoing coronavirus disease 2019 (&#8220;COVID-19&#8221;) and related public health measures and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions. We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified below under Risk Factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of the U.S. Securities and Exchange Commission, we do not undertake and specifically decline any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in the section entitled Risk Factors under Part II, Item 1A of this Quarterly Report in addition to the other information in this Quarterly Report on Form&#160;10-Q. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following management&#8217;s discussion and analysis of our financial condition and results of operations in conjunction with our audited Consolidated Financial Statements and related notes thereto included as part of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2021 and our unaudited Condensed Consolidated Financial Statements for the three months ended March 31, 2022 and other disclosures (including the disclosures under Part II, Item&#160;1A. Risk Factors) included in this Quarterly Report on Form&#160;10-Q. Our Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars. Certain amounts and percentages herein may not sum or recalculate due to rounding.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT OVERVIEW</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bulevirtide), Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (filgotinib), Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, we entered into a strategic research collaboration agreement with Dragonfly Therapeutics, Inc. (&#8220;Dragonfly&#8221;) (the &#8220;Dragonfly Collaboration Agreement&#8221;) to develop natural killer cell engager-based immunotherapies for oncology and inflammation indications. Upon closing of the Dragonfly Collaboration Agreement, we will make a $300 million upfront payment to Dragonfly, subject to antitrust clearances required by the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved a supplemental new drug application for Veklury for the treatment of pediatric patients under 12 years of age for the treatment of COVID-19.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We announced and discussed these updates in further detail in press releases available on our website at www.gilead.com. Readers are also encouraged to review all other press releases available on our website mentioned above. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Quarterly Report on Form 10-Q.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, FDA approved commercial production at our new CAR T-cell therapy manufacturing facility in Frederick, Maryland.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, FDA granted approval to Yescarta as initial treatment for adults with large B-cell lymphoma (&#8220;LBCL&#8221;) that is refractory to or relapses within 12 months of first-line chemoimmunotherapy.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, we announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) metastatic breast cancer who received prior endocrine therapy, cyclin-dependent kinase (&#8220;CDK&#8221;) 4/6 inhibitors and two to four lines of chemotherapy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Financial Highlights </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased by 3% to $6.6 billion for the three months ended March 31, 2022, compared to $6.4 billion for the same period in 2021, primarily due to the continued growth of Biktarvy sales, the continued uptake of cell therapy products and Trodelvy, and increased sales of Veklury. The increases were partially offset by the decrease in Truvada sales, as expected, primarily due to the continued generic competition following the October 2020 loss of exclusivity in the United States.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead was $19 million, or $0.02 diluted earnings per share, for the three months ended March 31, 2022, compared to $1.7 billion, or $1.37 diluted earnings per share for the same period in 2021. The decrease was primarily due to a partial in-process research and development (&#8220;IPR&amp;D&#8221;) impairment charge of $2.7&#160;billion during the three months ended March 31, 2022 related to assets we acquired from Immunomedics, Inc. (&#8220;Immunomedics&#8221;) in 2020, partially offset by increased operating income as a result of higher revenues and lower net unrealized losses from our equity investments.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_82"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Total revenues:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic hepatitis B virus (&#8220;HBV&#8221;) / hepatitis delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cell therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 2. Revenues of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q for further disaggregation of revenue by product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales increased by 2% to $3.7&#160;billion for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to continued higher demand for Biktarvy worldwide and for Descovy for pre-exposure prophylaxis ("PrEP") in the United States, partially offset by lower demand for Truvada due to loss of exclusivity in the United States in October 2020, and for Genvoya, primarily due to patients switching to Biktarvy. We expect that our HIV business will continue to recover from the COVID-19 pandemic in 2022. We also expect the impact of the Truvada loss of exclusivity will be largely behind us starting in the second quarter of 2022.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury product sales increased by 5% to $1.5 billion for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to higher demand in Asia, partially offset by lower demand in Europe. Sales of Veklury are generally affected by COVID-19 related rates of infections, hospitalizations and vaccinations as well as the availability, uptake and effectiveness of alternative treatments for COVID-19. As a result, future sales of Veklury are difficult to predict and may vary significantly from one period to the next.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 22% to $399 million for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to lower average net selling price driven by government and commercial rebates in the United States and Europe, and lower demand driven by fewer patient starts in the United States.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HBV / HDV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales increased by 7% to $235 million for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to higher demand for Vemlidy and the continued uptake of Hepcludex in Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy product sales increased by 43% to $274 million for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to the continued uptake of Yescarta for the treatment of relapsed or refractory LBCL in the United States and Europe, and follicular lymphoma in the United States. The increase was also driven by higher Tecartus sales volumes resulting from expansion of use in Europe for mantle cell lymphoma and continued adoption in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy product sales increased by 103% to $146 million for the three months ended March 31, 2022, compared to the same period in 2021 primarily due to the continued uptake in the second line setting for the treatment of metastatic triple-negative breast cancer in the United States and Europe as well as second-line metastatic urothelial cancer in the United States.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales decreased by 2% to $236 million for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to lower demand for Letairis, driven by the continued generic competition following the loss of exclusivity in 2019, partially offset by higher demand for AmBisome.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Impact</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sales,</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34%</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 33% were generated outside the United States for the three months ended March 31, 2022 and 2021, respectively. We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. Foreign currency exchange, net of hedges, had an unfavorable impact on our total product sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$97 million</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the first quarter of 2022, based on a comparison using foreign currency exchange rates from first quarter of 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Total costs and expenses:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">-30 bps</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin for the three months ended March 31, 2022 decreased to 78.2% compared to 78.5% for the same period in 2021, primarily due to changes in product mix and restructuring costs for the closing of a New Jersey manufacturing site, partially offset by lower inventory reserve adjustments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses for the three months ended March 31, 2022 increased by $131 million or 12%, compared to the same period in 2021, primarily due to ramp-up in Trodelvy development and costs related to headcount growth.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research and Development Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with HR+/HER2- metastatic breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $6.1&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject to separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. There were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022. The remaining balance of the IPR&amp;D intangible asset for the HR+/HER2- metastatic breast cancer indication can be ascribed to cash flows from earlier lines of therapy, where we have Phase 3 pivotal studies in development, in addition to the revised cash flows related to the third-line plus patient setting. If future events result in adverse changes in the key assumptions used in determining fair value, including the timing of product launches, information on the competitive landscape of treatments in this indication, changes to the probability of technical or regulatory success, failure to obtain anticipated regulatory approval or discount rate, among others, additional impairments may be recorded and could be material to our financial statements. No IPR&amp;D impairment charges were recorded during the three months ended March 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses of $62 million for the three months ended March 31, 2021 were related to licensing, collaboration, investment and other arrangements we entered into during the period. There were no such arrangements during the three months ended March 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the three months ended March 31, 2022 increased by $28 million or 3%, compared to the same period in 2021, primarily due to higher promotional and marketing expenses largely related to Trodelvy. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense and Other Income (Expense), Net</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in Interest expense and Other income (expense), net:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March 31, 2022 decreased by $19 million or 7%, compared to the same period in 2021, primarily due to lower debt balances.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Other income (expense), net for the three months ended March 31, 2022, compared to the same period in 2021, primarily reflect lower net unrealized losses from equity securities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in Income tax benefit (expense):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense) and effective tax rate differed for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to a partial IPR&amp;D impairment charge of $2.7 billion recorded in the three months ended March 31, 2022.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable debt securities as of March 31, 2022 decreased by $1.1 billion or 14%, compared to December&#160;31, 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities represents the cash receipts and disbursements related to all activities other than investing and financing activities. Net cash provided by operating activities is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Net cash provided by operating activities decreased by $770 million to $1.8 billion for the three months ended March 31, 2022, compared to the same period in 2021. The decrease was primarily due to the payment of the $1.25 billion settlement related to bictegravir litigation, partially offset by higher product sales during the three months ended March 31, 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities primarily consists of purchases, sales and maturities of our marketable debt securities, capital expenditures, acquisitions, including IPR&amp;D, net of cash acquired, purchases of equity securities and other investments. Net cash used in investing activities decreased by $1.0 billion to $1.1 billion for the three months ended March 31, 2022, compared to the same period in 2021. The decrease in Net cash used in investing activities was primarily due to a decrease in cash outflows related to acquisitions, including IPR&amp;D, net of cash acquired. The decrease was partially offset by an increase in cash outflows for collaborations, primarily related to the opt-in payments of $725 million made to Arcus Biosciences, Inc. in January 2022, classified in Other in investing activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended March 31, 2022 was $1.8 billion, compared to $2.5&#160;billion for the same period in 2021. During the three months ended March 31, 2022, we utilized cash for $500 million of debt repayments, $945 million of dividend payments and $352&#160;million of common stock repurchases. During the three months ended March 31, 2021, we utilized cash for $1.25 billion of debt repayments, $917 million of dividend payments and $309 million of common stock repurchases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our borrowings under various financing arrangements is included in Note 9. Debt and Credit Facilities of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. We may choose to repay certain of our long-term debt obligations prior to maturity dates based on our assessment of current and long-term liquidity and capital requirements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we repaid $500 million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. No new debt was issued during the three months ended March 31, 2022. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2022, we were not in violation of any covenants.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Resources and Material Cash Requirements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our capital resources and material cash requirements is presented in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2021. As of January 1, 2022, for U.S. tax purposes, R&amp;D expenses are required to be capitalized and amortized rather than immediately deducted. As a result, our annual cash tax payments to the U.S Treasury may increase in the current year. Other than as described above, there were no material changes to our capital resources and material cash requirements during the three months ended March 31, 2022.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts in the financial statements and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. A summary of our critical accounting policies and estimates is presented in Part II, Item 7 of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2021. With the exception of our revised estimates related to our HR+/HER2- IPR&amp;D intangible assets as described in &#8220;Result of Operations&#8221; above, there were no material changes to our critical accounting policies and estimates during the three months ended March 31, 2022.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued nor adopted during the three months ended March 31, 2022 that are of significance to us.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6. Acquisitions, Collaborations and Other Arrangements of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q for additional information.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_100"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risk during the three months ended March 31, 2022 compared to the disclosures in Part II, Item 7A of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of March&#160;31, 2022 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) under the U.S. Securities Exchange Act of 1934, as amended (the Exchange Act), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2022, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_109"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, please see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. </span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_112"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Quarterly Report on Form 10-Q. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During the three months ended March 31, 2022, sales of our HIV products accounted for approximately 57% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products, including generics, or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, many of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), which belongs to the nucleoside class of antiviral therapeutics, and any changes to the treatment paradigm for HIV may cause nucleoside-based therapeutics to fall out of favor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our supply and distribution of Veklury, which was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2020 as a treatment for patients hospitalized with coronavirus disease 2019 (&#8220;COVID-19&#8221;) and in January 2022 as a treatment for non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. While the utilization of Veklury has largely tracked rates of COVID-19 hospitalizations, we are unable to accurately predict our revenues or supply needs over the short and long term due to the dynamic nature of the pandemic, including the availability, uptake and effectiveness of vaccines and alternative treatments for COVID-19, fluctuating hospital utilization rates, the emergence of new variants and timing of surges in infection. If we do not accurately forecast demand or manufacture Veklury at levels sufficient to meet demand, then we may experience product shortages or build excess inventory that may be written off. We also remain subject to significant public attention and scrutiny over the complex decisions made regarding clinical data, supply, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation. </span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Tecartus or Yescarta, which are chimeric antigen receptor (&#8220;CAR&#8221;) T-cell therapies, creates significant challenges, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of cell therapy;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. While FDA has approved some cell therapies, including Tecartus and Yescarta, we must continue to demonstrate to the medical community the potential advantages of cell therapy compared to existing and future therapeutics. For challenges related to the reimbursement of Tecartus and Yescarta, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Tecartus and Yescarta to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a new automated CAR T-cell therapy manufacturing facility in Frederick, Maryland, which received FDA approval for commercial production in April 2022. We have not previously manufactured our products in an automated facility on a commercial scale, and as a result, we may require additional time and resources in order to effectively increase manufacturing capacity. In addition, we may not be able to produce or otherwise obtain an amount of supply sufficient to satisfy demand for our products. If we are unable to meet product demand, we will have difficulty meeting sales forecasts for products that we plan to manufacture at this facility.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products, our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the United States, which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not necessarily mirror patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels, and we may continue to see this trend in the future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. For the three months ended March 31, 2022, approximately 91% of our product sales in the United States were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end-user demand and may not be completely effective in matching their inventory levels to actual end-user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end-user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end-user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of technologies which are competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union (&#8220;EU&#8221;) and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. In the United States, the volume of drug pricing-related bills has dramatically increased in recent years. For example, Congress has enacted laws requiring manufacturer refunds on certain amounts of discarded drug from single-use vials beginning in 2023 and eliminating the existing cap on Medicaid rebate amounts beginning in 2024. Congress has also proposed bills to require the Department of Health and Human Services to negotiate prices for certain drugs, impose an inflation-based rebate on Medicare Part B and D drugs when list prices for drugs grow faster than inflation, and increase manufacturer contributions in some or all of the Medicare Part D benefit phases. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain. Many countries outside the United States, including the EU Member States, have established complex and lengthy procedures to obtain price approvals and coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of this review cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal products in the EU member states. Reductions in the pricing of our medicinal products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug Rebate Program. Among other changes, effective January 1, 2023, the final rule will change the requirements for excluding manufacturer co-pay coupons from the Medicaid &#8220;best price.&#8221; These changes are subject to ongoing litigation. If these changes go into effect, they could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B covered entities. The continued growth of the 340B program also limits the prices we may charge on an increasing percentage of sales.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently implemented a contract pharmacy integrity initiative for our branded hepatitis C virus (&#8220;HCV&#8221;) products. This integrity initiative will not involve any products from Asegua Therapeutics LLC. Our integrity initiative requires covered entities that enter into 340B bill to/ship to arrangements with contract pharmacies for our branded HCV products to provide claims level data for units dispensed from such contract pharmacies; covered entities without an in-house pharmacy that choose not to participate in the initiative can designate a single contract pharmacy for shipment. Certain manufacturers that have implemented other contract pharmacy integrity programs have received enforcement letters from the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) asserting that those programs violate the 340B statute, have been referred to the HHS Office of Inspector General for assessment of civil monetary penalties, and have been subject to administrative dispute resolution proceedings brought on behalf of covered entities. These manufacturers are currently challenging HHS&#8217; position in ongoing litigation. Although we believe that our integrity initiative complies with the requirements of the 340B statute, additional legal or legislative developments with respect to the 340B program, including potential litigation with HHS, may negatively impact our ability to implement or continue our integrity initiative. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity-adjusted diagnosis-related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the EU, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the United States, actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may experience adverse impacts resulting from the importation of our products from lower price markets or the distribution of illegally diverted or counterfeit versions of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. For example, U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allows generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the United States, Europe or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, we are required to permit products purchased in one EU member state to be sold in another member state. Purchases of our products in member states where our selling prices are relatively low for resale in member states in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the efficacy of the products and could harm patients and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various suppliers around the world that, without Gilead&#8217;s authorization, purport to source our products and generic versions of our products and sell them for use in countries where those products have not been approved. As a result, patients may be at risk of taking unapproved medications that may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could harm patients and adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties have illegally distributed and sold, and may continue to illegally distribute and sell, illegally diverted and counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. For example, as part of an ongoing U.S. investigation in coordination with law enforcement, and pursuant to court order, we seized thousands of bottles of Gilead-labeled medication with counterfeit supply chain documentation. Our investigation revealed that pharmaceutical distributors that are not authorized by Gilead to sell Gilead medicine sold purported genuine Gilead medicine sourced from an illegal counterfeiting scheme to independent pharmacies nationwide.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illegally diverted and counterfeit versions of Gilead-branded medicines exist and may pose a serious risk to patient health and safety. Our actions to stop or prevent the distribution and sale of illegally diverted and counterfeit versions of our medicines around the world may be costly and unsuccessful, which may adversely affect patients and our reputation and business, including our product revenues and financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of product candidates that we develop for each intended use through extensive preclinical studies and clinical trials. The results from preclinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face numerous risks and uncertainties with our clinical trials that could result in delays or prevent completion of the development and approval of our product candidates. These risks and uncertainties include challenges in clinical trial protocol design, our ability to enroll patients in clinical trials, and the possibility of unfavorable or inadequate trial results to support further development of our product candidates, including failure to meet a trial&#8217;s primary endpoint, safety issues arising from our clinical trials, and the need to modify or delay our clinical trials or to perform additional trials. For example, we have announced that FDA issued a complete response letter for the new drug application for lenacapavir and placed clinical holds on studies evaluating (1) injectable lenacapavir, (2) lenacapavir in combination with islatravir and (3) magrolimab. In addition, see Note 7. Goodwill and Intangible Assets of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q for a discussion of the partial in-process research and development impairment charge of $2.7 billion during the three months ended March 31, 2022 related to assets we acquired from Immunomedics, Inc. in 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may be unable to successfully complete our clinical trials on our anticipated timelines, or at all. Based on trial results, it is possible that FDA and other regulatory authorities may not approve our product candidates, or that any market approvals may include significant limitations on the products&#8217; use. In addition, clinical trials involving our commercial products could raise new safety issues for our existing products, which could adversely impact our business. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. Therefore, our product candidates may never be successfully commercialized, and we may be unable to recoup the significant R&amp;D and clinical trial expenses incurred. In 2022, we anticipate the continued expansion of our clinical pipeline, which includes multiple planned Phase 3 study initiations in oncology and virology. We expect to expend significant time and resources on our clinical trial activities without any assurance that we will recoup our investments or that our efforts will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also risks associated with the use of third parties in our clinical trial activities. We extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also need to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications and quality standards, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our existing products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase sufficient quantities of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers are interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the United States. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the United States from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will file, for marketing approval in additional countries and for additional indications and products over the next several years. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines, suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is subject to various federal, state and international laws and regulations pertaining to drug reimbursement, rebates, price reporting, health care fraud and abuse, and data privacy and security. In the United States, these laws include anti-kickback and false claims laws, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, the Medicaid Rebate Statute, laws that regulate written and verbal communications about our products, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state health care programs, including Medicare, Medicaid and Department of Veterans Affairs and Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex, and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement and other patient support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted subsequent to obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or patients taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time before a patent is issued, we may not know if our competitors have filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by third parties that such parties may claim cover the use of sofosbuvir, axicabtagene ciloleucel or bictegravir, as well as certain uses of combinations of emtricitabine (&#8220;FTC&#8221;) and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or TAF. For a description of our pending patent litigation, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources. These matters could require us to pay significant monetary amounts, including royalty payments for past and future sales. For example, on February 1, 2022, we reached an agreement with ViiV Healthcare Company and related parties (collectively, &#8220;ViiV&#8221;) for a global resolution of all pending or potential claims related to our sales of Biktarvy, pursuant to which (1) ViiV granted Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir, and (2) Gilead agreed to make a one-time payment of $1.25 billion and an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigation and other dispute-related matters, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the ongoing COVID-19 outbreak.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, such as COVID-19, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. For example, the COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets and has resulted in increased risks and adverse impacts to our operations, including as described below. We are monitoring a number of risks related to the pandemic, including the following:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: The pandemic could result in disruptions to our global supply chain and distribution in the future. For example, quarantines, shelter-in-place and other governmental orders and policies, travel restrictions, airline capacity and route reductions, safety guidelines and health impacts of the pandemic could impact the availability or productivity of products and personnel at manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in higher costs, disruptions in our supply chain and interruptions in our distribution capabilities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Trials: The pandemic has adversely affected and may continue to adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. For ongoing trials, clinical trial sites have imposed restrictions on patient visits to limit risks of possible COVID-19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. There is also a risk that closures at clinical sites may be necessary as the pandemic and related guidance and restrictions continue to evolve. For the foregoing reasons, we have experienced delays with new subject enrollment for most clinical trials during the course of the pandemic, and may continue to experience overall delays in our clinical trials. There is also the risk of biased data collection if only certain clinical trial sites remain open. As a result of these challenges, our anticipated filing and marketing timelines for certain products may be adversely impacted.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory Reviews: The operations of FDA, EMA or other regulatory agencies may be adversely affected. We may also experience delays in necessary interactions with regulatory authorities around the world, including with respect to any anticipated filing, which, together with other factors resulting from the pandemic, may adversely impact our ability to launch new commercial products.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Access to Healthcare Providers: The pandemic has limited patients&#8217; ability or willingness to access and seek care from healthcare providers and initiate or continue therapies, which has resulted in lower demand for our products during the course of the pandemic, particularly with respect to HCV treatment and HIV treatment and prevention. For example, we have observed lower levels of patient visits and testing volumes in HCV, resulting in fewer patient starts. In addition, at times during the pandemic, we have seen lower levels of screening and diagnosis for HIV, resulting in fewer treatment initiations, as well as higher levels of discontinuations, resulting in a reduction in prescription refills. With increased levels of unemployment at times during the pandemic, we have also experienced shifts in payer mix towards more government-funded coverage and the uninsured segment. Our field personnel have also had reduced access to healthcare personnel during the pandemic, including fewer in-person interactions, which has adversely impacted and may continue to adversely impact our commercial activities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employees: We face risks related to the health, safety, morale and productivity of our employees, including the safe occupancy of our sites during the pandemic. In the fourth quarter of 2021, we transitioned to a return-to-site phase for our U.S. flexible location employees. Our job site enhancements and risk protocols, which include health screenings and COVID-19 testing and vaccine requirements, do not guarantee that we can maintain the continued safe occupancy of our sites and may adversely impact employee recruitment and retention. On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial: The pandemic has had, and may continue to have, an adverse financial impact in the short term and potentially beyond. In particular, our HCV and HIV businesses have been and continue to be adversely impacted. For example, we have observed reductions in the overall U.S. HCV treatment, HIV treatment and HIV pre-exposure prophylaxis (&#8220;PrEP&#8221;) volumes at times during the pandemic, and it is uncertain when these volumes will all return to pre-pandemic levels. We may continue to experience fluctuating revenues as infection rates rise and fall and as pandemic restrictions are periodically tightened and eased. We have also experienced, and may continue to experience, volatility in our short-term revenues due to fluctuations in inventory channel purchases during the pandemic. We could also have additional unexpected expenses related to the pandemic, which could negatively affect our results of operations. These factors together with the overall uncertainty and disruption caused by the pandemic could result in increased volatility and decreased predictability in our results of operations and volatility in our stock price.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic has also amplified many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q. The extent to which the pandemic impacts our business and results will depend on future developments, which are uncertain and cannot be predicted with confidence, including any potential future waves of the pandemic, new variants of the virus that impact the severity and duration of the pandemic, the development, distribution, effectiveness and public acceptance of vaccines, and any other ongoing and future actions taken to contain the pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Currency Exchange: For the three months ended March 31, 2022, approximately 34% of our product sales were outside the United States. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest Rates and Inflation: We hold interest-generating assets and interest-bearing liabilities, including our available-for-sale debt securities and our senior unsecured notes and credit facilities. Fluctuations in the interest rate could expose us to increased financial risk. In addition, changes in the inflation rate could also adversely impact our business and financial results.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state-controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation, the imposition of compulsory licenses or similar actions, including waiver of intellectual property protections.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the United States or other governments.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires, extreme heat, drought or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we may be uninsured or inadequately insured. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry adequate earthquake insurance and significant recovery time could be required to resume operations. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes, including Russia and Ukraine. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to environmental, social and governance (&#8220;ESG&#8221;) matters expose us to numerous risks, including risks to our reputation and stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institutional and individual investors are increasingly using ESG screening criteria to determine whether Gilead qualifies for inclusion in their investment portfolios. We are frequently asked by investors and other stakeholders to set ambitious ESG goals and provide new and more robust disclosure on goals, progress toward goals and other matters of interest to ESG stakeholders. In response, we have adapted the tracking and reporting of our corporate responsibility program to various evolving ESG frameworks, and we have established and announced goals and other objectives related to ESG matters. These goal statements reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, any of which could have a material negative impact, including on our reputation and stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve any goal or objective, including with respect to environmental and diversity initiatives, is subject to numerous risks, many of which are outside of our control. Examples of such risks include: (1) the availability and cost of low- or non-carbon-based energy sources and technologies, (2) evolving regulatory requirements affecting ESG standards or disclosures, (3) the availability of suppliers that can meet our sustainability, diversity and other standards, (4) our ability to recruit, develop and retain diverse talent in our labor markets, and (5) the impact of our organic growth and acquisitions or dispositions of businesses or operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. Our selection of disclosure frameworks that seek to align with various reporting standards may change from time to time and may result in a lack of consistent or meaningful comparative data from period to period. In addition, regulatory authorities may impose mandatory disclosure requirements with respect to ESG matters. For example, in March 2022, the SEC proposed rule changes that would require companies to make certain climate-related disclosures, including information about climate-related risks, greenhouse gas emissions and certain climate-related financial statement metrics. Our processes and controls may not reflect evolving standards for identifying, measuring and reporting ESG matters, immediately or at all, our interpretation of reporting standards may differ from those of others and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals. In addition, enhancements to our processes and controls to reflect evolving reporting standards may be costly and require additional resources. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our goals, targets and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to government enforcement actions and private litigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. For example, we have collaboration arrangements with Janssen Sciences Ireland UC for Odefsey, Complera/Eviplera and Symtuza. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant cybersecurity incidents could give rise to legal liability and regulatory action under data protection and privacy laws and adversely affect our business and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta and Tecartus. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and ransomware attack. Likewise, data privacy or security breaches by employees or others can result in the exposure of sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners to unauthorized persons or to the public. Cybersecurity incidents are increasing in their frequency, sophistication and intensity. Cybersecurity incidents include, for example, the deployment of harmful malware, ransomware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many companies, we have experienced cybersecurity incidents, including data breaches and service interruptions. When cybersecurity incidents occur, our policy is to respond and address them in accordance with applicable governmental regulations and other legal requirements, including our cybersecurity protocols. There can be no assurance that our efforts in response to cybersecurity incidents, as well as our investments to protect our information technology infrastructure and data, will shield us from significant losses and potential liability or prevent any future interruption or breach of our systems. Such cybersecurity incidents can cause the loss of critical or sensitive information, including personal information, and could give rise to legal liability and regulatory action under data protection and privacy laws. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act and the California Privacy Rights Act and other laws that have been or may be passed, similarly introduce requirements with respect to personal information, and non-compliance with such laws may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Other changes or new laws or regulations associated with the enhanced protection of personal information, including, in some cases, healthcare data or other personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges related to the products, intellectual property and technologies that are acquired or licensed. For example, as a result of an impairment analysis we conducted following our receipt of data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with hormone receptor-positive, human epidermal growth receptor 2-negative metastatic breast cancer, we recognized a partial impairment charge of $2.7 billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic transactions, such as in connection with our collaborations with Arcus Biosciences, Inc. and Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics, Inc. in 2020, S&amp;P Global Ratings downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and various foreign jurisdictions. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. Our effective tax rates are affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, the introduction of new taxes, and changes in tax laws, regulations, administrative practices and interpretations, including in the United States, Germany and Ireland.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the examination of our tax returns and other tax matters by the U.S. Internal Revenue Service and tax authorities in various foreign jurisdictions. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of Shares&#160;Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share (in dollars) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Total Number of Shares Purchased as Part of Publicly Announced Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum&#160;Approximate Dollar&#160;Value of&#160;Shares that&#160;May&#160;Yet&#160;Be Purchased&#160;Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> (in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - January 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,152&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 - February 28, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 - March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion share repurchase program (&#8220;2016 Program&#8221;). Shares purchased during the period were made under the 2016 Program. In January 2020, our Board of Directors authorized a new $5.0 billion stock repurchase program, which will commence upon the completion of the 2016 Program. Share repurchases under both programs may be made in the open market or in privately negotiated transactions. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is due to shares of common stock withheld by us from employee restricted stock awards in order to satisfy applicable tax withholding obligations.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_118"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_121"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_124"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_127"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;EXHIBITS </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Exhibit Index included herein. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Exhibit Index </span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d3.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Reference is made to Exhibit 3.1 and Exhibit 3.2</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note and Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2025 Note and Form of 2045 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the Company and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000008/gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="gildq12022ex1082022employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">commencing</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1012.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="gildq12022ex10182022psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1015.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="gildq12022ex10222022psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 202</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="gildq12022ex10222022psuagr.htm">2</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="gildq12022ex10222022psuagr.htm">)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1057.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="gildq12022ex10282022employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">commencing</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1028.htm">Performance share award agreement for Daniel O&#8217;Day (for TSR Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Performance share award agreement for Daniel O&#8217;Day (for Revenue Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1030.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1043housin.htm">Letter Agreement between Registrant and Johanna Mercier, dated May 4, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1041.htm">Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1043.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1045.htm">Global restricted stock unit issuance agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12022ex311ceocertific.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12022ex312cfocertific.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12022ex32section906ce.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule&#160;15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ib054ed57a41746f6adeff83e9a6e8cad_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ANDREW D. DICKINSON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>gildq12022ex1082022employe.htm
<DESCRIPTION>2022 EMPLOYEE STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9f7c5ddde67c4851b587427499d4cd0c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.8</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2004 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL STOCK OPTION AGREEMENT </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s grant of an option to Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;All capitalized terms used but not otherwise defined in this Agreement shall have the meaning assigned to them in the attached Appendix.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby grants an option to Optionee upon the following terms and conditions&#58;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby grants to Optionee an option to purchase shares of Common Stock under the Plan. The Grant Date, the Option Shares, the Exercise Price, the Vesting Schedule and the Expiration Date are indicated on this Agreement. The option is a non-statutory option under the U.S. federal income tax laws. The remaining terms and conditions governing this option shall be as set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPTION GRANT SPECIFICS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Name of Optionee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Number of Option Shares&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The options have a four-year vesting schedule. 25% vest on the first anniversary date of the Grant Date. The balance will vest 6.25% quarterly thereafter until fully vested. However, one or more Shares may be subject to accelerated vesting in accordance with the provisions of Paragraph 3 or 5 of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Expiration Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rsons to whom the option is </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The term of this option shall commence on the Grant Date and continue to be in effect until the close of business on the last business day prior to the Expiration Date, unless sooner terminated in accordance with Paragraph 5 or 6 below.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This option shall be neither transferable nor assignable by Optionee other than to Participant's designated beneficiary or, if none, to Participant's estate following Optionee&#8217;s death and may be exercised, during Optionee&#8217;s lifetime, only by Optionee.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Dates of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This option shall vest and become exercisable for the Option Shares in a series of installments in accordance with the Vesting Schedule set forth under Option Grant Specifics. As the option vests and becomes exercisable for such installments, those installments shall accumulate, and the option shall remain exercisable for the accumulated installments until the last business day prior to the Expiration Date or any sooner termination of the option term under Paragraph 5 or 6 below.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The option term specified in Paragraph 2 above shall terminate (and this option shall cease to be outstanding) prior to the Expiration Date should any of the following provisions become applicable&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise expressly provided in subparagraphs (b) through (f) of this Paragraph 5, should Optionee cease to remain in Continuous Service for any reason while this option is outstanding, then Optionee shall have until the close of business on the last business day prior to the expiration of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration of the three (3)-month period measured from the date of such cessation of Continuous Service, or (ii) the Expiration Date, during which to exercise this option for any or all of the Option Shares for which this option is vested and exercisable at the time of Optionee&#8217;s cessation of Continuous Service. Upon the expiration of such limited exercise period, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event Optionee ceases Continuous Service by reason of his or her death while this option is outstanding, then (i) this option shall become fully vested and exercisable upon such cessation of Continuous Service and (ii) this option may be exercised by (A) the person or persons to whom the option is transferred pursuant to Optionee&#8217;s valid beneficiary designation, or, if none, (B) the personal representative of  Optionee&#8217;s estate. Any such right to exercise this option shall lapse, and this option shall cease to be outstanding, upon the close of business on the last business day prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (x) the expiration of the twelve (12)-month period measured from the date of Optionee&#8217;s death or (y) the Expiration Date. Upon the expiration of such limited exercise period, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should Optionee cease Continuous Service by reason of Permanent Disability while this option is outstanding, then (i) this option shall become fully vested and exercisable and (ii) Optionee shall have until the close of business on the last business day prior to the earlier of (A) expiration of the twelve (12)-month period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date, during which to exercise this option for any or all of the Option Shares for which this option is vested and exercisable at the time of such cessation of Continuous Service. Upon the expiration of such limited exercise period, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Optionee (i) cease Continuous Service at least twelve (12) months following the Grant Date and (ii) (x) after attaining age 55 and completing at least ten </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(10) years of Continuous Service or (y) after attaining age 65, then Optionee shall (1) continue to vest in any unvested options granted hereunder in accordance with the Vesting Schedule set forth under Option Grant Specifics as if such Optionee had remained in Continuous Service&#59; and (2) have until the close of business on the last business day prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of&#58; (A) expiration of the five (5) year period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date, during which to exercise this option for any or all of the Option Shares for which this option is vested and exercisable at the time of such cessation of Continuous Service or becomes vested and exercisable following such cessation of Continuous Service in accordance with this subparagraph (d). Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Optionee&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the option pursuant to this subparagraph (d) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable treatment at the time of Optionee&#8217;s cessation of Continuous Service, and the option will be treated as set forth in the other subparagraphs of this Paragraph 5, as applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The applicable period of post-service exercisability in effect pursuant to the foregoing provisions of this Paragraph 5 shall automatically be extended by an additional period of time equal in duration to any interval within such post-service exercise period during which the exercise of this option or the immediate sale of the Option Shares acquired under this option cannot be effected in compliance with applicable federal, state and foreign securities laws, but in no event shall such an extension result in the continuation of this option beyond the close of business on the last business day prior to the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Notwithstanding any other provision hereof, should Optionee&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any), or should Optionee engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then this option, whether or not vested and exercisable at the time, shall terminate immediately and cease to be outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the limited period of post-service exercisability provided under this Paragraph 5, this option may not be exercised in the aggregate for more than the number of Option Shares for which this option is at the time vested and exercisable (including after giving effect to any accelerated vesting hereunder). Except as set forth in this Section 5 or to the extent (if any) specifically authorized by the Administrator pursuant to an express written agreement with Optionee, this option shall not vest or become exercisable for any additional Option Shares, whether pursuant to the normal Vesting Schedule set forth under Option Grant Specifics or the special vesting acceleration provisions of Paragraph 6 below, following Optionee&#8217;s cessation of Continuous Service. Upon the expiration of such limited exercise period or (if earlier) upon the close of business on the last business day prior to the Expiration Date, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Special Acceleration of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This option, to the extent outstanding at the time of an actual Change in Control but not otherwise fully exercisable, shall automatically accelerate so that this option shall, immediately prior to the effective date of such Change in Control, become exercisable for all of the Option Shares at the time subject to this option and may be exercised for any or all of those Option Shares as fully vested shares of Common Stock. However, this option shall not become exercisable on such an accelerated basis if and to the extent&#58; (i) this option is to be assumed by the successor corporation (or parent thereof) or is otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction, (ii) this option is to be replaced with an economically-equivalent substitute equity award or (iii) this option is to be replaced with a cash retention program of the successor corporation which preserves the spread existing at the time of the Change in Control on any Option Shares for which this option is not otherwise at that time vested and exercisable (the excess of the Fair Market Value of those Option Shares over the aggregate Exercise Price payable for such shares) and provides for the subsequent vesting and concurrent payout of that spread in accordance with the same Vesting Schedule for those Option Shares as set forth under Option Grant Specifics. Notwithstanding the foregoing, no such cash retention program shall be established for this option (or any other option granted to Optionee under the Plan) to the extent such program would otherwise be deemed to constitute a deferred compensation arrangement subject to the requirements of Code Section 409A and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Immediately following the consummation of the Change in Control, this option shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in effect pursuant to the terms of the Change in Control transaction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If this option is assumed in connection with a Change in Control or otherwise continued in effect, then this option shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities into which the shares of Common Stock subject to this option would have been converted in consummation of such Change in Control had those shares actually been outstanding at the time. Appropriate adjustments shall also be made to the Exercise Price, provided the aggregate Exercise Price shall remain the same. To the extent the actual holders of the Company&#8217;s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of this option but subject to the Administrator&#8217;s approval, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control, provided such common stock is readily tradable on an established U.S. securities exchange or market.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If this option is assumed or otherwise continued in effect in connection with a Change in Control or replaced with an economically-equivalent equity award or a cash retention program in accordance with Paragraph 6(a) above, then&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  the option (or such economically equivalent award) shall vest and become immediately exercisable for all of the Option Shares or other securities at the time subject to the option (or such award) and may, within the applicable exercise period under Paragraph 5, be exercised for any or all of those Option Shares or other securities as fully vested shares or securities, or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:90.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the balance credited to Optionee under any cash retention program established in accordance with Paragraph 6(a) shall immediately be paid to Optionee in a lump sum, subject to the Company&#8217;s collection of all applicable Withholding Taxes&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if, within the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the earlier of (i) the termination of that definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, Optionee&#8217;s Continuous Service terminates due to an involuntary termination without Cause (or without a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any) or a voluntary termination by Optionee due to Constructive Termination.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Adjustment in Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of outstanding shares of Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable and proportional adjustments shall be made by the Administrator to (i) the total number and&#47;or class of securities subject to this option and (ii) the Exercise Price. The adjustments shall be made in such manner as the Administrator deems appropriate in order to reflect such change and thereby prevent the dilution or enlargement of benefits hereunder, and those adjustments shall be final, binding and conclusive upon Optionee and any other person or persons having an interest in the option. In the event of any Change in Control transaction, the adjustment provisions of Paragraph 6(c) above shall be controlling.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The holder of this option shall not have any stockholder rights including voting, dividend or liquidation rights, with respect to the Option Shares until such person shall have exercised the option, paid the Exercise Price and become a holder of record of the purchased shares.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Manner of Exercising Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable, Optionee (or any other person or persons exercising the option) must take the following actions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) Execute and deliver to the Company a Notice of Exercise as to the Option Shares for which the option is exercised or comply with such other procedures as the Company may establish for notifying the Company, either directly or through an on-line internet transaction with a brokerage firm authorized by the Company to effect such option exercises, of the exercise of this option for one or more Option Shares.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) Pay the aggregate Exercise Price for the purchased shares in one or more of the following forms&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">cash or check made payable to the Company&#59; or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall concurrently provide irrevocable instructions (i) to a brokerage firm (reasonably satisfactory to the Company for purposes of administering such procedure in accordance with the Company&#8217;s pre-clearance&#47;pre- notification policies) to effect the immediate sale of all or a sufficient portion of the purchased shares so that such brokerage firm can remit to the Company, on the settlement date, sufficient funds out of the resulting sale proceeds to cover the aggregate Exercise Price payable for all the purchased shares plus all applicable Withholding Taxes and (ii) to the Company to deliver the purchased shares directly to such brokerage firm on such settlement date.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must accompany the Notice of Exercise (or other notification procedure) delivered to the Company in connection with the option exercise.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Make appropriate arrangements with the Company (or the Employer) for the satisfaction of all applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">As soon as practical after the Exercise Date, the Company shall issue to or on behalf of Optionee (or any other person or persons exercising this option) the purchased Option Shares, subject to appropriate restrictions, if any.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In no event may this option be exercised for any fractional shares.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Responsibility for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee acknowledges that, regardless of any action the Company and&#47;or the Employer take with respect to any or all Withholding Taxes, the ultimate liability for all Withholding Taxes is and remains Optionee&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Optionee further acknowledges that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the option, including the grant, vesting or exercise of the options, the subsequent sale of any shares of Common Stock acquired at exercise and the receipt of any dividends&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the option to reduce or eliminate Optionee&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Optionee is subject to Withholding Taxes in more than one jurisdiction, Optionee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Prior to the relevant taxable event, Optionee agrees to make arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Withholding Taxes. In this regard, Optionee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following&#58;</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:60.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding&#160;&#160;&#160;&#160;from&#160;&#160;&#160;&#160;any&#160;&#160;&#160;&#160;wages&#160;&#160;&#160;&#160;or&#160;&#160;&#160;&#160;other&#160;&#160;&#160;&#160;cash compensation paid to Optionee by the Company and&#47;or the Employer&#59; or</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding from the proceeds of the sale of shares of Common Stock acquired upon exercise of the option.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Depending on the withholding method, the Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case Optionee will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent. Optionee shall pay to the Company and&#47;or the Employer any amount of Withholding Taxes that the Company and&#47;or the Employer may be required to withhold as a result of Optionee&#8217;s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to deliver any purchased Option Shares or the proceeds of the sale of shares if Optionee fails to comply with Optionee&#8217;s obligations in connection with the Withholding Taxes.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company and Optionee with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions including the United States and Optionee&#8217;s country or his or her broker&#8217;s country, if different, which may affect Optionee&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., options) or rights linked to the value of shares of Common Stock during such times as Optionee is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Optionee placed before he or she possessed inside information. Furthermore, Optionee could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Optionee acknowledges that it is Optionee&#8217;s responsibility to comply with any applicable restrictions and Optionee should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except to the extent otherwise provided in Paragraphs 3 and 6 above, the provisions of this Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns and Optionee, Optionee&#8217;s assigns, the legal representatives, heirs and legatees of Optionee&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at the most current address then indicated for Optionee on the Company&#8217;s employee records or shall be delivered electronically to Optionee through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect option exercises through the internet. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in this option.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to Delaware&#8217;s conflict-of- laws rules.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this option and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of this option is made and&#47;or to be performed.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Optionee acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Optionee or other Optionees.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Excess Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If the Option Shares covered by this Agreement exceed, as of the Grant Date, the number of shares of Common Stock which may without stockholder approval be issued under the Plan, then this option shall be void with respect to those excess shares, unless stockholder approval of an amendment sufficiently increasing the number of shares of Common Stock issuable under the Plan is obtained in accordance with the provisions of the Plan. In no event shall the option be exercisable with respect to any of the excess Option Shares unless and until such stockholder approval is obtained.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Leaves of Absence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The following provisions shall govern leaves of absence, except to the extent the application of such provisions to Optionee would contravene employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any.</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">For purposes of this Agreement, Optionee&#8217;s Continuous Service shall not be deemed to cease during any period for which Optionee is on a military leave, sick leave or other personal leave approved by the Company. However, Optionee shall not receive any Continuous Service credit, for purposes of vesting in this option and the Option Shares pursuant to the Vesting Schedule set forth under Option Grant Specifics, for any period of such leave of absence, except to the extent otherwise required by employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:76.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt">Optionee shall receive Continuous Service credit for such vesting purposes for (i) the first three (3) months of an approved personal leave of absence or (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In no event shall Optionee be deemed to remain in Continuous Service at any time after the earlier of (i) the expiration date of his or her leave of absence, unless Optionee returns to active Continuous Service on or before that date, or (ii) the date Optionee&#8217;s Continuous Service actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the option, Optionee acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future options, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the option grant and Optionee&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Optionee&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the option and the Option Shares, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the option and the Option Shares, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the Option Shares is unknown, indeterminable and cannot be predicted with any certainty&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if the Option Shares do not increase in value, the option will have no value&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if Optionee exercises his or her option and obtains the Option Shares, the value of those Option Shares acquired upon exercise may increase or decrease in value, even below the Exercise Price&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the option resulting from termination of Optionee&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any), and in consideration of the Award, Optionee irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives his or her ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Optionee shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the option and the Option Shares, and the income and value of same, are not granted as consideration for, or in connection with, any service Optionee may provide as a director of the Company or a Related Entity&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the option and the benefits evidenced by this Agreement do not create any entitlement to have the option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Option Shares&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the following provisions apply only if Optionee is providing services outside the United States&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the option and the Option Shares, and the income and value of same, are not part of normal or expected compensation or salary for any purpose&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Optionee acknowledges and agrees that neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Optionee&#8217;s local currency and the United States Dollar that may affect the value of the option or of any amounts due to Optionee pursuant to the exercise of the option or the subsequent sale of any Option Shares acquired upon exercise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee&#8217;s participation in the Plan or Optionee&#8217;s acquisition or sale of the Option Shares. Optionee should consult with his or her personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Optionee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that he or she needs to review the following information about the processing of his or her personal data by or on behalf of the Company, the Employer and&#47;or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare his or her consent. As regards the processing of Optionee&#8217;s Personal Data in connection with the Plan and this Agreement, Optionee understands that the Company is the controller of his or her Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. The Company collects, uses and otherwise processes Personal Data about Optionee for the purposes of allocating shares of Common Stock and implementing, administering and managing the Plan. Optionee understands that this Personal Data may include, without limitation, his or her name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Optionee&#8217;s favor. The legal basis for the processing of Optionee&#8217;s Personal Data, where required, will be his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company transfers his or her Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Optionee&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Optionee understands and acknowledges that the Company&#8217;s service provider will open an account for him or her to receive and trade shares of Common Stock acquired under the Plan and that he or she will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Optionee&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Optionee understands and acknowledges that his or her country may have enacted data privacy laws that are different from the laws of the United States. For </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">example, the European Commission has issued only a limited adequacy finding with respect to the United States that applies solely if and to the extent that companies self-certify and remain self-certified under the EU&#47;U.S. Privacy Shield program. The Company does not currently participate in the EU&#47;U.S. Privacy Shield Program. The Company&#8217;s legal basis for the transfer of Optionee&#8217;s Personal Data is his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company will use his or her Personal Data only as long as is necessary to implement, administer and manage his or her participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Optionee understands and acknowledges that the Company&#8217;s legal basis for the processing of his or her Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Optionee&#8217;s Personal Data for any of the above purposes, Optionee understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that his or her participation in the Plan and his or her consent is purely voluntary. Optionee may deny or later withdraw his or her consent at any time, with future effect and for any or no reason. If Optionee denies or later withdraws his or her consent, the Company can no longer offer Optionee participation in the Plan or offer other equity awards to Optionee or administer or maintain such awards and Optionee would no longer be able to participate in the Plan. Optionee further understands that denial or withdrawal of his or her consent would not affect his or her status or salary as an employee or his or her career and that Optionee would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that data subject rights regarding the processing of Personal Data vary depending on the applicable law and that, depending on where Optionee is based and subject to the conditions set out in the applicable law, Optionee may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about him or her and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about him or her that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of his or her objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of his or her Personal Data in certain situations where Optionee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Optionee&#8217;s Personal Data that he or she has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or his or her employment and is carried out by automated means. In case of concerns, Optionee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Further, to receive clarification of, or to exercise any of, Optionee&#8217;s rights, Optionee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Optionee may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Optionee acknowledges that he or she is sufficiently proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow Optionee to understand the terms and conditions of this Agreement. Further, if Optionee has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through the electronic acceptance procedure established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Optionee Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall this option be exercised in the absence of such acceptance. An exercise of any portion of the shares subject to this Option shall be deemed to be an acceptance by Optionee of the terms and conditions of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Depending upon the country to which laws Optionee is subject, Optionee may have certain foreign asset and&#47;or account reporting requirements that may affect Optionee&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Optionee&#8217;s country. Optionee&#8217;s country may require that he or she report such accounts, assets or transactions to the applicable authorities in Optionee&#8217;s country. Optionee is responsible for knowledge of and compliance with any such regulations and should speak with his or her own personal tax, legal and financial advisors regarding same.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any provision herein, Optionee&#8217;s participation in the Plan shall be subject to any additional terms and conditions as set forth in the Addendum for Optionee&#8217;s country of residence, if any. Moreover, if Optionee relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Optionee, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company reserves the right to impose other requirements on Optionee&#8217;s participation in the Plan, on the option and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Optionee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:12pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the option, Optionee agrees that this option is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Optionee&#8217;s country. Optionee has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><div id="i9f7c5ddde67c4851b587427499d4cd0c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions shall be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the addendum to this Agreement setting forth special terms and conditions for Optionee&#8217;s country.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Compensation Committee of the Board (or a subcommittee thereof) acting in its capacity as administrator of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean this Global Stock Option Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Applicable Acceleration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 2(b) of the Plan and shall be determined on the basis of Optionee&#8217;s status on the Change in Control date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the legal requirements related to the Plan and the option under applicable provisions of the federal securities laws, state corporate and securities laws, the Code, the rules of any applicable Stock Exchange on which the Common Stock is listed for trading, and the rules of any non-U.S. jurisdiction applicable to options granted to residents therein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s Board of Directors.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning given to the term &#8220;Cause&#8221; in any effective employment agreement between the Optionee and the Company or a Related Entity, or if none the meaning set forth below. For purposes of Paragraph 5 of the Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the termination of Optionee&#8217;s Continuous Service as a result of Optionee&#8217;s (i) performance of any act, or failure to perform any act, in bad faith and to the detriment of the Company or a Related Entity&#59; (ii) dishonesty, intentional misconduct, material violation of any applicable Company or Related Entity policy, or material breach of any agreement with the Company or a Related Entity&#59; or (iii) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person. However, for purposes of Paragraph 6(d) of the Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the termination of Optionee&#8217;s Continuous Service as a result of Optionee&#8217;s (a) conviction of, a guilty plea with respect to, or a plea of nolo contendere to, a charge that Optionee has committed a felony under the laws of the United States or of any State or a crime involving moral turpitude, including (without limitation) fraud, theft, embezzlement or any crime that results in or is intended to result in personal enrichment to Optionee at the expense of the Company or a Related Entity&#59; (b) material breach of any agreement entered into between Optionee and the Company or a Related Entity that impairs the Company&#8217;s or the Related Entity&#8217;s interest therein&#59; (c) willful misconduct, significant failure to perform his or her duties or gross neglect of his or her duties&#59; or (d) engagement in any activity that constitutes a material conflict of interest with the Company or a Related Entity</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in ownership or control of the Company effected through the consummation of any of the following transactions&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly (whether as a result of a single acquisition or by reason of one or more acquisitions within the twelve (12)-month period ending with the most recent acquisition) the beneficial owner (within the meaning of Rule 13d- 3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders or an acquisition, consolidation or other reorganization to which the Company is a party&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (a) have been Board members continuously since the beginning of such period or (b) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (a) above who were still in office at the time the Board approved such election or nomination.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall a Change in Control be deemed to occur upon a merger, consolidation or other reorganization effected primarily to change the State of the Company&#8217;s incorporation or to create a holding company structure pursuant to which the Company becomes a wholly-owned subsidiary of an entity whose outstanding voting securities immediately after its formation are beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to the formation of such entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Internal Revenue Code of 1986, as amended.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean shares of the Company&#8217;s common stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Gilead Sciences, Inc., a Delaware corporation, and any successor corporation to all or substantially all of the assets or voting stock of Gilead Sciences, Inc. which shall by appropriate action adopt the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Constructive Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 11(d) of the Plan.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.34pt;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person, including an advisor, who is compensated by the Company or any Related Entity for services performed as a non-employee consultant&#59; provided, however, that the term &#8220;Consultant&#8221; shall not include non-employee Directors serving in their capacity as Board members. The term &#8220;Consultant&#8221; shall include a member of the board of directors of a Related Entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean shall mean the performance of services for the Company or a Related Entity (whether now existing or subsequently established) by a person in the capacity of an Employee, Director or Consultant. For purposes of this Agreement, Optionee shall be deemed to cease Continuous Service immediately upon the occurrence of either of the following events&#58; (i) Optionee no longer performs services in any of the foregoing capacities for the Company or any Related Entity or (ii) the entity for which Optionee is performing such services ceases to remain a Related Entity of the Company, even though Optionee may subsequently continue to perform services for that entity. Subject to the foregoing and any applicable limitations of Code Section 409A, the Administrator shall have the exclusive discretion to determine when Optionee ceases Continuous Service for purposes of the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a member of the Board.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person who is in the employ of the Company (or any Related Entity), subject to the control and direction of the Company or Related Entity as to both the work to be performed and the manner and method of performance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company or the Related Entity employing or retaining Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the date on which the option shall have been exercised in accordance with Paragraph 9 of the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the exercise price payable per Option Share as specified under Option Grant Specifics.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date specified under Option Grant Specifics for measuring the maximum term for which the option may remain outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">U.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Fair Market Valu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e per share of Common Stock on any relevant date shall be the closing price per share of Common Stock (or the closing bid, if no sales were reported) on that date, as quoted on the Stock Exchange that is at the time serving as the primary trading market for the Common Stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if there is no reported closing price or closing bid for that date, then the closing price or closing bid, as applicable, for the last trading date on which such closing price or closing bid was quoted shall be determinative of such Fair Market Value. The applicable quoted price shall be as reported in The Wall Street Journal or such other source as the Administrator deems reliable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date on which the option is granted, as specified under Option Grant Specifics.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3.68pt;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Non-Statutory Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean an option not intended to satisfy the requirements of Code Section 422.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Notice of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the notice of option exercise in the form authorized by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Z.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the number of shares of Common Stock subject to the option as specified under Option Grant Specifics.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AA. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Optionee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the person identified under Option Grant Specifics to whom the option is granted pursuant to the Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BB. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;parent corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(e) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the inability of Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which is expected to result in death or to be of continuous duration of twelve (12) months or more. The Administrator shall have exclusive discretion to determine when Permanent Disability has occurred for purposes of this Agreement</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DD. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s 2004 Equity Incentive Plan, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) any Parent or Subsidiary of the Company and (ii) any corporation in an unbroken chain of corporations beginning with the Company and ending with the corporation in the chain for which Optionee provides services as an Employee, Director or Consultant, provided each corporation in such chain owns securities representing at least twenty percent (20%) of the total outstanding voting power of the outstanding securities of another corporation or entity in such chain and there is a legitimate non-tax business purpose for making this option grant to Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FF. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GG. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;subsidiary corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(f) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HH. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the schedule set forth under Option Grant Specifics, pursuant to which the option is to vest and become exercisable for the Option Shares in a series of installments over Optionee&#8217;s period of Continuous Service.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any and all income tax (including U.S. federal, state, and local tax and&#47;or foreign income taxes) and the employee portion of the federal, state, local and&#47;or foreign employment taxes (including social insurance, payroll tax, payment on account or other tax-related items) required or permitted to be withheld by the Company and&#47;or the Employer in connection with any taxable event attributable to the option or Optionee&#8217;s participation in the Plan.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>gildq12022ex10182022psuagr.htm
<DESCRIPTION>2022 PSU AGREEMENT-TSR GOALS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6441e5490b564df9a4e392cfcca7e8f5_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.18</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR PERFORMANCE GOAL</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">2004 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PERFORMANCE SHARE AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Gilead Sciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their service relationship with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;All capitalized terms in this Performance Share Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall have the meaning assigned to them herein or in the attached Appendix A. Capitalized terms not defined herein or in the attached Appendix A shall have the meanings assigned to them in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, it is hereby agreed as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Performance Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Award Date indicated below, an award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Performance Shares under the Plan. This Agreement provides the Participant with the right to receive one or more shares of Common Stock on the designated issuance date for those shares, based upon the extent to which each Performance Share vests pursuant to the terms hereof. The Target Shares subject to this Award, the applicable performance-vesting and Continuous Service vesting requirements for this Award, the date or dates on which the shares of Common Stock that vest hereunder shall become issuable and the remaining terms and conditions governing this Award, including the applicable vesting acceleration provisions, shall be as set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD SUMMARY</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 10, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Number of Performance Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of shares of Common Stock that may become issuable pursuant to the Performance Shares subject to this Agreement shall be determined in accordance with the performance-vesting and Continuous Service vesting provisions of attached Schedule I. For purposes of the applicable calculations under Schedule I, the target number of Performance Shares to be utilized is shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vesting Requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Performance Shares shall be subject to the performance-vesting and Continuous Service vesting requirements set forth in attached Schedule I and shall vest on the Certification Date (as defined in Appendix A). </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Control Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The shares of Common Stock underlying the Performance Shares may also vest on an accelerated basis in accordance with the applicable provisions of Paragraph 4 of this Agreement should a Change in Control occur after the start but prior to the completion of the Performance Period applicable to the Performance Shares or the Certification Date.</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The shares of Common Stock which actually vest and become issuable pursuant to the Performance Shares shall be issued in accordance with the provisions of this Agreement applicable to the particular circumstances under which such vesting occurs.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to the actual issuance of the shares of Common Stock which vest hereunder, Participant may not transfer any interest in the Performance Shares subject to this Award or the underlying shares of Common Stock or pledge or otherwise hedge the sale of those Performance Shares or underlying shares, including (without limitation) any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying shares of Common Stock. However, any shares of Common Stock which vest hereunder but otherwise remain unissued at the time of Participant&#8217;s death may be transferred to Participant&#8217;s designated beneficiary or, if none, to Participant&#8217;s estate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The holder of this Award shall not have any stockholder rights, including voting, dividend or liquidation rights, with respect to the shares of Common Stock subject to the Award until Participant becomes the record holder of those shares upon their actual issuance following the Company&#8217;s collection of the applicable Withholding Taxes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more shares of Common Stock subject to this Award on such record date have not otherwise vested and been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those shares of Common Stock are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account shall be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such shares of Common Stock at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such shares of Common Stock subsequently vest hereunder, the phantom dividend equivalents so credited to those shares of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock in the book account shall vest, and those vested dividend equivalents shall be distributed to Participant (in the form of additional shares of Common Stock or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested shares of Common Stock to which those phantom dividend equivalents relate and correspondingly as such shares of Common Stock are forfeited or cancelled under this Award the phantom dividend equivalents so credited to those shares of Common Stock in the book account shall be forfeited or cancelled.&#160;Each such distribution of phantom dividend equivalent amounts shall be subject to the Company&#8217;s collection of any Withholding Taxes applicable to that distribution. The Administrator shall have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination shall be controlling.&#160;No dividend equivalent amount shall be paid or distributed on shares of Common Stock under this Award that are forfeited or that otherwise are not vested and issued or issuable under this Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following provisions shall apply only to the extent a Change in Control is consummated prior to the Certification Date and shall have no force or effect if the effective date of the Change in Control occurs after the Certification Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should (i) the Change in Control occur within the first twelve (12) months of the Performance Period and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the Target Shares subject to this Award, without any measurement of Performance Goal attainment to date and without regard to the Continuous Service vesting provisions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should (i) the Change in Control occur at any time on or after the completion of the first twelve (12) months of the Performance Period but prior to the Certification Date and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">greater</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the Target Shares subject to this Award or (ii) the actual number of Performance-Qualified Shares determined by multiplying (A) the Target Shares subject to this Award by (B) the applicable percentage (determined in accordance with the payout slope set forth in attached Schedule I) for the level at which the TSR Performance Goal is attained over an abbreviated Performance Period ending with the close of the Company&#8217;s fiscal quarter coincident with or immediately preceding the effective date of the Change in Control, in either case, without regard to the Continuous Service vesting requirements. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The foregoing provisions of this Paragraph 4 shall also apply should Participant&#8217;s Continuous Service terminate, by reason of an involuntary termination (other than as a result of Retirement, death, or Permanent Disability) other than for Cause or his or her resignation due to Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the termination of the definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Participant cease Continuous Service by reason of his or her Retirement at least twelve (12) months following the Award Date but prior to the Certification Date and a Change in Control subsequently occurs prior to the Certification Date, then Participant shall, at the time of such Change in Control, immediately vest in that number of shares of Common Stock equal to the Target Shares subject to this Award, without any measurement of Performance Goal attainment to date and without regard to the Continuous Service vesting provisions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The number of shares of Common Stock in which Participant vests determined in accordance with the foregoing provisions of this Paragraph 4 shall be converted into the right to receive for each such share the same consideration per share of Common Stock payable to the other stockholders of the Company in consummation of the Change in Control, and such consideration shall be distributed to Participant on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (i) the tenth (10th) business day following the effective date of the Change in Control, provided such Change in Control also constitutes a Qualifying Change in Control, or (ii) the date those shares would have been issued to Participant in accordance with Paragraph 6 in the absence of such Change in Control. Each issuance or distribution made under this Paragraph 4(e) shall be subject to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Except for the actual number of shares of Common Stock in which Participant vests in accordance with this Paragraph 4, Participant shall cease to have any further right or entitlement to any additional shares of Common Stock under this Agreement following the effective date of the Change in Control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustment in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, extraordinary dividend or distribution or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of the outstanding shares of Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable adjustments shall be made by the Administrator to the total number and&#47;or class of securities issuable pursuant to this Award in order to reflect such change. The determination of the Administrator shall be final, binding and conclusive. In the event of any Change in Control transaction, the provisions of Paragraph 4 shall also be applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Issuance or Distribution of Vested Shares or Other Amounts.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in Paragraph 4 or Paragraph 7, the shares of Common Stock in which Participant vests pursuant to the performance-vesting and </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Continuous Service vesting provisions of attached Schedule I shall be issued in accordance with the following provisions&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;The issuance of the shares of Common Stock shall be effected during the period beginning on the first (1st) business day of February of the calendar year immediately succeeding the end of the Performance Period and ending no later than March 15 of that calendar year.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company shall, on the applicable issuance date, issue to or on behalf of Participant a certificate in electronic form for the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I and shall concurrently settle with Participant any phantom dividend equivalent amount with respect to those shares as provided in Paragraph 3.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in Paragraph 4, no shares of Common Stock shall be issued prior to the Certification Date. No fractional shares of Common Stock shall be issued pursuant to this Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement shall be rounded down to the next whole share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant acknowledges that, regardless of any action the Employer may take with respect to any or all Withholding Taxes related to Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Employer. Participant further acknowledges that the Employer (i) makes no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of shares of Common Stock or other property in settlement of the Award, the subsequent sale of the shares of Common Stock acquired pursuant to such issuance and the receipt of any dividends and&#47;or phantom dividend equivalent amount provided pursuant to Paragraph 3 and (ii) does not commit to, and is under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Participant is or becomes subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Employer (or former employer, as applicable) may withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company shall collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the shares of Common Stock issued under this Agreement (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) through an automatic share withholding procedure pursuant to which the Company will withhold, immediately as the shares of Common Stock are issued under the Award, a portion of those shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the foregoing, the Share Withholding Method </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall not be utilized if (i) such method is not permissible or advisable under local law or (ii) the Company otherwise decides no longer to utilize such method and provides Participant with notice to such effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">If the Share Withholding Method is to be utilized for the collection of Withholding Taxes, then the Company shall withhold the number of otherwise issuable shares of Common Stock necessary to satisfy the applicable Withholding Taxes based on the applicable minimum statutory rate or other applicable withholding rate, including maximum applicable rates, as determined by the Company in its sole discretion. If the maximum rate is used, any over-withheld amount will be refunded to Participant in cash by the Employer (with no entitlement to the Common Stock equivalent) or if not refunded, Participant may seek a refund from the appropriate tax authorities. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of shares of Common Stock subject to the vested Award, notwithstanding that a number of shares of Common Stock are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company shall have sole discretion to determine whether or not the Share Withholding Method shall be utilized for the collection of the applicable Withholding Taxes. Participant shall be notified (in writing or through the Company&#8217;s electronic mail system) in the event the Company no longer intends to utilize the Share Withholding Method. Should any shares of Common Stock become issuable under the Award (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) at a time when the Share Withholding Method is not being utilized by the Company, then the Withholding Taxes shall be collected from Participant through a sale-to-cover transaction authorized by Participant, pursuant to which an immediate open-market sale of a portion of the shares of Common Stock issued to Participant will be effected, for and on behalf of Participant, by the Company&#8217;s designated broker to cover the Withholding Tax liability estimated by the Company to be applicable to such issuance. Participant shall, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such open-market, sale-to-cover transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no sale-to-cover transaction shall be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Company determines that such sale-to-cover transaction is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the shares of Common Stock until such sale-to-cover transaction can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through a wire transfer of funds from Participant to the Company in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event shall any shares of Common Stock be issued in the absence of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes, and any such arrangement must be in compliance with any applicable requirements of Code Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Company shall collect the Withholding Taxes with respect to any phantom dividend equivalent amount as provided in Paragraph 3 that is distributed in a form other than shares of Common Stock by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing provisions of Paragraphs 6(d) through 6(i), the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the shares of Common Stock or any other amounts hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall in all events be collected from Participant no later than the last business day of the calendar year in which those shares or other amounts vest (as determined under applicable tax laws) hereunder. Accordingly, to the extent the applicable issuance date for one or more vested shares of Common Stock or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those shares or other amounts vest, Participant shall, if so requested by the Company, on or before the last business day of the calendar year in which such shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company ) in the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 6(j) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).Except as otherwise provided in Paragraph 4 or this Paragraph 6, the settlement of all Performance Shares or Performance-Qualified Shares which vest under the Award shall be made solely in shares of Common Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Special Deferral Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Provided Participant is a U.S. tax resident and Participant timely submits a properly completed deferral election in a form provided by the Company, any shares of Common Stock that become issuable pursuant to this Agreement shall be distributed in accordance with the terms of such deferral election, subject to Participant&#8217;s satisfaction of any applicable Withholding Taxes under Paragraph 6.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  For purposes of applying the various Continuous Service vesting provisions of this Agreement, Participant shall be deemed to cease Continuous Service on the commencement date of any leave of absence and not to remain in Continuous Service status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or pursuant to the following policy&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Participant shall be deemed to remain in Continuous Service status during (i) the first three (3) months of an approved personal leave of absence or (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave) and shall be deemed to cease Continuous Service upon the expiration of the applicable three (3)-month or seven (7)-month period.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;In no event, however, shall Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service or Employee status on or before that date, or (ii) the date Participant&#8217;s Continuous Service or Employee status actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Company and Participant with all Applicable Laws relating thereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In accepting the grant, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-bottom:0.12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past&#59; </font></div><div style="margin-bottom:0.12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:0.12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant is voluntarily participating in the Plan&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the termination of Participant&#8217;s Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the grant of the Award to which Participant is otherwise not entitled,&#160;Participant irrevocably agrees never to institute any claim against the Company, any Related Entity or the Employer, waives Participant&#8217;s ability, if any, to bring any such claim, and releases the Company, any Related Entity and the Employer from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agreed to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying shares of Common Stock. Participant should consult with Participant&#8217;s own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or shall be delivered electronically to Participant through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect sales of the Common Stock issued hereunder. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Code Section 409A</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is the intention of the parties that the provisions of this Agreement shall, to the maximum extent permissible, comply with the requirements of the short-term deferral exception to Section 409A of the Code and Treasury Regulations Section 1.409A-1(b)(4) with respect to one or more shares of Common Stock underlying this Award. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the requirements or limitations of Code Section 409A applicable to such short-term deferral exception, then those provisions, as they apply to such shares of Common Stock, shall be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Code Section 409A and the Treasury Regulations thereunder that apply to such exception.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">However, to the extent this Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Code Section 409A with respect to one or more shares of Common Stock underlying this Award, whether by reason of a deferral election that satisfies the requirements of Paragraph 7 above or the pro-rata Continuous Service vesting provisions of this Agreement, then the following provisions shall apply with respect to those shares, notwithstanding anything to the contrary set forth herein&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;None of those shares of Common Stock or other amounts which become issuable or distributable with respect to those shares by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant until the date of Participant&#8217;s Separation from Service or as soon thereafter as administratively practicable, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;None of those shares of Common Stock or other amounts which become issuable or distributable with respect to those shares by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Code Section 409A, as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred shares of Common Stock or other distributable amount shall be issued or distributed in a lump sum on the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or, if earlier, the first (1st) day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;No amounts that vest and become payable under Paragraph 4 of this Agreement with respect to those shares of Common Stock by reason of a Change in Control shall be distributed to Participant at the time of such Change in Control, unless that transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with the provisions of Paragraph 6(a) of this Agreement. </font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;If a deferral election under Paragraph 7 of this Agreement is in effect with respect to any shares of Common Stock underlying this Award, no amounts that vest and become payable under Paragraph 4 with respect to those shares by reason of a Change in Control shall be distributed to Participant at the time of that Change in Control unless the transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with Participant&#8217;s deferral election under Paragraph 7 of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement or otherwise relating to or arising from this Agreement, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Agreement or in the Plan shall confer upon Participant any right to remain in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Employer or of Participant, which rights are hereby expressly reserved by each, to terminate Participant&#8217;s Continuous Service at any time for any reason, with or without Cause.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Awards section on GNET</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">stockplanservices&#64;gilead.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Delivery</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">and</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or his or her broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares, rights to shares (e.g., Performance Shares) or rights linked to the value of shares of Common Stock (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before he or she possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall any shares of Common Stock be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance. By accepting the Award, Participant agrees that this Award is granted under and governed by the terms and conditions of the Plan and this Agreement. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"></td><td style="width:21.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature</font></td></tr></table></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i6441e5490b564df9a4e392cfcca7e8f5_53"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions shall be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Applicable Laws </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the legal requirements relating to the Plan and the Awards under applicable provisions of U.S. federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange, and the securities, tax and exchange control laws, rules, regulations, and requirements of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Award Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date the Performance Shares are awarded to Participant pursuant to the Agreement and shall be the date indicated in Paragraph 1 of the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Certification Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date following the completion of the Performance Period on which the Administrator certifies the attained level of the TSR Performance Goal for such Performance Period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in ownership or control of the Company effected through the consummation of any of the following transactions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly (whether as a result of a single acquisition or by reason of one or more acquisitions within the twelve (12)-month period ending with the most recent acquisition) the beneficial owner (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders or an acquisition, consolidation or other reorganization to which the Company is a party&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall a Change in Control be deemed to occur upon a merger, consolidation or other reorganization effected primarily to change the State of the Company&#8217;s incorporation or to create a holding company structure pursuant to which the Company becomes a wholly-owned subsidiary of an entity whose outstanding voting securities immediately after its formation are beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to the formation of such entity.  Should such holding company structure or other Parent entity be established for the Company, then subparagraph (iii) shall be applied solely to the board of directors of that holding company or Parent entity. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Gilead Sciences, Inc., a Delaware corporation, and any successor corporation to all or substantially all of the assets or voting stock of Gilead Sciences, Inc. which shall by appropriate action adopt the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the performance of services for the Company or a Related Entity (whether now existing or subsequently established) by a person in the capacity of an Employee, Director or Consultant.  For purposes of this Agreement, Participant shall be deemed to cease Continuous Service immediately upon the occurrence of either of the following events&#58; (i) Participant no longer performs services in any of the foregoing capacities for the Company or any Related Entity or (ii) the entity for which Participant is performing such services ceases to remain a Related Entity of the Company, even though Participant may subsequently continue to perform services for that entity. The Administrator shall have the exclusive discretion to determine when Participant ceases Continuous Service for purposes of the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean an individual who is in the employ of the Company (or any Related Entity), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company or any Related Entity employing Participant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">per share of Common Stock on any relevant date shall be the closing price per share of Common Stock (or the closing bid, if no sales were reported) on that date, as quoted on the Stock Exchange that is at the time serving as the primary trading market for the Common Stock&#59; provided, however, that if there is no reported closing price or closing bid for that date, then the closing price or closing bid, as applicable, for the last trading date on which such closing price or closing bid was quoted shall be determinative of such Fair Market Value.  The applicable quoted price shall be as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or such other source as the Administrator deems reliable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, provided each corporation in the unbroken chain (other than the Company) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the person to whom the Award is made pursuant to the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.34pt;text-decoration:underline">Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the total shareholder return performance goal specified on attached Schedule I (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TSR Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that must be attained in order to satisfy the performance-vesting requirement for the shares of Common Stock subject to this Award.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Performance Period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the period specified on attached Schedule I over which the attainment of the TSR Performance Goal is to be measured.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the maximum number of Shares in which Participant can vest based on the level at which the Performance Goal for the Performance Period is attained and shall be calculated in accordance with the provisions of attached Schedule I.  In no event shall the number of such Performance-Qualified Shares exceed two hundred percent (200%) of the Target Shares set forth in Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement. Each Performance-Qualified Share that vests pursuant to the terms of the Award shall entitle Participant to receive one share of Common Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Permanent Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">y shall mean the inability of Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more.  The Administrator shall have the exclusive discretion to determine when Permanent Disability has occurred for purposes of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Qualifying Change in Contro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in control of ownership of the Company effected by one or more of the following transactions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.69pt">a merger or consolidation in which the Company is not the surviving entity and in which one person or a group of related persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) acquires ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities or constituting more than fifty percent (50%) of the total fair market value of the Company&#8217;s outstanding securities&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.36pt">the sale, transfer or other disposition of all or substantially all of the assets of the Company in complete liquidation or dissolution of the Company&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:0.03pt">any reverse merger in which the Company is the surviving entity but in which one person or a group of related persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) acquires ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities or constituting more than fifty percent (50%) of the total fair market value of the Company&#8217;s outstanding securities&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:0.69pt">the acquisition, directly or indirectly, by any person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities or constituting more than fifty percent (50%) of the total fair market value of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing definition of Qualifying Change in Control shall in all instances be applied and interpreted in such manner that the applicable Qualifying Change in Control transaction that serves as an issuance event for the shares of Common Stock subject to this Award (or distribution event for any amounts relating to those shares) that vest upon the occurrence of a Change in Control and are otherwise at the time subject to the issuance or distribution restrictions of Code Section 409A will also qualify as&#58; (i) a change in the ownership of the Company, as determined in accordance with Section 1.409A-3(i)(5)(v) of the Treasury Regulations, (ii) a change in the effective control of the Company, as determined in accordance with Section 1.409A-3(i)(5)(vi) of the Treasury Regulations, or (iii) a change in the ownership of a substantial portion of the assets of the Company, as determined in accordance with Section 1.409A-3(i)(5)(vii) of the Treasury Regulations.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) any Parent or Subsidiary of the Company and (ii) any corporation in an unbroken chain of corporations beginning with the Company and ending with the corporation in the chain for which Participant provides services as an Employee, Director or Consultant, provided each corporation in such chain owns securities representing at least fifty percent (50%) of the total outstanding voting power of the outstanding securities of another corporation or entity in such chain.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Participant&#8217;s cessation of Continuous Service on or after the date on which he or she (i) attains age 55 and completes at least ten (10) years of Continuous Service or (ii) attains age 65.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Participant&#8217;s cessation of Employee status by reason of his or her death, Retirement or termination of employment.  Participant shall be deemed to have terminated employment for such purpose at such time as the level of his or her bona fide services to be performed as an Employee (or as a consultant or independent contractor) permanently decreases to a level that is not more than twenty percent (20%) of the average level of services he or she rendered as an Employee during the immediately preceding thirty-six (36) months (or such shorter period for which he or she may have rendered such services).  Solely for purposes of determining when a Separation from Service occurs, Participant will be deemed to continue in &#8220;Employee&#8221; status for so long as he or she remains in the employ of one or more members of the Employer Group, subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.  &#8220;Employer Group&#8221; means the Company and any Parent or Subsidiary and any other corporation or business controlled by, controlling or under common control with, the Company, as determined in accordance with Sections 414(b) and (c) of the Code and the Treasury Regulations thereunder, except that in applying Sections 1563(1), (2) and (3) of the Code for purposes of determining the controlled group of corporations under Section 414(b), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in such sections and in applying Section 1.414(c)-2 of the Treasury Regulations for purposes of determining trades or businesses that are under common control for purposes of Section 414(c), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in Section 1.414(c)-2 of the Treasury Regulations.  Any such determination as to Separation from Service, however, shall be made in accordance with the applicable standards of the Treasury Regulations issued under Section 409A of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">U.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3.68pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any and all income taxes (including U.S. federal, state and local tax) and the employee portion of the federal state and local taxes (including social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items) required or permitted to be withheld by the Company and&#47;or the Employer in connection with any taxable or tax withholding event, as applicable, attributable to the Award or Participant&#8217;s participation in the Plan.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div></div></div><div id="i6441e5490b564df9a4e392cfcca7e8f5_66"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE I</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PERFORMANCE GOAL AND PERFORMANCE PERIOD  </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Shares shall be the thirty-four (34) month period beginning March 1, 2022 and ending December 31, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal  &#8211; Total Shareholder Return&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares subject to this Award shall be tied to the percentile level at which the total shareholder return (including stock price appreciation and reinvestment of any cash dividends or other stockholder distributions) to the Company&#8217;s stockholders over the Performance Period stands in relation to the total shareholder return realized for that period by the companies comprising the following three subsets of the S&#38;P Healthcare Index&#58; Biotechnology, Pharmaceuticals and Health Care Equipment (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">S&#38;P Healthcare Sub-Index&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For such purpose, the total shareholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be determined pursuant to the following formula&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TSR  &#61;  (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ending Stock Price* - Beginning Stock Price**) + Reinvested Dividends***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                  Beginning Stock Price**</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*  Ending Stock Price is the average daily closing price per share of the Common Stock calculated for the last sixty (60) consecutive trading days within the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">**  Beginning Stock Price is the average daily closing price per share of the Common Stock calculated for the last sixty (60) consecutive trading days immediately preceding the commencement of the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*** Reinvested Dividends shall be calculated by multiplying (i) the aggregate number of shares (including fractional shares) that could have been purchased during the Performance Period had each cash dividend paid on a single share during that period been immediately reinvested in additional shares (or fractional shares) at the closing selling price per share of the Common Stock on the applicable dividend payment date by (ii) the average daily closing price per share calculated for the last sixty (60) consecutive trading days within the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each of the foregoing amounts shall be equitably adjusted for stock splits, stock dividends, recapitalizations and other similar events affecting the shares in question without the issuer&#8217;s receipt of consideration.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For each company in the S&#38;P Healthcare Sub-Index, the TSR with respect to its common stock shall be calculated in the same manner as for the Common Stock.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the following parameters shall be in effect for purposes of measuring the total shareholder return for the S&#38;P Healthcare Sub-Index&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           a company will be included in the S&#38;P Healthcare Sub-Index only if that company is in existence both at the start of the Performance Period and at the end of the Performance Period, and the stock price performance of any company that is acquired, or otherwise ceases to exist as an independent publicly-owned entity, during the Performance Period shall not be taken into account in determining the relative total shareholder return of the companies comprising the S&#38;P Healthcare Sub-Index for the Performance Period&#59; </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           any distribution (other than a regular cash dividend), whether in cash, securities (other than shares of the distributing company&#8217;s common stock) or other property, made during the Performance Period by a company included in the S&#38;P Healthcare Sub-Index for that period shall be treated in the same manner as a regular cash dividend paid by such distributing company (in an amount per share of the distributing company&#8217;s common stock deemed equal to the cash amount or the fair market value of the securities or other property distributed per share of the distributing company&#8217;s common stock) that is immediately reinvested in the distributing company&#8217;s common stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided and only if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the amount distributed per share of the distributing company&#8217;s common stock (as determined in the manner set forth herein) is at least ten percent (10%) of the closing price per share of the distributing company&#8217;s common stock on the effective date of such distribution&#59; otherwise, such distribution shall not be taken in effect in calculating the relative total shareholder return of the companies comprising the S&#38;P Healthcare Sub-Index&#59; and            </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           any spin-off distribution of shares of the common stock of one or more subsidiaries or other affiliated entities that is made during the Performance Period by a company included in the S&#38;P Healthcare Sub-Index for that period shall be treated in the same manner as a regular cash dividend paid by that distributing company (in an amount per share of the distributing company&#8217;s common stock deemed equal to the fair market value of the common stock (or fractional share thereof) of the spun-off entity distributed per share of the distributing company&#8217;s common stock) that is immediately reinvested in the distributing company&#8217;s common stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided and only if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the amount distributed per share of the distributing company&#8217;s common stock (as determined in the manner set forth herein) is at least ten percent (10%) of the closing price per share of the distributing company&#8217;s common stock on the effective date of such distribution&#59; otherwise, such spin-off distribution shall not be taken in effect in calculating the relative total shareholder return of the companies comprising the S&#38;P Healthcare Sub-Index.             </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of measuring the total shareholder return of the Company for the Performance Period, the foregoing parameters governing distributions and spin-off transactions shall also apply to any distribution (other than a regular cash dividend) or spin-off transaction that is effected by the Company during the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Should a Change in Control occur during the Performance Period, then the attained level of the Performance Goal shall be determined in accordance with the applicable Change in Control provisions of Paragraph 4 of this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Within sixty-five (65) days after the completion of the Performance Period, the Administrator shall determine and certify the actual level at which the TSR Performance Goal is attained. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of Performance-Qualified Shares that results from such certification may range from 0% to 200% of the Target Shares subject to this Award, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement.  The actual percentage shall be determined on the basis of the percentile level at which the Administrator certifies that the TSR Performance Goal has been attained in relation to the total shareholder return realized for that period by the companies comprising the S&#38;P Healthcare Sub-Index&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) the maximum number of shares of Common Stock that may qualify as Performance-Qualified Shares may not exceed 200% of the Target Shares, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement, and (ii) in no event shall the number of shares of Common Stock that may qualify as Performance-Qualified Shares pursuant to the Relative TSR Payout Slope below exceed 100% of the Target Shares (as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement) if the Company&#8217;s absolute TSR for the Performance Period is negative.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Levels of TSR Performance Goal&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of shares of Common Stock that may qualify as Performance-Qualified Shares on the basis of the certified percentile level of TSR Performance Goal attainment shall be calculated by multiplying the Target Shares (as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement) by the applicable percentage determined in accordance with the following payout slope for the TSR Performance Goal (with appropriate straight-line interpolation for any attained percentile level within two designated percentile levels in such slope)&#58; </font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TOTAL SHAREHOLDER RETURN PAYOUT SLOPE</font></div><div style="margin-top:12pt;text-align:center"><img alt="image1a.jpg" src="image1a.jpg" style="height:290px;margin-bottom:5pt;vertical-align:text-bottom;width:478px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payout Slope Details</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.955%"><tr><td style="width:1.0%"></td><td style="width:52.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Perce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ntile</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">% of Target</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">20th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">30th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">25%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">40th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">63%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">50th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">100%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">60th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">125%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">70th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">150%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">80th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">175%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">81st</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">200%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">90th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">200%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">100th</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">200%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CONTINUOUS SERVICE VESTING REQUIREMENT FOR PERFORMANCE-QUALIFIED SHARES </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of shares of Common Stock in which Participant may actually vest on the basis of the number of Performance-Qualified Shares certified by the Administrator in accordance with the performance vesting provisions of this Schedule I shall be tied to his or her completion of the following Continuous Service vesting requirements&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           If Participant remains in Continuous Service through the Certification Date, Participant shall vest in one-hundred percent (100%) of the Performance-Qualified Shares certified by the Administrator for the Performance Period.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           If Participant&#8217;s Continuous Service terminates prior to the Certification Date by reason of death or Permanent Disability, then Participant shall, at the time of such termination of Continuous Service, immediately vest in the Target Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such termination occurs upon or following the end of the Performance Period, then Participant shall instead vest in one-hundred percent (100%) of the Performance-Qualified Shares certified by the Administrator for the Performance Period..  The shares of Common Stock that vest pursuant to this paragraph shall be issued or distributed on the date of Participant&#8217;s cessation of Continuous Service or as soon as administratively practicable thereafter, but in no event later than the later of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day of the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) calendar month following the date of such Separation from Service.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           If Participant&#8217;s Continuous Service terminates by reason of his or her Retirement at least twelve (12) months following the Award Date but prior to the Certification Date, then Participant shall, following the completion of the Performance Period and the Certification Date, vest in one-hundred percent (100%) of the Performance-Qualified Shares certified by the Administrator for the Performance Period as if Participant had remained in Continuous Service through the Certification Date. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           If (i) Participant&#8217;s Continuous Service terminates by reason of an involuntary termination other than for Cause, or his or her resignation due to Constructive Termination, at any time after the completion of the Performance Period but prior to the Certification Date and (ii) such termination of Continuous Service also occurs during a period while there is in effect a definitive executed agreement for the Change in Control transaction, then Participant shall vest in the number of Performance-Qualified Shares in which Participant could vest, based on the actual level at which the TSR Performance Goal is attained and certified for the Performance Period, had Participant remained in Continuous Service through such Certification Date.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           If Participant&#8217;s Continuous Service ceases for any other reason (including, without limitation, any deemed cessation of Continuous Service under Paragraph 8 of this Agreement) prior to the Certification Date, then Participant shall not vest in any of the Performance-Qualified Shares, and all of Participant&#8217;s right, title and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interest to the shares of Common Stock subject to this Award shall immediately terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that should a Change in Control occur prior to the completion of the Performance Period, then the provisions of Paragraph 4 shall govern the vesting of the Performance Shares subject to this Award. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-11</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>4
<FILENAME>gildq12022ex10222022psuagr.htm
<DESCRIPTION>2022 PSU AGREEMENT-REVENUE GOALS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia7da90b21292453182239842a2c6a8c3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:0.24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.22</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> REVENUE PERFORMANCE GOAL</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">2004 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PERFORMANCE SHARE AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">Gilead Sciences, Inc. (the &#8220;Company&#8221;) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their service relationship with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;All capitalized terms in this Performance Share Award Agreement (this &#8220;Agreement&#8221;) shall have the meaning assigned to them herein or in the attached Appendix A. Capitalized terms not defined herein or in the attached Appendix A shall have the meanings assigned to them in the Plan.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> it is hereby agreed as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant of Performance Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company hereby awards to Participant, as of the Award Date indicated below, an award (the &#8220;Award&#8221;) of Performance Shares under the Plan. This Agreement provides the Participant with the right to receive one or more shares of Common Stock on the designated issuance date for those shares, based upon the extent to which each Performance Share vests pursuant to the terms hereof. The Target Shares subject to this Award, the applicable performance-vesting and Continuous Service vesting requirements for each separate Tranche of this Award, the date or dates on which the shares of Common Stock that vest hereunder shall become issuable and the remaining terms and conditions governing this Award, including the applicable vesting acceleration provisions, shall be as set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD SUMMARY</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">March 10, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Target Number of Performance Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The actual number of shares of Common Stock that may become issuable pursuant to the Performance Shares subject to this Agreement shall be determined in accordance with the performance-vesting and Continuous Service vesting provisions of attached Schedule I. For purposes of the applicable calculations under Schedule I, the target number of Performance Shares to be utilized is shares (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">&#8220;Target Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">).</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Performance Shares shall be divided into three separate Tranches with one third (1&#47;3) of the Target Shares allocated to each such Tranche.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Vesting Requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Each Tranche of Performance Shares shall be subject to the performance-vesting and Continuous Service vesting requirements set forth for that particular Tranche in attached Schedule I and shall vest on the Certification Date (as defined in Appendix A).</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Change in Control Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The shares of Common Stock underlying each Tranche of Performance Shares may also vest on an accelerated basis in accordance with the applicable provisions of Paragraph 4 of this Agreement should a Change in Control occur after the start but prior to the completion of the Performance Period applicable to that particular Tranche or the Certification Date.</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Issuance Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The shares of Common Stock which actually vest and become issuable pursuant to each Tranche of Performance Shares shall be issued in accordance with the provisions of this Agreement applicable to the particular circumstances under which such vesting occurs.</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the actual issuance of the shares of Common Stock which vest hereunder, Participant may not transfer any interest in the Performance Shares subject to this Award or the underlying shares of Common Stock or pledge or otherwise hedge the sale of those Performance Shares or underlying shares, including (without limitation) any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying shares of Common Stock. However, any shares of Common Stock which vest hereunder but otherwise remain unissued at the time of Participant&#8217;s death may be transferred to Participant&#8217;s designated beneficiary or, if none, to Participant's estate.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The holder of this Award shall not have any stockholder rights, including voting, dividend or liquidation rights, with respect to the shares of Common Stock subject to the Award until Participant becomes the record holder of those shares upon their actual issuance following the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more shares of Common Stock subject to this Award on such record date have not otherwise vested and been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those shares of Common Stock are not otherwise treated as issued and outstanding for purposes of entitlement to </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account shall be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such shares of Common Stock at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such shares of Common Stock subsequently vest hereunder, the phantom dividend equivalents so credited to those shares of Common Stock in the book account shall vest, and those vested dividend equivalents shall be distributed to Participant (in the form of additional shares of Common Stock or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested shares of Common Stock to which those phantom dividend equivalents relate and correspondingly as such shares of Common Stock are forfeited or cancelled under this Award the phantom dividend equivalents so credited to those shares of Common Stock in the book account shall be forfeited or cancelled. Each such distribution of phantom dividend equivalent amounts shall be subject to the Company&#8217;s collection of any Withholding Taxes applicable to that distribution. The Administrator shall have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination shall be controlling. No dividend equivalent amount shall be paid or distributed on shares of Common Stock under this Award that are forfeited or that otherwise are not vested and issued or issuable under this Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The following provisions shall apply only to the extent a Change in Control is consummated prior to the Certification Date and shall have no force or effect if the effective date of the Change in Control occurs after the Certification Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should (i) the Change in Control occur during a Performance Period that is in effect at the time with respect to a particular Tranche of Performance Shares but prior to the completion of that Performance Period and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the Target Shares allocated to that particular Tranche, without any measurement of Performance Goal attainment to date with respect to that particular Tranche and without regard to the Continuous Service vesting provisions. To the extent a Performance Period for a particular Tranche of Performance Shares has not commenced prior to the effective date of the Change in Control, the Performance Shares allocated to that Tranche in accordance with Paragraph 1 of this Agreement and the provisions of attached Schedule I shall be cancelled, and Participant shall not have any further right or entitlement to receive any shares of Common Stock with respect to those cancelled Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should (i) the Change in Control occur at any time on or after the completion of the Performance Period applicable to a particular Tranche of Performance Shares but prior to the Certification Date and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the actual number of Performance-Qualified Shares (if any) at the time subject to that Tranche by reason of the level at which the Revenue Performance Goal for that Tranche was in fact attained for the Performance Period applicable to that Tranche, without regard to the Continuous Service vesting provisions.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The foregoing provisions of this Paragraph 4 shall also apply should Participant&#8217;s Continuous Service terminate, by reason of an involuntary termination (other than as a result of Retirement, death, or Permanent Disability) other than for Cause or his or her resignation due to Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the earlier of (i) the termination of the definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Should Participant cease Continuous Service by reason of his or her Retirement at least twelve (12) months following the Award Date but prior to the Certification Date and during one or more Service Periods that are, pursuant to the provisions of attached Schedule I, in effect at that time with respect to one or more Tranches of Performance Shares and a Change in Control subsequently occurs prior to the Certification Date, then Participant shall, at the time of such Change in Control, immediately vest in that number of shares of Common Stock equal to the Target Shares allocated to that particular Tranche, without any measurement of Performance Goal attainment to date with respect to that particular Tranche and without regard to the Continuous Service vesting provisions. To the extent a Performance Period for a particular Tranche of Performance Shares has not commenced prior to the effective date of the Change in Control, the Performance Shares allocated to that Tranche in accordance with Paragraph 1 of this Agreement and the provisions of attached Schedule I shall be cancelled, and Participant shall not have any further right or entitlement to receive any shares of Common Stock with respect to those cancelled Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The number of shares of Common Stock in which Participant vests determined in accordance with the foregoing provisions of this Paragraph 4 shall be converted into the right to receive for each such share the same consideration per share of Common Stock payable to the other stockholders of the Company in consummation of the Change in Control, and such consideration shall be distributed to Participant on the earlier of (i) the tenth (10th) business day following the effective date of the Change in Control, provided such Change in Control also constitutes a Qualifying Change in Control, or (ii) the date those shares would have been issued to Participant in accordance with Paragraph 6 in the absence of such Change in Control. Each issuance or distribution made under this Paragraph 4(e) shall be subject to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Except for the actual number of shares of Common Stock in which Participant vests in accordance with this Paragraph 4, Participant shall cease to have any further right or entitlement to any additional shares of Common Stock under this Agreement following the effective date of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustment in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, extraordinary dividend or distribution or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of the outstanding shares of Common Stock be substantially reduced as a result of a spin- off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable adjustments shall be made by the Administrator to the total number and&#47;or class of securities issuable pursuant to this Award in order to reflect such change. The determination of the Administrator shall be final, binding and conclusive. In the event of any Change in Control transaction, the provisions of Paragraph 4 shall also be applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Issuance or Distribution of Vested Shares or Other Amounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4 or Paragraph 7, the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I shall be issued in accordance with the following provisions&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;The issuance of the shares of Common Stock underlying each particular Tranche of Performance Shares shall be effected during the period beginning on the first (1st) business day of February of the calendar year immediately succeeding the end of the Tranche Three Performance Period and ending no later than March 15 of that calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company shall, on the applicable issuance date, issue to or on behalf of Participant a certificate in electronic form for the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I and shall concurrently settle with Participant any phantom dividend equivalent amount with respect to those shares as provided in Paragraph 3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4, no shares of Common Stock shall be issued prior to the Certification Date. No fractional shares of Common Stock shall be issued pursuant to this Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement shall be rounded down to the next whole share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant acknowledges that, regardless of any action the Employer may take with respect to any or all Withholding Taxes related to Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Employer. Participant further acknowledges that the Employer (i) makes no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of shares of Common Stock or other property in settlement of the Award, the subsequent sale of the shares of Common Stock acquired pursuant to such issuance and the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">receipt of any dividends and&#47;or phantom dividend equivalent amount provided pursuant to Paragraph 3 and (ii) does not commit to, and is under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Participant is or becomes subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Employer (or former employer, as applicable) may withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Company shall collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the shares of Common Stock issued under this Agreement (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) through an automatic share withholding procedure pursuant to which the Company will withhold, immediately as the shares of Common Stock are issued under the Award, a portion of those shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the foregoing, the Share Withholding Method shall not be utilized if (i) such method is not permissible or advisable under local law or (ii) the Company otherwise decides no longer to utilize such method and provides Participant with notice to such effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;If the Share Withholding Method is to be utilized for the collection of Withholding Taxes, then the Company shall withhold the number of otherwise issuable shares of Common Stock necessary to satisfy the applicable Withholding Taxes based on the applicable minimum statutory rate or other applicable withholding rate, including maximum applicable rates, as determined by the Company in its sole discretion. If the maximum rate is used, any over- withheld amount will be refunded to Participant in cash by the Employer (with no entitlement to the Common Stock equivalent) or if not refunded, Participant may seek a refund from the appropriate tax authorities. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of shares of Common Stock subject to the vested Award, notwithstanding that a number of shares of Common Stock are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Company shall have sole discretion to determine whether or not the Share Withholding Method shall be utilized for the collection of the applicable Withholding Taxes. Participant shall be notified (in writing or through the Company&#8217;s electronic mail system) in the event the Company no longer intends to utilize the Share Withholding Method. Should any shares of Common Stock become issuable under the Award (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) at a time when the Share Withholding Method is not being utilized by the Company, then the Withholding Taxes shall be collected from Participant through a sale-to-cover transaction authorized by Participant, pursuant to which an immediate open-market sale of a portion of the shares of Common Stock issued to Participant will be effected, for and on behalf of Participant, by the Company&#8217;s designated broker to cover the Withholding Tax liability estimated by the Company to be applicable to such issuance. Participant shall, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such open-market, sale-to-cover transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no sale-to-cover transaction shall be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;If the Company determines that such sale-to-cover transaction is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the shares of Common Stock until such sale-to-cover transaction can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through a wire transfer of funds from Participant to the Company in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event shall any shares of Common Stock be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes, and any such arrangement must be in compliance with any applicable requirements of Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Company shall collect the Withholding Taxes with respect to any phantom dividend equivalent amount as provided in Paragraph 3 that is distributed in a form other than shares of Common Stock by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of Paragraphs 6(d) through 6(i), the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the shares of Common Stock or any other amounts hereunder (the &#8220;Employment Taxes&#8221;) shall in all events be collected from Participant no later than the last business day of the calendar year in which those shares or other amounts vest (as determined under applicable tax laws) hereunder. Accordingly, to the extent the applicable issuance date for one or more vested shares of Common Stock or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those shares or other amounts vest, Participant shall, if so requested by the Company, on or before the last business day of the calendar year in which such shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 6(j) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4 or this Paragraph 6, the settlement of all Performance Shares or Performance-Qualified Shares which vest under the Award shall be made solely in shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Special Deferral Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Provided Participant is a U.S. tax resident and Participant timely submits a properly completed deferral election in a form provided by the Company, any shares of Common Stock that become issuable pursuant to this Agreement shall be distributed in accordance with the terms of such deferral election, subject to Participant&#8217;s satisfaction of any applicable Withholding Taxes under Paragraph 6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of applying the various Continuous Service vesting provisions of this Agreement, Participant shall be deemed to cease Continuous Service on the commencement date of any leave of absence and not to remain in Continuous Service status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or pursuant to the following policy&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Participant shall be deemed to remain in Continuous Service status during (i) the first three (3) months of an approved personal leave of absence or (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave) and shall be deemed to cease Continuous Service upon the expiration of the applicable three (3)-month or seven (7)-month period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;In no event, however, shall Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service or Employee status on or before that date, or (ii) the date Participant&#8217;s Continuous Service or Employee status actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Company and Participant with all Applicable Laws relating thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the grant, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the termination of Participant&#8217;s Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the grant of the Award to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against the Company, any Related Entity or the Employer, waives Participant&#8217;s ability, if any, to bring any such claim, and releases the Company, any Related Entity and the Employer from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agreed to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company in writing, the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying shares of Common Stock. Participant should consult with Participant&#8217;s own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or shall be delivered electronically to Participant through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect sales of the Common Stock issued hereunder. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, the legal representatives, heirs and legatees of Participant&#8217;s estate</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Code Section 409A</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is the intention of the parties that the provisions of this Agreement shall, to the maximum extent permissible, comply with the requirements of the short-term deferral exception to Section 409A of the Code and Treasury Regulations Section 1.409A-1(b)(4) with respect to each Tranche of Performance Shares under this Award. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the requirements or limitations of Code Section 409A applicable to such short-term deferral exception, then those provisions, as they apply to each Tranche, shall be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Code Section 409A and the Treasury Regulations thereunder that apply to such exception.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">However, to the extent this Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Code Section 409A with respect to one or more Tranches of the Performance Shares, whether by reason of a deferral election that satisfies the requirements of Paragraph 7 above or the pro-rata Continuous Service vesting provisions of this Agreement, then the following provisions shall apply with respect to any such Tranche, notwithstanding anything to the contrary set forth herein&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No shares of Common Stock or other amounts which become issuable or distributable with respect to such Tranche by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant until the date of Participant&#8217;s Separation from Service or as soon thereafter as administratively practicable, but in no event later than the later of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No shares of Common Stock or other amounts which become issuable or distributable with respect to such Tranche by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant prior to the earlier of (i) the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Code Section 409A, as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred shares of Common Stock or other distributable amount shall be issued or distributed in a lump sum on the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or, if earlier, the first (1st) day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No amounts that vest and become payable under Paragraph 4 of this Agreement with respect to that Tranche by reason of a Change in Control shall be distributed to Participant at the time of such Change in Control, unless that transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with the provisions of Paragraph 6(a) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">If a deferral election under Paragraph 7 of this Agreement is in effect with respect to any Tranche of Performance Shares under this Award, no amounts that vest and become payable under Paragraph 4 with respect to that particular Tranche by reason of a Change in Control shall be distributed to Participant at the time of that Change in Control unless the transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with Participant&#8217;s deferral election under Paragraph 7 of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">The shares of Common Stock that are issuable pursuant to each Tranche of Performance Shares in accordance with the provisions of this Agreement and attached Schedule I shall be deemed a separate payment for purposes of Code Section 409A.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement or otherwise relating to or arising from this Agreement, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in this Agreement or in the Plan shall confer upon Participant any right to remain in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Employer or of Participant, which rights are hereby expressly reserved by each, to terminate Participant&#8217;s Continuous Service at any time for any reason, with or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; Stock Awards section on GNET. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or his or her broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares, rights to shares (e.g., Performance Shares) or rights linked to the value of shares of Common Stock (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before he or she possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Participant Acceptance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall any shares of Common Stock be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance. By accepting the Award, Participant agrees that this Award is granted under and governed by the terms and conditions of the Plan and this Agreement. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ia7da90b21292453182239842a2c6a8c3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"></td><td style="width:21.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">EVP, Human Resources</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PARTICIPANT</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Signature</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ia7da90b21292453182239842a2c6a8c3_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions shall be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Applicable Laws </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the legal requirements relating to the Plan and the Awards under applicable provisions of U.S. federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange, and the securities, tax and exchange control laws, rules, regulations, and requirements of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Award Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date the Performance Shares are awarded to Participant pursuant to the Agreement and shall be the date indicated in Paragraph 1 of the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt">Certification Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date following the completion of the Tranche Three Performance Period on which the Administrator certifies the attained level of the Performance Goal applicable to Tranche Three. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in ownership or control of the Company effected through the consummation of any of the following transactions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly (whether as a result of a single acquisition or by reason of one or more acquisitions within the twelve (12)-month period ending with the most recent acquisition) the beneficial owner (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders or an acquisition, consolidation or other reorganization to which the Company is a party&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:90pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall a Change in Control be deemed to occur upon a merger, consolidation or other reorganization effected primarily to change the State of the Company&#8217;s incorporation or to create a holding company structure pursuant to which the Company becomes a wholly-owned subsidiary of an entity whose outstanding voting securities immediately after its formation are beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to the formation of such entity.  Should such holding company structure or other Parent entity be established for the Company, then subparagraph (iii) shall be applied solely to the board of directors of that holding company or Parent entity. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Gilead Sciences, Inc., a Delaware corporation, and any successor corporation to all or substantially all of the assets or voting stock of Gilead Sciences, Inc. which shall by appropriate action adopt the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the performance of services for the Company or a Related Entity (whether now existing or subsequently established) by a person in the capacity of an Employee, Director or Consultant.  For purposes of this Agreement, Participant shall be deemed to cease Continuous Service immediately upon the occurrence of either of the following events&#58; (i) Participant no longer performs services in any of the foregoing capacities for the Company or any Related Entity or (ii) the entity for which Participant is performing such services ceases to remain a Related Entity of the Company, even though Participant may subsequently continue to perform services for that entity. The Administrator shall have the exclusive discretion to determine when Participant ceases Continuous Service for purposes of the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean an individual who is in the employ of the Company (or any Related Entity), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company or any Related Entity employing Participant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">per share of Common Stock on any relevant date shall be the closing price per share of Common Stock (or the closing bid, if no sales were reported) on that date, as quoted on the Stock Exchange that is at the time serving as the primary trading market for the Common Stock&#59; provided, however, that if there is no reported closing price or closing bid for that date, then the closing price or closing bid, as applicable, for the last trading date on which such closing price or closing bid was quoted shall be determinative of such Fair Market </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Value.  The applicable quoted price shall be as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or such other source as the Administrator deems reliable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, provided each corporation in the unbroken chain (other than the Company) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the person to whom the Award is made pursuant to the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.34pt;text-decoration:underline">Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean, with respect to each separate Tranche of Performance Shares, the net product revenue performance goal established or to be established for that Tranche at one or more designated levels of attainment in accordance with the provisions of attached Schedule I (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that must be subsequently attained in order to satisfy the performance-vesting requirement for the shares of Common Stock allocated to that particular Tranche. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Performance Period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the one-year period specified on attached Schedule I for each separate Tranche of Performance Shares over which the attainment of the Revenue Performance Goal applicable to that particular Tranche is to be measured.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean, with respect to each separate Tranche of Performance Shares, the maximum number of shares of Common Stock in which Participant can vest based on the level at which the Performance Goal applicable to that particular Tranche is in fact attained and shall be calculated in accordance with the provisions of attached Schedule I.  Each Performance-Qualified Share that vests pursuant to the terms of the Award shall entitle Participant to receive one share of Common Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Permanent Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">y shall mean the inability of Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more.  The Administrator shall have the exclusive discretion to determine when Permanent Disability has occurred for purposes of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Qualifying Change in Contro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in control of ownership of the Company effected by one or more of the following transactions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.69pt">a merger or consolidation in which the Company is not the surviving entity and in which one person or a group of related persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) acquires ownership of securities possessing more than fifty percent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(50%) of the total combined voting power of the Company&#8217;s outstanding securities or constituting more than fifty percent (50%) of the total fair market value of the Company&#8217;s outstanding securities&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.36pt">the sale, transfer or other disposition of all or substantially all of the assets of the Company in complete liquidation or dissolution of the Company&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:0.03pt">any reverse merger in which the Company is the surviving entity but in which one person or a group of related persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) acquires ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities or constituting more than fifty percent (50%) of the total fair market value of the Company&#8217;s outstanding securities&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:0.69pt">the acquisition, directly or indirectly, by any person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities or constituting more than fifty percent (50%) of the total fair market value of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing definition of Qualifying Change in Control shall in all instances be applied and interpreted in such manner that the applicable Qualifying Change in Control transaction that serves as an issuance event for the shares of Common Stock subject to this Award (or distribution event for any amounts relating to those shares) that vest upon the occurrence of a Change in Control and are otherwise at the time subject to the issuance or distribution restrictions of Code Section 409A will also qualify as&#58; (i) a change in the ownership of the Company, as determined in accordance with Section 1.409A-3(i)(5)(v) of the Treasury Regulations, (ii) a change in the effective control of the Company, as determined in accordance with Section 1.409A-3(i)(5)(vi) of the Treasury Regulations, or (iii) a change in the ownership of a substantial portion of the assets of the Company, as determined in accordance with Section 1.409A-3(i)(5)(vii) of the Treasury Regulations.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) any Parent or Subsidiary of the Company and (ii) any corporation in an unbroken chain of corporations beginning with the Company and ending with the corporation in the chain for which Participant provides services as an Employee, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Director or Consultant, provided each corporation in such chain owns securities representing at least fifty percent (50%) of the total outstanding voting power of the outstanding securities of another corporation or entity in such chain.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Participant&#8217;s cessation of Continuous Service on or after the date on which he or she (i) attains age 55 and completes at least ten (10) years of Continuous Service or (ii) attains age 65.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Participant&#8217;s cessation of Employee status by reason of his or her death, Retirement or termination of employment.  Participant shall be deemed to have terminated employment for such purpose at such time as the level of his or her bona fide services to be performed as an Employee (or as a consultant or independent contractor) permanently decreases to a level that is not more than twenty percent (20%) of the average level of services he or she rendered as an Employee during the immediately preceding thirty-six (36) months (or such shorter period for which he or she may have rendered such services).  Solely for purposes of determining when a Separation from Service occurs, Participant will be deemed to continue in &#8220;Employee&#8221; status for so long as he or she remains in the employ of one or more members of the Employer Group, subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.  &#8220;Employer Group&#8221; means the Company and any Parent or Subsidiary and any other corporation or business controlled by, controlling or under common control with, the Company, as determined in accordance with Sections 414(b) and (c) of the Code and the Treasury Regulations thereunder, except that in applying Sections 1563(1), (2) and (3) of the Code for purposes of determining the controlled group of corporations under Section 414(b), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in such sections and in applying Section 1.414(c)-2 of the Treasury Regulations for purposes of determining trades or businesses that are under common control for purposes of Section 414(c), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in Section 1.414(c)-2 of the Treasury Regulations.  Any such determination as to Separation from Service, however, shall be made in accordance with the applicable standards of the Treasury Regulations issued under Section 409A of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">U.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Service Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean, with respect to each Tranche of Performance Shares, the applicable service period specified for that particular Tranche in attached Schedule I over which the Continuous Service vesting requirement in effect for that Tranche is to be measured.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3.68pt;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Tranche</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the three separate tranches (Tranche One, Tranche Two and Tranche Three) into which the Performance Shares subject to this Award are divided in accordance with the provisions of Paragraph 1 of this Agreement and attached Schedule I.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any and all income taxes (including U.S. federal, state and local tax) and the employee portion of the federal state and local taxes (including social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items) required or permitted to be withheld by the Company and&#47;or the Employer in connection with any taxable or tax withholding event, as applicable, attributable to the Award or Participant&#8217;s participation in the Plan.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-6</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ia7da90b21292453182239842a2c6a8c3_74"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE I</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PERFORMANCE GOALS AND PERFORMANCE PERIODS FOR THE THREE TRANCHES OF PERFORMANCE SHARES </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ESTABLISHMENT OF SEPARATE TRANCHES</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Target Shares subject to the Award have, in accordance with Paragraph 1 of this Agreement, been divided into three (3) separate Tranches&#58; Tranche One, Tranche Two and Tranche Three.  Each such separate Tranche shall cover one-third of the Target Shares and shall have its own separate Performance Period and Service Period. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD FOR TRANCHE ONE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Goal for the Performance Shares allocated to Tranche One shall be the one-year period coincident with the Company&#8217;s 2022 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche One Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SERVICE PERIOD FOR TRANCHE ONE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Service Period for the Continuous Service vesting condition for Tranche One shall be the period beginning January 1, 2022 and ending on the Certification Date.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING FOR TRANCHE ONE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal for Tranche One&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares allocated to Tranche One shall be tied to the Company&#8217;s recognition of net product revenue for the Tranche One Performance Period in a dollar amount ranging from $21,790 Billion at twenty percent (20%) threshold level attainment to $24,211 Billion at target level attainment and to $25,422 Billion at maximum level attainment, with the net product revenue goal at any other point within such range to be in the dollar amount determined on a straight-line interpolated basis pursuant to the 2022 Fiscal Year Revenue Goal&#47;Revenue Payout Slope set forth below. For purposes of determining whether such Revenue Performance Goal is attained, the actual level of net product revenue recognized by the Company for the Tranche One Performance Period shall be the net product revenue of the Company and its consolidated subsidiaries that is reported on a consolidated basis in the Company&#8217;s audited consolidated financial statements for the fiscal year coincident with the Tranche One Performance Period, adjusted, however, to factor out (i) the effect of any changes in applicable accounting principles that occur after the start of such period and (ii) any product revenue realized during the 2022 fiscal year by any entity acquired by the Company during that year.   </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within sixty-five (65) days after the completion of the Tranche One Performance Period, the Administrator shall determine and certify the actual dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche One Performance Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of Performance-Qualified Shares that results from such certification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche One Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may range from 0% to 200% of the Target Shares allocated to Tranche One in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of Paragraph 5 of this Agreement. The actual percentage shall be determined on the basis of the dollar amount of net product revenue that the Administrator certifies has in fact been recognized for the Tranche One Performance Period, as measured and reported on a consolidated basis with the Company&#8217;s subsidiaries in accordance with the Company&#8217;s audited consolidated financial statements for the Company&#8217;s fiscal year coincident with the Tranche One Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the maximum number of the shares of Common Stock that may qualify as Tranche One Performance-Qualified Shares may not exceed 200% of the Target Shares allocated to Tranche One in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Level of Tranche One Performance Goal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of shares of Common Stock that may qualify as Tranche One Performance-Qualified Shares on the basis of the certified dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche One Performance Period shall be calculated by multiplying the number of Target Shares allocated to Tranche One in accordance with Paragraph 1 of this Agreement (as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement) by the applicable percentage determined in accordance with the following revenue goal&#47;payout slope for the Tranche One Performance Goal (with appropriate straight-line interpolation for any attained level within two otherwise designated levels in such slope)&#58; </font></div><div><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">2022 FISCAL YEAR REVENUE GOAL&#47;REVENUE PAYOUT SLOPE</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:431px"></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.948%"><tr><td style="width:1.0%"></td><td style="width:36.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Net Product Revenue Achievement (in millions)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">% of Target</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Performance Shares Earned Under Tranche</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$21,790</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">90.0%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">20%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$24,211</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">100.0%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$24,816</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">102.5%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">150%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$25,422</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">105.0%</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">200%</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD FOR TRANCHE TWO</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Goal for the Performance Shares allocated to Tranche Two shall be the one-year period coincident with the Company&#8217;s 2023 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Two Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SERVICE PERIOD FOR TRANCHE TWO</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Service Period for the Continuous Service vesting condition for Tranche Two shall be the period beginning January 1, 2023 and ending on the Certification Date.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING FOR TRANCHE TWO</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal for Tranche Two&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares allocated to Tranche Two shall be tied to the Company&#8217;s recognition of net product revenue for the Tranche Two Performance Period in the dollar amounts (at threshold, target and maximum levels, with appropriate straight-line interpolation between any two such designated levels) to be set by the Administrator no later than ninety (90) days after the start of that performance period.  The Performance Goal for the Tranche Two Performance Period shall be the same as the Performance Goal for the Tranche One Performance Period for any Performance Share Award granted to you in 2023, unless you are notified otherwise in writing promptly following the Administrator&#8217;s establishment of the applicable Performance Goal for the Tranche Two Performance Period.  </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within sixty-five (65) days after the completion of the Tranche Two Performance Period, the Administrator shall determine and certify the actual dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Two Performance Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of Performance-Qualified Shares that results from such certification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Two Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may range from 0% to 200% of the Target Shares allocated to Tranche Two in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement. The actual percentage shall be determined on the basis of the dollar amount of net product revenue that the Administrator certifies has in fact been recognized for the Tranche Two Performance Period, as measured and reported on a consolidated basis with the Company&#8217;s subsidiaries in accordance with the Company&#8217;s audited consolidated financial statements for the Company&#8217;s fiscal year coincident with the Tranche Two Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the maximum number of the shares of Common Stock that may qualify as Tranche Two Performance-Qualified Shares may not exceed 200% of the Target Shares allocated to Tranche Two in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Level of Tranche Two Performance Goal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of shares of Common Stock that may qualify as Tranche Two Performance-Qualified Shares on the basis of the certified dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Two Performance Period shall be calculated by multiplying the number of Target Shares allocated to Tranche Two in accordance with Paragraph 1 of this Agreement (as such number </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement) by the applicable percentage determined in accordance with the payout slope (with appropriate straight-line interpolation for any attained level within two otherwise designated levels in such slope) approved by the Administrator at the same time it establishes the applicable Performance Goal for the Tranche Two Performance Period.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD FOR TRANCHE THREE </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Goal for the Performance Shares allocated to Tranche Three shall be the one-year period coincident with the Company&#8217;s 2024 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Three Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SERVICE PERIOD FOR TRANCHE THREE </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Service Period for the Continuous Service vesting condition for Tranche Three shall be the period beginning January 1, 2024 and ending on the Certification Date.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING FOR TRANCHE THREE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal for Tranche Three&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares allocated to Tranche Three shall be tied to the Company&#8217;s recognition of net product revenue for the Tranche Three Performance Period in the dollar amounts (at threshold, target and maximum levels, with appropriate straight-line interpolation between any two such designated levels) to be set by the Administrator no later than ninety (90) days after the start of that performance period. The Performance Goal for the Tranche Three Performance Period shall be the same as the Performance Goal for the Tranche One Performance Period for any Performance Share Award granted to you in 2024, unless you are notified otherwise in writing promptly following the Administrator&#8217;s establishment of the applicable Performance Goal for the Tranche Three Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within sixty-five (65) days after the completion of the Tranche Three Performance Period, the Administrator shall determine and certify the actual dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Three Performance Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of Performance-Qualified Shares that results from such certification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Three Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may range from 0% to 200% of the Target Shares allocated to Tranche Three in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement. The actual percentage shall be determined on the basis of the dollar amount of net product revenue that the Administrator certifies has in fact been recognized for the Tranche Three Performance Period, as measured on a consolidated basis with the Company&#8217;s subsidiaries in accordance with the Company&#8217;s audited consolidated financial statements for the Company&#8217;s fiscal year coincident with the Tranche Three Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the maximum number of the shares of Common Stock that may qualify as Tranche Three Performance-Qualified Shares may not exceed 200% of the Target Shares allocated to Tranche Three in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Level of Tranche Three Performance Goal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of shares of Common Stock that may qualify as Tranche Three Performance-Qualified Shares on the basis of the certified dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Three Performance Period shall be calculated by multiplying the number of Target Shares allocated to Tranche Three in accordance with Paragraph 1 of this Agreement (as such number may be adjusted from time to time pursuant to the provisions of Paragraph 5 of this Agreement) by the applicable percentage determined in accordance with the payout slope (with appropriate straight-line interpolation for any attained level within two otherwise designated levels in such slope) approved by the Administrator at the same time it establishes the applicable Performance Goal for the Tranche Three Performance Period. </font></div><div style="margin-top:9pt;text-align:justify;text-indent:-0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CONTINUOUS SERVICE VESTING REQUIREMENT FOR PERFORMANCE-QUALIFIED SHARES </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of shares of Common Stock in which Participant may actually vest on the basis of the number of Performance-Qualified Shares certified by the Administrator for each separate Tranche of Performance Shares in accordance with the foregoing provisions shall be tied to his or her completion of the following Continuous Service vesting requirement applicable to each such Tranche&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           If Participant remains in Continuous Service through the Certification Date, Participant shall vest in one hundred percent (100%) of the Performance-Qualified Shares certified by the Administrator for that Tranche.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-         If Participant&#8217;s Continuous Service terminates prior to the Certification Date by reason of death or Permanent Disability, then&#58; (a) if such cessation of Continuous Service occurs at any time on or after the completion of the Performance Period applicable to a particular Tranche of Performance Shares, Participant shall immediately vest in the number of shares of Common Stock equal to the actual number of Performance-Qualified Shares (if any) that was earned for the Performance Period applicable to that Tranche, and (b) if such cessation of Continuous Service occur prior to the completion of the Performance Period applicable to a particular Tranche of Performance Shares, Participant shall immediately vest in the Target Shares allocated to that particular Tranche. The shares of Common Stock that vest pursuant to this paragraph shall be issued or distributed on the date of Participant&#8217;s cessation of Continuous Service or as soon as administratively practicable thereafter, but in no event later than the later of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-         If Participant&#8217;s Continuous Service terminates prior to the Certification Date but at least twelve (12) months following the Award Date by reason of Retirement, then Participant shall, following the Certification Date, vest in one hundred percent (100%) of the Performance-Qualified Shares certified by the Administrator for that Tranche as if Participant had remained in Continuous Service through the Certification Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-         If Participant&#8217;s Continuous Service ceases for any other reason (including, without limitation, any deemed cessation of Continuous Service under Paragraph 8 of this Agreement) prior to the Certification Date, then Participant shall not vest in any of the Performance-Qualified Shares covered by any Tranche, and all of Participant&#8217;s right, title and interest to the shares of Common Stock underlying each Tranche shall immediately terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that should a Change in Control occur prior to the Certification Date, then the provisions of Paragraph 4 of the Agreement shall govern the vesting of the Performance Shares (if any) allocated to each Tranche. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-           Notwithstanding anything to the contrary in the foregoing provisions of this Continuous Service section, should Participant&#8217;s Continuous Service cease for any reason (other than Participant&#8217;s death or Permanent Disability) prior to the start of the Service Period specified above for any particular Tranche of Performance Shares, then Participant shall not vest in any of the Performance Shares allocated to that Tranche, and all of Participant&#8217;s right, title and interest to the shares of Common Stock underlying that Tranche shall immediately terminate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHEDULE I-7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>5
<FILENAME>gildq12022ex10282022employ.htm
<DESCRIPTION>2022 EMPLOYEE RSU AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia1d48bb925944de2b941cd75c90a0dc9_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">2004 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL RESTRICTED STOCK UNIT ISSUANCE AGREEMENT</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Board has adopted the Plan for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;All capitalized terms in this Agreement shall have the meaning assigned to them herein and in the attached Appendix.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby awards Restricted Stock Units to Participant upon the following terms and conditions&#58; </font></div><div style="margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Award Date indicated below, Restricted Stock Units under the Plan. Each Restricted Stock Unit that vests hereunder will entitle Participant to receive one share of Common Stock on the specified issuance date for that unit. The number of Shares subject to the awarded Restricted Stock Units, the applicable vesting schedule for those Shares, the dates on which those vested Shares shall become issuable to Participant and the remaining terms and conditions governing the Award shall be as set forth in this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUMMARY</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares Subject to Award&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">shares of Common Stock (the &#8220;Shares&#8221;)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares have a four-year vesting schedule. 25% vest on the first anniversary of the Award Date. The balance will vest 6.25% quarterly thereafter until fully vested. However, one or more Shares may be subject to accelerated vesting in accordance with the provisions of Paragraph 3 or 5 of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Schedule</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares in which Participant vests in accordance with the Normal Vesting Schedule shall become issuable pursuant to the Plan on the applicable annual vesting date, subject to the Company&#8217;s collection of the applicable Withholding Taxes. In no event will the Shares in which Participant so vests be issued after the later of (i) the close of the calendar year in which the Shares vest pursuant to the Normal Vesting Schedule or (ii) the fifteenth (15th) day of the third (3rd) calendar month following such vesting date. The procedures pursuant to which the applicable Withholding Taxes are to be collected are set forth in Paragraph 7 of this Agreement.</font></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to actual receipt of the Shares which vest hereunder, Participant may not transfer any interest in the Award or the underlying Shares or pledge or otherwise hedge the sale of those Shares, including (without limitation) any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares. However, any Shares which vest hereunder but which otherwise remain unissued at the time of Participant&#8217;s death may be transferred to Participant&#8217;s designated beneficiary or, if none, to Participant's estate. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in this Paragraph 3 or in Paragraph 5 below, should Participant cease Continuous Service for any reason prior to vesting in one or more Shares pursuant to the Normal Vesting Schedule, then the Award will be immediately cancelled with respect to those unvested Shares, and the number of Restricted Stock Units will be reduced accordingly. Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Participant (i) cease Continuous Service at least twelve (12) months following the Award Date and (ii) (1) after attaining age 55 and completing at least ten (10) years of Continuous Service or (2) after attaining age 65, then Participant shall continue to vest in unvested Shares granted hereunder in accordance with the Normal Vesting Schedule as if such Participant had remained in Continuous Service. Any Shares which vest pursuant to this Subparagraph shall be issuable as set forth in Paragraph 1 above. Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Participant&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Award pursuant to this subparagraph (b) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable treatment at the time of Participant&#8217;s cessation of Continuous Service, and the Award will be treated as set forth in Subparagraph 3(a). Furthermore, if Participant is located in Australia, Hong Kong, the Netherlands, or Taiwan, he or she shall not be eligible for the provisions of this Subparagraph 3(b) and the Award will be treated as set forth in the Subparagraph 3(a).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should Participant cease Continuous Service as a result of Participant&#8217;s death or Permanent Disability, then Participant shall immediately vest in all the unvested Shares at the time subject to this Award. The Shares that vest pursuant to this Paragraph 3(c) shall be issued or distributed on the date of Participant&#8217;s cessation of Continuous Service or as soon as administratively practicable thereafter, but in no event later than the later of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding any other provision hereof, should Participant&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), or should Participant engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the sole discretion of the Administrator, then this Award will be immediately cancelled with respect to all Shares, whether or not vested at the time. Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The holder of this Award shall not have any stockholder rights, including voting, dividend or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance following the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to this Award on such record date have not otherwise vested and been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account shall be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such Shares subsequently vest hereunder, the phantom dividend equivalents so credited to those Shares in the book account shall vest, and those vested dividend equivalents shall be distributed to Participant (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those phantom dividend equivalents relate and correspondingly as such Shares are forfeited or cancelled under this Award the phantom dividend equivalents so credited to those Shares in the book account shall be forfeited or cancelled. Each such distribution of dividend equivalent amounts shall be subject to the Company&#8217;s collection of any Withholding Taxes applicable to that distribution. The Administrator shall have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination shall be controlling.&#160;No dividend equivalent amount shall be paid or distributed on shares of Common Stock under this Award that are forfeited or that otherwise do not vest and are not issued or issuable under this Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should Participant cease Continuous Service without vesting in one or more of the Shares subject to this Award (including any Shares which do not or will not otherwise vest after taking into account any applicable vesting acceleration or continuation provisions set forth in Paragraph 3 or 5 of this Agreement), then the phantom dividend equivalents credited to those unvested Shares shall be cancelled, and Participant shall thereupon cease to have any further right or entitlement to those cancelled amounts.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:90pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Any Restricted Stock Units subject to this Award at the time of a Change in Control may be (i) assumed or otherwise continued in full force and effect by the surviving corporation, (ii) replaced with an economically-equivalent substitute award or (iii) replaced with a cash retention program of the successor corporation that is in a dollar amount equal to the Fair Market Value of the Shares underlying those Restricted Stock Units (as measured immediately prior to the Change in Control) and provides for the subsequent vesting and payout of that dollar amount in accordance with the same vesting and issuance provisions that would otherwise be in effect for those Shares in the absence of the Change in Control. In the event of such assumption or continuation of the Award or such replacement of the Award with an economically-equivalent award or cash retention program, no accelerated vesting of the Restricted Stock Units shall occur at the time of the Change in Control. Notwithstanding the foregoing, no such cash retention program shall be established for the Restricted Stock Units subject to this Award to the extent such program would otherwise be deemed to constitute a deferred compensation arrangement subject to the requirements of Code Section 409A and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award shall be adjusted immediately after the consummation of the Change in Control so as to apply to the number and class of securities into which the Shares underlying those units immediately prior to the Change in Control would have been converted in consummation of that Change in Control had those Shares actually been issued and outstanding at that time. To the extent the actual holders of the outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation (or parent entity) may, in connection with the assumption or continuation of the Restricted Stock Units subject to the Award at that time and with the approval of the Administrator, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per Share in the Change in Control transaction, provided the substituted common stock is readily tradable on an established U.S. securities exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Any Restricted Stock Units which are to be assumed or otherwise continued in effect in connection with the Change in Control or are to be replaced with an economically equivalent award or cash retention program in accordance with Paragraph 5(a) shall be subject to accelerated vesting in accordance with the following provision&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If Participant&#8217;s Employee status is unilaterally terminated as a result of an involuntary termination without Cause, or if Participant resigns from such Employee status due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control transaction and ending with the earlier of (i) the termination of that definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, then Participant shall immediately vest in all the unvested Shares (or any replacement securities or cash proceeds) at the time subject to this Award. The Shares (or any </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">replacement securities or cash proceeds) that vest pursuant to this Paragraph 5(c) shall be issued or distributed on the date of Participant&#8217;s Separation from Service in connection with such termination of Employee status or as soon as administratively practicable thereafter, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service. The applicable Withholding Taxes with respect to such issuance shall be collected in accordance with Paragraph 7 of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Restricted Stock Units subject to this Award at the time of the Change in Control are not assumed or otherwise continued in effect in connection with the Change in Control or are not replaced with an economically equivalent award or cash incentive program in accordance with Paragraph 5(a), then those units will vest immediately prior to the closing of the Change in Control. The Shares subject to those vested units shall be converted into the right to receive for each such Share the same consideration per Share payable to the other stockholders of the Company in consummation of that Change in Control, and such consideration per Share shall be distributed to Participant upon the tenth (10th) business day following the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to occur of (i) the date the Share would have otherwise vested and been issued pursuant to the Vesting and Issuance Schedules set forth in Paragraph 1 in the absence of such Change in Control, (ii) the date of Participant&#8217;s Separation from Service, or (iii) the first date following a Qualifying Change in Control on which the distribution can be made without contravention of any applicable provisions of Code Section 409A. Such distribution shall be subject to the Company&#8217;s collection of the applicable Withholding Taxes pursuant to the provisions of Paragraph 7.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Adjustment in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, extraordinary dividend or distribution or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of outstanding Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable adjustments shall be made by the Administrator to the total number and&#47;or class of securities issuable pursuant to this Award in order to reflect such change. In making such adjustments, the Administrator shall take into account any amounts to be credited to Participant&#8217;s book account under Paragraph 4(b) in connection with the transaction, and the determination of the Administrator shall be final, binding and conclusive. In the event of a Change in Control, the provisions of Paragraph 5 shall be controlling. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Issuance of Shares or Other Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">On or after each date on which one or more Shares are to be issued in accordance with the express provisions of this Agreement, the Company shall issue to or on behalf of Participant a certificate (which may be in electronic form) for those Shares and shall concurrently distribute to Participant any phantom dividend equivalents with respect to those Shares (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances), subject in each instance to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant acknowledges that, regardless of any action the Company and&#47;or the Employer take with respect to any or all Withholding Taxes related to Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant further acknowledges that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares (or other property) upon settlement of the Award, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends and&#47;or phantom dividend equivalents&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Participant has become subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company shall collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this Agreement (including Shares issued in settlement of phantom dividend equivalents) through an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes, unless such Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides to no longer utilize the Share Withholding Method and provides Participants with a corresponding notice.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Share Withholding Method is to be utilized for the collection of Withholding Taxes, then the Company shall withhold the number of otherwise issuable Shares necessary to satisfy the applicable Withholding Taxes based on the applicable minimum statutory rate or other applicable withholding rate, including maximum applicable rates, as determined by the Company in its sole discretion. If the maximum rate is used, any over-withheld amount will be refunded to Participant in cash by the Company or Employer (with no entitlement to the Common Stock equivalent) or if not refunded, Participant may seek a refund from the local tax authorities. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">issued the full number of Shares subject to the vested Award, notwithstanding that a number of the Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company shall have sole discretion to determine whether or not the Share Withholding Method shall be utilized for the collection of the applicable Withholding Taxes. Participant shall be notified (in writing or through the Company&#8217;s electronic mail system) in the event the Company no longer intends to utilize the Share Withholding Method. Should any Shares become issuable under the Award (including Shares issued in settlement of phantom dividend equivalents) at a time when the Share Withholding Method is not being utilized by the Company, then the Withholding Taxes shall be collected from Participant through a sale-to-cover transaction authorized by Participant, pursuant to which an immediate open-market sale of a portion of the Shares issued to Participant will be effected, for and on behalf of Participant, by the Company&#8217;s designated broker to cover the Withholding Tax liability estimated by the Company to be applicable to such issuance. Participant shall, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such open-market, sale-to-cover transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no sale-to-cover transaction shall be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">If the Company determines that such sale-to-cover transaction is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such sale-to-cover transaction can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of his or her separate check payable to the Company in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event shall any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes and in compliance with any applicable requirements of Code Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in Paragraph 5, the settlement of all Restricted Stock Units which vest under the Award shall be made solely in Shares. In no event, however, shall any fractional Shares be issued. Accordingly, the total number of Shares to be issued at the time the Award vests (including any Shares issued in settlement of phantom dividend equivalents) shall, to the extent necessary, be rounded down to the next whole Share in order to avoid the issuance of a fractional Share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> The Company shall collect the Withholding Taxes with respect to phantom dividend equivalents distributed in a form other than Shares by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Notwithstanding the foregoing provisions, to the extent Participant is subject to taxation in the United States, the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall in all events be collected from Participant no later than the last business day of the calendar year in which those Shares or other amounts vest (as determined under applicable tax laws) hereunder. Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those Shares or other amounts vest, Participant shall, if so requested by the Company, on or before the last business day of the calendar year in which such Shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to the Employment Taxes required to be withheld with respect to those Shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Employment Taxes required to be withheld with respect to those Shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 7(i) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of applying the various vesting provisions of this Agreement, the Administrator, in its sole discretion, may determine that Participant shall be deemed to cease Continuous Service and Employee status on the commencement date of any leave of absence and not remain in Continuous Service or Employee status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant shall receive Continuous Service credit for such vesting purposes for (i) the first three (3) months of an approved personal leave of absence and (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service or Employee status beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service or Employee status on or before that date, (ii) the date Participant&#8217;s Continuous Service or Employee status actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability or (iii) the date Participant is deemed to have a Separation from Service.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The issuance of Shares pursuant to the Award shall be subject to compliance by the Company and Participant with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to this Award shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or his or her broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before he or she possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions and Participant should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Deferred Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, to the extent Participant is subject to taxation in the United States and this Award may be deemed to create a deferred compensation arrangement under Code Section 409A, then the following limitation shall apply&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No Shares or other amounts which become issuable or distributable under this Agreement upon Participant&#8217;s Separation from Service shall actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first day of the seventh (7th) month following the date of such Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Code Section 409A, as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred Shares or other distributable amount shall be issued or distributed in a lump sum on the first day of the seventh (7th) </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the extent there is any ambiguity as to whether any provision of this Agreement would otherwise contravene one or more requirements or limitations of Code Section 409A, such provisions shall be interpreted and applied in a manner that does not result in a violation of the applicable requirements or limitations of Code Section 409A and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each installment of Shares issuable pursuant to this Agreement shall be treated as a separate payment for purposes of Code Section 409A. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or shall be delivered electronically to Participant through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect the sale of the Shares issued hereunder. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, Participant&#8217;s assigns, the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or the federal courts for the Northern District of California, and no other courts where the grant of the Restricted Stock Units is made and&#47;or to be performed. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and Participant&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Participant&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with any certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from termination of Participant&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the Award, Participant irrevocably agrees not to institute any claim against the Company, the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employer or any Related Entity, waives his or her ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the following provisions apply only if Participant is providing services outside the United States&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation or salary for any purpose&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Participant acknowledges and agrees that neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan or Participant&#8217;s acquisition or sale of the underlying Shares. Participant should consult with his or her personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan or the Restricted Stock Units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or other Participants.</font></div><div style="text-align:justify;text-indent:94.5pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that he or she needs to review the following information about the processing of his or her personal data by or on behalf of the Company, the Employer and&#47;or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare his or her consent. As regards the processing of Participant&#8217;s Personal Data in connection with the Plan and this Agreement, Participant understands that the Company is the controller of his or her Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan. Participant understands that this Personal Data may include, without limitation, his or her name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant&#8217;s favor. The legal basis for the processing of Participant&#8217;s Personal Data, where required, will be his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company transfers his or her Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Participant&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Participant understands and acknowledges that the Company&#8217;s service provider will open an account for him or her to receive and trade Shares acquired under the Plan and that he or she will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Participant understands and acknowledges that his or her country may have enacted data privacy laws that are different from the laws of the United States. For </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">example, the European Commission has issued only a limited adequacy finding with respect to the United States that applies solely if and to the extent that companies self-certify and remain self-certified under the EU&#47;U.S. Privacy Shield program. The Company does not currently participate in the EU&#47;U.S. Privacy Shield Program. The Company&#8217;s legal basis for the transfer of Participant&#8217;s Personal Data is his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company will use his or her Personal Data only as long as is necessary to implement, administer and manage his or her participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Participant understands and acknowledges that the Company&#8217;s legal basis for the processing of his or her Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Participant&#8217;s Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that his or her participation in the Plan and his or her consent is purely voluntary. Participant may deny or later withdraw his or her consent at any time, with future effect and for any or no reason. If Participant denies or later withdraws his or her consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan. Participant further understands that denial or withdrawal of his or her consent would not affect his or her status or salary as an employee or his or her career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that data subject rights regarding the processing of Personal Data vary depending on the applicable law and that, depending on where Participant is based and subject to the conditions set out in the applicable law, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about him or her and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about him or her that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of his or her objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of his or her Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant&#8217;s Personal Data that he or she has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or his or her employment and is carried out by automated means. In case of concerns, Participant understands that he or she may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Participant&#8217;s rights, Participant understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">stockplanservices&#64;gilead.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Participant acknowledges that he or she is sufficiently proficient in English, or has consulted with an advisor who is sufficiently proficient in English so as to allow Participant, to understand the terms and conditions of this Agreement. Further, if Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Depending upon the country to which laws Participant is subject, Participant may have certain foreign asset and&#47;or account reporting requirements that may affect Participant&#8217;s ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends or phantom dividend equivalents received or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside Participant&#8217;s country. Participant&#8217;s country may require that he or she report such accounts, assets or transactions to the applicable authorities in Participant&#8217;s country. Participant is responsible for knowledge of and compliance with any such regulations and should speak with his or her own personal tax, legal and financial advisors regarding same.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, the Award shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for Participant&#8217;s country. Moreover, if Participant relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By Participant&#8217;s electronic acceptance and the signature of the Company&#8217;s representative above, Participant and the Company agree that this Award is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Participant&#8217;s country. Participant has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="ia1d48bb925944de2b941cd75c90a0dc9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions shall be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the addendum to this Agreement setting forth special terms and conditions for Participant&#8217;s country.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Compensation Committee of the Board (or a subcommittee thereof) acting in its capacity as administrator of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean this Global Restricted Stock Unit Issuance Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Applicable Acceleration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 2(b) of the Plan and shall be determined on the basis of Participant&#8217;s status on the Change in Control date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the legal requirements related to the Plan and the Award under applicable provisions of the federal securities laws, state corporate and securities laws, the Code, the rules of any applicable Stock Exchange on which the Common Stock is listed for trading, and the rules of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the award of Restricted Stock Units made to Participant pursuant to the terms of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Award Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date the Restricted Stock Units are awarded to Participant pursuant to the Agreement and shall be the date indicated in Paragraph 1 of the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s Board of Directors.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning given to the term &#8220;Cause&#8221; in any effective employment agreement between the Participant and the Company or a Related Entity, or if none, shall mean the termination of Participant&#8217;s Continuous Service as a result of Participant&#8217;s (i) conviction of, a guilty plea with respect to, or a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to, a charge that Participant has committed a felony under the laws of the United States or of any State or a crime involving moral turpitude, including (without limitation) fraud, theft, embezzlement or any crime that results in or is intended to result in personal enrichment to Participant at the expense of the Company or a Related Entity&#59; (ii) material breach of any agreement entered into between Participant and the Company or a Related Entity that impairs the Company&#8217;s or the Related Entity&#8217;s interest therein&#59; (iii) willful misconduct, significant failure to perform his or her duties or gross neglect of his or her duties&#59; (iv) engagement in any activity that constitutes a material conflict of interest with the Company or a Related Entity&#59; or (v) reasons that are comparable to Cause under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in ownership or control of the Company effected through the consummation of any of the following transactions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly (whether as a result of a single acquisition or by reason of one or more acquisitions within the twelve (12)-month period ending with the most recent acquisition) the beneficial owner (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders or an acquisition, consolidation or other reorganization to which the Company is a party&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall a Change in Control be deemed to occur upon a merger, consolidation or other reorganization effected primarily to change the State of the Company&#8217;s incorporation or to create a holding company structure pursuant to which the Company becomes a wholly-owned subsidiary of an entity whose outstanding voting securities immediately after its formation are beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to the formation of such entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Internal Revenue Code of 1986, as amended.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Common Stock or Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean shares of the Company&#8217;s common stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.34pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Gilead Sciences, Inc., a Delaware corporation, and any successor corporation to all or substantially all of the assets or voting stock of Gilead Sciences, Inc. which shall by appropriate action adopt the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Constructive Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 11(d) of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person, including an advisor, who is compensated by the Company or any Related Entity for services performed as a non-employee consultant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the term &#8220;Consultant&#8221; shall not include non-employee Directors serving in their capacity as Board members. The term &#8220;Consultant&#8221; shall include a member of the board of directors of a Related Entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the performance of services for the Company or a Related Entity (whether now existing or subsequently established) by a person in the capacity of an Employee, Director or Consultant. For purposes of this Agreement, Participant shall be deemed to cease Continuous Service immediately upon the occurrence of either of the following events&#58; (i) Participant no longer performs services in any of the foregoing capacities for the Company or any Related Entity or (ii) the entity for which Participant is performing such services ceases to remain a Related Entity of the Company, even though Participant may subsequently continue to perform services for that entity. Subject to the foregoing and any applicable limitations of Code Section 409A, the Administrator shall have the exclusive discretion to determine when Participant ceases Continuous Service for purposes of the Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a member of the Board.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person who is in the employ of the Company (or any Related Entity), subject to the control and direction of the Company or Related Entity as to both the work to be performed and the manner and method of performance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company or the Related Entity employing or retaining Participant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">per share of Common Stock on any relevant date shall be the closing price per share of Common Stock (or the closing bid, if no sales were reported) on that date, as quoted on the Stock Exchange that is at the time serving as the primary trading market for the Common Stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if there is no reported closing price or closing bid for that date, then the closing price or closing bid, as applicable, for the last trading date on which such closing price or closing bid was quoted shall be determinative of such Fair Market Value. The applicable quoted price shall be as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or such other source as the Administrator deems reliable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">U.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Normal Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the schedule set forth in Paragraph 1 of the Agreement, pursuant to which the Restricted Stock Units and the underlying Shares are to vest in a series of installments over Participant&#8217;s period of Continuous Service.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3.68pt;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;parent corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(e) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the person to whom the Award is made pursuant to the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s 2004 Equity Incentive Plan, as amended and restated from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Z.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the inability of Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which is expected to result in death or to be of continuous duration of twelve (12) months or more. The Administrator shall have exclusive discretion to determine when Permanent Disability has occurred for purposes of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AA. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Qualifying Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in the ownership of the Company, a change in the effective control of the Company or a change in ownership of a substantial portion of the Company&#8217;s assets, with each such event to be determined in accordance with the requirements for a change in control event set forth in Section 1.409A-3(i)((5) of the Treasury Regulations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that a change in the effective control of the Company will only be deemed to occur if there is an acquisition, within the applicable twelve (12)-month period, of ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BB. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) any Parent or Subsidiary of the Company and (ii) any corporation in an unbroken chain of corporations beginning with the Company and ending with the corporation in the chain for which Participant provides services as an Employee, Director or Consultant, provided each corporation in such chain owns securities representing at least twenty percent (20%) of the total outstanding voting power of the outstanding securities of another corporation or entity in such chain and there is a legitimate non-tax business purpose for making this Award to Participant. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Award in the form of a contractual right to receive Shares under this Agreement which will entitle Participant to receive one actual share of Common Stock per Restricted Stock Unit upon the satisfaction of the Continuous Service vesting requirements applicable to such Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DD. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Participant&#8217;s cessation of Employee status by reason of his or her death, retirement or termination of employment. Participant shall be deemed to have terminated employment for such purpose at such time as the level of his or her bona fide services to be performed as an Employee (or as a consultant or independent contractor) permanently decreases to a level that is not more than twenty percent (20%) of the average level of services such person rendered as an Employee during the immediately preceding thirty-six (36) months (or such shorter period for which he or she may have rendered such services). Solely for purposes of determining when a Separation from Service occurs, Participant will be deemed to continue in &#8220;Employee&#8221; status for so long as he remains in the employ of one or more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">members of the Employer Group, subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance. &#8220;Employer Group&#8221; means the Company and any Parent or Subsidiary and any other corporation or business controlled by, controlling or under common control with, the Company, as determined in accordance with Sections 414(b) and 414(c) of the Code and the Treasury Regulations thereunder, except that in applying Sections 1563(1), (2) and (3) of the Code for purposes of determining the controlled group of corporations under Section 414(b), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in such sections, and in applying Section 1.414(c)-2 of the Treasury Regulations for purposes of determining trades or businesses that are under common control for purposes of Section 414(c), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in Section 1.414(c)-2 of the Treasury Regulations. Any such determination as to Separation from Service, however, shall be made in accordance with the applicable standards of the Treasury Regulations issued under Section 409A of the Code. In addition, the following special provisions shall be in effect for any leave of absence taken by Participant while this Award is outstanding&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Should the period of such leave (other than a disability leave) exceed six (6) months, then Participant shall be deemed to incur a Separation from Service upon the expiration of the initial six (6) - month period of that leave, unless Participant retains a right to re-employment under Applicable Law or by contract with the Company (or any Parent or Subsidiary or other Related Entity).</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Should the period of a disability leave exceed twenty-nine (29) months, then Participant shall be deemed to incur a Separation from Service upon the expiration of the initial twenty-nine (29)-month period of that leave, unless Participant retains a right to re-employment under Applicable Law or by contract with the Company (or any Parent or Subsidiary or other Related Entity). For such purpose, a disability leave shall be a leave of absence due to any medically determinable physical or mental impairment that can be expected to result in death or to last for a continuous period of not less than six (6) months and causes Participant to be unable to perform the duties of his position of employment with the Company (or any Parent or Subsidiary or other Related Entity) or any substantially similar position of employment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FF. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GG. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;subsidiary corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(f) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HH. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any and all income taxes (including U.S. federal, state, and local tax and&#47;or foreign income taxes) and the employee portion of the federal, state, local and&#47;or foreign employment taxes (including social insurance, payroll tax, payment on account or other tax-related items) required or permitted to be withheld by the Company in connection with any taxable or tax withholding event, as applicable, attributable to the Award or Participant&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>gildq12022ex311ceocertific.htm
<DESCRIPTION>CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i627024f1eff04922bab1d37e68abdc67_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:8pt;padding-left:288pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>gildq12022ex312cfocertific.htm
<DESCRIPTION>CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i536b659acb904dce86e2c49b703b424e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:11pt;padding-left:252pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>gildq12022ex32section906ce.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i271c974b61f24417988a4a231645ff74_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>gild-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:047062f8-b3c9-4367-911c-0f45b6df8713,g:679ab3c4-b282-4926-9aaf-46591661bf28-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.gilead.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUES" roleURI="http://www.gilead.com/role/REVENUES">
        <link:definition>2104102 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESTables" roleURI="http://www.gilead.com/role/REVENUESTables">
        <link:definition>2305301 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails">
        <link:definition>2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails">
        <link:definition>2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESPerformanceObligationsDetails" roleURI="http://www.gilead.com/role/REVENUESPerformanceObligationsDetails">
        <link:definition>2408404 - Disclosure - REVENUES - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails">
        <link:definition>2409405 - Disclosure - REVENUES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2110103 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails">
        <link:definition>2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES">
        <link:definition>2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables">
        <link:definition>2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails">
        <link:definition>2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails">
        <link:definition>2421413 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTS" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS">
        <link:definition>2122105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSTables" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables">
        <link:definition>2323304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
        <link:definition>2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails">
        <link:definition>2427417 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS" roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS">
        <link:definition>2128106 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails">
        <link:definition>2429418 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>2130107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>2331305 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSGoodwillDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails">
        <link:definition>2432419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>2433420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
        <link:definition>2434421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1">
        <link:definition>2434421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails">
        <link:definition>2435422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>2136108 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>2337306 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails">
        <link:definition>2438423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONInventoriesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails">
        <link:definition>2439424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONInventoriesDetails_1" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1">
        <link:definition>2439424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>2440425 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIES" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES">
        <link:definition>2141109 - Disclosure - DEBT AND CREDIT FACILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESTables" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables">
        <link:definition>2342307 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
        <link:definition>2443426 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails">
        <link:definition>2444427 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2145110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2446428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2147111 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2348308 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails">
        <link:definition>2449429 - Disclosure - STOCKHOLDERS' EQUITY - Repurchases of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2450430 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS">
        <link:definition>2151112 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables">
        <link:definition>2352309 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails">
        <link:definition>2453431 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails">
        <link:definition>2454432 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.gilead.com/role/INCOMETAXES">
        <link:definition>2155113 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.gilead.com/role/INCOMETAXESTables">
        <link:definition>2356310 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.gilead.com/role/INCOMETAXESDetails">
        <link:definition>2457433 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.gilead.com/role/SUBSEQUENTEVENT">
        <link:definition>2158114 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTDetails" roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails">
        <link:definition>2459434 - Disclosure - SUBSEQUENT EVENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" abstract="false" name="LossContingencyAdditionalPatentsAllegedlyInfringedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A400SeniorUnsecuredNotesDueSeptember2036Member" abstract="true" name="A400SeniorUnsecuredNotesDueSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_VekluryMember" abstract="true" name="VekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GalapagosMember" abstract="true" name="GalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HepcludexMember" abstract="true" name="HepcludexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2024ExpirationMember" abstract="true" name="EuropeanPatentClaims2024ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2032ExpirationMember" abstract="true" name="EuropeanPatentClaims2032ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorNotesAndMediumTermNotesMember" abstract="true" name="SeniorNotesAndMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_NumberOfClinicalStageProgramsWithExercisedOptions" abstract="false" name="NumberOfClinicalStageProgramsWithExercisedOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" abstract="false" name="PotentialSalesBasedTieredRoyaltiesPercentageMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentEnhancedDamagesOnPastSales" abstract="false" name="JudgmentEnhancedDamagesOnPastSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" abstract="true" name="ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A415SeniorUnsecuredNotesDueMarch2047Member" abstract="true" name="A415SeniorUnsecuredNotesDueMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesAppealedNumber" abstract="false" name="LossContingencyPartiesAppealedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A195SeniorUnsecuredNotesDueMarch2022Member" abstract="true" name="A195SeniorUnsecuredNotesDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherHepatitisCVirusProductsMember" abstract="true" name="OtherHepatitisCVirusProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateFromOctober2017" abstract="false" name="JudgmentRoyaltyRateFromOctober2017" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2026ExpirationMember" abstract="true" name="EuropeanPatentClaims2026ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborativeAgreementOptInTerm" abstract="false" name="CollaborativeAgreementOptInTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_PaymentsToOptInTheCollaborativeAgreement" abstract="false" name="PaymentsToOptInTheCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PreExposureProphylaxisMember" abstract="true" name="PreExposureProphylaxisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" abstract="true" name="JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetMeasurementInput" abstract="false" name="IndefiniteLivedIntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_AccruedGovernmentAndOtherRebates" abstract="false" name="AccruedGovernmentAndOtherRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A250SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A250SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateOnFutureSales" abstract="false" name="JudgmentRoyaltyRateOnFutureSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A325SeniorUnsecuredNotesDueSeptember2022Member" abstract="true" name="A325SeniorUnsecuredNotesDueSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_QuiTamMember" abstract="true" name="QuiTamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyPartiesFilingOppositionNumber" abstract="false" name="LossContingencyPartiesFilingOppositionNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2027ExpirationMember" abstract="true" name="EuropeanPatentClaims2027ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A460SeniorUnsecuredNotesDueSeptember2035Member" abstract="true" name="A460SeniorUnsecuredNotesDueSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementMember" abstract="true" name="ArcusCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" abstract="false" name="EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AxicabtageneciloleucelDLBCLMember" abstract="true" name="AxicabtageneciloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TrodelvyMember" abstract="true" name="TrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A450SeniorUnsecuredNotesDueFebruary2045Member" abstract="true" name="A450SeniorUnsecuredNotesDueFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2016StockRepurchaseProgramMember" abstract="true" name="A2016StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DragonflyTherapeuticsIncMember" abstract="true" name="DragonflyTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A350SeniorUnsecuredNotesDueFebruary2025Member" abstract="true" name="A350SeniorUnsecuredNotesDueFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsTecartusMember" abstract="true" name="CellTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A295SeniorUnsecuredNotesDueMarch2027Member" abstract="true" name="A295SeniorUnsecuredNotesDueMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" abstract="true" name="InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A480SeniorUnsecuredNotesDueApril2044Member" abstract="true" name="A480SeniorUnsecuredNotesDueApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ViiVHealthcareCompanyMember" abstract="true" name="ViiVHealthcareCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" abstract="false" name="EquitySecuritiesFVNIAdditionalOptionPaymentWaived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_LossContingencyMaterialTransferAgreementsNumber" abstract="false" name="LossContingencyMaterialTransferAgreementsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A365SeniorUnsecuredNotesDueMarch2026Member" abstract="true" name="A365SeniorUnsecuredNotesDueMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2020StockRepurchaseProgramMember" abstract="true" name="A2020StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsYescartaMember" abstract="true" name="CellTherapyProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A565SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="A565SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyRoyaltyPercentageOnFutureSales" abstract="false" name="LossContingencyRoyaltyPercentageOnFutureSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DragonflyTherapeuticsCollaborationAgreementMember" abstract="true" name="DragonflyTherapeuticsCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A475SeniorUnsecuredNotesDueMarch2046Member" abstract="true" name="A475SeniorUnsecuredNotesDueMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A370SeniorUnsecuredNotesDueApril2024Member" abstract="true" name="A370SeniorUnsecuredNotesDueApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>gild-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:047062f8-b3c9-4367-911c-0f45b6df8713,g:679ab3c4-b282-4926-9aaf-46591661bf28-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3c19ffa7-434e-4cdd-9a8d-595342c8d691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec7a3f60-f4e5-4ce6-9b4f-2c41ba7ab77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c19ffa7-434e-4cdd-9a8d-595342c8d691" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec7a3f60-f4e5-4ce6-9b4f-2c41ba7ab77c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4de93100-a06d-4308-ba81-04ae355293b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c19ffa7-434e-4cdd-9a8d-595342c8d691" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4de93100-a06d-4308-ba81-04ae355293b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8930aaec-6c84-4d06-ac76-f7ae7adec045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c19ffa7-434e-4cdd-9a8d-595342c8d691" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8930aaec-6c84-4d06-ac76-f7ae7adec045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4fae855b-aa4b-4ea6-a010-8e8200c5a142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c19ffa7-434e-4cdd-9a8d-595342c8d691" xlink:to="loc_us-gaap_InventoryNet_4fae855b-aa4b-4ea6-a010-8e8200c5a142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d694bfd6-852f-4531-b968-c3a7cd63e3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c19ffa7-434e-4cdd-9a8d-595342c8d691" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d694bfd6-852f-4531-b968-c3a7cd63e3ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f24828af-2e07-4f1e-8978-7277543e30da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_924f2455-2f5f-4250-916b-eafc069feb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f24828af-2e07-4f1e-8978-7277543e30da" xlink:to="loc_us-gaap_AccountsPayableCurrent_924f2455-2f5f-4250-916b-eafc069feb59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_be2cb247-e554-4926-9aba-822516903d3d" xlink:href="gild-20220331.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f24828af-2e07-4f1e-8978-7277543e30da" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_be2cb247-e554-4926-9aba-822516903d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_85df4283-14ac-4200-a261-d2c68bad1b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f24828af-2e07-4f1e-8978-7277543e30da" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_85df4283-14ac-4200-a261-d2c68bad1b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_aca99b16-41ff-4638-b1e1-c6b584f64981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f24828af-2e07-4f1e-8978-7277543e30da" xlink:to="loc_us-gaap_DebtCurrent_aca99b16-41ff-4638-b1e1-c6b584f64981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d755d6f-5628-41af-a5fa-e70c09135f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6aa38fd5-0480-4a3f-84f2-ae7078242806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d755d6f-5628-41af-a5fa-e70c09135f66" xlink:to="loc_us-gaap_StockholdersEquity_6aa38fd5-0480-4a3f-84f2-ae7078242806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c5b5b836-fbb5-4c24-91d0-bb7651cb05e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d755d6f-5628-41af-a5fa-e70c09135f66" xlink:to="loc_us-gaap_MinorityInterest_c5b5b836-fbb5-4c24-91d0-bb7651cb05e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f5d8075f-e559-463c-91fe-01a61cdcf156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:to="loc_us-gaap_AssetsCurrent_f5d8075f-e559-463c-91fe-01a61cdcf156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0f00b918-041d-4a09-9cc9-dadf4541cfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0f00b918-041d-4a09-9cc9-dadf4541cfdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_cbe17872-3724-4d5a-81c1-3506f753e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_cbe17872-3724-4d5a-81c1-3506f753e3cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d00c77ac-52e0-4c1d-bfa7-30c4d3405ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d00c77ac-52e0-4c1d-bfa7-30c4d3405ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d40e1e09-7560-42f5-ac6f-9ba822631a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:to="loc_us-gaap_Goodwill_d40e1e09-7560-42f5-ac6f-9ba822631a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_468ea743-970b-4c33-9558-87c80edc53fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_446c7189-81da-4324-860f-2f8c903aa4ca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_468ea743-970b-4c33-9558-87c80edc53fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_44976b1f-ebb3-4e5e-ac64-e740f94deeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_44976b1f-ebb3-4e5e-ac64-e740f94deeb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_b82624a2-b285-42d4-b86c-f8fd3683200d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_b82624a2-b285-42d4-b86c-f8fd3683200d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2f56246d-ab84-4a40-87b3-ae1ed111b238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2f56246d-ab84-4a40-87b3-ae1ed111b238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_65518e07-586b-4f47-8e1f-db4c20c1d078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_CommitmentsAndContingencies_65518e07-586b-4f47-8e1f-db4c20c1d078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b90de30-8293-435c-b47a-b392c4bcb7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b90de30-8293-435c-b47a-b392c4bcb7e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_870a8850-6a6a-4184-811f-b5710466fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_LiabilitiesCurrent_870a8850-6a6a-4184-811f-b5710466fdfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2e61a91f-b753-42a7-bfcd-a513c39665e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fac6a2a4-71f8-49a9-96fc-ceb581886949" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2e61a91f-b753-42a7-bfcd-a513c39665e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98385631-cf22-4320-932d-f37625851213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_339baf98-2b7a-40fa-8755-5ac5a044360e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98385631-cf22-4320-932d-f37625851213" xlink:to="loc_us-gaap_PreferredStockValue_339baf98-2b7a-40fa-8755-5ac5a044360e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e19bb671-7da5-4613-ad8d-2107c8f8b216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98385631-cf22-4320-932d-f37625851213" xlink:to="loc_us-gaap_CommonStockValue_e19bb671-7da5-4613-ad8d-2107c8f8b216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e683c82d-fa67-4e53-9d72-95cd2b222b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98385631-cf22-4320-932d-f37625851213" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e683c82d-fa67-4e53-9d72-95cd2b222b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d79d8113-6f54-4240-8034-37a04d2f1aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98385631-cf22-4320-932d-f37625851213" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d79d8113-6f54-4240-8034-37a04d2f1aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f7e7229-d3b0-47d8-9ea8-31f3eda7e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_98385631-cf22-4320-932d-f37625851213" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f7e7229-d3b0-47d8-9ea8-31f3eda7e8fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_446e27bd-160c-499a-b974-a601de7c1e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f0be1d43-0038-4940-b084-8f29728e84e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_446e27bd-160c-499a-b974-a601de7c1e3b" xlink:to="loc_us-gaap_CostsAndExpenses_f0be1d43-0038-4940-b084-8f29728e84e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80906d5f-c3c3-4281-a267-d1f006e857bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_446e27bd-160c-499a-b974-a601de7c1e3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80906d5f-c3c3-4281-a267-d1f006e857bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ef8c06-84d3-4040-9a94-0bf79eca356a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_47eb941b-20c0-46bf-9e39-424b06a3b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ef8c06-84d3-4040-9a94-0bf79eca356a" xlink:to="loc_us-gaap_OperatingIncomeLoss_47eb941b-20c0-46bf-9e39-424b06a3b6de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9b9f7acf-4ecb-45e8-813b-00862a90ace6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ef8c06-84d3-4040-9a94-0bf79eca356a" xlink:to="loc_us-gaap_InterestExpense_9b9f7acf-4ecb-45e8-813b-00862a90ace6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_806691de-4878-498f-95a8-8a89240329ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70ef8c06-84d3-4040-9a94-0bf79eca356a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_806691de-4878-498f-95a8-8a89240329ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0c6e0637-50c6-4408-8b96-55c8222b5268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78760527-dbac-4597-8e04-8dcea3d308ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0c6e0637-50c6-4408-8b96-55c8222b5268" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78760527-dbac-4597-8e04-8dcea3d308ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2a474c8b-714d-46bd-8eff-8b13b3adff02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0c6e0637-50c6-4408-8b96-55c8222b5268" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2a474c8b-714d-46bd-8eff-8b13b3adff02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_61e557ae-77e2-4b00-9bda-83cd8c181e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0c6e0637-50c6-4408-8b96-55c8222b5268" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_61e557ae-77e2-4b00-9bda-83cd8c181e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e47097b7-0b9e-4a2c-b4f5-fb8e2d07779d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0c6e0637-50c6-4408-8b96-55c8222b5268" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e47097b7-0b9e-4a2c-b4f5-fb8e2d07779d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fa0b2328-741d-4a7d-8b2f-57b2d070671e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0c6e0637-50c6-4408-8b96-55c8222b5268" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fa0b2328-741d-4a7d-8b2f-57b2d070671e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_427c2c1e-8971-460b-8821-db3f4666b380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_462ec049-c421-4c15-9643-253019add23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_427c2c1e-8971-460b-8821-db3f4666b380" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_462ec049-c421-4c15-9643-253019add23d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_70695c41-ef3f-4a38-8dc0-4ebf47990490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_427c2c1e-8971-460b-8821-db3f4666b380" xlink:to="loc_us-gaap_ProfitLoss_70695c41-ef3f-4a38-8dc0-4ebf47990490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2515694-b97c-4413-a700-ca2c0214f3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_966bff5b-fcda-43f7-a00e-af74a99cfbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f2515694-b97c-4413-a700-ca2c0214f3f2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_966bff5b-fcda-43f7-a00e-af74a99cfbe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_825b15e8-5a57-4780-a711-f1cd262fc1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f2515694-b97c-4413-a700-ca2c0214f3f2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_825b15e8-5a57-4780-a711-f1cd262fc1ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0589855b-cfe7-4ff4-b91c-a57a21d698a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6666dd39-028f-4844-ba3a-f061cbb5b9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0589855b-cfe7-4ff4-b91c-a57a21d698a9" xlink:to="loc_us-gaap_ProfitLoss_6666dd39-028f-4844-ba3a-f061cbb5b9ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d2ba75c-8706-46ad-8f24-c3f0356ec024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0589855b-cfe7-4ff4-b91c-a57a21d698a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d2ba75c-8706-46ad-8f24-c3f0356ec024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_df1acd97-03eb-4a24-974b-8fba28a52ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ad546346-b64b-4437-a4a5-e615b88c44a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_df1acd97-03eb-4a24-974b-8fba28a52ea0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ad546346-b64b-4437-a4a5-e615b88c44a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_bb13a601-4479-4e23-b82e-f19f13b31500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_df1acd97-03eb-4a24-974b-8fba28a52ea0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_bb13a601-4479-4e23-b82e-f19f13b31500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f71e8b73-7aa8-450a-9766-bb0384a35c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_07e5ee48-3135-4b3a-9da3-3fb434e2ec8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f71e8b73-7aa8-450a-9766-bb0384a35c70" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_07e5ee48-3135-4b3a-9da3-3fb434e2ec8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_aeaa54be-e528-429d-87cf-09101ac3fa38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f71e8b73-7aa8-450a-9766-bb0384a35c70" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_aeaa54be-e528-429d-87cf-09101ac3fa38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eda0239-3098-4164-bcf5-a365face860a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f6388dea-291d-4c53-8ba5-5985a945c6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eda0239-3098-4164-bcf5-a365face860a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f6388dea-291d-4c53-8ba5-5985a945c6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1224da59-b812-4c28-820c-bc762493de51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eda0239-3098-4164-bcf5-a365face860a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1224da59-b812-4c28-820c-bc762493de51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a2e3056a-087d-4b72-844b-8d1747a4bd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1eda0239-3098-4164-bcf5-a365face860a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a2e3056a-087d-4b72-844b-8d1747a4bd2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1382c1a1-d58f-4a6d-bf25-5d3120d2736c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_26e9a1d0-c4e1-4461-b135-e864f5fc7aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1382c1a1-d58f-4a6d-bf25-5d3120d2736c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_26e9a1d0-c4e1-4461-b135-e864f5fc7aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_02126d46-ffc6-4ee9-9f1c-d8a519e1f4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1382c1a1-d58f-4a6d-bf25-5d3120d2736c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_02126d46-ffc6-4ee9-9f1c-d8a519e1f4fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41505b7e-1d1b-49dc-8125-c2c217aa2b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c89f685d-6dfe-4021-af35-1a6c0adf42e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41505b7e-1d1b-49dc-8125-c2c217aa2b73" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c89f685d-6dfe-4021-af35-1a6c0adf42e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd356778-9731-4f13-bcbe-603cf6f12825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41505b7e-1d1b-49dc-8125-c2c217aa2b73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd356778-9731-4f13-bcbe-603cf6f12825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29881ab6-d411-4872-8236-1de6c4473465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41505b7e-1d1b-49dc-8125-c2c217aa2b73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_29881ab6-d411-4872-8236-1de6c4473465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a991e022-9961-4d70-92ea-9ccdffee22ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41505b7e-1d1b-49dc-8125-c2c217aa2b73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a991e022-9961-4d70-92ea-9ccdffee22ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a48836-e15a-4894-bf1b-4da1f8f2038c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_210a7d34-55d2-4c94-b6c1-adcb0d7e83a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a48836-e15a-4894-bf1b-4da1f8f2038c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_210a7d34-55d2-4c94-b6c1-adcb0d7e83a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_7b6004d7-4f25-415c-a056-5e3d005813e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a48836-e15a-4894-bf1b-4da1f8f2038c" xlink:to="loc_us-gaap_PaymentsOfDividends_7b6004d7-4f25-415c-a056-5e3d005813e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3b719009-4fd6-440e-9211-6f16fb559808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a48836-e15a-4894-bf1b-4da1f8f2038c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3b719009-4fd6-440e-9211-6f16fb559808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7d7c42a7-5be7-4e7e-874b-b84b972b878d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a48836-e15a-4894-bf1b-4da1f8f2038c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7d7c42a7-5be7-4e7e-874b-b84b972b878d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_75eaae49-238c-4e85-8c0a-e4cffd9ba598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a48836-e15a-4894-bf1b-4da1f8f2038c" xlink:to="loc_us-gaap_RepaymentsOfDebt_75eaae49-238c-4e85-8c0a-e4cffd9ba598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_6a2c393b-7cf2-4016-9012-490e4cbc1de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_6a2c393b-7cf2-4016-9012-490e4cbc1de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_776f73cd-9423-48d2-b430-7be55a86f320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_776f73cd-9423-48d2-b430-7be55a86f320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c588365b-db3e-455d-b431-2c61609d0912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c588365b-db3e-455d-b431-2c61609d0912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c6004437-87eb-493a-b78a-b075d9066f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c6004437-87eb-493a-b78a-b075d9066f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1808401c-2b14-4af9-9967-01a8eda4f2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1808401c-2b14-4af9-9967-01a8eda4f2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_096d307f-786e-4f0e-ac0c-5429649fe9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_096d307f-786e-4f0e-ac0c-5429649fe9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_983c4265-c1c7-473f-8034-6eedfb7545d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9c6f6-328c-484d-b91b-dfbe1561fb3c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_983c4265-c1c7-473f-8034-6eedfb7545d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_78b880de-6d17-471b-bbae-11c34453ffbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_Depreciation_78b880de-6d17-471b-bbae-11c34453ffbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4581c990-b0e7-4890-a9b8-f8d379931c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4581c990-b0e7-4890-a9b8-f8d379931c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fcc4c948-b045-4eb7-bbb1-e39009ce2075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_ProfitLoss_fcc4c948-b045-4eb7-bbb1-e39009ce2075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a98162ca-d9f0-4a9c-a2bc-92f39b0f7b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a98162ca-d9f0-4a9c-a2bc-92f39b0f7b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_4ff11018-54b3-48c9-8a7c-56284ad3e55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_4ff11018-54b3-48c9-8a7c-56284ad3e55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_689d5a1b-1702-4872-afa8-80bdb468fac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_689d5a1b-1702-4872-afa8-80bdb468fac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ee304abd-63de-4360-9394-fc28e90d77df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ee304abd-63de-4360-9394-fc28e90d77df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_44d8b9c0-196a-4b47-b736-8fcca7c6ed1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_44d8b9c0-196a-4b47-b736-8fcca7c6ed1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7f4b330f-7970-4d9e-8a2d-20f0eee3440f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7f4b330f-7970-4d9e-8a2d-20f0eee3440f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_894fc477-61d8-41a4-98f2-b99f9e9cceff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_894fc477-61d8-41a4-98f2-b99f9e9cceff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b157a59b-f36e-42fe-8674-fd3b6320a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b157a59b-f36e-42fe-8674-fd3b6320a82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_47e93413-2b30-4ee8-a689-e5250581eddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_AdjustmentForAmortization_47e93413-2b30-4ee8-a689-e5250581eddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6959ea61-21bc-42e1-b56e-b3cb91e98fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6959ea61-21bc-42e1-b56e-b3cb91e98fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23fb6e69-4b06-4b22-83bd-2a2689d28b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_ShareBasedCompensation_23fb6e69-4b06-4b22-83bd-2a2689d28b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_44a8ad28-d79f-49e7-80c0-8f5c523ea38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3099ad5f-1342-47c1-9f98-ff424c5df044" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_44a8ad28-d79f-49e7-80c0-8f5c523ea38e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_eb46deec-8ba7-4901-8f2f-55b67e1f3356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7941b408-8395-48d0-919b-0eb3f5e34722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_eb46deec-8ba7-4901-8f2f-55b67e1f3356" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7941b408-8395-48d0-919b-0eb3f5e34722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_17db770c-21f3-45a7-912e-bf54984afd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_eb46deec-8ba7-4901-8f2f-55b67e1f3356" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_17db770c-21f3-45a7-912e-bf54984afd18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_75f63c43-5d6e-452b-8386-29f5102b3944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_eb46deec-8ba7-4901-8f2f-55b67e1f3356" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_75f63c43-5d6e-452b-8386-29f5102b3944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_755b9a05-68c5-4ff8-8b9a-ed9fe6d9cbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_91beb1fd-e798-4e69-8e49-74c325cd4af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_755b9a05-68c5-4ff8-8b9a-ed9fe6d9cbab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_91beb1fd-e798-4e69-8e49-74c325cd4af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_77e9b391-6a12-4637-96c2-1dd450bc6baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_755b9a05-68c5-4ff8-8b9a-ed9fe6d9cbab" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_77e9b391-6a12-4637-96c2-1dd450bc6baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_bc506d3e-c5af-4f7e-b967-cad640649437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_755b9a05-68c5-4ff8-8b9a-ed9fe6d9cbab" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_bc506d3e-c5af-4f7e-b967-cad640649437" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2a0bbb18-3413-46b4-923a-b8d06f9b0344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_219cb62c-dc0f-4cf5-a4bf-b9a2943f7336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2a0bbb18-3413-46b4-923a-b8d06f9b0344" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_219cb62c-dc0f-4cf5-a4bf-b9a2943f7336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_452012e5-5a96-4b7f-b096-845c4627fc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2a0bbb18-3413-46b4-923a-b8d06f9b0344" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_452012e5-5a96-4b7f-b096-845c4627fc62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_e5e6ee85-24bc-4f39-ac43-27350fc06cab" xlink:href="gild-20220331.xsd#gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2a0bbb18-3413-46b4-923a-b8d06f9b0344" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_e5e6ee85-24bc-4f39-ac43-27350fc06cab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a3ab706c-7e10-4865-9d97-50a4b572afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d5cf6a2e-2063-425c-9b6c-107ac72eaff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a3ab706c-7e10-4865-9d97-50a4b572afaa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d5cf6a2e-2063-425c-9b6c-107ac72eaff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_373352e9-5566-405e-b995-c1073de26647" xlink:href="gild-20220331.xsd#gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a3ab706c-7e10-4865-9d97-50a4b572afaa" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_373352e9-5566-405e-b995-c1073de26647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6f20ac1d-03d5-448a-9c44-746188c5a590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a3ab706c-7e10-4865-9d97-50a4b572afaa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6f20ac1d-03d5-448a-9c44-746188c5a590" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3def8ba5-3b72-4b69-a5cb-50161d1bb2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a7b85c70-b3fd-4f21-a208-c01e5442dd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3def8ba5-3b72-4b69-a5cb-50161d1bb2a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a7b85c70-b3fd-4f21-a208-c01e5442dd44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_da7a7af7-ecb1-4b2b-b613-cb9357f2e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ca13177a-a026-4f81-b286-fad3a70b43b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_da7a7af7-ecb1-4b2b-b613-cb9357f2e0b4" xlink:to="loc_us-gaap_DerivativeLiabilities_ca13177a-a026-4f81-b286-fad3a70b43b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_412b5e12-1862-4315-a5a6-7542d4ff4af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_da7a7af7-ecb1-4b2b-b613-cb9357f2e0b4" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_412b5e12-1862-4315-a5a6-7542d4ff4af6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_15893fac-ea5d-469f-a95b-c3aec0ab7d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_da7a7af7-ecb1-4b2b-b613-cb9357f2e0b4" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_15893fac-ea5d-469f-a95b-c3aec0ab7d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_05da1087-4043-4af6-9f6f-5d41aad24ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f6a6e4f5-4193-41c7-a587-16fcc55fa527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_05da1087-4043-4af6-9f6f-5d41aad24ff8" xlink:to="loc_us-gaap_DerivativeAssets_f6a6e4f5-4193-41c7-a587-16fcc55fa527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f212f5de-0f08-461d-afd3-2400a1b270a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_05da1087-4043-4af6-9f6f-5d41aad24ff8" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f212f5de-0f08-461d-afd3-2400a1b270a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_a1ae72e0-87bf-4467-bd8a-0309f6738462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_05da1087-4043-4af6-9f6f-5d41aad24ff8" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_a1ae72e0-87bf-4467-bd8a-0309f6738462" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df27c8c3-01cc-4247-93a6-cd1c71a6263e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_181c8575-5c4f-4aa6-9965-1beecb7a7c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df27c8c3-01cc-4247-93a6-cd1c71a6263e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_181c8575-5c4f-4aa6-9965-1beecb7a7c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_9acd3399-c34d-4b50-b7cc-28bd9b753b99" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df27c8c3-01cc-4247-93a6-cd1c71a6263e" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_9acd3399-c34d-4b50-b7cc-28bd9b753b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7f4063b7-b860-4c59-9f8d-ff65ab0da6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df27c8c3-01cc-4247-93a6-cd1c71a6263e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7f4063b7-b860-4c59-9f8d-ff65ab0da6ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9226d4fe-76fe-4292-9cca-bb1defee9d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_258c4ea9-9dbc-4127-addc-9cb6c39edd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9226d4fe-76fe-4292-9cca-bb1defee9d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_258c4ea9-9dbc-4127-addc-9cb6c39edd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_55735e40-a98b-4e45-a58e-904d5942f9d3" xlink:href="gild-20220331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9226d4fe-76fe-4292-9cca-bb1defee9d12" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_55735e40-a98b-4e45-a58e-904d5942f9d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_bc386e03-4ddf-4eca-8e2c-fda589a90fe3" xlink:href="gild-20220331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2d96909a-1f4a-44fb-b211-87e34ccda838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_bc386e03-4ddf-4eca-8e2c-fda589a90fe3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2d96909a-1f4a-44fb-b211-87e34ccda838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c84a4ccc-9db7-4920-8a41-7074f18ff4dd" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_bc386e03-4ddf-4eca-8e2c-fda589a90fe3" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c84a4ccc-9db7-4920-8a41-7074f18ff4dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_df675fdf-1c4c-4ea0-9667-3ee622feee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_aee5b96f-8d8c-446a-97c9-c92c1d9dd707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_df675fdf-1c4c-4ea0-9667-3ee622feee2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_aee5b96f-8d8c-446a-97c9-c92c1d9dd707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3ae6b681-c6d8-41c5-ad70-cdacd802cdea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_df675fdf-1c4c-4ea0-9667-3ee622feee2b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3ae6b681-c6d8-41c5-ad70-cdacd802cdea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_81e2e6be-d46d-4fb8-811f-78bbe4273b27" xlink:href="gild-20220331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c340bc17-6993-46cb-974b-21ac60819b63" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_81e2e6be-d46d-4fb8-811f-78bbe4273b27" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c340bc17-6993-46cb-974b-21ac60819b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_0ee0c68c-0a33-41a1-b92d-eefc32dba02f" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_81e2e6be-d46d-4fb8-811f-78bbe4273b27" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_0ee0c68c-0a33-41a1-b92d-eefc32dba02f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9170fd1d-66d8-4c64-a689-6ed3d5542273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_07997ed4-ddad-4d77-aebe-900fcee120fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9170fd1d-66d8-4c64-a689-6ed3d5542273" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_07997ed4-ddad-4d77-aebe-900fcee120fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5537ae62-b313-47d6-bba6-27809e60e313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9170fd1d-66d8-4c64-a689-6ed3d5542273" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5537ae62-b313-47d6-bba6-27809e60e313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_789b8f45-6269-4a04-af17-60e690797be6" xlink:href="gild-20220331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9170fd1d-66d8-4c64-a689-6ed3d5542273" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_789b8f45-6269-4a04-af17-60e690797be6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8658e230-1d64-4554-9ae7-569d6bbeae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8658e230-1d64-4554-9ae7-569d6bbeae0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6111d4b2-42b4-4706-9711-a8b77be329fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6111d4b2-42b4-4706-9711-a8b77be329fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_31e847b2-ffde-41b0-9e8a-f52d898eec6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_31e847b2-ffde-41b0-9e8a-f52d898eec6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_75957051-2e0b-47dc-aba1-90eb7fb5faa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_75957051-2e0b-47dc-aba1-90eb7fb5faa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5ad9296b-b0c9-44a8-87cb-2a844201975d" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:to="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5ad9296b-b0c9-44a8-87cb-2a844201975d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6123b6f2-7327-4f53-80ea-41225834d90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_478283b9-5a6b-45e9-affc-61ccde3e612f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6123b6f2-7327-4f53-80ea-41225834d90d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1b98470d-920c-45a2-b3f9-de8301c55b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4a1c8767-7f1c-4193-a2ed-3a31753dc0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1b98470d-920c-45a2-b3f9-de8301c55b1a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4a1c8767-7f1c-4193-a2ed-3a31753dc0b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_340ce47c-4df5-4e3d-a495-f82d3aa1cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1b98470d-920c-45a2-b3f9-de8301c55b1a" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_340ce47c-4df5-4e3d-a495-f82d3aa1cffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_47a9b10d-e9e6-41e3-912b-53f9bce27fbf" xlink:href="gild-20220331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1b98470d-920c-45a2-b3f9-de8301c55b1a" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_47a9b10d-e9e6-41e3-912b-53f9bce27fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_496d4460-5c99-4714-9a4e-4300de00ca44" xlink:href="gild-20220331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1b98470d-920c-45a2-b3f9-de8301c55b1a" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_496d4460-5c99-4714-9a4e-4300de00ca44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_f3d83b4c-d9ec-4a05-b545-a74e0d7cc57b" xlink:href="gild-20220331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_70b94d87-0e9b-4afc-8064-3eeedfebb846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_f3d83b4c-d9ec-4a05-b545-a74e0d7cc57b" xlink:to="loc_us-gaap_InventoryNet_70b94d87-0e9b-4afc-8064-3eeedfebb846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_683b0349-aba7-44bd-9e07-7fd68a919f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_f3d83b4c-d9ec-4a05-b545-a74e0d7cc57b" xlink:to="loc_us-gaap_InventoryNoncurrent_683b0349-aba7-44bd-9e07-7fd68a919f07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_4885c9fc-e49b-40ac-abf4-9c8b9eb5c416" xlink:href="gild-20220331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ff4a9af4-4145-486b-ba6d-e857da7a54fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_4885c9fc-e49b-40ac-abf4-9c8b9eb5c416" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ff4a9af4-4145-486b-ba6d-e857da7a54fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4155c587-a1cc-4641-912b-65017958be95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_4885c9fc-e49b-40ac-abf4-9c8b9eb5c416" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4155c587-a1cc-4641-912b-65017958be95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_38089cfa-7035-47cf-80af-cf06f6e3056b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_4885c9fc-e49b-40ac-abf4-9c8b9eb5c416" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_38089cfa-7035-47cf-80af-cf06f6e3056b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fe7295f9-4de3-48f7-9a3a-543acf5b2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_b493b2d1-eaf2-4807-a860-e677ec0f03f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe7295f9-4de3-48f7-9a3a-543acf5b2c6a" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_b493b2d1-eaf2-4807-a860-e677ec0f03f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_39fe85f0-a34e-4231-a44f-70fc11b30538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe7295f9-4de3-48f7-9a3a-543acf5b2c6a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_39fe85f0-a34e-4231-a44f-70fc11b30538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_7d121535-2bd1-4dc4-a482-b3f7a885bf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe7295f9-4de3-48f7-9a3a-543acf5b2c6a" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_7d121535-2bd1-4dc4-a482-b3f7a885bf89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b12b64fb-ecc5-4afa-a503-5aff7891a114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe7295f9-4de3-48f7-9a3a-543acf5b2c6a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b12b64fb-ecc5-4afa-a503-5aff7891a114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c65f637a-df9f-414b-9ad9-9ff4af0ea62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe7295f9-4de3-48f7-9a3a-543acf5b2c6a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c65f637a-df9f-414b-9ad9-9ff4af0ea62e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_69b3b9a8-6f4b-4f40-9ec5-77316707383f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c291e7ea-7854-433f-9c1a-a61396960894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69b3b9a8-6f4b-4f40-9ec5-77316707383f" xlink:to="loc_us-gaap_LongTermDebtCurrent_c291e7ea-7854-433f-9c1a-a61396960894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_090e523e-35a4-473c-b08a-7fa26640a78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69b3b9a8-6f4b-4f40-9ec5-77316707383f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_090e523e-35a4-473c-b08a-7fa26640a78b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9436bc5d-f08e-4768-a3a2-4edb382396de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_55b78a2a-20a4-4aed-9fb7-ceb329fde3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9436bc5d-f08e-4768-a3a2-4edb382396de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_55b78a2a-20a4-4aed-9fb7-ceb329fde3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6d69b8e5-86ec-4d96-82e3-9880eebf4444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9436bc5d-f08e-4768-a3a2-4edb382396de" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6d69b8e5-86ec-4d96-82e3-9880eebf4444" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_392e0b2f-62c0-4f6f-bdad-6dc7e8025da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5691e2a9-7d40-4324-b552-16d0e3410b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_392e0b2f-62c0-4f6f-bdad-6dc7e8025da9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5691e2a9-7d40-4324-b552-16d0e3410b7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2d89784b-b702-44f5-b05e-2d39727b84f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_392e0b2f-62c0-4f6f-bdad-6dc7e8025da9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2d89784b-b702-44f5-b05e-2d39727b84f3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>gild-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:047062f8-b3c9-4367-911c-0f45b6df8713,g:679ab3c4-b282-4926-9aaf-46591661bf28-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="iec695aa0f6d34590b522d6c9e7534fa8_CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_15b2ffa6-a17f-464e-9f65-8c8fc03cf6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_RevenuesAbstract_15b2ffa6-a17f-464e-9f65-8c8fc03cf6c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09ece196-4958-41ae-9814-d951e4c6b971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_15b2ffa6-a17f-464e-9f65-8c8fc03cf6c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09ece196-4958-41ae-9814-d951e4c6b971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c50e9093-dfe5-4f4b-b586-7b129511b387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c50e9093-dfe5-4f4b-b586-7b129511b387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1e59ea30-6210-46bd-ba2d-6ba6de1c449e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1e59ea30-6210-46bd-ba2d-6ba6de1c449e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e1731d06-4493-4ab0-9a51-0cddc306f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e1731d06-4493-4ab0-9a51-0cddc306f97e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c0283825-ae34-4cb4-bbeb-fdf01b3a4454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c0283825-ae34-4cb4-bbeb-fdf01b3a4454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b243f18-48e9-4690-9705-905f061956d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b243f18-48e9-4690-9705-905f061956d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9e021edf-8e61-4176-bf05-4cdce52d4ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_CostsAndExpenses_9e021edf-8e61-4176-bf05-4cdce52d4ae5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_62907a37-7341-4064-b66e-69b77d604ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_OperatingIncomeLoss_62907a37-7341-4064-b66e-69b77d604ce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c9068dd5-b632-4131-90d3-115564883d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_InterestExpense_c9068dd5-b632-4131-90d3-115564883d71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e5555e02-13e8-460d-91b9-fc9000c02a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e5555e02-13e8-460d-91b9-fc9000c02a30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_578ae0e5-473b-4549-ad9b-07c8b9e9aa55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_578ae0e5-473b-4549-ad9b-07c8b9e9aa55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2666d998-4d43-4e2b-b047-4cad7236df4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2666d998-4d43-4e2b-b047-4cad7236df4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea29675f-11e6-446e-a45a-3ea6603a395d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_ProfitLoss_ea29675f-11e6-446e-a45a-3ea6603a395d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d9f1c9e-510c-4393-87e6-00bd54e826a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d9f1c9e-510c-4393-87e6-00bd54e826a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e3d6114f-127e-4d18-bb51-950fe9cc45bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_NetIncomeLoss_e3d6114f-127e-4d18-bb51-950fe9cc45bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8f22c976-0273-44d1-a82e-19312d8c6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_EarningsPerShareBasic_8f22c976-0273-44d1-a82e-19312d8c6139" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_159cab5a-db73-48d6-88e5-a488ceb89a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_159cab5a-db73-48d6-88e5-a488ceb89a61" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fc0f7c89-63a8-4ca8-8274-97b41d507f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fc0f7c89-63a8-4ca8-8274-97b41d507f0f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0c4bd6a2-0650-4ecd-af09-3875b1b358d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0c4bd6a2-0650-4ecd-af09-3875b1b358d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:to="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cea544bd-327e-4c42-bf9c-c4cf709df7ca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:to="loc_srt_ProductsAndServicesDomain_cea544bd-327e-4c42-bf9c-c4cf709df7ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:to="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_21d7c9ef-8f71-4372-b757-f54c04f58f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:to="loc_us-gaap_ProductMember_21d7c9ef-8f71-4372-b757-f54c04f58f72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_19982a08-589a-4ff3-b66e-ed1546ffb796" xlink:href="gild-20220331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:to="loc_gild_RoyaltyContractAndOtherMember_19982a08-589a-4ff3-b66e-ed1546ffb796" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="id6b6d3d923e44609acf091aee7f409bd_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_559ff6e0-244b-4c9f-8e9f-0a1ae15264ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_559ff6e0-244b-4c9f-8e9f-0a1ae15264ce" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26183cb1-f707-4442-85df-e150d7a2b9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26183cb1-f707-4442-85df-e150d7a2b9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3772c3e0-0bb4-4f48-a551-c7e51cadc739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3772c3e0-0bb4-4f48-a551-c7e51cadc739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f67e7a1c-1ead-4e25-8c34-f914014f2999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_ProfitLoss_f67e7a1c-1ead-4e25-8c34-f914014f2999" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc1509a-fd8d-4903-b1b3-a99d1a148593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc1509a-fd8d-4903-b1b3-a99d1a148593" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d0a9f09e-815a-4bf8-ac66-5ba206c5bbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d0a9f09e-815a-4bf8-ac66-5ba206c5bbc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9209e4e2-e468-46dd-af0b-130832811b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9209e4e2-e468-46dd-af0b-130832811b32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22d2cc2d-3055-49a9-a74c-4224fac65867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22d2cc2d-3055-49a9-a74c-4224fac65867" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_63b89497-c663-4206-8b0d-765b6fe36ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_63b89497-c663-4206-8b0d-765b6fe36ca9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ce7abf-0893-4dc7-ad06-c59933a879b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ce7abf-0893-4dc7-ad06-c59933a879b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1abfc4d4-e137-4e00-afd3-e8d54e722e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1abfc4d4-e137-4e00-afd3-e8d54e722e73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1bcb71a7-f1c1-4927-b5d7-409c431ca1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1bcb71a7-f1c1-4927-b5d7-409c431ca1c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_0a132b9f-4241-4d18-9239-0a87d9ca8115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_Dividends_0a132b9f-4241-4d18-9239-0a87d9ca8115" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4eb0d309-de88-4616-823a-3a77bd57cbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34c4d26a-8344-420a-948e-6c501d52ff32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_559ff6e0-244b-4c9f-8e9f-0a1ae15264ce" xlink:to="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac99521d-ced6-46fa-a387-462a02ee0c9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:to="loc_us-gaap_EquityComponentDomain_ac99521d-ced6-46fa-a387-462a02ee0c9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:to="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6ed87b1-0321-4821-bec0-37019b1ba18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_CommonStockMember_d6ed87b1-0321-4821-bec0-37019b1ba18b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_039ddf10-6ccf-4d51-8b6d-32b6db8ace99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_039ddf10-6ccf-4d51-8b6d-32b6db8ace99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0251d19-0544-4d67-86ea-51fff605e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0251d19-0544-4d67-86ea-51fff605e8b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6f8dfa83-766c-4a68-bdba-ad50b31e7cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_RetainedEarningsMember_6f8dfa83-766c-4a68-bdba-ad50b31e7cf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1013b491-4492-4b7b-95e3-669a3c84c91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1013b491-4492-4b7b-95e3-669a3c84c91e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended" id="i848a778d26594f72963d43d02a8c4278_REVENUESDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d9ec5a30-6417-4494-8e29-39fec4e4cef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69cab765-a1d9-46e5-a692-269a64d298db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d9ec5a30-6417-4494-8e29-39fec4e4cef4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69cab765-a1d9-46e5-a692-269a64d298db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d9ec5a30-6417-4494-8e29-39fec4e4cef4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:to="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d97c5f6-78ce-481a-979c-997b25f2f024_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:to="loc_srt_ProductsAndServicesDomain_6d97c5f6-78ce-481a-979c-997b25f2f024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:to="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:to="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:href="gild-20220331.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_74fe5b60-ac07-4b5d-ad46-cc5b28755ba4" xlink:href="gild-20220331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsBiktarvyMember_74fe5b60-ac07-4b5d-ad46-cc5b28755ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_80ad998b-a6cc-49b9-b222-82049873c2d2" xlink:href="gild-20220331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_80ad998b-a6cc-49b9-b222-82049873c2d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_cf097394-09a6-4116-b5ad-539556785800" xlink:href="gild-20220331.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsDescovyMember_cf097394-09a6-4116-b5ad-539556785800" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_2c85fa89-b6e8-4770-bc4b-a47074036209" xlink:href="gild-20220331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsGenvoyaMember_2c85fa89-b6e8-4770-bc4b-a47074036209" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_09c3ba3d-e29c-405f-bbfa-4bd688550248" xlink:href="gild-20220331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsOdefseyMember_09c3ba3d-e29c-405f-bbfa-4bd688550248" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_d1644875-bb76-4e7c-81a1-73cec3d89632" xlink:href="gild-20220331.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsStribildMember_d1644875-bb76-4e7c-81a1-73cec3d89632" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_d4f33018-2a3d-45e4-b1ef-9acf7bee680a" xlink:href="gild-20220331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsTruvadaMember_d4f33018-2a3d-45e4-b1ef-9acf7bee680a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_922885e0-6712-4b62-9eef-ef430bdcf44f" xlink:href="gild-20220331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_922885e0-6712-4b62-9eef-ef430bdcf44f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_ccd508c5-790c-4450-ad12-fd9f43c028ff" xlink:href="gild-20220331.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_ProductsOtherHIVMember_ccd508c5-790c-4450-ad12-fd9f43c028ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_fbfaa985-16bf-412e-8dfb-c4232e9181d2" xlink:href="gild-20220331.xsd#gild_VekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_VekluryMember_fbfaa985-16bf-412e-8dfb-c4232e9181d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:href="gild-20220331.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_c0007bdb-85c1-46d8-9121-c62383ae26fa" xlink:href="gild-20220331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_c0007bdb-85c1-46d8-9121-c62383ae26fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_8eebdfd8-fca7-4f41-9dca-0b88cfe59db9" xlink:href="gild-20220331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_8eebdfd8-fca7-4f41-9dca-0b88cfe59db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_d0e889fd-136c-4b15-8851-7d643c190cc1" xlink:href="gild-20220331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_d0e889fd-136c-4b15-8851-7d643c190cc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_cd6946c2-15e9-4487-9b8e-8236dee9cf77" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_cd6946c2-15e9-4487-9b8e-8236dee9cf77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_ab6cfa3e-f4be-4ecf-a867-f8bcbf595e19" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_ab6cfa3e-f4be-4ecf-a867-f8bcbf595e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_6471c11e-1474-4d8f-9683-a644263f1c10" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_6471c11e-1474-4d8f-9683-a644263f1c10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_c9ef1005-ccc0-43c4-8245-2d42921b44a6" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:to="loc_gild_CellTherapyProductsTecartusMember_c9ef1005-ccc0-43c4-8245-2d42921b44a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_3dc1059b-ad0e-45e0-8e2a-71e97abf4cc6" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:to="loc_gild_CellTherapyProductsYescartaMember_3dc1059b-ad0e-45e0-8e2a-71e97abf4cc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_2a7e5b55-1dc4-404c-aade-1a6de3d8dace" xlink:href="gild-20220331.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_TrodelvyMember_2a7e5b55-1dc4-404c-aade-1a6de3d8dace" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:href="gild-20220331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_0e26dc4a-6285-4883-a90e-5ccbb76c41fd" xlink:href="gild-20220331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:to="loc_gild_OtherProductsAmBisomeMember_0e26dc4a-6285-4883-a90e-5ccbb76c41fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_b21c5e05-c1f6-454c-a0bf-7f34a29bfd2d" xlink:href="gild-20220331.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:to="loc_gild_OtherProductsLetairisMember_b21c5e05-c1f6-454c-a0bf-7f34a29bfd2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_ad89002a-3655-4845-99e4-1523ecca7626" xlink:href="gild-20220331.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:to="loc_gild_OtherProductsOtherMember_ad89002a-3655-4845-99e4-1523ecca7626" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_0703e22d-eeba-48a6-84ce-caf2eb66bc33" xlink:href="gild-20220331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:to="loc_gild_RoyaltyContractAndOtherMember_0703e22d-eeba-48a6-84ce-caf2eb66bc33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:to="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_552d4908-fc1b-4371-bcba-7e088fe20ad1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:to="loc_srt_SegmentGeographicalDomain_552d4908-fc1b-4371-bcba-7e088fe20ad1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:to="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7335d178-154a-4507-a7ec-a8cb8a0d5b32" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:to="loc_country_US_7335d178-154a-4507-a7ec-a8cb8a0d5b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_154c36bc-de16-4399-8e00-3a6c968c0066" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:to="loc_srt_EuropeMember_154c36bc-de16-4399-8e00-3a6c968c0066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_3ee0e1ea-02e3-42b2-b5e4-5a1180bac952" xlink:href="gild-20220331.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:to="loc_gild_OtherInternationalMember_3ee0e1ea-02e3-42b2-b5e4-5a1180bac952" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i5122e3233fa04200b93c619b3e56798f_REVENUESRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7736414d-f875-4287-9487-9fa3bee8c198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7fe28f3a-e719-42e9-a898-e257deeb3ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7736414d-f875-4287-9487-9fa3bee8c198" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7fe28f3a-e719-42e9-a898-e257deeb3ad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7736414d-f875-4287-9487-9fa3bee8c198" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a3ae051d-f072-4d40-bcbb-a9706f3816c9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:to="loc_srt_NameOfMajorCustomerDomain_a3ae051d-f072-4d40-bcbb-a9706f3816c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:to="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_20ffbbda-25ff-4d68-8cab-a4ce47174917" xlink:href="gild-20220331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:to="loc_gild_AmerisourcebergenCorpMember_20ffbbda-25ff-4d68-8cab-a4ce47174917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_0a85a38d-abc2-4e4c-aa95-d0f99251f42f" xlink:href="gild-20220331.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:to="loc_gild_CardinalHealthIncMember_0a85a38d-abc2-4e4c-aa95-d0f99251f42f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_1f987184-34c6-4212-931b-bcd6bf086c26" xlink:href="gild-20220331.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:to="loc_gild_MckessonCorpMember_1f987184-34c6-4212-931b-bcd6bf086c26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_774bb689-2717-4f3a-ba8e-3db45d5f7c82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_774bb689-2717-4f3a-ba8e-3db45d5f7c82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d05f644b-fe14-4f86-b123-3fad791c06eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d05f644b-fe14-4f86-b123-3fad791c06eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8c45e417-cb2d-443e-b455-7d9957662146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d05f644b-fe14-4f86-b123-3fad791c06eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8c45e417-cb2d-443e-b455-7d9957662146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_be91065d-2b34-41e1-a76f-ecbe395639e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_be91065d-2b34-41e1-a76f-ecbe395639e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_75360779-cebb-4ab4-8fb4-ed6a1b2e0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_75360779-cebb-4ab4-8fb4-ed6a1b2e0d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_aeac30a9-fd7c-48cc-8c39-2168f122ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_75360779-cebb-4ab4-8fb4-ed6a1b2e0d9b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_aeac30a9-fd7c-48cc-8c39-2168f122ac44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i0f7c634afb1345198d2497ca6ff11c03_FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1e1028d5-aa15-4452-b39d-ff93fd497d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1e1028d5-aa15-4452-b39d-ff93fd497d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_04e9c69b-8877-4498-8d84-3292ff4eb1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_04e9c69b-8877-4498-8d84-3292ff4eb1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_4e9539ad-014d-43aa-99fb-b1b9b9489601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_4e9539ad-014d-43aa-99fb-b1b9b9489601" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9780b36c-f82c-44c7-924e-11fff9e8faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9780b36c-f82c-44c7-924e-11fff9e8faf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b212f507-3644-47ec-b958-3ce5343815a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b212f507-3644-47ec-b958-3ce5343815a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_3eb09e76-f494-4aaf-b6bc-e41d244c65f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_3eb09e76-f494-4aaf-b6bc-e41d244c65f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_96ad9cff-5508-4df9-beca-ec0437d11221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_96ad9cff-5508-4df9-beca-ec0437d11221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_16888ec5-1249-49b4-bb39-8d41bccf8fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_16888ec5-1249-49b4-bb39-8d41bccf8fe7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dbce718b-8ca8-41a2-8138-9035dbbf544c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dbce718b-8ca8-41a2-8138-9035dbbf544c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2f3da84-2ae6-4b3a-bc7f-81c4499635e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2f3da84-2ae6-4b3a-bc7f-81c4499635e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d87d8ea6-1cc7-46e1-9e97-457f504186d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2f3da84-2ae6-4b3a-bc7f-81c4499635e1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d87d8ea6-1cc7-46e1-9e97-457f504186d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c708792-7cdd-4d67-adcb-2f11134813ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c708792-7cdd-4d67-adcb-2f11134813ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_29a38356-fbd6-401b-b68c-6fe6eaa341b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_29a38356-fbd6-401b-b68c-6fe6eaa341b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2514703c-1141-4d8c-86cf-1b7f260bf942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2514703c-1141-4d8c-86cf-1b7f260bf942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bfc70290-a546-4463-9853-7a3128f57fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bfc70290-a546-4463-9853-7a3128f57fb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_82c372e1-bc69-4332-9d24-2496933a58fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_82c372e1-bc69-4332-9d24-2496933a58fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_02fc3d5f-321e-4c04-ab13-1ed7a5e9631d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_82c372e1-bc69-4332-9d24-2496933a58fc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_02fc3d5f-321e-4c04-ab13-1ed7a5e9631d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4869cbe9-08ca-42b7-a798-d3ffd2647251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_02fc3d5f-321e-4c04-ab13-1ed7a5e9631d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4869cbe9-08ca-42b7-a798-d3ffd2647251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_206e0181-2e7e-41d3-aaa3-fbae2d8259bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_206e0181-2e7e-41d3-aaa3-fbae2d8259bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_944c853a-85ba-4de0-9683-5702e507bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_944c853a-85ba-4de0-9683-5702e507bd3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a47b6981-82b6-425a-99e0-e76de0356593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a47b6981-82b6-425a-99e0-e76de0356593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b6f7736e-c1ed-433b-ac78-bad37a976cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b6f7736e-c1ed-433b-ac78-bad37a976cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_11efcc11-3367-4a03-aa92-beb6d4e53d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_CertificatesOfDepositMember_11efcc11-3367-4a03-aa92-beb6d4e53d21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9a478012-d1a7-4ed0-9b29-564c0303307d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9a478012-d1a7-4ed0-9b29-564c0303307d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_3c6d3f9f-ce12-4099-bf45-683adfac8b28" xlink:href="gild-20220331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_3c6d3f9f-ce12-4099-bf45-683adfac8b28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bc615059-e181-4be7-bf1d-76a42a178514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bc615059-e181-4be7-bf1d-76a42a178514" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_16298a3f-f0e6-4332-ab14-fd096b458d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_EquitySecuritiesMember_16298a3f-f0e6-4332-ab14-fd096b458d14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_9519055e-52ea-49a8-a683-092bd3f57ef9" xlink:href="gild-20220331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_gild_DeferredCompensationPlanMember_9519055e-52ea-49a8-a683-092bd3f57ef9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_472d8fc2-c752-498e-83c2-5001386aa69d" xlink:href="gild-20220331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_472d8fc2-c752-498e-83c2-5001386aa69d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ded74ba4-750c-4f29-9682-c1dd59025a59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ded74ba4-750c-4f29-9682-c1dd59025a59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d253c105-db52-4253-bbbf-7414636289c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d253c105-db52-4253-bbbf-7414636289c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_f105ed12-5c43-42e2-90dc-36baba258e5b" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d253c105-db52-4253-bbbf-7414636289c2" xlink:to="loc_gild_MYRGmbHMember_f105ed12-5c43-42e2-90dc-36baba258e5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_0e239d93-e515-4de3-893a-18b709d74c7b" xlink:href="gild-20220331.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:to="loc_gild_GalapagosMember_0e239d93-e515-4de3-893a-18b709d74c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_bfe531d2-ec55-416f-8e69-b1893ed3e14d" xlink:href="gild-20220331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:to="loc_gild_ArcusBiosciencesIncMember_bfe531d2-ec55-416f-8e69-b1893ed3e14d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended" id="icca03cf3e48d4f4391071e303bec1d5d_FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a383e09c-e6fc-43c8-a85b-8597b83bb1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_LongTermDebtFairValue_a383e09c-e6fc-43c8-a85b-8597b83bb1ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f560e268-7038-42b0-b6e9-509109ec03b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f560e268-7038-42b0-b6e9-509109ec03b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9e28b994-33d6-4e7c-bb8e-103fbcd0a2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9e28b994-33d6-4e7c-bb8e-103fbcd0a2c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_60dd5e8b-d4a3-4bb1-9c36-2cb6382f80fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_60dd5e8b-d4a3-4bb1-9c36-2cb6382f80fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5a649410-b1d8-4bdf-a8cb-3e6de4afc886_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5a649410-b1d8-4bdf-a8cb-3e6de4afc886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_acebe21a-c315-48fa-91de-7107cabbfeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_acebe21a-c315-48fa-91de-7107cabbfeb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_acebe21a-c315-48fa-91de-7107cabbfeb0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_682cb43f-3afe-4b30-ae9a-c8c9f249b720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_682cb43f-3afe-4b30-ae9a-c8c9f249b720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6a0d74da-a7c1-4cc3-9138-af4a7b730d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6a0d74da-a7c1-4cc3-9138-af4a7b730d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d606d2e-d9ee-4c2e-b355-e48ad48f838a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d606d2e-d9ee-4c2e-b355-e48ad48f838a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2448d760-4b71-4f40-85c3-288271f75733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2448d760-4b71-4f40-85c3-288271f75733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8678632d-6c62-4aa6-b300-9b1583b784e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8678632d-6c62-4aa6-b300-9b1583b784e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbd55dd1-e58a-4c63-aa9a-12782bbebbde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbd55dd1-e58a-4c63-aa9a-12782bbebbde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4e96a15-41cd-4838-85e6-c6348580a432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4e96a15-41cd-4838-85e6-c6348580a432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_2babe420-cf6b-4d3b-8645-cfadb0f969e5" xlink:href="gild-20220331.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4e96a15-41cd-4838-85e6-c6348580a432" xlink:to="loc_gild_ImmunomedicsIncMember_2babe420-cf6b-4d3b-8645-cfadb0f969e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd573a99-ee87-4712-aa64-a2c8ab516006_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd573a99-ee87-4712-aa64-a2c8ab516006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_59401eb3-23df-4c9b-ae77-8ffe5de67796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_59401eb3-23df-4c9b-ae77-8ffe5de67796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0abd5492-ee4b-4b53-a2f7-801fcc358e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_59401eb3-23df-4c9b-ae77-8ffe5de67796" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0abd5492-ee4b-4b53-a2f7-801fcc358e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4cfb7542-3cd4-42cc-9837-85da6527be44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4cfb7542-3cd4-42cc-9837-85da6527be44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c1411c4c-b10c-4aae-810e-b04ecd6f6781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c1411c4c-b10c-4aae-810e-b04ecd6f6781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_120e7a49-73fb-4702-89a9-34847d4092de" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c1411c4c-b10c-4aae-810e-b04ecd6f6781" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_120e7a49-73fb-4702-89a9-34847d4092de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="extended" id="i6b19b15c09fe4b47819a190a5dae8f1d_FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_589e66eb-dd59-4885-8f18-7b013202dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_589e66eb-dd59-4885-8f18-7b013202dfbc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_555dece3-7708-4f48-9300-b27f98182c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_555dece3-7708-4f48-9300-b27f98182c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_b66d0c80-821a-4447-a36c-5f75a16c1906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_b66d0c80-821a-4447-a36c-5f75a16c1906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_672bd02a-fa23-41d8-b1b2-c238d2142cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_672bd02a-fa23-41d8-b1b2-c238d2142cfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_3c5e5cee-ffe6-487d-ad7f-db7fe73b0ed3" xlink:href="gild-20220331.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_3c5e5cee-ffe6-487d-ad7f-db7fe73b0ed3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23f41766-8384-4966-ba24-9e0fa1e586d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_589e66eb-dd59-4885-8f18-7b013202dfbc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b878b634-2a11-4307-a2a6-d361ab0e4f06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b878b634-2a11-4307-a2a6-d361ab0e4f06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_443a3903-989a-4cfc-9c75-b6c5185444f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_443a3903-989a-4cfc-9c75-b6c5185444f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember_337a0094-0408-4772-81c4-c5e05acf965a" xlink:href="gild-20220331.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_443a3903-989a-4cfc-9c75-b6c5185444f0" xlink:to="loc_gild_ContingentConsiderationLiabilityMember_337a0094-0408-4772-81c4-c5e05acf965a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d80827ca-ac3b-4aa4-a243-0e14c5c77651_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d80827ca-ac3b-4aa4-a243-0e14c5c77651_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2eafe48d-2f73-476c-aaa6-a904b0a0e4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2eafe48d-2f73-476c-aaa6-a904b0a0e4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_97d852a3-d4d6-4347-9d88-8a38ce2eb84d" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2eafe48d-2f73-476c-aaa6-a904b0a0e4a6" xlink:to="loc_gild_MYRGmbHMember_97d852a3-d4d6-4347-9d88-8a38ce2eb84d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="i1f39afeccc0d4a9ba065e72467483892_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cd160244-8479-4541-9d71-a1e1f23acc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cd160244-8479-4541-9d71-a1e1f23acc0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11d1921b-023e-4ad9-b32c-90a27e8f2982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11d1921b-023e-4ad9-b32c-90a27e8f2982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d866fdb-742a-4c97-94b3-beb6304dd9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d866fdb-742a-4c97-94b3-beb6304dd9fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19900932-4761-4a28-bbf2-7aa71f72df78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19900932-4761-4a28-bbf2-7aa71f72df78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b8f3667-275d-4d15-90b5-cb4491fe9809_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b8f3667-275d-4d15-90b5-cb4491fe9809_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a435cdc6-a3bb-4e07-864e-de9b69438437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a435cdc6-a3bb-4e07-864e-de9b69438437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3b017125-6d5d-4fef-8321-b743b5e37b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3b017125-6d5d-4fef-8321-b743b5e37b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_abd0400f-ee47-42b8-8a66-087724be9560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_abd0400f-ee47-42b8-8a66-087724be9560" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6de5d20f-2cac-45e8-85fa-fa2766ad4ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6de5d20f-2cac-45e8-85fa-fa2766ad4ace" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_aef4fc7b-ed52-4cfb-98c5-75eee5a3efb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_aef4fc7b-ed52-4cfb-98c5-75eee5a3efb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_c6bdf37d-e73d-4c34-9659-e923ee20283e" xlink:href="gild-20220331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_c6bdf37d-e73d-4c34-9659-e923ee20283e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i6c43203bdf7a43d2ab2c34e7811f2f0f_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7595ae31-1b95-454c-841f-4944086f9640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e524c67e-ae57-408f-b387-a7973195b8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7595ae31-1b95-454c-841f-4944086f9640" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e524c67e-ae57-408f-b387-a7973195b8d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7595ae31-1b95-454c-841f-4944086f9640" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1457c73b-79ed-4a31-93f7-9b662e2b995a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1457c73b-79ed-4a31-93f7-9b662e2b995a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_90e9c415-eea0-4240-8cfb-324139c18562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_90e9c415-eea0-4240-8cfb-324139c18562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_4f44c79d-14e8-422e-a161-af58951e9b11" xlink:href="gild-20220331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_4f44c79d-14e8-422e-a161-af58951e9b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_10b315bc-f148-41bc-8c36-95b99c5cf93e" xlink:href="gild-20220331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_10b315bc-f148-41bc-8c36-95b99c5cf93e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended" id="i51dbcd25d40f41ce9453a91a125009d7_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f4fb2bb5-6d12-4282-b336-658d7c796ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f4fb2bb5-6d12-4282-b336-658d7c796ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e9b55c93-5653-4ea2-962c-37c62a209e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e9b55c93-5653-4ea2-962c-37c62a209e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a547607e-00ac-4f08-8d4d-454ba6018a66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a547607e-00ac-4f08-8d4d-454ba6018a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb31bb6-4bdc-4e5e-9fda-d359548429f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb31bb6-4bdc-4e5e-9fda-d359548429f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4700eb4d-68e7-4e6e-a7eb-d91308d84849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb31bb6-4bdc-4e5e-9fda-d359548429f6" xlink:to="loc_us-gaap_EquitySecuritiesMember_4700eb4d-68e7-4e6e-a7eb-d91308d84849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9f1fe2fa-3671-432b-98af-723ab0195e39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9f1fe2fa-3671-432b-98af-723ab0195e39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_3752733b-06e7-420d-b4f6-a537e709ba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_3752733b-06e7-420d-b4f6-a537e709ba1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d6bb8240-a86b-4c4f-b046-4b3c23a4d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d6bb8240-a86b-4c4f-b046-4b3c23a4d6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e48dc407-770d-4247-b744-03024204b033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e48dc407-770d-4247-b744-03024204b033" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended" id="i8a0a788b85b54f0fa2fc031d05f03cb7_DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_046d5be9-b6ac-4029-a85c-e442abec9de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_046d5be9-b6ac-4029-a85c-e442abec9de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_b4181383-83a4-4597-973f-e08742715939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_b4181383-83a4-4597-973f-e08742715939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_184e9db7-bd2f-4b12-ae90-f27d1b6a89f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_184e9db7-bd2f-4b12-ae90-f27d1b6a89f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_75b5ec28-8240-408d-a6c3-c67e6c198528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_75b5ec28-8240-408d-a6c3-c67e6c198528" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:to="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_705f4a0c-d9d4-454a-af21-10e57ffafb0f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:to="loc_srt_RangeMember_705f4a0c-d9d4-454a-af21-10e57ffafb0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d10c5eb9-7714-48d9-bba5-2efc4b13a4f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:to="loc_srt_RangeMember_d10c5eb9-7714-48d9-bba5-2efc4b13a4f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_53a9bf09-ae1a-4e64-b3be-e001789f7b44" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d10c5eb9-7714-48d9-bba5-2efc4b13a4f8" xlink:to="loc_srt_MaximumMember_53a9bf09-ae1a-4e64-b3be-e001789f7b44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="ic4d39b61ec4846249355422d81f529ba_DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_e5ccc546-c838-4e3a-b433-995d18ef3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_e5ccc546-c838-4e3a-b433-995d18ef3da3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2bddb3b0-f6a7-40fb-82fb-aa370a4859e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2bddb3b0-f6a7-40fb-82fb-aa370a4859e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:to="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_668a46f8-e163-4c48-8c72-6d37ac9c8436_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:to="loc_us-gaap_HedgingDesignationDomain_668a46f8-e163-4c48-8c72-6d37ac9c8436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:to="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_55f7689a-b521-4749-8a17-5447953f7929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_55f7689a-b521-4749-8a17-5447953f7929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5da02133-31e3-476a-bb25-b14e02b535b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:to="loc_us-gaap_NondesignatedMember_5da02133-31e3-476a-bb25-b14e02b535b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_90436826-ca4b-47c7-acf4-c0d2dfc51765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_90436826-ca4b-47c7-acf4-c0d2dfc51765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_a1411d41-4399-4ca9-a6a8-ecc12a2f7833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_a1411d41-4399-4ca9-a6a8-ecc12a2f7833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_b37ef6ff-4f9d-49d0-a0e6-acbd9bc848db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_b37ef6ff-4f9d-49d0-a0e6-acbd9bc848db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_88cca201-ce75-4034-b8f6-fdcb96dad890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_88cca201-ce75-4034-b8f6-fdcb96dad890" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended" id="i12332faf7f564ebcb4499e997089e6dc_ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_729b07ec-82af-428b-a5be-616a666cb0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_729b07ec-82af-428b-a5be-616a666cb0e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ca2a6418-d034-4d62-9f14-9f8113d8099b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ca2a6418-d034-4d62-9f14-9f8113d8099b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95915281-67b1-4fd6-8993-95f2da25535f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95915281-67b1-4fd6-8993-95f2da25535f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_dc4efbc8-c101-49b8-bbc1-9cc543417792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_dc4efbc8-c101-49b8-bbc1-9cc543417792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4ec164e5-9154-4795-a9e2-a1a3004c90b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4ec164e5-9154-4795-a9e2-a1a3004c90b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm_ffa44913-c292-4695-9e75-036bf2241a1d" xlink:href="gild-20220331.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_CollaborativeAgreementOptInTerm_ffa44913-c292-4695-9e75-036bf2241a1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_c25cc254-bb00-4708-90bd-d6030c6ffa4b" xlink:href="gild-20220331.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_c25cc254-bb00-4708-90bd-d6030c6ffa4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement_8eaa06fa-099e-416f-9bf5-693d57d6ec66" xlink:href="gild-20220331.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_PaymentsToOptInTheCollaborativeAgreement_8eaa06fa-099e-416f-9bf5-693d57d6ec66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_a134e0d7-9ea6-4a88-9709-2d21e1f3f953" xlink:href="gild-20220331.xsd#gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_a134e0d7-9ea6-4a88-9709-2d21e1f3f953" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e67ad25-7f1e-4322-9388-32e5bd89e3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e67ad25-7f1e-4322-9388-32e5bd89e3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_cd9c9a29-41b2-42da-9754-3c75d15188d2" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e67ad25-7f1e-4322-9388-32e5bd89e3ac" xlink:to="loc_gild_MYRGmbHMember_cd9c9a29-41b2-42da-9754-3c75d15188d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:to="loc_srt_RangeMember_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e24ec10c-5c25-4bc1-9c4e-76ed9882792a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:to="loc_srt_RangeMember_e24ec10c-5c25-4bc1-9c4e-76ed9882792a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1ac4627-cfbb-48cc-974b-936d607e7331" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e24ec10c-5c25-4bc1-9c4e-76ed9882792a" xlink:to="loc_srt_MaximumMember_c1ac4627-cfbb-48cc-974b-936d607e7331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_36c711d2-7d02-4464-9ca3-55232f4f0f56_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_36c711d2-7d02-4464-9ca3-55232f4f0f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_098cf943-ee01-40e2-96c6-45bfa28ae375" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_098cf943-ee01-40e2-96c6-45bfa28ae375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_cd00bbfc-b491-4568-874c-24d7d833ee77" xlink:href="gild-20220331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_098cf943-ee01-40e2-96c6-45bfa28ae375" xlink:to="loc_gild_ArcusBiosciencesIncMember_cd00bbfc-b491-4568-874c-24d7d833ee77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c1a35ec-1f05-4bfc-8fd9-40003a19d069_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c1a35ec-1f05-4bfc-8fd9-40003a19d069_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2798d451-fc84-4ad9-8967-070eb921d797" xlink:href="gild-20220331.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2798d451-fc84-4ad9-8967-070eb921d797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_ca3ddb2e-37a3-4b61-bbed-86b175828e28" xlink:href="gild-20220331.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:to="loc_gild_ArcusCollaborationAgreementMember_ca3ddb2e-37a3-4b61-bbed-86b175828e28" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended" id="ic19fb2a06a364b2ebe7208cd064d0b83_GOODWILLANDINTANGIBLEASSETSGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_21229c9d-5bf1-4325-b68b-b8775b7ae496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_21229c9d-5bf1-4325-b68b-b8775b7ae496" xlink:to="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_93d2139e-2229-45ab-b3eb-95678d99403b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:to="loc_us-gaap_Goodwill_93d2139e-2229-45ab-b3eb-95678d99403b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4fcc020c-1416-47eb-b9dc-edd79cec301a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4fcc020c-1416-47eb-b9dc-edd79cec301a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e62ca7e-6d82-4bd7-ae35-7728f589938f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_21229c9d-5bf1-4325-b68b-b8775b7ae496" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b39e582-d5aa-44f4-846d-190259877c9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b39e582-d5aa-44f4-846d-190259877c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60975de7-13e7-4fbc-82d5-c4cd5575c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60975de7-13e7-4fbc-82d5-c4cd5575c0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_4dc3d0a8-5262-4819-8237-8f6d93dce071" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60975de7-13e7-4fbc-82d5-c4cd5575c0a5" xlink:to="loc_gild_MYRGmbHMember_4dc3d0a8-5262-4819-8237-8f6d93dce071" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended" id="i820c8f17a81c4004aa9d794032ef5b61_GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0567c97e-3f9c-4391-857b-bb8fede6379d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0567c97e-3f9c-4391-857b-bb8fede6379d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_148f6163-5a18-446a-813a-640fe00df4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_148f6163-5a18-446a-813a-640fe00df4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_507e67b3-7af4-4b34-8152-21b53bc09bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_507e67b3-7af4-4b34-8152-21b53bc09bcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_c6f459b7-e07e-4d45-bca3-dfa25dca2fb2" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_c6f459b7-e07e-4d45-bca3-dfa25dca2fb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8c59e833-f8bc-4f17-9c33-d0ec1396721d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8c59e833-f8bc-4f17-9c33-d0ec1396721d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_118e13a5-c401-45b5-bfeb-2a6a159f852e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_118e13a5-c401-45b5-bfeb-2a6a159f852e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb94fc4b-9fb8-4b0e-93ad-68200eb1f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb94fc4b-9fb8-4b0e-93ad-68200eb1f6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_343c5c7e-aade-4829-9b15-efa4b0bbd22f" xlink:href="gild-20220331.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb94fc4b-9fb8-4b0e-93ad-68200eb1f6ee" xlink:to="loc_gild_ImmunomedicsIncMember_343c5c7e-aade-4829-9b15-efa4b0bbd22f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16cd4861-4316-48d4-a71d-422bfc3a1c4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16cd4861-4316-48d4-a71d-422bfc3a1c4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c0780f3-b048-48a0-a227-954734cbe608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c0780f3-b048-48a0-a227-954734cbe608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_109e6524-a12f-4a6d-ab4e-e5bc08ff5051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c0780f3-b048-48a0-a227-954734cbe608" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_109e6524-a12f-4a6d-ab4e-e5bc08ff5051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5944c3c7-1b8c-4831-96a5-ecab484c5cf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5944c3c7-1b8c-4831-96a5-ecab484c5cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63326342-f387-4f19-84c5-1d8f1bd53516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63326342-f387-4f19-84c5-1d8f1bd53516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_f95d65c6-86f9-4adf-b099-ced6d7d0e559" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63326342-f387-4f19-84c5-1d8f1bd53516" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_f95d65c6-86f9-4adf-b099-ced6d7d0e559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_260a0aef-c158-42f3-acf2-a9507089fb38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_260a0aef-c158-42f3-acf2-a9507089fb38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_16f23b9d-7861-4386-b4d5-4f91e0a2e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_16f23b9d-7861-4386-b4d5-4f91e0a2e4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3c473db1-b507-4819-89e4-99592d16e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_16f23b9d-7861-4386-b4d5-4f91e0a2e4c3" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3c473db1-b507-4819-89e4-99592d16e5c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended" id="ie2ce6491639444e6ba75cd7edcc9a9f0_GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3fccecbc-2cfa-49f7-bdee-0d7f01fec6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3fccecbc-2cfa-49f7-bdee-0d7f01fec6db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b83d90b7-e2b6-4c6d-a02d-c275b2150601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b83d90b7-e2b6-4c6d-a02d-c275b2150601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6c6d57e9-9eb8-4c9e-b964-201c4dcc62f4" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6c6d57e9-9eb8-4c9e-b964-201c4dcc62f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d2a7e4e9-f9a2-48b8-b01e-c0b06937b17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d2a7e4e9-f9a2-48b8-b01e-c0b06937b17d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fba08305-a618-476c-bbe9-8b9b013e1e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fba08305-a618-476c-bbe9-8b9b013e1e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4cd503d9-1d8a-4144-8810-cb32d02f54f2" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4cd503d9-1d8a-4144-8810-cb32d02f54f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_19dbd2a1-ec61-4beb-8418-6df0a683866c" xlink:href="gild-20220331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_19dbd2a1-ec61-4beb-8418-6df0a683866c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6b443ceb-68e0-4940-8e9c-67c9a4c54098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6b443ceb-68e0-4940-8e9c-67c9a4c54098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4daac2e5-df39-4b94-8682-8d3ae7a2641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_35eb268c-f696-4c76-a91a-5fb1b233e417" xlink:href="gild-20220331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_35eb268c-f696-4c76-a91a-5fb1b233e417" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e229a85-35b3-43d8-ae59-b55b43eb2acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e229a85-35b3-43d8-ae59-b55b43eb2acf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19c9c9f2-5898-4167-a5e8-8f81271c3abe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19c9c9f2-5898-4167-a5e8-8f81271c3abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_92a6d1f6-343e-4154-9a3d-d64c4f9cb92d" xlink:href="gild-20220331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_92a6d1f6-343e-4154-9a3d-d64c4f9cb92d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_c210ce7b-d64b-4402-9316-362f06bb396a" xlink:href="gild-20220331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_c210ce7b-d64b-4402-9316-362f06bb396a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_b915db14-bfc5-4ded-96b9-45bc7e653e24" xlink:href="gild-20220331.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_TrodelvyMember_b915db14-bfc5-4ded-96b9-45bc7e653e24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_f1093087-be2a-484c-bac3-6c9f4535b0b8" xlink:href="gild-20220331.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_HepcludexMember_f1093087-be2a-484c-bac3-6c9f4535b0b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_dc2d7f46-e210-4802-8b5d-02078333e982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_dc2d7f46-e210-4802-8b5d-02078333e982" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8dae19d5-a298-4c9a-bd87-18d1b90d96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8dae19d5-a298-4c9a-bd87-18d1b90d96a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_17800250-af3a-426b-8db1-cf731f15dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8dae19d5-a298-4c9a-bd87-18d1b90d96a3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_17800250-af3a-426b-8db1-cf731f15dcd8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="i7597ad072b314a7eab24b0af09d168c8_DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8180f3e5-88d5-470f-b107-f6b1b87108d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8180f3e5-88d5-470f-b107-f6b1b87108d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_00e247d8-be94-4c2a-bae1-f105a4b3f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_LongTermDebt_00e247d8-be94-4c2a-bae1-f105a4b3f7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_40cc6ce8-4403-4702-b692-beac4161e4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_LongTermDebtCurrent_40cc6ce8-4403-4702-b692-beac4161e4b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_74efbe33-cba4-431f-8145-9d99961b66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_74efbe33-cba4-431f-8145-9d99961b66f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cf9ea175-7911-4050-b665-4647239f8b58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cf9ea175-7911-4050-b665-4647239f8b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_3df92e83-724c-418c-863f-8f30434de8f9" xlink:href="gild-20220331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_3df92e83-724c-418c-863f-8f30434de8f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f8b40654-b668-4e11-971a-43226423af9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_3df92e83-724c-418c-863f-8f30434de8f9" xlink:to="loc_us-gaap_SeniorNotesMember_f8b40654-b668-4e11-971a-43226423af9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_928a8d19-d14d-47dd-9e94-dd2889f74242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_928a8d19-d14d-47dd-9e94-dd2889f74242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:to="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5303c42b-2e2e-4e96-9bee-734b39ec53c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5303c42b-2e2e-4e96-9bee-734b39ec53c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_48e27c05-1037-492f-bea9-d5090583d2f7" xlink:href="gild-20220331.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_48e27c05-1037-492f-bea9-d5090583d2f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_0d1dd6b5-eb87-4dfb-9dc3-bff219f349d7" xlink:href="gild-20220331.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_0d1dd6b5-eb87-4dfb-9dc3-bff219f349d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_40e775ee-d7c4-4acf-b609-42b9845f3b54" xlink:href="gild-20220331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_40e775ee-d7c4-4acf-b609-42b9845f3b54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87b54463-b5c9-46d0-b6dd-130d01ecb12f" xlink:href="gild-20220331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87b54463-b5c9-46d0-b6dd-130d01ecb12f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_ac459361-a037-43a1-b385-0d2095c6f5f2" xlink:href="gild-20220331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_ac459361-a037-43a1-b385-0d2095c6f5f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_87052c61-dbf2-4677-93bf-086d9c183ab5" xlink:href="gild-20220331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_87052c61-dbf2-4677-93bf-086d9c183ab5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_d207d2c9-cdc2-47a1-b3f6-433b878571a6" xlink:href="gild-20220331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_d207d2c9-cdc2-47a1-b3f6-433b878571a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_eb044e09-70d3-4229-8ea7-f028d68a05ae" xlink:href="gild-20220331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_eb044e09-70d3-4229-8ea7-f028d68a05ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_52788b48-7627-4ef6-ba52-da097cc0c5ab" xlink:href="gild-20220331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_52788b48-7627-4ef6-ba52-da097cc0c5ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_aee3426b-fcf5-4e7a-b199-55ab79ba59b3" xlink:href="gild-20220331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_aee3426b-fcf5-4e7a-b199-55ab79ba59b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_9e3e74e7-4a64-425e-822a-e18e3ae30c31" xlink:href="gild-20220331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_9e3e74e7-4a64-425e-822a-e18e3ae30c31" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_7b244503-d830-44a9-adbd-552aed50c908" xlink:href="gild-20220331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_7b244503-d830-44a9-adbd-552aed50c908" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_33241c58-17c7-4c6b-8cdf-60ee9eee0f87" xlink:href="gild-20220331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_33241c58-17c7-4c6b-8cdf-60ee9eee0f87" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_068a079d-e70c-478e-81dc-fa8ddd42d345" xlink:href="gild-20220331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_068a079d-e70c-478e-81dc-fa8ddd42d345" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_b6c34bf0-868c-4372-b78e-4cb7bb246a72" xlink:href="gild-20220331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_b6c34bf0-868c-4372-b78e-4cb7bb246a72" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_b11183f1-c9e5-495c-a5d5-a6787f4e0f30" xlink:href="gild-20220331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_b11183f1-c9e5-495c-a5d5-a6787f4e0f30" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_c619de8e-c1a5-49dd-b4b1-57ec23076a40" xlink:href="gild-20220331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_c619de8e-c1a5-49dd-b4b1-57ec23076a40" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_3f0003ab-eb21-41a1-b6f1-51d230e84518" xlink:href="gild-20220331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_3f0003ab-eb21-41a1-b6f1-51d230e84518" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_848ed72f-25fc-4858-ae4c-f706ba71868f" xlink:href="gild-20220331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_848ed72f-25fc-4858-ae4c-f706ba71868f" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended" id="i29af3508d81142c7816c519571aa93cc_DEBTANDCREDITFACILITIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ca9e2c07-f938-4912-9c00-982576842b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_RepaymentsOfDebt_ca9e2c07-f938-4912-9c00-982576842b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_6050faa2-9b6c-4768-89f8-7b0f354b19ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_6050faa2-9b6c-4768-89f8-7b0f354b19ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f7cce7dd-8ae1-412c-9b9b-88e2259b11fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_LineOfCredit_f7cce7dd-8ae1-412c-9b9b-88e2259b11fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_47dfdb16-2755-4c43-9bed-328c5df64ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_47dfdb16-2755-4c43-9bed-328c5df64ba9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e408c713-51f1-463f-a0c7-8e8d8aa89357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e408c713-51f1-463f-a0c7-8e8d8aa89357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0bc1303c-ec5a-4ce2-a837-5520669c2554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:to="loc_us-gaap_SeniorNotesMember_0bc1303c-ec5a-4ce2-a837-5520669c2554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fff30ab6-4658-45e0-8e74-602dc86bb142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:to="loc_us-gaap_LineOfCreditMember_fff30ab6-4658-45e0-8e74-602dc86bb142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a740891-e419-402a-801e-e227d1456482_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:to="loc_us-gaap_CreditFacilityDomain_2a740891-e419-402a-801e-e227d1456482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b13bd76a-fabc-4e14-9b2f-75410a02b1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:to="loc_us-gaap_CreditFacilityDomain_b13bd76a-fabc-4e14-9b2f-75410a02b1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4288217f-e7e1-45d6-8066-2f118336961c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b13bd76a-fabc-4e14-9b2f-75410a02b1cd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4288217f-e7e1-45d6-8066-2f118336961c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c9f124ae-0439-403e-b955-416f8648d99f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c9f124ae-0439-403e-b955-416f8648d99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13b3b430-3404-4952-81e8-c7b9cb4b7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13b3b430-3404-4952-81e8-c7b9cb4b7b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_6c329503-6518-4331-9705-0bfe7b71452b" xlink:href="gild-20220331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13b3b430-3404-4952-81e8-c7b9cb4b7b59" xlink:to="loc_gild_CreditFacilityDueJune2025Member_6c329503-6518-4331-9705-0bfe7b71452b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="ia55427f1472144fbb4de4c586a3ba143_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_d19722e0-8629-4ff3-b3eb-55428bee8ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LitigationReserve_d19722e0-8629-4ff3-b3eb-55428bee8ee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_12b29999-dfa4-4ad9-88bc-6c22d9b12a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_12b29999-dfa4-4ad9-88bc-6c22d9b12a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_352320e9-9e36-4578-8e5b-a73ae20f6bdf" xlink:href="gild-20220331.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_352320e9-9e36-4578-8e5b-a73ae20f6bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_d1f990a5-52d9-4d19-8e52-43f49642fadc" xlink:href="gild-20220331.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_d1f990a5-52d9-4d19-8e52-43f49642fadc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_0d79e65b-2691-4144-87fe-e6d028e2886b" xlink:href="gild-20220331.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_0d79e65b-2691-4144-87fe-e6d028e2886b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_c839a34a-bc26-4a77-9684-3e8c560337af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_c839a34a-bc26-4a77-9684-3e8c560337af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_d7eb5bdd-4de2-4d52-8692-95caa22a04b3" xlink:href="gild-20220331.xsd#gild_LossContingencyRoyaltyPercentageOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_d7eb5bdd-4de2-4d52-8692-95caa22a04b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f32f8d2e-3c5b-43ba-a7f4-94c5532e902d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f32f8d2e-3c5b-43ba-a7f4-94c5532e902d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_e8ff44de-f3af-4cd1-b997-6e0be450c0ea" xlink:href="gild-20220331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_e8ff44de-f3af-4cd1-b997-6e0be450c0ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_c470c18b-1bef-444b-a129-c904ddab5f27" xlink:href="gild-20220331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_c470c18b-1bef-444b-a129-c904ddab5f27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_29ed1ed3-3158-4df4-9f47-d0516aef28f7" xlink:href="gild-20220331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_29ed1ed3-3158-4df4-9f47-d0516aef28f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_cd713818-ddaf-44f4-ad51-627ed2c97015" xlink:href="gild-20220331.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_cd713818-ddaf-44f4-ad51-627ed2c97015" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_04bf9ca9-1a44-411e-abe2-bc8e1495051e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_04bf9ca9-1a44-411e-abe2-bc8e1495051e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents_6f7976f0-5d62-40d9-a1e3-ab209072222d" xlink:href="gild-20220331.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyNumberOfPatents_6f7976f0-5d62-40d9-a1e3-ab209072222d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_c347f0aa-971e-4bf2-92e3-1c113f08c96a" xlink:href="gild-20220331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_c347f0aa-971e-4bf2-92e3-1c113f08c96a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_be16b5ae-a36d-41ba-a446-210642dcb94c" xlink:href="gild-20220331.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_be16b5ae-a36d-41ba-a446-210642dcb94c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_74a03f12-74ed-474a-9c89-7a0082f865cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_74a03f12-74ed-474a-9c89-7a0082f865cf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c17e9ae0-67a0-4c15-b57e-f048d48b0a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c17e9ae0-67a0-4c15-b57e-f048d48b0a69" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:to="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_84b191a8-dc87-4183-8986-31bded17282e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:to="loc_srt_LitigationCaseTypeDomain_84b191a8-dc87-4183-8986-31bded17282e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:to="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_7369b876-f8c4-494a-b945-5dab2f48878d" xlink:href="gild-20220331.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_ViiVHealthcareCompanyMember_7369b876-f8c4-494a-b945-5dab2f48878d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_8284b101-0b79-4dcd-8c2e-2107b4620406" xlink:href="gild-20220331.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_8284b101-0b79-4dcd-8c2e-2107b4620406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_acbea985-91d4-4ffc-9339-29272ea7b1c0" xlink:href="gild-20220331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_PreExposureProphylaxisMember_acbea985-91d4-4ffc-9339-29272ea7b1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember_20b8abcd-30c0-49a1-8ebc-2a742a4f892e" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2024ExpirationMember_20b8abcd-30c0-49a1-8ebc-2a742a4f892e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember_8693938b-55a9-4cef-ad89-4c29339b3640" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2026ExpirationMember_8693938b-55a9-4cef-ad89-4c29339b3640" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_3eb7ee49-da4d-485c-a867-70503bddd7ef" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_3eb7ee49-da4d-485c-a867-70503bddd7ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember_1cbacdd6-1ae2-4d9e-8af2-3d3767efad74" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2027ExpirationMember_1cbacdd6-1ae2-4d9e-8af2-3d3767efad74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_f08add93-61b9-4ab9-a634-9f1bd19214cf" xlink:href="gild-20220331.xsd#gild_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_ProductLiabilityMember_f08add93-61b9-4ab9-a634-9f1bd19214cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_e3b3ddd4-7b43-4079-88fb-883fc0248069" xlink:href="gild-20220331.xsd#gild_QuiTamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_QuiTamMember_e3b3ddd4-7b43-4079-88fb-883fc0248069" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6cde7d0e-d3a0-428b-8222-6ad36bae5b88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6cde7d0e-d3a0-428b-8222-6ad36bae5b88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0637aad2-0df2-41f1-8075-5b31be767bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0637aad2-0df2-41f1-8075-5b31be767bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_94253eee-ccc0-405b-9e42-61b7fa7a7fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0637aad2-0df2-41f1-8075-5b31be767bb6" xlink:to="loc_us-gaap_SubsequentEventMember_94253eee-ccc0-405b-9e42-61b7fa7a7fd1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails" xlink:type="extended" id="i3bf12cb8ceef447c99a27919898c8892_STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53e44e45-baef-4ecf-adac-9bc1243254e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53e44e45-baef-4ecf-adac-9bc1243254e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_05b42572-ff95-4bf0-a759-84fe23387934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_05b42572-ff95-4bf0-a759-84fe23387934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ea851c44-1606-4fb2-8515-67598b8aa23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ea851c44-1606-4fb2-8515-67598b8aa23b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_08c87495-6607-4b8a-a7bd-7735c08913c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_08c87495-6607-4b8a-a7bd-7735c08913c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_44605fce-b29e-469f-87fd-dbefaf12b5d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_44605fce-b29e-469f-87fd-dbefaf12b5d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_81d682d6-9394-4304-b084-70fe8fdbacdf" xlink:href="gild-20220331.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_81d682d6-9394-4304-b084-70fe8fdbacdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_3f8dd5b5-fba7-48b2-8fdd-84afabff97c5" xlink:href="gild-20220331.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_3f8dd5b5-fba7-48b2-8fdd-84afabff97c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i188f8b9de72b4de5bf6ba5cd662125c1_STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d2e868e3-a357-49fc-9387-d9ec7219d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d2e868e3-a357-49fc-9387-d9ec7219d7c6" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1968c9c-ecc4-41ce-bce3-c2b42af76efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1968c9c-ecc4-41ce-bce3-c2b42af76efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5011862c-5faf-4522-b228-7656216fc58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5011862c-5faf-4522-b228-7656216fc58b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bfaf0f15-8cde-4a28-a9d1-6fedc9831f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bfaf0f15-8cde-4a28-a9d1-6fedc9831f1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76aad8cd-9909-45bc-a514-133ba75e75af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76aad8cd-9909-45bc-a514-133ba75e75af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_caf326cd-4b6e-474c-b07b-89d1368860b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d2e868e3-a357-49fc-9387-d9ec7219d7c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_262d1f56-13b0-4d30-aca8-ce851907524b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:to="loc_us-gaap_EquityComponentDomain_262d1f56-13b0-4d30-aca8-ce851907524b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1e94994-78c7-4a79-9c3e-1964544b4a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:to="loc_us-gaap_EquityComponentDomain_b1e94994-78c7-4a79-9c3e-1964544b4a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1e94994-78c7-4a79-9c3e-1964544b4a8a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9bc5642e-3c62-49bd-9647-a1f621c68d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9bc5642e-3c62-49bd-9647-a1f621c68d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_783b20fc-0a9f-47d7-bd13-9739b675194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_783b20fc-0a9f-47d7-bd13-9739b675194d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c72d511a-5841-4c90-ab31-130672d561ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c72d511a-5841-4c90-ab31-130672d561ea" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#INCOMETAXESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INCOMETAXESDetails" xlink:type="extended" id="i44d042922653496d8b3341b7026966ea_INCOMETAXESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1138e583-a73b-406f-b98f-302341185442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1138e583-a73b-406f-b98f-302341185442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5e8e853e-fcb1-4eb9-8b6d-e52f136aa052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5e8e853e-fcb1-4eb9-8b6d-e52f136aa052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec80ce6e-6a2c-4913-9b96-9e5d6302ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec80ce6e-6a2c-4913-9b96-9e5d6302ab06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a74c2c2-6a91-4733-91ec-737ca83a6aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a74c2c2-6a91-4733-91ec-737ca83a6aec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd41a989-464f-4dc0-99da-bbd7d1119536_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd41a989-464f-4dc0-99da-bbd7d1119536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_765e0558-7f5a-4e5b-8d53-0e0ff6d106f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_765e0558-7f5a-4e5b-8d53-0e0ff6d106f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_93258d72-7194-4691-a8b4-9d8a5d67fe45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_765e0558-7f5a-4e5b-8d53-0e0ff6d106f1" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_93258d72-7194-4691-a8b4-9d8a5d67fe45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0930ae24-d317-4418-83d1-8b607683292d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0930ae24-d317-4418-83d1-8b607683292d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d88d61c3-36e4-4af0-9c88-95142dff74b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d88d61c3-36e4-4af0-9c88-95142dff74b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_4f170e16-1d1b-4f13-a630-5270d88b8310" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d88d61c3-36e4-4af0-9c88-95142dff74b0" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_4f170e16-1d1b-4f13-a630-5270d88b8310" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended" id="i497cca9b4c5c4cb4adf6e272f6d73134_SUBSEQUENTEVENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e9d4a599-f99d-4582-a1f7-9a68d8a7d9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e9d4a599-f99d-4582-a1f7-9a68d8a7d9ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_6d134e99-2bb6-4965-a3dd-fcccc2e1c7a6" xlink:href="gild-20220331.xsd#gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_6d134e99-2bb6-4965-a3dd-fcccc2e1c7a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:to="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8a8cda66-f009-4727-a52d-4d242ebde597_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8a8cda66-f009-4727-a52d-4d242ebde597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f741a823-3bcf-4f7a-a27a-b6565b2b7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f741a823-3bcf-4f7a-a27a-b6565b2b7a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_77e42500-f234-4c7d-9ce9-c4afa733b33f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f741a823-3bcf-4f7a-a27a-b6565b2b7a3f" xlink:to="loc_us-gaap_SubsequentEventMember_77e42500-f234-4c7d-9ce9-c4afa733b33f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87b59259-f975-4df6-8aaf-be777657ab9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87b59259-f975-4df6-8aaf-be777657ab9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85877c7c-51c5-47a6-a327-a8c7495903c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85877c7c-51c5-47a6-a327-a8c7495903c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_944b0759-6b24-45c2-9a98-45d4b7bdabcd" xlink:href="gild-20220331.xsd#gild_DragonflyTherapeuticsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85877c7c-51c5-47a6-a327-a8c7495903c1" xlink:to="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_944b0759-6b24-45c2-9a98-45d4b7bdabcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18d20029-52a3-455d-902a-dd708afd9c83_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18d20029-52a3-455d-902a-dd708afd9c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a66121d1-8717-4aad-9f8a-22c4a8d73c36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a66121d1-8717-4aad-9f8a-22c4a8d73c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsIncMember_9936aa3a-0bc4-4c6f-9930-2f70b05be886" xlink:href="gild-20220331.xsd#gild_DragonflyTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a66121d1-8717-4aad-9f8a-22c4a8d73c36" xlink:to="loc_gild_DragonflyTherapeuticsIncMember_9936aa3a-0bc4-4c6f-9930-2f70b05be886" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>gild-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:047062f8-b3c9-4367-911c-0f45b6df8713,g:679ab3c4-b282-4926-9aaf-46591661bf28-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_0c07b0c2-6bfb-422a-96e6-d8c20c62e3b8_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20220331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_38bf63a6-2565-4fc7-9d68-b63c8f3f78ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount under stock repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_e8e44269-1b45-41a0-afa1-063a46fe457d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_1957d891-8e16-4913-8480-db69074b9a9e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b3255ef2-a015-44e7-a5e6-85323770452a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_a0d6df65-f8bc-4235-9e35-0c63f4dd937d_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged, scenario two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:href="gild-20220331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da731abf-7d2e-426e-b47e-6e5af8da67ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_844b537d-431c-440e-b569-1a0eea1af65a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f01748aa-2e02-4482-b795-092c40d986f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_b32f2309-8836-4444-85fc-8243d92ce90f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_f782d1e1-4d3a-456d-9ba7-e6dcbb15ccc7_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional option fee on fourth, sixth and eighth anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Payment Waived</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Payment Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" xlink:href="gild-20220331.xsd#gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" xlink:to="lab_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d4e48cc2-50a6-4ac8-b6c9-ad7a17206ed4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a9196a8f-f5ef-430e-b211-8e8ed82a70a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_20770fac-e0ca-4eca-b3d7-00a5faf77acc_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate on future sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:href="gild-20220331.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:to="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_69b4134f-6734-4c17-91f1-b810cd120dea_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_11890c17-1f6e-486d-847c-895e64daee84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ff27b967-b96e-44f4-b310-d8045a445c00_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_7daae684-5be9-4ea2-ada5-f80e3f2e4b2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_14299a19-5219-4d49-bbba-e2ee859dd928_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cell therapy</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_499fe185-1b2e-44a4-a1e0-90c02f2b9519_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material transfer agreements</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_label_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:href="gild-20220331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:to="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_fbdfbc91-77c1-4675-a55a-6af266d5cdfb_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember" xlink:href="gild-20220331.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementMember" xlink:to="lab_gild_ArcusCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_7c57d6ea-4574-43e7-bea9-8b774fac1106_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_fd7d5737-af42-4d43-ba4e-7c7dea211b31_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e66bc9ab-777c-495b-85ee-aa768e5bf0d7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_84d621ac-b10c-4eb7-bdb3-05f94cb2cb85_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6ff94d9c-5d31-4f3e-a611-3c84cec4a4f3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_f6b4c108-c16f-4b1f-b330-d4d496ee89d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_2d8d5199-3b68-44c7-b842-b0a4abd4cd99_terseLabel_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember" xlink:href="gild-20220331.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2020StockRepurchaseProgramMember" xlink:to="lab_gild_A2020StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_c89029a6-2794-4e27-b6aa-2767a5bdb0d4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9ae0cae0-d1a2-43c5-b50f-40e3055827e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_28b9aab3-5ce3-4507-b2bb-f459a3e01555_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_ac98311a-3387-4a98-af02-ac812ad85865_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived assets - IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40d0e7a6-d147-4fa7-a4e5-a203d0b350c9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_ec51d278-f687-4551-8d40-c3a13a75c8a0_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HBV/HBD</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9fe09468-29f2-4ae8-a8fb-d617d0b25add_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_249db17d-14f4-4c55-9431-232216eb2386_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_88c5216c-5bf7-4eab-bacd-dc49af1f16cb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a322e894-5fc7-42b3-8bf0-01a4b6e35647_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5c65daf4-76fe-4c2a-b116-22c57e118c45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_564dccd4-1a35-4e52-890b-27494af66f2f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2c963055-75a1-499f-9ae4-2468f9c15d65_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_53b4b313-43ce-4005-8957-a9276a17b4d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_6f28b2bf-a603-4bac-a3ee-013543d502b5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_8481cbe7-5784-4af0-ae89-a39ccf4c98af_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged, scenario one</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:href="gild-20220331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0bd66165-0ae2-4469-baf5-95b119c65dc6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e89e9654-4d43-44ce-97ad-562ce78cb26e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_14979ea5-d38c-4be9-b03f-586f2f55eb39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_a5ec994d-a315-4fa0-96c8-bdfb33b3db35_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:href="gild-20220331.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:to="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ee95d3c0-f27e-4fab-a318-f856d1b6f19a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount under stock repurchase programs</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_3bc1fe4f-5459-4cb3-8b3c-5d2259d35ba5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0fbe3636-8060-4e04-b9df-33c6d578119b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9c3bc868-c650-4c1d-966e-90ce408717d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_89077668-3b14-4360-80cb-3988156cc934_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets, fair value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_e452fae6-cbe2-4ef1-a443-976c77969518_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20220331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_f611dbf6-eb70-4d60-9a8c-1516a4888184_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1a492654-2bf3-4a58-bcd9-b3826befc945_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e08af4f3-d963-4923-9146-3d342890a8a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1d6eb770-7db2-49ca-b86c-288cd1130c75_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_34b31fb2-a5db-4d4c-a68a-57e71a631c71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_8bd8c84c-34fa-4c3d-922d-3df7ab8cde89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_80a31d76-2a19-4ded-8220-4487a4c0dc85_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9c35ec94-af9a-4543-94c2-3e37f60f9f7e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_2ae69e86-8f5d-4656-a873-91d46e981207_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20220331.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3ebe55fa-2b5e-4fcd-9b06-7f6e72408502_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_a464242c-97de-407c-8cd8-6f40e0889fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_333df537-2d8a-4208-8f44-91ff2d94a9df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_699a8cb1-fdfa-486b-825a-362811221e12_terseLabel_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_label_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026 [Member]</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_documentation_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:href="gild-20220331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:to="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_66909e51-d7ea-4d5e-95e6-c1a5cc11cd58_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f3fca6b2-045e-44aa-b7ae-28cbd1446085_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_fa1fc90e-a438-4b8e-b18a-b5e39c757b09_terseLabel_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_label_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036 [Member]</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_documentation_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:href="gild-20220331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:to="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c353972f-c663-4946-8ebc-b2202bf83c64_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1c3c050a-f245-4d0f-8acd-3df3f1cc867e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_499d22be-1a47-4129-a2f2-032a2ff4b7ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7d65047b-d016-48b9-841a-2daf49d4b535_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_5ce067b9-bab0-4bfa-950d-d82f5401f675_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20220331.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_b53e623f-251c-4e89-b86d-69cb40ef5d8e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a146db83-04a8-4f6d-b1bb-9b8019f7b9c2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_317a3a5e-5e0d-4c80-aff3-1d2ae3f09373_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9799fcf8-57c8-4140-a363-588b3da6fccc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_f2352a49-a895-4645-b30d-449ecb81d51e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_df1aa943-9658-4879-910f-72d09f061b0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_745175d1-0cc5-4b21-ae77-931b1b0a7de9_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20220331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_0be8e29f-2a90-4b05-894e-6b1e1f5e49dd_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_b4cdcf32-6381-4e9c-8ab1-1c6ee9188a43_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c8697c40-0cd7-469d-adf4-c4118276a2c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_a7072308-0036-4d10-a28c-a93a08060570_terseLabel_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_label_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_documentation_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:href="gild-20220331.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:to="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_37996830-8376-4009-8fb0-1c0be9998ea1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ed82ea61-134d-4e2a-9b0a-ae5e27cb88e7_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d89fbe89-eb5c-404d-9daf-7962d3168e31_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0cba7514-a93c-4d3c-a8e5-f4c214d9bea4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_23c624e9-23b8-4bbb-9788-83f170ab8abd_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20220331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_6525ccde-4347-4d98-8357-af9e676f4d43_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20220331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9b2354b2-d2bc-4174-8c4f-8044ca49e3dd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dd10e0a8-b6d2-45ea-ba68-0941fe194fcc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_71f414ef-b202-45d5-9550-52c3edbbc8d7_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage (up to)</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties Percentage, Maximum</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties Percentage, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" xlink:href="gild-20220331.xsd#gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5df14909-7872-4736-8895-ca3087f05cdd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_647e6ebd-1689-47f5-906b-c0134816b1dd_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20220331.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9adc3b55-65ff-413f-b959-16e36f14b576_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_be19a23c-5153-4955-a125-30e3bf388c1c_terseLabel_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical stage programs with exercised options</link:label>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_label_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Stage Programs With Exercised Options</link:label>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_documentation_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Stage Programs With Exercised Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:href="gild-20220331.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:to="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_acddcd0d-f884-4516-8c96-70d90638c45a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6498cb58-0fcb-4bd5-96e1-cee4595cf2f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_934fc6df-5d12-4448-8169-00138d2d9ea6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_88803a46-675c-48eb-bf98-3b14a094950e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_a4152d6e-8fc2-40b6-8c5c-4568f522e832_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_011fc962-9d08-4dc3-ba3c-31a644bd269e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_26256b2e-4ed5-42a6-9d4a-600fceb185a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ec78a7d7-a555-4686-aa1f-5aecacb99ae1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_848580c4-7c08-4a06-a595-844a7fe53282_terseLabel_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to opt-in the collaborative agreement</link:label>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_label_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Opt-In The Collaborative Agreement</link:label>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_documentation_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Opt-In The Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:href="gild-20220331.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:to="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_68ed6305-2fe6-44fd-be8a-d902b4b7af5e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs involved</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_ecbc911e-2c05-4b7f-afa8-b3e12d111745_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimates</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_d8a35e24-3a9d-483b-89a8-3bcf23d56696_terseLabel_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_label_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_documentation_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:href="gild-20220331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:to="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_7b447fbd-aa94-45d0-b9ea-7028765e1e23_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time estimate for gains (losses) to be reclassified from AOCI to product sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_b268882f-85d8-4397-99f3-0354438ad1bf_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20220331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_9db28f51-fafa-46c2-9cfb-80e780c4d924_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_115cf787-8f2d-4fb0-af2f-62070ec8c9ce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_b2857d78-f8a8-4bb7-bbe1-f0d4650c25d9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_79bbc86f-ac78-4932-880e-2c74148a2b4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt, carrying values</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyMember_f760e4e8-0f92-4f51-b602-a66fa3f3b205_terseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_40f8d191-001a-4f96-94d6-0061f98e67b5_verboseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_label_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy [Member]</link:label>
    <link:label id="lab_gild_TrodelvyMember_documentation_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember" xlink:href="gild-20220331.xsd#gild_TrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyMember" xlink:to="lab_gild_TrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_6747eb9f-982a-4a1f-8e18-912489f3b02f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ce034f5c-c1ae-4dd7-be0b-a236a581870d_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_75c1f046-8e10-4fbb-ade5-1694e5c254e6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_be82f42a-05e1-418b-ba38-a679b4aaba00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9d63b20-7a14-4c2f-8088-c124d6139461_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_491108f3-8db1-4c87-876d-bb32dd8148d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d15f342b-866b-449f-92a0-c6a4518643c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_aed28b9f-38d2-4260-92e7-8d060de7b57a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_e66562d0-73f9-4860-8bdd-fb2001036121_terseLabel_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_label_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035 [Member]</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_documentation_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:href="gild-20220331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:to="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_4c47bfaa-f7a7-4ed0-a9e1-63b7d4444780_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_e0345f4d-fb27-48c6-ad57-0c8572d3d0f6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_77aaedc6-7d84-483d-9621-22d8c188573a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_f271b891-9d26-476a-8c16-61a5a8be7580_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e0969fb9-6af1-482e-8c0e-92d5c71da901_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_5ea0b6e9-ab57-44da-ba97-e808000a1a64_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_35e90665-cfe3-4ee6-9c99-23654dbc5925_terseLabel_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional patents allegedly infringed</link:label>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Patents Allegedly Infringed, Number</link:label>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:href="gild-20220331.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:to="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_34c21d9b-e24b-4cb2-b65f-1ed9bb8f51c9_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_d1975cee-13a1-4004-aebf-6e7d42ea4442_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_52ca3730-8794-430d-84d4-3a8df6b981f8_terseLabel_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Liability [Member]</link:label>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember" xlink:href="gild-20220331.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ContingentConsiderationLiabilityMember" xlink:to="lab_gild_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d5cdc9a8-0a4e-4981-a001-22a78ad01914_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0b222bff-e626-4b4d-8cea-5d3b4a986ccd_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54e7f9df-ebc2-4a73-b3cc-b56907e5dc75_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_39badf14-3dd7-429f-95bc-0557f2658c3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_f388b53a-0890-4892-9a97-4be4f9f9c828_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7d88410f-78e8-4442-abb3-2ea239dcaa49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_df8e2911-d8fd-4a64-b138-1dfdec8c0edf_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_73269702-e291-4147-8c95-a1f20430714b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3e9be1a0-f99d-426b-bfad-109a402e6fc0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1c6e77b6-6928-4e53-97e1-cfb9e97e9bce_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ad877137-708f-4129-be27-18cd79dd0dbf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c5177581-d536-40e3-81e9-9940ec01ca7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_9b241585-d117-438e-8cd8-f20b8d3a1564_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20220331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_8c7fa2e9-7cd1-4ad1-9de5-d519beedd2f6_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20220331.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_080076ee-486a-4791-8c57-b40d36f1e67c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_6583f34e-13f4-4111-9804-85d3d318791b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aecac900-2896-43f9-af94-0daa695865da_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_dcd5ebd7-5094-4c6c-bd35-b7ff348d20c6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_e3738ab3-0e38-48ff-8207-44436df41bd4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_039c0ec0-b063-453e-9d9d-0f2320712603_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20220331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7495bd90-2e58-41d0-a907-09882da3f27e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_edf66263-15e4-4e33-8239-6ef4dd5a693e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e72fb412-ebbe-48af-9649-3c1b880d9b04_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dccb1216-9116-41a0-869f-7c1199d1d0bd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cc7b82a8-52a4-48e8-9f29-aab42787cf09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_907580cb-3f69-460e-ac56-d6ac914e8ec7_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties filing opposition</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:href="gild-20220331.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:to="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_39d0f8a4-fe5d-41fb-a50d-a10fd4b70476_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd6b4a28-87fc-45ed-a3ac-2ff98419085a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a0dc4396-22b7-4982-b4c8-b5abc6fdb6e4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_da17581e-e906-43aa-9885-125c24d05fc5_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecartus</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTecartusMember" xlink:to="lab_gild_CellTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_5876171c-13bc-4d15-aeb5-ccbd5d7874d4_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20220331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_202bc376-c7d3-4514-bed9-d7ac94ec5904_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d6602b73-72e9-493f-9190-661ce2c70aad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_QuiTamMember_d3afb259-99ab-4244-bb97-4a9d72196d05_terseLabel_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:label id="lab_gild_QuiTamMember_label_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam [Member]</link:label>
    <link:label id="lab_gild_QuiTamMember_documentation_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember" xlink:href="gild-20220331.xsd#gild_QuiTamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_QuiTamMember" xlink:to="lab_gild_QuiTamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0fa7b318-9f01-411c-b6f1-18eb57c865a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_cd766f7e-494c-4308-a3b6-085519720da9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2ac99b2b-3a95-4c83-aaaf-313cb4c9e3d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT AND CREDIT FACILITIES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_a42b7caf-e909-46c7-8553-b360dd8f1831_terseLabel_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_label_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products [Member]</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_documentation_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember" xlink:href="gild-20220331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHepatitisCVirusProductsMember" xlink:to="lab_gild_OtherHepatitisCVirusProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1645b259-ad68-49e9-9451-d5e08c061a96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_c71fd3ff-71f4-4303-8643-272dcfd0094d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_b95d3b27-b113-4c26-9aba-2013bff28455_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_659a78ab-65e1-4ce6-9d33-9c1797ca2abb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_a6fe4bbc-6f62-4142-a00b-e4fd82232343_terseLabel_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20220331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductLiabilityMember_3c1c0df1-1048-4e18-a089-379efefc07ea_terseLabel_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_label_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_documentation_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember" xlink:href="gild-20220331.xsd#gild_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductLiabilityMember" xlink:to="lab_gild_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_7a4cdfd7-40f1-4275-a768-28e55f6d4092_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_1ce231fe-c167-4bf0-987d-9978bdac60de_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_661c50a5-4178-46dc-a2fa-65dc81b87a60_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_29e18f4f-b70f-4090-80c1-9146e608eb9f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6cfac41e-d2c8-45b9-ad49-ac2ecc1a97c8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1809eae2-95e3-4369-b743-e66d98d24e1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_9305a1f8-9992-4c22-9150-3a3c5a6b86cb_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2027ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f296efd1-f737-41ce-83ff-806e0e7e7174_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8a92e617-4b1a-4d0b-8d3a-40fa7af38162_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1855e138-48d0-4de9-9042-5ab82dd166aa_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d1b8eccb-df07-4eb9-b8b1-2af40660c814_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a615b4d0-a7f0-499d-9538-32a438aaba26_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_bbfff1cf-76fd-4a60-82fd-6e44dd29cf5e_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2024ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_6a724f0a-aacb-4da0-8d49-dad62d9ee860_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d340f12f-a440-4c0a-b289-0eab1059d411_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c0ef7828-e779-45a5-b342-7f6e56259085_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e17007b0-09f7-4811-9223-48de87e73dd0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_8d7ec554-643b-42b6-9ec6-fa8ff0581d32_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9241467e-3558-4d7e-bc43-bd1c6e909a9b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_a6267ab9-5b95-4c84-a518-ed832a6c9dff_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HBV/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_4a99dadf-607a-4849-a5cd-37484f4084d3_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20220331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_45557b2c-d1a9-459c-84be-27f130af4e6f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_82ae1c19-c2cc-4310-ae5e-917197673007_terseLabel_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_label_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_documentation_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates" xlink:href="gild-20220331.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedGovernmentAndOtherRebates" xlink:to="lab_gild_AccruedGovernmentAndOtherRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e5d6cc42-10dc-49ce-9587-846eca3f0963_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_952bc570-f8f5-4143-bd3e-2b35a1edd0bd_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6373485a-6224-4a77-9e2c-ef6d75871430_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_4d4af776-ba7d-4162-aea0-f16f925599f5_terseLabel_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20220331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_04d81140-5acf-4b0e-9766-4b55dcdd7eba_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2cf4286e-b36a-40c2-a209-f4ae10cb1d23_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ef046fd6-2cf2-4bd9-bccb-29c22560b73a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0b80ff8e-d1dc-4b62-bcac-13feb074b5b6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_108b274b-4130-4496-aded-ab2c5ed3294c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5b29a73e-3921-4fc9-af80-bee4f3082b91_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_618c6934-a22b-4d4f-aad5-a7d409288cae_totalLabel_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:href="gild-20220331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:to="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e18bc9b2-4353-49e2-a767-c632e2ecd1f7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_fee72f78-0207-45db-a92c-8a097b31ddc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0b66a64b-90b1-496d-a39d-aa118daa6cc2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_46612eb9-a76c-4c3c-a0f7-1ffcc6f89313_netLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_fe755053-91d6-43f9-98b0-c850e125eb41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_477923f8-b180-4edc-8e9d-79d8f8f435ab_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b8907dd2-be67-4d24-b2d7-db5297e9a0e8_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_1521bd86-9119-46f3-8d3e-3ea63e60726c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7bc73bd0-0e2d-4eb3-80cc-6d214d21f586_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a85f829d-ad02-4a40-b7fb-9dc286956ae7_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da721b05-5303-49d7-a4be-35d7bea80a4f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_b98fb570-11f5-4acf-aaa8-72efea1270d2_terseLabel_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_label_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_documentation_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:href="gild-20220331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:to="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_bef7007f-19e7-4486-a734-f22dc6cb3710_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86a93279-f628-4bad-be6a-cab9aca2006e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_4e040bab-bce2-4bea-88c6-6b1849d5b956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_c3a7f805-398d-4f73-bf86-d33e540d9092_terseLabel_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents" xlink:href="gild-20220331.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyNumberOfPatents" xlink:to="lab_gild_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_b8cf5403-86b2-4754-8272-250846eba5fa_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_a339a949-166b-4605-bc16-6300893f703c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_6d6888e4-1f79-4983-b7d9-32fcb350ef7c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2203fd43-cf84-4ad2-aea8-5455d51b5814_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca45dd48-f754-42b0-869e-9fd5eabb9a0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_de0693fa-ac95-4334-b119-0cb1bdc33fc0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_f84f3c90-07a1-48ff-8ee3-00de7455e8be_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yescarta</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsYescartaMember" xlink:to="lab_gild_CellTherapyProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_90656ecc-138b-46be-b619-ff6e55f61d57_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_f783a240-0040-45e0-9b9d-525c297b6321_terseLabel_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_label_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022 [Member]</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_documentation_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:href="gild-20220331.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:to="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_5f3d522e-cc66-4407-879b-2611b90aad75_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_8f2f25ca-953d-4a54-9a4d-f69f31987696_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20220331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_62ab2cec-cf26-4d9f-bf00-6a0252b93f14_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_c6af72ca-f4a5-49f9-b4b7-e0edf2b7f5df_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20220331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0f193bda-6ee3-4e70-b1de-2cbcd282af84_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7253c5db-5e05-4029-9e94-b3d5de44b983_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cdb355cb-2b1a-49b6-9abd-fb75eea0d812_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d0900571-cb10-4d06-99d3-b125c0a8e0d1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_aacdc2af-9d37-4971-baa2-6c75abfd7313_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_4f7f37c8-e0c2-44f1-a374-2c6a0320de7d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VekluryMember_4c9fabe9-dab7-4436-8933-be29be840649_terseLabel_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_VekluryMember_label_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury [Member]</link:label>
    <link:label id="lab_gild_VekluryMember_documentation_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember" xlink:href="gild-20220331.xsd#gild_VekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VekluryMember" xlink:to="lab_gild_VekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ffe61bb6-e30d-46c7-9d90-f78e9a450da1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e7ce4b7f-c449-40bb-8cf5-9268f2ff75ec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b287eac3-d704-4857-b28e-1a6cc4f78ba3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_ea345393-1cd4-4ecf-82e7-aed72d99a5bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c7937359-052b-4c75-88f5-a5a8425f42aa_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2bc91a6f-8fb5-47e0-a616-f98079f7dc8a_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_17e4fcc8-73c6-4a3c-bd46-2864b9335549_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_da71bb8f-2ba0-4a92-9d55-ebbbf5a248a9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_3f58c7ee-a273-4242-a29e-e18095a9ebdc_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20220331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_db8a866e-df6b-477a-b02b-adab63e969b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales_cfb0bfbf-2157-4655-b004-23f31e157198_terseLabel_en-US" xlink:label="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage on future sales</link:label>
    <link:label id="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales_label_en-US" xlink:label="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Percentage On Future Sales</link:label>
    <link:label id="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales_documentation_en-US" xlink:label="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Percentage On Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:href="gild-20220331.xsd#gild_LossContingencyRoyaltyPercentageOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:to="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3a19fa02-870b-4845-9ae7-d3665490c77d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9a5bc87a-8b42-4935-b3df-30b9613a9d94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d13887a1-c5e2-468f-bd1d-8b80e195d960_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_397e5c6f-bed5-4724-8a39-0707eeb0db7b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_b247128a-4501-476f-9067-d3f204b7ea25_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_d7b52973-2ffc-40f0-ab1f-2aae2cde7979_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20220331.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4982307d-ef5d-47c7-a4f3-93215fa3fa14_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_cf956af9-c05a-4578-8ae4-02e055852459_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_35a8eb1f-ad0e-411b-b9c3-7651aedcbd4a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_321b5910-0110-42c9-b0c4-f6569bff26e6_terseLabel_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember" xlink:href="gild-20220331.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2016StockRepurchaseProgramMember" xlink:to="lab_gild_A2016StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d336247b-a1cb-4f69-8497-fd487d11b039_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_eb9786c6-f1fd-44c6-9a45-f073932e0496_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1b99c70f-ceb1-4bee-a292-d40f059ddd3d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_c20e0240-9f31-4673-b07d-dfec58a824b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ddf1e4b-0ee9-4b61-8317-99401fb0adf4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_524dc272-5bab-4cfe-b179-b4b8f573cdc3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_76575b19-d093-4aec-9d86-bbef18529837_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7f36c2cc-ddcf-498d-996c-2e10d00e44a9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_fdc4254f-620a-445f-a9b5-80116d11bb5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from Major Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_48038c7d-8dfe-4957-b47a-892227509e5a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a50cd7ce-966a-49e4-8c81-b1a4e38cf674_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4e991a3c-9fea-4ac5-916c-521e5fc420f8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_f1a2aed7-c42f-4f2d-ad85-861672b3cc0b_terseLabel_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_label_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_documentation_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:href="gild-20220331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:to="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_6a39c48d-72e3-4cb6-8c37-10635e793b9b_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20220331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c4f68b21-1123-49d0-b6df-504b40dca6a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b8f13d29-bb72-42c4-a8b0-1763467588b3_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedges:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_716cdf47-1f89-42cb-832f-7619b3208f3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6f1a15dc-4c6e-41c3-b424-266cb4d2f07b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4e3a9ace-2669-41a3-b700-d682eeb8631c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d05710e8-313f-48fc-9c43-8577b86b6d32_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5fee0327-6dda-43a5-9c6a-40ddeba089ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_dfb98996-7239-41c2-b8b9-dbc3403ab2e8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e615f1f7-ad9e-427e-8862-3ddc61829b40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_2cc5492e-cc14-4cae-9df3-812a1c963d86_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share with Janssen and royalties for licenses of intellectual property</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_89eb9511-10a1-4cba-b19e-2162615512f1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_298572b7-c8a8-402f-94a7-bbb2cbfde009_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_71742d2a-cdba-4827-8b87-bcdb65f18c0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_94b977d4-b8b0-42cc-bb80-e058222702cd_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2026ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5512c8bd-cffb-4e21-9f02-00bb15b67d89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_8286a182-5b87-45d2-bc58-3002b61370f1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_30b1fe8a-1dc2-441a-aad1-9d85b6f36d57_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_34499d49-71ce-42cc-8076-d385fe1d536b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_f35d15f2-a494-4797-aa1b-5102754d33a1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_cb785397-ba6d-46eb-8ab6-522faba587ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0f393ad4-3256-49e3-b877-f5c4cdc95faa_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fe784ae1-3e85-4453-97cd-d33579191861_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_739fb478-574c-483c-801c-15f59e497acd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment recognized</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e0379d3d-b976-41d6-a5c1-3143f9996666_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effect of Foreign Currency Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_cde71cb4-ecf0-4d19-aa27-40483baf72fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_6ee4d9c7-0c61-4221-8cd4-319b0f152cae_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1cbcd6da-d3f3-4173-8b7e-bed4172e382d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1198bc34-c4cf-4e11-89c3-e14ddcc5b186_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0bd4913b-b91b-4182-92c8-b15fc088e2ac_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_843447e6-9049-4f32-af0c-7aa7cc9b92ad_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3692abbc-6be1-4854-8bd1-6c0fb7cbc370_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7a56bb4c-d2e5-40f2-996b-8408ab51a588_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_01d82c2e-3d4d-4751-89b0-5c1b7f9b04be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_41944dca-6cba-4cf2-ba9c-0c7ef12a3e94_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69c04ca6-b968-44a0-a0dc-d5635648e4d6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bdcab05b-3f18-493d-b4c3-e288dd03c15e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48131390-8e38-45de-be23-db8b20c62514_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd8d00b0-d830-4af4-903f-df0883141938_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f26788d-9e0b-4384-af12-00652677de69_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_d05dba6a-0444-4031-87d3-018ae7e8581d_terseLabel_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhancement rate on past damages</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_label_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_documentation_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:href="gild-20220331.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:to="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cff9e46e-e270-4a2d-8d20-55722b100e4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c8c139c7-dd17-490d-af32-e39641de8931_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f720200f-7023-4586-b759-767f711dd602_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DragonflyTherapeuticsIncMember_c5b5b404-0655-4a9e-b0a0-2e15b5b70488_terseLabel_en-US" xlink:label="lab_gild_DragonflyTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics, Inc.</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_DragonflyTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_DragonflyTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsIncMember" xlink:href="gild-20220331.xsd#gild_DragonflyTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DragonflyTherapeuticsIncMember" xlink:to="lab_gild_DragonflyTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_465b4c33-cbc8-4cfe-b37b-db5311703540_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8c590e39-e387-4be7-bfc6-b651e54431bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac9a0b9c-3fe6-4446-af3e-af3e65948011_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_965fecde-dccf-4b4e-8cc2-fc7fe0be0b66_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1fe07902-16ef-4dd5-8144-dfe6dde6df2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c210c445-4050-4a53-a3ef-c491075bc0d0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_55f08ac8-26cc-4311-8d69-6973543c1e07_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6a7f5085-6e4c-4cce-a6fe-a4c1895320f0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_99ebf5c2-0a4c-4ebe-8562-7400a2033a67_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_69654c0d-c774-4898-91d5-353cbb96c865_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_9ae267af-83dd-4b54-aa5b-6d0b345f839b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_4fb5f68f-88c4-4830-8201-876bf72deb2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3e4fc35e-6cb9-4640-b271-f65b6f6f8cfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_a1394098-6426-49a7-bd74-43d22bbfde27_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2b38afe-4b8b-47ed-85d3-39292090aaab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cb40897e-dafb-4911-bac9-523c2c6312a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4fb8b102-9387-4364-91d8-b6c5a04dced0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_d0932fd8-12e7-4ad0-a911-a7ec4605f609_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_176af92a-db78-4ba1-adfb-bde8875450c1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7270b0e8-2a08-4bf1-bfc2-81318248cf22_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f9949c72-b12a-4c93-af1b-24cbd9b67381_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f78b5e45-ab1b-4351-8e0c-f9dff07248a8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_35ab8638-4f5f-48c2-a257-bc31834295f3_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20220331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_343f9b96-56c8-462e-95e8-c6200b9b17a4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4d0f9f9e-3b4f-4e91-b426-3be290230eda_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_029b846e-7917-4623-b330-0e643fb07a23_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20220331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_c0b5f02e-d46a-4b0c-a572-476f6f47abb4_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_63d7b64a-9bde-4b39-ae80-873b65cf3fdd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6867ddf5-cc8e-4a30-bee5-139812edd4c3_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9a35c9ba-6f17-44a5-be63-9c0fbba78411_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_47d782f6-c28f-436d-ab32-14e33cef986c_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:href="gild-20220331.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:to="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d5c2f0dc-2f2d-4959-96bf-41bdb2547993_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_342ce23d-93af-4046-ad9c-781c841c0d7d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_83eaf891-a85a-46ff-9a05-b455ed07d8a1_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_1f3885d0-f46e-40cf-a3ec-22b840c6e2bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc68df20-5c1c-4c76-9b13-5f28ba12d421_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0749318-18d1-418d-b452-c3860f2aaa89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ca4d3b79-beb4-4940-9032-a0c13f84ba3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a80bc5d9-9ae4-4e78-80bc-4847ef600645_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8e2a2da8-0573-4bda-a2ab-27019852785f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies, Estimates and Judgments</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a5aef8b0-92cf-4e16-9f53-21a066ef3ccb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Calculation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_627e8136-68af-4584-9a79-ce1fd52c2a06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_970319a1-e74d-4b22-9711-4472d80f8f0f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e0149b9b-1171-4436-b0df-cac0b6986122_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_db0725db-c898-4a27-afe6-bab6fe626128_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_1e6eda35-4fe0-4c46-9420-1909c8f6d155_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to litigation</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6f3be5b0-7f00-4fd8-952d-90e5d3a195f6_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_99fc7dea-69bb-409c-a6ba-31b7b0c751aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3e0d5c27-81d5-45b2-be79-1efce2d08871_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_81fb2436-907a-46c1-987e-6cad3c378cf3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_7631fb4a-a5cf-4752-ae79-88a179db0ecc_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cddff129-b0b3-4316-b0be-a11de96ae86b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_2c6ee855-460b-45c8-a281-3801b86b3e12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PreExposureProphylaxisMember_f4708b44-cda9-4027-a925-461f26b16f0e_terseLabel_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_label_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis [Member]</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_documentation_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember" xlink:href="gild-20220331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PreExposureProphylaxisMember" xlink:to="lab_gild_PreExposureProphylaxisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_1c3c7a45-3f6d-44a4-94e6-1e7ea4e51eb2_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20220331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_79371f24-a4ac-4af7-b32a-f286527e84f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_d13981c5-3860-4622-afdf-12b5b2e25e9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e0a33e43-28ee-4bfe-b826-1d796e36c959_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9387e73-2784-451c-9d3b-aa61b4171288_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_b95d004f-11a0-4f35-9789-8874f5176476_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for settlement related to bictegravir litigation</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_79fa1d79-328d-4882-a8cf-695056ca97e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_efe3bae6-138e-463d-9842-b33800860fd9_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20220331.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_c9a47977-96a6-42ec-b4fe-f54d27774aea_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_5c66a2f4-0025-490c-b99b-8c77e700ef22_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_77720489-7ad0-4bd3-a238-9cc1143d409b_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20220331.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9689a785-8a5e-4807-a454-c503c3231b46_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0fa6b799-3696-4a41-8e56-11ebbe3d0f62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25d2f7ef-49c4-44b7-8716-a48f9474b440_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4f902709-51db-4082-8f95-59d6267a323f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_23583f69-1655-4f20-a356-ee0d724daf6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d01f335c-e273-43f2-9a7e-2562040e2e61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_0f51e42b-57bf-4307-9dac-e09f3b1882a7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_cb741a01-6a25-491d-a528-53a6e1b4df81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_1fb89845-0876-4de3-8040-3b9450cda7e5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c74dc449-56e0-454b-95b5-97b66cb294ff_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7bafd332-6d6d-4cb9-8a47-d1d9080e94bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e0defc5e-a709-42ec-8d9f-2c1fcc3c6f58_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a892d77d-a4dc-4e8c-a7c8-7b7c75ac2238_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9f3aee9-4230-45a2-ab2e-e00edce0da3a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_b445b9dc-b6f2-45a6-af4d-605608546cb6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_4acd6966-42ef-4e60-827a-9d8c849a10fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_ccd22f71-fdee-4f57-a0f8-bc292f481ba2_terseLabel_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_label_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_documentation_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:href="gild-20220331.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:to="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_d8d70e73-929c-41ac-85d9-0e24e296a83c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_cd4cb766-c031-4995-aab3-914916998343_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8da18dec-a73a-45fe-b315-3174ed32ddbb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_607a5002-0df1-473b-8117-9c58502623d2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d226864-a8cb-4d96-99a7-1c1f930dc3f7_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_44505f6b-7e97-45df-bbec-476456eb7d2b_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate, measurement input</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_12f8d2f9-243e-41f1-ba1c-67242229239b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_f32ba4e0-4124-4bc8-bd83-ea2abd8d16a6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinuances of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_99bcb104-8698-4892-a2b9-cc69f9301b26_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_91165221-9e1b-4361-99b7-ab7291a39e67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1d650520-2b6f-4fc3-b499-6fde851ff384_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0b8a8088-9abf-46fd-a0d5-1fb41b31b67b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0dc85b30-53ae-402c-8e7c-27d32ff0d06e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6dd5aa0c-7700-4156-8062-9638eeae1a92_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_987fbcf3-adc3-4107-afed-77e7ee170d78_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vemlidy</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_17300d91-4f31-4105-9742-ad65dae75280_terseLabel_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_label_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_documentation_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:href="gild-20220331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:to="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c92bdbcd-3008-4c73-aeee-9dd3daea63a0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5955a453-5b34-4aa7-aa81-e048aecfaff8_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c1c6cbae-651a-4f9f-b532-0cd34d0d3587_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6e90b982-5d93-441c-b6f2-a1b3698881f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_87ee862f-9add-43cd-bf98-934ac72cbc8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_03c116d5-3c1c-4a79-a100-e1b74272a59a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_1afcd258-917d-4b84-8fe6-3451270974b4_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_26a5b853-f4fb-4299-8213-4b7ca4a036d7_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9e79de14-5aa3-483e-a775-1c104f0bed64_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d4b70dd1-ab1b-4d99-a1e9-475b5d75c6cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b691037e-c49a-4a16-bb79-d9521d80a758_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c5071383-86ab-4e36-bbd8-c8bab06cedd8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_51db1551-bfae-479c-a68a-d35fc38afadc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8d457681-04b7-489d-a167-739bf9b7402a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_b9d95aaa-6106-4e1e-bb1d-512bbe31cef1_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20220331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_59abe40b-191c-4ac0-8beb-4905ba3beed2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_86c77c3e-15a8-479e-9ac2-c08898ed9f48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c2ca30fb-9be7-41e4-8a7e-d490b801eb7b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_13463387-f826-474f-b526-4fb6fdd2b1d4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acaaa98a-bea9-42b9-aae9-abe14872e6d0_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_ffef0aa9-0344-4d8c-a074-1816f7bf9e50_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_be8a704c-ae57-4d3f-a71b-7bc25c873714_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20220331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_19dea394-4a08-43e1-b79e-f39741669908_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_042a3bb3-f550-4e2a-95ab-17074e5c0b04_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_925ae4dc-1cad-46bf-ae99-2b763be979c1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c816b8a3-f88c-4ab8-bd5a-632711594f18_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2eeb5ae5-2a1d-4d01-a28f-3cb90ec91a5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_bcf1748a-7993-490b-a6c0-cf771452494a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_710e578a-dee3-4650-8b74-a6d7a9208d72_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_1280de08-6fa4-47a2-bbcb-2452608b6547_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments and equity method investments without readily determinable fair values</link:label>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</link:label>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:href="gild-20220331.xsd#gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_6ae536c9-d6d5-43bc-b96e-111d33df10e1_terseLabel_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2-</link:label>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_label_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2- [Member]</link:label>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_documentation_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2-</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:to="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c7525e6-09b5-40b9-85b5-822d63f447b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8becdd54-165b-4043-885d-2dc49ff9d36a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_aea47bfa-422d-4273-8d0d-ebda8473df84_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c42844cb-dbb6-496b-9dd9-6e32fd34c6f5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_5e756316-a483-42de-8ee6-34b88bf53f51_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20220331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember_5236d75f-5239-407b-b338-02920b8a398c_terseLabel_en-US" xlink:label="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics Collaboration Agreement</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:href="gild-20220331.xsd#gild_DragonflyTherapeuticsCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:to="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c332ead4-9bd6-4003-b9c9-2b4632d35f7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_9b48aec8-5bad-4302-ab40-2d0dba9fa910_terseLabel_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium-Term Notes</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_label_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes [Member]</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_documentation_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:href="gild-20220331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:to="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_d4f36eb1-135a-4e37-a847-b0715ca68998_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20220331.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_daab5f2f-4cbf-4b38-bf01-3e874f15498f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7fdbe7dd-ed61-46ee-8142-114ec2e31d38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_870b04fa-9889-4d6d-9062-656e0109d71e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_82d69d0d-7c9d-4b14-92d5-693b58d742d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_fb520891-69e0-4631-a5e0-9b0af3e916b0_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20220331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_04c928f4-c8af-41b8-bc96-122dc2a4db11_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_734777fd-f598-4fd9-b851-d27bf81f3ff3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosMember_dd79dd5b-cb08-4706-93ff-59ef061a2385_terseLabel_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos</link:label>
    <link:label id="lab_gild_GalapagosMember_label_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos [Member]</link:label>
    <link:label id="lab_gild_GalapagosMember_documentation_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos, a clinical-stage biotechnology company based in Belgium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember" xlink:href="gild-20220331.xsd#gild_GalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosMember" xlink:to="lab_gild_GalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4422763b-f6f6-4519-b803-e6fb7ccf0063_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_b6e76cb3-1c8d-47d3-935f-1fbbdca28e74_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_f4871d4f-9061-47dc-9c9f-d04f07ce9b83_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20220331.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_98229b09-79a3-4e6c-a05a-44d9c5ce85e4_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_d42ed9fc-21df-4eed-bfb2-9b7e5de6c0c2_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20220331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_688e9932-6d3e-41ff-b094-ade763018c6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fc02e861-29d3-4042-b192-1103708cc0c7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_cac19577-4049-4641-9e48-13476b1cf339_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20220331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_5939ba56-6a03-476e-9ce3-2e62eecc0f21_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_2115d4ee-866e-4d96-9ddd-9acc317f2dbf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions held in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1a3debc9-d0c0-4f57-baf2-ce86f24b8c7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_55d3b70b-fb0e-41f0-a181-d560123df0ab_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_b468b64e-eec4-404a-be70-b63ea0ae868c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_00cfc584-489f-4a13-888c-cd04b69685c9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_fdb55bdb-ff68-4fe1-bc37-99197f8eca20_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20220331.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_63a6001e-7579-4a09-906f-8c94a6b16ea4_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d985cf66-6bdd-461e-89b4-c7e0b62ffec6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9c4d65e2-e97c-4c5a-964b-44322ae5faec_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_fc268376-18ab-4590-8c47-173126b058a5_terseLabel_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_label_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company [Member]</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_documentation_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company (&#8220;ViiV&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember" xlink:href="gild-20220331.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ViiVHealthcareCompanyMember" xlink:to="lab_gild_ViiVHealthcareCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2dfa86e6-0dc3-4a13-a388-b1573ceaf56b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_71fbc479-3c4f-4379-b129-7229fb0685de_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b22cfaf1-7065-4935-94f1-756549689154_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_079e0cc2-e3aa-4e17-8572-e9187a7832ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_6659861e-6030-46f1-a743-9d8577aa04f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c9c64ad5-7dfd-4b81-8a41-29106f2f9a3a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepcludexMember_f7c80b44-a1a2-43de-ba02-1aee6deb09a1_verboseLabel_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexMember_label_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex [Member]</link:label>
    <link:label id="lab_gild_HepcludexMember_documentation_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember" xlink:href="gild-20220331.xsd#gild_HepcludexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepcludexMember" xlink:to="lab_gild_HepcludexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_39e80a79-5382-49c7-9204-38edea881136_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20220331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_df513c3a-893b-4652-a635-95d3406b2f02_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_304016cf-68ce-44d1-91e4-e2342365e6f3_terseLabel_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_label_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_documentation_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:href="gild-20220331.xsd#gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:to="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ed34c8a-5e26-4af5-8e30-b9430423ed08_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_945bf421-4b4f-41ff-adf7-d42e4759d6ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9519cbd7-92d1-4aa9-8c0a-aee6ea9e7bc8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_9ae5d21a-73e9-4bc5-9b3f-cfaf10e4e32e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potential Effect of Offsetting Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_e640d5c8-2957-473f-b3ea-99ec4210acd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6d7005f9-0e6f-4a20-acdb-271776c01d8c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b7bc50a2-ac80-4d94-a3f7-70918dbd629a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9d554e59-4d8c-4423-b3b3-2115d4260d29_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_0c76f7fc-c95a-428d-8b91-d234720fed3b_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20220331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b24a7ede-92ca-4be8-9727-e4a61c4ae21e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_56158791-eb48-4e4e-9e9a-143e746bb802_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5c663f18-bfec-496e-b0a2-69dd574d0bfb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e82d5252-5b01-468a-a609-f5c262fb2012_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_2b0d7abf-cf54-4ad3-8753-120619e485a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ccefb56b-4959-4d65-9659-6d51ea6ff55a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_a00acffb-8d0d-4085-a012-c231e4285c76_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_be597396-1f93-453e-82c1-441089cb0015_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a4cc9a7e-fa10-46fa-bc0e-0bcd92d9fd21_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_bb387694-6bd2-4fc6-80f1-4f032ec07a2e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8852e103-41f4-4e97-b2e0-34d92b874328_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65f4175e-9767-42f9-a4ab-33ee7993f561_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6ea8eb56-5b17-4437-bd82-d8e596f17abe_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5a185055-66fe-4d76-ac18-11dcd8b64c3e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_430f5502-1f51-47fd-8a32-26b000b0ae42_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire in process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_70e5fa48-d85a-4482-a91c-22ff38832691_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_20543c85-a535-440a-8340-c84fdb37bf18_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_26796502-62b7-4970-a8b7-b18f0a15b250_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_f0eac486-fb1a-41c7-879e-f791726a7733_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in term</link:label>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_label_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Opt-In Term</link:label>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_documentation_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Opt-In Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm" xlink:href="gild-20220331.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAgreementOptInTerm" xlink:to="lab_gild_CollaborativeAgreementOptInTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7255c75e-6331-45ef-bb04-f0125b2e288b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_4d504bf4-5363-4341-aae6-31032bea44b8_terseLabel_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_label_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_documentation_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:href="gild-20220331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:to="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0e1428a6-93f2-4751-b213-fb6db0a03c91_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_75b11105-8e43-4fdc-8ed0-cf6e94c2ca86_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_178d61b0-6dc2-4072-a0c6-ac3fa031455f_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viread</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d99eb140-eeae-4ce0-ab70-6d68a6e9cdd2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_0004db00-9911-45ae-8a9a-9e68949a5527_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_84240e82-23bf-4d7f-b5bd-8692c5c5d803_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_14b69ee2-cd8b-4f05-844b-95127b8343df_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20220331.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_eaed2a56-657b-41ee-b639-02047e9501a7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8dc9a6d4-e9b0-4d32-b0eb-63e0a56de028_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4af66dfc-c9d0-4e1d-a816-b16f206b4a06_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cfc707-0845-4a66-a10d-1aa59325cd88_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_c083e67b-68f8-47ce-8da8-2da79e9e8035_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedges:</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e90f239b-eddb-4849-8e86-a39f05f0d4d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_b1395298-e293-410a-9ab2-26583b560892_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20220331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_11f0ce90-f7fa-4f69-ac9f-0e2170fb5696_terseLabel_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_label_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_documentation_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:href="gild-20220331.xsd#gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:to="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_92215abd-3fd3-4663-9de9-296e079b2b8f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_b24103fd-4fed-406e-94b5-33fd2a344d91_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4915764a-2385-484b-8fd5-e0a970e1f907_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_214fa617-c74f-4ea1-8833-87d81128be38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aeae3f37-e8bc-4c4c-b43e-204d3a3d66d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_48cfbf19-f9a8-41a0-ae2d-d0a06952587d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7072fbd7-993a-4327-8fe7-530156c0ecaa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_d6e506b1-6aea-492d-a5b8-3648a167f95c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_67654781-8f68-423f-b64b-f3fbdc27abbf_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties appealed</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber" xlink:href="gild-20220331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesAppealedNumber" xlink:to="lab_gild_LossContingencyPartiesAppealedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4ce59450-0385-42a4-8d50-5f7377f1d806_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5a9c9c78-8ba6-4605-af14-d96eab9a296d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_62fadfef-a985-4d64-9145-387aa5e24d40_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_4916f799-833e-4f86-966f-961c2c490d92_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7fc35a11-ac1c-4656-a448-f974ac10ff64_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_47c4a90f-f48f-4bec-ac70-a671c963285d_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20220331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_70639575-c058-4959-a5d3-73db81d0f652_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8d8c5794-3c13-4c19-bf4c-5bb9ad518edf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_2f17aca1-694e-45d8-aa62-4e66c07cb8b2_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Equity Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d17ccebc-11ec-49c2-8716-aae165f99221_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_44135de1-7f13-46a8-9840-d99c75d7e0ce_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_7f03c051-2d6e-4568-a4f8-ef1897410a38_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - axicabtagene ciloleucel</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:href="gild-20220331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f38b5b5f-05a1-4fa5-b43d-bf44b7333af7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_b0c6d7d8-1616-4218-8e38-ae0a1e69c852_terseLabel_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_label_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_documentation_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:href="gild-20220331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:to="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_029659c3-021f-49af-b741-3841bf2c7016_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class action lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2d875e57-a9a7-42ad-87e0-52cd768622c7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_6af1e48f-7c2b-4b37-a662-3592ec93e648_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_ac0c1f0c-d353-4f83-ae29-429636339511_terseLabel_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange remeasurement</link:label>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_label_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</link:label>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_documentation_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:href="gild-20220331.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:to="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_38579e08-3eac-4998-a3c3-d6767f0d5032_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_38d5bb30-8ba9-4cfb-925b-79154420f645_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20220331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_1272477e-3ee0-4192-820b-2d6291770514_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c123a28b-937b-49c6-a082-6ec85c70d1c1_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0aebeac6-e483-4cce-a8f3-c446d724a6e2_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_bdd9b1bd-0842-4804-91e4-78b32b29af8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_7a6430e6-60eb-4339-a653-0109c70a81bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c70a2dc5-abf8-4d1e-8eb9-744f948fc869_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) reclassified from AOCI into Product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_688ce043-d87e-4695-ab84-de52849e4be3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_d18097ce-0457-403f-9956-0ae247e627a1_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20220331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_a81f643b-b530-4236-9aac-9e691c072053_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_ec230346-6550-4a86-9e5f-37203efec913_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ac98785-006b-4fc8-a496-feded7421ee7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2b2bb148-a1ab-40d0-b1ae-90d9360ff837_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_79e874a7-ad6b-4df3-81d2-a101657c5915_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification and Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d8b003c6-8ea1-44a7-a1ae-6b8acbf5f418_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_f8eb3430-f8a8-4055-83fc-c2e3e446847e_terseLabel_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_label_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_documentation_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:href="gild-20220331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:to="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_74cafa81-423f-47d8-a64c-90c310c145dd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_6986efa6-c3ba-4afb-9175-a8d1c9835819_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20220331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d6078ab5-9a9e-4e63-9cc7-38fc421435ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_cb7e3534-f9fe-460d-90c7-0ffbea257e16_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>gild-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:047062f8-b3c9-4367-911c-0f45b6df8713,g:679ab3c4-b282-4926-9aaf-46591661bf28-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CoverPage" xlink:type="simple" xlink:href="gild-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_29722569-5bb6-43c3-a8b6-ba4c74ee551e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_DocumentType_29722569-5bb6-43c3-a8b6-ba4c74ee551e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_56521caa-7f8b-4b02-a832-197c9d807cf7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_DocumentQuarterlyReport_56521caa-7f8b-4b02-a832-197c9d807cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_42df1239-8461-4573-8809-de60777c5c07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_DocumentPeriodEndDate_42df1239-8461-4573-8809-de60777c5c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8c63bd00-a49a-46ed-816d-8c711cdf36b6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_DocumentTransitionReport_8c63bd00-a49a-46ed-816d-8c711cdf36b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f6c425c9-39f1-41ab-9c7a-925a57e7fdf1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityFileNumber_f6c425c9-39f1-41ab-9c7a-925a57e7fdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e3793d6e-5112-4e6d-a5e6-45060913b276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityRegistrantName_e3793d6e-5112-4e6d-a5e6-45060913b276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8b46f7d3-f6d1-4dd3-ac87-5effab58dccf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8b46f7d3-f6d1-4dd3-ac87-5effab58dccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1053f4b2-3617-4d5f-8f4f-7611e4bf8575" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityTaxIdentificationNumber_1053f4b2-3617-4d5f-8f4f-7611e4bf8575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_37f17612-9185-42b7-91df-2c62e25740ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityAddressAddressLine1_37f17612-9185-42b7-91df-2c62e25740ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4e4eef84-a23a-4a20-90cd-9089bcf74a42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityAddressCityOrTown_4e4eef84-a23a-4a20-90cd-9089bcf74a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_728d8bf2-730a-41b6-b61e-72185c1929f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityAddressStateOrProvince_728d8bf2-730a-41b6-b61e-72185c1929f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b3c26df1-5ed6-4141-83a4-962a8c0e8609" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityAddressPostalZipCode_b3c26df1-5ed6-4141-83a4-962a8c0e8609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ddfb79e-4464-45a9-92d5-a1c050195941" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_CityAreaCode_8ddfb79e-4464-45a9-92d5-a1c050195941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e019bc8b-cfed-49b2-8d0d-ef35c9f6f399" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_LocalPhoneNumber_e019bc8b-cfed-49b2-8d0d-ef35c9f6f399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_247a0ef1-915d-4aee-8134-6520251af59f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_Security12bTitle_247a0ef1-915d-4aee-8134-6520251af59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3ad50e8c-2072-4b10-a1e4-d1ad99e3fa01" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_TradingSymbol_3ad50e8c-2072-4b10-a1e4-d1ad99e3fa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b57ba46f-69b0-443b-8181-36920192a511" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_SecurityExchangeName_b57ba46f-69b0-443b-8181-36920192a511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ae438ac-b852-4ad3-8732-2c0501ff7ae0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityCurrentReportingStatus_6ae438ac-b852-4ad3-8732-2c0501ff7ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f1b81d40-5135-485b-852c-43b14c08610c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityInteractiveDataCurrent_f1b81d40-5135-485b-852c-43b14c08610c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1aa64336-8300-4330-acfa-8ece01bc79cf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityFilerCategory_1aa64336-8300-4330-acfa-8ece01bc79cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ee521f47-3b61-4f61-b513-c9e99fddccdd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntitySmallBusiness_ee521f47-3b61-4f61-b513-c9e99fddccdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8ab322fa-4da0-41cb-8762-bba628ddc8af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityEmergingGrowthCompany_8ab322fa-4da0-41cb-8762-bba628ddc8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9716a960-2304-4f05-8deb-a4ebbad56c51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityShellCompany_9716a960-2304-4f05-8deb-a4ebbad56c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7a04546b-8907-4af8-93c6-1f5d0170cdc6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7a04546b-8907-4af8-93c6-1f5d0170cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5550848b-602d-4b05-901b-b6780abac044" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_EntityCentralIndexKey_5550848b-602d-4b05-901b-b6780abac044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0cfd5079-c009-410f-b447-9379a4f122d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_CurrentFiscalYearEndDate_0cfd5079-c009-410f-b447-9379a4f122d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_16606dd6-d83f-4caf-8e5f-1f92518ba870" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_DocumentFiscalYearFocus_16606dd6-d83f-4caf-8e5f-1f92518ba870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b30cdc98-64ab-47da-aeaf-d344a95b28b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b30cdc98-64ab-47da-aeaf-d344a95b28b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8ddbc907-b203-4e71-ad47-8b6083607f0a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_489671df-0803-45df-a6ff-184fd00e2b2e" xlink:to="loc_dei_AmendmentFlag_8ddbc907-b203-4e71-ad47-8b6083607f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72dc0adf-9741-4a2d-b035-589ff320a95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72dc0adf-9741-4a2d-b035-589ff320a95a" xlink:to="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fde674f8-f744-45bf-b00a-3ab0e30e11ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fde674f8-f744-45bf-b00a-3ab0e30e11ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_085c90eb-eb2f-4611-a8d1-14aae11b122a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_085c90eb-eb2f-4611-a8d1-14aae11b122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cb577cbd-b602-4614-a815-dfcb7332b770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cb577cbd-b602-4614-a815-dfcb7332b770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5f6af860-3899-452f-b814-07c6015d17ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:to="loc_us-gaap_InventoryNet_5f6af860-3899-452f-b814-07c6015d17ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f07e9065-51b6-4f67-a855-6236eba676d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f07e9065-51b6-4f67-a855-6236eba676d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d837e16b-f0ad-4bde-bed4-542ccfc4a258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c87895b2-d3e1-42bb-baef-7fe82e11d0a4" xlink:to="loc_us-gaap_AssetsCurrent_d837e16b-f0ad-4bde-bed4-542ccfc4a258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7a3520a2-ee60-4716-b37a-430989f1b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7a3520a2-ee60-4716-b37a-430989f1b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_76934102-8b0c-4f11-bf75-dffbb3eb0487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_76934102-8b0c-4f11-bf75-dffbb3eb0487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_372e0e87-524d-4ef0-8ff6-927fdcd8000b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_372e0e87-524d-4ef0-8ff6-927fdcd8000b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83714ec4-79d3-4d0d-acfc-b138bf3d88d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_Goodwill_83714ec4-79d3-4d0d-acfc-b138bf3d88d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9c19562e-92bb-4f1c-9182-dcd6fbf987c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9c19562e-92bb-4f1c-9182-dcd6fbf987c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_17466cdf-ef01-49ea-9da7-fa5498e5f742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_995a53ba-f94b-4c7a-8f47-92353388d9aa" xlink:to="loc_us-gaap_Assets_17466cdf-ef01-49ea-9da7-fa5498e5f742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72dc0adf-9741-4a2d-b035-589ff320a95a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_476679f8-6840-40ae-a263-3df7e33822ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:to="loc_us-gaap_AccountsPayableCurrent_476679f8-6840-40ae-a263-3df7e33822ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_673f07a2-7b63-4cdf-9d38-cc76d9a07dc7" xlink:href="gild-20220331.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_673f07a2-7b63-4cdf-9d38-cc76d9a07dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_76f24327-2c14-4776-938c-89b9cf66cf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_76f24327-2c14-4776-938c-89b9cf66cf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_215ee747-eae0-4db7-b4d8-07d435b75eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:to="loc_us-gaap_DebtCurrent_215ee747-eae0-4db7-b4d8-07d435b75eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c59b1a4c-7339-4d16-8cc5-c4337ef4a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2805ac90-5987-409a-b7a1-740cc06e38d4" xlink:to="loc_us-gaap_LiabilitiesCurrent_c59b1a4c-7339-4d16-8cc5-c4337ef4a7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7bf98070-5141-400b-b220-1b12648789f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7bf98070-5141-400b-b220-1b12648789f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e3148710-da99-46ad-91f5-fc696b3fee42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e3148710-da99-46ad-91f5-fc696b3fee42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e082fc43-9b75-4dec-a127-51b355922f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e082fc43-9b75-4dec-a127-51b355922f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6eff913e-536b-47d7-be69-57dfcf735b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6eff913e-536b-47d7-be69-57dfcf735b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6e05bac8-9c3f-4ee5-b9ae-ee6eec962e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6e05bac8-9c3f-4ee5-b9ae-ee6eec962e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ccb76b6e-484c-4926-b96d-3467353b95cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_PreferredStockValue_ccb76b6e-484c-4926-b96d-3467353b95cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7bfc1d4c-b054-4b84-9a40-97f199f2ffeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_CommonStockValue_7bfc1d4c-b054-4b84-9a40-97f199f2ffeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d08c5f8a-f22a-496c-b2b9-4e968d5c30c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d08c5f8a-f22a-496c-b2b9-4e968d5c30c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5bf65a49-5264-4292-a0ad-7bee778852ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5bf65a49-5264-4292-a0ad-7bee778852ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_05e2592a-568f-4afc-ac90-118b80fb77ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_05e2592a-568f-4afc-ac90-118b80fb77ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5194967c-56fa-4e4e-bd91-73350a1316e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_StockholdersEquity_5194967c-56fa-4e4e-bd91-73350a1316e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_94a279e7-5b4c-4f8b-9982-636afbe8a60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_MinorityInterest_94a279e7-5b4c-4f8b-9982-636afbe8a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25508e1c-4478-4a68-b251-6127fa1e659b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d77148f2-16b3-4704-9e41-9a333fe0f1cd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25508e1c-4478-4a68-b251-6127fa1e659b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_acd688c5-b763-45bf-8fe3-66d22a53671c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70279ba-982e-4dd5-89cc-38a482297c19" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_acd688c5-b763-45bf-8fe3-66d22a53671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4c02bbe7-f318-420c-beea-c01087e48e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61b10e53-7a5b-4c42-bf7d-8b8fd4c89196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c02bbe7-f318-420c-beea-c01087e48e5d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61b10e53-7a5b-4c42-bf7d-8b8fd4c89196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61b10e53-7a5b-4c42-bf7d-8b8fd4c89196" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5ef6eb22-9d9e-458b-9824-00608e587a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5ef6eb22-9d9e-458b-9824-00608e587a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fd18da47-8cb0-48f8-8318-67f780e9a6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fd18da47-8cb0-48f8-8318-67f780e9a6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_33a5fd92-0f39-4f8e-a1ca-cdc8d865233c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_33a5fd92-0f39-4f8e-a1ca-cdc8d865233c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dfc8d630-b531-4946-83ee-b7c7fb535b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dfc8d630-b531-4946-83ee-b7c7fb535b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f5419f95-700d-4814-9838-376b9c10e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f5419f95-700d-4814-9838-376b9c10e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0ca675d1-b9d0-485c-88d6-f42c700d57df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_CommonStockSharesIssued_0ca675d1-b9d0-485c-88d6-f42c700d57df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4460b44d-b21d-4050-8c50-02d54b9f02fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54507a01-a662-4ef6-8df9-44e38797f73a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4460b44d-b21d-4050-8c50-02d54b9f02fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c69f0342-cb4b-4906-9907-bb5de34eea13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c69f0342-cb4b-4906-9907-bb5de34eea13" xlink:to="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:to="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cea544bd-327e-4c42-bf9c-c4cf709df7ca" xlink:to="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_21d7c9ef-8f71-4372-b757-f54c04f58f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:to="loc_us-gaap_ProductMember_21d7c9ef-8f71-4372-b757-f54c04f58f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_19982a08-589a-4ff3-b66e-ed1546ffb796" xlink:href="gild-20220331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f371360-5f41-4a20-bec7-2bad54dd4f86" xlink:to="loc_gild_RoyaltyContractAndOtherMember_19982a08-589a-4ff3-b66e-ed1546ffb796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cbb7d08-bd75-4daa-b9b8-4814d1fbc3f1" xlink:to="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_15b2ffa6-a17f-464e-9f65-8c8fc03cf6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_RevenuesAbstract_15b2ffa6-a17f-464e-9f65-8c8fc03cf6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09ece196-4958-41ae-9814-d951e4c6b971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_15b2ffa6-a17f-464e-9f65-8c8fc03cf6c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09ece196-4958-41ae-9814-d951e4c6b971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c50e9093-dfe5-4f4b-b586-7b129511b387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c50e9093-dfe5-4f4b-b586-7b129511b387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1e59ea30-6210-46bd-ba2d-6ba6de1c449e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1e59ea30-6210-46bd-ba2d-6ba6de1c449e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e1731d06-4493-4ab0-9a51-0cddc306f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e1731d06-4493-4ab0-9a51-0cddc306f97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c0283825-ae34-4cb4-bbeb-fdf01b3a4454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c0283825-ae34-4cb4-bbeb-fdf01b3a4454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b243f18-48e9-4690-9705-905f061956d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b243f18-48e9-4690-9705-905f061956d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9e021edf-8e61-4176-bf05-4cdce52d4ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_427a9870-4c60-4c16-8049-31a6dfe6873b" xlink:to="loc_us-gaap_CostsAndExpenses_9e021edf-8e61-4176-bf05-4cdce52d4ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_62907a37-7341-4064-b66e-69b77d604ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_OperatingIncomeLoss_62907a37-7341-4064-b66e-69b77d604ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c9068dd5-b632-4131-90d3-115564883d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_InterestExpense_c9068dd5-b632-4131-90d3-115564883d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e5555e02-13e8-460d-91b9-fc9000c02a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e5555e02-13e8-460d-91b9-fc9000c02a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_578ae0e5-473b-4549-ad9b-07c8b9e9aa55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_578ae0e5-473b-4549-ad9b-07c8b9e9aa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2666d998-4d43-4e2b-b047-4cad7236df4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2666d998-4d43-4e2b-b047-4cad7236df4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea29675f-11e6-446e-a45a-3ea6603a395d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_ProfitLoss_ea29675f-11e6-446e-a45a-3ea6603a395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d9f1c9e-510c-4393-87e6-00bd54e826a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d9f1c9e-510c-4393-87e6-00bd54e826a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e3d6114f-127e-4d18-bb51-950fe9cc45bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_NetIncomeLoss_e3d6114f-127e-4d18-bb51-950fe9cc45bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8f22c976-0273-44d1-a82e-19312d8c6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_EarningsPerShareBasic_8f22c976-0273-44d1-a82e-19312d8c6139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_159cab5a-db73-48d6-88e5-a488ceb89a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_159cab5a-db73-48d6-88e5-a488ceb89a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fc0f7c89-63a8-4ca8-8274-97b41d507f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fc0f7c89-63a8-4ca8-8274-97b41d507f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0c4bd6a2-0650-4ecd-af09-3875b1b358d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87a2c7d2-22c1-4b2e-8b34-09bb4797c14f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0c4bd6a2-0650-4ecd-af09-3875b1b358d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef662206-2688-4940-99a5-e1fd4d2359fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ccd510c5-c830-4d1d-93d8-d026f53efd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef662206-2688-4940-99a5-e1fd4d2359fc" xlink:to="loc_us-gaap_ProfitLoss_ccd510c5-c830-4d1d-93d8-d026f53efd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e74e4f4-59b2-416d-98d4-694ad7c51b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef662206-2688-4940-99a5-e1fd4d2359fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e74e4f4-59b2-416d-98d4-694ad7c51b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1eb920ac-6d29-46c3-a190-2496a2622181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e74e4f4-59b2-416d-98d4-694ad7c51b8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1eb920ac-6d29-46c3-a190-2496a2622181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_0abdb2f2-67e0-4876-bc0b-7c88e5aa696d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e74e4f4-59b2-416d-98d4-694ad7c51b8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_0abdb2f2-67e0-4876-bc0b-7c88e5aa696d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3f8813fd-2fd3-43e2-bcbd-7bb2bd8a46fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_0abdb2f2-67e0-4876-bc0b-7c88e5aa696d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3f8813fd-2fd3-43e2-bcbd-7bb2bd8a46fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1cca99eb-1ba3-4644-b0c3-76c77334ff79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_0abdb2f2-67e0-4876-bc0b-7c88e5aa696d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1cca99eb-1ba3-4644-b0c3-76c77334ff79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aac90b0e-0b31-4b0d-8cfa-5149fc109d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_0abdb2f2-67e0-4876-bc0b-7c88e5aa696d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aac90b0e-0b31-4b0d-8cfa-5149fc109d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_49df4c86-3565-4537-b710-b4cd336d8d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e74e4f4-59b2-416d-98d4-694ad7c51b8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_49df4c86-3565-4537-b710-b4cd336d8d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_aeb0ed49-45e9-4d35-8936-80483b124c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_49df4c86-3565-4537-b710-b4cd336d8d12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_aeb0ed49-45e9-4d35-8936-80483b124c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c8cad3e8-bcdc-4d2f-9374-2d970f684096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_49df4c86-3565-4537-b710-b4cd336d8d12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c8cad3e8-bcdc-4d2f-9374-2d970f684096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_7398249a-2c0c-48ad-a92a-30baf3c4dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_49df4c86-3565-4537-b710-b4cd336d8d12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_7398249a-2c0c-48ad-a92a-30baf3c4dd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_565d462e-8756-48c0-9106-9ea6b46913a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e74e4f4-59b2-416d-98d4-694ad7c51b8c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_565d462e-8756-48c0-9106-9ea6b46913a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5b2c5f6d-87be-49a9-a1c6-2d171373e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef662206-2688-4940-99a5-e1fd4d2359fc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5b2c5f6d-87be-49a9-a1c6-2d171373e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_35f667ee-10fc-4973-af4c-d19cabe0698a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef662206-2688-4940-99a5-e1fd4d2359fc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_35f667ee-10fc-4973-af4c-d19cabe0698a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e6f4387-6376-4b92-a4c6-c35c0a91ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef662206-2688-4940-99a5-e1fd4d2359fc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e6f4387-6376-4b92-a4c6-c35c0a91ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_69438d52-bdc3-4c5a-bd6f-ab5d92a94d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_69438d52-bdc3-4c5a-bd6f-ab5d92a94d32" xlink:to="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac99521d-ced6-46fa-a387-462a02ee0c9c" xlink:to="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6ed87b1-0321-4821-bec0-37019b1ba18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_CommonStockMember_d6ed87b1-0321-4821-bec0-37019b1ba18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_039ddf10-6ccf-4d51-8b6d-32b6db8ace99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_039ddf10-6ccf-4d51-8b6d-32b6db8ace99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0251d19-0544-4d67-86ea-51fff605e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0251d19-0544-4d67-86ea-51fff605e8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6f8dfa83-766c-4a68-bdba-ad50b31e7cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_RetainedEarningsMember_6f8dfa83-766c-4a68-bdba-ad50b31e7cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1013b491-4492-4b7b-95e3-669a3c84c91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94eeeecd-128e-4809-9537-7d0b17e3b0ca" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1013b491-4492-4b7b-95e3-669a3c84c91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_559ff6e0-244b-4c9f-8e9f-0a1ae15264ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f53a434-0ebd-4316-a4c0-8a22d6d2d465" xlink:to="loc_us-gaap_StatementLineItems_559ff6e0-244b-4c9f-8e9f-0a1ae15264ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_559ff6e0-244b-4c9f-8e9f-0a1ae15264ce" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26183cb1-f707-4442-85df-e150d7a2b9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26183cb1-f707-4442-85df-e150d7a2b9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3772c3e0-0bb4-4f48-a551-c7e51cadc739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3772c3e0-0bb4-4f48-a551-c7e51cadc739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f67e7a1c-1ead-4e25-8c34-f914014f2999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_ProfitLoss_f67e7a1c-1ead-4e25-8c34-f914014f2999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc1509a-fd8d-4903-b1b3-a99d1a148593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc1509a-fd8d-4903-b1b3-a99d1a148593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d0a9f09e-815a-4bf8-ac66-5ba206c5bbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d0a9f09e-815a-4bf8-ac66-5ba206c5bbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9209e4e2-e468-46dd-af0b-130832811b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9209e4e2-e468-46dd-af0b-130832811b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22d2cc2d-3055-49a9-a74c-4224fac65867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22d2cc2d-3055-49a9-a74c-4224fac65867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_63b89497-c663-4206-8b0d-765b6fe36ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_63b89497-c663-4206-8b0d-765b6fe36ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ce7abf-0893-4dc7-ad06-c59933a879b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ce7abf-0893-4dc7-ad06-c59933a879b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1abfc4d4-e137-4e00-afd3-e8d54e722e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1abfc4d4-e137-4e00-afd3-e8d54e722e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1bcb71a7-f1c1-4927-b5d7-409c431ca1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1bcb71a7-f1c1-4927-b5d7-409c431ca1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_0a132b9f-4241-4d18-9239-0a87d9ca8115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_Dividends_0a132b9f-4241-4d18-9239-0a87d9ca8115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4eb0d309-de88-4616-823a-3a77bd57cbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4eb0d309-de88-4616-823a-3a77bd57cbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34c4d26a-8344-420a-948e-6c501d52ff32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e732d1d-6456-4ad1-8d26-543f17dbe483" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34c4d26a-8344-420a-948e-6c501d52ff32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1cc083c5-d89a-4b90-b2b0-7b606acf7c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_3db0024c-497e-422e-9ab5-018a034fe89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1cc083c5-d89a-4b90-b2b0-7b606acf7c86" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_3db0024c-497e-422e-9ab5-018a034fe89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25d934d4-5e64-4a56-84f1-6a0f1aa83e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25d934d4-5e64-4a56-84f1-6a0f1aa83e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a305aab6-9a11-45d5-988a-1e86e5a2b7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25d934d4-5e64-4a56-84f1-6a0f1aa83e4c" xlink:to="loc_us-gaap_ProfitLoss_a305aab6-9a11-45d5-988a-1e86e5a2b7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25d934d4-5e64-4a56-84f1-6a0f1aa83e4c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e56ffbf7-de8a-48e4-a89b-46e5aa45d377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_Depreciation_e56ffbf7-de8a-48e4-a89b-46e5aa45d377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_5a2f26ef-ec0a-4f99-9000-ea32641c49e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_AdjustmentForAmortization_5a2f26ef-ec0a-4f99-9000-ea32641c49e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a938d45f-0d0f-4aa7-bc88-cff85488e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_ShareBasedCompensation_a938d45f-0d0f-4aa7-bc88-cff85488e3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ed2342af-4fae-4a6f-a4fe-db36e9cae66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ed2342af-4fae-4a6f-a4fe-db36e9cae66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4a94b564-4789-433b-8fb7-5f14d94a7ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4a94b564-4789-433b-8fb7-5f14d94a7ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8fdba290-07cd-46c3-9de4-c7d57b1818f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8fdba290-07cd-46c3-9de4-c7d57b1818f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_08b17b5c-6daa-4abe-b000-101bfb84f781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_08b17b5c-6daa-4abe-b000-101bfb84f781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e0fdc8af-416e-4326-9fd3-55f6b45fd3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9ebfed9b-82c4-4568-b75d-76ce15965081" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e0fdc8af-416e-4326-9fd3-55f6b45fd3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25d934d4-5e64-4a56-84f1-6a0f1aa83e4c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_af6a4d44-71fe-4ae9-8f94-87f709e44941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_af6a4d44-71fe-4ae9-8f94-87f709e44941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_79909699-5a11-4eda-8cf9-c79719c83803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_79909699-5a11-4eda-8cf9-c79719c83803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7bd3dfe3-cb24-41a1-8764-810e2a841a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7bd3dfe3-cb24-41a1-8764-810e2a841a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d9d80cfc-519f-428d-a7ac-c50635791627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d9d80cfc-519f-428d-a7ac-c50635791627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b6f677bd-0109-43e8-9e30-378beb7333d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b6f677bd-0109-43e8-9e30-378beb7333d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82ea83cb-90bb-4a69-8c09-ed76d8fab01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02242c33-7a60-47f9-9712-5469a836e703" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82ea83cb-90bb-4a69-8c09-ed76d8fab01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7975d546-ef4a-43ad-b7d5-b9d4430c5541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25d934d4-5e64-4a56-84f1-6a0f1aa83e4c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7975d546-ef4a-43ad-b7d5-b9d4430c5541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_87a687bd-8899-4546-9dd8-b207fcece5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_87a687bd-8899-4546-9dd8-b207fcece5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6d303278-b49d-496f-82d8-53a69aff0067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6d303278-b49d-496f-82d8-53a69aff0067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4203bfa0-903f-45f6-a9d4-c483a8df4e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4203bfa0-903f-45f6-a9d4-c483a8df4e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c0e6fffe-38a9-43ef-b3e2-04080d917f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c0e6fffe-38a9-43ef-b3e2-04080d917f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_74e39e9a-502c-4a2f-bc9c-63d660751930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_74e39e9a-502c-4a2f-bc9c-63d660751930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d283628d-de4a-4ed0-b7a5-4c8cee718374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d283628d-de4a-4ed0-b7a5-4c8cee718374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3982759e-652a-41bc-a3e7-50501c7d4f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3982759e-652a-41bc-a3e7-50501c7d4f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53e59ce9-8cd8-4d12-b5c9-0d859f8e8393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27840ded-fb71-4910-92cc-7c00644265fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53e59ce9-8cd8-4d12-b5c9-0d859f8e8393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_afdc6761-0a33-4ce1-bb5f-c790ec038112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_afdc6761-0a33-4ce1-bb5f-c790ec038112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_744e0137-e722-4c27-a4c3-95cd494c9552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_744e0137-e722-4c27-a4c3-95cd494c9552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_4c798069-b776-48d2-a045-94d44e36426a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:to="loc_us-gaap_RepaymentsOfDebt_4c798069-b776-48d2-a045-94d44e36426a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_7718c825-cba4-4fd6-be05-d9ade4fabc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:to="loc_us-gaap_PaymentsOfDividends_7718c825-cba4-4fd6-be05-d9ade4fabc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_32a03883-2e80-47aa-9ee2-a91e20ec64d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_32a03883-2e80-47aa-9ee2-a91e20ec64d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4b0b60a6-7841-48c6-ade9-01b9a51850cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_804d1f3e-f2db-4311-8b40-8b29cb2b91f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4b0b60a6-7841-48c6-ade9-01b9a51850cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1194e7df-ef33-4f08-a223-34674dbb98f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1194e7df-ef33-4f08-a223-34674dbb98f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b1c1e3f-778a-4857-9b5b-270862ac0a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b1c1e3f-778a-4857-9b5b-270862ac0a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e7048a8-460e-469a-8788-9c2f6b127ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e7048a8-460e-469a-8788-9c2f6b127ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a341d9c9-6a3c-4856-85ac-66eab8810443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cc3a96d4-4d76-4fd4-a243-ea88bf734e86" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a341d9c9-6a3c-4856-85ac-66eab8810443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="gild-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad03fb14-8d91-47b4-9b36-804931000003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6ecbf3b4-2db7-4e99-8183-bfb42da993fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad03fb14-8d91-47b4-9b36-804931000003" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6ecbf3b4-2db7-4e99-8183-bfb42da993fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="gild-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8337332e-0e9d-4787-9ec2-e227e7d1e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f2327807-4b8b-4d84-aabc-7db19b1c4216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8337332e-0e9d-4787-9ec2-e227e7d1e080" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f2327807-4b8b-4d84-aabc-7db19b1c4216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1b1ee76a-5901-4cf7-b204-fa1caf7a945a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8337332e-0e9d-4787-9ec2-e227e7d1e080" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1b1ee76a-5901-4cf7-b204-fa1caf7a945a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5ef127a6-bc69-4f04-8da8-c314f08a2820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8337332e-0e9d-4787-9ec2-e227e7d1e080" xlink:to="loc_us-gaap_UseOfEstimates_5ef127a6-bc69-4f04-8da8-c314f08a2820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c0e689fd-dc31-4a3d-b096-756aec39e228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8337332e-0e9d-4787-9ec2-e227e7d1e080" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c0e689fd-dc31-4a3d-b096-756aec39e228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_24cb6e81-0af4-48b9-813f-d18c699b309b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8337332e-0e9d-4787-9ec2-e227e7d1e080" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_24cb6e81-0af4-48b9-813f-d18c699b309b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d109f119-c259-445a-927e-072721ea3fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ab2af17e-27ab-40c4-b22a-665d9dc29d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d109f119-c259-445a-927e-072721ea3fa9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ab2af17e-27ab-40c4-b22a-665d9dc29d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUES" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6bebecdf-09d4-4624-9271-71f0e86b5dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1026fcaf-f6f5-4ca7-894b-a10306b0b3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6bebecdf-09d4-4624-9271-71f0e86b5dc2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1026fcaf-f6f5-4ca7-894b-a10306b0b3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESTables" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4a04b42b-5a24-4e0b-b105-d0a898899d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_704aefd6-7ba3-429b-b1ba-2bfdb567e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4a04b42b-5a24-4e0b-b105-d0a898899d0c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_704aefd6-7ba3-429b-b1ba-2bfdb567e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_35d89708-4d4f-409b-91b3-e078236ebbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4a04b42b-5a24-4e0b-b105-d0a898899d0c" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_35d89708-4d4f-409b-91b3-e078236ebbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_ff1d1647-fdd9-4e64-8ab3-4cd1d322d815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4a04b42b-5a24-4e0b-b105-d0a898899d0c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_ff1d1647-fdd9-4e64-8ab3-4cd1d322d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33d849f8-f21d-4e77-a70a-e4afb96a6b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33d849f8-f21d-4e77-a70a-e4afb96a6b7e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:to="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6d97c5f6-78ce-481a-979c-997b25f2f024" xlink:to="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:to="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:href="gild-20220331.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_74fe5b60-ac07-4b5d-ad46-cc5b28755ba4" xlink:href="gild-20220331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsBiktarvyMember_74fe5b60-ac07-4b5d-ad46-cc5b28755ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_80ad998b-a6cc-49b9-b222-82049873c2d2" xlink:href="gild-20220331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_80ad998b-a6cc-49b9-b222-82049873c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_cf097394-09a6-4116-b5ad-539556785800" xlink:href="gild-20220331.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsDescovyMember_cf097394-09a6-4116-b5ad-539556785800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_2c85fa89-b6e8-4770-bc4b-a47074036209" xlink:href="gild-20220331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsGenvoyaMember_2c85fa89-b6e8-4770-bc4b-a47074036209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_09c3ba3d-e29c-405f-bbfa-4bd688550248" xlink:href="gild-20220331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsOdefseyMember_09c3ba3d-e29c-405f-bbfa-4bd688550248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_d1644875-bb76-4e7c-81a1-73cec3d89632" xlink:href="gild-20220331.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsStribildMember_d1644875-bb76-4e7c-81a1-73cec3d89632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_d4f33018-2a3d-45e4-b1ef-9acf7bee680a" xlink:href="gild-20220331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_HIVProductsTruvadaMember_d4f33018-2a3d-45e4-b1ef-9acf7bee680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_922885e0-6712-4b62-9eef-ef430bdcf44f" xlink:href="gild-20220331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_922885e0-6712-4b62-9eef-ef430bdcf44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_ccd508c5-790c-4450-ad12-fd9f43c028ff" xlink:href="gild-20220331.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_c3bbf9ba-d76a-4d46-921a-f0cb9e8f1924" xlink:to="loc_gild_ProductsOtherHIVMember_ccd508c5-790c-4450-ad12-fd9f43c028ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_fbfaa985-16bf-412e-8dfb-c4232e9181d2" xlink:href="gild-20220331.xsd#gild_VekluryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_VekluryMember_fbfaa985-16bf-412e-8dfb-c4232e9181d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:href="gild-20220331.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_c0007bdb-85c1-46d8-9121-c62383ae26fa" xlink:href="gild-20220331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_c0007bdb-85c1-46d8-9121-c62383ae26fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_8eebdfd8-fca7-4f41-9dca-0b88cfe59db9" xlink:href="gild-20220331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_8eebdfd8-fca7-4f41-9dca-0b88cfe59db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_d0e889fd-136c-4b15-8851-7d643c190cc1" xlink:href="gild-20220331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_fcf096e7-622f-4e69-ba98-7cb9bf6d1e4b" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_d0e889fd-136c-4b15-8851-7d643c190cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_cd6946c2-15e9-4487-9b8e-8236dee9cf77" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_cd6946c2-15e9-4487-9b8e-8236dee9cf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_ab6cfa3e-f4be-4ecf-a867-f8bcbf595e19" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_ab6cfa3e-f4be-4ecf-a867-f8bcbf595e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_6471c11e-1474-4d8f-9683-a644263f1c10" xlink:href="gild-20220331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15128bd5-f818-4b85-82a5-4b077b4083b1" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_6471c11e-1474-4d8f-9683-a644263f1c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_c9ef1005-ccc0-43c4-8245-2d42921b44a6" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:to="loc_gild_CellTherapyProductsTecartusMember_c9ef1005-ccc0-43c4-8245-2d42921b44a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_3dc1059b-ad0e-45e0-8e2a-71e97abf4cc6" xlink:href="gild-20220331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_47bbb98e-59ba-4150-ab73-d8383f8867f1" xlink:to="loc_gild_CellTherapyProductsYescartaMember_3dc1059b-ad0e-45e0-8e2a-71e97abf4cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_2a7e5b55-1dc4-404c-aade-1a6de3d8dace" xlink:href="gild-20220331.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_TrodelvyMember_2a7e5b55-1dc4-404c-aade-1a6de3d8dace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:href="gild-20220331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dfc5ec8c-f1b1-4acd-8c36-59b67fb79103" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_0e26dc4a-6285-4883-a90e-5ccbb76c41fd" xlink:href="gild-20220331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:to="loc_gild_OtherProductsAmBisomeMember_0e26dc4a-6285-4883-a90e-5ccbb76c41fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_b21c5e05-c1f6-454c-a0bf-7f34a29bfd2d" xlink:href="gild-20220331.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:to="loc_gild_OtherProductsLetairisMember_b21c5e05-c1f6-454c-a0bf-7f34a29bfd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_ad89002a-3655-4845-99e4-1523ecca7626" xlink:href="gild-20220331.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_96741c0b-e3b0-404b-bf04-4647070ce623" xlink:to="loc_gild_OtherProductsOtherMember_ad89002a-3655-4845-99e4-1523ecca7626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_0703e22d-eeba-48a6-84ce-caf2eb66bc33" xlink:href="gild-20220331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_01fe5df6-9bbf-4ca0-ba56-9934758a8b95" xlink:to="loc_gild_RoyaltyContractAndOtherMember_0703e22d-eeba-48a6-84ce-caf2eb66bc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:to="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_552d4908-fc1b-4371-bcba-7e088fe20ad1" xlink:to="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7335d178-154a-4507-a7ec-a8cb8a0d5b32" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:to="loc_country_US_7335d178-154a-4507-a7ec-a8cb8a0d5b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_154c36bc-de16-4399-8e00-3a6c968c0066" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:to="loc_srt_EuropeMember_154c36bc-de16-4399-8e00-3a6c968c0066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_3ee0e1ea-02e3-42b2-b5e4-5a1180bac952" xlink:href="gild-20220331.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed8b16e0-549f-4237-b363-78dbb1c6c2a7" xlink:to="loc_gild_OtherInternationalMember_3ee0e1ea-02e3-42b2-b5e4-5a1180bac952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d9ec5a30-6417-4494-8e29-39fec4e4cef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b52a0f93-5ed1-4bd1-9499-2a636eac3544" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d9ec5a30-6417-4494-8e29-39fec4e4cef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69cab765-a1d9-46e5-a692-269a64d298db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d9ec5a30-6417-4494-8e29-39fec4e4cef4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69cab765-a1d9-46e5-a692-269a64d298db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2e327b7-29d1-45ee-bdbd-cd088e1bdb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2e327b7-29d1-45ee-bdbd-cd088e1bdb33" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a3ae051d-f072-4d40-bcbb-a9706f3816c9" xlink:to="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_20ffbbda-25ff-4d68-8cab-a4ce47174917" xlink:href="gild-20220331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:to="loc_gild_AmerisourcebergenCorpMember_20ffbbda-25ff-4d68-8cab-a4ce47174917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_0a85a38d-abc2-4e4c-aa95-d0f99251f42f" xlink:href="gild-20220331.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:to="loc_gild_CardinalHealthIncMember_0a85a38d-abc2-4e4c-aa95-d0f99251f42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_1f987184-34c6-4212-931b-bcd6bf086c26" xlink:href="gild-20220331.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_167facb2-a00d-41d7-a2cd-87f4e53961ba" xlink:to="loc_gild_MckessonCorpMember_1f987184-34c6-4212-931b-bcd6bf086c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d05f644b-fe14-4f86-b123-3fad791c06eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_774bb689-2717-4f3a-ba8e-3db45d5f7c82" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d05f644b-fe14-4f86-b123-3fad791c06eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8c45e417-cb2d-443e-b455-7d9957662146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d05f644b-fe14-4f86-b123-3fad791c06eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8c45e417-cb2d-443e-b455-7d9957662146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_75360779-cebb-4ab4-8fb4-ed6a1b2e0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be91065d-2b34-41e1-a76f-ecbe395639e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_75360779-cebb-4ab4-8fb4-ed6a1b2e0d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_aeac30a9-fd7c-48cc-8c39-2168f122ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_75360779-cebb-4ab4-8fb4-ed6a1b2e0d9b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_aeac30a9-fd7c-48cc-8c39-2168f122ac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7736414d-f875-4287-9487-9fa3bee8c198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b8c37372-46f3-42bb-8ea0-3398633fd9cd" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7736414d-f875-4287-9487-9fa3bee8c198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7fe28f3a-e719-42e9-a898-e257deeb3ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7736414d-f875-4287-9487-9fa3bee8c198" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7fe28f3a-e719-42e9-a898-e257deeb3ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESPerformanceObligationsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2241c4fa-903a-436a-811c-b568182f9c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_e3e1f223-e650-474e-b370-bd26a3b2242d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2241c4fa-903a-436a-811c-b568182f9c34" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_e3e1f223-e650-474e-b370-bd26a3b2242d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_5b154446-91f7-4dd1-9fd4-c176cd811146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2241c4fa-903a-436a-811c-b568182f9c34" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_5b154446-91f7-4dd1-9fd4-c176cd811146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#REVENUESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eede6988-e0f7-40fe-9125-ff08788ffd45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b1820d46-ec91-4b82-9eaf-cd737aaa1562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eede6988-e0f7-40fe-9125-ff08788ffd45" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b1820d46-ec91-4b82-9eaf-cd737aaa1562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4ba4b54f-c851-4239-8ddf-dc39dbb57707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eede6988-e0f7-40fe-9125-ff08788ffd45" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4ba4b54f-c851-4239-8ddf-dc39dbb57707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_08beb16c-a113-469a-966d-6b71e369ad05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1d4392a8-bc15-4d41-aee4-08606da582c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_08beb16c-a113-469a-966d-6b71e369ad05" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1d4392a8-bc15-4d41-aee4-08606da582c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a1a70a62-e65e-430b-8ac2-b8d947ab17e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6a4a271-1535-412f-be84-7910b2e6645c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a1a70a62-e65e-430b-8ac2-b8d947ab17e1" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6a4a271-1535-412f-be84-7910b2e6645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_397ad3e6-1f6c-4631-8847-a249e06e4366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a1a70a62-e65e-430b-8ac2-b8d947ab17e1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_397ad3e6-1f6c-4631-8847-a249e06e4366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1a5151f3-977f-42a6-b17b-4c65d2931c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1a5151f3-977f-42a6-b17b-4c65d2931c06" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2f3da84-2ae6-4b3a-bc7f-81c4499635e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dbce718b-8ca8-41a2-8138-9035dbbf544c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2f3da84-2ae6-4b3a-bc7f-81c4499635e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d87d8ea6-1cc7-46e1-9e97-457f504186d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2f3da84-2ae6-4b3a-bc7f-81c4499635e1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d87d8ea6-1cc7-46e1-9e97-457f504186d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c708792-7cdd-4d67-adcb-2f11134813ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_29a38356-fbd6-401b-b68c-6fe6eaa341b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_29a38356-fbd6-401b-b68c-6fe6eaa341b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2514703c-1141-4d8c-86cf-1b7f260bf942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2514703c-1141-4d8c-86cf-1b7f260bf942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bfc70290-a546-4463-9853-7a3128f57fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ab650db-3167-455b-b7bc-ae3c797dc460" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bfc70290-a546-4463-9853-7a3128f57fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_82c372e1-bc69-4332-9d24-2496933a58fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ba067a2e-78bf-4d20-bcae-4be07e4a9b9c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_82c372e1-bc69-4332-9d24-2496933a58fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_02fc3d5f-321e-4c04-ab13-1ed7a5e9631d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_82c372e1-bc69-4332-9d24-2496933a58fc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_02fc3d5f-321e-4c04-ab13-1ed7a5e9631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4869cbe9-08ca-42b7-a798-d3ffd2647251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_02fc3d5f-321e-4c04-ab13-1ed7a5e9631d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4869cbe9-08ca-42b7-a798-d3ffd2647251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_206e0181-2e7e-41d3-aaa3-fbae2d8259bc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_944c853a-85ba-4de0-9683-5702e507bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_944c853a-85ba-4de0-9683-5702e507bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a47b6981-82b6-425a-99e0-e76de0356593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a47b6981-82b6-425a-99e0-e76de0356593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b6f7736e-c1ed-433b-ac78-bad37a976cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b6f7736e-c1ed-433b-ac78-bad37a976cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_11efcc11-3367-4a03-aa92-beb6d4e53d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_CertificatesOfDepositMember_11efcc11-3367-4a03-aa92-beb6d4e53d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9a478012-d1a7-4ed0-9b29-564c0303307d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9a478012-d1a7-4ed0-9b29-564c0303307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_3c6d3f9f-ce12-4099-bf45-683adfac8b28" xlink:href="gild-20220331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_3c6d3f9f-ce12-4099-bf45-683adfac8b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bc615059-e181-4be7-bf1d-76a42a178514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bc615059-e181-4be7-bf1d-76a42a178514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_16298a3f-f0e6-4332-ab14-fd096b458d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_us-gaap_EquitySecuritiesMember_16298a3f-f0e6-4332-ab14-fd096b458d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_9519055e-52ea-49a8-a683-092bd3f57ef9" xlink:href="gild-20220331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_gild_DeferredCompensationPlanMember_9519055e-52ea-49a8-a683-092bd3f57ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_472d8fc2-c752-498e-83c2-5001386aa69d" xlink:href="gild-20220331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8193eec2-fb73-4173-819c-96028b61eec8" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_472d8fc2-c752-498e-83c2-5001386aa69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d253c105-db52-4253-bbbf-7414636289c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ded74ba4-750c-4f29-9682-c1dd59025a59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d253c105-db52-4253-bbbf-7414636289c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_f105ed12-5c43-42e2-90dc-36baba258e5b" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d253c105-db52-4253-bbbf-7414636289c2" xlink:to="loc_gild_MYRGmbHMember_f105ed12-5c43-42e2-90dc-36baba258e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9a6584af-a5ab-4df3-a10a-6f2ce9cf1a62" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_0e239d93-e515-4de3-893a-18b709d74c7b" xlink:href="gild-20220331.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:to="loc_gild_GalapagosMember_0e239d93-e515-4de3-893a-18b709d74c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_bfe531d2-ec55-416f-8e69-b1893ed3e14d" xlink:href="gild-20220331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ddb8145-9d7a-4210-8fdb-6a1e5cf7e643" xlink:to="loc_gild_ArcusBiosciencesIncMember_bfe531d2-ec55-416f-8e69-b1893ed3e14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fd19eccc-9dfd-4b90-b35e-40d98a292a82" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1e1028d5-aa15-4452-b39d-ff93fd497d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1e1028d5-aa15-4452-b39d-ff93fd497d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_04e9c69b-8877-4498-8d84-3292ff4eb1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_04e9c69b-8877-4498-8d84-3292ff4eb1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_4e9539ad-014d-43aa-99fb-b1b9b9489601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_4e9539ad-014d-43aa-99fb-b1b9b9489601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9780b36c-f82c-44c7-924e-11fff9e8faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_74099e09-f8d7-46d3-9373-0a3745755a1b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9780b36c-f82c-44c7-924e-11fff9e8faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b71a6176-538b-4474-8176-edbde245dfef" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b212f507-3644-47ec-b958-3ce5343815a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b212f507-3644-47ec-b958-3ce5343815a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_3eb09e76-f494-4aaf-b6bc-e41d244c65f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_3eb09e76-f494-4aaf-b6bc-e41d244c65f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_96ad9cff-5508-4df9-beca-ec0437d11221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_96ad9cff-5508-4df9-beca-ec0437d11221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_16888ec5-1249-49b4-bb39-8d41bccf8fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7dc22723-0000-4d70-914b-fa2dea15e110" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_16888ec5-1249-49b4-bb39-8d41bccf8fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb9f3503-4c56-4262-b223-bfef06798844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb9f3503-4c56-4262-b223-bfef06798844" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_acebe21a-c315-48fa-91de-7107cabbfeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5a649410-b1d8-4bdf-a8cb-3e6de4afc886" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_acebe21a-c315-48fa-91de-7107cabbfeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_acebe21a-c315-48fa-91de-7107cabbfeb0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_682cb43f-3afe-4b30-ae9a-c8c9f249b720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_682cb43f-3afe-4b30-ae9a-c8c9f249b720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6a0d74da-a7c1-4cc3-9138-af4a7b730d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d3a9bc18-64e4-439f-8e88-f310f25ab327" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6a0d74da-a7c1-4cc3-9138-af4a7b730d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9d606d2e-d9ee-4c2e-b355-e48ad48f838a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2448d760-4b71-4f40-85c3-288271f75733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2448d760-4b71-4f40-85c3-288271f75733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8678632d-6c62-4aa6-b300-9b1583b784e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d01fb0a7-4b7c-46b0-9756-dd704bd87aad" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8678632d-6c62-4aa6-b300-9b1583b784e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4e96a15-41cd-4838-85e6-c6348580a432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bbd55dd1-e58a-4c63-aa9a-12782bbebbde" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4e96a15-41cd-4838-85e6-c6348580a432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_2babe420-cf6b-4d3b-8645-cfadb0f969e5" xlink:href="gild-20220331.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4e96a15-41cd-4838-85e6-c6348580a432" xlink:to="loc_gild_ImmunomedicsIncMember_2babe420-cf6b-4d3b-8645-cfadb0f969e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_59401eb3-23df-4c9b-ae77-8ffe5de67796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd573a99-ee87-4712-aa64-a2c8ab516006" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_59401eb3-23df-4c9b-ae77-8ffe5de67796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0abd5492-ee4b-4b53-a2f7-801fcc358e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_59401eb3-23df-4c9b-ae77-8ffe5de67796" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_0abd5492-ee4b-4b53-a2f7-801fcc358e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c1411c4c-b10c-4aae-810e-b04ecd6f6781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cfb7542-3cd4-42cc-9837-85da6527be44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c1411c4c-b10c-4aae-810e-b04ecd6f6781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_120e7a49-73fb-4702-89a9-34847d4092de" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c1411c4c-b10c-4aae-810e-b04ecd6f6781" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_120e7a49-73fb-4702-89a9-34847d4092de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1af3d4b3-090c-4707-a3e7-352ca2d2820b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_a383e09c-e6fc-43c8-a85b-8597b83bb1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_LongTermDebtFairValue_a383e09c-e6fc-43c8-a85b-8597b83bb1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f560e268-7038-42b0-b6e9-509109ec03b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f560e268-7038-42b0-b6e9-509109ec03b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9e28b994-33d6-4e7c-bb8e-103fbcd0a2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9e28b994-33d6-4e7c-bb8e-103fbcd0a2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_60dd5e8b-d4a3-4bb1-9c36-2cb6382f80fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1bfbc88f-1e44-44cf-adc7-1a05d6ad8232" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_60dd5e8b-d4a3-4bb1-9c36-2cb6382f80fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aa222a18-cee9-4a32-a61a-ea31052bc623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aa222a18-cee9-4a32-a61a-ea31052bc623" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_443a3903-989a-4cfc-9c75-b6c5185444f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b878b634-2a11-4307-a2a6-d361ab0e4f06" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_443a3903-989a-4cfc-9c75-b6c5185444f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember_337a0094-0408-4772-81c4-c5e05acf965a" xlink:href="gild-20220331.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_443a3903-989a-4cfc-9c75-b6c5185444f0" xlink:to="loc_gild_ContingentConsiderationLiabilityMember_337a0094-0408-4772-81c4-c5e05acf965a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2eafe48d-2f73-476c-aaa6-a904b0a0e4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d80827ca-ac3b-4aa4-a243-0e14c5c77651" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2eafe48d-2f73-476c-aaa6-a904b0a0e4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_97d852a3-d4d6-4347-9d88-8a38ce2eb84d" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2eafe48d-2f73-476c-aaa6-a904b0a0e4a6" xlink:to="loc_gild_MYRGmbHMember_97d852a3-d4d6-4347-9d88-8a38ce2eb84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_589e66eb-dd59-4885-8f18-7b013202dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_56076195-9a3b-4ac3-8702-435536a4d9d4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_589e66eb-dd59-4885-8f18-7b013202dfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_589e66eb-dd59-4885-8f18-7b013202dfbc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_555dece3-7708-4f48-9300-b27f98182c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_555dece3-7708-4f48-9300-b27f98182c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_b66d0c80-821a-4447-a36c-5f75a16c1906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_b66d0c80-821a-4447-a36c-5f75a16c1906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_672bd02a-fa23-41d8-b1b2-c238d2142cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_672bd02a-fa23-41d8-b1b2-c238d2142cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_3c5e5cee-ffe6-487d-ad7f-db7fe73b0ed3" xlink:href="gild-20220331.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_3c5e5cee-ffe6-487d-ad7f-db7fe73b0ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23f41766-8384-4966-ba24-9e0fa1e586d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f48eb691-704a-466e-a74d-e7d0c273d77c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23f41766-8384-4966-ba24-9e0fa1e586d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c2d2dfb2-72a6-45da-a114-1c9598f7253b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7a05e94c-6a02-4cf5-bfbb-a79ebcc0cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c2d2dfb2-72a6-45da-a114-1c9598f7253b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7a05e94c-6a02-4cf5-bfbb-a79ebcc0cc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e4753f3c-68a6-4de0-8b70-11198509c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6a9671cd-859a-48c6-ab86-0caa87a0906b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e4753f3c-68a6-4de0-8b70-11198509c8ca" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6a9671cd-859a-48c6-ab86-0caa87a0906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5748080d-8689-42e4-8b4f-9272c4622342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e4753f3c-68a6-4de0-8b70-11198509c8ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5748080d-8689-42e4-8b4f-9272c4622342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_469e8f1a-5686-4899-883b-58a1e7dbb209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e4753f3c-68a6-4de0-8b70-11198509c8ca" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_469e8f1a-5686-4899-883b-58a1e7dbb209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_6fc44d85-5adc-4988-a991-35a838bdf2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e4753f3c-68a6-4de0-8b70-11198509c8ca" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_6fc44d85-5adc-4988-a991-35a838bdf2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec15cf6d-c7f3-4867-9982-0f5bca7ee1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec15cf6d-c7f3-4867-9982-0f5bca7ee1ea" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2b8f3667-275d-4d15-90b5-cb4491fe9809" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a435cdc6-a3bb-4e07-864e-de9b69438437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a435cdc6-a3bb-4e07-864e-de9b69438437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3b017125-6d5d-4fef-8321-b743b5e37b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3b017125-6d5d-4fef-8321-b743b5e37b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_abd0400f-ee47-42b8-8a66-087724be9560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_abd0400f-ee47-42b8-8a66-087724be9560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6de5d20f-2cac-45e8-85fa-fa2766ad4ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6de5d20f-2cac-45e8-85fa-fa2766ad4ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_aef4fc7b-ed52-4cfb-98c5-75eee5a3efb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_aef4fc7b-ed52-4cfb-98c5-75eee5a3efb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_c6bdf37d-e73d-4c34-9659-e923ee20283e" xlink:href="gild-20220331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9bbffd80-3db4-4998-9209-c3b3ad8759bc" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_c6bdf37d-e73d-4c34-9659-e923ee20283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b40665fc-e9f5-4441-ac04-f747f10838d3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cd160244-8479-4541-9d71-a1e1f23acc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cd160244-8479-4541-9d71-a1e1f23acc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11d1921b-023e-4ad9-b32c-90a27e8f2982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11d1921b-023e-4ad9-b32c-90a27e8f2982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d866fdb-742a-4c97-94b3-beb6304dd9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d866fdb-742a-4c97-94b3-beb6304dd9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19900932-4761-4a28-bbf2-7aa71f72df78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6a8b9f6d-3b33-4c26-911e-db9d4ad64047" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19900932-4761-4a28-bbf2-7aa71f72df78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a417e7c-2b5f-4ee9-a7d1-b9ab8689f5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a417e7c-2b5f-4ee9-a7d1-b9ab8689f5b4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1457c73b-79ed-4a31-93f7-9b662e2b995a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_90e9c415-eea0-4240-8cfb-324139c18562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_90e9c415-eea0-4240-8cfb-324139c18562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_4f44c79d-14e8-422e-a161-af58951e9b11" xlink:href="gild-20220331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_4f44c79d-14e8-422e-a161-af58951e9b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_10b315bc-f148-41bc-8c36-95b99c5cf93e" xlink:href="gild-20220331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1cc612bf-45d8-4fdc-987c-555aa44ecedf" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_10b315bc-f148-41bc-8c36-95b99c5cf93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7595ae31-1b95-454c-841f-4944086f9640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_258481dd-249f-40dc-b30b-8cb160354de9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7595ae31-1b95-454c-841f-4944086f9640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e524c67e-ae57-408f-b387-a7973195b8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7595ae31-1b95-454c-841f-4944086f9640" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e524c67e-ae57-408f-b387-a7973195b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a8d91660-c22b-4aca-9605-bdf8cfcd2b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55f9c2f1-6c20-418b-bb6d-7e542ae2d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a8d91660-c22b-4aca-9605-bdf8cfcd2b7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55f9c2f1-6c20-418b-bb6d-7e542ae2d5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0b44167d-9a59-44fa-919d-846f15fa2dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55f9c2f1-6c20-418b-bb6d-7e542ae2d5d4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0b44167d-9a59-44fa-919d-846f15fa2dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7c53558a-0098-48eb-b392-2b95d375bf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55f9c2f1-6c20-418b-bb6d-7e542ae2d5d4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7c53558a-0098-48eb-b392-2b95d375bf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_3fdf81f6-e93c-4c80-a4d9-461990b594bf" xlink:href="gild-20220331.xsd#gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55f9c2f1-6c20-418b-bb6d-7e542ae2d5d4" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_3fdf81f6-e93c-4c80-a4d9-461990b594bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_87af08fc-16bb-4db7-b6cc-450a79789458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55f9c2f1-6c20-418b-bb6d-7e542ae2d5d4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_87af08fc-16bb-4db7-b6cc-450a79789458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f00dd4c-7262-4aea-ab5f-1da71da47a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a8d91660-c22b-4aca-9605-bdf8cfcd2b7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f00dd4c-7262-4aea-ab5f-1da71da47a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a966fd44-b9d1-4981-a25e-484e0a14d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f00dd4c-7262-4aea-ab5f-1da71da47a44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a966fd44-b9d1-4981-a25e-484e0a14d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1053aec2-5432-40eb-8505-869d9dd7950d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f00dd4c-7262-4aea-ab5f-1da71da47a44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1053aec2-5432-40eb-8505-869d9dd7950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_0b36f5a6-bcca-49ed-a73a-04bb3b55dc36" xlink:href="gild-20220331.xsd#gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f00dd4c-7262-4aea-ab5f-1da71da47a44" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_0b36f5a6-bcca-49ed-a73a-04bb3b55dc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_25f242bf-f430-4b5b-9153-f8185bfdc550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f00dd4c-7262-4aea-ab5f-1da71da47a44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_25f242bf-f430-4b5b-9153-f8185bfdc550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43990c7c-8a6d-40dc-8e31-639f775bbed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_fde98bbe-979d-4e68-9775-d2a59f5c0e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43990c7c-8a6d-40dc-8e31-639f775bbed2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_fde98bbe-979d-4e68-9775-d2a59f5c0e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_7dcf635a-d89a-42fd-939d-000fd4fa33ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43990c7c-8a6d-40dc-8e31-639f775bbed2" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_7dcf635a-d89a-42fd-939d-000fd4fa33ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_d0aa70e9-ba49-4b24-975b-934c5280973c" xlink:href="gild-20220331.xsd#gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43990c7c-8a6d-40dc-8e31-639f775bbed2" xlink:to="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_d0aa70e9-ba49-4b24-975b-934c5280973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1a2bc6b3-efc4-4686-b481-78c0215b7535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43990c7c-8a6d-40dc-8e31-639f775bbed2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_1a2bc6b3-efc4-4686-b481-78c0215b7535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_48d3bf88-04f3-4616-9f92-fd5ec9e9fabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_48d3bf88-04f3-4616-9f92-fd5ec9e9fabb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb31bb6-4bdc-4e5e-9fda-d359548429f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a547607e-00ac-4f08-8d4d-454ba6018a66" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb31bb6-4bdc-4e5e-9fda-d359548429f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4700eb4d-68e7-4e6e-a7eb-d91308d84849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb31bb6-4bdc-4e5e-9fda-d359548429f6" xlink:to="loc_us-gaap_EquitySecuritiesMember_4700eb4d-68e7-4e6e-a7eb-d91308d84849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9f1fe2fa-3671-432b-98af-723ab0195e39" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_3752733b-06e7-420d-b4f6-a537e709ba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_3752733b-06e7-420d-b4f6-a537e709ba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d6bb8240-a86b-4c4f-b046-4b3c23a4d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d6bb8240-a86b-4c4f-b046-4b3c23a4d6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e48dc407-770d-4247-b744-03024204b033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75730331-b64e-45df-8a34-a1768afa9520" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e48dc407-770d-4247-b744-03024204b033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ade2b8cb-cc4b-4397-9e3a-4de64fbea821" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f4fb2bb5-6d12-4282-b336-658d7c796ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f4fb2bb5-6d12-4282-b336-658d7c796ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e9b55c93-5653-4ea2-962c-37c62a209e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7551cf0b-e7db-491a-8ef7-4ad776272b8f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e9b55c93-5653-4ea2-962c-37c62a209e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bf994b1d-c40f-4bb0-91ec-9d070376e990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a6e48ee1-48c6-433e-a1a4-bfb8437fc786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bf994b1d-c40f-4bb0-91ec-9d070376e990" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a6e48ee1-48c6-433e-a1a4-bfb8437fc786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c9b284c-a341-400c-aa92-c88b1d1ba4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_68cbc7a4-17c4-4387-97f7-f69b53f97443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c9b284c-a341-400c-aa92-c88b1d1ba4ce" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_68cbc7a4-17c4-4387-97f7-f69b53f97443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2612c628-2d04-4a7c-96ac-b26aeb1a1b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c9b284c-a341-400c-aa92-c88b1d1ba4ce" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2612c628-2d04-4a7c-96ac-b26aeb1a1b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_fe849cea-d177-4536-9c58-7dbb11cce30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c9b284c-a341-400c-aa92-c88b1d1ba4ce" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_fe849cea-d177-4536-9c58-7dbb11cce30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_88d87b95-2e4e-40d2-b0d7-43d43015564b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_88d87b95-2e4e-40d2-b0d7-43d43015564b" xlink:to="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:to="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d10c5eb9-7714-48d9-bba5-2efc4b13a4f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_705f4a0c-d9d4-454a-af21-10e57ffafb0f" xlink:to="loc_srt_RangeMember_d10c5eb9-7714-48d9-bba5-2efc4b13a4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_53a9bf09-ae1a-4e64-b3be-e001789f7b44" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d10c5eb9-7714-48d9-bba5-2efc4b13a4f8" xlink:to="loc_srt_MaximumMember_53a9bf09-ae1a-4e64-b3be-e001789f7b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ac5d25e5-29fd-458e-82b8-c7b6e3a60c6b" xlink:to="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_046d5be9-b6ac-4029-a85c-e442abec9de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_046d5be9-b6ac-4029-a85c-e442abec9de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_b4181383-83a4-4597-973f-e08742715939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_b4181383-83a4-4597-973f-e08742715939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_184e9db7-bd2f-4b12-ae90-f27d1b6a89f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_184e9db7-bd2f-4b12-ae90-f27d1b6a89f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_75b5ec28-8240-408d-a6c3-c67e6c198528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_88e2e9df-61d0-4bcb-9e5b-4becbc718bd3" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_75b5ec28-8240-408d-a6c3-c67e6c198528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f286b8eb-1d10-4ea6-8ad2-270a9693996c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f286b8eb-1d10-4ea6-8ad2-270a9693996c" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:to="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_668a46f8-e163-4c48-8c72-6d37ac9c8436" xlink:to="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_55f7689a-b521-4749-8a17-5447953f7929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_55f7689a-b521-4749-8a17-5447953f7929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5da02133-31e3-476a-bb25-b14e02b535b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_aacdbe57-077b-4347-9310-16e6c5c7fd00" xlink:to="loc_us-gaap_NondesignatedMember_5da02133-31e3-476a-bb25-b14e02b535b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e46de9f3-e6cf-4cac-a8a4-e72dbb5a46f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_90436826-ca4b-47c7-acf4-c0d2dfc51765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_90436826-ca4b-47c7-acf4-c0d2dfc51765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_a1411d41-4399-4ca9-a6a8-ecc12a2f7833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_a1411d41-4399-4ca9-a6a8-ecc12a2f7833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_b37ef6ff-4f9d-49d0-a0e6-acbd9bc848db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_b37ef6ff-4f9d-49d0-a0e6-acbd9bc848db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_88cca201-ce75-4034-b8f6-fdcb96dad890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_56a7ff51-31d0-4070-a78c-36e7b3a8042a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_88cca201-ce75-4034-b8f6-fdcb96dad890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5e1091fe-ce3d-497f-bddc-a2e77541824a" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_e5ccc546-c838-4e3a-b433-995d18ef3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_e5ccc546-c838-4e3a-b433-995d18ef3da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2bddb3b0-f6a7-40fb-82fb-aa370a4859e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6d8c333e-41ce-49f2-9268-20521e88ba12" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_2bddb3b0-f6a7-40fb-82fb-aa370a4859e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c1ca410-fb71-49fe-a200-45de229e3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_496e25a3-fc14-4f08-a253-e4fc12c62b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c1ca410-fb71-49fe-a200-45de229e3dce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_496e25a3-fc14-4f08-a253-e4fc12c62b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_2e2b7fe1-bd04-4115-b24d-cc85721ca7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c1ca410-fb71-49fe-a200-45de229e3dce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_2e2b7fe1-bd04-4115-b24d-cc85721ca7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c09b5d0b-d1fe-45f2-a10b-b8cf98d07b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c1ca410-fb71-49fe-a200-45de229e3dce" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c09b5d0b-d1fe-45f2-a10b-b8cf98d07b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8eff6874-d09c-47ed-98f9-37fc32aabffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_ddb0f9bb-68b2-4003-af2c-97c297d5a3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8eff6874-d09c-47ed-98f9-37fc32aabffa" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_ddb0f9bb-68b2-4003-af2c-97c297d5a3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2e222dff-9e98-4274-9879-fdc088a04958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_ddb0f9bb-68b2-4003-af2c-97c297d5a3ae" xlink:to="loc_us-gaap_DerivativeAssets_2e222dff-9e98-4274-9879-fdc088a04958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_1d33f0fe-f1af-4655-8451-62c106ef7db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_ddb0f9bb-68b2-4003-af2c-97c297d5a3ae" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_1d33f0fe-f1af-4655-8451-62c106ef7db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_9b0bef11-00a7-4f89-94e9-e3b900d4aa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_ddb0f9bb-68b2-4003-af2c-97c297d5a3ae" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_9b0bef11-00a7-4f89-94e9-e3b900d4aa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_42f41c74-5f86-45d5-b849-3a177778288a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_ddb0f9bb-68b2-4003-af2c-97c297d5a3ae" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_42f41c74-5f86-45d5-b849-3a177778288a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_b377164b-3c0d-416a-b116-5dc94669c741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8eff6874-d09c-47ed-98f9-37fc32aabffa" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_b377164b-3c0d-416a-b116-5dc94669c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d5aaf84e-6b5a-4670-b411-1a5d267b65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b377164b-3c0d-416a-b116-5dc94669c741" xlink:to="loc_us-gaap_DerivativeLiabilities_d5aaf84e-6b5a-4670-b411-1a5d267b65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_0bcc32d6-acac-4f99-9b24-666f72c4e8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b377164b-3c0d-416a-b116-5dc94669c741" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_0bcc32d6-acac-4f99-9b24-666f72c4e8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_a20c1fdf-2b7b-4403-a258-45b9f0af00c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b377164b-3c0d-416a-b116-5dc94669c741" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_a20c1fdf-2b7b-4403-a258-45b9f0af00c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_307e68dd-6674-4a78-a87d-24b419359a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b377164b-3c0d-416a-b116-5dc94669c741" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_307e68dd-6674-4a78-a87d-24b419359a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="simple" xlink:href="gild-20220331.xsd#ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d5e00ebe-bb39-45be-ab4e-abde87ba4de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1489cf40-7da6-4a93-89b2-738c5aa4f7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d5e00ebe-bb39-45be-ab4e-abde87ba4de3" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1489cf40-7da6-4a93-89b2-738c5aa4f7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e34276b8-6fdc-4d00-8175-898297a93b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e34276b8-6fdc-4d00-8175-898297a93b14" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e67ad25-7f1e-4322-9388-32e5bd89e3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e6cb7d8-3c6f-41a3-a6d0-a03733bae0a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e67ad25-7f1e-4322-9388-32e5bd89e3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_cd9c9a29-41b2-42da-9754-3c75d15188d2" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e67ad25-7f1e-4322-9388-32e5bd89e3ac" xlink:to="loc_gild_MYRGmbHMember_cd9c9a29-41b2-42da-9754-3c75d15188d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e24ec10c-5c25-4bc1-9c4e-76ed9882792a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f9af9d6f-b77b-4fae-a718-7a85e73f0c8d" xlink:to="loc_srt_RangeMember_e24ec10c-5c25-4bc1-9c4e-76ed9882792a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1ac4627-cfbb-48cc-974b-936d607e7331" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e24ec10c-5c25-4bc1-9c4e-76ed9882792a" xlink:to="loc_srt_MaximumMember_c1ac4627-cfbb-48cc-974b-936d607e7331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_098cf943-ee01-40e2-96c6-45bfa28ae375" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36c711d2-7d02-4464-9ca3-55232f4f0f56" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_098cf943-ee01-40e2-96c6-45bfa28ae375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_cd00bbfc-b491-4568-874c-24d7d833ee77" xlink:href="gild-20220331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_098cf943-ee01-40e2-96c6-45bfa28ae375" xlink:to="loc_gild_ArcusBiosciencesIncMember_cd00bbfc-b491-4568-874c-24d7d833ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c1a35ec-1f05-4bfc-8fd9-40003a19d069" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2798d451-fc84-4ad9-8967-070eb921d797" xlink:href="gild-20220331.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2798d451-fc84-4ad9-8967-070eb921d797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_ca3ddb2e-37a3-4b61-bbed-86b175828e28" xlink:href="gild-20220331.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d95bd14-fe34-446f-90b3-3d4484dc0b5e" xlink:to="loc_gild_ArcusCollaborationAgreementMember_ca3ddb2e-37a3-4b61-bbed-86b175828e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7565fe8c-2901-40d3-bebb-aa86ff460903" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_729b07ec-82af-428b-a5be-616a666cb0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_729b07ec-82af-428b-a5be-616a666cb0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ca2a6418-d034-4d62-9f14-9f8113d8099b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ca2a6418-d034-4d62-9f14-9f8113d8099b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95915281-67b1-4fd6-8993-95f2da25535f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95915281-67b1-4fd6-8993-95f2da25535f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_dc4efbc8-c101-49b8-bbc1-9cc543417792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_dc4efbc8-c101-49b8-bbc1-9cc543417792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4ec164e5-9154-4795-a9e2-a1a3004c90b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4ec164e5-9154-4795-a9e2-a1a3004c90b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm_ffa44913-c292-4695-9e75-036bf2241a1d" xlink:href="gild-20220331.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_CollaborativeAgreementOptInTerm_ffa44913-c292-4695-9e75-036bf2241a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_c25cc254-bb00-4708-90bd-d6030c6ffa4b" xlink:href="gild-20220331.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_c25cc254-bb00-4708-90bd-d6030c6ffa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement_8eaa06fa-099e-416f-9bf5-693d57d6ec66" xlink:href="gild-20220331.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_PaymentsToOptInTheCollaborativeAgreement_8eaa06fa-099e-416f-9bf5-693d57d6ec66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_a134e0d7-9ea6-4a88-9709-2d21e1f3f953" xlink:href="gild-20220331.xsd#gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_8bb850a6-1275-4033-91c0-6f49fbd5e718" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived_a134e0d7-9ea6-4a88-9709-2d21e1f3f953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d04e19a-13cb-47dd-91f3-909b04bc92c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f8e18a1b-89bd-40da-86d8-9340f9e16b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d04e19a-13cb-47dd-91f3-909b04bc92c5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f8e18a1b-89bd-40da-86d8-9340f9e16b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b5273c2e-3532-416b-9bbc-641ac44fdb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_7666eed7-1612-4e94-b346-07c3af546c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b5273c2e-3532-416b-9bbc-641ac44fdb53" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_7666eed7-1612-4e94-b346-07c3af546c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_076f6d0c-7caa-42d1-9a5e-ea965f957723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b5273c2e-3532-416b-9bbc-641ac44fdb53" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_076f6d0c-7caa-42d1-9a5e-ea965f957723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_5ab29bda-74ab-429e-a0d7-fc6073d3b4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b5273c2e-3532-416b-9bbc-641ac44fdb53" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_5ab29bda-74ab-429e-a0d7-fc6073d3b4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_973dd3bc-d29c-4b8b-a7bb-6cd74ffa613c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b5273c2e-3532-416b-9bbc-641ac44fdb53" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_973dd3bc-d29c-4b8b-a7bb-6cd74ffa613c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ff5329c-40e7-4f08-8982-d4c9466b0dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ff5329c-40e7-4f08-8982-d4c9466b0dd2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60975de7-13e7-4fbc-82d5-c4cd5575c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8b39e582-d5aa-44f4-846d-190259877c9b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60975de7-13e7-4fbc-82d5-c4cd5575c0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_4dc3d0a8-5262-4819-8237-8f6d93dce071" xlink:href="gild-20220331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60975de7-13e7-4fbc-82d5-c4cd5575c0a5" xlink:to="loc_gild_MYRGmbHMember_4dc3d0a8-5262-4819-8237-8f6d93dce071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_21229c9d-5bf1-4325-b68b-b8775b7ae496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a6cfc3b1-326d-415e-9805-22e5ac939fe1" xlink:to="loc_us-gaap_GoodwillLineItems_21229c9d-5bf1-4325-b68b-b8775b7ae496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_21229c9d-5bf1-4325-b68b-b8775b7ae496" xlink:to="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_93d2139e-2229-45ab-b3eb-95678d99403b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:to="loc_us-gaap_Goodwill_93d2139e-2229-45ab-b3eb-95678d99403b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4fcc020c-1416-47eb-b9dc-edd79cec301a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_4fcc020c-1416-47eb-b9dc-edd79cec301a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e62ca7e-6d82-4bd7-ae35-7728f589938f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c6885998-fa62-4740-b0ed-1822e61f5122" xlink:to="loc_us-gaap_Goodwill_9e62ca7e-6d82-4bd7-ae35-7728f589938f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_005460a6-793a-4bd2-a200-cbcdd84396db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_005460a6-793a-4bd2-a200-cbcdd84396db" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb94fc4b-9fb8-4b0e-93ad-68200eb1f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_118e13a5-c401-45b5-bfeb-2a6a159f852e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb94fc4b-9fb8-4b0e-93ad-68200eb1f6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_343c5c7e-aade-4829-9b15-efa4b0bbd22f" xlink:href="gild-20220331.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb94fc4b-9fb8-4b0e-93ad-68200eb1f6ee" xlink:to="loc_gild_ImmunomedicsIncMember_343c5c7e-aade-4829-9b15-efa4b0bbd22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c0780f3-b048-48a0-a227-954734cbe608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16cd4861-4316-48d4-a71d-422bfc3a1c4d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c0780f3-b048-48a0-a227-954734cbe608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_109e6524-a12f-4a6d-ab4e-e5bc08ff5051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c0780f3-b048-48a0-a227-954734cbe608" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_109e6524-a12f-4a6d-ab4e-e5bc08ff5051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63326342-f387-4f19-84c5-1d8f1bd53516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5944c3c7-1b8c-4831-96a5-ecab484c5cf3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63326342-f387-4f19-84c5-1d8f1bd53516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_f95d65c6-86f9-4adf-b099-ced6d7d0e559" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63326342-f387-4f19-84c5-1d8f1bd53516" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_f95d65c6-86f9-4adf-b099-ced6d7d0e559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_16f23b9d-7861-4386-b4d5-4f91e0a2e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_260a0aef-c158-42f3-acf2-a9507089fb38" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_16f23b9d-7861-4386-b4d5-4f91e0a2e4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3c473db1-b507-4819-89e4-99592d16e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_16f23b9d-7861-4386-b4d5-4f91e0a2e4c3" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3c473db1-b507-4819-89e4-99592d16e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6c746f43-6b18-4684-ab6b-c18e55151e99" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0567c97e-3f9c-4391-857b-bb8fede6379d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0567c97e-3f9c-4391-857b-bb8fede6379d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_148f6163-5a18-446a-813a-640fe00df4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_148f6163-5a18-446a-813a-640fe00df4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_507e67b3-7af4-4b34-8152-21b53bc09bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_507e67b3-7af4-4b34-8152-21b53bc09bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_c6f459b7-e07e-4d45-bca3-dfa25dca2fb2" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_c6f459b7-e07e-4d45-bca3-dfa25dca2fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8c59e833-f8bc-4f17-9c33-d0ec1396721d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0ad1f8ad-66b8-4541-9e0a-200bc71bae6a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8c59e833-f8bc-4f17-9c33-d0ec1396721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3233b100-c444-4471-98d4-989128fb519c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3233b100-c444-4471-98d4-989128fb519c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19c9c9f2-5898-4167-a5e8-8f81271c3abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_92a6d1f6-343e-4154-9a3d-d64c4f9cb92d" xlink:href="gild-20220331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_92a6d1f6-343e-4154-9a3d-d64c4f9cb92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_c210ce7b-d64b-4402-9316-362f06bb396a" xlink:href="gild-20220331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_c210ce7b-d64b-4402-9316-362f06bb396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_b915db14-bfc5-4ded-96b9-45bc7e653e24" xlink:href="gild-20220331.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_TrodelvyMember_b915db14-bfc5-4ded-96b9-45bc7e653e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_f1093087-be2a-484c-bac3-6c9f4535b0b8" xlink:href="gild-20220331.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_gild_HepcludexMember_f1093087-be2a-484c-bac3-6c9f4535b0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_dc2d7f46-e210-4802-8b5d-02078333e982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3dcc3f3-0c8a-4dd3-a414-ed3d4debee5b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_dc2d7f46-e210-4802-8b5d-02078333e982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8dae19d5-a298-4c9a-bd87-18d1b90d96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dcca80e8-1678-4bc7-aeec-ac5ffb8d4fd7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8dae19d5-a298-4c9a-bd87-18d1b90d96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_17800250-af3a-426b-8db1-cf731f15dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8dae19d5-a298-4c9a-bd87-18d1b90d96a3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_17800250-af3a-426b-8db1-cf731f15dcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f46b01de-f9fe-4ca8-845f-a138b07e784c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3fccecbc-2cfa-49f7-bdee-0d7f01fec6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3fccecbc-2cfa-49f7-bdee-0d7f01fec6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b83d90b7-e2b6-4c6d-a02d-c275b2150601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b83d90b7-e2b6-4c6d-a02d-c275b2150601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6c6d57e9-9eb8-4c9e-b964-201c4dcc62f4" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6c6d57e9-9eb8-4c9e-b964-201c4dcc62f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d2a7e4e9-f9a2-48b8-b01e-c0b06937b17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d2a7e4e9-f9a2-48b8-b01e-c0b06937b17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fba08305-a618-476c-bbe9-8b9b013e1e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fba08305-a618-476c-bbe9-8b9b013e1e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4cd503d9-1d8a-4144-8810-cb32d02f54f2" xlink:href="gild-20220331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4cd503d9-1d8a-4144-8810-cb32d02f54f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_19dbd2a1-ec61-4beb-8418-6df0a683866c" xlink:href="gild-20220331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_52d5c54c-c353-4051-a1d0-9f948be7d0d3" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_19dbd2a1-ec61-4beb-8418-6df0a683866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70ef60a3-5487-42a7-a7c9-55c6c7f05534" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6b443ceb-68e0-4940-8e9c-67c9a4c54098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6b443ceb-68e0-4940-8e9c-67c9a4c54098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4daac2e5-df39-4b94-8682-8d3ae7a2641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4daac2e5-df39-4b94-8682-8d3ae7a2641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_35eb268c-f696-4c76-a91a-5fb1b233e417" xlink:href="gild-20220331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_35eb268c-f696-4c76-a91a-5fb1b233e417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e229a85-35b3-43d8-ae59-b55b43eb2acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_49c59d96-421c-4d6f-9694-3b8af682d927" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e229a85-35b3-43d8-ae59-b55b43eb2acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6e91c2bd-3f5c-45cb-801e-c45699609200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6e91c2bd-3f5c-45cb-801e-c45699609200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_87a534b4-8110-4b78-9788-2810f24087c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_87a534b4-8110-4b78-9788-2810f24087c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0a9e480e-6471-4f6f-bb7f-3d1baa9b7d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0a9e480e-6471-4f6f-bb7f-3d1baa9b7d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0fb63e32-67b1-4c18-9497-7bc77e5de804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0fb63e32-67b1-4c18-9497-7bc77e5de804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_54116d84-21f1-4046-8630-8a8680978d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_54116d84-21f1-4046-8630-8a8680978d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e06effe8-e011-4bed-bae4-0c8833be3589" xlink:href="gild-20220331.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e06effe8-e011-4bed-bae4-0c8833be3589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0c43f678-3e34-4703-89c6-45efae891a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b05d56ae-888c-4a06-8886-5b13a386b34f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0c43f678-3e34-4703-89c6-45efae891a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_d5953f34-d006-4467-a9b4-1a8e36f74991" xlink:href="gild-20220331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_6e1d1563-c4f8-4993-a045-68e318660848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d5953f34-d006-4467-a9b4-1a8e36f74991" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_6e1d1563-c4f8-4993-a045-68e318660848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_920f0873-a421-4a27-b555-6e6001ff0229" xlink:href="gild-20220331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5acc6a86-becd-4c12-aead-2958f6844f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_920f0873-a421-4a27-b555-6e6001ff0229" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5acc6a86-becd-4c12-aead-2958f6844f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2ee435dd-29f2-444f-a786-24f13bbdde28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_920f0873-a421-4a27-b555-6e6001ff0229" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2ee435dd-29f2-444f-a786-24f13bbdde28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fd1c384c-86e0-4ae3-94d5-6ab9b93377b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_920f0873-a421-4a27-b555-6e6001ff0229" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fd1c384c-86e0-4ae3-94d5-6ab9b93377b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_4e19ba4d-03bf-490d-95ad-e45fc7390886" xlink:href="gild-20220331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_8af9c8d2-c357-474e-8f8c-f0c5405c7993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_4e19ba4d-03bf-490d-95ad-e45fc7390886" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_8af9c8d2-c357-474e-8f8c-f0c5405c7993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_ea8cbf1a-eed0-4c5e-bf85-99a5f467aa76" xlink:href="gild-20220331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_4e19ba4d-03bf-490d-95ad-e45fc7390886" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_ea8cbf1a-eed0-4c5e-bf85-99a5f467aa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_942eb52b-3b62-4ba9-8ba8-b9018cb3b2ab" xlink:href="gild-20220331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_4e19ba4d-03bf-490d-95ad-e45fc7390886" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_942eb52b-3b62-4ba9-8ba8-b9018cb3b2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e26db954-b73d-43a4-98ae-6741ff8a3a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_4e19ba4d-03bf-490d-95ad-e45fc7390886" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e26db954-b73d-43a4-98ae-6741ff8a3a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_052dda70-497e-4453-b735-98628e12ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_4e19ba4d-03bf-490d-95ad-e45fc7390886" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_052dda70-497e-4453-b735-98628e12ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:href="gild-20220331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_20d14ada-0cf7-4f7e-8bba-c306d433e005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_20d14ada-0cf7-4f7e-8bba-c306d433e005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_88ba0fd1-8980-4672-92ea-6530a10ec01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_88ba0fd1-8980-4672-92ea-6530a10ec01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_514e7e60-7e36-4977-aabe-21d80173ec23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_514e7e60-7e36-4977-aabe-21d80173ec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_a36a2631-30f9-43a1-865d-9081f33cd545" xlink:href="gild-20220331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:to="loc_gild_InventoryNetAndInventoryNoncurrent_a36a2631-30f9-43a1-865d-9081f33cd545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cdc24688-1ad5-45f9-9874-be2f7dce9f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:to="loc_us-gaap_InventoryNet_cdc24688-1ad5-45f9-9874-be2f7dce9f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_964a3d55-c166-4fb5-9d64-20de544af893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_64972f7e-f85a-470b-8c8f-7ca04c57a62b" xlink:to="loc_us-gaap_InventoryNoncurrent_964a3d55-c166-4fb5-9d64-20de544af893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_90b02e5f-505c-4f71-baad-9c4838cfdbbc" xlink:href="gild-20220331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:href="gild-20220331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6aa3ea36-afa3-4a20-8bce-9de17a3af820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6aa3ea36-afa3-4a20-8bce-9de17a3af820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f2a692ca-b500-4d23-8cee-5f211a5d350b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f2a692ca-b500-4d23-8cee-5f211a5d350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_0f8caa6a-edbc-424b-81a8-8822f3550f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_0f8caa6a-edbc-424b-81a8-8822f3550f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_d23e513d-0ef9-48c7-822c-4e2c745dd3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_d23e513d-0ef9-48c7-822c-4e2c745dd3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63d8782f-a99e-42fb-8e26-c133a4d107dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63d8782f-a99e-42fb-8e26-c133a4d107dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6ad6ec53-85b8-4bc1-a6b8-9e8ebedd5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_608cab46-e563-4e23-a7e2-64864e829ba2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6ad6ec53-85b8-4bc1-a6b8-9e8ebedd5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_61190e5f-b115-4b09-aba6-d1c6a737e0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_9bea7d80-46cb-4ccc-b969-a9ba6bb3518e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61190e5f-b115-4b09-aba6-d1c6a737e0db" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_9bea7d80-46cb-4ccc-b969-a9ba6bb3518e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_74012873-809f-466b-abed-7a2479dfe0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_f97aef5f-bb0a-4ac6-ad59-cf4e2286d00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74012873-809f-466b-abed-7a2479dfe0ed" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_f97aef5f-bb0a-4ac6-ad59-cf4e2286d00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e26a6b0b-9ec6-4fb0-bc8f-9cc155e7a524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e26a6b0b-9ec6-4fb0-bc8f-9cc155e7a524" xlink:to="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cf9ea175-7911-4050-b665-4647239f8b58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_3df92e83-724c-418c-863f-8f30434de8f9" xlink:href="gild-20220331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_3df92e83-724c-418c-863f-8f30434de8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f8b40654-b668-4e11-971a-43226423af9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_3df92e83-724c-418c-863f-8f30434de8f9" xlink:to="loc_us-gaap_SeniorNotesMember_f8b40654-b668-4e11-971a-43226423af9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_928a8d19-d14d-47dd-9e94-dd2889f74242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c6d36e2-8812-47f2-b03b-f2afe9de50a1" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_928a8d19-d14d-47dd-9e94-dd2889f74242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:to="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5303c42b-2e2e-4e96-9bee-734b39ec53c0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_48e27c05-1037-492f-bea9-d5090583d2f7" xlink:href="gild-20220331.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_48e27c05-1037-492f-bea9-d5090583d2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_0d1dd6b5-eb87-4dfb-9dc3-bff219f349d7" xlink:href="gild-20220331.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_0d1dd6b5-eb87-4dfb-9dc3-bff219f349d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_40e775ee-d7c4-4acf-b609-42b9845f3b54" xlink:href="gild-20220331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_40e775ee-d7c4-4acf-b609-42b9845f3b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87b54463-b5c9-46d0-b6dd-130d01ecb12f" xlink:href="gild-20220331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87b54463-b5c9-46d0-b6dd-130d01ecb12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_ac459361-a037-43a1-b385-0d2095c6f5f2" xlink:href="gild-20220331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_ac459361-a037-43a1-b385-0d2095c6f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_87052c61-dbf2-4677-93bf-086d9c183ab5" xlink:href="gild-20220331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_87052c61-dbf2-4677-93bf-086d9c183ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_d207d2c9-cdc2-47a1-b3f6-433b878571a6" xlink:href="gild-20220331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_d207d2c9-cdc2-47a1-b3f6-433b878571a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_eb044e09-70d3-4229-8ea7-f028d68a05ae" xlink:href="gild-20220331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_eb044e09-70d3-4229-8ea7-f028d68a05ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_52788b48-7627-4ef6-ba52-da097cc0c5ab" xlink:href="gild-20220331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_52788b48-7627-4ef6-ba52-da097cc0c5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_aee3426b-fcf5-4e7a-b199-55ab79ba59b3" xlink:href="gild-20220331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_aee3426b-fcf5-4e7a-b199-55ab79ba59b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_9e3e74e7-4a64-425e-822a-e18e3ae30c31" xlink:href="gild-20220331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_9e3e74e7-4a64-425e-822a-e18e3ae30c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_7b244503-d830-44a9-adbd-552aed50c908" xlink:href="gild-20220331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_7b244503-d830-44a9-adbd-552aed50c908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_33241c58-17c7-4c6b-8cdf-60ee9eee0f87" xlink:href="gild-20220331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_33241c58-17c7-4c6b-8cdf-60ee9eee0f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_068a079d-e70c-478e-81dc-fa8ddd42d345" xlink:href="gild-20220331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_068a079d-e70c-478e-81dc-fa8ddd42d345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_b6c34bf0-868c-4372-b78e-4cb7bb246a72" xlink:href="gild-20220331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_b6c34bf0-868c-4372-b78e-4cb7bb246a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_b11183f1-c9e5-495c-a5d5-a6787f4e0f30" xlink:href="gild-20220331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_b11183f1-c9e5-495c-a5d5-a6787f4e0f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_c619de8e-c1a5-49dd-b4b1-57ec23076a40" xlink:href="gild-20220331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_c619de8e-c1a5-49dd-b4b1-57ec23076a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_3f0003ab-eb21-41a1-b6f1-51d230e84518" xlink:href="gild-20220331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_3f0003ab-eb21-41a1-b6f1-51d230e84518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_848ed72f-25fc-4858-ae4c-f706ba71868f" xlink:href="gild-20220331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b3a68e-67bf-4dd0-aa68-87f962566487" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_848ed72f-25fc-4858-ae4c-f706ba71868f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ba8784cd-1996-411b-a2d6-f888914f5e5c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8180f3e5-88d5-470f-b107-f6b1b87108d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8180f3e5-88d5-470f-b107-f6b1b87108d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_00e247d8-be94-4c2a-bae1-f105a4b3f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_LongTermDebt_00e247d8-be94-4c2a-bae1-f105a4b3f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_40cc6ce8-4403-4702-b692-beac4161e4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_LongTermDebtCurrent_40cc6ce8-4403-4702-b692-beac4161e4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_74efbe33-cba4-431f-8145-9d99961b66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3ba56a-62a0-43cd-85bb-1c71f8d0bab3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_74efbe33-cba4-431f-8145-9d99961b66f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_54a04039-2cbb-4f7c-8e65-9b4c4aed073d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_54a04039-2cbb-4f7c-8e65-9b4c4aed073d" xlink:to="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e408c713-51f1-463f-a0c7-8e8d8aa89357" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0bc1303c-ec5a-4ce2-a837-5520669c2554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:to="loc_us-gaap_SeniorNotesMember_0bc1303c-ec5a-4ce2-a837-5520669c2554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fff30ab6-4658-45e0-8e74-602dc86bb142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ed4b24d-40ee-4e55-9f7d-ba0ada8e385d" xlink:to="loc_us-gaap_LineOfCreditMember_fff30ab6-4658-45e0-8e74-602dc86bb142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b13bd76a-fabc-4e14-9b2f-75410a02b1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2a740891-e419-402a-801e-e227d1456482" xlink:to="loc_us-gaap_CreditFacilityDomain_b13bd76a-fabc-4e14-9b2f-75410a02b1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4288217f-e7e1-45d6-8066-2f118336961c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b13bd76a-fabc-4e14-9b2f-75410a02b1cd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4288217f-e7e1-45d6-8066-2f118336961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13b3b430-3404-4952-81e8-c7b9cb4b7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9f124ae-0439-403e-b955-416f8648d99f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13b3b430-3404-4952-81e8-c7b9cb4b7b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_6c329503-6518-4331-9705-0bfe7b71452b" xlink:href="gild-20220331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13b3b430-3404-4952-81e8-c7b9cb4b7b59" xlink:to="loc_gild_CreditFacilityDueJune2025Member_6c329503-6518-4331-9705-0bfe7b71452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b76850b-0e5b-4625-bfc5-0a6ced666f55" xlink:to="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ca9e2c07-f938-4912-9c00-982576842b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_RepaymentsOfDebt_ca9e2c07-f938-4912-9c00-982576842b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_6050faa2-9b6c-4768-89f8-7b0f354b19ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_6050faa2-9b6c-4768-89f8-7b0f354b19ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f7cce7dd-8ae1-412c-9b9b-88e2259b11fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_LineOfCredit_f7cce7dd-8ae1-412c-9b9b-88e2259b11fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_47dfdb16-2755-4c43-9bed-328c5df64ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62ce194b-0ae5-443b-aaa3-62ac42a400d8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_47dfdb16-2755-4c43-9bed-328c5df64ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gild-20220331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d94b946-acd0-439a-8690-4b68a83aea2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_25157800-a040-42a6-8c25-2d7316801f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d94b946-acd0-439a-8690-4b68a83aea2f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_25157800-a040-42a6-8c25-2d7316801f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f74a33c-c505-4bfe-bf66-743d96a0e423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f74a33c-c505-4bfe-bf66-743d96a0e423" xlink:to="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:to="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_84b191a8-dc87-4183-8986-31bded17282e" xlink:to="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_7369b876-f8c4-494a-b945-5dab2f48878d" xlink:href="gild-20220331.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_ViiVHealthcareCompanyMember_7369b876-f8c4-494a-b945-5dab2f48878d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_8284b101-0b79-4dcd-8c2e-2107b4620406" xlink:href="gild-20220331.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_8284b101-0b79-4dcd-8c2e-2107b4620406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_acbea985-91d4-4ffc-9339-29272ea7b1c0" xlink:href="gild-20220331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_PreExposureProphylaxisMember_acbea985-91d4-4ffc-9339-29272ea7b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember_20b8abcd-30c0-49a1-8ebc-2a742a4f892e" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2024ExpirationMember_20b8abcd-30c0-49a1-8ebc-2a742a4f892e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember_8693938b-55a9-4cef-ad89-4c29339b3640" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2026ExpirationMember_8693938b-55a9-4cef-ad89-4c29339b3640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_3eb7ee49-da4d-485c-a867-70503bddd7ef" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_3eb7ee49-da4d-485c-a867-70503bddd7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember_1cbacdd6-1ae2-4d9e-8af2-3d3767efad74" xlink:href="gild-20220331.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_EuropeanPatentClaims2027ExpirationMember_1cbacdd6-1ae2-4d9e-8af2-3d3767efad74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_f08add93-61b9-4ab9-a634-9f1bd19214cf" xlink:href="gild-20220331.xsd#gild_ProductLiabilityMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_ProductLiabilityMember_f08add93-61b9-4ab9-a634-9f1bd19214cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_e3b3ddd4-7b43-4079-88fb-883fc0248069" xlink:href="gild-20220331.xsd#gild_QuiTamMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5b8e2376-b7e5-4680-b3ce-735c25f31002" xlink:to="loc_gild_QuiTamMember_e3b3ddd4-7b43-4079-88fb-883fc0248069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0637aad2-0df2-41f1-8075-5b31be767bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6cde7d0e-d3a0-428b-8222-6ad36bae5b88" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0637aad2-0df2-41f1-8075-5b31be767bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_94253eee-ccc0-405b-9e42-61b7fa7a7fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0637aad2-0df2-41f1-8075-5b31be767bb6" xlink:to="loc_us-gaap_SubsequentEventMember_94253eee-ccc0-405b-9e42-61b7fa7a7fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_275dcda5-9197-41e9-81e8-244a161bd01a" xlink:to="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_d19722e0-8629-4ff3-b3eb-55428bee8ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LitigationReserve_d19722e0-8629-4ff3-b3eb-55428bee8ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_12b29999-dfa4-4ad9-88bc-6c22d9b12a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_12b29999-dfa4-4ad9-88bc-6c22d9b12a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_352320e9-9e36-4578-8e5b-a73ae20f6bdf" xlink:href="gild-20220331.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_352320e9-9e36-4578-8e5b-a73ae20f6bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_d1f990a5-52d9-4d19-8e52-43f49642fadc" xlink:href="gild-20220331.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_d1f990a5-52d9-4d19-8e52-43f49642fadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_0d79e65b-2691-4144-87fe-e6d028e2886b" xlink:href="gild-20220331.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_0d79e65b-2691-4144-87fe-e6d028e2886b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_c839a34a-bc26-4a77-9684-3e8c560337af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_c839a34a-bc26-4a77-9684-3e8c560337af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_d7eb5bdd-4de2-4d52-8692-95caa22a04b3" xlink:href="gild-20220331.xsd#gild_LossContingencyRoyaltyPercentageOnFutureSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_d7eb5bdd-4de2-4d52-8692-95caa22a04b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f32f8d2e-3c5b-43ba-a7f4-94c5532e902d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f32f8d2e-3c5b-43ba-a7f4-94c5532e902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_e8ff44de-f3af-4cd1-b997-6e0be450c0ea" xlink:href="gild-20220331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_e8ff44de-f3af-4cd1-b997-6e0be450c0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_c470c18b-1bef-444b-a129-c904ddab5f27" xlink:href="gild-20220331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_c470c18b-1bef-444b-a129-c904ddab5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_29ed1ed3-3158-4df4-9f47-d0516aef28f7" xlink:href="gild-20220331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_29ed1ed3-3158-4df4-9f47-d0516aef28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_cd713818-ddaf-44f4-ad51-627ed2c97015" xlink:href="gild-20220331.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_cd713818-ddaf-44f4-ad51-627ed2c97015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_04bf9ca9-1a44-411e-abe2-bc8e1495051e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_04bf9ca9-1a44-411e-abe2-bc8e1495051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents_6f7976f0-5d62-40d9-a1e3-ab209072222d" xlink:href="gild-20220331.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyNumberOfPatents_6f7976f0-5d62-40d9-a1e3-ab209072222d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_c347f0aa-971e-4bf2-92e3-1c113f08c96a" xlink:href="gild-20220331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_c347f0aa-971e-4bf2-92e3-1c113f08c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_be16b5ae-a36d-41ba-a446-210642dcb94c" xlink:href="gild-20220331.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_be16b5ae-a36d-41ba-a446-210642dcb94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_74a03f12-74ed-474a-9c89-7a0082f865cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_74a03f12-74ed-474a-9c89-7a0082f865cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c17e9ae0-67a0-4c15-b57e-f048d48b0a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4ca69fc6-038a-4978-bf54-16012fe43e08" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_c17e9ae0-67a0-4c15-b57e-f048d48b0a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5d04c0ae-4083-4fb2-ae90-9d195bbf180c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_630d5b0d-98ed-4f80-8aa2-1744e83d3b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d04c0ae-4083-4fb2-ae90-9d195bbf180c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_630d5b0d-98ed-4f80-8aa2-1744e83d3b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c156c880-4f15-4c78-8703-4d724265b62d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_8b50c541-f71c-4aa0-925c-aafd6a1caca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c156c880-4f15-4c78-8703-4d724265b62d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_8b50c541-f71c-4aa0-925c-aafd6a1caca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3cfa6107-6011-413c-bd73-ce5154ae0678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c156c880-4f15-4c78-8703-4d724265b62d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3cfa6107-6011-413c-bd73-ce5154ae0678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1b3046d0-4112-4e62-893a-f358841b3c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1b3046d0-4112-4e62-893a-f358841b3c0b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_44605fce-b29e-469f-87fd-dbefaf12b5d0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_81d682d6-9394-4304-b084-70fe8fdbacdf" xlink:href="gild-20220331.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_81d682d6-9394-4304-b084-70fe8fdbacdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_3f8dd5b5-fba7-48b2-8fdd-84afabff97c5" xlink:href="gild-20220331.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_e397ae56-275d-4f9e-9929-4dade2230139" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_3f8dd5b5-fba7-48b2-8fdd-84afabff97c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7765c7af-f855-4840-9061-5821070b49a1" xlink:to="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53e44e45-baef-4ecf-adac-9bc1243254e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53e44e45-baef-4ecf-adac-9bc1243254e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_05b42572-ff95-4bf0-a759-84fe23387934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_05b42572-ff95-4bf0-a759-84fe23387934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ea851c44-1606-4fb2-8515-67598b8aa23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_ea851c44-1606-4fb2-8515-67598b8aa23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_08c87495-6607-4b8a-a7bd-7735c08913c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1bbfbdd5-c5ed-4c0e-a589-7e523981f7e8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_08c87495-6607-4b8a-a7bd-7735c08913c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_050797b8-4e3a-47d3-8f61-f38419b003fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_050797b8-4e3a-47d3-8f61-f38419b003fb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1e94994-78c7-4a79-9c3e-1964544b4a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_262d1f56-13b0-4d30-aca8-ce851907524b" xlink:to="loc_us-gaap_EquityComponentDomain_b1e94994-78c7-4a79-9c3e-1964544b4a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1e94994-78c7-4a79-9c3e-1964544b4a8a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9bc5642e-3c62-49bd-9647-a1f621c68d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9bc5642e-3c62-49bd-9647-a1f621c68d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_783b20fc-0a9f-47d7-bd13-9739b675194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_783b20fc-0a9f-47d7-bd13-9739b675194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c72d511a-5841-4c90-ab31-130672d561ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af882c1e-11ae-4cd9-bcf4-1060a5afd217" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c72d511a-5841-4c90-ab31-130672d561ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d2e868e3-a357-49fc-9387-d9ec7219d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_810a9db5-925c-4aba-a735-8092045dcfc5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d2e868e3-a357-49fc-9387-d9ec7219d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d2e868e3-a357-49fc-9387-d9ec7219d7c6" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1968c9c-ecc4-41ce-bce3-c2b42af76efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1968c9c-ecc4-41ce-bce3-c2b42af76efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5011862c-5faf-4522-b228-7656216fc58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5011862c-5faf-4522-b228-7656216fc58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bfaf0f15-8cde-4a28-a9d1-6fedc9831f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bfaf0f15-8cde-4a28-a9d1-6fedc9831f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76aad8cd-9909-45bc-a514-133ba75e75af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76aad8cd-9909-45bc-a514-133ba75e75af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_caf326cd-4b6e-474c-b07b-89d1368860b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8abfe8d6-7827-415c-9f50-fa7db1d814f0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_caf326cd-4b6e-474c-b07b-89d1368860b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="simple" xlink:href="gild-20220331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_294b3756-fa29-4482-98a8-c9f283d1577d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_47fdac87-4800-4424-abdb-41f2466210dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_294b3756-fa29-4482-98a8-c9f283d1577d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_47fdac87-4800-4424-abdb-41f2466210dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="simple" xlink:href="gild-20220331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37685c91-f3f9-49a0-be69-1a77786092e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b2103fc6-9a05-4d28-8551-9aea2c6afea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37685c91-f3f9-49a0-be69-1a77786092e2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b2103fc6-9a05-4d28-8551-9aea2c6afea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c4b3bebd-f0f7-4deb-86da-54dd50328282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c407433-1372-484b-942c-31959e925794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4b3bebd-f0f7-4deb-86da-54dd50328282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c407433-1372-484b-942c-31959e925794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ba36438f-5669-4cf1-90c1-03b4d6dcb125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:to="loc_us-gaap_NetIncomeLoss_ba36438f-5669-4cf1-90c1-03b4d6dcb125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9140456-dad0-42f1-8953-2078deb0d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9140456-dad0-42f1-8953-2078deb0d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_14c438a1-ee0d-4d34-a6e8-41e3e7011e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_14c438a1-ee0d-4d34-a6e8-41e3e7011e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e7a0e38c-be52-4a30-8a4f-f7698dbd6d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e7a0e38c-be52-4a30-8a4f-f7698dbd6d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_45e16981-e409-4300-bb85-0149a7b0b2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:to="loc_us-gaap_EarningsPerShareBasic_45e16981-e409-4300-bb85-0149a7b0b2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1c3fb42b-1536-4a65-b07a-c5e8f368690e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393c08e5-d36b-43d5-abc8-8b4e44365aa4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1c3fb42b-1536-4a65-b07a-c5e8f368690e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXES" xlink:type="simple" xlink:href="gild-20220331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_171541aa-ac4e-4b0c-ba7b-9b80b6d5dfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c6c25489-eaaf-40d0-a7f1-c2e1f141187f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_171541aa-ac4e-4b0c-ba7b-9b80b6d5dfb6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c6c25489-eaaf-40d0-a7f1-c2e1f141187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="gild-20220331.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fd5ad061-fac0-47dc-82e6-c5d4d26ea393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0602f5fb-a45b-4d29-b875-64d360ed8ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd5ad061-fac0-47dc-82e6-c5d4d26ea393" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0602f5fb-a45b-4d29-b875-64d360ed8ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cbb5fb49-98aa-47fc-a37f-c1339454ebc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbb5fb49-98aa-47fc-a37f-c1339454ebc1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_765e0558-7f5a-4e5b-8d53-0e0ff6d106f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fd41a989-464f-4dc0-99da-bbd7d1119536" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_765e0558-7f5a-4e5b-8d53-0e0ff6d106f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_93258d72-7194-4691-a8b4-9d8a5d67fe45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_765e0558-7f5a-4e5b-8d53-0e0ff6d106f1" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_93258d72-7194-4691-a8b4-9d8a5d67fe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d88d61c3-36e4-4af0-9c88-95142dff74b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0930ae24-d317-4418-83d1-8b607683292d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d88d61c3-36e4-4af0-9c88-95142dff74b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_4f170e16-1d1b-4f13-a630-5270d88b8310" xlink:href="gild-20220331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d88d61c3-36e4-4af0-9c88-95142dff74b0" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_4f170e16-1d1b-4f13-a630-5270d88b8310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_328e942a-b72d-44bb-9516-bb7d9f3d3ee3" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1138e583-a73b-406f-b98f-302341185442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1138e583-a73b-406f-b98f-302341185442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5e8e853e-fcb1-4eb9-8b6d-e52f136aa052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5e8e853e-fcb1-4eb9-8b6d-e52f136aa052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec80ce6e-6a2c-4913-9b96-9e5d6302ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec80ce6e-6a2c-4913-9b96-9e5d6302ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a74c2c2-6a91-4733-91ec-737ca83a6aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_abb715da-feff-45ab-be87-cb0047943b8f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a74c2c2-6a91-4733-91ec-737ca83a6aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="gild-20220331.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_7fd37ee9-13e1-4c1c-98ea-317376478cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_994f1e44-33a4-4b09-b669-3d0632988489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_7fd37ee9-13e1-4c1c-98ea-317376478cc6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_994f1e44-33a4-4b09-b669-3d0632988489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="gild-20220331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e174b825-0872-4356-92a8-e877c7019519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e174b825-0872-4356-92a8-e877c7019519" xlink:to="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f741a823-3bcf-4f7a-a27a-b6565b2b7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8a8cda66-f009-4727-a52d-4d242ebde597" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f741a823-3bcf-4f7a-a27a-b6565b2b7a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_77e42500-f234-4c7d-9ce9-c4afa733b33f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f741a823-3bcf-4f7a-a27a-b6565b2b7a3f" xlink:to="loc_us-gaap_SubsequentEventMember_77e42500-f234-4c7d-9ce9-c4afa733b33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85877c7c-51c5-47a6-a327-a8c7495903c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87b59259-f975-4df6-8aaf-be777657ab9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85877c7c-51c5-47a6-a327-a8c7495903c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_944b0759-6b24-45c2-9a98-45d4b7bdabcd" xlink:href="gild-20220331.xsd#gild_DragonflyTherapeuticsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85877c7c-51c5-47a6-a327-a8c7495903c1" xlink:to="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_944b0759-6b24-45c2-9a98-45d4b7bdabcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a66121d1-8717-4aad-9f8a-22c4a8d73c36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_18d20029-52a3-455d-902a-dd708afd9c83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a66121d1-8717-4aad-9f8a-22c4a8d73c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsIncMember_9936aa3a-0bc4-4c6f-9930-2f70b05be886" xlink:href="gild-20220331.xsd#gild_DragonflyTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a66121d1-8717-4aad-9f8a-22c4a8d73c36" xlink:to="loc_gild_DragonflyTherapeuticsIncMember_9936aa3a-0bc4-4c6f-9930-2f70b05be886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ac08fa1-dc74-4639-86b5-5ff72dce5b13" xlink:to="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e9d4a599-f99d-4582-a1f7-9a68d8a7d9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e9d4a599-f99d-4582-a1f7-9a68d8a7d9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_6d134e99-2bb6-4965-a3dd-fcccc2e1c7a6" xlink:href="gild-20220331.xsd#gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_51ab7801-9bfc-4eff-bae8-9fefd0e7d282" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum_6d134e99-2bb6-4965-a3dd-fcccc2e1c7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image1a.jpg
<DESCRIPTION>EXHIBIT 10.18 GRAPHIC
<TEXT>
begin 644 image1a.jpg
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M(  !" Q( .$=$#9%00 "$(  !!!>V@ $(  !"$!@0 (([X"P*0H"$(  !""
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M[?4]-8= &P*]"Z]'O)YF]G$JT\T(;YOF-MVXB.YT?4O-(+!N @AO1Z((;T>
M$TB.Z$[ B50! @,2Z%UX!ZS+1HI">#>"O9A"$=UB7($A$!@- 82WHZL0WHX
M1YP<T1VQ\S = ALD,(CPQON\VATJMY_RJ@R4E^X;QUVGTIVKO'E'M".NLM;N
M5:OLTRR;$=Y5/3?N=(CNN/V']1#8)('>A=>KFKVH2@(IH8MO%UH5@ 7S]NW;
M"^&5N.[M[2WV8E8<[^/L[2)ET]'1T>SQX\<SQ=_?WY^?KV('PKL*M7&G073'
M[3^LA\"F"?0NO!YE2G#]0H)U"*_$TR\[<+Z"J=%N',WJFL+C^W>C\,:TJS@#
MX5V%VGC3(+KC]1V60Z 4 AL17HT\NSY.Y-&K0$;QU/54>!W7?P1H]!V%N(LS
M!)!_V\& E]AOAY_Y/>/G)FW@Y.1D9>E0_COZK\^/A-%3S3ZFXMBF_'3$W%1X
M8QG*X_CX^,Q;CGPO.,9;=MXWNV7E$SX, 4:ZPW"F% AL X%!A#>]S]MU%ZMT
M\93%W*/85-0ES%%4XWU=B[:$>)4%5@CO]'\FB.[T?4P-(3 D@5Z%-PIDUZGE
M.B@63\61@'HQ5>Y[O#>L<*>5&!\<',Q.3T_KBCH7AO">0S*I"XCNI-Q)92!0
M!('>A#?>3_6(M.M(MXJ8Q=/A4?!5=GS4R/=['5="?>G2I7./)#E\V1'A749H
MO.&([GA]A^40*)E ;\*;CCPE>'V.>C<%&>'=%/E^RT5T^^5+[A#89@*]"F]\
M5C<5XJE 1WBGXLG/ZH'H?L:",PA 8/T$>A5>3^%ZJCD>IS+Z17C7WR@WF2.B
MNTGZE V![2" \';T,\+;$>" R>]?O3K[AYV=RG__ZR_^XDS8OWSE*[,_/7DR
MH(44!0$(; .!WH1W&^"IC@CO>#Q=)[II&*(['K]B*03&1@#A[>@QA+<CP &3
MI^):]1W1'= I% 6!+22 \'9T.L+;$>" R:N$-EY'= =T"$5!8$L)(+P='8_P
M=@0X8/(HL%7GW-,=T"$4!8$M)8#P=G0\PML1X(#)J\0V7A_0'(J"  2VE,!H
MA3?N3I7NB!7#] B3]VF.NVG%_9SUC/$J^S2KS2"\X_GE1(&M.A]/;; 4 A 8
M*X%1"F_<5]DO8(CBNK>W-WOX\.'<)W'C#F\7&=_'J[SV]_=GCQ\_7LF'".]*
MV 9/]%\??WSF42&$=W 74" $(/ I@5$*;^H]"ZJN:[0;1[.ZIKV<_>8B':/P
MIOL\IWDO^X[P+B.T^? /WWIK]H^[N[/7:I[AE1#?NWAQ\\9B 00@,'D"HQ=>
MCWC](@2)<"J\%N8XU1R%N(N7!9!_93*X^\HKL[_]XA?/C71U36'XK4R_X1?\
M,H8V<')RLK)TJ'X[^F^LGU1HT^^JEX4WUE%3T,?'Q_/7"'IK2T]7QWC+SL?,
M;EG=QAS^G[_\Y>R?GGGFC.AJU*O1+Q\(0  "FR0P:N&5H*8+JW+"ZZEF@X[W
M=3W5O.H"*X375,LXZG&@A]_ZUAG!U33ROWWM:S/=Y^4# 0A 8-,$1BN\$LQT
M2EDPXV*JW'=-31\>'BX67UEXXX*M-DY!>-O0ZC?NQ^^_/_O9<\^=$=W7/_>Y
MV:,WW^RW8'*'  0@T(+ *(57XNKI8;_Q*+[M*'V<R/=_Q26==HYYQ7A-&2*\
M34GU&^^]NW=G/WWJJ3.BJUVH3G__^WX+)G<(0  "+0F,4GA;UK'7Z AOKWB7
M9O['1X^RH]S_>/WUI6F)  $(0& 3!!#>CM01WHX .R27N&HJ.3Z3JZEFB3$?
M"$   J420'@[>@;A[0APA>2:/M8T<A1<33-KNID/!"  @=()(+P=/83P=@38
M,KD62N5&N5I8Q0<"$(# & @@O!V]A/!V!-@PN1X%TB-!<92K<STZQ!N%&D(D
M&@0@4 0!A+>C&Q#>C@ ;)/>6CU%TM3F&-LG@ P$(0&!L!!#>CAY#>#L"K$FN
MD>R_?_.;YT:YNL8HMP8<01" 0-$$$-Z.[D%X.P*L2,Z6CQ5@N P!"(R> ,+;
MT85MA/?^U:OG1F]Q^E3A4_XTJ3];/DZY!5 W"$! !"8GO.FN57[Q07PS4=QJ
M<M4]FMU\V@AO%-FJ<^<[Q6-5G>-UMGR<HN>I$P0@$ E,2G@EKGM[>XM]F..^
MS=XJ,KZ+-[XL(4)I<X[P-J<5!;;).5L^-F=+3 A 8#P$)B6\&NW&T:S<X#<3
MY837+TCHXBZ$MSF])F*K.'I.ERT?FW,E)@0@,"X"DQ+>W"L!+;AQJEG3S[[>
MU5WK%MZFXC35>&SYV+5%DAX"$"B=P-8(;W2$IJ"/CX_GKQ#T6XY\+SC&:W+^
M@Q_\8'ZC7""7_9NJ6*ZS7LL8$KZ\G<$(1K2!_MO R<E)$XG(QI%_=O3?%#ZY
M$:^GFEV_>%_74\U=%U@Y[V7')@*U+(\QAV][_<?L.VR'  361V!2PAL74PE1
M^ET+JPX/#Q>+KRR\$N.#@X/9Z>GI^LAF<MIVX=GV^F>:!)<@ ($M)# IX97_
MTL>)XLOMT_NZ$F9/-<=X?;6#>Q<OUC['J_ I?[:]_E/V+76#  2:$YB<\#:O
M.C$A  $(0  "PQ- >(=G3HD0@  $(+#%!!#>+78^58< !"  @>$)(+S#,Z=$
M"$   A#88@(([Q8[GZI#  (0@,#P!!#>X9E3(@0@  $(;#$!A'>+G4_5(0 !
M"$!@> (([_#,*1$"$(  !+:8 ,*[Q<ZGZA"   0@,#P!A'=XYJ,H,>YIO0F#
M*?_);']_?_;X\>--X)_!?[OY;Z31?5KHIMM>6O<^[$%X4\H#?4^WMESU[4A5
MYCK_="M,7]_9V9GIG\M-]['NTMAB&=>N73NS!W8,ZZM\;0WJ^EVX<&&Q-[=8
M#5&^?6([H@_Z+E]^O'GSYJ+^XA#?4=UW^:Z[]D&W#YY^^NG%'Q!]EY_F+QN&
M++^NC=6%]?7[4_W]&[=OS"BV2X?%8VI3#*LZ=]XJ=\C?GLM-Z^3K;HN112XL
M5^<N?6$5)X2WBDR/U^7(O;V]A2"D+W/H6K0Z/76V?@F$\ZLK-VUPJS8VI?,+
M)Y2G1,"-?>CR5>_XQJHARC=K^?3&C1NSV[=OS]P9#%&^F;M,VZ/C$.6K'+>_
M6/:0Y<=RU;GZ#X\AZI\KX_+ER_,_/')AN[N[\WY@G;^_M&]Q^=$W:=\0F?D\
MM<G7JXYJ\[$LL?<?/7W6W>TMK5-=F55A[[[[[ID7Z:BNBKONV2>$MZH5]7@]
M=@8N1HW& N5K78]I0ZPJ]Z677CHS2M(H]:.//IHWMGD#^71TG.O,E]D87TRQ
MB?(CUZ'*CQU6],$0Y=<)[Q#EUW520Y0?VV/*8HCR<QVZQ6C3Y4<VL5WJNEEY
M9*C1ZK///KN8M4AGKF)>/H]_Y.I:9#%$W=,Z596I?K8JS/77T75VF^[:%YJ3
MC@AOI#'0>=I 56P4J'69D3;$NG*C6*A\-;8K5ZXL1@MJJ/[KM:E]_C%;L(<J
M7^7X!^31CAG'[[ZF'^(ZZQ]]&7TP1/W-W/77<4C^&O5<OWY]\=8OE6_F0]0_
MMDVU67>>]K5M<3S[:IW^%P._]2S^9H:J?U7YKK..L5WJ>TZ(4B8Q?>X\[2/<
M%M7^AJA[6J>Z,JO"- B)KXY5/=?1%Z:\$-Z4R #?JYS>]XBWKMST1^:_\KRX
M)_W>!%-:7OI=>>A:E?#%Z9U5RG?^[GR'*#^=;HN=P1#EIWZ)G>$0Y:?U=Z>U
M2N?;Q?^QTS>3(>KO-B?!??#@P5R +?:;+M\<=(SM4M_MI_B'0MHGQ/15Y\HW
M_M'G^[Q#U#VM4UV956%5PMNE+>98(;PY*CU?RSE=C683PNMRTQ]9*G3I]V6(
M5$<+GN/6U7O=Y;M,V>U[7D.4+Z&+'8_/Y=LARG>]?1RZ_JGPR@YWB$/6/_[!
M819#E*]R8[N/?P!LNGQSB#Z)UW2N]J*9+@GP;W_[VW.COS1^W??89PQ1=[<S
MVU179E48PFMZ$SRJ<_*B"E4O_;ZN*J<-,2TG?E^G\*E<_Y4?ZQ++2^N]KO+5
M\<6R8P<\1/FQOCJ//MA$^4/7/PI-ZN,AZR_NZ1^R0Y2?"J^%3"/^39<?VV9L
ME_&ZSNW#-]YXHY/PQGY@B+JG=:HKLRJLR>*J^ =%RJ[I=T:\34FM.9Y^H!X-
MZ>C[<.LH1@TPYNWI'N5=5Z[^"E0Z_<7NQ55MIYK5H'U_RS;$Z:N^RW>GD2M[
MB/JG_DL[@[[K[XY^D_5/VT!LVWW77_Q5OA<TI?X8HOST]Q?_ -AT^:EM[AO\
MVW>[\1^OOAY'\2E3?T_][CP<WE?=J^JD<NO*K I+ZYP*;?K=]6MS1'C;T"(N
M!"   0A H",!A+<C0))#  (0@  $VA! >-O0(BX$(  !"$"@(P&$MR- DD,
M A"   3:$$!XV] B+@0@  $(0* C 82W(T"20P "$(  !-H00'C;T"(N!"
M 0A H",!A+<C0))#  (0@  $VA! >-O0(BX$(  !"$"@(P&$MR- DD,  A"
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M*<^8UW>_^]WY8KRX<C_')MK">7D$$-[R?()%$(# IP0LF%%$@?/?!& SWI:
M\([7=U@.@<D30%RJ70R;:C:EAR"\I7L(^R   0A 8%($$-Y)N9/*0  "$(!
MZ000WM(]A'T0@  $(# I @COI-Q)92   0A H'0""&_I'L(^"$   A"8% &$
M=U+NI#(0@  $(% Z 82W= ]A'P0@  $(3(H PCLI=U(9"$   A HG0#"6[J'
ML \"$(  !"9% .&=E#NI# 0@  $(E$X X2W=0]@' 0A   *3(H#P3LJ=5 8"
M$(  !$HG@/"6[B'L@P $( "!21% >"?E3BH# 0A   *E$T!X2_<0]D$  A"
MP*0((+R3<B>5@0 $( "!T@D@O*5["/L@  $(0&!2!.;"^Z,?_6BF$_[!@#9
B&Z -T 9H _VV 6GN_P>M@M63-V)"PP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>imagea.jpg
<DESCRIPTION>EXHIBIT 10.22 GRAPHIC
<TEXT>
begin 644 imagea.jpg
MB5!.1PT*&@H    -24A$4@   :\   $%" 8   !4[&B)   @ $E$051X >S=
M![A5U;4W?#]O>6]N2=Z;FYL;8XS7$C6V!!/%7A)CC\82>T7!BKV7V'M-;(E=
M$:1)%T2*%%$$4014.DI7!*6(G?$]OVF6[\G)*?L@&\X^S/4\Z^RSUUYKKCG_
M<Z[Q7V/,,<=8X\DGGXPA0X;D/6.0QT > WD,Y#'0*,= SYX]X]Y[[XT;;K@A
M??J^!N+*6T8@(Y 1R AD!!HK N^\\TZT;=LVD1>%R_=,7HVUMW*],@(9@8Q
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M].7-&DDR,Q5OVPB%X*9E?.][WTL$IDYV&@U!Z'Q$57VKC;R<9_Z(J<R;O#K
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M6I#_F2UI.LB2IL%4YCP"T]L^#4$;W),)#*[%AKR0(6WIE[_\91+25<E+76A
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M^R-2 A-I, \I!XD@-62#&)1%<'F[)_#4#0$0R 1>39H7PB%DO=G3EI3A/.U
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M*2[ADS_Z43RSYYXQ]D]_2LDB\]Q68^O57)^,0&4AT"3("W$)$X6@NG?OGL)
MB64H+-2++[Z8PD$5\0R+Q)0"^EKP7"2SK*_;2B$O&LG43IVB:_/F=0:0??3;
MWXZ!QQP3[[_V6GVW;92_?SA^?(HM^, __$.M[7Q@S353(-W'O_>]Z/*+7P3/
MPK>[=X_%,V;$EY]]UBC;E2N5$<@(5 X"38*\Q-MZ]MEG4^XNX9^$A!+^Z8HK
MKHC[[[\_GGSRR11%7EXO,0[E 1,7D78FZD8I6TGDM7AQ3&[?/KK\\I>U"O6_
MK+%&//(?_Q$#CCPRYKWR2BFW;G3G?/#66TF[U):Z=NWLM?ON,>[NN]/<UF=<
MX$O$N]$U.E<H(Y 1:%0(5#QYT;J$T[_AAAOBG'/.29'?F0;%+3SEE%-2N"@I
M4:ZZZJITCIB'(M*+Q,&L6.JV(LE+:@_:F1Q5XQ]^N.+V5Z^[+KINLTV=Q(74
MVJV_?KQ^^^VQ9/;LK[2M/+=5ZG#+YV4$,@+U(- DR L1B75XUEEGI=!1\L(\
M]MAC<?KIIZ>LR1TZ=$A:F+B'-+$V;=J$A)1%!/IZ,$H_(Z]ITZ;%^/'C8\Z<
M.37N,Z=,B5?^_.?H\+.?U2G8F=0>_M=_#0X,UCI5VB[VH/K7I74E\MIHHWCE
M_OMC]JQ9->)5&X[Y>,WC*^.2<6FJ8T#(OE+CS!;RNDF0E\24\GD5R2B!()\7
M34S229J9H+WFN9":WR2KM#___/,I,W,!2&V?S(O,C.(IUI;/:\J;;\;PN^^.
MI[;8HD[!_N __5,\M<$&T?>  V+PB2=6W/[<(8<DK:H^\FJ[T4;Q\GWWU8I7
M;3CFX^7-EY;QS?@VMC'0Y/-YU40LS(:"]?[I3W]*Y"4_E\"\M]QR2UQ]]=4I
MV21@.G7JE$C+G%B[=NV24T?GSIWCF6>>2<%[:RJ[ZC'W$=SWDT\^J75?,G]^
MC&_3)CIOM56=Y/7PO_U;BC A/Y6($Y6VSQHT*)[=?_\ZVXC8.FRZ:4QHUZY6
MO.K",O]6^SC+V&1LFMH8D.RW5/^#0BY7O.:E(4QZ,APC+*E.)*8TM_7<<\\E
M+T1>A;0MKO&(C/;UAS_\X>MSD-**V"RVS0X;_\^)H^-FF\64CAU7!+2YC(Q
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M6V^]%:^__GIZ&+19^_Q>:KJ;HEY(UH+V;MVZI3JH"[+7OH$#!Z8RW<]Y/@D
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MZ-$C!"(NTK^(]WC^^><GX>NWTTX[+6Z]]=;T4!M0==5%&SS0!B?!I?["<'E
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LPH>^BD''0,= QT#'P%$? ]^_?U]YT?,?BT3T-@(!G3T     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215452328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,313,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544216602248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,296<span></span>
</td>
<td class="nump">$ 5,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,629<span></span>
</td>
<td class="nump">14,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,253<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">30,331<span></span>
</td>
<td class="nump">33,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,314<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">5,126<span></span>
</td>
<td class="nump">4,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,080<span></span>
</td>
<td class="nump">67,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccruedGovernmentAndOtherRebates', window );">Accrued government and other rebates</a></td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,558<span></span>
</td>
<td class="nump">11,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">25,183<span></span>
</td>
<td class="nump">25,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">4,793<span></span>
</td>
<td class="nump">4,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,687<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,867<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,986<span></span>
</td>
<td class="nump">16,324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">19,927<span></span>
</td>
<td class="nump">21,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">19,915<span></span>
</td>
<td class="nump">21,064<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 63,080<span></span>
</td>
<td class="nump">$ 67,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedGovernmentAndOtherRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Government And Other Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedGovernmentAndOtherRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215425624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215622984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,590<span></span>
</td>
<td class="nump">$ 6,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">6,393<span></span>
</td>
<td class="nump">3,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(152)<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">164<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 1,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,534<span></span>
</td>
<td class="nump">$ 6,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544216616280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 1,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain, net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized loss, net of tax</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain, net of tax</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Gilead</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544209592680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
<td class="nump">$ 14,381<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 18,964<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,092<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">14,821<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">16,324<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 19,915<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4,867<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 14,986<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215141320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544216667896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 1,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(651)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net loss from equity securities</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(1,657)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,840<span></span>
</td>
<td class="nump">2,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities</a></td>
<td class="num">(613)<span></span>
</td>
<td class="num">(931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(2,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of dividends</a></td>
<td class="num">(945)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,794)<span></span>
</td>
<td class="num">(2,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,042)<span></span>
</td>
<td class="num">(1,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">5,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,296<span></span>
</td>
<td class="nump">$ 4,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211238744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess at the inception of an arrangement with another entity whether the relationship results in it being a variable interest entity (&#8220;VIE&#8221;) and, if so, whether we are the primary beneficiary of the VIE. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of March&#160;31, 2022.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </span></div>We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211586664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cell therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cell therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Atripla, Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues from Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen and royalties for licenses of intellectual property</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $160 million and $174 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $117 million and $79 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211251384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,813&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (&#8220;SOFR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $25.6 billion and $28.6 billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and the carrying values were $25.1&#160;billion and $25.6 billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the change in fair value of our contingent consideration: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in valuation assumptions were primarily related to updated probability rate estimates. The changes in the fair value of this contingent consideration were included in Research and development expenses on our Condensed Consolidated Statements of Income.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a liability related to the sale of future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.1 billion and $1.3&#160;billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and the carrying value was $1.1&#160;billion as of March&#160;31, 2022 and December&#160;31, 2021. See Note 9. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Level Transfers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we recorded a partial impairment charge of $2.7&#160;billion related to certain in-process research and development (&#8220;IPR&amp;D&#8221;) assets. See Note 7. Goodwill and Intangible Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211296232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a total of 618 and 203 positions which were in unrealized loss positions as of March&#160;31, 2022 and 2021, respectively. No impairment was recognized for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities Measured at Fair Value</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Equity Securities</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $375 million and $338 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized Gains and Losses </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized on equity securities were $96&#160;million and $351 million for the three months ended March 31, 2022 and 2021, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211280344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE FINANCIAL INSTRUMENTS</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses on these hedges are recorded in Accumulated other comprehensive income (&#8220;AOCI&#8221;) and are reclassified into Product sales on our Condensed Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of March&#160;31, 2022 are expected to be reclassified to Product sales within 12 months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the three months ended March 31, 2022 and 2021 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts of foreign currency exchange contracts outstanding of $3.2 billion and $2.9 billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the three months ended March 31, 2022 and 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211104024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</a></td>
<td class="text">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments. We also have equity investments in third parties focused on the development and commercialization of products and product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. MYR is a wholly-owned subsidiary of Gilead.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;1.3 billion (or $1.6 billion) primarily consisted of &#8364;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#8364;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date. The estimated fair value of the contingent liability was $322 million as of March&#160;31, 2022. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. Measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three months ended March 31, 2022 amounted to $18 million. See Note 7. Goodwill and Intangible Assets for additional information. The fair value estimates for the assets acquired and liabilities assumed have been completed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arcus</span></div>In 2020, we entered into an option, license and collaboration agreement with Arcus (the &#8220;Arcus Collaboration Agreement&#8221;), which granted us the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction. In November 2021, we exercised our options to three of the clinical-stage programs and amended the Arcus Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving a $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The collaboration opt-in payments of $725 million were recorded in Accrued and other current liabilities on our Consolidated Balance Sheets as of December 31, 2021 and paid to Arcus in January 2022. Our payments to Arcus were included in Other in investing activities on our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544296667496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, goodwill decreased by $18&#160;million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,937&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,827)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $445 million and $395 million for the three months ended March 31, 2022 and 2021, respectively, and is primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2022:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) metastatic breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $6.1&#160;billion as of March&#160;31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. There were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211126232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 10. Commitments and Contingencies for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211107144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT AND CREDIT FACILITIES</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,076&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,571&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,208&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,695&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we repaid $500 million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. No new debt was issued during the three months ended March 31, 2022. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2022, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211126232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below as of March&#160;31, 2022. As of December&#160;31, 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation described below, which we paid during the three months ended March 31, 2022.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. In April 2022, we filed a motion for grant of a compulsory license before the Federal Patent Court in Germany. The hearing date for the German NuCana infringement case has been scheduled for May 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hearing date for the UK NuCana case has been scheduled for January 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $585 million in an upfront payment and a 27.6% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict, finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#8217;s petition for rehearing. We believe that the likelihood of a material adverse outcome in this matter is remote.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;VHC&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes VHC&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering VHC&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. In its lawsuit, VHC was seeking billions of dollars for alleged damages comprised of VHC&#8217;s lost profits and a royalty on U.S. sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we also expected VHC to seek a royalty on U.S. sales after the trial.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, VHC also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound infringes VHC&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and VHC. The &#8217;282 patent is the compound patent covering VHC&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In November and December 2019, VHC filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206; in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 and 1363875. These patents all relate to molecules that VHC claims would act as integrase inhibitors. We believe that bictegravir does not infringe any valid claims of VHC&#8217;s patents and have prevailed in court proceedings to date in Canada and Germany. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, Gilead reached an agreement (the &#8220;Settlement&#8221;) with VHC, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi &amp; Co., Ltd. and GlaxoSmithKline Mercury Limited (collectively, &#8220;ViiV&#8221;) for a global resolution of all pending or potential claims related to Gilead&#8217;s sales of Biktarvy, including the litigation pending in the U.S. District Court of Delaware and other jurisdictions outside the United States as described above. In February 2022, the lawsuit pending in the United States was dismissed as well as the lawsuits in Canada, France, Germany, Ireland, the UK, Australia, Japan and Korea.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir. In connection with the Settlement, Gilead (1) made a one-time payment to ViiV of $1.25 billion in the first quarter of 2022, and (2) will provide ViiV an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027. In connection with the Settlement, Gilead recorded a pre-tax charge of $1.25 billion to Cost of goods sold on our Consolidated Financial Statements in our <a href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or tenofovir alafenamide (&#8220;TAF&#8221;) prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of four material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd. (&#8220;Lupin&#8221;), Apotex Inc., Shilpa Medicare Ltd. (&#8220;Shilpa&#8221;), Sunshine Lake Pharma Co. Ltd. (&#8220;Sunshine Lake&#8221;), Laurus Labs (&#8220;Laurus&#8221;), Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (&#8220;Cipla&#8221;) (collectively, &#8220;Generic Manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our TAF-containing products. Between them, these Generic Manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. The Generic Manufacturers have challenged the validity of two to four patents listed on the Orange Book and associated with TAF. We filed lawsuits against the Generic Manufacturers, and we intend to enforce and defend our intellectual property. In November 2021, we reached an agreement with Shilpa to resolve the lawsuit against Shilpa. In addition, in January 2022, we reached an agreement with Sunshine Lake to resolve the lawsuit against Sunshine Lake. The settlement agreements have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law. In April 2022, the case against Laurus was dismissed after Laurus agreed not to challenge any of the Orange Book-listed patents associated with TAF.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen, filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of two additional patents in the same court. This second case has been stayed pending resolution of the generic litigation regarding our TAF-containing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2022, we received letters from Lupin, Laurus and Cipla indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of three of the five patents listed in the Orange Book as associated with Biktarvy. We intend to enforce and defend our intellectual property. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2028. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes&#8212;one of direct purchasers consisting largely of wholesalers, and another of indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the fall of 2021, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have been coordinated with the class actions. Trial is set for March 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#8220;Cipla Defendants&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and Teva Pharmaceutical Industries Ltd. were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Missouri and New Jersey, involve more than 27,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8220;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA. In December 2021, Gilead and relators executed a settlement agreement to resolve the lawsuit, and in February 2022, the court issued an order dismissing the lawsuit with prejudice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement does not have a material impact to our Consolidated Financial Statements. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211596168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the remaining authorized repurchase amount under both programs was $5.9 billion</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases through open market transactions under the 2016 Program:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to Net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to Net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211058536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</a></td>
<td class="text">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were 16 million and 15 million, for the three months ended March 31, 2022 and 2021 respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211596168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 107.9% for the three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in state deferred tax liabilities associated with a partial IPR&amp;D impairment charge of $2.7&#160;billion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 23.9% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to settlements with taxing authorities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211142392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENTIn April 2022, we entered into a strategic research collaboration agreement with Dragonfly Therapeutics, Inc. (&#8220;Dragonfly&#8221;) (the &#8220;Dragonfly Collaboration Agreement&#8221;) to develop natural killer (&#8220;NK&#8221;) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we will make a $300 million upfront payment to Dragonfly. In addition, Dragonfly is eligible to receive potential opt-in payments and performance-based development, regulatory and commercial milestone payments. Dragonfly will also be eligible to receive royalties of up to 20% on worldwide net sales. The closing of the Dragonfly Collaboration Agreement is subject to antitrust clearances required by the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544214347112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess at the inception of an arrangement with another entity whether the relationship results in it being a variable interest entity (&#8220;VIE&#8221;) and, if so, whether we are the primary beneficiary of the VIE. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of March&#160;31, 2022.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Significant Accounting Policies, Estimates and Judgments</a></td>
<td class="text">The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (&#8220;SOFR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215344376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cell therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cell therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Atripla, Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Revenues from Major Customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen and royalties for licenses of intellectual property</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544214091992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,813&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the change in fair value of our contingent consideration: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544209571048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Equity Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215090104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Value of Derivative Instruments</a></td>
<td class="text">The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Effect of Foreign Currency Exchange Contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Potential Effect of Offsetting Derivatives</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211161304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,937&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,827)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,937&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,827)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2022:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215157752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 10. Commitments and Contingencies for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211142392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Debt Carrying Amount</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,076&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,571&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,208&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,695&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544214073128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases through open market transactions under the 2016 Program:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211279224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211263064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of the Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211250552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544200778200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,590<span></span>
</td>
<td class="nump">$ 6,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,355<span></span>
</td>
<td class="nump">4,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,534<span></span>
</td>
<td class="nump">6,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,862<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,151<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">801<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_VekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_VekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215427144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Revenues from Major Customers (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_MckessonCorpMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215043240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Performance Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue share with Janssen and royalties for licenses of intellectual property</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Changes in estimates</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215235160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205084536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,514<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,337<span></span>
</td>
<td class="nump">5,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,935<span></span>
</td>
<td class="nump">8,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,360<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,360<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,122<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205012776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | Level 3 | Immunomedics | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt, carrying values</a></td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 3 | Immunomedics | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544216555400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details) - Contingent Consideration - MYR GmbH - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in valuation assumptions</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement', window );">Effect of foreign exchange remeasurement</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=gild_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=gild_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205550488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 2,536<span></span>
</td>
<td class="nump">$ 2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">2,514<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 407<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544213925400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,514<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211536712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5', window );">After five years</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,536<span></span>
</td>
<td class="nump">$ 2,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5', window );">After five years</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 2,514<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544213966168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions held in an unrealized loss position | position</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount', window );">Equity investments and equity method investments without readily determinable fair values</a></td>
<td class="nump">375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net unrealized loss on investment of equity securities</a></td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="nump">$ 351,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544208248168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details) - Equity Securities - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 4,337<span></span>
</td>
<td class="nump">$ 5,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,360<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 1,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544213923304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Discontinuances of cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturities of derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Time estimate for gains (losses) to be reclassified from AOCI to product sales</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544204960872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Other&#160;long-term&#160;obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedges:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedges: | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedges: | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544214180200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain recognized in AOCI</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from AOCI into Product sales</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain recognized in Other income (expense), net</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205074248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash Collateral Received/Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash Collateral Received/Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544208788520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>May 27, 2020</div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 18, 2021 </div>
<div>program</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus Collaboration Agreement and Stock Purchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeAgreementOptInTerm', window );">Opt-in term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfClinicalStageProgramsWithExercisedOptions', window );">Number of clinical stage programs with exercised options | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsToOptInTheCollaborativeAgreement', window );">Payments to opt-in the collaborative agreement</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived', window );">Additional option fee on fourth, sixth and eighth anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAgreementOptInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Opt-In Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAgreementOptInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Additional Option Payment Waived</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfClinicalStageProgramsWithExercisedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Clinical Stage Programs With Exercised Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfClinicalStageProgramsWithExercisedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToOptInTheCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Opt-In The Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToOptInTheCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211306696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">8,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments</a></td>
<td class="num">$ (18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544208678312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="nump">$ 445<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived intangible assets, fair value</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | In Process Research And Development Trodelvy For HR+/HER2- | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetMeasurementInput', window );">Discount rate, measurement input</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544200546456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">$ 25,937<span></span>
</td>
<td class="nump">$ 25,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,827)<span></span>
</td>
<td class="num">(8,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">17,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">39,157<span></span>
</td>
<td class="nump">41,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,827)<span></span>
</td>
<td class="num">(8,381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">30,331<span></span>
</td>
<td class="nump">33,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Indefinite-lived assets - IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="nump">15,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="nump">15,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset - sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,826)<span></span>
</td>
<td class="num">(5,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,894<span></span>
</td>
<td class="nump">5,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,826)<span></span>
</td>
<td class="num">(5,651)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember', window );">Intangible asset - axicabtagene ciloleucel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,603)<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,507<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,603)<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Intangible asset - Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">5,630<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">5,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember', window );">Intangible asset - Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(682)<span></span>
</td>
<td class="num">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (682)<span></span>
</td>
<td class="num">$ (650)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544208667544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (remaining nine months)</a></td>
<td class="nump">$ 1,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">8,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 17,111<span></span>
</td>
<td class="nump">$ 17,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211441624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 4,559<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: chargebacks</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: cash discounts and other</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 3,787<span></span>
</td>
<td class="nump">$ 4,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544208285976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InventoryNetAndInventoryNoncurrent', window );">Total</a></td>
<td class="nump">2,675<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Net And Inventory Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544215624472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Accrual for settlement related to bictegravir litigation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="nump">2,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 6,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205151688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 26,208<span></span>
</td>
<td class="nump">$ 26,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total Long-term debt, net</a></td>
<td class="nump">25,183<span></span>
</td>
<td class="nump">25,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember', window );">Senior Notes and Medium-Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">25,076<span></span>
</td>
<td class="nump">$ 25,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.95% Senior Unsecured Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.25% Senior Unsecured Notes Due September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.75% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.70% Senior Unsecured Notes Due April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.50% Senior Unsecured Notes Due February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.65% Senior Unsecured Notes Due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.95% Senior Unsecured Notes Due March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.60% Senior Unsecured Notes Due September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.00% Senior Unsecured Notes Due September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 987<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.65% Senior Unsecured Notes Due December 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.80% Senior Unsecured Notes Due April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Unsecured Notes Due March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,220<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% Senior Unsecured Notes Due March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,727<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,132<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544208684776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility | Credit Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205332440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>patent</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>agreement </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>opposingParty </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>lawsuit </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>party</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued litigation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo', window );">Number of patents challenged, scenario two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne', window );">Number of patents challenged, scenario one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber', window );">Number of additional patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents challenged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyNumberOfPatents', window );">Number of patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV Healthcare Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyRoyaltyPercentageOnFutureSales', window );">Royalty percentage on future sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss related to litigation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateFromOctober2017', window );">Running royalty rate from October 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentEnhancedDamagesOnPastSales', window );">Enhancement rate on past damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateOnFutureSales', window );">Running royalty rate on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember', window );">Pre-Exposure Prophylaxis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyMaterialTransferAgreementsNumber', window );">Number of material transfer agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember', window );">European Patent Claims 2024 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember', window );">European Patent Claims 2026 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember', window );">European Patent Claims 2032 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember', window );">European Patent Claims 2027 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesFilingOppositionNumber', window );">Number of parties filing opposition | party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember', window );">Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of class action lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_QuiTamMember', window );">Qui Tam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentEnhancedDamagesOnPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Enhanced Damages On Past Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentEnhancedDamagesOnPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateFromOctober2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate from October 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateFromOctober2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate on Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Additional Patents Allegedly Infringed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMaterialTransferAgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Material Transfer Agreements, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMaterialTransferAgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesFilingOppositionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Filing Opposition, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesFilingOppositionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyRoyaltyPercentageOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Royalty Percentage On Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyRoyaltyPercentageOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_QuiTamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_QuiTamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544216863816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Repurchases of Common Stock (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount under stock repurchase programs</a></td>
<td class="nump">$ 5,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (in shares)</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Amount</a></td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="nump">$ 309,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember', window );">2016 Stock Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount under stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember', window );">2020 Stock Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount under stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544209411064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="nump">$ 18,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">19,915<span></span>
</td>
<td class="nump">18,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544211295400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544213781816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 1,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544205486952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">$ (152)<span></span>
</td>
<td class="nump">$ 2,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="num">$ (542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">107.90%<span></span>
</td>
<td class="nump">23.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140544213965608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details) - Subsequent Event - Dragonfly Therapeutics Collaboration Agreement - Dragonfly Therapeutics, Inc.<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum', window );">Royalty percentage (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalties Percentage, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_DragonflyTherapeuticsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_DragonflyTherapeuticsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>gild-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:gild="http://www.gilead.com/20220331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20220331.xsd" xlink:type="simple"/>
    <context id="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1850f3306cd34634bedc7f64be32424a_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i04455f0253cf41bea3d4447eaf0b5f43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if150cff9011c4cb8865c7d010dea19b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ad8a561a83946e2be71c0773364df03_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6adca2cb2df45159579306959cd9182_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92f491d481954bfb91bb63808792a107_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0589a869ef75463baf4882764f90b836_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic69dcda8ca004abb9ed728a2c520c160_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id97be958f8ea44f6bf64ec6b93653cd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaede3fb2344847fea92949ea16a03f84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bbba3bf8d68467f8171054b804a1ac9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if538f3fabd96439a81d45376a26388ff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8cea6550adf3442f91f94178b881760a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e9781941f584349a74927f787b7e812_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if31c7f678df04d0dac0d6728662443f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id993c220a3874424a2e4ebabbf6841f5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i042afe2516664edcbb58b11b031f07c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e28083e946c46d38dd4c1bbf423acfb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6e9f66d43a49486cb27df9c7ce53de4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i004764dee0dd403db285a0bdf557180f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8beedc1ba15342129f01b711293f2310_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4874edd47334bd394e3a3ea1da5ca86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a1673112d964a58a17fc93e7d35ff26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if27321762d2f4ae8a9a783e43673fccc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ice22d99dfaaf407181dfa92cad25c12d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib900b75bb57c4248b64d9bdcf700306e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0889fbcdb67f4509b5f885c5a7468633_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i997fc483bf224ea9a20e7b632dfba8b9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i72674008e77942a3986c777c8aab4eb4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic7d7f1d99b11464eb7135895f195aaa9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4eec7f2c8c1a4636ba925954742eba86_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia9796d93b2414e28a30a1b8602920120_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ied51c768bed843aea34aaed4b945684f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47f1dd54de90447294f3c861a9ee3e1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icf3a3af70db64f0f978246427bb3f9d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf8c7affd72e42ca9f179e85ebb2f9d3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i783425dee7ca4e6694dbf5913283547c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieb25c59c64f544eea1c86c507469316f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i656b35f1983b428c8545aed7327ea2c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib4f1409918fc427bb29d5b500a1321e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8346dabbdc9f40229cb19c819e8c69f7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1d8e2e5477841eaa52ff3b838cba27f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab1ba0c7461d47268493fb140371a2e3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81d0cd2f382340f197f0214e199101db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26ceb4bbcd084712bfcf12627e4a8876_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fee41710daf4f27b3133b3886edbf83_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id3afddfa05b845c7b30a26d393a73e1b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9938c6a4da9146d99d8b8dd9069cfcd6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee884799ae424e94b23704c602366eee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3aae21f9faa440b8b79c88263d1f048f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i537a84e24dc24f9d9f384863ce96bd8a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib2dad0f86f1e46f4882d989fb19a2630_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i073c91ae4254439ab6ef2904a9afe007_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff23fb99e7024ad4aa2ad12bcfbf8f61_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib607ac8cf58544f0ba59e08838b4c390_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i890c16b438d54cc18fc29556f4322577_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i59c6687c2bfa42828d22e4837dbb5dea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa3ea5627de74bc29c321695fbae0bb9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i84542ccfad574a82827956f97ca98665_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i22e989af964740d3828ca89bb31ed8c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i636c5da3398c47caa2887765bc8fb4c4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i776ae62f154a426aa156b5d44009a287_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id360b7a80ef8475ba2077b3d656c6b26_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c8e37ffa86f41faa81072218b874e20_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i318393636e2047c38e33f9a92263613f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff5e11317cc34eee936bb532fbcc45b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f008fe0e88941f2ba5d03745e0d1c14_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i513c8fd2c5fc4a58bff490e075395991_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i01e711dc3d84406db6c1a10ada56e5c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee0154ed0d254253a0dc7d64c5706bc1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia918f81a777249f2bfcf4b1d5bbc499e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3c3deebc7b364524b98fef879ed25401_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i850f290111644c449e9a3a3812c4622f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0f0286c60ccf4c62918cb03477641fe6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6cddc469a4df4ece9423e33e5c08e8de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d1e75cd345542ebbf1359781e3b4ce3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i289d747c6aa447e1b03b39c79c030884_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i774c61105333410bb42045f3a93ac5d4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i981cb25bb09f433d8815cfd0cac49e61_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie612932f7fc7413bb9340d0712dddb5d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i520f60d941974d6582ab8ff03d2bb9f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iac86cc9d45a445d1b66e5d3b1328b298_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if20f6a7498f24890ba6109800b4579f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic364bf5827b344f9b7277fa3059e41b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib80f4c1c06954aecbea13eb8c57c84cb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7f542fe236ba49be97003a22c3952e2f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9b924aff33144adbbdbe4b55024bc966_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab8df5b8207746d79c0457bf4ecf84e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0309aadc6ff4ac2b67d133870ecfc21_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0f78bff3afeb44fabb11776d7ffc143b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ad40f3526c94d2a8d401c53ce69ea1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7716776c36cb4bd491d74086bfb7ecb2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if12564811a9e4bdca5202382aefc69f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c956ed6342b42718cec14ac863bdb58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5bb10d32aec44247a4f5d7cd6e811377_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d5f964326e14b269641c03739405c1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id7a3b05ecdb94c10ab42d41aa1405831_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c6a13f318f24325a71e2857063f5848_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie82e4d1739634b57a20ede2010592159_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibefee3ae93504f46a2d372c49fdf40ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic97f28b8981248dbad7137dfc8e3f6db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a54006651944977a0f2ea299b135a39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i900a3386106549a885dd226281746116_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0dbbdd491da34ec79838d8ba4a860828_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i640cb048ad564d1eb126e98c3f9dd4cb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice89761ab066473ebe252ea4efa20c75_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d27e27d65994e5c99f272ab08bdca75_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i972d712715ae466db4de275f56044425_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92246dae9bf04aeda16066d6e5e604ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic905d65961ca41f2a16684c08c4b1170_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id1f3508e4df94ef2aa9af3131d031ebf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a89c780806d4aaf9d6742d4500a8692_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9080da0fd2da4f02a87f7d29708792ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b77ced81c9d459e8714ab97c49ac8e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i17ec7cb46bf4485eb4111720cefb6f25_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8dcfee614954446f890fad6e3acec329_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2bc5bd1f95304695811a90a3fb77aa6c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49e4003abdc8446fb15dd00423d76bfe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d6ba86f84d04fbbbe732f5893719820_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34a987fb1a2345cf9feca51b56f3002e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e1151230a7249eba5e92c53b6c99591_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3886fecdb734baca592defec1da8854_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ab0e630afcb4839815382487e6d7a71_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i990036800e314c019d9924b8c48d9a69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i654b56035ac5429299e0bf0750f7c159_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i912899de9e384b4991388b77ab326802_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i22a0eb3a98cb45b6a547ce971f34baae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icbcc4494362d4aeb9f8d78936bd67dea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic3fc4821b2594c9bb862fc7dfbd1c7e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d9bd2c916494ddfa644ed66486ffa3c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id9ca5a367cbb4823bbb2ddbaa8ba1531_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2191fce5382f493f98627963be2fd34f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d13d672db4940049677cdc0bedae177_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5736172bd8c74fa9b0b84ecba12b6da4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia072a52bdb734592ad37964a3ef65749_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib3ac5763bfd14785880a550fa2c4b4a7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i362e3866a26a48cd8450a9aed1b9c71a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b64a5280a334b8d87dd853cc7b50fb2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice1247c9718f48619c3461a53ade8241_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38923dc977ec4c608fd74bd8d1002b89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibce473a465f24a4587c7b09d8571a2e7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibd98d98b9029490083e145d555397c64_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49d9927d07794d42b9acd485d0be4ccc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i28cc147626d342f18fa203f1fffaeda0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i45dd1b2780dc41fb9de50648b1af8b36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88b0273edd1d40f39c13f63cfaa3039f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib343c66d342c48b188ec538e601a802f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i331f92fda21545a788d654fdc98d17fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id370a2241bdc4d15986cd6b2356a1be4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i24a17bd8d6a14480b89ee581a835b1a4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c5e3587978b4fad9196cbbc06ce3e95_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f7bc0ebe5e34348a81d50bcaaf131cc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i37ef9863b06448f19486cc46a20126f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3fe7dfedae9e4ea69012d15a904e0bed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iedc8c47023174a3ca739f65aee4d80be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idcc10b00ada44fdc804e51838f1acfc3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ffa5ec1dd4840c3b41240ec44fb1a8d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a3c2ed8de2c45ed8ea22f65a1300661_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i92b98d9083b942118db200dec1a903da_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf0b2687f723400eb3f2b51560d5627e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia7bb17eb8edf4095affa55b5c94b7511_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e82886013e34e8cb5b040660f8b2134_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if62e1f4cdbc94d6496e8d6e303892aea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e3a26232e49487cb08e72e73e05cd8f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i601e9f250eff46568a11f08fe9496e7f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0f013c8b8554acdb3ac0e4cb83b0826_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ade0cdccab94dbcad52ed0019f0c921_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ae0e683ad6b40c2a698b3d311bc01d7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i88dee8c0fd39453297ea8ac9fead6e30_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if1ab69156b914bd9a8d4a4bf92a01786_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ac685a4449e4a41827017a39c195f98_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c9317885eae4f5e974a6c62a56a7eca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b9e05a885fd437c97e145bf9ebb7f92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8982d5cbae8145d4a736780033c94930_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i258f51e659e04edd969980eb593baee3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab12b495137c43e6886d664932ca0d4e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6427ea1ce218423483ed2d165863e48f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c48e2dcd6644766923dc0cb2bf31d07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id4ce309faae5419f8ed78774354b4a97_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38350f5e76ed41d99e350a0226a0b299_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3578cd64764c43b28d8596a841916105_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b523e88394b42e49bca13934b5204c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i04b50daaafcf4acdb978f2b3cbc02a69_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic4df11eb0e9c46829ee856f8acd0ac01_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2b9973fb9aa4626ae5ac04a936c01e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50a95859331e4ac19317036e0daf101a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47f5a7f19d504c2ba7ff905f67f4d127_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i63c624c206e4400e9df42232adf50e0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1322e9bf1b8348f6aa69afe538a30158_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ife80ece44c874be5a32808230e9cd4aa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if82cf194379246a1859100c8bba11cca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia6781ab9027f460c9cf7dcef1a2581ab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc5f0d1cad9a4d5c88b552349bd0e426_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1092026c503d4c2caf06ab450b1a56e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d9cb25ede7b47f58962912789bb85f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f208e609ef24694949d9d18a38323a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6282aee3fc5402ba404682fb65354b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i39dd6b3aa4eb4ccc9b8976c09c4c815c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1077536f948c4d599ca3de2b9fa0caf0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i591623e8a2444a6294da53ce3e3564dd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e7a0afec35c4ec89e02da19e66297a3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5e1f408f244494e83312207a23684ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id370f64f9232406da268e72edab2bb89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9a1637a55bc47ce876af3c9b975c36b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i004d4d1e19524166b98a5650d0a3d5b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4868996536f41c395fd9eb7bf456345_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if9510dc0a1cb48a09b7cf7cee5127926_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i14f21e46dfd54c5088e33fe80e268c5e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i506b80edb1094a058227180fe89d36be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc2da0fa42e9465fa82e367afd29d07d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45d45fdbebfa497793e9c785c45cd171_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icbd6c25925024d0ca5e62c2eb0d94599_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie575076324b442bb96747058f585fc96_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9ab947b2302b41098d510e78eec884f9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87e1c13afe4c4b36b0e56bcf32399b38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i99e85eb47143437996c24d62ee7a5072_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie8e4818a6e7548a7bbf17c683d46095a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19f6ecb369e549f69bab7f9d26c72c13_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc546c6f7ee04e13856084c40921bee6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2dc670dab94b43efac0330f320d308ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie9d67453bf2b4b61b493a79e64689edf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibedf0dddfad54c6d83baf2098d0cce00_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i636b58243bec406486f70783ac586b07_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iceea7510047144d48d7b55394af029e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9fee66d032984dd9a95ce2b80bdc73e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ab28717012a4316be156607025ebbee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc1e16a6586047f7aa6d8cdf0cc52aee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i707cbcb9a5dd45609f9783347b2969a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifcd56e62b9064dbfa19723ea33df5f2d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i28abe53df7b94be6bd5527b6651854c4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i883d4917ebfd4efa968bd072df8d5d90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i611a9bb6162246d68e854f3e608a8ba8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie3f69128a6d940b0969c29eb905e9e01_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72629c36c3ac4b5c90339697d9b5841c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4aab0d0a8a054b2191999850619d3215_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5f81b41c6ab4c1a8172650fc81804cb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3b35be1f6524162a052f75f2c305f1d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9470361de7e54728a05b1c0b65a767b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibb419930edcc478c9416d2a9cb5ddb57_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib36489d020f7443788b3cbd0ccfb9d0f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4c4299b47fa4635908637e78b2e1670_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic2e9c418833d40b2b818caa3cd26b3b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c739ead4a5e450393f03a09963c462d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i12ca722e30584518aa14b0e7bf67600b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd10541ce9cb4f0baa1c775e04fcff49_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i842cc6151e23445faaa596d0f12d6d10_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id4d0c4f130c9455faf16cf800852d2a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i133f797d043a461884b3be51d030f6bd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0b794129571f4c3d90efb49ef01d3118_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i82d4742d49c541aaaa995cdc86772e9d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6352cfc350f64fb58df0dbdcb47f284a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iac215de11e334702b29490e622de1ee9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ee61ad8ad9b4ceeafdbe187f3ac6b18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9db6c1894c24e5c940af32de705648b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f41643b44694636b95fbedee07cb74a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58b4c37dbec149e580bc98a08db8a779_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i562545855775425380ef8229edbcd63c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie425b655a72c4978a3a152d215d89082_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5e961357d334fe1868904f1cf61fe7f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i35f038b7cb5048789472b556cec62a76_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i450e90b0899c413f9adda90b2983c33f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e918b0999104da8bcafade720bc9b31_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3686af1f019f450eb7208b0baaafb092_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i574f697fada244ed8d5d02623914c1e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0734cb68049494fafe29592fc4b53af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i67e181e2c5404c43aaf1a8e699cb5ecc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i176dd2b5900a430a8769d523c75624e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95bedcc32b2b473584af9e33a7e1d845_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8bb49adc0c914214b0cf681200d4116f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d9ccec8490648f89cb63618723a451e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i328a5479a2be4ecabc38b95ddd05d567_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia4739475a7bf45baa7a16fc49ba98df2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76465e7067f243bca6ad8e5ab38fa633_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i140c790345dd4179834f4c8b07bfb8b8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96ce8aecccf3444880c9cbaeee334a73_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia8429eedb67b4e29966dd05758722f62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7f66a5967db44f1b832d3882c44a50ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74725ac875c8489088c9e3ce59925700_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98f3a5ba27de450689d4df428849595e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63ef3595a00743e5a7af8c76c459e14b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if01ae90f5f764dcda9f3b84fb3c0c54b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia88cec99f19b4e1aba4ef2f6127972fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i68d68f81dce946ce9958065f41c11dd2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i200e82b6162646ee8c54e3be1e9b651b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia86049893a634ee3bb28b8e42ec50e44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i862defdf94944941b57660ed32b562fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1a7c5c399874ea6acc5ea1cb2da6ec1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7ebbebfdaf14b6faa9cf2fe95f1a416_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22c3072371fb40e1a27e1c3eedd45a42_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4f5096915ac2409d8fc7cf00977aa468_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i22e40aa5ee08404a8b9fba38e9c1d51f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i19d00e372db14beba5926893075d82e6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i057d3b67bbe0417c9f5751710eecc36e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03b8f69f452145d684659547efc6183b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcf9472d8837472bb72056071e3bcc2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a947129bd0b4128a5b74a946315b11d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb035999fbde4492a61824d97546fcf6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e163c502c3149529b2710b48e018b35_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8a70f62d258b4e2a84bcf2d184731151_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i021f337b4cdf48d7921f51bc2532b923_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id6bc8a9e6e2c4acd97a125ed75216ff4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48bc95c69093435488202bb8c647ad08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ided8687dc3744e439646e8257fdd793f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad5c5562a7eb4824ac24cfd6ad279dd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88c103262dfb4e5284221d8be36cba80_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia39db5b06f794fb18a7032c5fc0bc7ad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i270271b7414b4aee9f1a3da9ce2b7382_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8b2f24271294a2eb663d0975ebee946_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a0d52cd14ad4c7580e4dec70cc96976_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99ccd9e592044f67803b6e2b75ca4260_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5efd8fc300e2405d8b1f4a654504ec05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idae51e28be204725a4f236b9b15f9524_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65cb7a08d6804ff499cfb7252fb8d9fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i59ccd377ef1345a6926dc2a8fa826850_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i205b417c4c654633a4bbb6e38d915d6a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ife6351d7d85d4ec18acf7c5279c0884a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iee9028ea70334edabc968f604261d6af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05e3897facac41f1a56e386be016d76c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11f063731fee4046908c3a1a1e0053e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b3f51c3344b4ed2b2fab26b0aa77412_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99305aacdd484354bade2301930b1542_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i857c66ec002c4aa9adc11ff5a2424048_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id6e34a0b5b1545cda6d7fa644e9297c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib2525c2cad7949b99b59099149545ad3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9cb98e1a8d414c63a4f91b8642e4d776_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc4c6d7874ba4f5fa0cd030ee16e21e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib298944c5a5b499fbefa89414cfbc34f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f568032fe6c4908a1cc54d8e025aeaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b04d9ed9c25401c862faf9f0dfe47e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i14683cfbcb854f06a1133e77aa8126c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iadf1e7edcd4c402a93bfc7b9231c5eda_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if272f16215814e408fee0ea6c0c68918_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifaf49983739c4f4a92b0acd7196c9d45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5214efc2a7ec4769aefb4a504c5a9fa7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5c97fddb35a4c2fbd8c78085e1dd095_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib84f70f7509f4f20b5f383de8dfd0a74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba3a5f1c0fd04bc09a8d036709d8b1f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia8b37e4f1d2046feaafd8f5615f12122_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0a71d4ce57724fd3ac83a73b7bbef78c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if50020f5f6954fe0a1e6658494e5a775_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i99a5f1893f3547fa829f8586420e43d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7331130ff6d8406cb228958b17149855_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1008a176c6de4b40a6a73b757acc7f70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieabf4e0443f74462a97365b827ffa008_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i358f4a3297e542349a9a568ed3b11df3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id569202dda104d39a7a750670b0d84bb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d750d13d4f649cab754bb9764317fb5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iccf1acc9c421458f93a3f08a21c062ba_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0d6618cd7c4444e8afb57f3ae24ade4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66a0bbba08f347d193e2b1828a35d52d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i309bbd4aa703457b9a31d2fde9c76235_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedb39a7d3f58491b9ccb76970fd032bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8e18d952c0446c1ad43e7467144a8d1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c5c242b674b44679c627a7248ef2819_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i09ffe45070124a318e73e7a6e504352a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i71e3eeefe5c946fba06a0bee7b36d266_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae857828574b4a668d913b270f8b36f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9d49299020542a392c3db192ea63db8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43e2337e11144df5a90e99b5c638a73c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic70726c081bb4947af4189a219572868_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16f3a3d42167442d9bea77b4bb2f39e6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i03f1eba71d184d8ca513113104bff510_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b1cdaa3e0f34234bf362b822775dec5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8204c7a6c9e14f10be68903951892472_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iebf92a809cfe4430bf1591de1f172efd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e0e2e41b80c40d189eb508b9f0e5d8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4692d33efa2e4c1a903bbfa6eb1bf652_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a9a9dc69fb240d1812e5cdbb79f5bf4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e426ceed16d4ea0b50c79b82c4ac9ed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie023e3f9d84842d5b43ecca161e36545_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc443f74d743469fa8a5404cb1d7b20d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9276731dd9df4019aaff0654ed7ba115_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcf82d3635af4b94b02308fda06d4aaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7023a532dbca4fdcb35a761a941711f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if019e7ba00f744d384b6d00260c70676_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic736f3c433054ecab5e86925ad5cd22e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81d2ad95a1744b048be0fefbdfa02051_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibafcf9464f63422d9fb63a2de8d93d48_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic7f5465ec02d4a35b998d802608fff25_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i874752c3de8541159a7aed9141a3553e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide78159bcbbd42a48bbbcc894680d340_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a54e53274284e9ea52e289b3ec3aaee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44d6fced1e674a6a8d953ff5bc008fef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb992b77b3444d00b7b2813dab4e0089_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd69502271af4d6eb175d2a6ec3ec8ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90dc5662383a49e5addf18ac3694d3f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia58d2c0a64564683a5f1a7c8f578f7a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4ca803e36054d509ef339b251361ad7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49c0710e6642417481cd192d1e448da3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7300d904ed1b4713acd2ddc7fb40833f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id78d4bd4a4574be68dce08afe8061e93_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i120e85817179476683841797ae988eef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0978b5f9be8f41cb89b77a87ab36cfa2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d9c20940c1043059e2558cfbd912517_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7b177f8e4b4d4b6080d2cf0a7bb6b531_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i98a57fe489af45e99b1deeafae96476c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a35912508b74867862fe94d3155d586_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6297966b092c4f5a888d0ccf4cd376a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d44fdf6091a441db520ad3f8f024aa5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib456b5dd5eba41d78d922d73a09bf090_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id130f892b445421ba418a4ff87945c26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic528c221d89a4614bb571ddc51d780fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4be735be6bd241ddb4bb0c132722eb91_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecd6c25aa9ef435ca2a940cd82ec2eab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id76e15d8f3034561bc0f77901e95f300_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i734040fec2ae4fefa9ac801de7c29378_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i972796d2c85047ffae7e45d4d942a4ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61f8d6f5408d437593d6ed14249728b1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i366bb0c4a80d436dab4d980a44b57763_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54513ac7f8334fc5b465981879a0f801_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7f1a320253be4fd0b8481aa6a57537c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0589c2ad7eb480b8da2a801c4d25063_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4120862280544540a63c21d7e97b6c0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a456fff65c843b6a626df4ea2ce55e3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ed49fdba2a147c4b79505826a478d36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee6ff6cc00ff41f8b7ec36a69139238b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b085d7670ea434382d8a85edb3d068e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdc2166d764d47b790982ea8d24ca4c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1bb3d84561ec4098843a2d085b4a0ca6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie3f2d07dee1c49d6beb026214523051a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7427f7cf7f37493d9bdc7a0ae323cc7b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05ff03aad47143d2886a6c27847acb8c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f27f012480540869dfec449f56f64fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i541ecc08f5ab4ef1b08aa8faf2073803_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c84a15b4f764e02becb348c2b986e0e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0e169fb1551b4471ac0f7b68e6ded3af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i755866e871aa435bbe8cc99ea9405032_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3654deba3ec8484aa044f0318ffe9226_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i590c1dfde3d24201beae31f590843dfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4108efc629d9462db4043d3b73894ef6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a9099c763634be097da7c2e31d5b983_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d2c11db705040bb991212a1df88c126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dcd9ccfcbe9446eb6f087a60e2891fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf3a437f7d5e4a888f6943960ee7df17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="icbff931ce23a4b7fbc85927c27dcbb38_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i82997a4df3f84a3ea62a3b4b42b70d35_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i282910930ada4568b9f7fbf7401e7ebe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2aa635ad0e1a44f7b6c2b98f4ad871c7_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i84e131229c44421889bd64bd4ca11a35_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i13a9e3a52328474db24a8e8398a645e2_D20211221-20211221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-21</startDate>
            <endDate>2021-12-21</endDate>
        </period>
    </context>
    <context id="i86cf8f539a93434791137d23f91be357_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i840ba75e346d4681849daddb6e34dc67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4196245fb7d144eb9adbee95335379ec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb2cc7630cdb422387b0f6b01196b3cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8151e3893ea4621a6b91e28a0a81267_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8335947a672a4bf581dd7173d631b531_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6d2e499098c4f4ba1e2564a683b808a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iff62af4097e04403ac73d0cac08de46b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cf48242a25a48a49a44e99af42e2e75_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i414779d0bb44463e89fae77dc259101a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3ea8eac0938446ea3ef964301fddeea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i67b791ce935c423893acbd1d5237a6a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80486df441b94309bf7388e71d0392a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i257ea51d20324ca09177cd0d150f10e5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i18f249c798e6480c85ff4095cc8ec9fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf5248381b9f4abebf4c2f5778f80f05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia203cc43338e4b63a44ff1ec45bc1a31_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf7de9e17b244038bf3bc1cff4883ce2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0d50a2523c6d40889f73a7fabfab2e49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ea02e471b61436f9c0ec424b611b358_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if53a5ab8e03f4ffb92c7f39803b6595b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e70a13105b4454e9983b755cf5e801b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia375ee6d18984f8cb58cbf41605a3a02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d36da1631914269907cd58f8afe4bac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i19ffac061a264104a18929d13674c19e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b34c3a4e3a3433c96acaa5ecaa28b50_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icec48a6ac3ce4cb08310b8ee51083fde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i778b869054c9463e8cd09ca793264290_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a458700e8ab46c588af1e244ecdd413_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86e1179fb9c24e2fa4872abe26299e32_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic80beed14e70493c85b0036c04e5e1b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie1898e2ef2bd41e092d17dd630de1f86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i766605ef96f74675add6345046f2ff5f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i87c33c2ee7674cc6a7f7187ddd22ac13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i849968d6d54e42b7a4440de8cb2b01f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i60bc99a828e44a87aeb970348be95119_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if52d4ee07275499f9e21b3b419e65345_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2259043e9523429d8166efc5e113295f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i406c686943914b65a05b788e6714fa04_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35dedb6bce1648f5aacca48840848457_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb3ff054de0246f682af95f77b83ccd9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8297424984554341a6cf87b296e9e43d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic27643ccf07b464b925ac68cbdb116cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6dc99172f8b246e88d87b181a2923978_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i498ffcf1be474bd3918aef4609196972_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb76d2db3b804d9dababcc6f82e2d016_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fa725b2b3e84d07b775bc9eaa5463c8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibd14cdab0be64d6aabc8c30d9b047909_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06221e90836348968d49234dbf14d1bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icbeb6c7348bb4b8aaa56ac4ec2c04a5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9a2802dbbc844e2858b672dfcde8038_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifd02b491e1a447e7bed36e4655ecccb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6813bb08ecdd4b31892315a2074efcc6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i388fe16439ae47f3b185a0de4b4ddf82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5317908672c2495db89fbaa4d6ab0754_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i02ab28eb41e345ada758ce1aab74170a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9c0fa504fd846aabc3b372785f24c97_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i6007d0be2b424a0c8e7fc133a041c624_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacaf1b5ba1374bdbbdfce05c8d032bab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic477d5bf6c90403e856da095ce607bef_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9d9c9741d4e4098bcc97e45010d58c3_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ic03333a449154cb7b8232d024d98f8f8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1c1bf3df91d4e6db4587e1096299bf0_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="i80ccebc28b844e218656b87fdf4c2179_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0018ba912b0047809cae45058f13a571_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i185d5cd8a06a4180acfc1cbdbf6ae18f_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaf92539a830e4f129492e4de6932612b_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i9df3344fe2684c4db01931149342fe76_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc02333637e24bd4ab2f7235cb6e6be5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2024ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a3b1fcfcfcf4d1288de350903d04105_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2026ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc6a4c4eb7dd45e19e3d027acae2a40c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie253cd11e2894e2eb71ca1ebfd05ee3a_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="if2e36e12155d43ce870b52c07b49d3b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i480272d3e47746109dccd3cc3b185332_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a21d016ed3f4fef846e7281366b96ba_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ie28098faeeb64ff9abedb2ceb8db8e9b_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ic645773c025f4573b8df34872cf19436_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ife2b570214ba4b4380a34ff9a40f2812_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f95a618e4294659ad494cd557c4c835_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i218acb5be9394b00a1883e43cf92536c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8302b75564a54dd8a549d442749edb52_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i85d01a7b28f14000ac327b84cdbf6de2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6073554deb9e48ac9edef34f381a133d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9eb3a8cc8d58460b859489810a00ad9d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iba93b576592245e8aad3a67ae9a4d33a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i363d24e7ddb249f281fc0dcd63f42999_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaddf54d089b4e758cb7bcdc7898e276_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida8a7d072c434eef82e6df74c248a6fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id77b97648262458092baafbed5c40ad1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6704da2f166c4ccaba27a2d1ce1023bc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6451f2f16f341a48298ff3195581dc3_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ife8577a82d764a7eb6649aba6ff99894_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>gild:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>gild:position</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="program">
        <measure>gild:program</measure>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="patent">
        <measure>gild:patent</measure>
    </unit>
    <unit id="opposingparty">
        <measure>gild:opposingParty</measure>
    </unit>
    <unit id="party">
        <measure>gild:party</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gild:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl80LTEtMS0xLTEwNDUyMg_a57fdc67-ae99-4ea1-b8ba-b089b7c23717">0000882095</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl81LTEtMS0xLTEwNDUyMg_1f908578-2053-4701-a300-c8e06b63fcea">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl85LTEtMS0xLTEwNDUyMg_946c0a9a-f380-4a2f-aaa2-9d0b46b201f7">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl8xMC0xLTEtMS0xMDQ1MjI_5c34101f-1a4b-444d-b2f9-6d94d4aa6734">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80L2ZyYWc6Y2VjNjkxYTBlNjA5NDBkY2JlZGVlMzIzNTJmN2M0OTYvdGFibGU6YWFkOTdhMDI2ZTBlNDkxNWE2NGFmMmIxMWIyZDU4NWYvdGFibGVyYW5nZTphYWQ5N2EwMjZlMGU0OTE1YTY0YWYyYjExYjJkNTg1Zl8xMy0xLTEtMS0xMDQ1MjI_09a9d0f0-d90e-4e40-a000-eadd22787fa8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl84OA_a0da87a8-9069-4f51-9aa2-f95d04cf9b34">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YzgzZjMwYjVmYWQ5NDdjMzk1N2E4OTE1YzA3NjM2YjcvdGFibGVyYW5nZTpjODNmMzBiNWZhZDk0N2MzOTU3YTg5MTVjMDc2MzZiN18wLTAtMS0xLTEwNDUyMg_3ff49d67-08f3-4296-bf20-e93e3755e976">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8xMDY_b3b71db3-9ae5-4390-8429-0aeaf75ad398">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6ODc1NTRmMGUxNWQ1NGRkZTg1NzdmNzBkZDRiNjQyODMvdGFibGVyYW5nZTo4NzU1NGYwZTE1ZDU0ZGRlODU3N2Y3MGRkNGI2NDI4M18wLTAtMS0xLTEwNDUyMg_37d8e4e8-e88a-499a-ba51-6bed305e8cd8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8xOTM_2a1ba557-f461-4f8c-947c-7b928999e097">0-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDE_493068dc-91ca-40be-9814-7314d018a864">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6MDgyNWQ2NGQ4OWZjNDEwYmJmNGVlYzg5ZjE4ZTk0YzMvdGFibGVyYW5nZTowODI1ZDY0ZDg5ZmM0MTBiYmY0ZWVjODlmMThlOTRjM18wLTAtMS0xLTEwNDUyMg_c8c0c1b8-ea5d-4521-b099-6a9956f2562d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6MDgyNWQ2NGQ4OWZjNDEwYmJmNGVlYzg5ZjE4ZTk0YzMvdGFibGVyYW5nZTowODI1ZDY0ZDg5ZmM0MTBiYmY0ZWVjODlmMThlOTRjM18wLTEtMS0xLTEwNDUyMg_5ffdd222-e932-41c9-9b3a-0eddf90da0ee">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNjU_eb9879fd-6c98-4ac6-8013-9aba027cc81c">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNjk_563f4af8-2bf9-43c2-8569-75d8aff31c1d">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNzM_68de628b-297a-4f34-921e-4aaf013df786">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yNzY_de0dac20-0fee-4640-8bee-319e50421e4c">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8zMzI_f0946c9b-b61b-4791-b6d7-6b8c9af3d83d">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8zMzU_93cc0e60-4fa9-4905-8781-f967e3606eb9">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YThmZGE3NjEyNzZkNDRiYjg4N2NmYmIxNjdmZDM1YjMvdGFibGVyYW5nZTphOGZkYTc2MTI3NmQ0NGJiODg3Y2ZiYjE2N2ZkMzViM18xLTAtMS0xLTEwNDUyMg_0ddcc3d3-8d98-472a-93e5-660b0152a2b7">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YThmZGE3NjEyNzZkNDRiYjg4N2NmYmIxNjdmZDM1YjMvdGFibGVyYW5nZTphOGZkYTc2MTI3NmQ0NGJiODg3Y2ZiYjE2N2ZkMzViM18xLTItMS0xLTEwNDUyMg_987680af-55a7-4778-a3de-d55f2a897637">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGFibGU6YThmZGE3NjEyNzZkNDRiYjg4N2NmYmIxNjdmZDM1YjMvdGFibGVyYW5nZTphOGZkYTc2MTI3NmQ0NGJiODg3Y2ZiYjE2N2ZkMzViM18xLTQtMS0xLTEwNDUyMg_03c19f47-4420-41c6-9d13-f5d1f2a5f346">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl84MDM_5143d08b-c0ab-4c79-8b43-6d8c34d98675">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8xMTIy_7164e4f3-608c-4dc8-9d3c-80b0d1b35fb6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDg1_61306d24-ac9d-4a5f-80f2-3bb066522c8c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDg2_20b1680a-6459-40f7-9285-1a3bf22326c8">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDgz_01330df0-9c8f-4e3b-9420-e692c22e0652">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDg5MDcyMDkyOTgzNQ_2fa8ec8a-a241-4256-93be-e0aa8b759c0a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1850f3306cd34634bedc7f64be32424a_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xL2ZyYWc6ZGI3MDM5MDA0NzVhNDk4NzgyNzkyMDY5MmEyNTBjZmIvdGV4dHJlZ2lvbjpkYjcwMzkwMDQ3NWE0OTg3ODI3OTIwNjkyYTI1MGNmYl8yMDgw_be2e1b4b-aac4-4893-9902-c282fff55357"
      unitRef="shares">1254313448</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMy0yLTEtMS0xMDQ1MjI_735ef562-ff3c-4767-b5fa-6d1da4aaac72"
      unitRef="usd">4296000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMy00LTEtMS0xMDQ1MjI_05ad5963-bfe8-4d62-805d-3b1d3ddf17c7"
      unitRef="usd">5338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNC0yLTEtMS0xMDQ1MjI_1991c886-3ccd-4ba0-8a7d-2708350cccc9"
      unitRef="usd">1029000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNC00LTEtMS0xMDQ1MjI_af2a2070-93b5-4cbd-8a60-b4cd7bcc00fb"
      unitRef="usd">1182000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNS0yLTEtMS0xMDQ1MjI_bea1a8d6-928f-455e-9b53-b49a61fe7cb7"
      unitRef="usd">3787000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNS00LTEtMS0xMDQ1MjI_7912dec3-06f7-437b-a3a8-fad7fc6fd141"
      unitRef="usd">4493000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNi0yLTEtMS0xMDQ1MjI_00679a2d-12cf-48bc-99e1-5e7993960a9d"
      unitRef="usd">1482000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNi00LTEtMS0xMDQ1MjI_e8e0b34b-abac-4fdb-8aad-081f9e201638"
      unitRef="usd">1618000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNy0yLTEtMS0xMDQ1MjI_2271bb40-8514-4b3b-a9ff-371d8f227eda"
      unitRef="usd">2035000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfNy00LTEtMS0xMDQ1MjI_a0e28587-3dc7-4b18-acfb-161865417613"
      unitRef="usd">2141000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOC0yLTEtMS0xMDQ1MjI_29bdc680-de11-4d98-857c-9993d9fb65e5"
      unitRef="usd">12629000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOC00LTEtMS0xMDQ1MjI_b86f9c80-9c0c-441c-8efa-ce272ed6e115"
      unitRef="usd">14772000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOS0yLTEtMS0xMDQ1MjI_ae4524fa-727d-4407-9112-2232195c900e"
      unitRef="usd">5253000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfOS00LTEtMS0xMDQ1MjI_08648e77-b1bb-4747-94b1-3f2dbbe05605"
      unitRef="usd">5121000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTAtMi0xLTEtMTA0NTIy_11604ae4-3225-4c65-9d89-61cbd0a709d7"
      unitRef="usd">1427000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTAtNC0xLTEtMTA0NTIy_658a68c1-9705-4d84-bf6b-326720d94e54"
      unitRef="usd">1309000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTEtMi0xLTEtMTA0NTIy_a51c3554-c900-4535-bd8c-d876c06cdb04"
      unitRef="usd">30331000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTEtNC0xLTEtMTA0NTIy_5d85c9b8-fef3-4a94-8d5c-ab7781ef392a"
      unitRef="usd">33455000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTItMi0xLTEtMTA0NTIy_8b93488b-1182-4631-8699-a0605fbdfd1b"
      unitRef="usd">8314000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTItNC0xLTEtMTA0NTIy_cd58db2a-2d11-4d0d-829a-974ddb8ee5be"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTMtMi0xLTEtMTA0NTIy_e5cb5701-fd8f-4fee-9a4e-5750537139bc"
      unitRef="usd">5126000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTMtNC0xLTEtMTA0NTIy_87365ec1-755c-427a-9d4b-0f5bba22cb94"
      unitRef="usd">4963000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTQtMi0xLTEtMTA0NTIy_01d5fcfd-3178-43b2-9e4b-a2f929071544"
      unitRef="usd">63080000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTQtNC0xLTEtMTA0NTIy_03a48bb0-f34e-4ef3-865a-c170f21af8e8"
      unitRef="usd">67952000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTctMi0xLTEtMTA0NTIy_a329859f-3c65-4b51-92eb-09e6273925fe"
      unitRef="usd">583000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTctNC0xLTEtMTA0NTIy_9ce1c08f-eaa1-4417-80f5-d70221fa6d15"
      unitRef="usd">705000000</us-gaap:AccountsPayableCurrent>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTgtMi0xLTEtMTA0NTIy_2eb7cd1f-7040-4e54-9ab3-965c455d6f11"
      unitRef="usd">3450000000</gild:AccruedGovernmentAndOtherRebates>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTgtNC0xLTEtMTA0NTIy_5ebdf5dc-a62e-404b-a636-a98449b24897"
      unitRef="usd">3244000000</gild:AccruedGovernmentAndOtherRebates>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTktMi0xLTEtMTA0NTIy_7118b1eb-9040-4fa8-9e87-d57f25559f39"
      unitRef="usd">3500000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMTktNC0xLTEtMTA0NTIy_a09f489f-e0fb-4e9e-9441-897e89d5fa49"
      unitRef="usd">6145000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjAtMi0xLTEtMTA0NTIy_1e7a26b3-4570-4fcf-930d-cf8125da15e2"
      unitRef="usd">1025000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjAtNC0xLTEtMTA0NTIy_c6f62a59-7b26-41c4-89fe-77297510e3ae"
      unitRef="usd">1516000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjEtMi0xLTEtMTA0NTIy_63589b7b-7f73-4d8a-a424-a347be43a96f"
      unitRef="usd">8558000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjEtNC0xLTEtMTA0NTIy_556ad3f6-444d-4c4e-b16f-60748e1f114e"
      unitRef="usd">11610000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjItMi0xLTEtMTA0NTIy_90a79d34-8baa-4be3-9097-9158a0d30053"
      unitRef="usd">25183000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjItNC0xLTEtMTA0NTIy_660ebe06-62fc-4698-afb7-a23f083d88bf"
      unitRef="usd">25179000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjMtMi0xLTEtMTA0NTIy_2ef2526f-aa17-4f1e-aada-90637997894f"
      unitRef="usd">4793000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjMtNC0xLTEtMTA0NTIy_2d35848a-a7f6-4b7e-81eb-3a86ebbe56c9"
      unitRef="usd">4767000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjQtMi0xLTEtMTA0NTIy_1d9604cf-cc42-44c3-9af0-57d1515712bc"
      unitRef="usd">3687000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjQtNC0xLTEtMTA0NTIy_d8221b86-d883-41b9-acb3-7c4a35ad7268"
      unitRef="usd">4356000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjUtMi0xLTEtMTA0NTIy_e8b29536-d05f-4c3b-8275-4b938144dd8d"
      unitRef="usd">944000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjUtNC0xLTEtMTA0NTIy_2bca657a-26f7-44e5-8edd-d99cc1fdc496"
      unitRef="usd">976000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjYtMi0xLTEtMTA0NTIy_9ab2b02a-4dce-4d0a-8517-f9168d5c03d4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjYtNC0xLTEtMTA0NTIy_57cec06a-383b-418e-adf5-1243097ee1b6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfMzE_7b48b453-5da2-4025-b68e-33040ad11907"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfMzE_8f5bfd80-2516-4c3f-935c-642d630ca46c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNDU_2b7c7ad7-22bc-4e0c-8c32-18071a44bc9f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNDU_9d776e26-7d8a-4869-97ac-88f9a31056ca"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNjc_8d38b8bd-36e3-4da1-907d-9c1494eb2ca4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246NTA1OTJmOGM5YjUyNGI3M2JiNDI1MGZmZTRjY2VkNmVfNjc_d63e1023-8f8b-4c7e-adab-6dbce0fba980"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtMi0xLTEtMTA0NTIy_f91cc731-ea28-43b8-92cb-afc47b54fb03"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjgtNC0xLTEtMTA0NTIy_c620dc73-1036-4085-a2fd-105a8e65e3ba"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfMjg_3919b854-aa78-4f0a-a8b3-67d1a2971f9a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfMjg_765e7e0f-2b3b-4d3c-999e-a6d495498189"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNDI_142d348e-a067-4a28-b22f-a74fdfe4cc2d"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNDI_b57bfb96-22da-4311-b3d3-698d73487a43"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNjQ_8626fc89-0dd7-4877-93e0-611d73d04d50"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNjQ_e0ea9558-0bc8-4750-bc48-88f6e005c942"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNzE_0832e308-3add-43ff-952e-21b705a181fa"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMC0xLTEtMTA0NTIyL3RleHRyZWdpb246YTQwYWE3ZDVlMmM1NDU0YmI1ZWM1M2I0NTU0ZmVjYWZfNzE_bf6ae982-4e91-48ae-a882-d3a040bd2274"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktMi0xLTEtMTA0NTIy_fbf4b77c-43c0-47d6-9b1e-683708fb257d"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMjktNC0xLTEtMTA0NTIy_d021fda9-b0ec-4c92-a63f-1a6cdd93a1bb"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzAtMi0xLTEtMTA0NTIy_363018a8-8d5e-4f4c-a8da-5b8827e155c8"
      unitRef="usd">4867000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzAtNC0xLTEtMTA0NTIy_3bcf0057-99b1-4802-858b-eb83c89754fb"
      unitRef="usd">4661000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzEtMi0xLTEtMTA0NTIy_cd429d66-3220-48f1-8aec-f6667c348ea2"
      unitRef="usd">73000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzEtNC0xLTEtMTA0NTIy_d67126ba-c766-4afd-8901-002590e08c78"
      unitRef="usd">83000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzItMi0xLTEtMTA0NTIy_4c43eb12-a317-4e47-9053-a3618055d88c"
      unitRef="usd">14986000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzItNC0xLTEtMTA0NTIy_07c64403-a7b5-47bb-b080-00ca1b56e413"
      unitRef="usd">16324000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzMtMi0xLTEtMTA0NTIy_60e18d5c-e402-465a-bba6-2f4ffecbacc7"
      unitRef="usd">19927000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzMtNC0xLTEtMTA0NTIy_e9eb9507-48c6-44ac-bc6f-04ab76172ed7"
      unitRef="usd">21069000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzQtMi0xLTEtMTA0NTIy_127b5028-1409-4b5f-b47c-721f92265d5e"
      unitRef="usd">-12000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzQtNC0xLTEtMTA0NTIy_681fae63-1de4-4fe3-9485-6ee02dc6a756"
      unitRef="usd">-5000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzUtMi0xLTEtMTA0NTIy_09bbd724-9498-4d98-964f-afea34fdf288"
      unitRef="usd">19915000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzUtNC0xLTEtMTA0NTIy_b2dc4ad1-9086-4994-9077-2d2e5f721f06"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzYtMi0xLTEtMTA0NTIy_5a929e4b-59eb-4143-9f55-4d0bf18baab9"
      unitRef="usd">63080000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xNi9mcmFnOjE2M2EzMjE3ZjY1NjRhNDQ5ZTBiMjNhMmEyZTJjNDNjL3RhYmxlOjIwYTJjODBhOWM4YTRmYjM5M2VhNzFkYTM2Zjg0NmUwL3RhYmxlcmFuZ2U6MjBhMmM4MGE5YzhhNGZiMzkzZWE3MWRhMzZmODQ2ZTBfMzYtNC0xLTEtMTA0NTIy_549c761b-d9f9-4dff-8245-373d3e19b0fb"
      unitRef="usd">67952000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if150cff9011c4cb8865c7d010dea19b6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNC0yLTEtMS0xMDQ1MjI_36fd48ff-92bf-468c-9fd6-1758b8d13295"
      unitRef="usd">6534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ad8a561a83946e2be71c0773364df03_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNC00LTEtMS0xMDQ1MjI_78286d4b-5174-408e-b931-dc461e9c8f95"
      unitRef="usd">6340000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6adca2cb2df45159579306959cd9182_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNS0yLTEtMS0xMDQ1MjI_b4833e94-8be6-48fe-b38f-20b85ef820e1"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92f491d481954bfb91bb63808792a107_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNS00LTEtMS0xMDQ1MjI_4fc95d75-fec4-4485-a990-4c84c0f86d50"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNi0yLTEtMS0xMDQ1MjI_f22a2d3c-77da-49d6-a01f-da7dbc248d0f"
      unitRef="usd">6590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfNi00LTEtMS0xMDQ1MjI_35b88e90-8a37-4fb2-ba8a-05675b8e4f1d"
      unitRef="usd">6423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOC0yLTEtMS0xMDQ1MjI_1c4d87a1-bb91-4f52-9022-eec55446f363"
      unitRef="usd">1424000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOC00LTEtMS0xMDQ1MjI_5c13f043-3129-4803-b61c-24cf7e889446"
      unitRef="usd">1361000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOS0yLTEtMS0xMDQ1MjI_8d7dd6fa-29af-41a8-982d-d9305e6cd15e"
      unitRef="usd">1186000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfOS00LTEtMS0xMDQ1MjI_f0247cc3-cd30-47fc-a001-ef235da531e8"
      unitRef="usd">1055000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtMi0xLTEtMTIzOTc5_46794cdf-40dd-4287-b03f-5d8a6e60ea82"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtNC0xLTEtMTIzOTc5_b2b3ae34-ebbb-424e-9ec6-d2baf4a38d54"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtMi0xLTEtMTA0NTIy_f72c8812-143c-456b-aa17-962506c48dbc"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTAtNC0xLTEtMTA0NTIy_dc944efd-0d2a-47f0-b3cd-fa80b62658e8"
      unitRef="usd">62000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTEtMi0xLTEtMTA0NTIy_6551cf3b-802a-4ebf-aa96-227776e6b03b"
      unitRef="usd">1083000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTEtNC0xLTEtMTA0NTIy_67d82ce0-cc56-40a0-91bd-ba7cf1406543"
      unitRef="usd">1055000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTItMi0xLTEtMTA0NTIy_77b29eb1-b118-4b48-9857-5101006383df"
      unitRef="usd">6393000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTItNC0xLTEtMTA0NTIy_64ddd63b-fc40-40ee-9599-0c9d5887269d"
      unitRef="usd">3533000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTMtMi0xLTEtMTA0NTIy_3b70b8c8-c050-4212-9c75-d6b6eb0b4283"
      unitRef="usd">197000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTMtNC0xLTEtMTA0NTIy_ebd12bbf-ca9a-4bcd-877b-5032bb8967b8"
      unitRef="usd">2890000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTQtMi0xLTEtMTA0NTIy_c2c5e09f-8f3c-4ce3-ade9-db5b7e6171df"
      unitRef="usd">238000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTQtNC0xLTEtMTA0NTIy_92de9d04-8e86-403d-9cc9-1b2642ffc131"
      unitRef="usd">257000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTUtMi0xLTEtMTA0NTIy_1881bee4-c18c-43f4-aed8-a1d97e3dfbb5"
      unitRef="usd">-111000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTUtNC0xLTEtMTA0NTIy_d3e31954-f9d7-4ab6-8db3-b3b817200a1a"
      unitRef="usd">-369000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTYtMi0xLTEtMTA0NTIy_5f236620-4567-403e-9017-a2aa392030a9"
      unitRef="usd">-152000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTYtNC0xLTEtMTA0NTIy_1ab812a5-c30a-4006-adea-cabd5cde7545"
      unitRef="usd">2264000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTctMi0xLTEtMTA0NTIy_5a97b446-71bc-4362-b146-f8fe88154238"
      unitRef="usd">-164000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTctNC0xLTEtMTA0NTIy_8870ad5f-aab6-4ae7-a929-03555a21558d"
      unitRef="usd">542000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTgtMi0xLTEtMTA0NTIy_a22177c9-ded7-4f52-a8a4-7657a5bd0b0a"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTgtNC0xLTEtMTA0NTIy_3123fb9f-4d08-4c43-af17-fde82165959e"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTktMi0xLTEtMTA0NTIy_7c7c7b91-00e5-43a3-a6b7-30177e6d00d1"
      unitRef="usd">-7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMTktNC0xLTEtMTA0NTIy_dd680e55-06a9-4469-9919-52de7f882a04"
      unitRef="usd">-7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjAtMi0xLTEtMTA0NTIy_fb286ff2-b784-4579-a514-5576d3c0dbbb"
      unitRef="usd">19000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjAtNC0xLTEtMTA0NTIy_ad52e8f3-b082-491d-836e-47985326a3fb"
      unitRef="usd">1729000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjEtMi0xLTEtMTA0NTIy_32dac2d5-da9d-494d-b34c-b69a71ae2e9d"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjEtNC0xLTEtMTA0NTIy_256981ea-fda5-474c-a0d9-cdd467941983"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjItMi0xLTEtMTA0NTIy_419536d3-4fc8-4a28-b272-97c17ae57ff0"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjItNC0xLTEtMTA0NTIy_aac54c2d-3d56-470b-a0ab-e7ca00b12e97"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjMtMi0xLTEtMTA0NTIy_f34f5233-9615-4557-8bfb-dbcd119b2604"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjMtNC0xLTEtMTA0NTIy_5db5e269-394e-4c33-8f7b-56bb87d2588a"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjQtMi0xLTEtMTA0NTIy_de8b67c9-4f49-45bc-a66e-4846a251d9b5"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xOS9mcmFnOjE3NjM2NTEzNzU0ODRmYjg5Yzk5MTA0YmFkYWI2MTA5L3RhYmxlOmUyYmVjNDdjMWRmOTQ1YTc5NmVlMjI4ZmI2YzI0MGQ5L3RhYmxlcmFuZ2U6ZTJiZWM0N2MxZGY5NDVhNzk2ZWUyMjhmYjZjMjQwZDlfMjQtNC0xLTEtMTA0NTIy_18a34b22-8210-4b63-b509-39baedaf1ff3"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMy0yLTEtMS0xMDQ1MjI_a22177c9-ded7-4f52-a8a4-7657a5bd0b0a"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMy00LTEtMS0xMDQ1MjI_3123fb9f-4d08-4c43-af17-fde82165959e"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNS0yLTEtMS0xMDQ1MjI_f507674a-c761-42b9-a55a-712cd18f0e85"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNS00LTEtMS0xMDQ1MjI_2b0c17ff-169f-449d-b442-5f431c6295d2"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNy0yLTEtMS0xMDQ1MjI_072b5e69-16d3-479d-91f9-2eaeb8863dbd"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfNy00LTEtMS0xMDQ1MjI_edff0a3d-284a-4d18-8dc1-ba1556fb84a7"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOC0yLTEtMS0xMDQ1MjI_4597db75-700e-46aa-88de-d830a693313a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOC00LTEtMS0xMDQ1MjI_f7741b1b-8262-4887-bec8-d9e579b1d32d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOS0yLTEtMS0xMDQ1MjI_d0acdd68-3ba1-4532-804f-9768af8a2540"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfOS00LTEtMS0xMDQ1MjI_6824b71f-2552-4b23-b62b-39aa74fbd928"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTEtMi0xLTEtMTA0NTIy_ffe88c4f-b9f3-4d4c-baae-80aa22202b3a"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTEtNC0xLTEtMTA0NTIy_00f77eaf-fd57-495b-ba92-ba9db848f6df"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTItMi0xLTEtMTA0NTIy_b0e52aef-f0f5-4dc3-80cf-1451534ba211"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTItNC0xLTEtMTA0NTIy_bface712-92b1-4caa-9ba2-e7bd20abe3f3"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTMtMi0xLTEtMTA0NTIy_e6475c58-c576-4267-96b0-4db66eee3738"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTMtNC0xLTEtMTA0NTIy_5fdbc021-2638-4687-a6c4-0fea28c60333"
      unitRef="usd">90000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTQtMi0xLTEtMTA0NTIy_5a974c46-cd14-46a1-8558-9571dfa49848"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTQtNC0xLTEtMTA0NTIy_03d63158-4e22-44de-a19b-5530aa30e750"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTUtMi0xLTEtMTA0NTIy_73816bb8-b596-4320-82a2-a7c799957190"
      unitRef="usd">2000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTUtNC0xLTEtMTA0NTIy_69605c84-78a6-4dc5-8019-8d2693791132"
      unitRef="usd">1820000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTYtMi0xLTEtMTA0NTIy_f37fd5a7-f9ed-420e-a9eb-3249e3f50c2c"
      unitRef="usd">-7000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTYtNC0xLTEtMTA0NTIy_c76e105f-0329-4893-a937-04c6170cc600"
      unitRef="usd">-7000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTctMi0xLTEtMTA0NTIy_94bcc5e5-b1eb-4cc1-ad12-2b953dd7a403"
      unitRef="usd">9000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yMi9mcmFnOjE5MWQ3N2IxZDNhNDRkM2ZiOTdiZjQ0YmM5MDQ0NTA5L3RhYmxlOjZkODhkMDYwNjgzYzRmODg5ODVkZTc2MjMxYTViY2M0L3RhYmxlcmFuZ2U6NmQ4OGQwNjA2ODNjNGY4ODk4NWRlNzYyMzFhNWJjYzRfMTctNC0xLTEtMTA0NTIy_68063788-70aa-41d7-8461-31cf4e852ceb"
      unitRef="usd">1827000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0589a869ef75463baf4882764f90b836_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0yLTEtMS0xMDQ1MjI_d2a4aee9-de1e-4af4-b124-b6beb6791de0"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0589a869ef75463baf4882764f90b836_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC00LTEtMS0xMDQ1MjI_568f13d7-a6a5-4e84-85f4-17714f77b02e"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic69dcda8ca004abb9ed728a2c520c160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC02LTEtMS0xMDQ1MjI_21abcc15-f70d-4c6c-b6aa-81f8c2e91d56"
      unitRef="usd">4661000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id97be958f8ea44f6bf64ec6b93653cd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC04LTEtMS0xMDQ1MjI_8d048280-8336-4b12-bc4f-9325980b169f"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaede3fb2344847fea92949ea16a03f84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0xMC0xLTEtMTA0NTIy_6c5ea87f-15a2-4b4a-9fb8-3c4620a75602"
      unitRef="usd">16324000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bbba3bf8d68467f8171054b804a1ac9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0xMi0xLTEtMTA0NTIy_14d2f7d7-9aa3-45e0-85d2-4076ac311bef"
      unitRef="usd">-5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNC0xNC0xLTEtMTA0NTIy_7ec09e93-faa3-463e-9fb5-a4af3522717c"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNS0xMC0xLTEtMTA0NTIy_68abb57d-aa9f-4d0c-a2d3-a1223dda25e7"
      unitRef="usd">19000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if538f3fabd96439a81d45376a26388ff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNS0xMi0xLTEtMTA0NTIy_fa21408f-fdb0-414c-bd35-c34fc9b2326b"
      unitRef="usd">-7000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNS0xNC0xLTEtMTA0NTIy_0db58815-d682-4597-99e7-d4570cb223b5"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8cea6550adf3442f91f94178b881760a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNi04LTEtMS0xMDQ1MjI_ea0ecc0e-5789-483d-b64d-bd0c24f940fc"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNi0xNC0xLTEtMTA0NTIy_96957240-28b0-41e9-b1db-667df43addf5"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNy0yLTEtMS0xMDQ1MjI_5f7a6555-492f-490e-98ae-0899708e1f2c"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNy02LTEtMS0xMDQ1MjI_11f2c8e8-fdcd-4dac-838f-3d3a1687d0b5"
      unitRef="usd">73000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfNy0xNC0xLTEtMTA0NTIy_27e036b6-1f6c-48cd-a06a-d31c0cb05089"
      unitRef="usd">73000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOC0yLTEtMS0xMDQ1MjI_f52488a3-9d2e-451a-8bd5-ddec0fbe0880"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOC02LTEtMS0xMDQ1MjI_624dee4b-7663-4a20-ae6a-54c210e6a80d"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOC0xNC0xLTEtMTA0NTIy_fd25671b-580b-4134-8de3-95cddd9a2733"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOS02LTEtMS0xMDQ1MjI_3988e8da-8b31-4a0d-b8e4-74f785afc489"
      unitRef="usd">131000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfOS0xNC0xLTEtMTA0NTIy_7fe7a778-3b79-4b7a-b80c-0fe5c6c41c26"
      unitRef="usd">131000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i7926fc6885354eb19d70d1c1447d9b44_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtMi0xLTEtMTA0NTIy_f5161a96-68fb-442c-ba7b-b59346c5f367"
      unitRef="shares">7000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i31615af5b3664e9e827ea7e8c7f1b1ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtNi0xLTEtMTA0NTIy_c9353846-b7f2-44fb-8b07-8e5d6b665bad"
      unitRef="usd">19000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtMTAtMS0xLTEwNDUyMg_fe94d630-f0f3-4726-b5ca-19f5b9c3b601"
      unitRef="usd">425000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTAtMTQtMS0xLTEwNDUyMg_b85939cd-0e39-417d-933d-f25e2979f701"
      unitRef="usd">444000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTEtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246Y2U4OTcyYjA0MWM5NDMyNjk0NTQxOWNhMDIyOWU3MTBfMTA5OTUxMTYyNzgyMQ_ae82a30a-1d3c-4416-b4b2-d8af5e493073"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="id929e16b05944ab1b6f97d198b58f890_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTEtMTAtMS0xLTEwNDUyMg_cab2db12-9e68-48e3-b81a-28633a8a5476"
      unitRef="usd">932000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTEtMTQtMS0xLTEwNDUyMg_d654fad7-67b1-4724-939d-d54e24f1d1ac"
      unitRef="usd">932000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e9781941f584349a74927f787b7e812_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMi0xLTEtMTA0NTIy_02899246-19a8-4c9a-8d24-19a813dd741b"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e9781941f584349a74927f787b7e812_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItNC0xLTEtMTA0NTIy_29354d4a-6206-4a52-9d48-69ae4ec228d1"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if31c7f678df04d0dac0d6728662443f9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItNi0xLTEtMTA0NTIy_cce74a97-320a-4c3c-ad66-b6b48f323fba"
      unitRef="usd">4867000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id993c220a3874424a2e4ebabbf6841f5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItOC0xLTEtMTA0NTIy_32231eb3-89d3-46bd-8df8-59447ad48599"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i042afe2516664edcbb58b11b031f07c0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMTAtMS0xLTEwNDUyMg_0f68371e-a488-470e-81bb-fdf397235205"
      unitRef="usd">14986000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e28083e946c46d38dd4c1bbf423acfb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMTItMS0xLTEwNDUyMg_42f68c38-7876-4e6b-9845-4d8b5105a94f"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjE1MmZlMmEwNWQ2MzQ4M2VhNTdhNTAxZGI3OGQ5ZDkxL3RhYmxlcmFuZ2U6MTUyZmUyYTA1ZDYzNDgzZWE1N2E1MDFkYjc4ZDlkOTFfMTItMTQtMS0xLTEwNDUyMg_9a14a0a3-eacf-4462-ab4a-d651ee226541"
      unitRef="usd">19915000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6e9f66d43a49486cb27df9c7ce53de4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0yLTEtMS0xMDQ1MjI_251a483c-ca13-4739-8ecf-d333c610939c"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e9f66d43a49486cb27df9c7ce53de4c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC00LTEtMS0xMDQ1MjI_f67c8de6-71d8-4ed0-9930-601f1484d79b"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i004764dee0dd403db285a0bdf557180f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC02LTEtMS0xMDQ1MjI_97dc97e7-62bf-48d2-a24d-229a1e10b0f5"
      unitRef="usd">3880000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8beedc1ba15342129f01b711293f2310_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC04LTEtMS0xMDQ1MjI_2b1489ea-88eb-4e26-bcf7-c86127967da2"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4874edd47334bd394e3a3ea1da5ca86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0xMC0xLTEtMTA0NTIy_9d9eee94-0a27-4c49-b42c-c4978ff531cd"
      unitRef="usd">14381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a1673112d964a58a17fc93e7d35ff26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0xMi0xLTEtMTA0NTIy_4c39e0a1-db31-485e-bf38-b3996b263b34"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if27321762d2f4ae8a9a783e43673fccc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNC0xNC0xLTEtMTA0NTIy_358f81b4-c232-4248-86cd-ef2627247467"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNS0xMC0xLTEtMTA0NTIy_7ff10f32-bb7a-4820-ae04-5bbb32976a3b"
      unitRef="usd">1729000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ice22d99dfaaf407181dfa92cad25c12d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNS0xMi0xLTEtMTA0NTIy_17b8c732-3621-4add-bba0-0e95e92230ea"
      unitRef="usd">-7000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNS0xNC0xLTEtMTA0NTIy_bcb65df7-f985-4673-b1af-f2bf67b29721"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib900b75bb57c4248b64d9bdcf700306e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNi04LTEtMS0xMDQ1MjI_3bf57514-8dc4-45fa-959c-f8a429c0edd3"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNi0xNC0xLTEtMTA0NTIy_dfa221be-8bff-4d6f-af0f-c03f82efdcd9"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNy0yLTEtMS0xMDQ1MjI_80af0e16-934e-4440-9ac8-1616637292d4"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNy02LTEtMS0xMDQ1MjI_5025f455-b286-47eb-8dae-7c4f4881a94b"
      unitRef="usd">76000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfNy0xNC0xLTEtMTA0NTIy_49652d2a-d3fa-42e5-94f5-6414b432180c"
      unitRef="usd">76000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOC0yLTEtMS0xMDQ1MjI_d4af0c5c-5214-47f8-85a8-0e3b998c7f77"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOC02LTEtMS0xMDQ1MjI_aa50ff9e-78ff-4263-9fb1-4e14b9b5ce56"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOC0xNC0xLTEtMTA0NTIy_baa44d0f-032f-4685-9d5d-50fb15fb7ebf"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOS02LTEtMS0xMDQ1MjI_dcb001b2-4788-4991-ac30-21115caf9757"
      unitRef="usd">140000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfOS0xNC0xLTEtMTA0NTIy_05089c52-9023-48b0-9cb9-553ec3e2381a"
      unitRef="usd">140000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0f5d6f7089ae4668862ae4efadfaaece_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtMi0xLTEtMTA0NTIy_0a4f5742-2cab-40a4-bf8f-17dd1a520736"
      unitRef="shares">6000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5e09fe499d5f444d8abf2dc656a0be55_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtNi0xLTEtMTA0NTIy_945ae89f-4a5f-41a5-b7b4-9b0fe9ea2708"
      unitRef="usd">16000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtMTAtMS0xLTEwNDUyMg_628d5d9a-6cf3-4800-8386-7db141172b9c"
      unitRef="usd">383000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTAtMTQtMS0xLTEwNDUyMg_60223773-8f92-4195-88a8-0ff0bb548abf"
      unitRef="usd">399000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTEtMC0xLTEtMTA0NTIyL3RleHRyZWdpb246MzczOGEyZTkzNTkzNDRkMWI4MzYzYzQxNWM5ZWU1MTRfMTA5OTUxMTYyNzgyMQ_49fce0ed-e2b5-495b-bf1a-3067454ce1f4"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="id062f72d80ac465197fd03ccc95a272d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTEtMTAtMS0xLTEwNDUyMg_482169b5-d86e-4300-8c47-6639eae55c37"
      unitRef="usd">906000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTEtMTQtMS0xLTEwNDUyMg_1c62098f-91a1-40b4-b6e7-83b5fee072b5"
      unitRef="usd">906000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0889fbcdb67f4509b5f885c5a7468633_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMi0xLTEtMTA0NTIy_f2ac76d4-d786-4593-8a9b-03b6d7806ec1"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0889fbcdb67f4509b5f885c5a7468633_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItNC0xLTEtMTA0NTIy_8175715f-4392-4d39-81fa-852647a644a8"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i997fc483bf224ea9a20e7b632dfba8b9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItNi0xLTEtMTA0NTIy_ca50d0a7-2ddb-445a-b5de-585806ebf936"
      unitRef="usd">4092000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72674008e77942a3986c777c8aab4eb4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItOC0xLTEtMTA0NTIy_80c963a5-0e3b-414d-9977-5353f699b95b"
      unitRef="usd">38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7d7f1d99b11464eb7135895f195aaa9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMTAtMS0xLTEwNDUyMg_8fa7452c-77fd-42bf-94e9-a28b4662f52f"
      unitRef="usd">14821000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4eec7f2c8c1a4636ba925954742eba86_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMTItMS0xLTEwNDUyMg_11550991-24cc-46a0-a9c4-cfc8fe66e370"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9796d93b2414e28a30a1b8602920120_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yNS9mcmFnOjg3YmUwNzFjMGViMDRlMDY5NzU5YTlkYjJiMzdjNTBmL3RhYmxlOjMwNThkZDAwOTE0MjQ0ZWI5NWI5ZWIyM2NiNmY3MDBkL3RhYmxlcmFuZ2U6MzA1OGRkMDA5MTQyNDRlYjk1YjllYjIzY2I2ZjcwMGRfMTItMTQtMS0xLTEwNDUyMg_372b2cf8-5d14-4962-8f1b-08f5bfa305aa"
      unitRef="usd">18964000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNC0yLTEtMS0xMDQ1MjI_ca37b482-a380-49eb-9c50-39b1ea59d08e"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNC00LTEtMS0xMDQ1MjI_9063375b-3ee4-4dfa-a880-2103a3df83c0"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNi0yLTEtMS0xMDQ1MjI_04dcd89a-6a0a-4fd9-adf4-c56209dd0639"
      unitRef="usd">80000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNi00LTEtMS0xMDQ1MjI_853ad9bb-df23-4632-9717-12402969c082"
      unitRef="usd">78000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNy0yLTEtMS0xMDQ1MjI_2b31ef96-6377-4a38-8ae3-81b8b5b2d72e"
      unitRef="usd">445000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNy00LTEtMS0xMDQ1MjI_c4304c50-5a16-43c8-8bb9-0ab411128635"
      unitRef="usd">395000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOC0yLTEtMS0xMDQ1MjI_5d8d56b8-fd2e-470d-8d62-60d22217f726"
      unitRef="usd">130000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOC00LTEtMS0xMDQ1MjI_6635ee44-02a2-4136-a34c-ddbccd13962e"
      unitRef="usd">139000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOS0yLTEtMS0xMDQ1MjI_29444af9-9719-40c3-9811-b9bb608cdd54"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfOS00LTEtMS0xMDQ1MjI_176886c1-373b-4438-a736-c5905d17356d"
      unitRef="usd">62000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtMi0xLTEtMTIzMDAx_f679b262-f360-41ae-a7eb-93e7c7604eb9"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtNC0xLTEtMTIzMDAx_5ef35fd5-8710-4d3d-92e0-9d536a861162"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtMi0xLTEtMTA0NTIy_7a854fa1-8cf2-4b79-96cb-991b03bba0ed"
      unitRef="usd">-651000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTAtNC0xLTEtMTA0NTIy_f7c75432-b762-4a71-a31f-8f0f689b8525"
      unitRef="usd">71000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTEtMi0xLTEtMTA0NTIy_719f931c-ac45-4ce8-b558-a599c1efab40"
      unitRef="usd">-96000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTEtNC0xLTEtMTA0NTIy_46ef0e37-0c53-48db-b10d-9729b59faf8b"
      unitRef="usd">-351000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTItMi0xLTEtMTA0NTIy_67130a77-568f-4df5-a91b-e276793fce23"
      unitRef="usd">-190000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTItNC0xLTEtMTA0NTIy_b6ac6d16-e6a3-4478-b589-909d24517abe"
      unitRef="usd">-201000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTQtMi0xLTEtMTA0NTIy_a660f6a9-7f45-4f3e-9958-0b326c1c8ce7"
      unitRef="usd">-699000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTQtNC0xLTEtMTA0NTIy_32179264-9f41-470f-a86b-bc1d607ffa82"
      unitRef="usd">-975000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTUtMi0xLTEtMTA0NTIy_d080a5ff-8959-4318-b5cd-8a650336c0b3"
      unitRef="usd">-53000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTUtNC0xLTEtMTA0NTIy_fc56d569-c95a-422e-b9a9-8e20551fa83d"
      unitRef="usd">69000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTYtMi0xLTEtMTA0NTIy_482a041c-1b7b-472d-bf73-51fd25e117ee"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTYtNC0xLTEtMTA0NTIy_c2535cfb-6447-4198-a6a0-6d60271d6b36"
      unitRef="usd">8000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTctMi0xLTEtMTA0NTIy_4bc64fdb-2641-4a08-a174-e556b8305294"
      unitRef="usd">-91000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTctNC0xLTEtMTA0NTIy_e689bc8b-d788-4fcf-bce9-b75056fe69c9"
      unitRef="usd">-253000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTgtMi0xLTEtMTA0NTIy_c6017fd2-889a-43ad-a004-a28b9e9a618f"
      unitRef="usd">-146000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTgtNC0xLTEtMTA0NTIy_778c3b60-a364-45ee-88b6-87273ef49ff2"
      unitRef="usd">-316000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTktMi0xLTEtMTA0NTIy_a8f30868-ad71-455b-879e-0479dc932e0c"
      unitRef="usd">-1657000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMTktNC0xLTEtMTA0NTIy_5d6754de-a129-47b9-8f61-b0f8ac64715a"
      unitRef="usd">-738000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjAtMi0xLTEtMTA0NTIy_8bfe47e8-3b3d-46cb-a942-65d2ccee4977"
      unitRef="usd">1840000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjAtNC0xLTEtMTA0NTIy_2bfd40f2-d64a-45c2-bd19-e25d2087e1e5"
      unitRef="usd">2610000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjItMi0xLTEtMTA0NTIy_6b69f051-aa3e-4db0-b76d-f66fbd41bb97"
      unitRef="usd">613000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjItNC0xLTEtMTA0NTIy_3fad441b-e8f8-48f2-9db3-b7bf77564e56"
      unitRef="usd">931000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjMtMi0xLTEtMTA0NTIy_8ce68965-8877-472b-a6cc-1ecda07325fb"
      unitRef="usd">119000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjMtNC0xLTEtMTA0NTIy_7c24402e-da85-43f0-9707-e7bb56e2309e"
      unitRef="usd">60000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjQtMi0xLTEtMTA0NTIy_b92a66c0-2e64-4c11-bbd0-d6fb01ae724d"
      unitRef="usd">506000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjQtNC0xLTEtMTA0NTIy_11b0d7d6-d713-4f83-8290-51073eee6c44"
      unitRef="usd">619000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjUtMi0xLTEtMTA0NTIy_d27ba6a7-a5bc-40a5-ae5d-f6267c3cba6d"
      unitRef="usd">30000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjUtNC0xLTEtMTA0NTIy_047b37f2-821f-4734-9b1c-24a9f0d23c1d"
      unitRef="usd">1255000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjYtMi0xLTEtMTA0NTIy_9e51fd6c-f3bc-4ea0-bf64-479c1c290438"
      unitRef="usd">28000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjYtNC0xLTEtMTA0NTIy_38d807dd-d22d-4416-a9c2-7b31cb9df6dc"
      unitRef="usd">279000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjctMi0xLTEtMTA0NTIy_6f5d5c08-267c-4c56-a866-ae0fc584cf50"
      unitRef="usd">247000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjctNC0xLTEtMTA0NTIy_85e96549-8ae5-4b69-b123-60099ce2981c"
      unitRef="usd">165000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjgtMi0xLTEtMTA0NTIy_070282ca-c1b4-44fa-b302-1d33416967a7"
      unitRef="usd">777000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjgtNC0xLTEtMTA0NTIy_2c0bc68b-e9c8-42d3-8286-29dba9d3054c"
      unitRef="usd">91000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjktMi0xLTEtMTA0NTIy_8b70eb32-67fb-4972-9270-97e481da9791"
      unitRef="usd">-1070000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMjktNC0xLTEtMTA0NTIy_4851ef68-0b23-4432-9364-a6fb15caae26"
      unitRef="usd">-2042000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzItMi0xLTEtMTA0NTIy_8ff0dcc5-4aed-4c83-8813-43abed9768a5"
      unitRef="usd">94000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzItNC0xLTEtMTA0NTIy_2929958a-4196-4806-950c-d57edd9eefc1"
      unitRef="usd">88000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzMtMi0xLTEtMTA0NTIy_eed935eb-fbb6-4187-8543-19c9c3af44e3"
      unitRef="usd">352000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzMtNC0xLTEtMTA0NTIy_ab486f07-689d-456b-bc46-3f084f9ca0d0"
      unitRef="usd">309000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzQtMi0xLTEtMTA0NTIy_aa0f1cc3-7261-4ced-b8f9-0d2596f4d857"
      unitRef="usd">500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzQtNC0xLTEtMTA0NTIy_32cf001a-5995-4f8a-bd39-c8d27833e613"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzUtMi0xLTEtMTA0NTIy_8669225d-0785-44a1-8faa-9711e4ef795d"
      unitRef="usd">945000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzUtNC0xLTEtMTA0NTIy_60d7f656-6950-45c6-8418-f385e44f4ff2"
      unitRef="usd">917000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzYtMi0xLTEtMTA0NTIy_1da3b77e-be47-4c7a-9066-d4e61459014a"
      unitRef="usd">-91000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzYtNC0xLTEtMTA0NTIy_1a756906-d8eb-420c-860b-c3432c6855ff"
      unitRef="usd">-89000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzctMi0xLTEtMTA0NTIy_c4a884b8-8436-405c-a74c-76c305e05923"
      unitRef="usd">-1794000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzctNC0xLTEtMTA0NTIy_b6f17ade-1318-46ea-8a78-0bfb5d2b49fb"
      unitRef="usd">-2477000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzgtMi0xLTEtMTA0NTIy_043095b0-0b9e-4435-90fd-4b8070bedb3d"
      unitRef="usd">-18000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzgtNC0xLTEtMTA0NTIy_d8abf082-7466-4deb-bd5e-95da66a42395"
      unitRef="usd">-23000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzktMi0xLTEtMTA0NTIy_f530ce85-dab9-4ecd-b357-a1767fc61661"
      unitRef="usd">-1042000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfMzktNC0xLTEtMTA0NTIy_26abe5d0-2e30-4483-b0c5-d986db05dbf7"
      unitRef="usd">-1932000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDAtMi0xLTEtMTA0NTIy_099d6582-ad24-4fb2-a962-fc5d9340c62e"
      unitRef="usd">5338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if27321762d2f4ae8a9a783e43673fccc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDAtNC0xLTEtMTA0NTIy_22a1a535-fcd5-4a73-a9ac-e98e166525de"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDEtMi0xLTEtMTA0NTIy_982a2c2d-8a0b-4368-8818-4d4eb4b0fc7a"
      unitRef="usd">4296000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9796d93b2414e28a30a1b8602920120_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8yOC9mcmFnOmYzM2I4MzU4NTQ1MzRlNDdhNTNiNGZjY2RmZTY0YmU3L3RhYmxlOmJlZmViNWY3NTcwZjRmMDI5OGY0ZDFkNTEyYTdjZGJhL3RhYmxlcmFuZ2U6YmVmZWI1Zjc1NzBmNGYwMjk4ZjRkMWQ1MTJhN2NkYmFfNDEtNC0xLTEtMTA0NTIy_d5cf6f79-3893-460e-8ff5-42f8f0cfb296"
      unitRef="usd">4065000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE3NQ_83adaebc-8bcd-44c0-9b20-b3e33cf24a01">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess at the inception of an arrangement with another entity whether the relationship results in it being a variable interest entity (&#x201c;VIE&#x201d;) and, if so, whether we are the primary beneficiary of the VIE. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies, Estimates and Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. &lt;/span&gt;&lt;/div&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE2NA_7fd03f93-dbe4-4fea-ad67-645283a1b459">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess at the inception of an arrangement with another entity whether the relationship results in it being a variable interest entity (&#x201c;VIE&#x201d;) and, if so, whether we are the primary beneficiary of the VIE. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE1NA_5e68a445-7ba2-42bd-97b0-df63648dbe07">We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfMTgyNw_be08046e-83c9-43bc-918b-d5dc6b72fe6c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE3Nw_db4240cc-9c24-4b9c-b510-75fe5576d516">The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNC9mcmFnOjYyNWI4OTM5OGNiMTQxYzQ5YzllODFiMmIwYjJkMWI0L3RleHRyZWdpb246NjI1Yjg5Mzk4Y2IxNDFjNDljOWU4MWIyYjBiMmQxYjRfNTE1OA_ab1fea19-99d4-4f1d-8c01-486850805834">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjU0MA_c64b5c36-48e8-4c64-98bd-2fd2dcd9081f">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Atripla, Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues from Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues recognized from performance obligations satisfied in prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue share with Janssen and royalties for licenses of intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $160 million and $174 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $117 million and $79 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjUzNA_f76a3c4a-bb69-418e-8a1b-3faf78e1745c">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cell therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Atripla, Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied51c768bed843aea34aaed4b945684f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0yLTEtMS0xMDQ1MjI_a17d27ea-42be-4f15-91ed-4acb277c071b"
      unitRef="usd">1706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47f1dd54de90447294f3c861a9ee3e1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS00LTEtMS0xMDQ1MjI_a1dd5d4d-3c1b-4f7a-bebb-b68eb0243487"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf3a3af70db64f0f978246427bb3f9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS02LTEtMS0xMDQ1MjI_e669ac90-103e-478d-994c-d3e01a81fd0a"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf8c7affd72e42ca9f179e85ebb2f9d3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS04LTEtMS0xMDQ1MjI_1a2b54b7-c76a-4aad-a962-36a60257939c"
      unitRef="usd">2151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i783425dee7ca4e6694dbf5913283547c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xMC0xLTEtMTA0NTIy_41487c19-81b4-4cb8-a723-597ea052a307"
      unitRef="usd">1465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb25c59c64f544eea1c86c507469316f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xMi0xLTEtMTA0NTIy_0d54fb54-7a0a-4bd6-a9e9-a47880088a46"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i656b35f1983b428c8545aed7327ea2c2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xNC0xLTEtMTA0NTIy_7bbb1ff8-be76-4201-afab-4c2179da99cc"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4f1409918fc427bb29d5b500a1321e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNS0xNi0xLTEtMTA0NTIy_c4a234e4-9ca5-4949-b3e6-3df418fff3d4"
      unitRef="usd">1824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8346dabbdc9f40229cb19c819e8c69f7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0yLTEtMS0xMDQ1MjI_ef775b91-fcce-450f-8522-91789427db05"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1d8e2e5477841eaa52ff3b838cba27f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi00LTEtMS0xMDQ1MjI_f6a6ef1f-1c06-4055-8b7a-e797bf108a80"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab1ba0c7461d47268493fb140371a2e3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi02LTEtMS0xMDQ1MjI_8c3fb8af-6b8a-43c2-b059-45e21080de42"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81d0cd2f382340f197f0214e199101db_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi04LTEtMS0xMDQ1MjI_0a043a6b-6da8-4d86-9680-97d5e90a31b7"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26ceb4bbcd084712bfcf12627e4a8876_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xMC0xLTEtMTA0NTIy_51244b5f-8791-46a5-bae4-c19360cae2e5"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fee41710daf4f27b3133b3886edbf83_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xMi0xLTEtMTA0NTIy_6b25744e-93bb-4f96-8703-c44382ba899a"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3afddfa05b845c7b30a26d393a73e1b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xNC0xLTEtMTA0NTIy_e46551a7-85e2-4125-8577-be01b3bb41ec"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9938c6a4da9146d99d8b8dd9069cfcd6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNi0xNi0xLTEtMTA0NTIy_3561aaf7-c9db-40ef-a20c-07f57dbe49f8"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee884799ae424e94b23704c602366eee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0yLTEtMS0xMDQ1MjI_1f945c5e-8f33-4a40-bc48-b9b308e9d35a"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aae21f9faa440b8b79c88263d1f048f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy00LTEtMS0xMDQ1MjI_5770f2c4-c810-4d21-a971-859fcf00ac52"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i537a84e24dc24f9d9f384863ce96bd8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy02LTEtMS0xMDQ1MjI_5db95ad3-1e4e-4aff-ab7b-41d62f9eef82"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2dad0f86f1e46f4882d989fb19a2630_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy04LTEtMS0xMDQ1MjI_d6d6e74e-2b7b-46d0-a6b9-259621a1d4b5"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i073c91ae4254439ab6ef2904a9afe007_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xMC0xLTEtMTA0NTIy_a7ee4ddb-547a-4b10-9c94-6617b2c3047b"
      unitRef="usd">282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff23fb99e7024ad4aa2ad12bcfbf8f61_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xMi0xLTEtMTA0NTIy_e4d442c6-04d8-4d45-93a3-26ed7c9c5fce"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib607ac8cf58544f0ba59e08838b4c390_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xNC0xLTEtMTA0NTIy_b6156df5-ffd8-4290-8016-fe722aa7de96"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i890c16b438d54cc18fc29556f4322577_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNy0xNi0xLTEtMTA0NTIy_b4349eba-2bfa-4f6b-b49e-cf8671e0687c"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59c6687c2bfa42828d22e4837dbb5dea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0yLTEtMS0xMDQ1MjI_ec750cea-94cc-4ad3-92cd-5936ba15fb14"
      unitRef="usd">457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa3ea5627de74bc29c321695fbae0bb9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC00LTEtMS0xMDQ1MjI_b85ae090-2c9f-47d5-b4a6-6e751d17fe62"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84542ccfad574a82827956f97ca98665_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC02LTEtMS0xMDQ1MjI_65a61f63-8190-4212-b5f9-912ffe8c9489"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22e989af964740d3828ca89bb31ed8c4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC04LTEtMS0xMDQ1MjI_a99c6e92-648d-4553-a9c7-cce7ff3369f4"
      unitRef="usd">582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i636c5da3398c47caa2887765bc8fb4c4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xMC0xLTEtMTA0NTIy_64e59c3f-f95c-4a7c-9183-90192ff15f4c"
      unitRef="usd">506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i776ae62f154a426aa156b5d44009a287_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xMi0xLTEtMTA0NTIy_ab04a5d9-89ef-4e32-b873-9c64e261431f"
      unitRef="usd">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id360b7a80ef8475ba2077b3d656c6b26_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xNC0xLTEtMTA0NTIy_492d7693-c5e2-4173-960e-cfeacadadcde"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c8e37ffa86f41faa81072218b874e20_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOC0xNi0xLTEtMTA0NTIy_89b97ba4-bc8a-494c-be73-b10489885792"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i318393636e2047c38e33f9a92263613f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0yLTEtMS0xMDQ1MjI_942adb79-4e27-4ac4-b809-7dc27ab53c18"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff5e11317cc34eee936bb532fbcc45b3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS00LTEtMS0xMDQ1MjI_593f6969-45a4-43bb-9ee3-897b34c252e9"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f008fe0e88941f2ba5d03745e0d1c14_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS02LTEtMS0xMDQ1MjI_66ec35aa-3ab9-4828-803d-aeadbc4bf3ee"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i513c8fd2c5fc4a58bff490e075395991_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS04LTEtMS0xMDQ1MjI_86555663-c462-4d2b-a0b7-4fe75a295d6f"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01e711dc3d84406db6c1a10ada56e5c3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xMC0xLTEtMTA0NTIy_ac17b4d1-5d0f-4157-b32f-f3fb22a709eb"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee0154ed0d254253a0dc7d64c5706bc1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xMi0xLTEtMTA0NTIy_e2975af1-ce34-4add-ae34-1e4f1f5f4e9f"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia918f81a777249f2bfcf4b1d5bbc499e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xNC0xLTEtMTA0NTIy_0d699bc1-59f5-4a0a-99c6-ae230bb51175"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c3deebc7b364524b98fef879ed25401_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfOS0xNi0xLTEtMTA0NTIy_c353e7bd-5514-4923-beff-664ac273de87"
      unitRef="usd">367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i850f290111644c449e9a3a3812c4622f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMi0xLTEtMTA0NTIy_229f9a90-c41d-4646-a0f1-a20bd4329615"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f0286c60ccf4c62918cb03477641fe6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtNC0xLTEtMTA0NTIy_e2f86984-908d-49b2-bb4f-d6bc16fe73d5"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cddc469a4df4ece9423e33e5c08e8de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtNi0xLTEtMTA0NTIy_95fb31f0-8689-4ec5-b3bb-6fdd0304bd36"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d1e75cd345542ebbf1359781e3b4ce3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtOC0xLTEtMTA0NTIy_c80869d1-4a26-4f8d-b02d-abc53dc4dd47"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i289d747c6aa447e1b03b39c79c030884_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTAtMS0xLTEwNDUyMg_ed281e2c-ef01-4ded-a1d1-3d943af3793c"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i774c61105333410bb42045f3a93ac5d4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTItMS0xLTEwNDUyMg_fda54870-f993-4021-84d2-2f814f935b6a"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i981cb25bb09f433d8815cfd0cac49e61_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTQtMS0xLTEwNDUyMg_764e14cf-351e-4e91-aa4f-91ca0a4ea547"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie612932f7fc7413bb9340d0712dddb5d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTAtMTYtMS0xLTEwNDUyMg_8025f18e-22ed-4966-98ca-b6225f3735cb"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i520f60d941974d6582ab8ff03d2bb9f6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMi0xLTEtMTA0NTIy_f81b1ee0-254e-435b-9078-931a0fa3d626"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac86cc9d45a445d1b66e5d3b1328b298_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtNC0xLTEtMTA0NTIy_c6fcd4ac-2846-4f32-83e8-1be466d9fb0a"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if20f6a7498f24890ba6109800b4579f9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtNi0xLTEtMTA0NTIy_e838f406-f043-422c-b6bd-abbcefc13bd0"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic364bf5827b344f9b7277fa3059e41b9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtOC0xLTEtMTA0NTIy_5d977a94-4579-4c86-bf3c-62af59a789c6"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib80f4c1c06954aecbea13eb8c57c84cb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTAtMS0xLTEwNDUyMg_d4fdb3db-aa0e-4d72-a547-b6141dcb35d9"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f542fe236ba49be97003a22c3952e2f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTItMS0xLTEwNDUyMg_774d7263-b0ab-48e4-a054-5f43f3fdcb2f"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b924aff33144adbbdbe4b55024bc966_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTQtMS0xLTEwNDUyMg_22a8413f-887b-4ffa-9008-2751e9ae9b68"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab8df5b8207746d79c0457bf4ecf84e4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTEtMTYtMS0xLTEwNDUyMg_6180070c-c6fe-42a6-b6a2-6e9f4cff6fb7"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0309aadc6ff4ac2b67d133870ecfc21_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMi0xLTEtMTA0NTIy_0761ec7b-5054-420f-a896-cf0889412d17"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f78bff3afeb44fabb11776d7ffc143b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItNC0xLTEtMTA0NTIy_c620771f-2cfd-4661-95b6-e3e0a4aa2cfa"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ad40f3526c94d2a8d401c53ce69ea1a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItNi0xLTEtMTA0NTIy_5d81cbdd-d543-47d1-9b04-586bc4f40169"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7716776c36cb4bd491d74086bfb7ecb2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItOC0xLTEtMTA0NTIy_0e948c73-9965-454b-990a-593b64198d15"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if12564811a9e4bdca5202382aefc69f6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTAtMS0xLTEwNDUyMg_34cca6ce-3ea3-4fb0-a671-498d2136479f"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c956ed6342b42718cec14ac863bdb58_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTItMS0xLTEwNDUyMg_dd671c37-9a65-4085-a787-f677050c9dde"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb10d32aec44247a4f5d7cd6e811377_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTQtMS0xLTEwNDUyMg_1f0b8a63-ea90-4051-bc81-3ab0ce3e7e6c"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d5f964326e14b269641c03739405c1e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTItMTYtMS0xLTEwNDUyMg_469189c3-76a8-41e2-ad65-fee21116ea64"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7a3b05ecdb94c10ab42d41aa1405831_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMi0xLTEtMTA0NTIy_ef9d3a40-9fba-441a-b010-e1e7514b8641"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c6a13f318f24325a71e2857063f5848_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtNC0xLTEtMTA0NTIy_1e626381-ee8d-4bfa-8f49-0121ade342e1"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie82e4d1739634b57a20ede2010592159_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtNi0xLTEtMTA0NTIy_21a7084e-e6a5-4266-b1f3-db0640a31905"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibefee3ae93504f46a2d372c49fdf40ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtOC0xLTEtMTA0NTIy_54bd0fe9-fe77-494f-b649-f5c9ec24b0ed"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic97f28b8981248dbad7137dfc8e3f6db_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTAtMS0xLTEwNDUyMg_bd51ec28-4a56-4c43-b959-007322c0bc04"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a54006651944977a0f2ea299b135a39_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTItMS0xLTEwNDUyMg_9e1b4f7a-897b-45b3-9a39-52d60a10615a"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i900a3386106549a885dd226281746116_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTQtMS0xLTEwNDUyMg_9555ad2a-267c-4d98-9d08-6d5e46795528"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dbbdd491da34ec79838d8ba4a860828_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTMtMTYtMS0xLTEwNDUyMg_6026b5a2-5570-453c-be6b-81193964e9fd"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i640cb048ad564d1eb126e98c3f9dd4cb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMi0xLTEtMTA0NTIy_897b10e8-af23-4331-9e4b-5122ccabb001"
      unitRef="usd">2862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice89761ab066473ebe252ea4efa20c75_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtNC0xLTEtMTA0NTIy_ba4ffb8f-4e79-4f68-8d44-e164359baf3f"
      unitRef="usd">550000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d27e27d65994e5c99f272ab08bdca75_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtNi0xLTEtMTA0NTIy_23536fa9-15cf-42df-a52a-f9d8d7317fb1"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i972d712715ae466db4de275f56044425_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtOC0xLTEtMTA0NTIy_7e25cd8d-a6bc-483f-8342-b7c6104c07e9"
      unitRef="usd">3707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92246dae9bf04aeda16066d6e5e604ca_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTAtMS0xLTEwNDUyMg_1464ada2-8502-4aca-83dd-38eab5209e36"
      unitRef="usd">2786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic905d65961ca41f2a16684c08c4b1170_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTItMS0xLTEwNDUyMg_6c301e44-8412-4798-8c15-a8bb826618f8"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1f3508e4df94ef2aa9af3131d031ebf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTQtMS0xLTEwNDUyMg_951c091a-13a4-4a52-acd7-12c2bb944d37"
      unitRef="usd">286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a89c780806d4aaf9d6742d4500a8692_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTQtMTYtMS0xLTEwNDUyMg_5e433278-1092-4e0b-86cd-48cd69fabeb1"
      unitRef="usd">3650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9080da0fd2da4f02a87f7d29708792ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMi0xLTEtMTE4NjA5_2b769192-f54c-4348-8cf0-26fec5888bb8"
      unitRef="usd">801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b77ced81c9d459e8714ab97c49ac8e6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNC0xLTEtMTE4NjA5_317e7e5d-3ead-4841-a34a-e3309e18402f"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17ec7cb46bf4485eb4111720cefb6f25_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNi0xLTEtMTE4NjA5_8f8967dd-37b2-48e4-b648-3fa075b2518d"
      unitRef="usd">430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8dcfee614954446f890fad6e3acec329_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtOC0xLTEtMTE4NjA5_400f2083-1337-4c27-99df-59c15baad836"
      unitRef="usd">1535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bc5bd1f95304695811a90a3fb77aa6c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTAtMS0xLTExODYwOQ_bcc5d86d-f8f0-4238-9317-a0f0051ae055"
      unitRef="usd">820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49e4003abdc8446fb15dd00423d76bfe_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTItMS0xLTExODYwOQ_fe6e7b54-16da-4f30-b4f4-fea7d22773b6"
      unitRef="usd">388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d6ba86f84d04fbbbe732f5893719820_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTQtMS0xLTExODYwOQ_9687e8bc-bfcf-4d1c-937e-421fde7c0035"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34a987fb1a2345cf9feca51b56f3002e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTYtMS0xLTExODYwOQ_60622f47-6095-4e9c-9fd6-2b02c3450098"
      unitRef="usd">1456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e1151230a7249eba5e92c53b6c99591_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMi0xLTEtMTA0NTIy_55b2e086-3673-45f1-9736-dd9a0c4ea891"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3886fecdb734baca592defec1da8854_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNC0xLTEtMTA0NTIy_faaa9da2-3a68-49d3-95ea-4dc1e03b9b12"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ab0e630afcb4839815382487e6d7a71_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtNi0xLTEtMTA0NTIy_c1a287c4-ec15-4273-9ff7-9680737420d7"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i990036800e314c019d9924b8c48d9a69_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtOC0xLTEtMTA0NTIy_8a6404ac-6ced-4e31-95b3-72336f6b79df"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i654b56035ac5429299e0bf0750f7c159_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTAtMS0xLTEwNDUyMg_9645c601-f8aa-41db-8730-3ef5fb9c95ad"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i912899de9e384b4991388b77ab326802_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTItMS0xLTEwNDUyMg_7b25b99f-6f1f-4021-9894-362aea3aea29"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22a0eb3a98cb45b6a547ce971f34baae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTQtMS0xLTEwNDUyMg_161182ec-d075-4c12-9264-a9e41123132a"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbcc4494362d4aeb9f8d78936bd67dea_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTYtMTYtMS0xLTEwNDUyMg_2d525dcd-5e81-4776-8a74-ff1b337ee40e"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3fc4821b2594c9bb862fc7dfbd1c7e6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMi0xLTEtMTA0NTIy_b2b97fd5-4a17-4f3a-99f4-59b7a68bf262"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d9bd2c916494ddfa644ed66486ffa3c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctNC0xLTEtMTA0NTIy_a5b52cae-3a69-42c6-8df8-b5d41d6be585"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9ca5a367cbb4823bbb2ddbaa8ba1531_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctNi0xLTEtMTA0NTIy_322300d0-e2b1-4f14-bfff-6f757119728f"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2191fce5382f493f98627963be2fd34f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctOC0xLTEtMTA0NTIy_f69d8c1b-3dc7-4b61-8ac7-125fed2a648c"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d13d672db4940049677cdc0bedae177_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTAtMS0xLTEwNDUyMg_37bc8827-1fec-43a3-94ef-be5b17ed68b0"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5736172bd8c74fa9b0b84ecba12b6da4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTItMS0xLTEwNDUyMg_e4388a7d-724e-4578-81e1-2a60bde8be09"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia072a52bdb734592ad37964a3ef65749_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTQtMS0xLTEwNDUyMg_aaee60aa-c5cf-469c-83a7-f38ccbc1f27c"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3ac5763bfd14785880a550fa2c4b4a7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTctMTYtMS0xLTEwNDUyMg_fcc1ee76-e05e-4360-9db7-53991c6255ba"
      unitRef="usd">381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i362e3866a26a48cd8450a9aed1b9c71a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMi0xLTEtMTA0NTIy_ad1df343-4c04-498b-bf24-cc296258b682"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b64a5280a334b8d87dd853cc7b50fb2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtNC0xLTEtMTA0NTIy_2b3c0894-b18d-479d-a18a-694fa8b9d64e"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice1247c9718f48619c3461a53ade8241_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtNi0xLTEtMTA0NTIy_30d19e47-1efe-4b71-b634-00b217d4f796"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38923dc977ec4c608fd74bd8d1002b89_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtOC0xLTEtMTA0NTIy_d230fc59-b270-42c4-83d5-02cbbe3799a8"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibce473a465f24a4587c7b09d8571a2e7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTAtMS0xLTEwNDUyMg_53619a59-b718-4a49-b2d7-554fc4846b09"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd98d98b9029490083e145d555397c64_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTItMS0xLTEwNDUyMg_267d07c6-acba-44cc-ae8c-123a2bca7091"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49d9927d07794d42b9acd485d0be4ccc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTQtMS0xLTEwNDUyMg_70db9f1d-7482-4ab3-97b4-3ca6edf15f85"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28cc147626d342f18fa203f1fffaeda0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTgtMTYtMS0xLTEwNDUyMg_793d24fa-f1c9-412b-b55c-a7103759e5bb"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45dd1b2780dc41fb9de50648b1af8b36_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMi0xLTEtMTA0NTIy_7c4fc935-c5ec-4b94-aa9e-7d17b0fc8998"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88b0273edd1d40f39c13f63cfaa3039f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktNC0xLTEtMTA0NTIy_592bbb2e-bc24-48bb-9895-3907c4b4c31a"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib343c66d342c48b188ec538e601a802f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktNi0xLTEtMTA0NTIy_062e1c8f-b479-49bd-bd77-289e9a84543d"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i331f92fda21545a788d654fdc98d17fe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktOC0xLTEtMTA0NTIy_10e30a90-1294-4a60-b78f-553e3c6707a9"
      unitRef="usd">399000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id370a2241bdc4d15986cd6b2356a1be4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTAtMS0xLTEwNDUyMg_7483f75a-1f6d-4dee-ad54-de12947713ce"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24a17bd8d6a14480b89ee581a835b1a4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTItMS0xLTEwNDUyMg_01b54fb7-82d1-4e04-90e2-c4cb37dcc97a"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5e3587978b4fad9196cbbc06ce3e95_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTQtMS0xLTEwNDUyMg_6c894881-967c-4a29-ad61-bb31d55d6d56"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f7bc0ebe5e34348a81d50bcaaf131cc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMTktMTYtMS0xLTEwNDUyMg_cdf41d97-f84c-4fa5-9aed-5333f01876cd"
      unitRef="usd">510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37ef9863b06448f19486cc46a20126f6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMi0xLTEtMTA0NTIy_8b97c10c-5fe1-4d3f-8e49-30db6586ec6e"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fe7dfedae9e4ea69012d15a904e0bed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtNC0xLTEtMTA0NTIy_8648669b-5a38-478b-bfcb-a12ca12493e8"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedc8c47023174a3ca739f65aee4d80be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtNi0xLTEtMTA0NTIy_28936303-8261-4b1f-8939-5d364f2494c5"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcc10b00ada44fdc804e51838f1acfc3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtOC0xLTEtMTA0NTIy_e8e54fb3-026b-41b0-8511-19ac968c2f7b"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ffa5ec1dd4840c3b41240ec44fb1a8d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTAtMS0xLTEwNDUyMg_586aefb9-10fe-4de0-b394-8af1e963c0b5"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a3c2ed8de2c45ed8ea22f65a1300661_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTItMS0xLTEwNDUyMg_900ef2f2-5d77-4f32-b42b-2611d4fc9cd6"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92b98d9083b942118db200dec1a903da_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTQtMS0xLTEwNDUyMg_ebee309e-e00b-4792-8670-1f1d0cf6a0bd"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf0b2687f723400eb3f2b51560d5627e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjEtMTYtMS0xLTEwNDUyMg_7f9af099-49ee-4187-9c94-3c10e431c15f"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7bb17eb8edf4095affa55b5c94b7511_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMi0xLTEtMTA0NTIy_cc14e041-9891-49ad-94c4-e38bbc4f1183"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e82886013e34e8cb5b040660f8b2134_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItNC0xLTEtMTA0NTIy_a3ea7e2e-56eb-49bc-824b-42e030d1b28f"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if62e1f4cdbc94d6496e8d6e303892aea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItNi0xLTEtMTA0NTIy_36644848-913c-4e66-8cf3-d068bb4fe796"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e3a26232e49487cb08e72e73e05cd8f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItOC0xLTEtMTA0NTIy_3e8c0a94-7752-4700-9d07-b51283857725"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i601e9f250eff46568a11f08fe9496e7f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTAtMS0xLTEwNDUyMg_972fc4d7-d91d-42e4-bafa-8e581c40704a"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0f013c8b8554acdb3ac0e4cb83b0826_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTItMS0xLTEwNDUyMg_892fe2a8-69c6-4699-b1c6-f866bdb7a29e"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ade0cdccab94dbcad52ed0019f0c921_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTQtMS0xLTEwNDUyMg_83492df6-882f-4d93-8c7f-849a59012e77"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ae0e683ad6b40c2a698b3d311bc01d7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjItMTYtMS0xLTEwNDUyMg_629a8e54-6a4f-49a7-a70c-ab497a9c79bc"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88dee8c0fd39453297ea8ac9fead6e30_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMi0xLTEtMTA0NTIy_094a5e4a-3e57-4d37-a4b8-778a67aac255"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1ab69156b914bd9a8d4a4bf92a01786_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtNC0xLTEtMTA0NTIy_de821fc5-d51b-4875-a41f-aaff811e8d99"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ac685a4449e4a41827017a39c195f98_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtNi0xLTEtMTA0NTIy_276e6e73-851a-4153-9a86-5632b4d9eb12"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c9317885eae4f5e974a6c62a56a7eca_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtOC0xLTEtMTA0NTIy_c4c30d79-37f3-453e-96d3-b96e5c9236b4"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b9e05a885fd437c97e145bf9ebb7f92_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTAtMS0xLTEwNDUyMg_208a3e3b-89f0-4b83-bb2b-a9215ac32d33"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8982d5cbae8145d4a736780033c94930_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTItMS0xLTEwNDUyMg_91983b3f-4946-4e12-9a92-e5f0393562c3"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i258f51e659e04edd969980eb593baee3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTQtMS0xLTEwNDUyMg_38ffc887-9b0c-4edf-b03d-a8751d0588dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab12b495137c43e6886d664932ca0d4e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjMtMTYtMS0xLTEwNDUyMg_bc3ada64-f828-4b8e-946b-367f6ccce55e"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6427ea1ce218423483ed2d165863e48f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMi0xLTEtMTA0NTIy_57b0ea39-ccde-4d1f-a59a-e02217eb34db"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c48e2dcd6644766923dc0cb2bf31d07_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtNC0xLTEtMTA0NTIy_3821b083-d4c9-400f-9afb-4ae36e5c6fa9"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4ce309faae5419f8ed78774354b4a97_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtNi0xLTEtMTA0NTIy_975b968f-1a03-4741-93ff-0ba00a2258e5"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38350f5e76ed41d99e350a0226a0b299_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtOC0xLTEtMTA0NTIy_92e1fdf4-6436-433d-8218-bf2f1e2127b1"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3578cd64764c43b28d8596a841916105_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTAtMS0xLTEwNDUyMg_0c74087e-e562-456b-a9d2-83df9174cc38"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b523e88394b42e49bca13934b5204c0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTItMS0xLTEwNDUyMg_9d879529-01ba-493c-8208-f779e00b7cc0"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04b50daaafcf4acdb978f2b3cbc02a69_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTQtMS0xLTEwNDUyMg_489f8a67-9f4f-4e84-a185-835651053264"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4df11eb0e9c46829ee856f8acd0ac01_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjQtMTYtMS0xLTEwNDUyMg_b2f572f8-eaeb-4341-b174-0297cc0d095d"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b9973fb9aa4626ae5ac04a936c01e4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMi0xLTEtMTA0NTIy_2aeb7a58-a21b-402e-96bd-9e2a79896c6d"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50a95859331e4ac19317036e0daf101a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktNC0xLTEtMTA0NTIy_5d178b4d-97da-4e24-ad5c-fa6a9934d512"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47f5a7f19d504c2ba7ff905f67f4d127_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktNi0xLTEtMTA0NTIy_1250c031-441f-407b-b523-ae41311f1ca3"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63c624c206e4400e9df42232adf50e0d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktOC0xLTEtMTA0NTIy_85b90de9-46ba-489a-bdee-2bff084d91b3"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1322e9bf1b8348f6aa69afe538a30158_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTAtMS0xLTEwNDUyMg_2fe79d6c-1e3c-4613-b133-36463cad7236"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife80ece44c874be5a32808230e9cd4aa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTItMS0xLTEwNDUyMg_23655d1b-c642-4522-9f4f-e213ef38b25d"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if82cf194379246a1859100c8bba11cca_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTQtMS0xLTEwNDUyMg_9c16c8a3-308a-4451-9f1a-86aea1e4c784"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6781ab9027f460c9cf7dcef1a2581ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMjktMTYtMS0xLTEwNDUyMg_e24ba681-2ecd-49b0-81f6-7afc41ecfa12"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc5f0d1cad9a4d5c88b552349bd0e426_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMi0xLTEtMTA0NTIy_1cf9dc55-489f-40cf-ab2c-3007ca8627eb"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1092026c503d4c2caf06ab450b1a56e6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtNC0xLTEtMTA0NTIy_21f1110c-4c38-4f19-919e-f0db2dcfeda4"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d9cb25ede7b47f58962912789bb85f0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtNi0xLTEtMTA0NTIy_12f83c5f-97f7-448a-be94-58c3d4482c0d"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f208e609ef24694949d9d18a38323a4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtOC0xLTEtMTA0NTIy_5e517fee-7f16-4337-97b4-c70b636d71e5"
      unitRef="usd">211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6282aee3fc5402ba404682fb65354b3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTAtMS0xLTEwNDUyMg_44716598-b840-4f87-923b-e4d970b15981"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39dd6b3aa4eb4ccc9b8976c09c4c815c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTItMS0xLTEwNDUyMg_1024249c-6d90-4852-8c43-feedb1ce2263"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1077536f948c4d599ca3de2b9fa0caf0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTQtMS0xLTEwNDUyMg_ec9205df-64c3-4969-a1a9-27f7e9c1ba96"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i591623e8a2444a6294da53ce3e3564dd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzAtMTYtMS0xLTEwNDUyMg_6aa711f7-e2de-4ae2-b20f-1b17e344751f"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e7a0afec35c4ec89e02da19e66297a3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMi0xLTEtMTA0NTIy_520afb66-0914-4765-acce-933dfc909d3d"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5e1f408f244494e83312207a23684ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtNC0xLTEtMTA0NTIy_4e9540e7-cbed-40f3-a28d-c164598e979c"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id370f64f9232406da268e72edab2bb89_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtNi0xLTEtMTA0NTIy_b01c9049-00c6-4008-931a-28e88e31c8a8"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9a1637a55bc47ce876af3c9b975c36b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtOC0xLTEtMTA0NTIy_a8529be9-b63d-41cd-9f15-b14fad41d368"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i004d4d1e19524166b98a5650d0a3d5b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTAtMS0xLTEwNDUyMg_c9bb368c-986d-4ca0-b487-c1d0608ca0c2"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4868996536f41c395fd9eb7bf456345_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTItMS0xLTEwNDUyMg_237153d6-a18d-4152-9d1b-4cce5ac0a406"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9510dc0a1cb48a09b7cf7cee5127926_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTQtMS0xLTEwNDUyMg_5ab4d3d9-4164-4fca-8246-51c0a307e5b0"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14f21e46dfd54c5088e33fe80e268c5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzEtMTYtMS0xLTEwNDUyMg_af428052-df34-45f8-a384-802a70836401"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i506b80edb1094a058227180fe89d36be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMi0xLTEtMTA0NTIy_48681040-e565-47bd-b845-101302898360"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc2da0fa42e9465fa82e367afd29d07d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtNC0xLTEtMTA0NTIy_30b06da0-e366-419d-9d8d-ed680915300e"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45d45fdbebfa497793e9c785c45cd171_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtNi0xLTEtMTA0NTIy_a58b6118-5edd-4ccf-af2e-e7243fb0b43b"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbd6c25925024d0ca5e62c2eb0d94599_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtOC0xLTEtMTA0NTIy_814dbc2f-f37e-4bcc-b012-734e602bf819"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie575076324b442bb96747058f585fc96_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTAtMS0xLTEwNDUyMg_2de44423-7a0a-4510-a9cf-4104c3a91c31"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ab947b2302b41098d510e78eec884f9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTItMS0xLTEwNDUyMg_e033237b-e7de-4872-9bf8-d67264f24d4c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87e1c13afe4c4b36b0e56bcf32399b38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTQtMS0xLTEwNDUyMg_f25e8f10-9afc-4f1b-9c19-a0f7c18058f0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99e85eb47143437996c24d62ee7a5072_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzMtMTYtMS0xLTEwNDUyMg_5b0980bb-27be-418c-bc2b-dba016ab7262"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8e4818a6e7548a7bbf17c683d46095a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMi0xLTEtMTA0NTIy_eb22d7df-4258-40e0-9840-4efc0b92c1d1"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19f6ecb369e549f69bab7f9d26c72c13_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtNC0xLTEtMTA0NTIy_d61d8521-a620-4630-ab6e-2656ba22a7cb"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc546c6f7ee04e13856084c40921bee6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtNi0xLTEtMTA0NTIy_bb74e02c-c399-4216-8fba-0505e24318f7"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dc670dab94b43efac0330f320d308ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtOC0xLTEtMTA0NTIy_36d396ff-b4ff-4ebe-8a07-51fbb6704d25"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9d67453bf2b4b61b493a79e64689edf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTAtMS0xLTEwNDUyMg_68c68a09-3aa8-43b8-a4b7-9527bac183ea"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibedf0dddfad54c6d83baf2098d0cce00_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTItMS0xLTEwNDUyMg_4be2de65-03aa-43aa-8ed2-4b99bb6eeb69"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i636b58243bec406486f70783ac586b07_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTQtMS0xLTEwNDUyMg_a5583074-4859-4dab-ae08-9d7794ad5caf"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceea7510047144d48d7b55394af029e5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzYtMTYtMS0xLTEwNDUyMg_db4e1ea2-a887-48ba-901e-06f9d5de35c3"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fee66d032984dd9a95ce2b80bdc73e4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMi0xLTEtMTA0NTIy_c605960c-ce2f-456f-8f3d-7e20c7767801"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ab28717012a4316be156607025ebbee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctNC0xLTEtMTA0NTIy_d5010182-0c96-4766-af44-28cdf35d2540"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc1e16a6586047f7aa6d8cdf0cc52aee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctNi0xLTEtMTA0NTIy_7d78f743-fab8-43b5-97c5-9be1f114b42b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i707cbcb9a5dd45609f9783347b2969a7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctOC0xLTEtMTA0NTIy_aef4f39b-3ccc-4769-bc52-94f2c8441137"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd56e62b9064dbfa19723ea33df5f2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTAtMS0xLTEwNDUyMg_335cfbe5-dc7d-4395-b25a-380f26cd4f2a"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28abe53df7b94be6bd5527b6651854c4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTItMS0xLTEwNDUyMg_250d349e-303b-41ac-8323-8a0e1f7bfe19"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i883d4917ebfd4efa968bd072df8d5d90_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTQtMS0xLTEwNDUyMg_950a563e-68c5-4708-98fd-c4558fc80644"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i611a9bb6162246d68e854f3e608a8ba8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzctMTYtMS0xLTEwNDUyMg_ec5fe45b-85c6-476c-b912-0af17cbed9a9"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3f69128a6d940b0969c29eb905e9e01_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMi0xLTEtMTA0NTIy_956a460e-fb65-4b0f-93ce-3d0075e3de70"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72629c36c3ac4b5c90339697d9b5841c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktNC0xLTEtMTA0NTIy_40e4ab87-76df-4579-a989-48572688e0f3"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aab0d0a8a054b2191999850619d3215_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktNi0xLTEtMTA0NTIy_cbaaa799-ee24-4129-bb69-173a4c3b74e2"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5f81b41c6ab4c1a8172650fc81804cb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktOC0xLTEtMTA0NTIy_d1b25bc5-c6be-4986-b300-3054e0be03b5"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3b35be1f6524162a052f75f2c305f1d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTAtMS0xLTEwNDUyMg_02a37201-082e-4124-85ce-37f2649b1304"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9470361de7e54728a05b1c0b65a767b4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTItMS0xLTEwNDUyMg_1d9376fc-86a4-4098-86b5-61c4febf2ec3"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb419930edcc478c9416d2a9cb5ddb57_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTQtMS0xLTEwNDUyMg_1c97d320-a0f3-495f-a034-82217d411756"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib36489d020f7443788b3cbd0ccfb9d0f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfMzktMTYtMS0xLTEwNDUyMg_1d004b20-46cb-45e1-a377-ebf526b02ced"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c4299b47fa4635908637e78b2e1670_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMi0xLTEtMTA0NTIy_276ae63a-c49c-45ed-9738-57673f0795f4"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2e9c418833d40b2b818caa3cd26b3b4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtNC0xLTEtMTA0NTIy_f010686a-a839-411a-9979-58c323acb347"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c739ead4a5e450393f03a09963c462d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtNi0xLTEtMTA0NTIy_073b8266-80cd-431d-bcd0-85b215a72413"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ca722e30584518aa14b0e7bf67600b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtOC0xLTEtMTA0NTIy_77438d70-1fb6-4960-9ac9-330f01b48e04"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd10541ce9cb4f0baa1c775e04fcff49_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTAtMS0xLTEwNDUyMg_abbfa0c9-5faf-4af1-893d-bac3415b720e"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i842cc6151e23445faaa596d0f12d6d10_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTItMS0xLTEwNDUyMg_2498db20-554e-47bf-9152-68d4935514fe"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4d0c4f130c9455faf16cf800852d2a2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTQtMS0xLTEwNDUyMg_b77c3d21-1c82-4204-874c-12cbfa17ba17"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i133f797d043a461884b3be51d030f6bd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDAtMTYtMS0xLTEwNDUyMg_a293ecf4-891f-4a7a-9601-88900887bcf6"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b794129571f4c3d90efb49ef01d3118_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMi0xLTEtMTA0NTIy_70e8457b-2b39-4557-9c50-7f68ca4142fa"
      unitRef="usd">4329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82d4742d49c541aaaa995cdc86772e9d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtNC0xLTEtMTA0NTIy_81c6c79b-083a-427d-b903-ea10c650fddc"
      unitRef="usd">1174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6352cfc350f64fb58df0dbdcb47f284a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtNi0xLTEtMTA0NTIy_d998fe15-967f-40b1-b0e3-b126c3a2062a"
      unitRef="usd">1031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if150cff9011c4cb8865c7d010dea19b6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtOC0xLTEtMTA0NTIy_31e271b0-a00c-44b5-bcb9-3f7d8c8461da"
      unitRef="usd">6534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac215de11e334702b29490e622de1ee9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTAtMS0xLTEwNDUyMg_0a764d9c-bd11-4cbc-95cf-0bb32d0e5711"
      unitRef="usd">4240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ee61ad8ad9b4ceeafdbe187f3ac6b18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTItMS0xLTEwNDUyMg_57aad22b-f4b8-48f4-9003-3262e9d3dd0e"
      unitRef="usd">1275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9db6c1894c24e5c940af32de705648b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTQtMS0xLTEwNDUyMg_7c377f5f-0382-4d0c-913a-90e3d33e174a"
      unitRef="usd">825000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ad8a561a83946e2be71c0773364df03_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDEtMTYtMS0xLTEwNDUyMg_ad3afcf4-4f6b-4fa4-bbc8-b945af52a9a1"
      unitRef="usd">6340000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f41643b44694636b95fbedee07cb74a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMi0xLTEtMTA0NTIy_ecb1baa8-6f79-46d6-b8df-bba81ef2c918"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58b4c37dbec149e580bc98a08db8a779_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItNC0xLTEtMTA0NTIy_4f08d92c-3034-4293-a803-6b793aaa595e"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i562545855775425380ef8229edbcd63c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItNi0xLTEtMTA0NTIy_696ce9dc-554b-4351-a849-9f14ecfee51a"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6adca2cb2df45159579306959cd9182_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItOC0xLTEtMTA0NTIy_146ba18d-356f-4418-86f3-7acce6e15be3"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie425b655a72c4978a3a152d215d89082_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTAtMS0xLTEwNDUyMg_a2e7e4a3-74f9-4b42-a3c9-16e889ef7e30"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5e961357d334fe1868904f1cf61fe7f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTItMS0xLTEwNDUyMg_42dbb1d0-1238-4a13-8186-82fa9472ff2f"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35f038b7cb5048789472b556cec62a76_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTQtMS0xLTEwNDUyMg_e3137f8e-44ab-4440-b610-4a1f053bb968"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92f491d481954bfb91bb63808792a107_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDItMTYtMS0xLTEwNDUyMg_4164a112-8648-408f-b635-59f5a9cc26a2"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i450e90b0899c413f9adda90b2983c33f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMi0xLTEtMTA0NTIy_27538656-cfdb-44cf-b6f1-30f15107bcaf"
      unitRef="usd">4355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e918b0999104da8bcafade720bc9b31_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtNC0xLTEtMTA0NTIy_4fdb3889-789d-4cea-9089-794273f1a245"
      unitRef="usd">1202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3686af1f019f450eb7208b0baaafb092_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtNi0xLTEtMTA0NTIy_c932841c-21ad-4446-8b47-8a0c7fc16d39"
      unitRef="usd">1033000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtOC0xLTEtMTA0NTIy_b990cd25-8f13-42c8-bade-128173cc456d"
      unitRef="usd">6590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i574f697fada244ed8d5d02623914c1e9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTAtMS0xLTEwNDUyMg_632099fb-a12e-4453-95d9-c9a0facdec94"
      unitRef="usd">4260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0734cb68049494fafe29592fc4b53af_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTItMS0xLTEwNDUyMg_c47b289c-5604-4f18-a063-5661ed8f813e"
      unitRef="usd">1336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67e181e2c5404c43aaf1a8e699cb5ecc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTQtMS0xLTEwNDUyMg_5039f048-89ad-4b2e-af72-16c3a106556e"
      unitRef="usd">827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmY0MDZiNGJlZGQ2YTRjODE5ZjY3YmVjMDZiZjUwYWEzL3RhYmxlcmFuZ2U6ZjQwNmI0YmVkZDZhNGM4MTlmNjdiZWMwNmJmNTBhYTNfNDMtMTYtMS0xLTEwNDUyMg_a98077ae-6d73-471c-9457-395abdd4da19"
      unitRef="usd">6423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjU0NA_34f428a2-294e-4e8f-8c50-d0b9b6d20d63">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i176dd2b5900a430a8769d523c75624e5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfMy0yLTEtMS0xMDQ1MjI_7c6b7085-c4ed-4afe-a94f-52934fe68bd8"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i95bedcc32b2b473584af9e33a7e1d845_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfMy00LTEtMS0xMDQ1MjI_ced3f01f-a6ed-4913-9582-1cfa3f67f093"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8bb49adc0c914214b0cf681200d4116f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNC0yLTEtMS0xMDQ1MjI_318d6acf-eacd-44a4-b551-9817a6c42625"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5d9ccec8490648f89cb63618723a451e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNC00LTEtMS0xMDQ1MjI_3cc4c446-dcdd-4965-bd21-d58204c1c7a8"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i328a5479a2be4ecabc38b95ddd05d567_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNS0yLTEtMS0xMDQ1MjI_e35bcd78-41ed-4aca-95df-b5058d84b98a"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia4739475a7bf45baa7a16fc49ba98df2_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOjRkNTRmYzg0OWUwYzRhMTJiMDdmOWU2NDVkNmY2YzJiL3RhYmxlcmFuZ2U6NGQ1NGZjODQ5ZTBjNGExMmIwN2Y5ZTY0NWQ2ZjZjMmJfNS00LTEtMS0xMDQ1MjI_85fbab75-12f6-49e6-a646-2ac7fac14dc6"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfOTM0NTg0ODg0MzIzNw_b77b7b76-b1d2-4b28-a519-79e59906b1bb">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues recognized from performance obligations satisfied in prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue share with Janssen and royalties for licenses of intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMS0yLTEtMS0xMzIyMzA_9bc9391b-eb09-4077-92b5-69e07be9feba"
      unitRef="usd">184000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMS00LTEtMS0xMzIyMzA_4a0d01a1-bc2f-4862-ab4b-bdd80a0b0770"
      unitRef="usd">226000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMi0yLTEtMS0xMzIyMzA_502f9a4a-d3fa-4420-bf30-45c249135ff1"
      unitRef="usd">230000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RhYmxlOmRmM2Q2NjRhYTZkMzRlNmU4Mzk0MjFjMzQwMWI1NzM5L3RhYmxlcmFuZ2U6ZGYzZDY2NGFhNmQzNGU2ZTgzOTQyMWMzNDAxYjU3MzlfMi00LTEtMS0xMzIyMzA_23a45783-d8d1-406c-800a-d619b0ab75cf"
      unitRef="usd">332000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMTk5Nw_db95270b-b93c-487e-979e-046e8f5600d3"
      unitRef="usd">160000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfMjAwNA_9137152f-52b7-4e85-9224-f0ff9b6476dd"
      unitRef="usd">174000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfNTQ5NzU1ODE0NDkzNA_47dd9695-03fc-45e1-9333-7d73ced1c5a1"
      unitRef="usd">117000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8zNy9mcmFnOmQ0NmU1ZTNjNDhkODQzZTBhMmE1OTJiMWY5YzcwYTE5L3RleHRyZWdpb246ZDQ2ZTVlM2M0OGQ4NDNlMGEyYTU5MmIxZjljNzBhMTlfNTQ5NzU1ODE0NTAwNA_f74cdc79-9f42-4fc9-ab3f-afd14cd1c84e"
      unitRef="usd">79000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNzg1Mg_1f3def52-7658-4d01-b53f-69256cbf197f">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Derivative Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $25.6 billion and $28.6 billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and the carrying values were $25.1&#160;billion and $25.6 billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the change in fair value of our contingent consideration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange remeasurement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in valuation assumptions were primarily related to updated probability rate estimates. The changes in the fair value of this contingent consideration were included in Research and development expenses on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to the Sale of Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded a liability related to the sale of future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.1 billion and $1.3&#160;billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and the carrying value was $1.1&#160;billion as of March&#160;31, 2022 and December&#160;31, 2021. See Note 9. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Level Transfers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we recorded a partial impairment charge of $2.7&#160;billion related to certain in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) assets. See Note 7. Goodwill and Intangible Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfOTM0NTg0ODg2NDczNw_4f4dad93-6e98-4ec5-83a5-30fcd029bbfa">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Derivative Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNzg2Ng_193ee416-3d8a-4efa-bb34-b4b704e9341d">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i76465e7067f243bca6ad8e5ab38fa633_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0yLTEtMS0xMDQ1MjI_6afa7e92-8261-42e4-87fc-a99288bc1473"
      unitRef="usd">476000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i140c790345dd4179834f4c8b07bfb8b8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC00LTEtMS0xMDQ1MjI_3b4df6ce-b7fa-4bb3-8a1d-707172d9f32d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i96ce8aecccf3444880c9cbaeee334a73_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC02LTEtMS0xMDQ1MjI_102e46fe-c2cd-4d50-8914-7b05b36416d4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia8429eedb67b4e29966dd05758722f62_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC04LTEtMS0xMDQ1MjI_22853ae3-2032-4ee5-8600-09e59ad742ba"
      unitRef="usd">476000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7f66a5967db44f1b832d3882c44a50ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xMC0xLTEtMTA0NTIy_52eba0db-6e78-47e8-9e8c-fbebd7cacc7d"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i74725ac875c8489088c9e3ce59925700_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xMi0xLTEtMTA0NTIy_0ac9fed2-69cc-45db-ac46-52ab79b285ab"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i98f3a5ba27de450689d4df428849595e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xNC0xLTEtMTA0NTIy_1c0cc295-37c6-4768-8d13-fc8fbf1a9fd7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i63ef3595a00743e5a7af8c76c459e14b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNC0xNi0xLTEtMTA0NTIy_570c39fa-232b-4360-a786-1c068c6265af"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if01ae90f5f764dcda9f3b84fb3c0c54b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0yLTEtMS0xMDQ1MjI_d3cffdf5-dced-4813-a80e-da854a4c2afe"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia88cec99f19b4e1aba4ef2f6127972fe_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS00LTEtMS0xMDQ1MjI_04af66b2-040c-47ba-82ae-a588b0637643"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i68d68f81dce946ce9958065f41c11dd2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS02LTEtMS0xMDQ1MjI_671c7c47-b038-4c04-8e4f-33568623e9a6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i200e82b6162646ee8c54e3be1e9b651b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS04LTEtMS0xMDQ1MjI_a0125fe0-82b4-4f04-925b-7c20b18367b3"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia86049893a634ee3bb28b8e42ec50e44_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xMC0xLTEtMTA0NTIy_f0a57e9a-b1b7-4f54-a543-2be4f5827da1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i862defdf94944941b57660ed32b562fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xMi0xLTEtMTA0NTIy_74d33b3a-54df-4167-bdf6-502736a6a689"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia1a7c5c399874ea6acc5ea1cb2da6ec1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xNC0xLTEtMTA0NTIy_2c058a8f-642c-484e-b9f1-6d69610193b6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if7ebbebfdaf14b6faa9cf2fe95f1a416_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNS0xNi0xLTEtMTA0NTIy_641b022b-1e92-4e82-aca3-772b121749fa"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i22c3072371fb40e1a27e1c3eedd45a42_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0yLTEtMS0xMDQ1MjI_a0cd7045-e498-40ed-a314-bccef88f4185"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4f5096915ac2409d8fc7cf00977aa468_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi00LTEtMS0xMDQ1MjI_fa7a00f4-0b10-42b7-8691-a8cef5bb775d"
      unitRef="usd">30000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i22e40aa5ee08404a8b9fba38e9c1d51f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi02LTEtMS0xMDQ1MjI_ad6b78d1-604b-4cd5-b789-5c9934397e4c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i19d00e372db14beba5926893075d82e6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi04LTEtMS0xMDQ1MjI_fa2a92b0-33d1-4c5e-89eb-87c49d9a868e"
      unitRef="usd">30000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i057d3b67bbe0417c9f5751710eecc36e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xMC0xLTEtMTA0NTIy_9ef018df-3677-4a68-a98c-edae7163b71e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i03b8f69f452145d684659547efc6183b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xMi0xLTEtMTA0NTIy_ce7b6913-8843-4656-b015-f04d1e4cda48"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifcf9472d8837472bb72056071e3bcc2b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xNC0xLTEtMTA0NTIy_e1c873c4-6733-47ed-b0cf-129bdf523015"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8a947129bd0b4128a5b74a946315b11d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNi0xNi0xLTEtMTA0NTIy_6c747dd6-ff45-415d-b7db-fc8ad4818ce2"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icb035999fbde4492a61824d97546fcf6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0yLTEtMS0xMDQ1MjI_11ac28ed-10b7-45cb-8fdc-43b8e4c336b5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7e163c502c3149529b2710b48e018b35_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy00LTEtMS0xMDQ1MjI_c517f0f7-4f77-4e13-9915-d8eb940e4615"
      unitRef="usd">153000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8a70f62d258b4e2a84bcf2d184731151_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy02LTEtMS0xMDQ1MjI_12e3475b-7882-449f-a944-9a8403e85c0e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i021f337b4cdf48d7921f51bc2532b923_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy04LTEtMS0xMDQ1MjI_eef92ec1-5875-45a6-89c2-11742e80a7a2"
      unitRef="usd">153000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id6bc8a9e6e2c4acd97a125ed75216ff4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xMC0xLTEtMTA0NTIy_1876567e-94c2-488c-81f9-e28fb21433b6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i48bc95c69093435488202bb8c647ad08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xMi0xLTEtMTA0NTIy_9e8e60ab-761d-4176-831e-b74c873c840d"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ided8687dc3744e439646e8257fdd793f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xNC0xLTEtMTA0NTIy_e874f288-d217-4d7a-ad1f-5a23a380f9c9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iad5c5562a7eb4824ac24cfd6ad279dd2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfNy0xNi0xLTEtMTA0NTIy_96c41785-143e-4ec8-a247-4c741d8961c9"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i88c103262dfb4e5284221d8be36cba80_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0yLTEtMS0xMDQ1MjI_813de5b0-cf11-45ef-9be5-1855b797523d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia39db5b06f794fb18a7032c5fc0bc7ad_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC00LTEtMS0xMDQ1MjI_7b7b36d9-5c9b-4693-a64c-3fe9efef89de"
      unitRef="usd">1442000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i270271b7414b4aee9f1a3da9ce2b7382_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC02LTEtMS0xMDQ1MjI_fd4ddab3-656a-4da6-900f-4581496c1e20"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id8b2f24271294a2eb663d0975ebee946_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC04LTEtMS0xMDQ1MjI_e7b122ff-42d6-42f8-826e-8e71bb250d28"
      unitRef="usd">1442000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5a0d52cd14ad4c7580e4dec70cc96976_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xMC0xLTEtMTA0NTIy_04ed836d-a2f8-472e-bdc7-e96c45ce73e0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i99ccd9e592044f67803b6e2b75ca4260_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xMi0xLTEtMTA0NTIy_750bd55a-9e72-474d-8be3-f9d3ac4b305f"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5efd8fc300e2405d8b1f4a654504ec05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xNC0xLTEtMTA0NTIy_2dca1958-5b75-4ebc-8486-e901cb04910c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idae51e28be204725a4f236b9b15f9524_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOC0xNi0xLTEtMTA0NTIy_ab5c78bc-b5de-49b5-8e9b-0017c44037aa"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i65cb7a08d6804ff499cfb7252fb8d9fe_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0yLTEtMS0xMDQ1MjI_bd3d5f92-a2a6-4b3d-bbc9-49184a63e305"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i59ccd377ef1345a6926dc2a8fa826850_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS00LTEtMS0xMDQ1MjI_19e72150-6e76-4d5c-bc71-d422b4e1a230"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i205b417c4c654633a4bbb6e38d915d6a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS02LTEtMS0xMDQ1MjI_153676c3-072d-47a4-aec8-90a726493b21"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ife6351d7d85d4ec18acf7c5279c0884a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS04LTEtMS0xMDQ1MjI_21524f6c-2576-40e9-bff7-ab4798f66051"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iee9028ea70334edabc968f604261d6af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xMC0xLTEtMTA0NTIy_425e30ba-6735-477f-8fff-4e23b33ea336"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i05e3897facac41f1a56e386be016d76c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xMi0xLTEtMTA0NTIy_0f1ebd85-0bae-45b6-98aa-90ac904d7104"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i11f063731fee4046908c3a1a1e0053e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xNC0xLTEtMTA0NTIy_e0ea33b8-faa4-4b98-b342-b28f7140341b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3b3f51c3344b4ed2b2fab26b0aa77412_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfOS0xNi0xLTEtMTA0NTIy_8f5b40d4-4fe2-422d-8009-1e09417b5e53"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i99305aacdd484354bade2301930b1542_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMi0xLTEtMTA0NTIy_ff99d8f1-3119-4d63-be44-b966e210f225"
      unitRef="usd">2360000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i857c66ec002c4aa9adc11ff5a2424048_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtNC0xLTEtMTA0NTIy_597d294f-ce40-4579-905a-75f8c070af2e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id6e34a0b5b1545cda6d7fa644e9297c0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtNi0xLTEtMTA0NTIy_0da6fefb-2e4a-4e53-a33d-eaf94d9ce6b4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib2525c2cad7949b99b59099149545ad3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtOC0xLTEtMTA0NTIy_f862c001-e1a3-40a5-9966-c1ed35f88daf"
      unitRef="usd">2360000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9cb98e1a8d414c63a4f91b8642e4d776_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTAtMS0xLTEwNDUyMg_9de527b5-1203-4990-bba3-7e224ae83b58"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idc4c6d7874ba4f5fa0cd030ee16e21e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTItMS0xLTEwNDUyMg_37ca43f2-8790-4cea-bc1d-0763cce37b36"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib298944c5a5b499fbefa89414cfbc34f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTQtMS0xLTEwNDUyMg_9715c5fa-3203-4661-9a89-d0630d37ca57"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6f568032fe6c4908a1cc54d8e025aeaa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTEtMTYtMS0xLTEwNDUyMg_01cfa4b5-1a16-4cec-a691-1b8354966912"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9b04d9ed9c25401c862faf9f0dfe47e0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMi0xLTEtMTA0NTIy_05b4d098-dac8-430a-955c-216750d5a025"
      unitRef="usd">1046000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i14683cfbcb854f06a1133e77aa8126c6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItNC0xLTEtMTA0NTIy_2adc4a39-0627-47d0-9afb-5525a9cb5b82"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iadf1e7edcd4c402a93bfc7b9231c5eda_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItNi0xLTEtMTA0NTIy_a69fd48f-0d4b-43d7-a490-d5b09023d827"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if272f16215814e408fee0ea6c0c68918_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItOC0xLTEtMTA0NTIy_8b2a72a8-ecd1-4b81-9e9f-62e599e1e662"
      unitRef="usd">1046000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifaf49983739c4f4a92b0acd7196c9d45_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTAtMS0xLTEwNDUyMg_98890c10-0e42-4a67-8626-30ba5b2edcbb"
      unitRef="usd">931000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5214efc2a7ec4769aefb4a504c5a9fa7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTItMS0xLTEwNDUyMg_3bf2801d-0ea9-4ef1-8ee3-36861ebef94a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id5c97fddb35a4c2fbd8c78085e1dd095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTQtMS0xLTEwNDUyMg_c82672ca-1120-4f49-afda-8867d2efec69"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib84f70f7509f4f20b5f383de8dfd0a74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTItMTYtMS0xLTEwNDUyMg_e569df50-bcf9-4a30-a852-1e52d2b1d403"
      unitRef="usd">931000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iba3a5f1c0fd04bc09a8d036709d8b1f9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMi0xLTEtMTEzOTYz_207b40c1-d6a7-4d2f-a0fb-513b04c7ca09"
      unitRef="usd">436000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia8b37e4f1d2046feaafd8f5615f12122_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNC0xLTEtMTEzOTYz_d7b5f1be-cf63-4cf6-843d-9bf3cdb40493"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0a71d4ce57724fd3ac83a73b7bbef78c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNi0xLTEtMTEzOTYz_3eacc498-b064-40ef-a200-4936038ec747"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if50020f5f6954fe0a1e6658494e5a775_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtOC0xLTEtMTEzOTYz_cab68d2f-39f3-4a85-a018-474eaa9ad9ff"
      unitRef="usd">436000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i99a5f1893f3547fa829f8586420e43d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTAtMS0xLTExMzk2Mw_8e0b4707-7402-44d1-8b80-6cfe8381d87b"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7331130ff6d8406cb228958b17149855_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTItMS0xLTExMzk2Mw_62e5fbe8-cf24-43ec-ad0b-dae6158ea1d9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1008a176c6de4b40a6a73b757acc7f70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTQtMS0xLTExMzk2Mw_82df13b6-ccb3-424c-bca1-a3cec317e3b7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ieabf4e0443f74462a97365b827ffa008_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTYtMS0xLTExMzk2Mw_4b9b17bb-2e82-4fcf-8d9c-4f2f6a921bc5"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i358f4a3297e542349a9a568ed3b11df3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMi0xLTEtMTA0NTIy_6dcd0032-d794-4418-9c42-8c68e76a5e34"
      unitRef="usd">243000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id569202dda104d39a7a750670b0d84bb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNC0xLTEtMTA0NTIy_3a81f245-84a6-49b5-8397-3f8a007eba09"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7d750d13d4f649cab754bb9764317fb5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtNi0xLTEtMTA0NTIy_30fd8aa2-a6c0-415a-9c38-d2c479fd6bae"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iccf1acc9c421458f93a3f08a21c062ba_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtOC0xLTEtMTA0NTIy_d7aa1f80-c0d5-497b-ad62-0c6ff3a6d193"
      unitRef="usd">243000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib0d6618cd7c4444e8afb57f3ae24ade4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTAtMS0xLTEwNDUyMg_b32f7c1e-2acf-43cb-b2af-592288ea80a4"
      unitRef="usd">331000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i66a0bbba08f347d193e2b1828a35d52d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTItMS0xLTEwNDUyMg_b0a8da61-94d8-450f-b159-abfe8527c6b8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i309bbd4aa703457b9a31d2fde9c76235_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTQtMS0xLTEwNDUyMg_eb06394d-e5c4-415c-88f3-dcb2ef7eb57e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iedb39a7d3f58491b9ccb76970fd032bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTMtMTYtMS0xLTEwNDUyMg_406926d1-0a7e-484b-8add-f8392b8fa605"
      unitRef="usd">331000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if8e18d952c0446c1ad43e7467144a8d1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMi0xLTEtMTA0NTIy_dd2ac758-12ae-448c-bb70-8fda8e51c1eb"
      unitRef="usd">253000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8c5c242b674b44679c627a7248ef2819_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtNC0xLTEtMTA0NTIy_5cbfc957-4264-46a3-8450-80c7d2739c9c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i09ffe45070124a318e73e7a6e504352a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtNi0xLTEtMTA0NTIy_de8f2201-ca8e-437e-a5d2-547fd0f7dbb0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i71e3eeefe5c946fba06a0bee7b36d266_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtOC0xLTEtMTA0NTIy_ef636fc9-422a-4bee-9477-cc4b465bbbd3"
      unitRef="usd">253000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iae857828574b4a668d913b270f8b36f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTAtMS0xLTEwNDUyMg_7f9cd8fd-7155-4edc-84da-c94e5148864f"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id9d49299020542a392c3db192ea63db8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTItMS0xLTEwNDUyMg_23048ace-a546-4e8c-8ffc-ff39c06fae1b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i43e2337e11144df5a90e99b5c638a73c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTQtMS0xLTEwNDUyMg_27c4fe09-ef4e-4703-8c1e-1e3aabc1879a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic70726c081bb4947af4189a219572868_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTQtMTYtMS0xLTEwNDUyMg_b45f6a94-bcf2-461e-9f07-273565e19b54"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i16f3a3d42167442d9bea77b4bb2f39e6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMi0xLTEtMTA0NTIy_5cb65a50-73ea-41d9-b7bc-8c5ff5491c9a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i03f1eba71d184d8ca513113104bff510_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtNC0xLTEtMTA0NTIy_71c8ca05-5ee7-46a5-8dab-0e885e8ea65c"
      unitRef="usd">84000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0b1cdaa3e0f34234bf362b822775dec5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtNi0xLTEtMTA0NTIy_d66d46ff-0278-4874-86e7-b73a0e98aa5f"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8204c7a6c9e14f10be68903951892472_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtOC0xLTEtMTA0NTIy_98c2b828-7330-42ae-b97c-e0832aca3c57"
      unitRef="usd">84000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iebf92a809cfe4430bf1591de1f172efd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTAtMS0xLTEwNDUyMg_2aebf6f1-a56d-4fd0-86a5-3ebd66dc811a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0e0e2e41b80c40d189eb508b9f0e5d8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTItMS0xLTEwNDUyMg_11be32f4-5b72-4fc2-a9d4-2025d569606f"
      unitRef="usd">80000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i4692d33efa2e4c1a903bbfa6eb1bf652_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTQtMS0xLTEwNDUyMg_69018aef-c86c-4a6c-b090-eb692973b895"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3a9a9dc69fb240d1812e5cdbb79f5bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTUtMTYtMS0xLTEwNDUyMg_b415bd4b-045a-4b6e-8fe1-30b81ba9a85f"
      unitRef="usd">80000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e426ceed16d4ea0b50c79b82c4ac9ed_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMi0xLTEtMTA0NTIy_87652bc7-a92c-48c9-925b-ff69e8898c17"
      unitRef="usd">4813000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie023e3f9d84842d5b43ecca161e36545_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtNC0xLTEtMTA0NTIy_e510db05-2b5b-4395-ae53-5cec4550063a"
      unitRef="usd">2122000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc443f74d743469fa8a5404cb1d7b20d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtNi0xLTEtMTA0NTIy_2c58b954-1c52-4828-a1c5-5ad62aedbce1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtOC0xLTEtMTA0NTIy_2e684bba-0df1-47c6-bd69-21d6eed21243"
      unitRef="usd">6935000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9276731dd9df4019aaff0654ed7ba115_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTAtMS0xLTEwNDUyMg_6cd0e985-2a91-457e-a64a-cdb5842cd429"
      unitRef="usd">6150000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifcf82d3635af4b94b02308fda06d4aaf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTItMS0xLTEwNDUyMg_50e09fde-c529-4f13-8190-28784eaa6db2"
      unitRef="usd">2170000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7023a532dbca4fdcb35a761a941711f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTQtMS0xLTEwNDUyMg_d76b2a3e-b889-4dcd-b7d6-1d9a3cd67f84"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if019e7ba00f744d384b6d00260c70676_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTYtMTYtMS0xLTEwNDUyMg_a53823a3-60a3-4577-ab65-bf7005fa8a4a"
      unitRef="usd">8320000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic736f3c433054ecab5e86925ad5cd22e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMi0xLTEtMTA0NTIy_76ce4c25-f6fe-4926-bdc3-ad81a286b6ee"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i81d2ad95a1744b048be0fefbdfa02051_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtNC0xLTEtMTA0NTIy_76b9a7b7-6a24-4020-bbe0-4adda2e8c3da"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibafcf9464f63422d9fb63a2de8d93d48_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtNi0xLTEtMTA0NTIy_a0aadfc1-356c-44d1-bf1e-63f4de548e8c"
      unitRef="usd">322000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic7f5465ec02d4a35b998d802608fff25_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtOC0xLTEtMTA0NTIy_d5b8c1ac-747c-4063-8880-c73d8621e950"
      unitRef="usd">322000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i874752c3de8541159a7aed9141a3553e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTAtMS0xLTEwNDUyMg_447da145-505b-49d3-bb1e-4fd049d9b29b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ide78159bcbbd42a48bbbcc894680d340_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTItMS0xLTEwNDUyMg_0114fb90-9f3f-4b0d-8e75-8a383c647041"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3a54e53274284e9ea52e289b3ec3aaee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTQtMS0xLTEwNDUyMg_4ca3a327-900a-469f-be2d-a8a5db5d974d"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i44d6fced1e674a6a8d953ff5bc008fef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTgtMTYtMS0xLTEwNDUyMg_26a28418-9956-4255-bae8-bca7c392d766"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if8e18d952c0446c1ad43e7467144a8d1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMi0xLTEtMTA0NTIy_c356a5c4-3a38-47ab-8965-c2fc5cfc34b0"
      unitRef="usd">253000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i8c5c242b674b44679c627a7248ef2819_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktNC0xLTEtMTA0NTIy_e350aab3-427f-4aea-8730-544d2f412cfd"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i09ffe45070124a318e73e7a6e504352a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktNi0xLTEtMTA0NTIy_312c1b7c-84cc-4a85-b2da-1bde2e3ce221"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i71e3eeefe5c946fba06a0bee7b36d266_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktOC0xLTEtMTA0NTIy_dfaeb27f-f761-46c2-9eff-d848e3f12d50"
      unitRef="usd">253000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="iae857828574b4a668d913b270f8b36f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTAtMS0xLTEwNDUyMg_30fe1229-e3f8-4c20-a156-c97c5d12edf2"
      unitRef="usd">261000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="id9d49299020542a392c3db192ea63db8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTItMS0xLTEwNDUyMg_ac526e49-1712-4b1d-a5b7-242fc96eaeb6"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i43e2337e11144df5a90e99b5c638a73c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTQtMS0xLTEwNDUyMg_94f55190-54f5-4313-b887-8f5e76f98a29"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ic70726c081bb4947af4189a219572868_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMTktMTYtMS0xLTEwNDUyMg_d529ab00-fdca-4f09-a779-ad886cd5149a"
      unitRef="usd">261000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i16f3a3d42167442d9bea77b4bb2f39e6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMi0xLTEtMTA0NTIy_969f2120-cbb4-49f0-b928-e24189936ecf"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i03f1eba71d184d8ca513113104bff510_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtNC0xLTEtMTA0NTIy_584076b8-d661-4db9-affb-80951ff8ad5f"
      unitRef="usd">11000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0b1cdaa3e0f34234bf362b822775dec5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtNi0xLTEtMTA0NTIy_11004db1-bb93-48d2-8cca-040038f33a92"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i8204c7a6c9e14f10be68903951892472_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtOC0xLTEtMTA0NTIy_8aaf67cf-6eec-4155-a3b6-ff212065ea4b"
      unitRef="usd">11000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iebf92a809cfe4430bf1591de1f172efd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTAtMS0xLTEwNDUyMg_5ee06c0a-f510-4c94-a54e-e750771d395d"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0e0e2e41b80c40d189eb508b9f0e5d8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTItMS0xLTEwNDUyMg_922b4836-b334-49ac-89f4-940db1aa47d8"
      unitRef="usd">5000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i4692d33efa2e4c1a903bbfa6eb1bf652_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTQtMS0xLTEwNDUyMg_47f00c0b-5df8-47e7-8a36-4ee4851ac5f6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3a9a9dc69fb240d1812e5cdbb79f5bf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjAtMTYtMS0xLTEwNDUyMg_532b82b7-3bd2-4bd7-9190-ba36accc7f7e"
      unitRef="usd">5000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5e426ceed16d4ea0b50c79b82c4ac9ed_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMi0xLTEtMTA0NTIy_2ba67594-d34b-42e2-8820-3f6ecfc6bf96"
      unitRef="usd">253000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie023e3f9d84842d5b43ecca161e36545_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtNC0xLTEtMTA0NTIy_938f4a4a-c839-4f75-8b59-052011e489fc"
      unitRef="usd">11000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibc443f74d743469fa8a5404cb1d7b20d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtNi0xLTEtMTA0NTIy_44f3092d-4cc7-4feb-8408-aae05db21c7e"
      unitRef="usd">322000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtOC0xLTEtMTA0NTIy_092bda81-d3eb-4df5-af0d-becac7942546"
      unitRef="usd">586000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9276731dd9df4019aaff0654ed7ba115_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTAtMS0xLTEwNDUyMg_c08e0215-8474-4638-9483-c4c718b5af97"
      unitRef="usd">261000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifcf82d3635af4b94b02308fda06d4aaf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTItMS0xLTEwNDUyMg_fede4433-960f-4624-bbe9-eab50fbf1fef"
      unitRef="usd">5000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7023a532dbca4fdcb35a761a941711f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTQtMS0xLTEwNDUyMg_0a201571-0157-4aa4-bfe3-67ce1fdf97f3"
      unitRef="usd">317000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if019e7ba00f744d384b6d00260c70676_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ0NTRiMzg1NTI5MjQxNGY4OTdlYWVlNjVlYzA0NjQ2L3RhYmxlcmFuZ2U6ZDQ1NGIzODU1MjkyNDE0Zjg5N2VhZWU2NWVjMDQ2NDZfMjEtMTYtMS0xLTEwNDUyMg_33ac6f3b-cba4-4b43-90ae-f89955043969"
      unitRef="usd">583000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LongTermDebtFairValue
      contextRef="idb992b77b3444d00b7b2813dab4e0089_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNjY0MA_7ba0c1b8-f3ed-4cb2-bf7a-74b6558e2a71"
      unitRef="usd">25600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="idd69502271af4d6eb175d2a6ec3ec8ee_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNjY0Nw_94b99952-6ed9-49de-84ed-6e97b2ee6f44"
      unitRef="usd">28600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i90dc5662383a49e5addf18ac3694d3f8_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNTQ5NzU1ODE2MzMwNg_379682b0-fbbe-4b91-83bf-cab96e4e524a"
      unitRef="usd">25100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia58d2c0a64564683a5f1a7c8f578f7a2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNjcxNw_cb442fc6-8dae-41fd-a1b8-ac276d2d29c8"
      unitRef="usd">25600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfOTM0NTg0ODg2MzU2Mw_19eee1a2-f1fb-4ae7-b45f-a4144aaca370">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the change in fair value of our contingent consideration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange remeasurement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id4ca803e36054d509ef339b251361ad7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfMS0yLTEtMS0xMjExNDE_3c3c8daf-2d31-4079-8e0e-fc6c8624b663"
      unitRef="usd">317000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i49c0710e6642417481cd192d1e448da3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNC00LTEtMS0xMzMxNjk_d4284e56-4a3a-4b91-95f3-729efb7b7ed2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNS0yLTEtMS0xMzMxNDM_7798920b-5e64-4893-a364-f30dd2fc95f9"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNS00LTEtMS0xMzMxMzc_b67de630-94b0-4d48-b93b-46684d6d113b"
      unitRef="usd">341000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfMi0yLTEtMS0xMjY3MjY_0eabc17f-1302-4e27-aef0-7c7ca2984e58"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNi00LTEtMS0xMzMxNTc_af7aff58-d495-40bd-98bb-392ba0752982"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement
      contextRef="i0709b059280d46d097ee75bd5e11f822_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfMy0yLTEtMS0xMjY3MjY_ce368028-965c-4f0c-8678-4dcd6df03f57"
      unitRef="usd">-6000000</gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement>
    <gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement
      contextRef="ia035fa2caa754f57971eb00a3c0ebfe1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNy00LTEtMS0xMzMxNTc_4a83d9d8-f734-4ecc-9dc6-8e67f3573b2f"
      unitRef="usd">0</gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7300d904ed1b4713acd2ddc7fb40833f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfNC0yLTEtMS0xMjY3MjY_8b5fe326-bb72-46c4-ba13-8688d96697ec"
      unitRef="usd">322000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id78d4bd4a4574be68dce08afe8061e93_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RhYmxlOmQ1MjM1MjdmZWY1NDQxNmM5YTM2MTI5ZTg1ZjUwZWNkL3RhYmxlcmFuZ2U6ZDUyMzUyN2ZlZjU0NDE2YzlhMzYxMjllODVmNTBlY2RfOC00LTEtMS0xMzMxNjQ_da2a297f-8874-460f-865d-dc9c5ae8a59e"
      unitRef="usd">341000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i120e85817179476683841797ae988eef_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODExNA_6471393f-b3b8-4db4-b473-cfe38a83e042"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i0978b5f9be8f41cb89b77a87ab36cfa2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODEyNw_3bf19d37-cb75-4476-891d-89bb5d63cdc6"
      unitRef="usd">1300000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i7d9c20940c1043059e2558cfbd912517_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODE0MA_60cf6268-0a56-4ff8-87ad-fd086c6566f2"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i7b177f8e4b4d4b6080d2cf0a7bb6b531_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfMjE5OTAyMzI2ODE0MA_bf2b74a1-0288-41f4-acc5-34ddf1503845"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80MC9mcmFnOjEyNjIzOTQ0NWQ1MjRhNGRhNzVjODY1NGYyYmVmMWFlL3RleHRyZWdpb246MTI2MjM5NDQ1ZDUyNGE0ZGE3NWM4NjU0ZjJiZWYxYWVfNTQ5NzU1ODE1OTU4OQ_eeb492c2-0a0a-4ff0-80fa-022d9e506532"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjU2_538242db-f09e-47cf-a1e9-3f198549d6e7">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held a total of 618 and 203 positions which were in unrealized loss positions as of March&#160;31, 2022 and 2021, respectively. No impairment was recognized for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Securities Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments and other equity investments without readily determinable fair values were $375 million and $338 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized Gains and Losses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net unrealized losses recognized on equity securities were $96&#160;million and $351 million for the three months ended March 31, 2022 and 2021, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjI2_7dde92f4-899d-4ee6-abb3-8f90fb9506df">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0yLTEtMS0xMDQ1MjI_c09b8002-63f1-4b66-b2a9-6d0317c4ae37"
      unitRef="usd">481000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi00LTEtMS0xMDQ1MjI_e9b266b8-40d3-4d26-acf6-6a6012a58c09"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi02LTEtMS0xMDQ1MjI_0c6b4ef5-abf8-43aa-a102-560284e2bf44"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i17c16bb301b54c84b267f1a8eb4d6be1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi04LTEtMS0xMDQ1MjI_aaf91f3c-3840-4b7f-a1d6-c783ef75405e"
      unitRef="usd">476000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xMC0xLTEtMTA0NTIy_3a405dd4-dea4-4105-a6f0-4cacdfe22560"
      unitRef="usd">408000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xMi0xLTEtMTA0NTIy_1beca765-587c-4564-a1c9-1e3ff2df4f2f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xNC0xLTEtMTA0NTIy_cffc3563-128e-4242-81a8-8b31323395c5"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i98a57fe489af45e99b1deeafae96476c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMi0xNi0xLTEtMTA0NTIy_e4a9a921-20cf-403a-b528-47ee9134ed88"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9a35912508b74867862fe94d3155d586_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0yLTEtMS0xMDQ1MjI_00592bf5-3668-4fcc-a9dc-86d4da52d496"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9a35912508b74867862fe94d3155d586_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy00LTEtMS0xMDQ1MjI_3f26beb4-a4d5-4aab-acbc-cedaed8f7d95"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9a35912508b74867862fe94d3155d586_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy02LTEtMS0xMDQ1MjI_5bc96538-bbf6-469d-8d9c-9d9aca2ec613"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9a35912508b74867862fe94d3155d586_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy04LTEtMS0xMDQ1MjI_03081edd-d091-49ea-b8c8-33e765294019"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xMC0xLTEtMTA0NTIy_837a8157-2e23-4f50-a3d6-8b1063ffdfdc"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xMi0xLTEtMTA0NTIy_42978181-cb9c-4d51-89c2-0d5247030cf4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xNC0xLTEtMTA0NTIy_dc747f42-b663-425d-b4dd-1f89643ba541"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6297966b092c4f5a888d0ccf4cd376a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfMy0xNi0xLTEtMTA0NTIy_4e990d67-c4c4-44e9-be20-4e83a6870de9"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0yLTEtMS0xMDQ1MjI_658d0b98-e266-4218-a4d0-84aa0545cef4"
      unitRef="usd">30000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC00LTEtMS0xMDQ1MjI_c127478a-e9aa-45c5-9cd2-5629cc8644d6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC02LTEtMS0xMDQ1MjI_7f09d1af-1bfd-4a8a-9e92-efc22dfaeaef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9d44fdf6091a441db520ad3f8f024aa5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC04LTEtMS0xMDQ1MjI_0a2978ef-a75f-4f16-a2a3-211fb9249ac0"
      unitRef="usd">30000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xMC0xLTEtMTA0NTIy_9a06a7d5-7200-4c9a-a742-6e98bf8302ad"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xMi0xLTEtMTA0NTIy_be0794c9-36ef-4d62-99e6-3274c7c8e7b5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xNC0xLTEtMTA0NTIy_e21c0eac-6b1b-4c33-b50f-e70af214b99f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0686faed9f3d48b5ba1aea7cc705a7ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNC0xNi0xLTEtMTA0NTIy_238c511a-1222-4cee-9118-50f2a3da2f72"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0yLTEtMS0xMDQ1MjI_65c1f7b5-e971-4729-a7dd-55caf5200217"
      unitRef="usd">153000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS00LTEtMS0xMDQ1MjI_baa0aa14-b504-4432-9c11-0f63e501081d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS02LTEtMS0xMDQ1MjI_b4cc3fa3-cede-4db1-a446-ea4ad8b4ef5c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib456b5dd5eba41d78d922d73a09bf090_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS04LTEtMS0xMDQ1MjI_940634bf-52ff-4cb0-8c01-2d23919733eb"
      unitRef="usd">153000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id130f892b445421ba418a4ff87945c26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xMC0xLTEtMTA0NTIy_8ceb2f10-0b82-4ed7-8154-16240160cddf"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id130f892b445421ba418a4ff87945c26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xMi0xLTEtMTA0NTIy_dc1d3509-0207-4012-b82c-57197eb19e3e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id130f892b445421ba418a4ff87945c26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xNC0xLTEtMTA0NTIy_d5440f97-733e-4713-826a-4a5c0d7fecf4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id130f892b445421ba418a4ff87945c26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNS0xNi0xLTEtMTA0NTIy_804a55cb-e50d-4230-b243-269641b0ca1f"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0yLTEtMS0xMDQ1MjI_ef4bd06a-15a5-476e-8014-26ac954aab03"
      unitRef="usd">1457000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi00LTEtMS0xMDQ1MjI_0188e06f-52d1-42c2-bbb9-99c4eacbc979"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi02LTEtMS0xMDQ1MjI_97839ab1-2a6a-4378-b39e-1cf06d7c4dd0"
      unitRef="usd">15000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5a01243e2a6c4eff8fdaabfda90ee0a9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi04LTEtMS0xMDQ1MjI_0ed47ca5-fef3-4240-a45a-ac60c7f61c2e"
      unitRef="usd">1442000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xMC0xLTEtMTA0NTIy_7e1e4d94-a400-4ba9-b3a7-81d2f39feefe"
      unitRef="usd">1365000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xMi0xLTEtMTA0NTIy_cf94801f-8b2d-49e6-9637-8e3e909c5c82"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xNC0xLTEtMTA0NTIy_325db30e-30a4-47d2-a8fb-268900747bba"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic528c221d89a4614bb571ddc51d780fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNi0xNi0xLTEtMTA0NTIy_a4a6c09c-a5eb-4402-8324-60691cda5038"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0yLTEtMS0xMDQ1MjI_6d61034a-9bd1-4651-9866-dba369924997"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy00LTEtMS0xMDQ1MjI_4e36bf6d-f6b5-44ae-b5b1-93327a39ff9c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy02LTEtMS0xMDQ1MjI_a439af9a-9b58-4bc1-aa4a-4f5d7aff25b3"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4be735be6bd241ddb4bb0c132722eb91_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy04LTEtMS0xMDQ1MjI_a0f3c5a9-9eb6-4e9b-89d7-fef033258729"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xMC0xLTEtMTA0NTIy_f5a45adc-1dc9-4794-8400-b4591e7c1a55"
      unitRef="usd">425000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xMi0xLTEtMTA0NTIy_a7360677-07ee-4004-9314-eddaf0ec4b3e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xNC0xLTEtMTA0NTIy_8c2f3d89-435b-4328-9496-6e184106ac2b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib9cf360eb5e3415a9a0263a4cc8a6ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfNy0xNi0xLTEtMTA0NTIy_b3d0568e-c879-4d1e-8a43-0db0216f8999"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0yLTEtMS0xMDQ1MjI_da07a98e-60ce-4df2-9227-808fac733fee"
      unitRef="usd">2536000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC00LTEtMS0xMDQ1MjI_ffe733a8-6893-49b3-b9b7-b237babb6499"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC02LTEtMS0xMDQ1MjI_0a6c0352-cd5f-48cf-a70b-c40efa8365bf"
      unitRef="usd">23000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC04LTEtMS0xMDQ1MjI_9588f326-d8d7-41b6-9388-0e522e817b06"
      unitRef="usd">2514000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xMC0xLTEtMTA0NTIy_0cb23c22-4d65-4f8c-91b9-4b4336684bbe"
      unitRef="usd">2501000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xMi0xLTEtMTA0NTIy_4d1d7f9f-680e-4582-b584-f0b417280bbb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xNC0xLTEtMTA0NTIy_b661883e-7ff3-437c-9233-22819b605809"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjk3YmJkMzZkYjg3ZjQ4MTBhNjM0ZjViZTc3NzAwMjAxL3RhYmxlcmFuZ2U6OTdiYmQzNmRiODdmNDgxMGE2MzRmNWJlNzc3MDAyMDFfOC0xNi0xLTEtMTA0NTIy_3e537204-8bfc-40c6-ac4c-de645b63a645"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjIz_bc347487-aa18-4c34-96e7-8d2ca623e745">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iecd6c25aa9ef435ca2a940cd82ec2eab_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMS0yLTEtMS0xMDQ1MjI_55812d08-84b2-4498-8133-9a6bf8c62d8c"
      unitRef="usd">57000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id76e15d8f3034561bc0f77901e95f300_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMS00LTEtMS0xMDQ1MjI_d844262b-fec5-4bca-bfca-2c16e6b702fe"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i734040fec2ae4fefa9ac801de7c29378_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMi0yLTEtMS0xMDQ1MjI_325832b7-0cb5-477e-a886-513c9e17ed6b"
      unitRef="usd">1029000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i972796d2c85047ffae7e45d4d942a4ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMi00LTEtMS0xMDQ1MjI_cc7b602a-c283-4e06-98fa-907436ec2c8b"
      unitRef="usd">1182000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i61f8d6f5408d437593d6ed14249728b1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMy0yLTEtMS0xMDQ1MjI_fc0c8e8e-0c5b-4153-8a62-f7cdb6d3c2eb"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i366bb0c4a80d436dab4d980a44b57763_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfMy00LTEtMS0xMDQ1MjI_05666835-c93b-46e9-acb3-a61fbce3a57f"
      unitRef="usd">1309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfNC0yLTEtMS0xMDQ1MjI_2be23c89-35e9-4350-a032-89975adff1e8"
      unitRef="usd">2514000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjFhZTZmZWI5ZWFhMzQ4NDJiNTQ2NjNhOWVjMDM5YWY2L3RhYmxlcmFuZ2U6MWFlNmZlYjllYWEzNDg0MmI1NDY2M2E5ZWMwMzlhZjZfNC00LTEtMS0xMDQ1MjI_15e255bc-0ce2-48ca-962c-1afd4e55a8f4"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNjI0_5fc12776-4345-4e29-b9dc-009fd2405024">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMi0yLTEtMS0xMDQ1MjI_59347e90-7c7e-4e10-b37e-0ab92db9bd42"
      unitRef="usd">1091000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMi00LTEtMS0xMDQ1MjI_2e7dbf9b-1ef0-4aa5-8d2a-bcb9571f4aa3"
      unitRef="usd">1086000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMy0yLTEtMS0xMDQ1MjI_7ef98d84-6169-469b-b3ca-f15db9f6b99c"
      unitRef="usd">1414000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfMy00LTEtMS0xMDQ1MjI_ba563ad0-15f6-4c5e-bc32-cb61dd0cfd0a"
      unitRef="usd">1397000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <gild:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNC0yLTEtMS0xMDQ1MjI_7a4b8f06-40a8-4f22-8deb-bb881695c49d"
      unitRef="usd">31000000</gild:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <gild:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNC00LTEtMS0xMDQ1MjI_9ed63bc8-3a3b-4e51-b9ca-892f69d3b7e1"
      unitRef="usd">31000000</gild:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNS0yLTEtMS0xMDQ1MjI_beddf1db-c81b-4a86-9437-f9579d106b33"
      unitRef="usd">2536000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjY3Mzk5YzY3OWMyNDQxZGE5NDEzYzNlMDQwMTYyMzQzL3RhYmxlcmFuZ2U6NjczOTljNjc5YzI0NDFkYTk0MTNjM2UwNDAxNjIzNDNfNS00LTEtMS0xMDQ1MjI_95ad106f-ecd8-4936-99fe-c7df7be97a39"
      unitRef="usd">2514000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMzA3_c641800a-2c18-4149-bc96-fb916956d67a"
      unitRef="position">618</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia9796d93b2414e28a30a1b8602920120_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMzE0_e695f8d0-a8c3-4af2-930c-4d08ad10708c"
      unitRef="position">203</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTc3_0b300bc4-cc9b-45bf-8a83-b2136605f3ff"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTc3_18a1be71-cb73-47ae-a57d-b1c66356adbe"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfOTM0NTg0ODgzODU3OA_d187c464-0f2b-4610-8cd6-6795ec03e7ce">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i54513ac7f8334fc5b465981879a0f801_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMS0yLTEtMS0xMjIwMzM_0d9bd69e-d136-43dc-af25-c7902ff703c8"
      unitRef="usd">2360000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7f1a320253be4fd0b8481aa6a57537c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMS00LTEtMS0xMjIwMzM_e400a970-3de1-4f4a-9834-98225e95e964"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic0589c2ad7eb480b8da2a801c4d25063_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMi0yLTEtMS0xMjIwMzM_a1904df2-8b00-4938-9c87-f91702a3523e"
      unitRef="usd">692000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4120862280544540a63c21d7e97b6c0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMi00LTEtMS0xMjIwMzM_ec828040-246e-42e9-a09f-ea454ed06982"
      unitRef="usd">885000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2a456fff65c843b6a626df4ea2ce55e3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMy0yLTEtMS0xMjIwMzM_23c59880-9d53-4992-b7c1-1c2c3e8d1fbf"
      unitRef="usd">1286000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3ed49fdba2a147c4b79505826a478d36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfMy00LTEtMS0xMjIwMzM_a6d47e4c-d4f0-44fd-81d5-43572a13d92f"
      unitRef="usd">1197000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee6ff6cc00ff41f8b7ec36a69139238b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfNC0yLTEtMS0xMjIwMzM_079f1f46-c672-434d-b00b-eca83e43e95f"
      unitRef="usd">4337000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b085d7670ea434382d8a85edb3d068e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RhYmxlOjAwYTc3MjEwNWZmMTQ5ZGY4YzdhZWUzMThiNWRkMjJlL3RhYmxlcmFuZ2U6MDBhNzcyMTA1ZmYxNDlkZjhjN2FlZTMxOGI1ZGQyMmVfNC00LTEtMS0xMjIwMzM_0e6f3a44-6e3d-4582-8539-c5408c4c5bb6"
      unitRef="usd">5743000000</us-gaap:AssetsFairValueDisclosure>
    <gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMTA5OTUxMTYyOTUwOQ_26fae77b-5968-4fa8-b613-8a2ce1e59687"
      unitRef="usd">375000000</gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount>
    <gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfMTA5OTUxMTYyOTUxOA_14e47a32-721c-42c7-86a0-78a32cb5d4ec"
      unitRef="usd">338000000</gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTQ5NzU1ODE0MDkwMg_8cb72680-e217-4cce-8d3d-6899cf6d1562"
      unitRef="usd">96000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80My9mcmFnOjFjZmZmMTI1YjhkZDQ0OTQ5MDUxYTM1NTMyMWYwMWRhL3RleHRyZWdpb246MWNmZmYxMjViOGRkNDQ5NDkwNTFhMzU1MzIxZjAxZGFfNTQ5NzU1ODE0MDkxMA_a43c324f-ff40-45c4-bf4d-b65f6a2d2397"
      unitRef="usd">351000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzM0Ng_62e5252e-521b-4ed8-a84e-7379a9497261">DERIVATIVE FINANCIAL INSTRUMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses on these hedges are recorded in Accumulated other comprehensive income (&#x201c;AOCI&#x201d;) and are reclassified into Product sales on our Condensed Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of March&#160;31, 2022 are expected to be reclassified to Product sales within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the three months ended March 31, 2022 and 2021 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had notional amounts of foreign currency exchange contracts outstanding of $3.2 billion and $2.9 billion as of March&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from AOCI into Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the three months ended March 31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral Received/Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount (Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ibdc2166d764d47b790982ea8d24ca4c5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMTg3NQ_f632e393-8ce6-4c39-9a71-4e3e22796ec3">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="ibdc2166d764d47b790982ea8d24ca4c5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMjM0MA_0635a688-42b2-4eb3-89c7-01566138d163">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMjU2NA_0c894d40-17e1-4fc6-9eb8-ddee9ba3e94b"
      unitRef="usd">3200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMjU3MQ_acd16a4c-2f0d-4b96-81b4-9cd614d2d244"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzMzMg_beb4c27d-33ee-484c-9fe1-051782e30b1d">The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i1bb3d84561ec4098843a2d085b4a0ca6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNC00LTEtMS0xMDQ1MjI_643cebbc-6967-4dc7-998c-df39965260db"
      unitRef="usd">77000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ie3f2d07dee1c49d6beb026214523051a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNC04LTEtMS0xMDQ1MjI_14ac9bb3-6d2d-4504-a5a6-827589772bff"
      unitRef="usd">6000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i7427f7cf7f37493d9bdc7a0ae323cc7b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNS00LTEtMS0xMDQ1MjI_4c18f4ac-8424-4ee3-9bf8-4f78b0c35a88"
      unitRef="usd">3000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i05ff03aad47143d2886a6c27847acb8c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNS04LTEtMS0xMDQ1MjI_5103ca1a-14ac-4e2f-bdef-9001de5ac2cc"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8f27f012480540869dfec449f56f64fc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNi00LTEtMS0xMDQ1MjI_5b7c76a9-165f-4719-b8db-cf91d3d33a09"
      unitRef="usd">81000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8f27f012480540869dfec449f56f64fc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfNi04LTEtMS0xMDQ1MjI_5138aa54-668b-4a03-8b09-6a7f49bcdc7a"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i541ecc08f5ab4ef1b08aa8faf2073803_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOC00LTEtMS0xMDQ1MjI_a8c4a4fd-1ad3-4e19-985b-d37249e34ba6"
      unitRef="usd">3000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i4c84a15b4f764e02becb348c2b986e0e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOC04LTEtMS0xMDQ1MjI_20d8e00c-94d8-4d5f-b930-f166690a923e"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0e169fb1551b4471ac0f7b68e6ded3af_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOS00LTEtMS0xMDQ1MjI_e705ecef-6fd6-440e-8ffb-69d170aa8d7a"
      unitRef="usd">3000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0e169fb1551b4471ac0f7b68e6ded3af_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfOS04LTEtMS0xMDQ1MjI_d0b0f9f7-2c46-41c7-b441-1525a50680d2"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfMTAtNC0xLTEtMTA0NTIy_726abf6d-8247-40e1-b658-e7d1df3666fc"
      unitRef="usd">84000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjk0NmE0Y2E5MzMwZTQ5Y2E5YTdlNTJiNTBmYWU3MjYyL3RhYmxlcmFuZ2U6OTQ2YTRjYTkzMzBlNDljYTlhN2U1MmI1MGZhZTcyNjJfMTAtOC0xLTEtMTA0NTIy_87dde558-2366-4821-9027-46a70175f15a"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i755866e871aa435bbe8cc99ea9405032_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNC00LTEtMS0xMDQ1MjI_92cac24a-e736-491f-956b-69a8d22bb579"
      unitRef="usd">75000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3654deba3ec8484aa044f0318ffe9226_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNC04LTEtMS0xMDQ1MjI_4819732f-621b-4746-94d8-f432a41a3e2c"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i590c1dfde3d24201beae31f590843dfe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNS00LTEtMS0xMDQ1MjI_4c51ac4d-66fc-46a1-b720-7ac7cfd91f93"
      unitRef="usd">5000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i4108efc629d9462db4043d3b73894ef6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNS04LTEtMS0xMDQ1MjI_4247feab-6f74-46da-b455-6c7b1898e616"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3a9099c763634be097da7c2e31d5b983_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNi00LTEtMS0xMDQ1MjI_d9c604eb-6284-4f20-806e-2d3b7ee463ec"
      unitRef="usd">80000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3a9099c763634be097da7c2e31d5b983_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfNi04LTEtMS0xMDQ1MjI_5afdcff8-9f3d-45c0-b13f-2c47be0a2133"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0d2c11db705040bb991212a1df88c126_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOC00LTEtMS0xMDQ1MjI_bd50753e-5465-4874-8387-3da25e752d6a"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8dcd9ccfcbe9446eb6f087a60e2891fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOC04LTEtMS0xMDQ1MjI_315be5fc-f080-4cf9-9e53-519ed6283618"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ibf3a437f7d5e4a888f6943960ee7df17_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOS00LTEtMS0xMDQ1MjI_3d049ac3-7ef3-41c8-8f55-1dd087882d0d"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ibf3a437f7d5e4a888f6943960ee7df17_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfOS04LTEtMS0xMDQ1MjI_36d9c909-91d6-4099-bff8-ebd12a95e54a"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfMTAtNC0xLTEtMTA0NTIy_abf95f74-4993-4009-b863-42c141f3881d"
      unitRef="usd">80000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjBkMmY1M2Q1MTUyNTRmMTNiMzA5MThkZWI1OWU5MTkxL3RhYmxlcmFuZ2U6MGQyZjUzZDUxNTI1NGYxM2IzMDkxOGRlYjU5ZTkxOTFfMTAtOC0xLTEtMTA0NTIy_1181c0cb-1f00-436a-b625-62a26211e36d"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzM0Nw_dd77960a-92f1-45c7-9d14-68cda927a37d">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from AOCI into Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNC0yLTEtMS0xMDQ1MjI_7c831260-acd6-4654-805b-853be267c475"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNC00LTEtMS0xMDQ1MjI_71f4e7b5-3bfb-43b4-a0dc-eff339e1f89b"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNS0yLTEtMS0xMDQ1MjI_ee08c880-8bd2-4727-ba73-d9d0292f10bb"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNS00LTEtMS0xMDQ1MjI_4bf13e22-2653-4ed1-a803-71492a0b4054"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNy0yLTEtMS0xMDQ1MjI_8b5de066-7d99-4aee-8f92-dcc60a0d4b96"
      unitRef="usd">19000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOjczZTljZTdlZTI2YTQzYzBhZDFmN2Y3MTdmMzc2Y2NjL3RhYmxlcmFuZ2U6NzNlOWNlN2VlMjZhNDNjMGFkMWY3ZjcxN2YzNzZjY2NfNy00LTEtMS0xMDQ1MjI_c5fe2626-8a52-4d0c-9e65-bbd5841269c6"
      unitRef="usd">34000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzA2OA_b7962f18-1a0f-4138-9b79-0a97793d9a55"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzA2OA_ef4ebf62-5e12-426a-a65b-a42ed9662169"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RleHRyZWdpb246YjE4NWNjZTg3MzAzNDU5M2JjYjIyODM2ZmY1NzY3NjJfMzM0OA_e44268ce-bfc3-48ee-af13-a851a8e20fed">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral Received/Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount (Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy02LTEtMS0xMTkxMDk_06e10464-700c-431c-a142-664473687af1"
      unitRef="usd">84000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy04LTEtMS0xMTkxMDk_85a12ce2-ff41-406c-a5f8-5dc06065451d"
      unitRef="usd">9000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy01LTEtMS0xMzczMjM_478c814f-b691-4be5-a83d-d2e692b6f5a5"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfMy0xMi0xLTEtMTE5MTA5_b3e70197-2ed7-46ae-8833-9fb3c00ef4d1"
      unitRef="usd">75000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilities
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC02LTEtMS0xMTkxMDk_8af1389e-9172-4a6e-9c11-cfae6ac5b3f4"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC04LTEtMS0xMTkxMDk_ddd0f663-cd12-42c0-ac79-1157dbb2865a"
      unitRef="usd">9000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC01LTEtMS0xMzczMjM_402c5970-2364-4c0e-a0a5-d04a59da33cc"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNC0xMi0xLTEtMTE5MTA5_436cfd94-bf65-4869-b6ad-a52d409b4a76"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssets
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi02LTEtMS0xMTkxMDQ_b1328c73-aaff-4f73-b19a-d8a240614af1"
      unitRef="usd">80000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi04LTEtMS0xMTkxMDQ_3026bd7a-075a-4b86-8c8d-99af81344d55"
      unitRef="usd">4000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi01LTEtMS0xMzA3MTQ_dafd2963-e976-4b0b-8474-9685e131a9e9"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNi0xMi0xLTEtMTE5MTA0_93fbe3dd-1457-4920-acd0-098244f38535"
      unitRef="usd">76000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilities
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy02LTEtMS0xMTkxMDQ_c19e8d30-ab5f-4ced-9c96-f0e3c70a1ae4"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy04LTEtMS0xMTkxMDQ_ab445809-2df3-4d86-8bf8-d87ae08d0018"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy01LTEtMS0xMzA3MTQ_2b319a83-b910-4c0b-9fc1-9b80207dfafa"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80Ni9mcmFnOmIxODVjY2U4NzMwMzQ1OTNiY2IyMjgzNmZmNTc2NzYyL3RhYmxlOmY2ODMyMmNjNmIwNTQzZWFhNDdkMzY1NGVjZmZhMzM0L3RhYmxlcmFuZ2U6ZjY4MzIyY2M2YjA1NDNlYWE0N2QzNjU0ZWNmZmEzMzRfNy0xMi0xLTEtMTE5MTA0_584b6c83-2eda-43a9-8f11-6ca666512463"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfNzQ0MA_97090999-8b25-48d7-a386-90db37b1f03a">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments. We also have equity investments in third parties focused on the development and commercialization of products and product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#x201c;EMA&#x201d;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. MYR is a wholly-owned subsidiary of Gilead.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate consideration for this acquisition of &#x20ac;1.3 billion (or $1.6 billion) primarily consisted of &#x20ac;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#x20ac;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date. The estimated fair value of the contingent liability was $322 million as of March&#160;31, 2022. See Note 3. Fair Value Measurements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. Measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three months ended March 31, 2022 amounted to $18 million. See Note 7. Goodwill and Intangible Assets for additional information. The fair value estimates for the assets acquired and liabilities assumed have been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborations and Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arcus&lt;/span&gt;&lt;/div&gt;In 2020, we entered into an option, license and collaboration agreement with Arcus (the &#x201c;Arcus Collaboration Agreement&#x201d;), which granted us the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction. In November 2021, we exercised our options to three of the clinical-stage programs and amended the Arcus Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving a $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The collaboration opt-in payments of $725 million were recorded in Accrued and other current liabilities on our Consolidated Balance Sheets as of December 31, 2021 and paid to Arcus in January 2022. Our payments to Arcus were included in Other in investing activities on our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjAzMg_400a1238-fd53-44d8-95f1-2da8986dd600"
      unitRef="eur">1300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjAzOQ_3c7aebd4-9869-4dde-9b88-5275eb184a4c"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjA2NQ_c9f656cf-519c-4d9e-ade9-d923184d74eb"
      unitRef="eur">1000000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i934f69a70c1f477da49b9dc88f97ddb1_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjA3Mg_03b5912a-3eb4-49b9-9f59-6871887d4ac8"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icbff931ce23a4b7fbc85927c27dcbb38_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjEzMg_2361930b-5e34-4f72-a106-1106507d8447"
      unitRef="eur">300000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i82997a4df3f84a3ea62a3b4b42b70d35_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMjM2Ng_6dd48e2e-a4c7-45be-98d6-bb676159f88b"
      unitRef="usd">341000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i282910930ada4568b9f7fbf7401e7ebe_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfODc5NjA5MzA2NjYyOQ_05c58772-dd88-444a-a9e5-7260f51bd19a"
      unitRef="usd">322000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTA5OTUxMTY3NzY5Mw_b96b18d7-3290-46d5-a7c3-94f304af6ea9"
      unitRef="usd">-18000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <gild:CollaborativeAgreementOptInTerm
      contextRef="i2aa635ad0e1a44f7b6c2b98f4ad871c7_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTIyMw_15f56c4f-7e8c-4c86-9744-776abe8e5e8f">P10Y</gild:CollaborativeAgreementOptInTerm>
    <gild:NumberOfClinicalStageProgramsWithExercisedOptions
      contextRef="i84e131229c44421889bd64bd4ca11a35_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTIzMw_39417c83-8cac-429b-9b1b-849dd9a23ce8"
      unitRef="program">3</gild:NumberOfClinicalStageProgramsWithExercisedOptions>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i13a9e3a52328474db24a8e8398a645e2_D20211221-20211221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTI0OQ_109cec9c-1934-468d-96f7-37a6efb920ec"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i86cf8f539a93434791137d23f91be357_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTI0OQ_e9a4684b-6d80-40c1-b3b5-48f6192e3883"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <gild:EquitySecuritiesFVNIAdditionalOptionPaymentWaived
      contextRef="i840ba75e346d4681849daddb6e34dc67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTI2NQ_d4dcd988-3552-442d-b301-c247314daf8f"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionPaymentWaived>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i13a9e3a52328474db24a8e8398a645e2_D20211221-20211221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTMwMQ_109cec9c-1934-468d-96f7-37a6efb920ec"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i86cf8f539a93434791137d23f91be357_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF80OS9mcmFnOjk0NmVhZjU3MzM0NzQ1MWQ4MmFmMGE3OWFlNmM2NzMyL3RleHRyZWdpb246OTQ2ZWFmNTczMzQ3NDUxZDgyYWYwYTc5YWU2YzY3MzJfMTY0OTI2NzQ5MTMwMQ_e9a4684b-6d80-40c1-b3b5-48f6192e3883"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYyNA_abfc1af9-8109-4286-919c-2f1786e48aa5">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of Goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, goodwill decreased by $18&#160;million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $445 million and $395 million for the three months ended March 31, 2022 and 2021, respectively, and is primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;amp;D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#x201c;HR+/HER2-&#x201d;) metastatic breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#x201c;third-line plus patients&#x201d;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;amp;D intangible asset to $6.1&#160;billion as of March&#160;31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. There were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYxMg_8ad97607-eb8a-46a6-89a9-1b77c401b10a">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of Goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjI1MWRlZTA2NjhiYzQ3Mjc4ZTEwNzIzMjRlN2FjMDMzL3RhYmxlcmFuZ2U6MjUxZGVlMDY2OGJjNDcyNzhlMTA3MjMyNGU3YWMwMzNfMS0yLTEtMS0xMDQ1MjI_7eef9a78-44d3-4134-95c8-05dcf838b7a6"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjI1MWRlZTA2NjhiYzQ3Mjc4ZTEwNzIzMjRlN2FjMDMzL3RhYmxlcmFuZ2U6MjUxZGVlMDY2OGJjNDcyNzhlMTA3MjMyNGU3YWMwMzNfMy0yLTEtMS0xMDQ1MjI_1a8cf234-d1cc-4b75-b00f-925b9ee83063"
      unitRef="usd">-18000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjI1MWRlZTA2NjhiYzQ3Mjc4ZTEwNzIzMjRlN2FjMDMzL3RhYmxlcmFuZ2U6MjUxZGVlMDY2OGJjNDcyNzhlMTA3MjMyNGU3YWMwMzNfNC0yLTEtMS0xMDQ1MjI_6782fbfe-93bd-4c3d-b3a6-5644735f7836"
      unitRef="usd">8314000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="if3374a4b8975404aae3bf90a8f7a2f8d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTA5MDA3Mg_1a8cf234-d1cc-4b75-b00f-925b9ee83063"
      unitRef="usd">-18000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYzMw_42b089ae-514e-40e4-b82d-e7712bf918ba">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYzNA_8a85700a-116e-4412-8f91-efabca5a7b7b">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0yLTEtMS0xMDQ1MjI_136a4c78-8d40-41fc-a6d7-b98b008b2ba4"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy00LTEtMS0xMDQ1MjI_30e2a803-1438-4151-867e-c96fb1ae46d9"
      unitRef="usd">5826000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy02LTEtMS0xMDQ1MjI_8929da05-c3f6-4b9d-9d98-7877baf52c0f"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4196245fb7d144eb9adbee95335379ec_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy04LTEtMS0xMDQ1MjI_bacb9720-e7a2-4732-98db-42ab98cc819e"
      unitRef="usd">4894000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xMC0xLTEtMTA0NTIy_180aa90d-6a7b-4b15-8eab-cd5527162a4d"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xMi0xLTEtMTA0NTIy_f48f9e98-caa1-476a-a355-8ebaf6e9d9c0"
      unitRef="usd">5651000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xNC0xLTEtMTA0NTIy_c9ac563e-304d-466b-9001-3b5110e3aa52"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icb2cc7630cdb422387b0f6b01196b3cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMy0xNi0xLTEtMTA0NTIy_dee09282-9419-47df-968e-7bf910a2cead"
      unitRef="usd">5069000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0yLTEtMS0xMDQ1MjI_a27e7709-eb8c-491a-90be-ee9c0b915155"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC00LTEtMS0xMDQ1MjI_cfe0c6d6-f5ac-4304-96fd-a497afc0d0f0"
      unitRef="usd">1603000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC02LTEtMS0xMDQ1MjI_d6816c67-a6fd-43cd-a606-9c7ee9b8e6a8"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id8151e3893ea4621a6b91e28a0a81267_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC04LTEtMS0xMDQ1MjI_6d9490d6-0034-48fc-8e54-12bdb97fbc4b"
      unitRef="usd">5507000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8335947a672a4bf581dd7173d631b531_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xMC0xLTEtMTA0NTIy_52d8c01a-7def-4025-ac95-3ceed042de64"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8335947a672a4bf581dd7173d631b531_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xMi0xLTEtMTA0NTIy_671bc77f-b1a0-4531-9c21-72e59bb197fe"
      unitRef="usd">1501000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i8335947a672a4bf581dd7173d631b531_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xNC0xLTEtMTA0NTIy_b9a09898-7967-403b-b590-36cf6bb29b76"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8335947a672a4bf581dd7173d631b531_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNC0xNi0xLTEtMTA0NTIy_0393cefb-ac9d-4cf5-8a09-5da193158a8f"
      unitRef="usd">5609000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0yLTEtMS0xMDQ1MjI_3d1a926b-e5a5-48af-a954-933a1b34f08d"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS00LTEtMS0xMDQ1MjI_2fd2671c-817b-4a32-b8a6-e52bef1e5d55"
      unitRef="usd">623000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS02LTEtMS0xMDQ1MjI_6993ee46-edb1-42de-9621-f6a721288ff1"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie6d2e499098c4f4ba1e2564a683b808a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS04LTEtMS0xMDQ1MjI_458619ec-1767-4599-836c-44122815b752"
      unitRef="usd">5007000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xMC0xLTEtMTA0NTIy_0dc6f3a1-7c71-4c80-a996-ff50b9d56f4d"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xMi0xLTEtMTA0NTIy_79f3f754-a5e6-410f-a664-4729de2501b1"
      unitRef="usd">507000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xNC0xLTEtMTA0NTIy_02bb0af0-fbd2-491c-b8fb-f0da31a29251"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iff62af4097e04403ac73d0cac08de46b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNS0xNi0xLTEtMTA0NTIy_09d52da8-3612-4f03-ba47-68a738b91431"
      unitRef="usd">5123000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0yLTEtMS0xMDQ1MjI_0e63277e-de89-43f3-acd4-180f1c026325"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi00LTEtMS0xMDQ1MjI_70139600-4b04-44de-9698-8899f2714e80"
      unitRef="usd">93000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi02LTEtMS0xMDQ1MjI_f0d8887e-29dc-44df-b3cb-7e92b5bca831"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1cf48242a25a48a49a44e99af42e2e75_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi04LTEtMS0xMDQ1MjI_f94834b7-cbe4-47ad-9c39-392cc1f0c3f3"
      unitRef="usd">752000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i414779d0bb44463e89fae77dc259101a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xMC0xLTEtMTA0NTIy_b6e21d23-fa88-4615-89ff-96018c0b736b"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i414779d0bb44463e89fae77dc259101a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xMi0xLTEtMTA0NTIy_f5d3cf47-be93-4626-9283-777668604e88"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i414779d0bb44463e89fae77dc259101a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xNC0xLTEtMTA0NTIy_f4eb8c14-79ce-422f-bb15-0e41aece1f13"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i414779d0bb44463e89fae77dc259101a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNi0xNi0xLTEtMTA0NTIy_3ff64e9f-7c94-470e-9e62-4306ce6f2bb7"
      unitRef="usd">773000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0yLTEtMS0xMDQ1MjI_1066c0f1-fd70-40f1-abf4-024ff43a07aa"
      unitRef="usd">1632000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy00LTEtMS0xMDQ1MjI_adad9af6-bccc-40f2-82bf-6bc7c30ebf74"
      unitRef="usd">682000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy02LTEtMS0xMDQ1MjI_5d747bce-26eb-488e-8d81-2215297fd14b"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie3ea8eac0938446ea3ef964301fddeea_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy04LTEtMS0xMDQ1MjI_dbdf918c-90a9-401d-8235-12e5dedb61fe"
      unitRef="usd">951000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xMC0xLTEtMTA0NTIy_83c82bf1-c98c-403e-b40d-8fb862d980e0"
      unitRef="usd">1610000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xMi0xLTEtMTA0NTIy_13be700d-63ec-4245-ac05-2cb6ceb7e0a1"
      unitRef="usd">650000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xNC0xLTEtMTA0NTIy_7a5dd10c-b99c-43fa-a468-b211970e9b02"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i67b791ce935c423893acbd1d5237a6a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfNy0xNi0xLTEtMTA0NTIy_145d7f17-17ed-476a-8d0a-bec3d5ef1b62"
      unitRef="usd">961000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0yLTEtMS0xMDQ1MjI_51290464-0f49-477e-95ba-a53f19735b4b"
      unitRef="usd">25937000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC00LTEtMS0xMDQ1MjI_66ccf2f2-97bf-4bec-b01f-28db0e40c0fb"
      unitRef="usd">8827000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC02LTEtMS0xMDQ1MjI_60dfa8d6-fc8c-499b-8c59-8337e22bc9d5"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC04LTEtMS0xMDQ1MjI_0150b8f8-fd02-47f3-91dc-e9e217499712"
      unitRef="usd">17111000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xMC0xLTEtMTA0NTIy_54ab095e-3653-4f15-a341-118e743bf9ae"
      unitRef="usd">25915000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xMi0xLTEtMTA0NTIy_fec1346c-d3a0-4e47-91d5-a9fe352e50b2"
      unitRef="usd">8381000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xNC0xLTEtMTA0NTIy_50c940c4-8024-4971-b192-73b86d32ba85"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOC0xNi0xLTEtMTA0NTIy_b2493840-ba32-43e1-9f52-aeb6cf3db45c"
      unitRef="usd">17535000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0yLTEtMS0xMDQ1MjI_8e9dbf7d-894a-4cae-b477-952ced4b2d52"
      unitRef="usd">13220000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS02LTEtMS0xMDQ1MjI_18f8cb83-7443-4bbf-a977-4c6af3f8e434"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i64dc9cdb5c0c4dbe8f53b6c6b869fbe7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS04LTEtMS0xMDQ1MjI_76cee353-ec53-4272-b3a1-676528da821f"
      unitRef="usd">13220000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0xMC0xLTEtMTA0NTIy_38f779ce-f64e-4bc6-aee3-4b4c27d0975f"
      unitRef="usd">15920000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0xNC0xLTEtMTA0NTIy_de7a11e7-41c4-496b-9679-346283163760"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5d416509f0f54cfb8d432cad6b5b4ce6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfOS0xNi0xLTEtMTA0NTIy_238b6fdf-1b2a-43ff-8a39-afd6a691f5a3"
      unitRef="usd">15920000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMi0xLTEtMTA0NTIy_f27b0ecb-14c7-4fd3-ae3f-ff6f66f5979c"
      unitRef="usd">39157000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtNC0xLTEtMTA0NTIy_257aebfb-7bde-45bd-90de-d52e94c29b4e"
      unitRef="usd">8827000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtNi0xLTEtMTA0NTIy_20f6312b-e62f-4acb-a5eb-798708644040"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtOC0xLTEtMTA0NTIy_1bbd5d8d-4e4f-47d2-92a4-f7b0e38b5881"
      unitRef="usd">30331000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTAtMS0xLTEwNDUyMg_a3aeeb08-d679-465f-8257-c91ec9f4c9fc"
      unitRef="usd">41835000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTItMS0xLTEwNDUyMg_ce335b03-e3b1-4f9d-95ab-b77d2266b92a"
      unitRef="usd">8381000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTQtMS0xLTEwNDUyMg_c3f63d63-c0ba-45ee-b464-26dee7c54bea"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjRmMmQ0NjFhNmNiYjQwNzQ5ZTFiOWNiYjZkMmQzOWRkL3RhYmxlcmFuZ2U6NGYyZDQ2MWE2Y2JiNDA3NDllMWI5Y2JiNmQyZDM5ZGRfMTAtMTYtMS0xLTEwNDUyMg_84757b10-5357-44aa-89c0-a616494647a7"
      unitRef="usd">33455000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTM0OA_8bab340e-fb2d-4437-95d6-c95f8b3781b0"
      unitRef="usd">445000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTM3Mw_1944bdbf-58ac-4617-95f2-ae51a9572ab7"
      unitRef="usd">395000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMTYyMg_9ee6911f-b6ac-4ae4-a7bd-b3cf2dfb2472">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfMS0yLTEtMS0xMDQ1MjI_598a6051-c427-49dc-825a-34f52ada2152"
      unitRef="usd">1336000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfMi0yLTEtMS0xMDQ1MjI_c7b7cee4-6efe-42a0-a456-a4ef74e6dd91"
      unitRef="usd">1781000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfMy0yLTEtMS0xMDQ1MjI_4e30c9f4-db16-4b74-b8cd-05089957c18c"
      unitRef="usd">1781000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNC0yLTEtMS0xMDQ1MjI_f6f9634c-81be-45cc-bc6f-97cd9b1f9f34"
      unitRef="usd">1776000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNS0yLTEtMS0xMDQ1MjI_6f4b03c3-8278-462a-903f-f35fc49901df"
      unitRef="usd">1768000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNi0yLTEtMS0xMDQ1MjI_699eaa8e-7554-4880-8f58-ddbd93364aa1"
      unitRef="usd">8669000000</gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RhYmxlOjVkZWVhZjZjYTFmNzQyZTY4YTBkYjM3MTI1MWM5NmE2L3RhYmxlcmFuZ2U6NWRlZWFmNmNhMWY3NDJlNjhhMGRiMzcxMjUxYzk2YTZfNy0yLTEtMS0xMDQ1MjI_f974136c-e6a8-4e96-860e-6a82ef096325"
      unitRef="usd">17111000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i80486df441b94309bf7388e71d0392a0_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDk2MA_4a5cc3a6-db78-486b-b291-1b50f815b206"
      unitRef="usd">8800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i257ea51d20324ca09177cd0d150f10e5_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDkyMw_e87bee1a-773b-412a-8f23-84ee11cf099a"
      unitRef="usd">6100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <gild:IndefiniteLivedIntangibleAssetMeasurementInput
      contextRef="i18f249c798e6480c85ff4095cc8ec9fc_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDcyMg_a238bb05-2bd1-41ce-a21a-82806a581030"
      unitRef="number">0.0675</gild:IndefiniteLivedIntangibleAssetMeasurementInput>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81Mi9mcmFnOjZlMWM1NzNmNTIyYzQzZTU5OWU1OWFmZDQ0MTEyZWZlL3RleHRyZWdpb246NmUxYzU3M2Y1MjJjNDNlNTk5ZTU5YWZkNDQxMTJlZmVfMjc0ODc3OTEzMDczNw_eeb492c2-0a0a-4ff0-80fa-022d9e506532"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjM4_c0612450-8713-418c-b37b-ada23a619719">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual for settlement related to bictegravir litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 10. Commitments and Contingencies for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjUw_77990da2-a634-4b0f-871a-ea85de401e61">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMS0yLTEtMS0xMDQ1MjI_11b8d3da-058d-41f1-8bf3-af3cf7360f80"
      unitRef="usd">4559000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMS00LTEtMS0xMDQ1MjI_6eb0f796-91b5-44e3-b7f2-81e5c3780679"
      unitRef="usd">5278000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMi0yLTEtMS0xMDQ1MjI_437a3629-616d-4690-8a8e-83433d1b5d9f"
      unitRef="usd">642000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMi00LTEtMS0xMDQ1MjI_ec4fb4dc-0e91-464c-8cc0-74fc87937b98"
      unitRef="usd">671000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMy0yLTEtMS0xMDQ1MjI_d47cf350-bff1-4948-b553-0b214ad13754"
      unitRef="usd">76000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfMy00LTEtMS0xMDQ1MjI_052192a6-058b-4e20-a908-0cabb02c34e5"
      unitRef="usd">67000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNC0yLTEtMS0xMDQ1MjI_71c9b8b5-d434-4a0f-87fa-2cc09e878db0"
      unitRef="usd">54000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNC00LTEtMS0xMDQ1MjI_d17b072d-6cdf-4964-9c4c-c32ac133ed0a"
      unitRef="usd">47000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNS0yLTEtMS0xMDQ1MjI_2c7cb104-0847-4a0a-b151-4a5d153f20be"
      unitRef="usd">3787000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjgzMWMzYTYwODQyMTRkZTc4MjhjMmQ4ZjM3OGI0ZWJlL3RhYmxlcmFuZ2U6ODMxYzNhNjA4NDIxNGRlNzgyOGMyZDhmMzc4YjRlYmVfNS00LTEtMS0xMDQ1MjI_1559abae-c9bc-483c-87ea-396b26514ef2"
      unitRef="usd">4493000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjM5_617789b0-635e-42bb-b79f-8744f89648d9">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMS0yLTEtMS0xMDQ1MjI_9b3ac5cf-6f4e-4304-9d8b-6ca6598e6760"
      unitRef="usd">1091000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMS00LTEtMS0xMDQ1MjI_e28a71c8-de42-4949-8eb5-ffcaf561e373"
      unitRef="usd">1112000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMi0yLTEtMS0xMDQ1MjI_d6bd358f-997c-4d67-910e-c3e932d768d1"
      unitRef="usd">540000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMi00LTEtMS0xMDQ1MjI_2e51b486-90bc-4808-af91-aeeb114b1c71"
      unitRef="usd">590000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMy0yLTEtMS0xMDQ1MjI_42cf67a0-2bc8-403d-9096-d1c400c5132f"
      unitRef="usd">1044000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfMy00LTEtMS0xMDQ1MjI_8bdc78b0-f652-4694-a40d-22eed795abcf"
      unitRef="usd">1032000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNC0yLTEtMS0xMDQ1MjI_bd26194a-33f9-4fef-95df-099da2a1a3a3"
      unitRef="usd">2675000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNC00LTEtMS0xMDQ1MjI_3feaada8-e1ca-4346-b5d2-d298066e2d75"
      unitRef="usd">2734000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNy0yLTEtMS0xMDQ1MjI_00679a2d-12cf-48bc-99e1-5e7993960a9d"
      unitRef="usd">1482000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfNy00LTEtMS0xMDQ1MjI_e8e0b34b-abac-4fdb-8aad-081f9e201638"
      unitRef="usd">1618000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOC0yLTEtMS0xMDQ1MjI_d3022016-0f6e-4283-8311-e8f3615a63f9"
      unitRef="usd">1194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOC00LTEtMS0xMDQ1MjI_ae76079f-7d26-4279-8a8c-40475b07cc28"
      unitRef="usd">1116000000</us-gaap:InventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOS0yLTEtMS0xMDQ1MjI_1d7cf2f0-69ce-478b-9f7d-d039d1fd708f"
      unitRef="usd">2675000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOmFiNWVlMmVhMjAzNjQ5NjRhMGVmYzgyMDk2Zjk1MGVjL3RhYmxlcmFuZ2U6YWI1ZWUyZWEyMDM2NDk2NGEwZWZjODIwOTZmOTUwZWNfOS00LTEtMS0xMDQ1MjI_1fe435b7-6424-4cb9-9ddb-7792e8fdfbd4"
      unitRef="usd">2734000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RleHRyZWdpb246M2U5OTI4ZGM1Mzk4NDg1Zjg2YjcyYTg1YzU5ODk1MWJfMjQy_afd21017-2513-497f-998d-fde768d27cac">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual for settlement related to bictegravir litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 10. Commitments and Contingencies for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMS0yLTEtMS0xMDQ1MjI_b3fb5da4-3f2a-45d2-abb7-7af9160c65df"
      unitRef="usd">559000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMS00LTEtMS0xMDQ1MjI_58e1d7e2-d89f-4e2e-bd7e-f3bcf52907f8"
      unitRef="usd">927000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMi0yLTEtMS0xMDQ1MjI_d02102b7-478f-4ebc-ab92-e26e4f2f6832"
      unitRef="usd">467000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMi00LTEtMS0xMDQ1MjI_7d50cad7-7f8c-420f-bb43-3df9c322a162"
      unitRef="usd">539000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMy0yLTEtMS0xMDQ1MjI_491efb3f-f79e-4dd0-bae6-46b3d4fbd872"
      unitRef="usd">403000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfMy00LTEtMS0xMDQ1MjI_ca88d0f2-4c10-47ab-8596-2c39125d2371"
      unitRef="usd">499000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC0yLTEtMS0xMTU0ODA_26f8b207-6ee2-49e5-af94-c76b304f4771"
      unitRef="usd">0</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC00LTEtMS0xMTU0ODA_14eb030f-246c-4d83-a05c-8178168efc17"
      unitRef="usd">1250000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC0yLTEtMS0xMDQ1MjI_f41357c6-436d-4bff-8757-7bb04bcc22fb"
      unitRef="usd">2071000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNC00LTEtMS0xMDQ1MjI_07700d52-e791-4fc6-ad72-42e733ebd6e8"
      unitRef="usd">2930000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNS0yLTEtMS0xMDQ1MjI_50618106-0113-4ee5-83f5-34c9d307ec6b"
      unitRef="usd">3500000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF81NS9mcmFnOjNlOTkyOGRjNTM5ODQ4NWY4NmI3MmE4NWM1OTg5NTFiL3RhYmxlOjk2OTFhODQ3OThhYTRjNTM5ZDQ4NTc5YTY2NzM0NTNmL3RhYmxlcmFuZ2U6OTY5MWE4NDc5OGFhNGM1MzlkNDg1NzlhNjY3MzQ1M2ZfNS00LTEtMS0xMDQ1MjI_609216c9-01fd-4320-880e-ebcc947b5eab"
      unitRef="usd">6145000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTEzNQ_8e22c535-dd5d-4c0b-a7bd-7e2ee3d2a372">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we repaid $500 million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. No new debt was issued during the three months ended March 31, 2022. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2022, we were not in violation of any covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTE1OA_fb772bde-f4df-4826-8c7d-2a63dffe0d62">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf5248381b9f4abebf4c2f5778f80f05_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNS02LTEtMS0xMDQ1MjI_d00a91d2-9eb8-41cf-ad46-1879e8d81e2c"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia203cc43338e4b63a44ff1ec45bc1a31_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNS04LTEtMS0xMDQ1MjI_2c7fe632-57d8-4295-abb5-df15bd08d45e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idf5248381b9f4abebf4c2f5778f80f05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNS0xMC0xLTEtMTA0NTIy_4f85ec3a-9661-46ce-b5dc-ec708499d0f3"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf7de9e17b244038bf3bc1cff4883ce2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNi02LTEtMS0xMDQ1MjI_ef702c5a-9d1d-46e1-b5fd-6736752475c5"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idf7de9e17b244038bf3bc1cff4883ce2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNi04LTEtMS0xMDQ1MjI_5d9f6b09-708f-4c1d-9694-08599ac2cbc2"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0d50a2523c6d40889f73a7fabfab2e49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNi0xMC0xLTEtMTA0NTIy_11abda29-d2a6-44ee-9b15-758bd083f243"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ea02e471b61436f9c0ec424b611b358_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNy02LTEtMS0xMDQ1MjI_60fc98e5-2e1c-43eb-91d6-d9805923ec7d"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2ea02e471b61436f9c0ec424b611b358_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNy04LTEtMS0xMDQ1MjI_779d6fd6-b485-4e41-a589-7ab664d51452"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if53a5ab8e03f4ffb92c7f39803b6595b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfNy0xMC0xLTEtMTA0NTIy_f14d7849-a0b9-4f91-a132-da60fab3e326"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e70a13105b4454e9983b755cf5e801b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS02LTEtMS0xMDQ1MjI_d8f3c793-bc1b-402f-836e-ab0b09a48a6e"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e70a13105b4454e9983b755cf5e801b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS02LTEtMS0xMDQ1MjI_da52f47e-16b6-4588-b487-8c4feae8d9d8"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8e70a13105b4454e9983b755cf5e801b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS04LTEtMS0xMDQ1MjI_9a8d9383-73a9-40a0-8ec6-928354601702"
      unitRef="usd">1497000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia375ee6d18984f8cb58cbf41605a3a02_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfOS0xMC0xLTEtMTA0NTIy_c96670b1-273e-44af-bd0a-15583242f928"
      unitRef="usd">1496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d36da1631914269907cd58f8afe4bac_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTEtNi0xLTEtMTA0NTIy_198bd4cf-69ba-4544-b836-d696f095394f"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2d36da1631914269907cd58f8afe4bac_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTEtOC0xLTEtMTA0NTIy_91e94741-1cf7-4b21-8de3-93783d59af42"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i19ffac061a264104a18929d13674c19e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTEtMTAtMS0xLTEwNDUyMg_f545cfbc-ed0e-41b0-8c50-1ca5eaeff7ba"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2b34c3a4e3a3433c96acaa5ecaa28b50_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTItNi0xLTEtMTA0NTIy_53006091-9f14-4c39-84b8-7ad90d9438d9"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2b34c3a4e3a3433c96acaa5ecaa28b50_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTItOC0xLTEtMTA0NTIy_8cf6ef11-4f25-4b48-bc14-932fef7a3c70"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icec48a6ac3ce4cb08310b8ee51083fde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTItMTAtMS0xLTEwNDUyMg_f8a7eb1a-bce3-490d-9502-437104ded069"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i778b869054c9463e8cd09ca793264290_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTMtNi0xLTEtMTA0NTIy_eb199303-1b9d-430a-a1c6-f7d032b47cc2"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i778b869054c9463e8cd09ca793264290_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTMtOC0xLTEtMTA0NTIy_9cc4d77a-beb1-4d2d-8c0e-55eb3e729ecd"
      unitRef="usd">2740000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1a458700e8ab46c588af1e244ecdd413_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTMtMTAtMS0xLTEwNDUyMg_0b301436-64dc-44d0-948a-4c8978789d7b"
      unitRef="usd">2739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86e1179fb9c24e2fa4872abe26299e32_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTQtNi0xLTEtMTA0NTIy_81975d5a-c0d9-4ab8-9a4f-40099b020542"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i86e1179fb9c24e2fa4872abe26299e32_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTQtOC0xLTEtMTA0NTIy_f745dea1-92b0-486f-ba00-14e694e2a1c0"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic80beed14e70493c85b0036c04e5e1b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTQtMTAtMS0xLTEwNDUyMg_cee91ce7-4b99-42a2-b50e-15f0f5b7bddd"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtNi0xLTEtMTA0NTIy_86457f94-adac-4f6f-be53-74db6050b8f2"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtNi0xLTEtMTA0NTIy_ba25e006-3eec-4227-aea6-216baca24fc7"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie4ef6bfde6d04dfab5c24e3609ff3a01_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtOC0xLTEtMTA0NTIy_febe1f00-6812-4356-a046-3598ebc1ee19"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie1898e2ef2bd41e092d17dd630de1f86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTUtMTAtMS0xLTEwNDUyMg_ca52a6a9-1d3d-4740-ab34-bacc1e2da634"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i766605ef96f74675add6345046f2ff5f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtNi0xLTEtMTA0NTIy_1605785d-e84a-4f84-abd6-8aa6c90ae6b0"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i766605ef96f74675add6345046f2ff5f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtNi0xLTEtMTA0NTIy_a29a2f7c-0fec-42fb-bab8-333e4e44c27c"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i766605ef96f74675add6345046f2ff5f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtOC0xLTEtMTA0NTIy_e7aad822-6802-4aa5-94cd-74076f0e4f91"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i87c33c2ee7674cc6a7f7187ddd22ac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTYtMTAtMS0xLTEwNDUyMg_6598d399-1f30-47ba-9ac2-7ede3c719406"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i849968d6d54e42b7a4440de8cb2b01f9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTctNi0xLTEtMTA0NTIy_3badde69-ce8a-4db2-ae4b-becfbad91e29"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i849968d6d54e42b7a4440de8cb2b01f9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTctOC0xLTEtMTA0NTIy_521d3134-0453-40d4-ab17-deda47c5eb45"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i60bc99a828e44a87aeb970348be95119_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTctMTAtMS0xLTEwNDUyMg_23e9500a-d682-48ee-ba8b-3c78e709d088"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if52d4ee07275499f9e21b3b419e65345_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTgtNi0xLTEtMTA0NTIy_13cb720f-4b78-4855-8982-815d174a3ecb"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if52d4ee07275499f9e21b3b419e65345_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTgtOC0xLTEtMTA0NTIy_26a5e004-657d-4eb7-b93c-a0a59f8d7df9"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2259043e9523429d8166efc5e113295f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTgtMTAtMS0xLTEwNDUyMg_22c92d0a-7626-4f71-8c3f-5c9e98141929"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i406c686943914b65a05b788e6714fa04_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktNi0xLTEtMTA0NTIy_6dc8ccd2-e340-468d-acf7-5544d40ce260"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i406c686943914b65a05b788e6714fa04_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktNi0xLTEtMTA0NTIy_7ccec520-2b2b-47e9-bae3-caa8e8903e3f"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i406c686943914b65a05b788e6714fa04_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktOC0xLTEtMTA0NTIy_2329332b-431a-4f19-9fc9-a3430fd01eaa"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i35dedb6bce1648f5aacca48840848457_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMTktMTAtMS0xLTEwNDUyMg_5809f794-233c-41cc-90f3-f91813fb1a83"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb3ff054de0246f682af95f77b83ccd9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjAtNi0xLTEtMTA0NTIy_cdea2f30-5580-412b-87ef-fa42424574a1"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ifb3ff054de0246f682af95f77b83ccd9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjAtOC0xLTEtMTA0NTIy_4577686d-4f7c-469f-9206-c1c40924710f"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8297424984554341a6cf87b296e9e43d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjAtMTAtMS0xLTEwNDUyMg_c21a25e9-2fcd-40e0-86f9-4aba6c0976d2"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic27643ccf07b464b925ac68cbdb116cb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjEtNi0xLTEtMTA0NTIy_92d018c0-c953-4608-8088-9a5a955af6b8"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ic27643ccf07b464b925ac68cbdb116cb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjEtOC0xLTEtMTA0NTIy_9aaf4294-7435-43a2-ac43-cf01c7616815"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6dc99172f8b246e88d87b181a2923978_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjEtMTAtMS0xLTEwNDUyMg_ed1a710a-bd17-46e6-ba8c-f1b3ead1ab47"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i498ffcf1be474bd3918aef4609196972_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjItNi0xLTEtMTA0NTIy_d40ca763-7d2e-42d4-a88e-3c71c07d5f1b"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i498ffcf1be474bd3918aef4609196972_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjItOC0xLTEtMTA0NTIy_e960ab61-be80-41a6-9964-e07679a4d91f"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icb76d2db3b804d9dababcc6f82e2d016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjItMTAtMS0xLTEwNDUyMg_7e5698b6-93d6-46db-acaa-c24ab4db2d00"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8fa725b2b3e84d07b775bc9eaa5463c8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjMtNi0xLTEtMTA0NTIy_9844a121-cfc8-4a0a-be86-cd8fad02b6d8"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8fa725b2b3e84d07b775bc9eaa5463c8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjMtOC0xLTEtMTA0NTIy_721f0856-7c6b-44cd-8556-b290d3a734d3"
      unitRef="usd">2220000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibd14cdab0be64d6aabc8c30d9b047909_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjMtMTAtMS0xLTEwNDUyMg_41459526-ed17-4c97-afdd-54dcf46f3117"
      unitRef="usd">2220000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06221e90836348968d49234dbf14d1bd_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjQtNi0xLTEtMTA0NTIy_63fab4f4-b295-4339-a88d-beda350d3bea"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i06221e90836348968d49234dbf14d1bd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjQtOC0xLTEtMTA0NTIy_116278c2-a617-4d24-bf36-94d98fbaad08"
      unitRef="usd">1727000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icbeb6c7348bb4b8aaa56ac4ec2c04a5f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjQtMTAtMS0xLTEwNDUyMg_5409bbca-8f87-4bf2-83bc-e76124e47b64"
      unitRef="usd">1727000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib9a2802dbbc844e2858b672dfcde8038_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtNi0xLTEtMTA0NTIy_64318f78-79cb-49dc-8ef3-a3a5d1f77a31"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib9a2802dbbc844e2858b672dfcde8038_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtNi0xLTEtMTA0NTIy_eeeb4636-9c49-47c7-ab63-7e8c028bf7d0"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib9a2802dbbc844e2858b672dfcde8038_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtOC0xLTEtMTA0NTIy_6e1e4919-547f-4da2-b840-b0ad2fc720da"
      unitRef="usd">1477000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifd02b491e1a447e7bed36e4655ecccb3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjUtMTAtMS0xLTEwNDUyMg_aa69731d-db2f-4d16-a3b2-367afb53a5dd"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6813bb08ecdd4b31892315a2074efcc6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjYtOC0xLTEtMTA0NTIy_8d03ef06-2945-4ef8-8816-c50c40de43f1"
      unitRef="usd">25076000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i388fe16439ae47f3b185a0de4b4ddf82_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjYtMTAtMS0xLTEwNDUyMg_2511dc45-6340-49ea-a33d-b2de4f48d053"
      unitRef="usd">25571000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5317908672c2495db89fbaa4d6ab0754_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjctOC0xLTEtMTA0NTIy_47760f34-2ffa-4386-a45b-c2b626a31d68"
      unitRef="usd">1132000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i02ab28eb41e345ada758ce1aab74170a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjctMTAtMS0xLTEwNDUyMg_a22e7042-1ef4-4fef-82cb-e3b3b9e80de1"
      unitRef="usd">1124000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjgtOC0xLTEtMTA0NTIy_ac59922a-b8dc-4106-9de0-c96220882499"
      unitRef="usd">26208000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjgtMTAtMS0xLTEwNDUyMg_855a5a71-019a-40a9-8726-969f8cc5c16b"
      unitRef="usd">26695000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjktOC0xLTEtMTA0NTIy_8d02d380-45a8-4a83-86f7-2440a3162273"
      unitRef="usd">1025000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMjktMTAtMS0xLTEwNDUyMg_9ab1bb18-3390-43b8-94ce-d6e8a14face3"
      unitRef="usd">1516000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMzAtOC0xLTEtMTA0NTIy_ca5bda9c-46bd-4f5f-bd4b-d85499a015c4"
      unitRef="usd">25183000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RhYmxlOmFhOTIxMGI3Y2JmYzQ1MmE4ZTE4NmM4OTQ4ZjRlM2RlL3RhYmxlcmFuZ2U6YWE5MjEwYjdjYmZjNDUyYThlMTg2Yzg5NDhmNGUzZGVfMzAtMTAtMS0xLTEwNDUyMg_7f1c260e-b8c8-4354-b987-dcd23072d656"
      unitRef="usd">25179000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="ib9c0fa504fd846aabc3b372785f24c97_D20220201-20220228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTY0OTI2NzQ0MjgzMw_c5684219-d71a-4f7c-920f-7ea3be7ee86e"
      unitRef="usd">500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfNzU4_9045e1c7-8d0a-4545-96d8-7ff62c10bd86"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LineOfCredit
      contextRef="i6007d0be2b424a0c8e7fc133a041c624_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMzI5ODUzNDg4NTM3OQ_20814aad-2095-46d1-95fd-6ea5b50a0732"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="iacaf1b5ba1374bdbbdfce05c8d032bab_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMzI5ODUzNDg4NTM3OQ_e972c575-2ed6-48d9-9728-333409c9a7b5"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iacaf1b5ba1374bdbbdfce05c8d032bab_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82MS9mcmFnOmYxNGMyMTY4ZTRlNjQ5OWY4NzU1Y2RmNmUzMTVlODZkL3RleHRyZWdpb246ZjE0YzIxNjhlNGU2NDk5Zjg3NTVjZGY2ZTMxNWU4NmRfMTAzOA_0c1335d5-8a0b-4a65-97fe-8f3848cbd9e8"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjQ4OTA_26492f7e-290c-4556-bd55-6e6f904d4271">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any material accruals for the matters described below as of March&#160;31, 2022. As of December&#160;31, 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation described below, which we paid during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#x2019;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with NuCana plc. (&#x201c;NuCana&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NuCana has obtained European Patent No. 2,955,190 (the &#x201c;EP &#x2019;190 patent&#x201d;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#x201c;EPO&#x201d;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#x2019;190 patent in amended form. We believe that the amended EP &#x2019;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#x2019;190 patent in the High Court of England &amp;amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp;amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#xfc;sseldorf alleging patent infringement of the German counterpart of the EP &#x2019;190 patent and seeking damages and injunctive relief. In April 2022, we filed a motion for grant of a compulsory license before the Federal Patent Court in Germany. The hearing date for the German NuCana infringement case has been scheduled for May 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hearing date for the UK NuCana case has been scheduled for January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Axicabtagene Ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#x201c;Juno&#x201d;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#x201c;&#x2019;190 patent&#x201d;). A jury trial was held on the &#x2019;190 patent, and in December 2019, the jury found that the asserted claims of the &#x2019;190 patent were valid, and that we willfully infringed the asserted claims of the &#x2019;190 patent. The jury also awarded Juno damages in amounts of $585 million in an upfront payment and a 27.6% running royalty from October 2017 through the date of the jury&#x2019;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#x2019;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#x201c;CAFC&#x201d;) reversed the jury verdict, finding the asserted claims of Juno&#x2019;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#x2019;s petition for rehearing. We believe that the likelihood of a material adverse outcome in this matter is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Bictegravir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV Healthcare Company (&#x201c;VHC&#x201d;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes VHC&#x2019;s U.S. Patent No. 8,129,385 (the &#x201c;&#x2019;385 patent&#x201d;) covering VHC&#x2019;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#x2019;385 patent. In its lawsuit, VHC was seeking billions of dollars for alleged damages comprised of VHC&#x2019;s lost profits and a royalty on U.S. sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we also expected VHC to seek a royalty on U.S. sales after the trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, VHC also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound infringes VHC&#x2019;s Canadian Patent No. 2,606,282 (the &#x201c;&#x2019;282 patent&#x201d;), which was issued to Shionogi &amp;amp; Co. Ltd. and VHC. The &#x2019;282 patent is the compound patent covering VHC&#x2019;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#x2019;282 patent. In November and December 2019, VHC filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206; in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 and 1363875. These patents all relate to molecules that VHC claims would act as integrase inhibitors. We believe that bictegravir does not infringe any valid claims of VHC&#x2019;s patents and have prevailed in court proceedings to date in Canada and Germany. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2022, Gilead reached an agreement (the &#x201c;Settlement&#x201d;) with VHC, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi &amp;amp; Co., Ltd. and GlaxoSmithKline Mercury Limited (collectively, &#x201c;ViiV&#x201d;) for a global resolution of all pending or potential claims related to Gilead&#x2019;s sales of Biktarvy, including the litigation pending in the U.S. District Court of Delaware and other jurisdictions outside the United States as described above. In February 2022, the lawsuit pending in the United States was dismissed as well as the lawsuits in Canada, France, Germany, Ireland, the UK, Australia, Japan and Korea.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir. In connection with the Settlement, Gilead (1) made a one-time payment to ViiV of $1.25 billion in the first quarter of 2022, and (2) will provide ViiV an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027. In connection with the Settlement, Gilead recorded a pre-tax charge of $1.25 billion to Cost of goods sold on our Consolidated Financial Statements in our &lt;a href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Annual Report on Form 10-K&lt;/a&gt; for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir disoproxil fumarate (&#x201c;TDF&#x201d;) or tenofovir alafenamide (&#x201c;TAF&#x201d;) prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of four material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and a clinical trial agreement (&#x201c;CTA&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in December 2019, we received letters from Lupin Ltd. (&#x201c;Lupin&#x201d;), Apotex Inc., Shilpa Medicare Ltd. (&#x201c;Shilpa&#x201d;), Sunshine Lake Pharma Co. Ltd. (&#x201c;Sunshine Lake&#x201d;), Laurus Labs (&#x201c;Laurus&#x201d;), Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (&#x201c;Cipla&#x201d;) (collectively, &#x201c;Generic Manufacturers&#x201d;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our TAF-containing products. Between them, these Generic Manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. The Generic Manufacturers have challenged the validity of two to four patents listed on the Orange Book and associated with TAF. We filed lawsuits against the Generic Manufacturers, and we intend to enforce and defend our intellectual property. In November 2021, we reached an agreement with Shilpa to resolve the lawsuit against Shilpa. In addition, in January 2022, we reached an agreement with Sunshine Lake to resolve the lawsuit against Sunshine Lake. The settlement agreements have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law. In April 2022, the case against Laurus was dismissed after Laurus agreed not to challenge any of the Orange Book-listed patents associated with TAF.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, we received a letter from Lupin indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen, filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of two additional patents in the same court. This second case has been stayed pending resolution of the generic litigation regarding our TAF-containing products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in March 2022, we received letters from Lupin, Laurus and Cipla indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of three of the five patents listed in the Orange Book as associated with Biktarvy. We intend to enforce and defend our intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2028. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We (along with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and Johnson &amp;amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes&#x2014;one of direct purchasers consisting largely of wholesalers, and another of indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the fall of 2021, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These cases have been coordinated with the class actions. Trial is set for March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#x201c;Cipla Defendants&#x201d;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we along with BMS and Teva Pharmaceutical Industries Ltd. were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Missouri and New Jersey, involve more than 27,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#x2019;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. Following the California Attorney General&#x2019;s Office&#x2019;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#x201c;CFCA&#x201d;) and employment law claims. Relators seek all available relief under the CFCA. In December 2021, Gilead and relators executed a settlement agreement to resolve the lawsuit, and in February 2022, the court issued an order dismissing the lawsuit with prejudice.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The settlement does not have a material impact to our Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice Advocates, LLC (&#x201c;Health Choice&#x201d;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#x2019;s dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationReserve
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfOTM0NTg0ODk4MjQ1OA_8154a752-c0f1-4b19-bb52-4c0ccffcb347"
      unitRef="usd">0</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i04455f0253cf41bea3d4447eaf0b5f43_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTc3ODMzOA_b6db48a0-8535-4a8b-b2b7-aea3143a66b9"
      unitRef="usd">1250000000</us-gaap:LitigationReserve>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ic477d5bf6c90403e856da095ce607bef_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI4MA_55cd25f4-d4b3-40da-afed-07c4098436cc"
      unitRef="usd">585000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:JudgmentRoyaltyRateFromOctober2017
      contextRef="ic477d5bf6c90403e856da095ce607bef_D20191201-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI4NA_3f02f5a7-5673-4c88-bc7b-749f94f243a0"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateFromOctober2017>
    <gild:JudgmentEnhancedDamagesOnPastSales
      contextRef="ie9d9c9741d4e4098bcc97e45010d58c3_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI4OA_3b590672-3654-48ba-b140-812f5f98cb12"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesOnPastSales>
    <gild:JudgmentRoyaltyRateOnFutureSales
      contextRef="ie9d9c9741d4e4098bcc97e45010d58c3_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTY4MDI5Mg_b608af32-cb74-4b77-94d5-44004007463f"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateOnFutureSales>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ic03333a449154cb7b8232d024d98f8f8_D20220101-20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTA5OTUxMTc3ODc5Mw_96a93e7d-3103-44c0-9c3e-11d8d6791364"
      unitRef="usd">1250000000</us-gaap:PaymentsForLegalSettlements>
    <gild:LossContingencyRoyaltyPercentageOnFutureSales
      contextRef="id1c1bf3df91d4e6db4587e1096299bf0_D20220201-20220201"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM2OA_9fbed281-4276-47db-8c35-f7f535981753"
      unitRef="number">0.03</gild:LossContingencyRoyaltyPercentageOnFutureSales>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i80ccebc28b844e218656b87fdf4c2179_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM3Mg_49e62d64-3dac-433d-9936-14b5562464e3"
      unitRef="usd">-1250000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <gild:LossContingencyMaterialTransferAgreementsNumber
      contextRef="i0018ba912b0047809cae45058f13a571_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM3OA_ba90ff45-aea7-48d0-b8c7-3ebba0c6bb13"
      unitRef="agreement">4</gild:LossContingencyMaterialTransferAgreementsNumber>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo
      contextRef="i185d5cd8a06a4180acfc1cbdbf6ae18f_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM5MA_dbf1881a-05a0-44c6-aace-5babcd4fe967"
      unitRef="patent">2</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne
      contextRef="i185d5cd8a06a4180acfc1cbdbf6ae18f_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM4NA_e159044d-3ef6-4b8d-b3a5-04e01d9a757d"
      unitRef="patent">4</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne>
    <gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber
      contextRef="iaf92539a830e4f129492e4de6932612b_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDM5OA_7aa68011-35fa-406a-a431-1c83f5d56eb6"
      unitRef="patent">2</gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="i9df3344fe2684c4db01931149342fe76_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTY0OTI2NzU4OTQzNA_a9278cef-9efe-422f-b827-8c365a35924b"
      unitRef="patent">3</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <gild:LossContingencyNumberOfPatents
      contextRef="i9df3344fe2684c4db01931149342fe76_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMTY0OTI2NzU4OTQ0MQ_74d9bbca-9383-4cc4-81e0-b670b41c281b"
      unitRef="patent">5</gild:LossContingencyNumberOfPatents>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ibc02333637e24bd4ab2f7235cb6e6be5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3MzcyOA_7255a7ed-0133-4e5f-9fd0-1fd226988a85"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i3a3b1fcfcfcf4d1288de350903d04105_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3MzczNQ_833b4fa1-a9cf-499b-87d5-fc8713728725"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ifc6a4c4eb7dd45e19e3d027acae2a40c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3Mzc0Nw_5df183b8-7996-4cc0-91b5-200334074d68"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesFilingOppositionNumber
      contextRef="ie253cd11e2894e2eb71ca1ebfd05ee3a_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3Mzc1NA_e454447f-ad85-47ed-a477-3b3120cca87b"
      unitRef="party">3</gild:LossContingencyPartiesFilingOppositionNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="if2e36e12155d43ce870b52c07b49d3b0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM3Mzc2MA_16245a28-53e0-4999-8a9e-67dfb1fbeb15"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i480272d3e47746109dccd3cc3b185332_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDQzOQ_864ac7c5-0cc6-414c-b427-395e98cdc268"
      unitRef="lawsuit">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i480272d3e47746109dccd3cc3b185332_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDQ1Mg_08ba85a5-8573-40f1-9370-7531df5c485c"
      unitRef="plaintiff">27000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i8a21d016ed3f4fef846e7281366b96ba_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82NC9mcmFnOjg4ZDczYjVhMmI5YjRiMzI5ZjNmYzEyZjk3NTBkZGI4L3RleHRyZWdpb246ODhkNzNiNWEyYjliNGIzMjlmM2ZjMTJmOTc1MGRkYjhfMjE5OTAyMzM1MDQ1Ng_7a2136b0-567b-4b85-bb09-88dcd7180284"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTU5Nw_46ddee76-9e0c-42a2-8a28-2fe9fd3d98b6">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#x201c;2016 Program&#x201d;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, our Board of Directors authorized a $5.0 billion&#160;stock repurchase program (&#x201c;2020 Program&#x201d;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the remaining authorized repurchase amount under both programs was $5.9 billion&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases through open market transactions under the 2016 Program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts reclassified to Net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to Net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie28098faeeb64ff9abedb2ceb8db8e9b_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTA0_f4713ec4-e351-4db6-9c60-82e50928654f"
      unitRef="usd">12000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ic645773c025f4573b8df34872cf19436_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMzU3_3e1326aa-7858-49ec-be32-a2ea5150a93b"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ic34802f125ed4c2dba4e404cfaed8ab7_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTA5OTUxMTYzMDIxMA_df3c29d6-e3e8-47d6-9993-40ea7cd62568"
      unitRef="usd">5900000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfOTM0NTg0ODgzOTU1Mg_3bdc6b9c-6c8e-4651-9628-257503f86364">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases through open market transactions under the 2016 Program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMi0yLTEtMS0xMjE2NzU_3a2106e7-3517-4816-aa54-82176048b829"
      unitRef="shares">5500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMi00LTEtMS0xMjE2NzU_21357535-a99d-47b3-9d32-69a03b02750b"
      unitRef="shares">4800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMy0yLTEtMS0xMjE2NzU_90f6c05d-5b8a-4dfa-9aa7-90982856928a"
      unitRef="usd">352000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjY4OTVlM2RlNGQ3YzRjMWU5ZWZmOWUxNzRkOGYyMjk0L3RhYmxlcmFuZ2U6Njg5NWUzZGU0ZDdjNGMxZTllZmY5ZTE3NGQ4ZjIyOTRfMy00LTEtMS0xMjE2NzU_860ba81e-c673-4e54-8a87-a588b6f8745c"
      unitRef="usd">309000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RleHRyZWdpb246ZTY4NTFjY2NlYWQ2NDdlOGFiODQwOGI4YmVhODc4MmJfMTYwNQ_de417cb6-672a-462c-82ee-9fda2bb91bef">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife2b570214ba4b4380a34ff9a40f2812_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS0yLTEtMS0xMDQ1MjI_228c45b1-1ee4-4b2a-b084-d3a199050c2d"
      unitRef="usd">13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f95a618e4294659ad494cd557c4c835_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS00LTEtMS0xMDQ1MjI_b00bab2b-633f-46b7-876e-09c932fb0eea"
      unitRef="usd">-4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i218acb5be9394b00a1883e43cf92536c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS02LTEtMS0xMDQ1MjI_01c2fc93-b3b5-4514-a16a-19a66d3b51b4"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id97be958f8ea44f6bf64ec6b93653cd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMS04LTEtMS0xMDQ1MjI_05124ec1-7bb8-4350-aa72-11d3a390229e"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8302b75564a54dd8a549d442749edb52_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi0yLTEtMS0xMDQ1MjI_ac4b8464-5217-45dc-ac4e-cf19e5590f7b"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi00LTEtMS0xMDQ1MjI_996d34bc-28f5-458a-a6e0-e0a4bbdd9a7d"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi02LTEtMS0xMDQ1MjI_5468a2fb-3670-4b51-9e1c-0897b09c9b86"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMi04LTEtMS0xMDQ1MjI_9cb86c9c-31f7-48a0-a93f-e75e563f1b3f"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8302b75564a54dd8a549d442749edb52_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy0yLTEtMS0xMDQ1MjI_476d88bd-1f07-4ee2-978d-b537e49d547b"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy00LTEtMS0xMDQ1MjI_bb3ef6c9-67b3-46e1-9769-86abed2fd116"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy02LTEtMS0xMDQ1MjI_8b875328-5dcf-4a04-9d0c-14717761bc6e"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfMy04LTEtMS0xMDQ1MjI_15ab2faf-ccd0-47c5-b983-6cb145067512"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8302b75564a54dd8a549d442749edb52_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC0yLTEtMS0xMDQ1MjI_c43351ef-2a6a-4492-a0f5-6601e814f692"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i856d53f37f074e8085cef38eae0d2e03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC00LTEtMS0xMDQ1MjI_9727ec53-6594-4f86-88fc-02bb71b4d4cb"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8a260dbf5aec48c9834d86d44d2f1b14_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC02LTEtMS0xMDQ1MjI_0bf270ff-031a-41c7-b406-e1427242099b"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNC04LTEtMS0xMDQ1MjI_353cdfe5-a9b9-4828-b66a-337c090244c5"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85d01a7b28f14000ac327b84cdbf6de2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS0yLTEtMS0xMDQ1MjI_3455511e-d88e-4638-a787-3e18f6be047b"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6073554deb9e48ac9edef34f381a133d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS00LTEtMS0xMDQ1MjI_e98f5852-6d94-4245-a3d9-be0b19f1dce3"
      unitRef="usd">-23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9eb3a8cc8d58460b859489810a00ad9d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS02LTEtMS0xMDQ1MjI_cc2daea3-57c5-4d07-a6c1-5c391579c35c"
      unitRef="usd">78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id993c220a3874424a2e4ebabbf6841f5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOjEyMDZlODkyMzhjNjQwNDI5YzIyYWM4MWM5MzkxYTFkL3RhYmxlcmFuZ2U6MTIwNmU4OTIzOGM2NDA0MjljMjJhYzgxYzkzOTFhMWRfNS04LTEtMS0xMDQ1MjI_735a1c82-1a2b-4e58-bbfd-e609b8c0d7da"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba93b576592245e8aad3a67ae9a4d33a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS0yLTEtMS0xMDQ1MjI_bec5d15c-a76b-4888-93d1-e882e31b6055"
      unitRef="usd">51000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i363d24e7ddb249f281fc0dcd63f42999_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS00LTEtMS0xMDQ1MjI_f3a6d15f-f7ea-4a25-8b52-ec22f4fff887"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaddf54d089b4e758cb7bcdc7898e276_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS02LTEtMS0xMDQ1MjI_e8a7ce5f-2f2b-4863-8074-120b18786f77"
      unitRef="usd">-113000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8beedc1ba15342129f01b711293f2310_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMS04LTEtMS0xMDQ1MjI_9b4f5508-5113-4190-bc7e-6b3a367dace5"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi0yLTEtMS0xMDQ1MjI_606edf6b-bff4-41a3-852a-92a1cd603391"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi00LTEtMS0xMDQ1MjI_3d99dc7b-b06c-44cd-8949-bb2e4c90646e"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi02LTEtMS0xMDQ1MjI_0c4946cb-b239-4672-a8fd-b8a696c8d538"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMi04LTEtMS0xMDQ1MjI_06a12a0d-87ef-4503-85aa-c41c8e310ca3"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy0yLTEtMS0xMDQ1MjI_2f1bc658-0e03-4844-a4f5-6a82aa8608f1"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy00LTEtMS0xMDQ1MjI_1550b538-8188-4724-87c5-aef737246a1e"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy02LTEtMS0xMDQ1MjI_fbf8bd10-d104-4a56-9d51-0efbf3c9a889"
      unitRef="usd">-22000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfMy04LTEtMS0xMDQ1MjI_d8cf8e0a-c585-4e58-abd2-19cdaa4e55a1"
      unitRef="usd">-22000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d868e26d0b34825975a43a35ff1a443_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC0yLTEtMS0xMDQ1MjI_d93fecf6-2ba3-45c5-85b1-bbcf3cd562f3"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ica4450bb470447a7abe40a53ced8d308_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC00LTEtMS0xMDQ1MjI_3815a840-345b-45b7-b7b3-7a111b1de038"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i11e2b8394ceb4e13b88c48568eac27a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC02LTEtMS0xMDQ1MjI_42d26565-852f-494b-a071-941088d3449e"
      unitRef="usd">90000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNC04LTEtMS0xMDQ1MjI_de54345b-b4e1-476f-8e1f-9fd5ff1001d2"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida8a7d072c434eef82e6df74c248a6fc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS0yLTEtMS0xMDQ1MjI_eb536b1b-55d3-4cf5-8917-df63f782f0fd"
      unitRef="usd">61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id77b97648262458092baafbed5c40ad1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS00LTEtMS0xMDQ1MjI_4bf37e4c-f7b9-407e-abe8-ab0c13651728"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6704da2f166c4ccaba27a2d1ce1023bc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS02LTEtMS0xMDQ1MjI_372d5f29-4865-412e-bf09-bacf3735e740"
      unitRef="usd">-23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72674008e77942a3986c777c8aab4eb4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF82Ny9mcmFnOmU2ODUxY2NjZWFkNjQ3ZThhYjg0MDhiOGJlYTg3ODJiL3RhYmxlOmU5ZjQwZWVmMzg3MTQ4MjNiMThiYTAyMjgyMzJmNzQ0L3RhYmxlcmFuZ2U6ZTlmNDBlZWYzODcxNDgyM2IxOGJhMDIyODIzMmY3NDRfNS04LTEtMS0xMDQ1MjI_14466c51-2ee8-4738-b88e-03a98d4f64d5"
      unitRef="usd">38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfMTAyMQ_640a1cc6-fb37-4974-b326-9c812a5a5125">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were 16 million and 15 million, for the three months ended March 31, 2022 and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfODA1_267833ae-1628-4b0e-ab41-7037d0f30428"
      unitRef="shares">16000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfODI0NjMzNzIwOTU0NA_d02be4a9-b21b-4629-a382-cea73b82a925"
      unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RleHRyZWdpb246ODAyMjYyMDE1NjAwNGJlN2JhZmVlNmMyYzJlZDMwNGFfMTAyOA_6f8d0be4-c451-433c-84f8-2bf2f4c95023">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfMy0yLTEtMS0xMDQ1MjI_fb286ff2-b784-4579-a514-5576d3c0dbbb"
      unitRef="usd">19000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfMy00LTEtMS0xMDQ1MjI_ad52e8f3-b082-491d-836e-47985326a3fb"
      unitRef="usd">1729000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNC0yLTEtMS0xMDQ1MjI_e6ad8943-0e20-49f9-aced-3dcefee05aa1"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNC00LTEtMS0xMDQ1MjI_cd892dc1-062b-4bd4-b422-775655bc6904"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNS0yLTEtMS0xMDQ1MjI_b246a18a-700b-4ae9-a82c-63770ac01b56"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNS00LTEtMS0xMDQ1MjI_048fc301-692c-4713-af66-a4a52fd6417a"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNi0yLTEtMS0xMDQ1MjI_3145d47a-1fbc-4bcd-8b9e-186d6d1b71d2"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfNi00LTEtMS0xMDQ1MjI_ae4bc811-c232-4f13-bfa3-57f86f1ac8c7"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOC0yLTEtMS0xMDQ1MjI_32dac2d5-da9d-494d-b34c-b69a71ae2e9d"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOC00LTEtMS0xMDQ1MjI_256981ea-fda5-474c-a0d9-cdd467941983"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOS0yLTEtMS0xMDQ1MjI_f34f5233-9615-4557-8bfb-dbcd119b2604"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83MC9mcmFnOjgwMjI2MjAxNTYwMDRiZTdiYWZlZTZjMmMyZWQzMDRhL3RhYmxlOmQ4MWY0ZDZiYWRhNDRjNmJhMWQzYjk2YmQ4YmJlM2MxL3RhYmxlcmFuZ2U6ZDgxZjRkNmJhZGE0NGM2YmExZDNiOTZiZDhiYmUzYzFfOS00LTEtMS0xMDQ1MjI_5db5e269-394e-4c33-8f7b-56bb87d2588a"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMjEyOA_884a348e-f6a3-450b-b010-59e3859e3ab9">INCOME TAXES &lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Income tax benefit (expense):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 107.9% for the three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in state deferred tax liabilities associated with a partial IPR&amp;amp;D impairment charge of $2.7&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 23.9% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to settlements with taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMjEyOQ_0034281d-4e31-4b90-b6b2-b7f7d9410225">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Income tax benefit (expense):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfMy0yLTEtMS0xMDQ1MjI_5f236620-4567-403e-9017-a2aa392030a9"
      unitRef="usd">-152000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfMy00LTEtMS0xMDQ1MjI_1ab812a5-c30a-4006-adea-cabd5cde7545"
      unitRef="usd">2264000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNC0yLTEtMS0xMDQ1MjI_5a97b446-71bc-4362-b146-f8fe88154238"
      unitRef="usd">-164000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNC00LTEtMS0xMDQ1MjI_8870ad5f-aab6-4ae7-a929-03555a21558d"
      unitRef="usd">542000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNS0yLTEtMS0xMDQ1MjI_a428dd98-0dc9-440d-a626-a43ddc272937"
      unitRef="number">1.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RhYmxlOmNmMWFhMWNjZDUyMzQ1MjBhYzZkMzI1NDEyMjJiOWRjL3RhYmxlcmFuZ2U6Y2YxYWExY2NkNTIzNDUyMGFjNmQzMjU0MTIyMmI5ZGNfNS00LTEtMS0xMDQ1MjI_bdd1fa89-77da-44fe-a74f-de775de124d5"
      unitRef="number">0.239</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMTAy_a428dd98-0dc9-440d-a626-a43ddc272937"
      unitRef="number">1.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia1434227c77547c2b6b94ab0161a58ad_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMTA5OTUxMTYzNDg1NQ_eeb492c2-0a0a-4ff0-80fa-022d9e506532"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic4778b82d1c74d7396e559fe603c6447_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF83My9mcmFnOjE3OTNhMDliZTU5NzRjMjg5OGRhOWExZjliZDA1YzBhL3RleHRyZWdpb246MTc5M2EwOWJlNTk3NGMyODk4ZGE5YTFmOWJkMDVjMGFfMjE5OTAyMzI1NzcwMA_8ce31cdf-0a6b-4f52-9d94-54ccbb04d04b"
      unitRef="number">0.239</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xMjE2L2ZyYWc6ZmFiMTM1NzY2MmYwNGVkOThiYTVlNmJkZTVkMzFlMTgvdGV4dHJlZ2lvbjpmYWIxMzU3NjYyZjA0ZWQ5OGJhNWU2YmRlNWQzMWUxOF85MzQ1ODQ4ODQxMDg5_90f9c976-d2ba-4fe6-9170-3d806be25e37">SUBSEQUENT EVENTIn April 2022, we entered into a strategic research collaboration agreement with Dragonfly Therapeutics, Inc. (&#x201c;Dragonfly&#x201d;) (the &#x201c;Dragonfly Collaboration Agreement&#x201d;) to develop natural killer (&#x201c;NK&#x201d;) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we will make a $300 million upfront payment to Dragonfly. In addition, Dragonfly is eligible to receive potential opt-in payments and performance-based development, regulatory and commercial milestone payments. Dragonfly will also be eligible to receive royalties of up to 20% on worldwide net sales. The closing of the Dragonfly Collaboration Agreement is subject to antitrust clearances required by the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ib6451f2f16f341a48298ff3195581dc3_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xMjE2L2ZyYWc6ZmFiMTM1NzY2MmYwNGVkOThiYTVlNmJkZTVkMzFlMTgvdGV4dHJlZ2lvbjpmYWIxMzU3NjYyZjA0ZWQ5OGJhNWU2YmRlNWQzMWUxOF8xMDk5NTExNjMyNzU2_37838568-03c4-4736-a00d-0dadc9723560"
      unitRef="usd">300000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:PotentialSalesBasedTieredRoyaltiesPercentageMaximum
      contextRef="ife8577a82d764a7eb6649aba6ff99894_I20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwNTRlZDU3YTQxNzQ2ZjZhZGVmZjgzZTlhNmU4Y2FkL3NlYzpiMDU0ZWQ1N2E0MTc0NmY2YWRlZmY4M2U5YTZlOGNhZF8xMjE2L2ZyYWc6ZmFiMTM1NzY2MmYwNGVkOThiYTVlNmJkZTVkMzFlMTgvdGV4dHJlZ2lvbjpmYWIxMzU3NjYyZjA0ZWQ5OGJhNWU2YmRlNWQzMWUxOF8xMDk5NTExNjMyNzYz_30454161-0626-4428-8301-286b67ae38d5"
      unitRef="number">0.20</gild:PotentialSalesBasedTieredRoyaltiesPercentageMaximum>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/'[D;8<:@9DHZN8O>FQM@Q'*-K429=L8%)1YM?O/?K:!V&N 0T<#TC8@KVU
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M]V%B=Z/$NCG;GPNE1-E<KF!^<ZD-X/=[ <5!>Z,_%W2?AZ;_ E!+ P04
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M$5M#2/MJ!/U3%,=JQ8/BN_QD:L65XG%^NX6YB(G, /Y?<ZZ^'K(/5(>;L_\
M4$L#!!0    ( $.#I%1FW9=?\ ,  +X-   8    >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&ULM5?;CAHY$/T5JY6'1,I,7[B/ (EA2((4F-$PR3ZL]L$TAK;B
MMHEM8+)?OV5W3S?TC>1A7\!V5Y7/.2Z7[>%)R!\J(D2CUYAQ-7(BK?=WKJO"
MB,18W8H]X?!E*V2,-73ESE5[2?#&.L7,#3ROZ\:8<F<\M&-/<CP4!\TH)T\2
MJ4,<8_GKGC!Q&CF^\S;P3'>1-@/N>+C'.[(B^MO^24+/S:)L:$RXHH(C2;8C
M9^+?3?V^<; 6WRDYJ;,V,E360OPPG?EFY'@&$6$DU"8$AK\CF1+&3"3 \3,-
MZF1S&L?S]EOT3Y8\D%EC1::"_44W.AHY?0=MR!8?F'X6IR\D)=0Q\4+!E/U%
MI]36<U!X4%K$J3,@B"E/_O%K*L29 \2I=@A2AZ#HT*YQ:*4.+4LT069I/6"-
MQT,I3D@::XAF&E8;ZPUL*#?+N-(2OE+PT^/IX_)AMES-'A"T5H]?YP^3%^BL
M7N!O,5N^K-#C)_BT>'J>?0&[^?<9FB^A/T,WZ-OJ ;U_]P&]0Y2C!64,UD4-
M70VP3' W3"'<)Q""&@@MM!!<1PK-^(9L+OU=H)-Q"MXXW0>- 1=8WJ*6_Q$%
M7A!4X)G^OKO? *>52=RR\5HU\58::P*9KY'8HJF(8;M%9A\<"9KS4,0$_3U9
M*RTAH_]IF*Z=3=>VT[5KIEO"WJ<V;M52)+Y=ZVNV^''L@T3'<W4J3'I!;G0!
MJI.!ZC1J\*@C(E%X03X!B=XSH=2'NP;FW6R2[E7F4-A@YW+8.E(2'OY"H"M7
M#-N:L8.R]A%Q8E="X]<J@9(I.F?L.P5]RA:^5ZU.+P/>:U1G<L24X34C-P#_
M1F%&H!*M-5($:%!-B6J2IY_-TK\JSX%#K6?T7[)!1O9K8O1+5&_\04&."IN:
M9!ED0 >-0)])R+!2=$M#NVX*:6&!)AES#?2@!,@K0&ZRN$#L>WD9]:Z*&T:8
M[RIW7>K<+&2548V2_EEY]QM3:XI5A+9P6*.(;';-B>0'>=3@3U+I=_95&O&<
M7= N*E"VZ?9K%,BKK]_Z/[,IC7ZY*L6$JC"JJYA^7L?]ZX6\(:7:I2E+<I9-
M!G6)GA=RO].(ZFHEKP3;J<C_DHAEHT'=ZN='@M]\)DPK@%8B+%?UXKE88>+W
M@SI!\]KO]_X H9$08:TE71^T.1)LM@K S;44<,7B.V"AB21*5_+HE4#VBCR:
M3"Y)Y$>+WWRV5,E<HO&9,GAH5*+NE^X<I>I8-@'UB\#=LYMP3.3./A 4I.N!
MZ^0"F8UFCY")O7H7QN_-X\3>L/,PR<L&KH<["E6$D2V$]&Y[(*1,'@M)1XN]
MO6^OA8;;NVU&P)M(8P#?MT+HMXZ9('NRC?\#4$L#!!0    ( $.#I%2-QB^=
M P8  ,@;   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULO5EM<YLX$/XK
M&K?3:V;J&@F,H74\T_@ES5SS<G%R-S<W]T$%)68*R$5RW/[[DS !(PDY:3OW
MQ4;VLZM'JUT]"XRWM/C"5H1P\"U+<W;<6W&^?C<8L&A%,LS>TC7)Q3]WM,@P
M%\/B?L#6!<%Q:92E ^0X_B##2=Z;C,O?KHK)F&YXFN3DJ@!LDV6X^'Y"4KH]
M[L'>XP_7R?V*RQ\&D_$:WY,EX;?KJT*,!K67.,E(SA*:@X+<'?<^P'>G;FE0
M(OY,R);M70.YE,^4?I&#L_BXYTA&)"41ERZP^'H@4Y*FTI/@\;5RVJOGE(;[
MUX_>%^7BQ6(^8T:F-/TKB?GJN!?T0$SN\";EUW3[D50+&DI_$4U9^0FV%=;I
M@6C#.,TJ8\$@2_+=-_Y6!6+/ +H=!J@R0*J!UV'@5@:N8H!&'09>9> I!I[?
M83"L#(8JI:##P*\,?)52UQI&E<&HW*Q==,NMF6&.)^.";D$AT<*;O"CWM[06
M.Y+D,A67O!#_)L*.3Z:7%[/YQ7(^ ^)J>?GI;/;A1@R6-^+K?'YQLP27"S&Z
MG/[^\?+3;'Z]?/4B0'#T'LS_N#V[^1OTP>UR!EZ_/ )LA0O"0)*#\R1-19JQ
M-^#E_G \X(*PG'805>1.=N10![D;RG%J,)M:S63UOF-K')'CGBA/1HH'TIM,
M:9:)U%]R&GUY]0+ZSGN#XYF=SX<X3F0!X11<X23NG^5@BM>)F>3\@*\HVF2;
M%',2@TN^(@40# 7=E2SS!P+.\HAF!+S^1!D[,KA?V-U?$R[.(>%[CHL\R>]-
MT3^UN[B@@D+."RJV+[\7A#@1T>1M1P.1;W72H3KI4.G9Z_!\0NZ37+(2ITB*
M\T@L4^3)+H&. .9@1J*WP(5O '*08TJ G?]AZ5^>M@\3B(;>>/!@8.76K-QG
MLGH"DY.=3W^?28 0K*GL^!I0;<1,1[A!X+1!<QW4]Q7,PC"5YP;*=*<&5&@.
MGU>'SRMMW([PB8056LC$7HJ8E5='LOK+@EO1-"8%^PW,OVX2_AW\<RV2"@@M
MV>(B_M>24<-Z\J%U[RZ$:"=5Q:0=%7,RU)-FA) 2/B,H5**G@_HC<_3\>@&^
M=0&[(R!J'0$'%^1K-,) R1@KI,5T5#,=69F>,;:1U<' )A>;"DBV3NEW0@"3
M.PW6FR):R318BQK:KVM3&8_T8)O)!36YX)>1,T4TT B-?*50K9 6Z; F'3Z)
M]"/G78V(W2>Y[--*LNQ0*$.-UM#,"CI-:^ \+YA&8D99=PSGLQ)'.Z9->:^;
M@5;*Y6G3E[UI7!:3J"0L%=M($NH$/$=E:0>U:3;Z!^T">$T>,Y$!>B>9RMYD
MEZ,']AGJTM?OR#_8*!^T2Y^%CS%RKL[!#4,U= 845*II8705N!T+:K0(>M8%
MS9*')"9YS,1M292*8,;&=7CZY*&C43R :E-L% O:)6N>QY8.Z!P7==\!C7E@
M$*K.%@@V,@3M.J2P>@*3D\ICNP4*?4]I@4PP-6-TM?*<4#DXY@:4&ZA[IF.@
M%ZAMV:D)UG4&-?H([0+YK.[6'%&#+N[O;170 Z@V_49!H5U"#[;!9LJ!MKL(
M.GH2Z# M"72!]7P?JDF@H_9.C2H)= ST7>2I2:##^EW:V4@Z#/__;A@UTHWL
MTOVD?A@=5NF%":-VPP9,5SN,&B5'=B7_H888Z6K=A^I-U %0F^_>+:U=TG]E
M6XP,M[<=_!J)1W:)_]G.&.E"/5(*;F;'M(DW4H[L4OY+NF.D:WA7AC8"CNP"
M_N/M,=*U6Y6FF1W3IMRH.[*K^W/:8V301E=C:0>U:38*BNP*^A/M,=)%L?,L
M:B01V27QF>TQ,@B*YWEJZ PH]6A=&%VA#G5"C3HA^QWGT]KCRDGK<5/H:@JA
MWWFV4.UG<8V"N78%>WI[C(R/Y4S:-APJ[<@A5)M[HUVN7;OL3;29+S0\D NA
M1M@ 4Q\DZA O\$>*"!I0ZG&^,$WFA8%R?W1J@/6U+GJP]XI"ON,2 1%M)@,I
MN1-6SMN1V(-B]]IH-^!T7;ZU^$PYIUEYN2)8G+,2(/Z_HY0_#N2+D/KEW>0_
M4$L#!!0    ( $.#I%29D\AL?0(  & %   8    >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&ULC51M3]M #/XK5C9M0V*D3;J!6%JI;P@TH!TIFZ9I'ZZ)VYRX
MY,+=M85_/]\ES3K4HGW)V3X_C^US[&@CU8/.$ T\Y:+072\SICSW?9UDF#-]
M(DLLZ&8A5<X,J6KIZU(A2QTH%W[0:GWV<\8+KQ<YVU3U(KDR@A<X5:!7><[4
M\P"%W'2]MK<UW/%E9JS![T4E6V*,YKZ<*M+\AB7E.1::RP(4+KI>OWT^[%A_
MY_"=XT;OR& KF4OY8)6KM.NU;$(H,#&6@=&QQB$*88DHC<>:TVM"6N"NO&6_
M<+53+7.F<2C%#YZ:K.N=>9#B@JV$N9.;2ZSK^63Y$BFT^\*F]FUYD*RTD7D-
MI@QR7E0G>ZK?80= //L!00T(7@(Z!P!A#0A=H55FKJP1,ZP7*;D!9;V)S0KN
M;1R:JN&%[6)L%-URPIG><'([&M_&XQ&0%$^NKT;]&2GQC(Z;\>TLALD%:9/A
MU\O)]6A\%[][<Q:T3[_ ^-O]U>PG?)@RA87)T/"$B2/X"&_!!YV154>^H0QM
M'#^ILQE4V00'L@GA1A*9AG&18OHOWJ?*FO*";7F#X%7"&Z9.(&P?0] *@CWY
M#/\?WGXEG;!Y[=#QA0?X8L,,T@P8D N(C4P>,BE25/H]C!]7W#S#K_Y<&T4_
M]^]7PG6:<!T7KG.HN3+/:52T#70,*5_S%(M4TV^>"&I0"A]X :D4I&@H455]
M.]K7MRK0F0MD-\.ZUSHY#2-_O?N8>YW:C5-5@[_SL^:HEFZ&-21R59BJL8VU
M61-]-QTO[ -:']6T_Z6I=@^U;<D+#0(71$DYT/"I:IXKQ<C2C<1<&AHP)V:T
M E%9![I?2&FVB@W0+-7>'U!+ P04    " !#@Z14>P=AGM,&  !E'0  &
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MM-8&ZO<UY_+U1K^@.UD]_1]02P,$%     @ 0X.D5'R.Q*>U"0  $1<  !@
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M<)*\2( R-U:%\477X)J6;DZYMY/V"JY,Y,I<+#.) !AW"!);>PB,7KDNA:1
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M0@W8A><JZ(IPF9!.*;WU#)27'TAPMI0D5'\?Q(!^ 2M[AL @P"7?2*3/Z/5
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MG I *:IE>P3]3!M'"L;PSFAKE^^!=9(JE:C?XS\TA@UPU,9L81850^  XEY
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M"?!CAR:C3<0\8NG=;DA;X0F]@UX(-SJ?OF)!''8YO*V3:A268+\"U%?"-UI
M0IL(-^""LT<XYBQVNL>^7G&IK8.W0AKX)%2!\%FZE$.2(RQ0&+*67#\)RF^O
M _T)>;YAN]3H8IK"A X2GN(])R_)<_*QG%UA1@$_VVE9 O,9(45%20_.\RF'
M.D'/AR]L1>"KE,V'>2K)M3D:Y.PI<NI9RCNCN*-MY@E?WUM E.)"^C5H9^B/
M0&K1H X#,IL1$+ZWS&FMP41/<R^8X/=93NXB4HGZ71MYU]XGO@$#RC:WJ.X+
MNY3WOMN2%/$L"/^XWK#44,F/K*)APAJ>O 8^_;&#A3&L@DYQDK9WF2>J&#.A
M(BQ#E^HQ\9[0NLP7#Z'^C@J3SJC:>H_[A@YF'J55;,"?,EDOM['93$D:L^%5
M(V;E,=3R_!'2%,H3ZL0C4L3'6Y90>EL0U$8MV#(*2JXSF?C8$L]BU;0Z>_;_
M]).06GF+OE&]TPG@UB E4^F^)C,-,-9^&^2>;J%S$D*OUX:/GJG6/67)#NHA
M51LU'.X4RW*)ZU'$3:M=[\;1<N'>+/M&V#:V+$-;9<ZI\.F* GR/D6I!C8;-
MD;E/ODW0;%EW!U&WO0+.RSV(HMZ&L*_P=A!]7H5U/VE9V)R*R [L@^A'(MV
MATV;>$<WLQ*-&VH8Y-('NNIMM1%\5O^D:K>T2B!..ELXM(,UX<?;Q@_@012=
M(1SBUQF[?U2'G-QX&92AHT\9;PK0M9?0^-:YO5FY/V5HIOZ6:&FK*7)77J76
MU/5%M%_>OS;3RULL>3IEO!5.:&FKT6W7P)0WP_+'Z9F_C8VTH[N='Z:4A&AX
M O$G6KO5#RM87\_/_P902P,$%     @ 0X.D5 5SMA-]"   >AH  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&ULW5E=4QNY$OTK*B]U"ZI8&]N0$ )4
M&0*[5"6$ I(\W+H/\HQL:]%(OI(&Q_?7[^G6V!X;FT!M=A_NBS]F6OUQ^JB[
M-7,\<?XAC)2*XGMA;#AIC&(<'[5:(1NI0H:F&RN+.P/G"QGQUP];8>R5S'E1
M85J=O;TWK4)JVS@]YFLW_O38E=%HJVZ\"&512#\]4\9-3AKMQNS"K1Z.(EUH
MG1Z/Y5#=J?AE?./QKS77DNM"V:"=%5X-3AJ]]M'9/LFSP%>M)J'V6U D?><>
MZ,]5?M+8(X>445DD#1)?C^I<&4.*X,9_*YV-N4E:6/\]TW[)L2.6O@SJW)EO
M.H^CD\9A0^1J($L3;]WD=U7%<T#Z,F<"?XI)DGT#X:P,T1758GA0:)N^Y?<*
MA]J"P[T-"SK5@@[[G0RQEQ]DE*?'WDV$)VEHHQ\<*J^&<]I24NZBQUV-=?'T
MP\7MU=?>_=77"W%Y==V[/K_J?117UW?WMU\^75S?WQVW(JR0;"NK-)XEC9T-
M&KOBD[-Q%,2%S56^O+X%[^8N=F8NGG6>5?A)^J;HMG=%9Z_3>49?=QYRE_5U
M-X6LO'Z41 9Q94/T)3@6@Y V%[^K?*CM4/2(*SIJ%<0''3+C0NF5^'>O#W'P
MZ#_/>+$_]V*?O=C_B< _JY&V[U$8RTR=-+ _@_*/JO%#,^)SZ06VN)>T28+0
M5F"G@\M69*ZTT1,&ZOO8!27*(*(#^?P#BH77X4'($%RF950Y:!M'BZ6E]\IF
M4ZS,1M(.E8!^)0:FS&)96>JK.%'*BCA2XDOSKBER9XSTG(='Z;6#N15]\&57
MC+V&"]I,>>5%Z5U3W)-;%D4$UW1@WW;%1(D1\JF$%&/GN0:X@7"(=XV;8TXQ
MEBK#X2!0E+ 0X0T1HG!6110MBEA59#%:]K5)+)$!YHRA;U*>R4!*QM[EB%@$
M:2!3!M*T&2+<F4B? W?++ M-\%,,E45RS"Y'6\>^YBEN(3WS=0(0N,$ CHK^
M%)=A*(Q="F2(.EVY[Q *!%,&&"DH\](&R043YN]Q(_,JUQO2O<9NCKV%I))=
MCHH9I6U4\"&RW?7<8)]V"3^)R )JZBZS@#Q\5%Y$=(*F.)MRD:= G 4#V(M"
M_N&H--N'%!AM5X6;R)F.SI-PLAEG^&4$!L?(+ E*/1",1A>(E-#@:.-(QK0)
ME!]+SWE> W8AI^"R**WL&T4"V$S4+)OB&ZAG@EO13P1D_2 CY8"P4F2#' 52
MKJ:;78 ^6@<"0E.,1E&]$I*BB:77<<J)0C,#LW99/2$FP<8E,SHE6CW2:ER4
M]=BFLTY&.60_Y\P2LB Y7F*GB!.]W^C_X7[B$FVKVDY9.+^MFZI)O'5+>'%,
M(_F8]F707(@'4GODVY1JAR(CLSE5#!BM'&,X<R>LBPFNA%6^*.8+$T""F,S^
MC$M/Q:MB<TU<UVK_A(H;)R]5# )Q41-(7:9\1+@_+@3H$^1BK@)V.6\5<)JU
MKJ-X;9,@9F"P ()5H90XCS9* I\A05%GKE!B&^YA-%([NTP,3H(7YR V7<WI
M5W!&Y^S!7<17BA2 7K&&OXC'QBI'7B\'#S%T!DQ_-1@2 2H"\R8?B/8AH4N3
M _1#%5+V!64+AE561LJE9 UUEK$N);,1D.(B3QE'3"XG/,'4 9C"FYSR%:I,
M"#48*!X'+5U+A=FK(8+C81.MQ$R#KCCSE/%^N7@&-8]L)66]+"N+,M5IQ^D#
M]&C.(YIJ&?.4S'_]<MCI[+WO?3Z_XI_M]SL<6:7/P'D]T*P3.;E9 OSUJ1>3
M4=5WJ3$D(-8U "$9)N#K+1"JX.!RBZI#^IYTD^6F-%-:(\N2_I2S"BK$3FR!
M5@Q\2.ALXF,0B.U9I;B_@LD31*@K0&.[4_&I:F1S&J;LA]DTL+F$C&B>\$K-
M>*EHHGWB'J+'CS9(YCFCILRK!@DGKJG=D&7LDD=--U#NJWF+&+T8-%^3QW/2
M>(E8 I?%D<RIZ !3::IRS6*;9XU%H/7:C25;W69'H)J9M ]RL=5IOEM<6)L?
M2'U0F2KZX'=U%9\+;AETJ&\C;:@=FLV0XR:20T,F=V"<IG@*2X/,^G*;ACPJ
M)3SQ6JXXL_CAKAAZ[K!ROID'CJQ0L)'[=3J,8G,GLS-:93+. %A4Y)#:T=J*
MJ9_-WIDTTF9*W-$Y+1RM(E@[D?12G+4K'VO=99LZ4,I%V!'GR\Y>DJ-?N75L
MOK-0'-;VJ"-Q^0+2W&#G2ITS/E5=JR:L*D];XNU;JGZ^5.NDZAUS2[QYD<W4
M_HRSPU]1TXN9I>Z3&ZYO]+ Z9+1Q-(C8%/D/PA:';?%V"9Q-3?PG =1](3H'
M:P+8.%]TUXIOB<-]?+3;3W?I_R?S#E[,O/V_PKR#G\2\/6CZ!YE' T:[\_Z%
M&,VD7\'"V9+-2[<HZ"TBZX\K<FK6SYS<GW:T9TOQI;8HQ1H>+5KJ$1RA-E]_
M<%6KT<O<YXJ]LGDV,?HW.C+00#BT/#_.YIPMT3DDIAXFB6V:GG:6IYJ!=T42
M7C/S87T'']N=@YT74F>-)\^=)U NWN&CBPU"?M#IFV<Z?'//I4-OK@.!KFVI
MUL[X*T>=-!?/)\19F_Y[#C:8Q'@<LZ[F)K5@%GSB[>NGO1=-$V,7X1MQK<9B
MGF=X^/LYA%Z=+7[CD:=7P7L-1GQ.(U3UI.=%:E8XOZP34:1FT:IWB)OY!/8J
M0[5^L]B:]>>R/.N>T[/!2$\UQ"V:&*3SUHU)IPL:L9-K8ONC&D(D!;P#+]>,
MJS6#\Y;!#7+[W0X^9U6+^TA-=KEQH)D^7="I##[;9A<VJ01N[Z_8?+/9YL$:
M^;98]RBZ57L?4"@_Y+<>(3WO2:\&YE?G+U9ZZ7W"0CR]E0%X0SKC&37 TKWF
MVX-&FLUG?Z(;\]N%OHO1%?QSI"2J/0G@_L!A$U1_R,#\==/IGU!+ P04
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M-1Z4$'X6X$-A20#G<X-D-PMRL/[4W?L'4$L#!!0    ( $.#I%31N)8/Q0@
M 'D5   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*U8:V_;.!;]*X0W
M,TBQ\D/R,VT:P$DZ;8 ^@B0[Q6*Q'VB)MCF51)6DXKB_?LXE)5E.G$P7.U]L
MBB+O\]S#2YUNE/YFUD)8]I"EN7G;65M;O.[W3;P6&3<]58@<;Y9*9]SB4:_Z
MIM"")VY3EO:CP6#2S[C,.V>G;NY:GYVJTJ8R%]>:F3++N-Z>BU1MWG;"3CUQ
M(U=K2Q/]L]."K\2ML/\JKC6>^HV41&8B-U+E3(OEV\X\?'T^HO5NP>]2;$QK
MS,B3A5+?Z.$J>=L9D$$B%;$E"1Q_]^)"I"D)@AG?*YF=1B5M;(]KZ;\YW^'+
M@AMQH=*O,K'KMYU9AR5BR<O4WJC-!U'Y,R9YL4J-^V4;OW8\[+"X-%9EU698
MD,G<__.'*@ZM#;/!,QNB:D/D[/:*G)67W/*S4ZTV3--J2*.!<]7MAG$RIZ3<
M6HVW$OOLV?LO7RZ_7GW\R.:?+]G5Y[OYY_=7YQ_?L?GM[;N[V].^A0Y:V8\K
M>>=>7O2,O"'[I'*[-NQ=GHAD?W\?MC4&1K6!Y]&+ C]QW6/#,&#1((I>D#=L
M'!XZ></G'%8JV<@T93Q/V%5N>;Z2BU2PN3'"&G8I39PJ4VK!_C-?&*L!F_^^
MH';4J!TYM:._+<[_CSS6>'FW%FRI4M2>S%?,<G+5%Z#\(0RS>!VO$0.,9>X?
MN=9;6LPS5>:6J64C[34[QJ(,(Q24><7F?L4Y3WD>"\8-+;X4L<@60M=)"]D1
MFP7#8<0^"4Z!14E;5@@M5<)X\@<P3C.&'8>S5X]D(?GQNLF^%Q2.V&6IG3>P
MUJZU$"SSF!.$N4>; K:J8Y&(&+QEL&2Q94?AK/:$E'$PC$$ED]:ES'DJ?]0J
M=G'@\?=2:NS/P9;@1<TM+0)>C/#V_OLF8)NUA'XO#FL1,=ZH9E8YF20 W"$T
M2;/\@:62+V0J[;91TCN SK_(IBIU>Q-WFP)2]OIQ*)]F:3^U[S6<8O,X+K,R
MY>0'2! 4E[.+$D;G\9;=:9X;O*,(SIL\LL]P[:+&4(60OU?:;S*75G13T'E2
M.?GZB=^LRXQ:*K,H[Z4&<L)!,(T&&!R/@UDT>871K_^816'T!J-1,#L9/5HT
M&8?[B\;!8')R2 ]_D#%?6)QA.<I'IBH592Q2-@W"< !8!Y/!\%4C:!R,!]/=
MN_$@;+^;# ZJN-,J$>G]EE8,L6\2[4D<0&+U!L+;;\)H>$C>!U'$:9F(!S8;
MC=GQ24O:=!SYR6G4FIP.V1< 5S-X@U(^GLSP-F0GXY!FR)7)>.!F)B&[4Y:G
M5$:/T\2B<7 RG++C&7(PI>4A!2)T\^&8YH>SL)H?#\<P'55R0$Z775W?_,JS
MXLTE"X=!A*35IM;_U70(R8?>^FEOJ7Q<,\CV\"0(QU."0F4KT$'3 U 9#49A
M,(.!1XW-U?MA,!J/V7RUTF(%I!-[:"M_>&"+!S138 $M?!6 #?:\>VK(!MQT
M-$(Z&J["L74T/-E-H#'[.29T6ZG4 R*G0KA^*-T&;EX:5FA)1))N888#A^.N
M"V4<]Q&+&I14FC H)::Y4%"2$YUBA!<R<3[=6OQY1L>VJSQ6F>C]S#DDC(4!
M)&)96CJ #X8.<5&Q=,LVTJZ=)7\1PT-GR3-'F8O3,<XHM+-D*'[JF+H,(_D3
M6C3$<#H+:3C:#<<TG+H%$QI.9N0WB']I43FS8 +^\(@[JH&_@_%55G"I'>E=
MY2Q6>5XUKHV;[F0PTDU2:+.LS!'<1,;N\(;6 4X?N(TPQRY"G!440K^>8ER4
M" *=0TAV[$ZCYDS;6?(D@CTV+PJM'EQZ@(^C66_&%A7^"*%8!C+W@'Y!3AOW
M#:,Y_")&GN]A9X&$._@XQ]?HO55.)1.+PBK=+12%X%X$;%UF', H9"+0GZ=L
MA9X,.Y9HV2"SWL"B;DZEB"WLF,H_&KSY<///_H=W-U'7/8=O7K%,6&Z 7!FS
M!9W4%GT0^A!-IW %'=]-;+PI#FH /&=+K3(7VVL7V"&[N_ER+2]NNX.(&5LF
M6R;N>5KZ5J'Q&OG:][,QZ5E3T%@HMN;W+0.013B(8E>Q)J020_,")1UO8W2,
MW404Q 2(ZS?T-+!NU)] ]5HN)")C7.7;C7(\1 BC+M,5"]W]5"6MB9I=2YUT
M:0TKTM(T#M1![*%[(SJH^*%V>X<^'P[?&9F*=YY"W>%4BX+KO<W4E>6H_)29
M'</4Y/>]Y!HUYM)3%IZ(G T5IS1"4&*,['(SM&(7]^>!2_$YFO3"!O.'&*7'
MOCQ2V%)6&E^-6BVJ/J^[<1=&1UA$D8Q3B?&8_.=H#G$/(48RCOCB%BO&W #C
M(%)3-Y,(EJ$<.U6[_M/5M:=6J">#/@H0/A#:,BS;]>2F2DA14G+\&4"8W?&R
MQOZ\%'@;XU2H,MCRR459Q.L<_9"_8.$0I(9/Z2W8/HZ%,?XH:)QJ>=.<.JTY
M5UP_41H>!X?AZ:VL'P XP74J10OM-=!]Y+@6'JWEX@\820N,1R."CSW..8*R
M%,8G'7&1E. Z:?L^;' "X(Z O]81FY2>?7$+2+FC@Y27.65?9A3T%QWR=L:\
M0E5SN9"^\*#B&T!KUN0) %QF!162<9\O7'G:O12HK!#6<2JH!-VRR@D./7]V
M>?-SU;XFDI("]S0$3^\I:/%[N_KV4XH][6PX6Y[)2(]];6JG#B[357E->M/Q
M+U4LY&/G&LUUF75!G!HMNH.NHSA>2->FPAX* <^13\] @/12IG@R2$;*=>6/
MJ2!=U9LO+6>-*]DJ[$ *\"DACS*E2C1,I;_X^8JC30=.6#B:"% 8LD\!),D5
MJEI]T:YNZ=1=T">U_3M[0VWNXNJX"S8'[1MN?82I58[6R[$264QM\*X#0;+U
MR@DZBGK3AO>0KJN\B_!0)9,\X2B0PI(0MZC"[6X)^M][193&S]_N>X<^S?1;
MG\,R 3_HHY]A#CW^RU@SVWQ7G/O/:;OE_J,DM*TD@)V*);8.@+@.T_Y#GW^P
MJG ?UQ;*6I6YX5IP-"2T .^72MGZ@10T7UO/_@102P,$%     @ 0X.D5&<C
MVP$ !   20D  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULK5;;;ALW
M$/V5P=8H$D#5WG5Q90&R$R,"8MF0W>:A* IJ=Z0ES"4W)&79_?H.N2M%!2+#
M*:H'\3:7,W-FR)WLE'XT%:*%YUI(<Q%4UC;G86B*"FMF^JI!22=KI6MF::DW
MH6DTLM(KU2),HF@0UHS+8#KQ>W=Z.E%;*[C$.PUF6]=,OURB4+N+( [V&TN^
MJ:S;"*>3AFWP'NUOS9VF57BP4O(:I>%*@L;U13"+SR\S)^\%?N>X,T=S<)&L
ME'ITBWEY$40.$ HLK+/ :'C"*Q3"&2(87SN;P<&E4SR>[ZU?^]@IEA4S>*7$
M%U[:ZB(8!5#BFFV%7:K=)^SBR9V]0@GC_V'7RJ;C (JML:KNE E!S64[LN<N
M#T<*H^B$0M(I)!YWZ\BC_, LFTZTVH%VTF3-37RH7IO <>E(N;>:3CGIV>GM
MPZ>/2[B>+V:+J_GL,\P7U[?+F]G#_'8Q"2TY<&)AT1F[;(TE)XRE<*.DK0Q\
ME"66_]8/"=@!7;)'=YF\:O"&Z3ZD<0^2*$E>L9<>HDV]O?14M+9"#==<,EEP
M)F NV[)V]?'';&6LIBKY\Q5'V<%1YAUE_T]:_[,QF!6%VDIKJ$$*Y$]L); '
MDIKYH4)8*T%-Q^4&K#OH.H__C0;45I_4/8=W7%*Q"4%Y,>^!6"BJ PWP@:3K
M%>6QVXF_9PC.(.OE^9C&O)<,1_ 9C3F'HF)Z@RM6/!H89 D,AO'^A)D*2FXZ
M2TR6H#Q;PP%)=4+,Q4/<40!$'!0:2VY!*&-H)\\@&YY.R!FDO>%HZ(%EXY2X
M?T)IE>:D^H9D'8G_<'Z6;$<]:U%3S1D"$/>B<>S'.$[@"UU;0 8;K2@P%T<$
M^3AR9<JIL4O8*%4:IY1E[C]-X$%9JMXS2'J#8>['89K!$ANE+2DP@G@<GO.4
MC1(_#N(1M&T@E-S\0J!JDC=(&7L7OW>0QID'-CCAY:_7?][*K&XY:#1W.10O
M4%"FN+&@UJ"/L]%WA.FM WU@O-AJ3=A!<+;B@MLW,$1ZY*)NE$3GE[R\R>P/
M,WE%/NA%:F\,9QKK1J@71%BAQ#6W+MEMV8^3(9% H)#@/A/&AKUXV!F5<YZ.
M8;8O9E_+A@ET16NW6AK(HA2R\;B-@DCP$FBMP-J%H%$P1[15L.*%Q8UF3YP8
MI: V+3;'PL\_C9(X^9783/*H(YUU:3G.;=*+J V3WCB-#IRGO3R*:!STXBQ_
M$^?WE(2%L@AQU'=YJKFM<=_*5_0N$'%(UV[7NZRDUB6DY(U_NX7[W[M[PZ/G
MK4:Z/]PC;L#W>?O2'78/WPFS]GG\)MY^9!#!&T[Y%;@FU:@_S /0[</=+JQJ
M_&.Y4I:>7C^MZ%L'M1.@\[6B$+N%<W#X>IK^ U!+ P04    " !#@Z14]I;*
MC"\%  !&#0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM5UMOVS84
M_BL'7CIL@&=+E&3971+ <1+,0]H52;H^#'N@)=HF2I$J2=GU?OT.25E)FIL[
M[$&4>/F^<^$AS]'Q5NG/9LV8A:^5D.:DM[:V?CL<FF+-*FH&JF829Y9*5]1B
M5Z^&IM:,EAY4B2&)HM&PHESV3H_]V =]>JP:*[AD'S28IJJHWITQH;8GO;BW
M'[CFJ[5U \/3XYJNV VS'^L/&GO#CJ7D%9.&*PF:+4]ZT_CM6>K6^P5_<K8U
M][[!6;)0ZK/KS,N37N048H(5UC%0?&W8C GAB%"-+RUGKQ/I@/>_]^R7WG:T
M94$-FRGQB9=V?=(;]Z!D2]H(>ZVVO['6GLSQ%4H8W\(VK"5Y#XK&6%6U8-2@
MXC*\Z=?6#_< X^@9 &D!Q.L=!'DMSZFEI\=:;4&[U<CF/KRI'HW*<>DVY<9J
MG.6(LZ?G%V>W,'U_#K/KB_/Y+5Q.9_.K^>W\XN9X:)'?K1H6+==9X"+/<"7P
M3DF[-G A2U8^Q ]1KTXYLE?NC+Q(^([J 21Q'TA$R M\26=LXOF2YXQE"POG
MW!1"F48S^&NZ,%9C8/S] GG:D:>>//U?//E?N>!VS6"I!!XF+E=@Z4*P]D3Q
M?Y@!B],%U7KG9FFE&FE!+4$U&+Q*:X\RT. &:=@@1C4&EEQ267B UE2N&!XZ
M:]["3UQBR F!I\?\#+,]ZS2PWNYJYJC/]K0P-Z9A@&'(X!VUC>9V%WIS:9EF
MQL)UF-/%NMM6.&<%JQ:H3CL2PPV37&GX* TK<)M*'*AM6$.B>-02>' \F&1O
MX A^_&%,8O(K?F51] I!]J"+),F ($G<CQ ZF4Q>E?\ G@ 99-$;R-,)/N.7
MP23Z%AP-<B\[G>2^'3TFV)L;IS"M-1<.F*+2>>2 3J9K\\? ]VK3:9W")5OH
M!N]=!\\0GKT&_\9IG=='"!ZAT@1AD6N3UUW6@7-TU\1;3-*\;5]SV1^%56T'
M(0/BO3WRS^'0)$*H4WLR2?SS/4&29) .1I$#$_]\3X@D(P1'7FGBG\.5=OX-
M<L>Y?QY!N].#8N/[O32&K+5WY)]#XBI-4=5Q" Q4.[2'QU7JW-3&59*T[:%Q
ME3HWY3ZN"(G:]M"XPBA*![&/J]P%B6\/]W/F_!SL3G-_$/,1W"I+!9A TG0D
M4EF\9TG6CW -OK(\ABM.%URX^TXS@7=<"5;YJ]A0X2_)96-=PM%J1X7EB(_[
M<4)<BT<Y""HQ.?5!8AU&1GT2C=UK-,G@BAF\BV>-UG@K0ZVTKV:04RBY^@4O
MULI#@<H2%,K4H!:"KZA;9@(A7FUXY.-^%N^MNGJ #:N.G#7Q.&D_\B=.]7MO
M^UP^N$Q('[9H&JLI+^'(W;]MTG!*/N,^C#<<;9UT[SZO]GECL0/VE>F"&Y^7
MH*8:\YH0H&IGV !50:6WP?0M-<!=\BFA1+C+BTAKUYHQJ$))PEQ)\DWJ&< G
MABG/Z?ZEX3KL6J&J6NRP"K-K*)BV6-?BV(9ABK3[Q.FRJ;,#.':EVUD#*URC
MI9/M9I\V>P!3XYSR4 WOOBTF2+<(*6'#E:#[7:9R=R=_ -=LH\3&B9DA+;=P
M28L0>4]1^Z!XE&#[SCVZD]F6"0AOK+&(<.QWAAYA?H-%NZ.Z$U\$\<N]^+!S
M.($&_-Y(YM-,WRNP-\][$KW+L=I@P<-N1^^L>ZH*&]ZK;2NF5[Z"-PA"E4.9
MVXUV/PG34!O?+0]_&.B;%9<&!%LBU&7>'NA0M8>.5;6OE!?*8MWM/]?XH\.T
M6X#S2X6[V':<@.[7Z?1?4$L#!!0    ( $.#I%3(1U$_VR   &%J   9
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M+"H0$IS(2 ",J>Y1G/#.X$SE$A^#+RR D*Q#%YRFW5 AH;->0@C&@1"5 LZ
M"5XKS-2X<AN>@G7$I75C!YU/S:Z\=DU]YCBMBWDM<AJR13F2>IGB*M+[#C ]
M^D_R$7/?X[9O3.\J>ON;O0<_J1I+J#"B[N82,VPH\U,KTGIH: #U<,[]GU5H
M^(N]=M@=ZAN! &JE^ C@=+)4%>G@*>A+&U.G'T].@^JI.PA9+'5J =R!P(2>
M6\ZE<!A2I=MT4K/)I[!?=+3< :GCPTE=LN5>0Q0_AZTJGBR]]:@Y$GP[ #:O
M#SXP3CR!X&X.FBL]5>#0O<-B)Q *8;2W.+&J"T_]X0-,G6U[Y%Y"Q)S6%5O6
M_59"S-@AEV)7+P6E%J+8$G:!]J50U#X'\M=TBY!4Q%!I-D-[0V"'M1/Z/B%_
MX.STXYMIS(8-E(E:,D2[7N$:X!-TEEO0^@?QB=64F3*P$U=F/]#;Y <8;7OT
MU8W/HP&VZ,8I!*55N!FMUVM9*U09^%C-T:/S'CL9@,ZU 0#F WSSJL AZ6^.
M^!QIG]J#S?+9O$C"#O#@R'<+WC][4OZ)W)4?D*^VFU4("+ L$AS/QMW9L#G&
MM9B"G8'X%=RH@HL$Q/4;V\%(HW%^_C"OEW:#EXHO!I"+^Z%;P6A*D7C6TT>1
M]U/,9-Q1J9[R*^5*BG.T@ A4O0?YR_CD95?;)?JZ'^2U<LWQ,6L:GDI'Q8<_
MR [=Z@]R%AT*_BR.^2C!ROJ)<=(,8!#;2L$L]#Y]BS<U#$\6TD$G>E7*_E[H
MHX!HXW'-*."&9[!FE[NXS9G6M5-IXC4J'K+:>EXGX=D*;Y-8ZP)-[J)W$!"6
M&M42YX1XA8$88"Q\WA''JKU%)(--59ES3,;M!XE\W,38HI\@9K *Z.+=#4J#
MJPJ<!M?2,CXU-^Y[$!YI";LUN#+I@$?G$J.JT,/PB7OICXVY9F-KK<D9T\@D
MPODI?SI(9*>.\>C60ND)_?.:O$'7V$Y?<)LV47BT67P8XX3;,R/Y4-JG4R:J
M<UM3N@[@H1_/HP9U(#VLS=Z_4$\1'UHO'>P0.M[#2=S\:!F9T/V67N\P43^O
MH-N)+-JA9K ]]),VMOF#68$=;K1DD2>('KW?ML.+0;Z1T--]15LO?/XNN@%T
M^VT^E*QG3N9"YGQ,R#;*[+U;-PYI4Z =P@/UV-H$&X!YJ27X6G08-4R7ZZKM
M_BFSQ$*E*4@F,H@3D*QV5V0:Y[2Y%)D%,.6N&F\RQX4=@T;C.PG\C!?!M_RP
M<\'0Z[[*8D?"2)??4#"9@A)S$<\ ID$']7S^V&0  8)%:8.5RG72=.)T"N\J
M;EG0UX0V>A !J9+'O:2X#5E9N<9Z5"*L@"L Y6+8;\<=QSZ'WB\IX#2>GTD
M&6]&W8OVJ3L0^DPG#_D"P?)&$_D?L6D^:[S3WU:6[.M!2T+W_!P=Y^C^#>R)
M'K$GFYH>=_+KMYN&8;G3Q9%<4#_,0#AN""[[?6*Q:SN(%398)_0%?33Q"J"[
ME(#[\-%*6-B?/=2=8X<XLY4<:=9R$)2CP74;7'=+$[=W/V+I$3>03)_<=6'G
M?+1I/^MW?MD6 WIWK1"7-(U>Z#H4U-P%,T>WX1BF'/4/,T'C%16_>I;2$3L2
M$V+NB&GH1_/M47YN0(]!EZQO)HMJ35>72G<7EMO4*!6  ]  K54; WR7M (*
M)]=R_D4"L5T2>M6K^V7A@-T 7 DAK,N=I:(6.4\>SG( /Y.K!IK[18@*B?#X
MBVU7 *"/9-RC>!8$]M]/O*!% +]C)'LQN&%UC_KT^S8<I"?-K@ABH\00(W=>
M!C*;WCQ*[QIX)RS=!ZJ:[T^@E!MM]S\FDD@$3#N%>L@FE?<G?G>OOI'*O06^
M@>0)1*;/_!OE+3<S#:NWLKT7M;]%[)*I RENS5?+GL\Q8H*CQ8##RPUG-%Q/
M'6UM_%92<LL;<PP .7/*: 7/JFW X+?+D"#R-XX??SF;8]^$0?Y-%K@@!$#A
MVC*N&>_G;CR6N2QJD]Y_[U] 0C+,E*AETYA;E K*.YEK%=NGW ,^!^F::-/[
M^2"KV:; <E]"8)J7L<_QMC0X:/ 5]:&@V5J:!E;B3:A25UB=5'A]NP49*M=$
MA#3N1FJXS3)FU,;E<3?<"ASJA3<(*]/+=[X!M7#R-!7JB(.O'XK;$.SC=H %
M>*,F'>]7 )-Y>C[U3"OC#?(A$6-PM[F1A]-_D9 ^@XBMN=5*D@7T>7V6Z]BR
M$RZ^J]#!0_EAX ]'570'/SV6YNY1]#I:W398SW?O\+$=Q&D80OE#@0_U- FR
MCAO@O2F?G:_1C;^$H'DVV^AP/C[O%\7?FV5M82YNDG*_\6V<[Y*POI85]^RP
M D@7W(!<@W;S^V]B=F7NF\D0C6D5+%JFE37_:A[,_%K.&=/U8@6B^_;=E[3I
M*1DR:(26)"-<H<::(%TG L&]B $A-^P*WQ;[U&L9"VX\RW<@< NYX#7\YIQ_
MXUW01O+ZH;L=A_IR*%5#79J#>-ZR4GH6(FV2+W+/S41$<8B[K.H(Z5M/(QOR
MI*\D(SU[1!/8(Z\-]]<.:;\9FQIG'? ]/!!ES7W,RZR@#BF2!<6%G,EK%WX4
MP"%8:-6!OP&*W5A^.P>;O!([:TI2RMNE*15F_WWJ3=;,(WH=@YL%D:HNGJWD
M&IOJPI2IM"RY*P1B=LXP<DMG :I5=!R7:Z[X)4)")W4MW1E%J;)F$S.X##A^
M_Y$B2@?Y[%$%YRBNP2KADPZ1RER$8# QJY8#^3:QR5&],%F Q DY",<3OO/;
M) !/LX6\@VNP6W4MUST<GWR_*DW;$S&#"848\PXW@D]209/R&+XFZ?S)?2+)
MI5JU(1NTNY$-6HP6NSB0CR']Y\LI7PI\VIJ%:NF55&EN7KP)ZIOT:J.WN@6L
MY"A<1;3ZG?K#F;/\&O#S1@/NB N#38/N\K23Q3.09/AGL:14B^MA>H?22B\]
MNB*P\%C=FXV^BLT_J2*.*<6.V'RZ)S%X(L#G@]&,+KX2C,H#G0V>R9#H'IWX
M^21S5VB[PF:7U(/?R#B@T3W%+J@;F?4Z%J;P&2X42GW4 ("I(THN>=G!6YKK
M6 9,"X#KS.$RWM!P^8C[L)E=I_L .8 %887]'6 QN"9/5S&B 3^_Y/=>J!OI
MBE8Y78^5>(6VP%Y7=+ZI3'6_H(_*]AGU>+X'H*1FQ"U23CV**%58[#]7=SHW
M&0ZI.52XA$4D',-G*N(HX!SX:+5:<T4%JY!7]P]PYMD^QCY["TPNY78;G*SV
M-0R^;Y,]EH]P-00HR;M; JY^\VNCR)]-# @#?!J*<.7;)\"^];U(W(0<0X3?
M%'L\]TJVNV:+>B5O#!GIN-4=G^47']RKWM8AV]?W)67D,/7#UFH<H9'FWBGS
M58LRS!UL:>)??M'X\M8 +)E'E8S\8? R&&LNX5.8I=CJ,SYNGN=  C^5H 8F
MDN+*]5L"VQ6"^[4N:BR2S@SW?#XGZ#+DKF!+OMKB_@W</(8O["AWF);[EPBD
MU]1CY^.YMOAV*4TG1D%_C_<JZ6+!#57^*GXY 01PDY?9[NYNGY?#ZDH0[=1M
MVE +-%">98N& JW>#3H@BJ5*"1V="\98$S$5UC?\:]%BAOU&+PQ,8_'"8$BP
M6P7;3_85_)/_WRJY(WZ*S7[OZAM,$+ER3TCH](N+H+<KH_"%(5B["7Z,A[+0
M'^+>XQ*@'@ZVX="@A/S=--=I;JHP.5]]'K[]#+21+ZTC3JZ4O&: A="\8GY#
M,!=>< >>)4?3\7XQO= **0-AVW]U6ES)*NUJHY<3(FCS!0(%*F?6*K:^PI.B
ME=5&M<Z5*I-$Y]Y+_.T^[^Y48K=VGQ87JJ[MNKR1%!Z=]=X6&!LRXXT]_[(C
M5U>FWMX;? &$SU;1;=-0K\:,;%=;3J+U&W7\E?UPLM12)CT>@^M#^#8Z=U^3
MZFI88J,T1+Q-Z5PCMK,>0LYDB1VQ[!Y.\S[D,N#,:8A_DPY5%:^6SLG##!59
M27J_%EXFHZNG#@JHK=>I(/5 M<HE_!UW/5_M5S V-D/WD2\$V%1L[;,L&36T
M\@,5>9BEF3\Y F&#:NCVYF,F=Z&%X(*O,/H7!CC6QF\]<_O-U8,=;[ H-"J=
MG4Q[*1TFIZ^;APK++W&_V,-V+Z<$3DH.:RJ3>^&>#&?)W'SJ3N7T'C0Y'DN,
M-YF$]R^,7"=S%LV]3 R+2[@OU\L1;L(YV2"" V[_AH[M9I=*N"#I>@%#NSKG
M[CR2/7AC9\=':R=+@R Z+2A?CU' AP\G\=)).FCC70)?*]?17-\GU\FHWRW7
M?:CJ']D)>F=3(8^EV'NE?13(W+%[D)0<9D/D??<J52C\70 %_B!!4,_PN'?5
M\OT@V=R8FG_V[^RDS]]]\1DA?)DQ%BK\'/U-/P;<[MOXQGNR<#QWA=_WND4G
M\!L2WN<*UI&34DQOXLAOG@J#LO[3OOF%G;?'&%2^Y@)Z1/5YWVI,?)6AP'6E
M[J2]3V9YP!]%7)/.K:^55SY(Z((]:V37NT^20O75^=E%Q.H_M#335C>3>4YV
M^=!;7WESJ>]:_T8Z_UWPJU)9=SXFM1VT<IW,'7N<G+6D2_%VV"0U)UZF+SUZ
MC"^WF1^)?F(FN&TP[[AMD*\]_^&"$:Y2]DI:_R>AR278^H8]R<11?T<W!RO<
MKAWVXFA^BWM%R?PD%<I)?=/8A\M,_=QU^'L+:9WIR-69J,/=O>V="\;1K.N^
M,.^]ZH6W\66+R2,]E.A=6G15BO#BR=[(T :T-;.P03%D<E*I2 @PZK';R >J
M+>G-.\[I$OYZS3',91:XY@=WH7W:O\LAKAI3@"BO?4\5^(H8;Y!$A/<;.$;
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M-/P#?9]K"E?]P@::*]W1WU!+ P04    " !#@Z14D[](@/@#  "F"@  &0
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M5#"'XP+(-GK&^QC!HE"M)VN/W4Y9C'#I4"I1+O%4H:N&SX:OVS;-IF@E^AH
M,%-MP'\Z.P9;)W%-Z.=TW_ B3YFTA_)F='.E.6]/\B?S]CZ$KITK9*BIA.NP
M?W30$ZZ]8[0_P39\KL]LP"V!/RM<R\@E \R7UH;'GP2PN>B=_0U02P,$%
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M\B'2:"B3.:54P4?D<C)FEJ69MB/6-MF&S1.&EH&RB;@7:U*^.%?+58^]'):
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M,J$_R7JM-X+B9$SC,<49)?B> %6 '\!*QQ%]0N);N:$07";X D;1!!)'6$:
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M#<;(6M/^GJ!]<7KE[^8S[9!V?KG$V"<-$^#[7&NW>V$!W2]KSO\+4$L#!!0
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M%KQVL#.<9'YXNB,GV4CIA=)HY25SX-7#=K<<>^3A:J$H]/$9=)XB/O*/G22
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M9X)W0JYI .IG2MGM'W)0WC+[?P-02P,$%     @ 0X.D5/.RF/_2!    1
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MJ'5F=CH' C@&#8T>$J^27AL?S2;&%T"Z1$\Y\YK_3^9USF9>^Y\PK_.#F-=
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MM2O>IDW-\K]X4_GAX6VY-"#8!J'N)0Q -]54,[%J[RN8E;)8#_GA#@M0IIT
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M<O'WAM?_ ^I!ZS'N%?SLAH1'C:I$O?/MV! LE;#I6=UNU_&G3:-[-6]^%W1
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M>E"9.-&5UI'*L8FN=,.:<=;7I**B\6AJ/:P,>]A!4]V!2]B>2QS@2NM#Y=@
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MRO+"M_H,>#DI?/E!W0A'!BR<BM3A$&AQ*D:'P\(-?G4VW#41J]CWN#DPYJ1
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M>*)G(8J!MV>%M__2+>:SFQ $P@#(,R5.A8Q=T*/:H >U9:'79^9XAU!%7O/
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M.FND'P5[E(#FLM%E1H0&-*$MY4F!$71'QG3."-'=@,5I*D9SC"?8W 2J$VW
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MC(%^ON%<'3?F@F)&'?X)4$L#!!0    ( $.#I%3M*Y/&& ,  "@(   9
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M'B6/*X)#(@Q ?U]PKMX&YFHCO\H:_@)02P,$%     @ 0X.D5-L($U/K @
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M[0SH>ZJ4?9FX'U376_\/4$L#!!0    ( $.#I%19- @C(@,   0*   9
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;,V62T_C,!#'OXH5<0!I(8\^06VE
MTL)N)>A6+;!GDTQ:"\?NVF[+?OL=)R&$-LURX+"7Q(^9?WXS]L3N[:1ZT2L
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ME#7 ^5CB69QW[$6@N/@-_@)02P,$%     @ 0X.D5.I<]2:C!   _Q   !D
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M7I::)?#('*]\.6&;6Y(X5-/V7.8+\PN;9*Q5 G<E) L2L&(0T#!^XM<D$ <
M&^4 [ 1@GPIP$H!S*J": *K_ B G!U!+ +539Z@G@/JI@$8":)P*:": YJF
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M3*AC_46"J?P7-J6MYT"4*2W2$FP8I)07_^2I/(@]@/%3#PA*0/ 2T#X :)6
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MM,,ZXH7_SAZIH.=Y+YAW7C'WZGEW*][=-WC#?<E[MN4]-KS#/=X/4L3(UK_
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MTAJ8_840>CNQ :KOD]%_4$L#!!0    ( $.#I%1K,?=*(P8  ,HC   9
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M@JN6B4CEUTH^0;EQG7DNT?1Y-UR;FQB4-3#_EU+BQ\0V^_)N[_\%4$L#!!0
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MC=^MC/^.OK XC<F<"\2::.D: U6[DT&Z[R)PRPK'/C@!8Q!+<_60)-!Z94=
ML5I<;_KF4#]:'SHW?G9)>:7)[DS8H9<LD22"!5+6:_J2(;)K2#91?&W.V3E7
M>&J;X0JO;B"T ;Y?</RH\XEV4%P&>W\!4$L#!!0    ( $.#I%1-X[WXV04
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M8>LY*,REXJP @P)&4_N+GXM$[ " IQH0%(!@'] Z &@6@.:Q'EH%H+4/Z!P
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M.DX0"DRM8V T/.$$A7!$).-7PQFTOW3 T_F1_;//G7+9,H,3);[SS.;#X%,
M&>Y8)>Q*'6ZQR>?*\:5*&/^%0Q/;"2"MC%5% R8%!9?UR)Z;.IP B.<\(&H
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !#@Z14@AP?7D0%  "E+
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M^4R="PN_3#>77;:7'<(/?P)02P,$%     @ 0X.D5,A<P5(@ @  T"<  !H
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M.^KM!'H[ZNT$>OMDLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.] O8-
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M<',O87!P+GAM;%!+ 0(4 Q0    ( $.#I%3D($')[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " !#@Z14(XR[^,,"  #*"   &
M    @($O%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M0X.D5";=_5))!0  Z!0  !@              ("!*!<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $.#I%1FW9=?\ ,  +X-   8
M          " @:<<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " !#@Z14C<8OG0,&  #(&P  &               @('-(   >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 0X.D5)F3R&Q] @  8 4
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $.#I%2O$WS$U 4  *H/   9
M      " @<M/  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ 0X.D5 5SMA-]"   >AH  !D              ("!UE4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !#@Z14_%N'ECT&  #V#@
M&0              @(&*7@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( $.#I%31N)8/Q0@  'D5   9              " @?YD  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 0X.D5&<CVP$
M!   20D  !D              ("!^FT  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " !#@Z14]I;*C"\%  !&#0  &0
M@($Q<@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $.#
MI%3(1U$_VR   &%J   9              " @9=W  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ 0X.D5+8I)1<W!0  W@T  !D
M         ("!J9@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " !#@Z14D[](@/@#  "F"@  &0              @($7G@  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $.#I%2U310D>@0  /0)
M   9              " @4:B  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ 0X.D5)3$L_4H!   1 D  !D              ("!]Z8
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !#@Z144_M2
MA\(/  #6*@  &0              @(%6JP  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( $.#I%2F$6&O[ <  +@1   9
M  " @4^[  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M0X.D5/A$?2@7!0  D T  !D              ("!<L,  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " !#@Z14AO77'4X%  !Q#@  &0
M            @(' R   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( $.#I%3SLIC_T@0   $0   9              " @47.  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 0X.D5.+\UF*Z!
MZP\  !D              ("!3M,  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " !#@Z145P"+R$0$   I"@  &0              @($_
MV   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $.#I%1+
MJ</I200  -X*   9              " @;K<  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ 0X.D5.=<W^/W P  ^0D  !D
M     ("!.N$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $.#I%0- AQJQP(  /<(   9              "
M@8$! 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 0X.D
M5$>@5X:0 @  _@4  !D              ("!?P0! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " !#@Z14:_P$1S "   9!0  &0
M        @(%&!P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( $.#I%0+I2LKL P  ,EK   9              " @:T) 0!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 0X.D5";$.-J_ P  KPX
M !D              ("!E!8! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " !#@Z14[2N3QA@#   H"   &0              @(&*&@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $.#I%1 1XG7
M* 4  #8;   9              " @=D= 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ 0X.D5/,F/A[? @  Y@@  !D
M ("!.",! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !#
M@Z14C)F)*0<#  "]"   &0              @(%.)@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $.#I%1E;O/2+@,  %<(   9
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M970T.2YX;6Q02P$"% ,4    " !#@Z14630((R(#   $"@  &0
M    @(&U.@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M $.#I%3J7/4FHP0  /\0   9              " @0X^ 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ 0X.D5%(_P5!V @  ! 8  !D
M             ("!Z$(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " !#@Z14(G0F3:T#  "K#   &0              @(&510$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $.#I%1K,?=*(P8
M ,HC   9              " @7E) 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ 0X.D5&;V(G#' @  8 <  !D              ("!
MTT\! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !#@Z14
MY/1?ZK("   A!P  &0              @('14@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( $.#I%1/19*BM@(  'T'   9
M      " @;I5 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ 0X.D5"\VU8+[ @  YP<  !D              ("!IU@! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !#@Z148OF/R&,'  "G+P
M&0              @('96P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( $.#I%2G&2A[,P,  !@*   9              " @7-C 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ 0X.D5$WCO?C9
M!0  >AH  !D              ("!W68! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " !#@Z14_)8H'28#   Q"@  &0
M@('M; $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( $.#
MI%16'O\,) 4  .L7   9              " @4IP 0!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ 0X.D5*!"8?&( @  B 4  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( $.#I%2"'!]>1 4  *4L   /
M  "  4^& 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !#@Z14R%S!4B "
M  #0)P  &@              @ ' BP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !#@Z14XB$R0O$!   9)P  $P
M@ $8C@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2P!+ (04   ZD $
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>559</ContextCount>
  <ElementCount>305</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>132</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUES</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128106 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS</Role>
      <ShortName>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136108 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - DEBT AND CREDIT FACILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</Role>
      <ShortName>DEBT AND CREDIT FACILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151112 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155113 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/REVENUES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables</Role>
      <ShortName>DEBT AND CREDIT FACILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2352309 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INCOMETAXES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails</Role>
      <ShortName>REVENUES - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails</Role>
      <ShortName>REVENUES - Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - REVENUES - Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESPerformanceObligationsDetails</Role>
      <ShortName>REVENUES - Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - REVENUES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESAdditionalInformationDetails</Role>
      <ShortName>REVENUES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2427417 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails</Role>
      <ShortName>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - STOCKHOLDERS' EQUITY - Repurchases of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Repurchases of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INCOMETAXESTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="gild-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - SUBSEQUENT EVENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUBSEQUENTEVENTDetails</Role>
      <ShortName>SUBSEQUENT EVENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SUBSEQUENTEVENT</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="gild-20220331.htm">gild-20220331.htm</File>
    <File>gild-20220331.xsd</File>
    <File>gild-20220331_cal.xml</File>
    <File>gild-20220331_def.xml</File>
    <File>gild-20220331_lab.xml</File>
    <File>gild-20220331_pre.xml</File>
    <File>gildq12022ex10182022psuagr.htm</File>
    <File>gildq12022ex10222022psuagr.htm</File>
    <File>gildq12022ex10282022employ.htm</File>
    <File>gildq12022ex1082022employe.htm</File>
    <File>gildq12022ex311ceocertific.htm</File>
    <File>gildq12022ex312cfocertific.htm</File>
    <File>gildq12022ex32section906ce.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1115">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 559,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 568,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 30,
   "keyStandard": 275,
   "memberCustom": 82,
   "memberStandard": 43,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.gilead.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - REVENUES",
     "role": "http://www.gilead.com/role/REVENUES",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128106 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS",
     "role": "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS",
     "shortName": "ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136108 - Disclosure - OTHER FINANCIAL INFORMATION",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - DEBT AND CREDIT FACILITIES",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIES",
     "shortName": "DEBT AND CREDIT FACILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151112 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155113 - Disclosure - INCOME TAXES",
     "role": "http://www.gilead.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.gilead.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - REVENUES (Tables)",
     "role": "http://www.gilead.com/role/REVENUESTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables",
     "shortName": "DEBT AND CREDIT FACILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352309 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.gilead.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)",
     "role": "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails",
     "shortName": "REVENUES - Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i450e90b0899c413f9adda90b2983c33f_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i176dd2b5900a430a8769d523c75624e5_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)",
     "role": "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails",
     "shortName": "REVENUES - Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i176dd2b5900a430a8769d523c75624e5_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - REVENUES - Performance Obligations (Details)",
     "role": "http://www.gilead.com/role/REVENUESPerformanceObligationsDetails",
     "shortName": "REVENUES - Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - REVENUES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
     "shortName": "REVENUES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i2903bd78a9744d49a6e8dda11ba3d6a6_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "idb992b77b3444d00b7b2813dab4e0089_I20220331",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "id4ca803e36054d509ef339b251361ad7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "id4ca803e36054d509ef339b251361ad7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "iecd6c25aa9ef435ca2a940cd82ec2eab_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "iee6ff6cc00ff41f8b7ec36a69139238b_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i54513ac7f8334fc5b465981879a0f801_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427417 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i2aa635ad0e1a44f7b6c2b98f4ad871c7_D20200527-20200527",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAgreementOptInTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "role": "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
     "shortName": "ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i2aa635ad0e1a44f7b6c2b98f4ad871c7_D20200527-20200527",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAgreementOptInTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i04455f0253cf41bea3d4447eaf0b5f43_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i6e9f66d43a49486cb27df9c7ce53de4c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i6e9f66d43a49486cb27df9c7ce53de4c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i04455f0253cf41bea3d4447eaf0b5f43_I20211231",
      "decimals": "-7",
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - STOCKHOLDERS' EQUITY - Repurchases of Common Stock (Details)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Repurchases of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ic34802f125ed4c2dba4e404cfaed8ab7_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i04455f0253cf41bea3d4447eaf0b5f43_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.gilead.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ib6451f2f16f341a48298ff3195581dc3_D20220401-20220430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - SUBSEQUENT EVENT (Details)",
     "role": "http://www.gilead.com/role/SUBSEQUENTEVENTDetails",
     "shortName": "SUBSEQUENT EVENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "ib6451f2f16f341a48298ff3195581dc3_D20220401-20220430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20220331.htm",
      "contextRef": "i290f773a19dd425cb3450b8cda3a7575_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 132,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "0.75% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A195SeniorUnsecuredNotesDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "label": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due March 2022"
       }
      }
     },
     "localname": "A195SeniorUnsecuredNotesDueMarch2022Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2016StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Repurchase Program [Member]",
        "label": "2016 Stock Repurchase Program [Member]",
        "terseLabel": "2016 Stock Repurchase Program"
       }
      }
     },
     "localname": "A2016StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2020StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Repurchase Program [Member]",
        "label": "2020 Stock Repurchase Program [Member]",
        "terseLabel": "2020 Stock Repurchase Program"
       }
      }
     },
     "localname": "A2020StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A250SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.50% Senior Unsecured Notes Due September 2023",
        "label": "2.50% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A250SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A295SeniorUnsecuredNotesDueMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "label": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due March 2027"
       }
      }
     },
     "localname": "A295SeniorUnsecuredNotesDueMarch2027Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A325SeniorUnsecuredNotesDueSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.25% Senior Unsecured Notes Due September 2022",
        "label": "3.25% Senior Unsecured Notes Due September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due September 2022"
       }
      }
     },
     "localname": "A325SeniorUnsecuredNotesDueSeptember2022Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A350SeniorUnsecuredNotesDueFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "label": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due February 2025"
       }
      }
     },
     "localname": "A350SeniorUnsecuredNotesDueFebruary2025Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A365SeniorUnsecuredNotesDueMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.65% Senior Unsecured Notes Due March 2026",
        "label": "3.65% Senior Unsecured Notes Due March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due March 2026"
       }
      }
     },
     "localname": "A365SeniorUnsecuredNotesDueMarch2026Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A370SeniorUnsecuredNotesDueApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "label": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due April 2024"
       }
      }
     },
     "localname": "A370SeniorUnsecuredNotesDueApril2024Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A400SeniorUnsecuredNotesDueSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Senior Unsecured Notes Due September 2036",
        "label": "4.00% Senior Unsecured Notes Due September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due September 2036"
       }
      }
     },
     "localname": "A400SeniorUnsecuredNotesDueSeptember2036Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A415SeniorUnsecuredNotesDueMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "label": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due March 2047"
       }
      }
     },
     "localname": "A415SeniorUnsecuredNotesDueMarch2047Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A450SeniorUnsecuredNotesDueFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "label": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due February 2045"
       }
      }
     },
     "localname": "A450SeniorUnsecuredNotesDueFebruary2045Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A460SeniorUnsecuredNotesDueSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.60% Senior Unsecured Notes Due September 2035",
        "label": "4.60% Senior Unsecured Notes Due September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due September 2035"
       }
      }
     },
     "localname": "A460SeniorUnsecuredNotesDueSeptember2035Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A475SeniorUnsecuredNotesDueMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "label": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due March 2046"
       }
      }
     },
     "localname": "A475SeniorUnsecuredNotesDueMarch2046Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A480SeniorUnsecuredNotesDueApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "label": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due April 2044"
       }
      }
     },
     "localname": "A480SeniorUnsecuredNotesDueApril2044Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A565SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "label": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due December 2041"
       }
      }
     },
     "localname": "A565SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedGovernmentAndOtherRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Government And Other Rebates",
        "label": "Accrued Government And Other Rebates",
        "terseLabel": "Accrued government and other rebates"
       }
      }
     },
     "localname": "AccruedGovernmentAndOtherRebates",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement and Stock Purchase Agreements",
        "label": "Arcus Collaboration Agreement and Stock Purchase Agreements [Member]",
        "terseLabel": "Arcus Collaboration Agreement and Stock Purchase Agreements"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementAndStockPurchaseAgreementsMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement",
        "label": "Arcus Collaboration Agreement [Member]",
        "terseLabel": "Arcus Collaboration Agreement"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AxicabtageneciloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "axicabtagene ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset - axicabtagene ciloleucel"
       }
      }
     },
     "localname": "AxicabtageneciloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Tecartus",
        "label": "Cell Therapy Products, Tecartus [Member]",
        "terseLabel": "Tecartus"
       }
      }
     },
     "localname": "CellTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total cell therapy"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Yescarta [Member]",
        "label": "Cell Therapy Products, Yescarta [Member]",
        "terseLabel": "Yescarta"
       }
      }
     },
     "localname": "CellTherapyProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CollaborativeAgreementOptInTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Opt-In Term",
        "label": "Collaborative Agreement, Opt-In Term",
        "terseLabel": "Opt-in term"
       }
      }
     },
     "localname": "CollaborativeAgreementOptInTerm",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Liability",
        "label": "Contingent Consideration, Liability [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "Credit Facility Due June 2025"
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5",
        "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DragonflyTherapeuticsCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragonfly Therapeutics Collaboration Agreement",
        "label": "Dragonfly Therapeutics Collaboration Agreement [Member]",
        "terseLabel": "Dragonfly Therapeutics Collaboration Agreement"
       }
      }
     },
     "localname": "DragonflyTherapeuticsCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DragonflyTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragonfly Therapeutics, Inc.",
        "label": "Dragonfly Therapeutics, Inc. [Member]",
        "terseLabel": "Dragonfly Therapeutics, Inc."
       }
      }
     },
     "localname": "DragonflyTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount",
        "label": "Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments and equity method investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIAdditionalOptionPaymentWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Additional Option Payment Waived",
        "label": "Equity Securities, FV-NI, Additional Option Payment Waived",
        "terseLabel": "Additional option fee on fourth, sixth and eighth anniversaries"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAdditionalOptionPaymentWaived",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EuropeanPatentClaims2024ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2024 Expiration",
        "label": "European Patent Claims 2024 Expiration [Member]",
        "terseLabel": "European Patent Claims 2024 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2024ExpirationMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2026ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2026 Expiration",
        "label": "European Patent Claims 2026 Expiration [Member]",
        "terseLabel": "European Patent Claims 2026 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2026ExpirationMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2027ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2027 Expiration",
        "label": "European Patent Claims 2027 Expiration [Member]",
        "terseLabel": "European Patent Claims 2027 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2027ExpirationMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2032ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2032 Expiration",
        "label": "European Patent Claims 2032 Expiration [Member]",
        "terseLabel": "European Patent Claims 2032 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2032ExpirationMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement",
        "terseLabel": "Effect of foreign exchange remeasurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos, a clinical-stage biotechnology company based in Belgium",
        "label": "Galapagos [Member]",
        "terseLabel": "Galapagos"
       }
      }
     },
     "localname": "GalapagosMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product [Member]",
        "terseLabel": "Total HBV/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]",
        "terseLabel": "Other HBV/HBD"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductOtherMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "terseLabel": "Vemlidy"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "terseLabel": "Viread"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVireadMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepcludexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepcludex",
        "label": "Hepcludex [Member]",
        "verboseLabel": "Intangible asset - Hepcludex"
       }
      }
     },
     "localname": "HepcludexMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics"
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Process Research And Development Trodelvy For HR+/HER2-",
        "label": "In Process Research And Development Trodelvy For HR+/HER2- [Member]",
        "terseLabel": "In Process Research And Development Trodelvy For HR+/HER2-"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentTrodelvyForHRHER2Member",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Asset, Measurement Input",
        "label": "Indefinite-Lived Intangible Asset, Measurement Input",
        "terseLabel": "Discount rate, measurement input"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetMeasurementInput",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset - sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Net And Inventory Noncurrent",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_JudgmentEnhancedDamagesOnPastSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Enhanced Damages On Past Sales",
        "label": "Judgment: Enhanced Damages On Past Sales",
        "terseLabel": "Enhancement rate on past damages"
       }
      }
     },
     "localname": "JudgmentEnhancedDamagesOnPastSales",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateFromOctober2017": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate from October 2017",
        "label": "Judgment: Royalty Rate from October 2017",
        "terseLabel": "Running royalty rate from October 2017"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateFromOctober2017",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate on Future Sales",
        "label": "Judgment: Royalty Rate on Future Sales",
        "terseLabel": "Running royalty rate on future sales"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateOnFutureSales",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, \u201cJuno\u201d)",
        "label": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]",
        "terseLabel": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center"
       }
      }
     },
     "localname": "JunoTherapeuticsIncAndSloanKetteringCancerCenterMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Additional Patents Allegedly Infringed, Number",
        "label": "Loss Contingency, Additional Patents Allegedly Infringed, Number",
        "terseLabel": "Number of additional patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyAdditionalPatentsAllegedlyInfringedNumber",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyMaterialTransferAgreementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Material Transfer Agreements, Number",
        "label": "Loss Contingency, Material Transfer Agreements, Number",
        "terseLabel": "Number of material transfer agreements"
       }
      }
     },
     "localname": "LossContingencyMaterialTransferAgreementsNumber",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Appealed, Number",
        "label": "Loss Contingency, Parties Appealed, Number",
        "terseLabel": "Number of parties appealed"
       }
      }
     },
     "localname": "LossContingencyPartiesAppealedNumber",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesFilingOppositionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Filing Opposition, Number",
        "label": "Loss Contingency, Parties Filing Opposition, Number",
        "terseLabel": "Number of parties filing opposition"
       }
      }
     },
     "localname": "LossContingencyPartiesFilingOppositionNumber",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "terseLabel": "Number of patents challenged, scenario one"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioOne",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "terseLabel": "Number of patents challenged, scenario two"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyRoyaltyPercentageOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Royalty Percentage On Future Sales",
        "label": "Loss Contingency, Royalty Percentage On Future Sales",
        "terseLabel": "Royalty percentage on future sales"
       }
      }
     },
     "localname": "LossContingencyRoyaltyPercentageOnFutureSales",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR GmbH"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_NumberOfClinicalStageProgramsWithExercisedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Clinical Stage Programs With Exercised Options",
        "label": "Number Of Clinical Stage Programs With Exercised Options",
        "terseLabel": "Number of clinical stage programs with exercised options"
       }
      }
     },
     "localname": "NumberOfClinicalStageProgramsWithExercisedOptions",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHepatitisCVirusProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Hepatitis C Virus Products",
        "label": "Other Hepatitis C Virus Products [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHepatitisCVirusProductsMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total other"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentsToOptInTheCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Opt-In The Collaborative Agreement",
        "label": "Payments To Opt-In The Collaborative Agreement",
        "terseLabel": "Payments to opt-in the collaborative agreement"
       }
      }
     },
     "localname": "PaymentsToOptInTheCollaborativeAgreement",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltiesPercentageMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalties Percentage, Maximum",
        "label": "Potential Sales Based Tiered Royalties Percentage, Maximum",
        "terseLabel": "Royalty percentage (up to)"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltiesPercentageMaximum",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PreExposureProphylaxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Exposure Prophylaxis",
        "label": "Pre-Exposure Prophylaxis [Member]",
        "terseLabel": "Pre-Exposure Prophylaxis"
       }
      }
     },
     "localname": "PreExposureProphylaxisMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_QuiTamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qui Tam",
        "label": "Qui Tam [Member]",
        "terseLabel": "Qui Tam"
       }
      }
     },
     "localname": "QuiTamMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorNotesAndMediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes And Medium-Term Notes",
        "label": "Senior Notes And Medium-Term Notes [Member]",
        "terseLabel": "Senior Notes and Medium-Term Notes"
       }
      }
     },
     "localname": "SeniorNotesAndMediumTermNotesMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy",
        "label": "Trodelvy [Member]",
        "terseLabel": "Trodelvy",
        "verboseLabel": "Intangible asset - Trodelvy"
       }
      }
     },
     "localname": "TrodelvyMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_VekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Veklury",
        "label": "Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "VekluryMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ViiVHealthcareCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Company (\u201cViiV\u201d)",
        "label": "ViiV Healthcare Company [Member]",
        "terseLabel": "ViiV Healthcare Company"
       }
      }
     },
     "localname": "ViiVHealthcareCompanyMember",
     "nsuri": "http://www.gilead.com/20220331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r65",
      "r68",
      "r136",
      "r137",
      "r304",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r207",
      "r379",
      "r385",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r303",
      "r341",
      "r401",
      "r403",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r574",
      "r630",
      "r634",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r207",
      "r379",
      "r385",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r204",
      "r379",
      "r383",
      "r575",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r204",
      "r379",
      "r383",
      "r575",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r303",
      "r341",
      "r391",
      "r401",
      "r403",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r574",
      "r630",
      "r634",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r303",
      "r341",
      "r391",
      "r401",
      "r403",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r574",
      "r630",
      "r634",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r67",
      "r68",
      "r136",
      "r137",
      "r304",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r379",
      "r384",
      "r632",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r379",
      "r384",
      "r632",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r17",
      "r583",
      "r612"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r19",
      "r583",
      "r612"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r587",
      "r620"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Future royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r78",
      "r87",
      "r88",
      "r89",
      "r90",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r78",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r76",
      "r77",
      "r78",
      "r614",
      "r639",
      "r640"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r75",
      "r78",
      "r87",
      "r88",
      "r89",
      "r140",
      "r141",
      "r142",
      "r466",
      "r635",
      "r636",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r70",
      "r78",
      "r87",
      "r88",
      "r89",
      "r466",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "OTHER FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r411",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r408",
      "r409",
      "r410",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r122",
      "r264"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r404",
      "r405",
      "r412",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r30",
      "r210",
      "r238"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r122",
      "r257",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborations and Other Arrangements [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r131",
      "r188",
      "r197",
      "r202",
      "r236",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r460",
      "r467",
      "r522",
      "r538",
      "r540",
      "r581",
      "r611"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r57",
      "r131",
      "r236",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r460",
      "r467",
      "r522",
      "r538",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r216",
      "r219",
      "r602"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r216",
      "r218",
      "r601"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r478",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r400",
      "r402",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r447",
      "r448",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Acquisition consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r446",
      "r449",
      "r452"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Liability for MYR GmbH (\u201cMYR\u201d) contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "verboseLabel": "Fair value of contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination, Separately Recognized Transactions [Line Items]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Table]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r118",
      "r124",
      "r125"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r118",
      "r523"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r276",
      "r588",
      "r619"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r285",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r83",
      "r85",
      "r86",
      "r97",
      "r594",
      "r625"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Gilead"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r85",
      "r96",
      "r458",
      "r459",
      "r471",
      "r593",
      "r624"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r85",
      "r95",
      "r457",
      "r471",
      "r592",
      "r623"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r207",
      "r520",
      "r521",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r207",
      "r520",
      "r521",
      "r642",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r207",
      "r520",
      "r521",
      "r642",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r174",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r178",
      "r179",
      "r207",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r207",
      "r520",
      "r521",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r364",
      "r366",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r364",
      "r365",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Changes in estimates"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue share with Janssen and royalties for licenses of intellectual property"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r392",
      "r399",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r100",
      "r575"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r177",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r317",
      "r324",
      "r325",
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT AND CREDIT FACILITIES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r130",
      "r138",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r330",
      "r331",
      "r332",
      "r333",
      "r536",
      "r582",
      "r584",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r328",
      "r584",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Short-term and long-term debt, carrying values"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r130",
      "r138",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r330",
      "r331",
      "r332",
      "r333",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r130",
      "r138",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r326",
      "r330",
      "r331",
      "r332",
      "r333",
      "r356",
      "r359",
      "r360",
      "r361",
      "r533",
      "r534",
      "r536",
      "r537",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "netLabel": "Available-for-sale debt securities",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r223",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of positions held in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r132",
      "r425",
      "r432",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r122",
      "r271"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r58",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r60",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r59",
      "r63",
      "r68",
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Abstract]",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r61",
      "r64",
      "r66",
      "r490"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "terseLabel": "Cash Collateral Received/Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r61",
      "r64",
      "r66",
      "r490"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "terseLabel": "Cash Collateral Received/Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r496",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Time estimate for gains (losses) to be reclassified from AOCI to product sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r485",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r59",
      "r63",
      "r68",
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Gross Amounts of Assets/Liabilities Presented on the Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r58",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "verboseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r60",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "negatedLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturities of derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r486",
      "r489",
      "r491",
      "r494",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedges:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r379",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r362",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r98",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r153",
      "r155",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r498",
      "r499",
      "r595",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share attributable to Gilead common stockholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r98",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r155",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r498",
      "r499",
      "r595",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r87",
      "r88",
      "r89",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r169",
      "r237",
      "r355",
      "r362",
      "r408",
      "r409",
      "r410",
      "r428",
      "r429",
      "r497",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r635",
      "r636",
      "r637",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net unrealized loss on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r12",
      "r16",
      "r229",
      "r610",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r315",
      "r330",
      "r331",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement",
        "verboseLabel": "Market value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r501",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r315",
      "r330",
      "r331",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r502",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r315",
      "r330",
      "r331",
      "r501",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r501",
      "r502",
      "r505",
      "r506",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r315",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r315",
      "r392",
      "r393",
      "r398",
      "r399",
      "r502",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r315",
      "r330",
      "r331",
      "r392",
      "r393",
      "r398",
      "r399",
      "r502",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r315",
      "r330",
      "r331",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r502",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r507",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in valuation assumptions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r315",
      "r330",
      "r331",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r501",
      "r502",
      "r505",
      "r506",
      "r510",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r478",
      "r482",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r231",
      "r232",
      "r233",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r326",
      "r353",
      "r496",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining nine months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r258",
      "r260",
      "r263",
      "r267",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r263",
      "r577"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r258",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r263",
      "r576"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r392",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "terseLabel": "Discontinuances of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Loss related to litigation"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r251",
      "r252",
      "r540",
      "r580"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r253",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Measurement period adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r476",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r122",
      "r268"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "In-process research and development impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Indefinite-lived assets - IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r188",
      "r196",
      "r198",
      "r201",
      "r203",
      "r578",
      "r589",
      "r597",
      "r627"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before income taxes",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r420",
      "r421",
      "r423",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r419",
      "r422",
      "r424",
      "r430",
      "r435",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r151",
      "r152",
      "r187",
      "r417",
      "r431",
      "r436",
      "r628"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r116",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net loss from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r162"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r259",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure",
        "terseLabel": "Indefinite-lived intangible assets, fair value"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r259",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r256",
      "r261"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Including Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r91",
      "r186",
      "r532",
      "r535",
      "r596"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r250"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 3.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r55",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r250"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r32",
      "r250"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r579",
      "r603",
      "r646",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r131",
      "r236",
      "r522",
      "r540",
      "r586",
      "r617"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r131",
      "r236",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r461",
      "r467",
      "r468",
      "r522",
      "r538",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r18",
      "r584",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amounts outstanding under revolving credit facilities"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r50",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Accrued litigation"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r314",
      "r329",
      "r330",
      "r331",
      "r584",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less: Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Current",
        "terseLabel": "Accrual for settlement related to bictegravir litigation"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r276",
      "r279",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs involved"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents challenged"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r44"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "verboseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Equity Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r54",
      "r131",
      "r236",
      "r289",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r522",
      "r585",
      "r616"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r120",
      "r123"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r81",
      "r84",
      "r89",
      "r93",
      "r123",
      "r131",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r159",
      "r188",
      "r196",
      "r198",
      "r201",
      "r203",
      "r236",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r499",
      "r522",
      "r590",
      "r621"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Gilead",
        "totalLabel": "Net income attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r84",
      "r89",
      "r151",
      "r152",
      "r463",
      "r470"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r362",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedges:"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r196",
      "r198",
      "r201",
      "r203"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r45"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r78",
      "r87",
      "r88",
      "r90",
      "r524",
      "r526",
      "r530"
     ],
     "calculation": {
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r71",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r71",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "verboseLabel": "Net unrealized gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r71",
      "r76",
      "r480",
      "r483",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain (loss) reclassified from AOCI into Product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Net foreign currency translation gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r82",
      "r85",
      "r87",
      "r88",
      "r90",
      "r94",
      "r355",
      "r524",
      "r529",
      "r530",
      "r591",
      "r622"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r228"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment recognized"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Settlement payment"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r105",
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payments of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r103",
      "r106",
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r107",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Payments to acquire in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Debt issued"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r103",
      "r104",
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r112",
      "r115"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r103",
      "r104",
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r81",
      "r84",
      "r89",
      "r117",
      "r131",
      "r143",
      "r151",
      "r152",
      "r188",
      "r196",
      "r198",
      "r201",
      "r203",
      "r236",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r457",
      "r462",
      "r464",
      "r470",
      "r471",
      "r499",
      "r522",
      "r597"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r272",
      "r540",
      "r604",
      "r618"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r78",
      "r87",
      "r88",
      "r90",
      "r524",
      "r528",
      "r530"
     ],
     "calculation": {
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r362",
      "r411",
      "r540",
      "r615",
      "r638",
      "r640"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r237",
      "r408",
      "r409",
      "r410",
      "r428",
      "r429",
      "r497",
      "r635",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r184",
      "r185",
      "r195",
      "r199",
      "r200",
      "r204",
      "r205",
      "r207",
      "r378",
      "r379",
      "r575"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r178",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377",
      "r381",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r78",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r217",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of the Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Debt Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r479",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Effect of Foreign Currency Exchange Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r486",
      "r489",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Potential Effect of Offsetting Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the Calculation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r258",
      "r262",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r258",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r34",
      "r35",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Revenues from Major Customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r51",
      "r128",
      "r170",
      "r171",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r348",
      "r353",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r336",
      "r337",
      "r338",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock by Class"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r126",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r52",
      "r87",
      "r88",
      "r89",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r169",
      "r237",
      "r355",
      "r362",
      "r408",
      "r409",
      "r410",
      "r428",
      "r429",
      "r497",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r635",
      "r636",
      "r637",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r169",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r362",
      "r406",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount under stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount under stock repurchase programs"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r21",
      "r22",
      "r355",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r131",
      "r211",
      "r236",
      "r522",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r88",
      "r131",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r236",
      "r237",
      "r362",
      "r408",
      "r409",
      "r410",
      "r428",
      "r429",
      "r455",
      "r456",
      "r469",
      "r497",
      "r522",
      "r524",
      "r525",
      "r530",
      "r636",
      "r637",
      "r675"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r340",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r531",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r531",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r531",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r531",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r231",
      "r232",
      "r233",
      "r326",
      "r353",
      "r496",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborations and Other Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r135",
      "r392",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r135",
      "r392",
      "r399",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r172",
      "r173",
      "r175",
      "r176",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies, Estimates and Judgments"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r154",
      "r162"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in per share calculation - diluted (in shares)",
        "totalLabel": "Shares used in per share calculation - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r153",
      "r162"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in per share calculation - basic (in shares)",
        "verboseLabel": "Shares used in per share calculation - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r664": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r665": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r666": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r671": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r672": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r673": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r674": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0000882095-22-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-22-000013-xbrl.zip
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M03,C'M )!5(-J"5 *L7=5T4K[_F57JYAPV5/<P;8(7;JS(A!FE32(<62+/:
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M#&TV;4)IUJI9RTFURE (BYE;< BLY+] YR*AHQX!JU*-K6,KD31AB9P3FS?
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M/^2'K[I_Q(_]^]_]W<WEE6Y\>%N_3K?V5Y 8SD(^@_ISD/B]4_\+)#;TF"(
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M #_8C.(XZ ].KLA[E!\J!66G'ZIH"N0^!UD/T&>.".0.TVA3R@&J68CN,&!
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M,)QY%D,SO,KGMBOE=@>QJI)S>=:&/[?%H6SX"S+\&5IC) _*1L-7%EI *;)
M^J"!]5A@[WB$@V3X=%6(>653'\#PYY2S66K:\V[0/X[#.5DMCCLZ$9^>*T^&
M'7>CT>0M+95A.:=R?)>D& .[VJD,<SYZGMAWQ986[2G#-(*=P,)%[(,"J.B=
M ,8$(\6L@M"G,P?1GRU12)<->4E92S;D!S+DV<-#DE/IA0 &&0.HH-&0J4&
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MGN$JS$EFE9$@^$  U8H"Z9@%$9B%1/%W"NMHTF0U2GR)3/HY9%9.+2!G3ZI
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M;=1V*R(&JE6%Y]60[ $:O&?SKR8ERN:_6/.?H4!>>:,83&<D+ >4:@N,Y0%
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MV7&/3=2?MHN=.Q-/ MP.;Y+XTE$A/_C:MGZX&P69/>F\/.GV%8N[R%(GA4;
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MW8&YW^O!XTY42FS?9*'A9@_]'*</W<:(YM2D>*E7N>Y9<'5^YWV>VZGW.\Q
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M T=!Y;+0PC"DK7$(,R?A3UA&7S53I8(OZ3#YTC3JD0.%CXL<3</P_WJT9;"
M^)L$J+.T<5EH6N'H4;\+LS?<J2IQ[O9\=YPG[&U_D$>Q-1H-.FX\LC#?A_UV
MOY?',>AW8?B?=F%$@,"C JT+0NO,21--E% DYPZR'(D-S"!-DD5:4,F5!4O
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M$$5^7BZ2O.C/PS<7<Y^+O^3)T90_SJ5;:O,M#_.^S$E\U8EA+36R01' /.$
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MWAJ/BSVZ/'R=4T4H"89]U (%ZPSBT0?DF%#($B55\I)(65<1NE.!D.*T>KI
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MGMY'KZU%INR1:Y??;+)N7KE\WA,^4N7QFSW: G7'8Q#$*ZE=#)HS&RWCUL;
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MEA:-VN(@)@#[NQ!7->OFR.R3W;-T0N NA2RS@.*0F[%:]>1*;U!84FRA'I_
M*F<]8""/D32$&$IK$55URBALY&%(:YADF4)O$,B[9>D41Z8\7: M,L%I8$>J
MT54+52(V2*!T?$('V,AOX?B9Y]7PO@[U6BM9=@'"J?M8,*GOH85U!K=!'.^>
MI6=M,3&[R&)@KE!=];$[5ENG&\J(JL<GRR;F@'&<0FQU=)AE4LBIRAA(7GU)
MD1)16#C>'HYWSM)K3BGE/,UC,TR;&''LQ4+LH24Q4.IY')_$N"7!_0+RGLO2
M@Y80>HN](OK<);? P7/GE#6UY0J]02#?4I;>0A'LP5DT-1R&5)Q8<N1&' +
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MY#G@H)@D\SZTJ@O*FX4RU= $DHBG@3'V6D-JH_O&#4E7OX:-0ODO-Z%<,FK
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M48G9]4[L&RI7"K.]Y(:\(Q>0]]SW*-8Z=:==2D1[!)P(NMI?A#[MG7$!>8-
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MV!$K^" 6R$EQ%7IPJ!X=>077L$DLO34J//M^KMQ@,<%SF* EC:D6*E5P<*=
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M1LI:>[:,='8;8%W=NC:)XYWF('G*%[$Z"K$YU)Q=;2.Z[K,MRSCTNCG(WLJ
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MY]?MLG/0=-9:&KX'RS:)L:=6JZ0$T?#0O2*L5AJ;H[/OWMD];@]M4&\IS?W
MN;G?AF.!9K&*+XUKAJ(R"^?W53![1U7O!XWDX,D0FEORL6.#QL-G%DQ> J>L
M"\E;1/+.>3N$$4*87IXM5H>643H*I,Y(6J"WH9TMS2BK9_#A AD[-8&D78O,
ML_=*&2A J212;;5>0-XBD'?/VT>-%EPY*J,XQ,I.E-"EVHR?L4+S_?B$%HX/
M%L=E@*^:/>D S(3V3Z<>*L<:(?)2LFX1QSOG[4E3*$/5E1&NO6B*(5K0M>(E
MQ]Q+F)Y4$+;4+W@A>=][?E!AVN6/EM"#,/I9.#HDIVDP]XI<]!>2?UF2O'O@
MCEA"3E2=5/067$_??(CBU$(N@W.P'P5;DV%!^6"A'*GW+)$95;"U1E*IY.:I
M8:LAM07E34)YY\ ]>$! :BYW,BC7!*XVC,Y6ZB[3%1SRE,&M5?EPH1Q\*2GF
M06@CWQ-1X]@5A ;[N?NUH+Q)*.^<K&LC\*D/E[%%AY3)<6!R8(FS4@O"E(]/
MUH[7X2(Y4<C3I8T!$2W8)NR<8M.H,67L?2%YDTC>.5//S"6$49S"[.; "D[
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M6].L(8G&XY.TRB\7#3RG/81% )+3]/AI2*5RY# ++T/JE7Q=Y9=;I(';#!M
MBR(;\G&00T%P'!NYD+56TE$T^GUXRB\B.% BZ$DIAYA*CQ&'AIH-_SA"&SD,
M+<O'>IM$L*-M0.@BH7L7(%:''**K-IBNPF#" F/ .#[)=ZCZ<A'!JSU*3</'
M*J5)\EA+G9-&4K)LLV7@DA<1;)((=F01&D,LHZIE!2SV!WHG.?A)"<.G*$)Y
M'A<L'E@\<'NW*1A(H6,-E%"&4!#)L?I:"#CXU:)FFSRPHYJ81[\< KB:T0("
M7X?Q0$PNT4A,K4%F.#ZI=VBG<*]V#'!'^EZ\E([B9V1D/_=[3\?TR4-X*]JC
MZ^>/Y$RO1_6E27)KS_O__%*5T/X>SZ&L'9B\DA=?:?8(B(/L0[+]!5"-+<:Q
M*N/NUL)R[[8&(BG6G+)KH\_PLLUE9007_0C)P@-I/*Y-+=*^=+=[@]EK%NTN
MMEULN^>:)0I5/!$%CYWKA!YW+3#U/1+#8MN[QK:WB'ZZQ%K)E4K=8=-9WC"_
M)8021V# =%VQY%\ZH5]LN]AVL>U/[(_.?DDC#!]HS#AW>J$;^PHS#R/A5R2<
M6&R[1[:]&=LVBE Q- >!^]PZS:X*%E?9MS):R#W2$WN7E]XU66R[V':Q[?/9
M%LB/4B('ZATAS89TR4MMG2.75-)BV[O&MCL:-B'RK4-R=83H$&9%GZ4O+D -
M);:&*?=KCQW:5UG?8MO%MHMM;RL-*#@RE<'=$DK47GOJ'C)$"MC",CJZ>VQ[
MBU0P1_!$0QP'F.J %!VE3JX1^\'-GC3AM=%17GR[^';Q[6_I(.E+Q":Y>B3[
M9_!0H$0P&DJ*_(I$EXMO]\FW.XK,AD6@4G,I^^E=$:ICGZ-]FX,ML:.&>.TV
M%5^^K^;BV\6WBV]_PIJ[:*A!H27TV# RC\!5,U&3I*TM3=LF*75'VSH;S0^/
MU56:&[1B<2R/ BY,]^W@<TIY=AU\^2+X1:B+4!>A/I]0+;8I52KTT KV$BEK
M2C0T^]@RXBL2":\ =I]LN^N[1M67PNJRC;##$IHC3,5%2BR]8^= <X,6X6".
MPZXEQG^\8GM/^V\__?KD_]D?S^[[Z3NX26AOT8])[DN;J:?C\9._.GW0]<'5
M6XZN67BO4"X_!V684/[G3__O^W'YR4\8Z@M\Q'G1OC]C>A->X%.^_?#\\G1.
MMK<N](RO3K_6M^?4</#FO.^;P\R7.E_@^.0/X3^>??Q7R['7 W/T!!B[?_Y5
M'U[HI3W2RZ/S1]_;YQT-(T2C7CEMIY=7?'7TAW__MPK@WW[W^K_A[?]XXTCO
M7UW8CVW2VKM]?\%_?OK])=>N?%?ZX'R<?WUZ<<1G/-38][3_Z^I/W_G/[Z\^
M?7#TR>/[5X^^XZ,_=+YX](#MM_[X[A_M%?]HU]D[\M$X_5:[@?-2[>;NVQOS
M]8KQK'V@_9V1=CNU9_^=72>/C_[+'IE]NJ-/VJD^:/8X/YR#9O?UMP=GI_=/
MK^RJ=\_OVW@\_OZ>GO[*L_MZ\W<]:6&3D_;#!W-9MO=YQZ;@PS-^X^C].1F_
MYNLI]^EC.;^\^GV/6]SDN+USWQ9?8QJ+Z2Z-5X[.QY..G_.+#_CBZ_,'IT](
MXPL]XD=77YQ?7./X<WU@]]&.[.->3KC_X&I;BJ]Q/KGK4A_R!5_IT>4CN3SM
MIWSQ^(VC=R[U\T=\].D7>L$/]9$]KLNC__[O=W_?LP/OW.QX_Z$A_I)?<'8\
MNWK-CE\S.](F9\?WG/]W6_V_?L(3GYQ_S6?]]/<]7'G;P_6!/KS^ZMOK$;/O
M[(WX]SUB9=LC]BX_OKPZ?_#&T7\]MEO69N'57_F!?ON$??_QN-OG^/S&"#[-
MPS]Z=']R\9/OY\[-Z8-'UR'ZC\;XZ?T@O%EF+>SN4_SFM%]]\6QWZ >_^#1!
M]__Z%1;C^$=7S_^5^WSQ^>F#Z^3]1B?T9K-'+_8]<X)_H5&@&X_O!W]^<?$O
M+'RN3BZ4OW(\[%[?XK-O;&R.__CC3V@?[\83?=[#N+DI\?3#G_P_N;#7O.6.
M;HSBDRVM6HJ/..U@M6"/E4OP[*>KEV_:6G_N /P&VQ([CWO',?[Z<3_=YKM\
MDM?>XR_/+XZ>[?%=_OB#_V@B[T$<^N/]QD_:%]H?G>G'X^DM_>GQ]=U\?S-_
M>FP9^;DQQX///]'/[\_$_-.Y+?2IW<6?SL[;5W=S7_%,/_CKXW_\;W\H@/D?
M[]D]??KWLWMPSW_\Y[_@1^]]=';OS^\__NS3OZ5[]S_\]A]?GGWYT7?V6I^>
MC7M?_LU_],X_(PZ$RN" 4!UJ':[.GN;="TGNX'N.QT=ZV2R,LWE^\4B?.POQ
MS?3SJPK O.HUD8.%HT?C_.SL_!N;!4?7NX(6M=ZWSV O<OE]:?Z3R:S<OI@Q
M[XQQV[-9=/3-%^=']E%.OS[MC_CL[/$1MS:C:XN7A\W]X/_OD?WG_OF%/OO=
MJQ^5_;_UW 7ZZ9-\2L5H'^@'SS8]AV*??H9G+'Z]GVI/\XPM&GCKV1=O]]-+
M2^8?OW7ZX/J97/_2VS]^O[2[L%Z_WY,?_XOXWO1/R.^I;</3=W[ZXS>O?W1C
M<_C)SPJ]F7UX[H_]F[_V9RD^_TU_ZC=_\F;?K*'>G7N%%[N?G[';^%F?G5]P
M*>U<>LLQXI-)O*7^)Y]^<:%Z=,^N^^+RZ'TCK/ZC X\7?("O]<2T7)/PSY\-
MWGZ>\SL:ZWM\8?P>PQMW;HA?[//]@2^/^.BA7LQ';_'N7(Y^O!3]QSY&_P<B
MAE]TFK?MR3&CS!<QZ'FQC_S[>WCAEX#JYTZ/;WLHV^BJ]?-AY_4#>6>F/)<6
M"S;]DUY\K@^.WCV_L%SD.O7[+7R@7L@:[^<?\H[:Y35;X[W@XWZN[.7!H_MB
M4?,-TXV2>P=)Y#U;[LVU9.H)8BLISW:B/U.8"#<3T7?/'TQ(/AG<OYY>?O4_
MWU-P^%[$XN!N9IM/5"Q?_O4KN[?[GWWWN?_X?__VS6??_=4R2KOVO7[?OH>/
MWOO[5]?O_=U_G=Y4L7ST9[N_/__C2WN?9._SY4=_?O_;>_.SPF?V_6?^H_^]
M_IQ?WKO_7^/>8__XNL#P$__MO??^$NY]^>$_2\M2?$VNH7:'/-0QX7 ):+H=
MYRJ]'I\$VJ]^Y3=2J+P.</S?Q3>OEV\HB?;6(@@(EIBJ36+2&+EHZ!73SRCM
M%M_\EGSC;_)-TQZ'#\-QGGQ#8=;857"A#8XCE^$I[J-)U^^$;^YT#]47_,3O
M\H7=J^59'RB?77WQQM&'#]J;OXIU]VB ?/"T6D60N#??*" $%-]&K@&\[QA"
M_CFGRD6KOQFM?O3N;A@70^V9VW#*;1KSS [0*05'-13.#2%#,EK=EY?QG>?-
MQ1C[9XS4R5;=5I%\QCHJ-<DQAUH@,J:@*Q![C8RQ$XA-_Y@V#;QZZS,0R\E)
MA^"Z16,>6VB%9^)7%V/LU5M]TY'6O?;_Z>7E^::VTPZ>-B-43EB(012UL;18
MA5+OW:>><EF!UFNCS4]V RV-25HOU6&XWB]K/#UBAD5;/M5>4:CR/MK)_41G
MACM%FXLQ]L\8C"42EL1%!B9A+FP)64,2IMK'S[6F7(SQ6S+&3J!5TQ"6DER
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M;3U]]/*7%T^WGFZ_>KE< _W,D8/E2MK_?.?/1XJ&6*:P0 L8@&DC.'Y"5D1
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MBB9U,_HN +QZ2HE2+5@5)%<18ZZZ4K15(5-^E]&;!>2S,MJQ6B6U3D*U0@%
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M"[:7PO2D<O F@W#>F%9\J3"V<Q5*QU2JU8:!WH7T'0!X0,;WL.HR@=(!;?+
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M@_)Q.D37GO7J(H.P%%02BHGHT5OIO$R2;?^4>L1K Z"[=#;;8%!LXEL1 )V
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MWFDUC^U98C-6RMK\>29 <D5*[63VTGG7U;P-H[VES$.65X&EEA%.\@^V;;W
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MSD\WYZ[1][1\R 7 %U1@A96M>$,LA@TZUIU:K5_^*R8=;W._S4Y7MY2N"OG
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M&H-1=P%]!^ =M(3LT>5("JJ2B5R(TC"_AZC!ZRZ@-PC&2X'V@%B=SU4XHBQ
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M%+2AZ"S1@77@>"O8JM#G4*T/3&9?*D[2=\$:>"5_8%[)"5IC'B="05YY58O
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M;"6CG4C):P$N@TBH#*N?(93H'!LCN3?KZXS;&?<;Y@W[4" 50+ >$KE0,LF
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M2>@Y<BD[VZ1(TM) F<D:CYB,/+T27W>O'' 'X06?M(]C[=_QQVF65?]9KYT
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M1GL4$C-&"BIQ<&N;ZFG+N?8YI$#]+]AYR_O.69P&]:U;_'D%[PO>WU*1E26
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M,%9ZV:'?ER@;("] CGSOEQ&\.E"-/_))9W6\?G8C5.%6903(#"CV>-RRYKE
M Z7&@Z9,B=;&!<E=X-X28H>6-?Q/C^HA.XVW-R@)9@6CVTVO!Y3],1/VW_T'
M=C\#K[T9#G>W/]))V@)EY(JV!GH(?ME4=@E4Q@PG*H?;:F^!RJAQR#B2RVN8
M$(RES$<-5);UU4E59&CY3L!-M2W]H)WCOGJ;?_=3\.LK(GTZNR*^ZUM4H#I"
MM15!5]A\70*S3[L]P,F#6*G:-\$9[HUR"-0P! 9&?Q?-FC"P\I@5E-%<>R3
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M,X2S++G7R10?^,HGYL]\-!^:W\=:V:#\^U>R.N%?FK/[_\93WSH+\<?5GL#
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MDO%V#!C8'WX8(]DVS#1&#,BO A8Y[L%31C'+V+K2!EZ/ _H]OH]]0+"%@9T
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M></'=&U@PY.UO436]Y_XYGT(NVXI#[-;RLL8B_WA)!:,;A=/AB<GO<E);L>
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M.+'F\\VT6RLAX^(XVFQ68 ;7<>QG_6LQ5Y2UVZ"WODBE^\!&8#0-SI'K?!L
M9^Q9;-QX<]2;PKQ@]FG2[%^>1>L3K:]>MSMYW7HHZW',\#B41WFP>_9LGN'3
M+$J=FV:+#S!IV*MLAH_Q[:E7"YJLP"WM0+UVQ7D< LH?S^B^WI[\UM^F_<77
M+K"^S<20I](;S]Y<;]G".GP&!C)#C8#D>H/Y(BZ8 S6UG<Y=]@];1.Y/GX ]
M4YSVP2QJF:O^K&6O!R(IFXF>DWK/IJB*P5@6)!_?,F6YQ<QYR??LCQ:J\9OS
MPF\&.Z@%MP)OO(R^P],V[6"1N #6@:%K6; \F@80?Y@-X6 NN]>A2\TL<%EQ
M,'_74Y"EF3FGI_DFO"0S6J,NU+>L3B[;CB>U/P0=9TN2JQ&1[15KG["*O6"M
M3MT8=&SXNG^65>\9W)Q;E6Q1YUM:[_U?_T&IA=B%T/6ED>-W_X;-;W@>KGXV
M..HC6/^//3G]N?@',&3< %R3D@W+UY!(JUXT[\O36*-C?/'Y<[DT&]BR<;(R
MKVS6Q/@.[VKLC 4/V@C7/^5Q[X#QW#\_[@6!?)%N]&L<G:!;N-F^W^'11QBN
M/9X43__GOWC)?P;8[H?A*%UJ\/7C+KTQ%TVN-W@[':#6%]?.L/;FM!-K-!64
MDUF!J4-RF%TTA?D#*X!9&P?CN,A9SR/@'P9BZW'4FS9?CEI\M-([DUPKAIL9
M-BM\;@VR;H1PDHWCL3^.8=JON:45FW/?X<TB'K\4XA5WF:ERX8H"P3>K^;D%
M_,T.6EP377+8E59^X6C/E>2P.\CS6IOZ\<54CJ74#R&D"*&T*F@FI:YLLI9'
M7Y66)1V]N7!C[JE??N<C6,,.3R4$L^-)KS_LQZF/_0>BB@&XST]419OTM^E@
MB!@\LJ=Q"I;9N/'3HW!XV1_""/^3LR9RT47M)7B26:SX <:,?C5@;50H&E4)
MGS?3E;[.6X#O0=&QW@R[M-O +FZHGVWH%M:0AA7G_BM,O!JA5V+N3X#G+#MI
MU):4U8JJ>J&>NEWL%&^G *J3;%O/K-3A8-$5,;]OJQ'.LX@O[I:IM<S\G(15
MM O*X'J3;U4/R"G!6;O;:G)1Z@0.-,UJ9^[<TW&5!]=R/ \MZT+H_T;M-)-7
MJW!DO;9)=+]::-I+I4+I4N4-E51$75;!4E/Z6%$%V@;F,C+#ZHI-_.7+M>7C
M\3R?\>QI/<*=>M1_V_[TDD'KNRZ#N+N@-8SEZ:[<VWE3EC[P,DF"1T0128,%
ML18#H<I+:K04E?>/'I=Z3<SZ9!ZSMF@FI=$0FR_6M;2-@^=JA]=^):&(EDZ.
M>OWPTV_3<(0C>9&/WSC#DVNQ&+,!4,3/S3FX]JX)87_GC4B4)U 42%DI( 2O
M-7%>.:*D248F+H7%(VC5]FI#K_\N1M-!=N?61YV<U7'915%USE44FH3 %@]G
M'BTP_S$:5,-1&]9J/*7#\834^%L;,C,AE'HC$$K_-T7'7 Z]8NWWUBQ7K[[G
M+1!#+++HRS+M;4,<.>&BM9=H_>+%.VR"QY\T<+INK%OPT&.4K/4EIQ;&TB*F
M.[LB_4<3C#=*LH#I8D8[#W]%65)&0ZE]G<-#J11TD>SY6K)_U@RK <>#P1\P
MM)=H7G=DWY+] 9"]*PVM%!XH64HBM;/$,4F)9L -R6CO&,<:]C5$CQ2&WM#&
M)Y8S&-JC?E W: *]K4Z2CP4:HP?A-HCBBUAX,'B>Q]>1Q"))E'M';UQ%M4V"
M$^\4D(13BA@92B)!*8?_*UF)=!$2GG? T$4'S*!UD;>>'#!71ICYW"0'SR!I
M.&I#^387M]=X%.J0=1R-AJ,QT%V(;3!K :]FFN=2(*!^\[B)7Z%[ ;37'$(<
M'>7SW6N?WL[T"&R>A?MF7KJ=Y@&M=M\ZAI[T1AYM@T4]^LG.\R<S(Z*9X1Q
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M;2.3!*IO&X&MNQ8U33>DEJ+[EF'83/K50OI5(?W/*?W*K/1KJ@X(K9LR<=U
M-FQ/E]U UV3+)8KN*9H-2/[JG=%T=D3ZUS:30O;?3IE"?!-C(Y-G9K:SH+?
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MBN$;NFZJ-)0U8A'9,%Q-)DIHRI:EJ-11C=!RM>WE4]0HHU:(_4YG8P@ V P
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M&>@H$$0I !4$_^##>,X]Z,JH-\(WU6[<J%;YB8  AXC*O*)#[YD5*O$A6 /
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M&K1J0S/G=VD?7)3E'F':S5I,+Q$AMFY*"81X+H28,[5\P <M\%59L31/-KS
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M<6S=HEY 8'WLV4./YU_?GQ]]^7ITTI&.OL'/NT_'[F988_&AWGLI]>YX(+7
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M60N_.-^9\!][XMLH@Q'X*Y62 >SY,@(<H0D U!D=QDF&X/8!U*JD*O(7IK?
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MO'@QP5R&^<\.0HQ@G_/Z%^=3]2_N&+S1G$FB>"1Q7FG!^3@"ZL<)DYBWH"I
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M'!;7-06%2! /68P-[B0!FD^E#P<N7'<99=[+[*%@9_FC)(7OB#_*:/X2KT>
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M&H*$&O6R!L=;/DE&)#:4PA3)$0/&*'70I1G!Z!'_JQX.BX;F$(VD:.:>!1L
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M(6C$ Q8MXZJ=@4>4^*,^4(7'+C@1$9P8:-YT(Y_Y5GWV#2,% TY8%9SM9"4
M7D99OCF3)&/\$JG%;>;%.QGYZN5F (PNP#@,&:+K"Q-B34#X)',0:DI'$SZ
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M>.>O\HX0G5ZYK.CJ):J;L!)@I>H'/#$=Q9+[Q9M"VF7Q7 1IK)U0A5F-)"Y
M\C$X3A;PYVHZ21$)_A#M\F3D7'95YK?2FXRC$&'<[+6[!Q+!C!?@7Q8"LU<Q
M*G\C?1E@,6L"ENP+LMP=;:8W1^[:ZJ\>=4L6A1S<$;ZF^O[@Q=[=%6@HAT<=
MRBMF%TKWBR+-'@2$M/^N6'@_@T OA6FK$="FUAPQ4GA+%_@7:/]BLG)1&)OH
MK@M05F*2#-5\(O515!>TEDZ G;A" /!,2]H[!)>2'F8QL4NE1%>/2C"E]UC4
M_O0V7MH[ 7_&"E[+S2M$-BMSD&-S'F?Q.$9K*"GE^:6O&K0):&JKD.Y0S=@C
M(),*O/3.!4=/G()T"4&F;;K,9Z626<5((:9,P2(X,)JPNO[U;$J; =Z0 3[:
MC@SP-BCXMRR9.]0'ADT=/)SOV!3:#1EZV9AT)$IW3>' WSS:CHO? A8-<6B\
M" 9:_5H D(;X'E7+C<$<55$CA,Z->1R^K>J4LV"1:C8%6\$2O"0Z<:(DP!;"
MZ(3FS(7.SB.)+2,XE82+9FPIJ3\H-2PH(KAFH6Y 4,P89<2ZA$[-GIHL8 9A
M!!OSTJ!$XDKB>R[*FF1:6((-P>J)Z7.0V&@9<$^%C(5R&M^68IMS!,.%;S!Q
MN)"TMRH+;1Z-0TP0:(XQ$1HLTV+A:AD,B$8W"<+>AR#G,RHY@B^#]AHP\P8N
M8!97ZM-;-V04S_%MO] ")NHKV+?6GW:P'TZ*X.78$X5[TM!RD1/#>%U\59BD
M_HN8:S"FOQ!\ZTK-/\R=FNN\PN8J8NNP>RH+08JR0SJU%/;.24I:4+B,9.AV
M-O!^XJ#]B>EL1-,2A _<XLI_!_^)((.3N*RT9[U]0T?*[%9PQ-QYQ498R(BE
M%"6"W9G+ M<@'-!+BS684WRY%K*F)"PGG55I6^)\Y48DT98+!7V<8K]JO$IE
MJ<DD.&4=I_.UTPQ&#$IF\1HG" W@.(?]V=ZN6K3$OQRN1K;Y$-/S.:9!3R06
M5&Z;8RH$9ZK1[-&G2O4^1SAN$HS^Y7#2%;ZLYX,713U?WA2JJBCB:XLMX7B9
M'R*%!;[B%D()GBZBNR<(A+<\+B,"&V'&#99]S5/6_D3:HIQF1):1?M*B7)/2
M@37WHU^(O$M3ZXA]I(*]!@$5@F8N?H-C1#:I_IU3B!KFD9P/TK3PY++K:KKT
MJ^C1A!S:0*BQ!0"E *,Y9E@SX(37(<G'-KE!&\1I'C^B&G[/4L5P,E0@GI8&
M6IX""D-2E&)AVG9.F%'BTYW9RD8CW+29E?[-[]9698P6]?6"^)BPEC->2SI2
M,,9WZGDYC(6CIUG_L#PSP9.4B94'ZG04?E1JT+W7<L4231)E'QOGX2%:8;?=
M%439V2;FQUHNOUQ'7^3B6*0,G5CW+X^&OQ3,*_Z2WUEM'JO$M8HPB*^Y]TB
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MU$*,/.!N6$;N=H%B3"M<%TEAT["T  'W,DMRW)&ULR0QZJ^4]">A8XV,S41
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M[&+#F*&SB]^AFP,"C0^A.) U[<Y@B,BK$Z M"X[Z#GEZ:L *GT]@8-&E<6=
M*YS&FLJJY<6D[%MN-6S+:@YK/WJ[J4PJ3'<QI),J]PR9]"IH>*!6"J68A^=*
M@9CYE,/GP"_XAMS]**)906'EI>1J)8JV0A&?5B_,<C6*;,!*$(-%E%0XBM>
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M#%<="VT[Y[=)PBR>UX2(]^'U+V]]?[LA>,'3*"Q;Z"9'V\LP3W(L<V6FF(3
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MA,7=)0RLT<(+<;HU8Q 4QS>HZ4)8>V755@$["9NS2R&#9R$)?;PVZ$ @@=?
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MU 25$IZT+);8]40F->)))=(T#,F'4S;U+A9%WF&"B9&Q:7$O'H=<SHYZM/9
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M\O1IRM.#[LEI]P#DZ=')R<'IB2=/WT^3XLO$*9NGQR1*#[ZE*.T?T.OI<9Z
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MI@62#RX:>]U6-CX]V:@)K@'^/#B13']OT.ON_4&Y_L$7B,D??MN_VO_QLP$
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M>$P2LV6!V3:)N=M5O/VVBO<)2\QFF$W_P+5Z?'C9^4ARV(]C(YXX &QU05H
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MM8RNXK1!Z,:S'$Q2WW:MRSR+62@)I/F^6)15])_Q;/XB.H<?\W$2I]&5*6Y
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MW*K8!RPJ?GN I=DVAX-^_*&C:^VW/NF'GH?QO!OF.EY 0$R(1DF=^@<R%X/
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MQ5SQITK,_J2C4=P);,_)(_B7CULA"7P7XOT@+&8G!O%:YX71/!#7D/$M,ER
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MN%CZV7L_F/SFA^>XH,[\8#B]"W>YYGQ5G[]^^[YVXJC4X&\!X>91@VD<C@N
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M<RI*E4Y:O?=1CUN]_4JRQU+M:^AFJ4*T\OEJ4];,)0W6UX%A2I/#E0E<R9Y
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MVTP#O /4=T-G,STUF"5X UH%=O[^=(&V7?/F$MR#L6S64^1]!-E0"]NP9ZY
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M8[4\95!DN]'9B08(L7+:L: :9>,^KHK?QFQ900E]5\X<G)R<#D<GF ?I2N6
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MTJ9H$H3:(R)XIB(+=/*'-E[OXZJ$;LN65930=O:QM]EI$21D5<=G2&7!9^?
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MAMWI>M1$40V"?[\=_CSZBN/A[-WZA+1VG%QW@N;9/)%QRX4&D^L[5[" D\2
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M)2S7OE$0J/7*GA(O'X#N&]ARE^M[-SH[+O9.1J?#Z1%WBF06R8K(HI"HN("
MGD$1-G-Z#QWYS(TY>1W14^+2!K)N$%R<T_G]L&87S>8?GL[X_+Z<=T4Z<T+2
MM^K/OCX>_?D+YD_XZI2(7'\AA0FQ?4;ID.J_^W4\BC44^[[00M^G\Q#M.YR2
M]1LU)N%@YKXHYC($DR34.E^3N'=:M&DNL[TU/GZ>/E ^-.B$="FY\ZN#I+/0
MJ$'X4N\\'1*PZ"#9:% &PY)I$Q1; +*M?+)V.]SJ\MQU;M=D/#WZ$(:?<!81
MMN1FJ< 2U/F>]?8[0"BD.LY0VU)"B:Q36CE]ZA46T'>+#+CVV%U=OFVDM]&F
M\NO1K+D <1X5Z0)CE<NQ[NKL/_1T_PW8!BI85.(&\FNHSLQ9TA@]6,L)CJMS
M>F(@FF))9#:1!5TZF0\/0XU+;JOZU^(J8NM9>V_#7X.3TY-S(+52*19&[COR
M4+,P%$1)6Q0RQBU9N38JU9O^KCUZ>U;91L(?]2&Y;8P&O3OXN*2B+ PO1SR.
MRJVN=;,8\.:0&@>*>Y;90C0YJ2Q]-!R3<LH(Y:762HCL>-'"QW!/-'ES<'T9
MZI>E,)<FJ\DN25DGM_%$?_@BP OCB!Y:<'0N!M[FFO).6/TY)[.+GHL'S(:$
MS7YT,#QOG45NU>%I_!],TX^CM]7[&I-S-:U94N-QW8JJ)HY0IY2T,I"<=+2%
MR !120G>Z\P=%IE#ZQ!]+PO9I8.]*?N6.TS;UW'32/D\>>_;]25=_'BU98F8
M,QUW#(H)M15<B>2/T!\A2,N"<MHWZK#6:$%/D\*[TWG+"H;)%='==J__XMOE
M+[P<#:?C0,NBA[SX5J-BM*A7.!E\&LY^]\R[ULA9G>0""6N#76\+T%H3!('6
M:L6=4&V:N+5;T_8#5GW3^('H>]=1L+DX;JYEYHT:XX(RQ0%R4T<%*@<N60$F
M2QN23T[)-N4WM^/9>;+ZCLDRZEUI#7;2FZC.4Z&ZX&J:N;X,V6[RUOO0WKV$
MV$#TVZ1&""G'VO:765MK.)0%+SD#;M DG6S)K$V6S78I<4^^^C89L8K$F^0A
MG '"O#<YQW@91)C'P'2QQGER:>@X!V65!Q>X!:V4]5H6ZT4K+^!><-NWZ/O1
MY UCOE\U-/ QWXV&^0+E'%(.I#GR<R5'6>=4$[@H-$2ND(FHI8YM0ANW@'DB
M3-A4S%NJ<)IMB*A,1E\DT+(*;8B!S"7:(@&MR#'JNEFVB?\]V"+*AV67]J*X
M[595=D'VO:IR91UVKYU;1P';K:K4)MA2=-5<391AED&P+H$T:*,,CBFQO5[\
M#[&JLA$S5I%[ T:L4*?E&5GB3AA(H5:BVV0AI*(@L2QR29I;H[^7SZVIV?7+
MYU912P,#]BJN:ST.SN;Y<<5Y5K4*V?OZTG@()I"OEQ(7013K6A;0+8/U9&C2
MG_"W7%@9I<5B"NVCQ5?[BU8>&!IB;LP^DL_O<IO4U,=26+DQ*WH0? ,;=0':
M3<XZEU(0I+>$5M.ZI8+HBH&24_0FA^Q\FU#9?<B>*CLV4\'2+/8^&[N__*_?
M#@X//AZ\?W?X\OV;-WLOWG_8FWVW]^[5^X^_['_8^_!A[]W/^[/<GDV:M:_U
MH,T;L&^^OH7T*"ZD%"446[11&%-4RGOTWC+GT>1TM-XC-_0]3B>#(4XF+T<G
M<7#FBQ^2D5-' 1]_JTVT/@T'_WNMT.)*<U<7H],L&.#BC),2/$\,3%&^Q*S1
M\C:5-IN@WMA;N_GLE_3Y WK/SD(9YV5W8\S\R H?F<4$3H12&W!'"#HB&&Z"
M,29%AFTF1*Z"<@>;Z+98=\/E:Z6\%CU4PK>SP<VCO?2OT\$8Y^!Q,LMY.:+S
M(!C%'>1Z&JAL!/C"%?WA.)?9,>_;F&OW(7M&A.I522UB2[<2ON9!$>IKU+](
MH3KRVG,M' =C(Z\3:@PX[TDHNH@<A-92-YK=MCK89T2UUJIL$?R^"?E20@>S
MD?%E4$/_YPT9SUZA?+TQ(_W=Z0GFR[5>+B\GA87\(TB<V*1\=!!CXN!K@JI4
MW%K?Z%*F[<*>-ZMW1I$&U;\_CT;YS\'Q\:^GX_0Y3' OI5J.7_-0\_^<3J:S
MP^-(8>+D$V@2FZ9#PGH-P:. P(-D3"7/8ALSL1.\9\3&_M5UDU-JH^EZ+T?'
M]*/1^"RA_],89SF9[[],#X8?<7QR5$H@OY)+2,(+4(:P^1HQ8-+$(H3B@>?[
M7.XN#WH&I.A=WC>YH#?BPKO3*K'WY27][2"%X\-I^(2_CD>?QN%D\L_!]//^
M7SA.@PEFPEOE<92$3O1_BO9 QHBYS &1-4,V3+)DZF)B)W:L_.CGPI>V.KG)
M(+,1@R[=ES-&?\;;^7[D, 1F2@#R5VKNNRG@8]%@O,S:9H-I<>;,$N)T?>)S
MX4L3#=RDB=V()C>&R_W^[N"R^=\9D<\7\L] J/-1X%(AR[4M.@E%!4>DMLR#
MR((C+[)X+3OQ9>5'/Q?BM-7)30:Y!L[@?6(Z2PNSVNB"+H'PU81G64+$6*NT
M'.V.RC#/VEQ7KXMX6Y5*#\EIZU^5#Z5,:;[8F>LY&5RD'CDT*=KL0-(A31MR
MD!#,[.96UL[; 5EHT[UN":!=)81NAPQ+&+B)4AJ&6Z_".HM8X/DE<1> ;9,^
M[X.XH]S//A3:@22;:V,GM/%H;,A"@RT<Z_0( 5[2 2X%ZIA='3Z3GA)=[LL'
MW0E;5E%"CRR9F7MO__O#SR?QE_-LD)1]\D%X6F*L@YUS(%..7$B9K,Y<<^>R
MZ&1>7_O8W9G./<E\U(O >KS+O=YGJ_A0?"9BQEFM3 EU0!AW8(,C<TL6EESN
M\A(_CH9_6[4+UA=TC]=>BVVYNL!XJIT!5U+!DIYRZ\BO86= %#7PSQ+H1/N1
M.KM%4@C68/;.">N[%6,\##5VZ@S8AQ97$5O3SH")AZ2,L) *[2;*I41G@(IT
MGIA<YY&2A=#)87M,G0%7$O[2SH"K2*[GT_,P?<9\6OLZGP6\WN+T\R@?#+_B
MV6W<S9\BO@LG9_25)EG.LP";&9WZRBA:/=F$6@LI2IUXHCNU$NFD\4V0/ILS
M>FOJ[/$NO^)>ANO<2NV"K/>3_FY,VS_\MZ?;45/%]'P(W8.0>9>*5Q(09V\2
MDH-CD@&E8PG"!92V4P'?@Z7,'8;&0V3,*OKHV\DG09].7@Q&DS3 8<+)P3!=
M^*^,Q5@21.4)E38.G%6T_:ILLY,2T2YD""UQ^)<^8KLV2I]*&/4NP0;9W+7S
MP?MRI?G@6>=MLJRDQ@2\L&J>$3Q7LJ<5,R8#]YF9-NUF;H7S+*R0_A328VK7
M'-05.).SZ>/A\B=7US_OG=\!;M/;A!4![^9NH0=5C[:OIP;W#*O"]MGKF+F"
M@K5X0=6<$Q8ER*R44SFQJ/'ITNJ>.XC=LVH5]30Q5:ZD*I&PYZE*!/UP.DI_
M7"31SO]BCEM8[[+2'$IRA#N0>)PWM844P^@%S]:O8,RL!V+[=QU-M7O#!MJ"
M:GJTDN[#/;?A@LPY"@1IR=!7T7"($3,X$[G53CA<'.VV.G&>,SW6$//2?:7'
M6O.?W[]_]<^#-V_VWKTZ>/=Q[]W/!R_>[.\='NY_/)PG[&]08+["IV]<5;[N
M2A8G;7!?H@C,!&D4*2JB%<R1AV-49M')HQ6>TT]]RYN+O#+!A?#)9R!7K38Y
MJ;W[C(L0G;4ZVH#*MVG?? -*7[4['^A=>3T:_QG&^2@9Y[3W#DHPHC:F9! 9
MO1K<"8&&%TVK;[JZ*V"VOT=MINUEQ3;KRK>!ESZ'=.1E%EQZ!"%JTH .M"2)
M$;PVUF7O%9-M:JOG"':GW+75L42]*\FR@=/3L::KI,0$([M=<4,K)7S1YP28
MR>1)F"3C;3KM/= 2O%9LZ$\++:847U 6C4C!(ICL:*4Q6P@H-5@K7-&UA-JU
M*8&__?5??267D?7Y)YY/W32I)!GIN<)D4%PC>$>.*BE0A^2E+]@F:7D)H&VE
MRO=[<O4AW0>?WAYIRR9C'[(.@?R+HL I6A7W3&A/0DJ-NHL\L/3V7G3=-7M]
M!9GO)GN] \#OV>MK*G3U[/4UM+$3VACFK<YH@4OZ0Y58>RIE#4FEK+75B84V
M36H?6?9Z4[:LHH2VV>LJ)YE9<*!%M2,=]X1$6G#%9'(6$C*[8(0\UNSUE62^
M/'M]%8%M8S+O'>&ERQ+4@V$9C4_.&F0VB<[=^:B6H;KN:UR(VSER;5SA-CB>
M%&,J!$]^#?F_ HN.AM\5M[OSH9MMX ?#<Q'AFUHH?#"<AN&GP47/G1??WH;_
M&8UG8WDO[6<6,B\N9# FNCHTG(-'%DA[+";+8T#3QF%>!^W&%Z<GH_%T\+\S
MF;\OBX\\8MK0WDSNHBP^U<;.')RVY$M$5S"CD=9W*NQ8_9[T3ES;WQ&;,^G&
ME6E_BFD03NRSN=4]HCWBBDZ#.JQ+!^[J?5  QV4 HUA!QG)1N+5FK*T6^0P(
M_5 IT\!ON ?>_E_GHWSG?O?%Y*%7@TF-D)R.\4@SB\9&"3:0M:RB)).9:P&"
M1RUC8CZF-E&*'L _ S9O6\4]QH1G9OC=^-]BJ AK%.Y@^.5T>I1,4=I'"V20
M(ZBL-,2:DIQ+$#JG($KL5I:[VG.?,)%::Z%!R\>#DR_$XEF7N!L&R>5*CNM*
M;O#_R"7MT4D)Q9&OJ,A7 )_HV\PP<>F-%8OM^_K:SS9 _83YMW6E-D@JOHQ@
MWR.VL\"V25;1&R3!Q&H5&*<@1!,A<8=:<\W1M\E)7PWGMFZ.MDZUANIZZ'=.
MG#"3 5KC8S6?7T?:N0M&$,$$KGUQ6K3)-WZP=T[]4Z#C5=0JJMC)G4(7@-^O
MHM94Z,J7"^MH8R>T*=&KDFKM>JD[<V0(7M:-VM'>C)$7@]O;8A[N551;MJRB
MA+ZOH@Y.3DZ'HQ/,@W2E.E J6:=5(X20R6=PPH./7 /6[KLLQBQ$Z>:YW?;Q
M#_%J:B4=C'H58(-(ZT7@@.RQ2W_P]1C_=8K#].V,TR9EY4Q-]JG)92ZKVLPD
M@Q(BEB0#3ZJ-;]4!W#.P-/I648/\OPN(MP&<GW0=(#:U.SJ W(WET;N"EQ&H
M9^TTL$.Z0!6)6<>*A,@4O4LN, A"6/!:6:E21,/:7-CLC$#WV"(/@3^K*&5+
MO)F\&PW'M<WW>##\='[:<N;1:$&+YZ* "B;3/JP04,?$7"F:Z39IO!T!;M_@
MZ5VY'<BSJ68:V$$K1*MF[Y/V2B69+/#H$HE$<O"&S'Y,A-HI,NE*F][J*P)]
M!O912]6UN.:X&^XEV"MM7;I ;FH[K0%Z-[944S*L1KS>-+G]%();H1LIA9%*
M0)&NYF369$H"##R[PF/64O,V!:H/AGSWV&$/G7NK*+#WZ-'PU_$HX63R 2=(
M'_MY;YA?X5<\'GTYJ],?93S^^NWU:/S+AU_V/XB+3K8Z&YT,.%-\;:M0R ;Q
M'A)FDVUF=#@LW*DM30Q8Y_D/[H)V<[V.MJN4!J;:8MY"[2<S>Y^$88$%+&0U
M:#(B!!FL(14!P6M6A\67*-LXALL0/0/CJQ=E-+B[OPW7W)OI@*RI,;4<VVYL
MIGYTV($8&RB@@0UT!T)NBI#19[!G(1-G(*JL:6_U'%D02.?VDZ#&/1;-MIFQ
MBMRWP(B:3%F+[3^$Z;PON$S*RAPY1%KH>4611P7>:R\R-TCGXE:8<1/;]HV5
MOC1Y#T$V5,.."[L.3T].POC;Z$;Z6YOBKGL?U[+ :[6U+A1YH4AHE.=&DE^D
MT,1@=<H6<TH^^,+N*O*Z]\$;AI>7FU!O+G+7+,-"VZ($K:H9+H*%8),'35Q,
MMC"MI6H36^Z ;N, ^_)G_#P>329'LJ2$*280J010OEB(&1%8IJ7S@LGD-@4%
M]R';04B];[;<B*GWJ8P6207+\>VE='IR>DP[>;Y:@G84G<QU_#N@B 94JN%_
M)C(D87447#/#&EW,K(SU>1&J#X7U'4RZ ^[KT1@'GX8O3\?C>H$UZ_]X/$/\
M,TGZ#;T<+\^60_]X_A-R@$W6%CUXK"D]R2-$;Q11IEZ+IF1$4?<=R2V /2&F
M[5QO+;)>EB_G'4Z/,@D&%:$K/M3F P0Q,HZ06&3&2QNY;90V=2>N)T2J!HK8
M_H7?C;*7O3B9CD.:'FF1==(J09):@F*:0^"9@2^>%H$VL[R3.^:EB)\@M;:B
MO ;QSU5Q'Y48F)-,0S U"&Q-JKV+R:V.GEX6B1Q;%="MB/3!W<GTQ($-B;>2
M ON_W;L3[%J'>^WTP\C&K-=8Y,-PI< YSB!%*3(31:O21TWP(S',MLK!!Z'3
MODO2/XZFM070BF\5]SF2_<"!?&8.*F($I^C],KFP8)QTQJ1.+%SK\<^!9^WU
MTL2FNV%F'@R7B4;YI'WVY"4+GD#5L;#>> 4RNE",$]D+V^AH[8[R2=INC91T
MDU"Z;T+-XG@W:6^B4C(1V8U#!LHK!@Y]@MJM*2AZ_YAOD^+0#=\N]JM6.KZ'
M3#THJ$4>_.J!/)5#2 (UY"(][:0D#T>R )=E0!N$47SK@?M.D=?U@X9[P_M:
M/*UEW4B-41B7H)C*L60-!,\#Z!)Y%%*BXMW&,S6'^@3?TP>HX^W8'3?W((]"
M^. T2!W)%)/904#M(6H=E23\(;5IPM\%W1.D7C/E-.UI<\?V>Y866)2)C&>$
MX@L2U8,C$UL7,NNEBW5XO5.I"8VZ8]Q6+YOFIFHCM3R4OC5W+.I&5CSWB?Y?
M$:"==Z"X(3%JI$46QX7E2=+';]L>>7A55?W2I/M]RD;JVJ[!>VNN?!>X;:O0
M'T(AR[T5Z:T(T)UHO6GO 9 NR9R2+!)8JF'/G"4$Q15@EEEEC(AZZR[6@ZF:
M>JA<6T5I_=^G7 -X."JC23S].AC/9YB*8#(O!B29C'6&C@(?9(9L5%+%I^A%
M[N1IWO.@!Q44W%Q+HT8B[GV@[U^#%.(T?,(AIL$QB>\TX?&K-R]>OIE/FA6<
M);2QPHF@%!/@:V,':41A)D;I%X<(+!OH>]^CGC %^A5SWWO O/KN'$KT7.=(
MRXHE:5HE9G),8QT+&9-%HR6*;CEJUS_W":MW P'V???X"WZI<0#\:UY!R9F7
MC+S$B(+61*8XQ) D&#K<E)8ZLMAM'O?"!S]A;6XBP@:!N/?3SSB^L>(S:#F)
M;,G_ J3M@Z#1KN&BSL $LTY*B=ZUF75\!ZBGR8R^M;']1*P;)BX)(3A&-BT9
MM[6]8*H35#%!2+J4Z+(JN=5E\2-K+-,T!-)2;0U2D==I&] %\O>F,LW)T$-C
MCW4T^4":RK@<D/NL(0@_2^$/$#.=ZMQE'CW+9&#O),?YP81''CKW5E%@$\[=
MV<)DWES..L:$9A"*)-M"F BN5@^G8B4OY!>DW"IMI@.\!Y?EM[FB;Q"K;RUM
MHZC[U?Z+CWOO7KW\L/_JX./KO9<';PX^'NQ?UAJ_PCA]&<;C;X/AI[V36J&^
M04GW^@_;N*"[IW4NE'-;[6W(S(HHN0H60Q0JLE"8S]RXY([6?^QF6T;]W(/A
M9#H^K=R[<G^+,@9M A@1R%&0*8/3,0)/EA>760RQS5&T!-"F6^/UCZ5W',<X
MF351.)S6S*I?R>BFOPB?\,CQVMX3-3A7>S185B!R9J&8R*.SG+G<9G1-=XS;
MWR3[X,GB1MA()PUJN-^,AI\^XOBD(CYB#(6RV4%$KVCO%[3WTVD A3,=5)3%
M-IH6>!7%TV# VG)M8#Q=Q7*6!C<]4BPED[".M62RTDY -)[^P) 4-QQ5;!-_
MN 7,T]/X.E)N$"ZX"NG=:)C.45F%):*4D&)0M5-X <>5!I^]]X9'8TJ;8^!V
M/$]/_6O*ND'\^OI*S^)E,;@:$LO ?4V Y#R2K9\-%.><YZIHU&T2_FX!LZW,
MOO:'_.JR?2A9>Y6YTW/F7G1^2\5CX%:#]9S7.B]&.Y<A \4H*Z0O+NHVKO1M
M:'85A-Y8P[?L$1M)NI%Q<!73_)JF ZJF4>/;<>TF,+RYWNXAP@9"WQXE?#)9
M&A2UEE>0,5/(CF$R0A&AH,^H66C3NVF;5+@G3+LM)JPBZ[XS4@YQ.!B-WXVF
M.-D;YK>8!Z<GU;*9_63>F#$7+]!)L$(EV@5= F<DV39%,B551K=H0B[);.CP
ML.W;AWTH9=10H@WB %<@SC,O7%3,:%6Y3 X,$K6]Y8&,)"&,$C(4WZ:\Z :4
M[1&@C;86BT V$G6#_7X&Y=?PK=HWLQ2+\Z_G\+QPP67N(7.5B?<Y@Z^!C)P%
MV3S%*J':)+K< ^Q1;PPMA-^ &]=-X+-Y%I+)I$0$@0*)K60&^X@(5JHH/28M
M$]N"__B4'(,-I=P@='0=T=7)-AUP-74,EB';C6NPJ>;N),*&8F^^'5S-39%1
M!N,0C(VEIO4Q"/0].%N\$=H8Y=K$D[=+AWO<@VVQ815I]^T>['&OSTR8WX:3
M.MT/\^P,>W6*;^N=?[7QS\\NY5#8Q#1P)BTH+TJ-?--1IIEGVLDL2K=."=V?
MN>M@\KI*&K67<._E*U(L@WF(7Z8S@%>@LLQS-E$#QEHWG4L$GY.$6(K@ODCE
M%S->EY%AI><^"4*TDW3ONX/0K -4.><O0VLU;8?9)@4J).*O81YHP_0UB5=&
MW:W<9;7G/@E2M)-TWW4Q>\QVX>\<JK.$11DBK$X$T.0:3R._ATN6&<<4N2C=
M2+'2<Y\$*=I)NL?;R?--S2[C[]Z7\>"88*ISF"$I[:7A$&:GG P<HG0:6!;,
MZV2*[M@CM/LSGP09VDBXQ^J9<YA+-[+7&,>G8?R-D.H+RC(M:C/('(L@REH+
M7I)<F#/9)^YDB+HC%U9X[-.@0RLY]]@H\1RIN<\ -O.R+\%L%K1YI9QJZ&U&
MW&*(PI*,'Z<M#Z8C';H^\VEPH8F$;Q+!;&A-WNL)V7.8&)E22 :-95F252,\
M. P6"A,N&Q>8#O<F9Z_XS"=!A#82ODD$NV'002S;N]ZGZ>C,JID#U<(Z%Y4#
M:P0=9DADC4$+R(%YFQ)+.L1N5%CAJ4^"#*VD?),.;D,Z+-V^+H!*-K=M$.6L
MRJ2DH@FH#?#_MW=M36TE2?I]_TM%U/WRLA&8QM/,M(W79CIVGXBZ9(%FA<3H
MXC;[ZS=+(,!"@B.=4T>@;C\X;.Q0?2?S4YW,K*PO W-%L,T'XQ"S6VWXWTB'
MYJL>!ATJ6?DY'5P[.DC=(!46R]#&@0"#"#$+UI@*<P7$<NX), O"@Z!1L&:$
MV&K=@Z!$/4NOJ42UK$]*V@3K,LXQ@4NIJ"#)"DJD]([X%!(2F'M(BD9'FXEU
M;+?N8;"BFJ77L*)M@7(C@Q\V-;G<U(3@DD5E"3/1E.EW@=B8,M$4P $ S:NG
M6AN#RN:K'@0C:EEY#1]:UB;5QI?<+Q#OJ2O9LK1>XESC$@%#(R9#:!K+4B39
MVY22Y$G(AM6';98]"$94L_,:2K2L3$K[2MU,+NMF04<A0Z9%2Q]Q"L-)*&!E
M#";@-J>]:5B9;+SF09"ACH77,*%E:5(V*)G)9;03&&-69$:B PR!G8K$JW*3
M7ANT"*;.6="&9-ABV</@0RT[KZ%$R]JDW'C"<E\PD<LX)VKF$J Y(O,%9THD
MR,"(,A"YH$9[V90/3=<\##)4L? :)K0L3DKV&LYEK41D2JGP@4#@C$A6:J@:
M":Q80IA@I6)-<XNF:QX&$ZI8> T36E8G^<;7V4.TJY;1KI46DN&9<)7QA695
MF0PA,;0Q5 =O&+[G&IYN;['J0;"AEI77\,'VI3)SE-+B@\MLO#R>7"\&TW2O
M+_/B,K6499H_VXJF#'<^"T5MLHQ)'HUE.BKFRE&3=R+&39HR+RY81TU&\PC,
MR4"H+[&(% '9[$6Y3QPEQ]</K20Y54E-YBO<^-ORB=.SA3+/1?0.>"R")$Y8
M?,4R3ERDE#C+E=%6\L#K:(*L(MGW%K:;SU=;>EO9M\*]KX5@%Z3I1WSZT^ET
M[D<1[I%IW$VS]X@'<[ R:1CW:)<M,0$#;(5AEEL]1NO(\YLQ'08'.K)YC9N_
M^'QG^1C?K(/9138Q0KEO9(M6C60\(BH7B+7 N7*8A>4Z$WJ>HC@,C^]LUQJB
M,$^P?/1Q,!S,;C_Y'X/K^?6'\60R_F,PNCSV-_@OL]L+:5).@6G"C<*'CE*4
MVPN)"&ZC2EG+X"M)Q6R!\O XTJE?>I*580%W*T7QV4$%(C&4OY/@IUY'2%KK
MK%0/D=";D)5IPX.VMGW3LC(@J8V&"<S+,3F7Y<JTI]$0"QCL>V^=4/5DQ]ZR
MK,Q6'FXB*[.-I?O3$&F"ZL\M*[.5WYJ)B>QB]/XH(2')P,O==@KE@B2^SUPV
MB01/??(6A%7IW5-A%UF9"DS8QM85&/!<^8*&R,H%60)1>8QC@!-OA2FM(%1K
M%[E:O?_U_D5&NO31J](BVQBXAKSLDZ!V*7:2LZ ^:&2TLD0JH,AH(XFF/$6K
M0V"5U$2>8SD(G[<T<86O^<\YS&(OX][@;N88 <D</B7WQ%(&!#->DYA46E::
ME?0<RZ%$?2VM7*&R\#.B>VHWP50UXEN':C_Q7EN/O4B %N:NO@7<8PM,A&2T
M)]F'6&2N)'&!9V*49-13'EBL$^GU1X%7XKP^&+"-E2MX_BM\'P^_EUK5SY6L
M^UOHW%K.3"9@2NU3)8U/JS7AN;3T".TTJZ,]_"*L_N. ]IY[=J[4E=DK1(%K
M9'&BRXQ+#X1*46@O@ 172IE,9XN<3ZZ2NN#;%A%K$Q"TM'+U,O'3(9 -</VY
M1<2V\EQ3V:A=S-ZGB!CN?R)(08F05);&3DXL TNB"2X&&4Q0?<RG>7LB8E78
ML(VUNY8)6GG_S>'O\Q$\41_047!7K@AIQ6RY:EX442GN@R&#"0;CHM6NDPU-
M<J\LM.^CPUW=,:YDRXTO_PX[X8[//GTZ/?]T\OG\6^GA.OM\?OKY;R>?CT]/
MOK5H?&OPJ:W[W+9%OM+6YI62W&0F#6=2YA!D AF5U5X$SZ2X:/#Y;4OPT^GQ
M>#3#.!%&<0#3WQZ.+&7TVN6H"15E+K,S%B,/)0G3E/$,4L#J]<?.RO";,+4O
M/LX&EXL>P#*/</(=+A)SAO-2#M,<]]&<!0D" BF.L0'  E22L%^%LH_28R>^
M?UY^;&/D&B7GGY[S]A=_[2]A>O2'Q\]/O_OA'*-L'KC#7R3E,I3')T>LQ91+
M1\Z3"XS[:D=.KV$['%YTZX:N Y"_S].BR^'K^-8/9[=E-%]IQWMH)&?F0B@N
M. 5'' B-23,^O2U9F3?"X_LUZY":->J_OM:[]WH-FW:M0KB$=S*Z*AV7Z9Z2
M9Z,O?CK[YH<PQ:TK.T>](@H)2&2174=X'(.F+)V6//L4MW+YYK4.R^4=V;1K
MC<$UC#P;?9S/YA.X T>3<:"1@%R[THLI9;F' @1THMP"MU8WRS->6^FPW-V)
M/3O4$7SHK+[OK?\XGOP&EW[X#6:SN[8VS*&M<%Y(3T+DN/7X(FBGK20";%0:
MO6E\G8KC"Z#>/2NZ-GS72H(K4<@];Q_'[_[,WF0@J) 2[E* &U0J*7@9U^E4
M])YS3V5#I:BMEGWW)*ALZ0Y%!9<&^!M:J0#^"L,RCOE\_)C%/#+W(@N>;>)
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M$IX-#50%L+;9D=S+Z_074%3TS*MAQ&YFW;9AY/['Y;> C_B?__'_4$L#!!0
M   ( $.#I%18E)7UA@P! )P3"P 5    9VEL9"TR,#(R,#,S,5]L86(N>&UL
MW+UK<^0VEBWZ?7X%KN?,A!TAV'R )-@],R=4*I6M>ZI*=4JR^TPX;F3@18GM
M5*::S)1+_>LOP$>^DPD@"8IQ.J++4BI)K+U +FP &WO_Q__\]C0%+Z(H\_GL
M/[_S?_2^ V+&YCR?/?SG=[_>?X#XN__Y7__R+__Q_T#X?]Y]_0C>S]GR2<P6
MX*H09"$X^#-?/(*_<5'^ ;)B_@3^-B_^R%\(A/]5770U?WXM\H?'!0B\(-C]
M:_$7#R5>'&08TI"E$(5Q E/?9]#+4$1CGN'$#R\>_A(G*9'?0) &.( H#6*8
M$I)!%$>I'\<^S0)<W72:S_[XB_J'DE( :=RLK'[]S^\>%XOGO_STTY]__OGC
M-UI,?YP7#S\%GA?^U'[[N^;KW_:^_V=8?=M/T_2GZJ^KKY;YH2_*V_H__9]/
M'^_8HW@B,)^5"S)CJH$R_TM9??AQSLBBXOPD+G#T&^HWV'X-JH^@'\#0__%;
MR;_[KW\!H*:CF$_%5Y$!]=]?O]X<;3+]27WCIYEX4#W[113YG-\M2+'X2*B8
M2O35W1:OS^(_OROSI^>I:#][+$1V^+;3HMBZJT*9*I1^K%#^Z['&?CH#?D]X
M%_M8>P!7F?NY+XQ=G'[N#>Z]U ?A'O!&,V=#KA^HZQD?ZME=-74V=/>(^WHL
MY@LR'>"Q6#>S 7FJ/O@H?VJ:43?J$-.JG4:Z-Z"*;PLQXZ)6RZU;@YS_YW?R
MI\E#/N63FYE4\(><3L5E68K%W3R;EW3YDA>?Q!,5Q<1C7D(]%L"89A2B(" P
MC44,.6:!Q^) A!1/%JOG>R)F\->[%DK5GGYCWQE8O#CRYA:BG"\+MA[SGJ:'
M!C(YAJE1#_\T(T^B?";-!1*Q<@]J(_YK#1<0A1= 4*X@_\=/:Q//Y'@Z*'/3
MP4B[;$A;HP6_UWC_OQ[9XXWC5GD=@[&XU:H[-DVHF[,M&%/EB,V+72[FS(B+
M6N34%5#YN5Y8.V'_JG6/G_:Z]K)H09*"G>"Y^<9/;"Y=S.<%W'IPE4MN;LUB
M;OXTU&Q*,-^!><%%(2<3!PQ;/;/+$CX0\CRY6\S9'U_%LWP2'J43^Z68/Q3D
MZ7*Y>)P7^3\%OWR:+V<+?Q)BFL4AB6$0Q1%$&9/S!![+:4,<,IR%68*%T!%8
MPW;'IK5K@(!4",%2#E\%*)4YH%C9 YYK@_0$Q+0SNI78(<6.1;E"#-:008/Y
M FSP7L,^7UXL:5J[4Z6TL.(H(R6MC&QN*0D+_)_$=%&VGRA1\J'G-W/#?S5M
M>Q"%LB2D%2O;R^UTZQ?!'_+9PWM1Y@^S:G1[/W\BN1Q9L4 HB*4?2Y$4*I]X
MD&1$DB_5"\690%'"383J6$-C4Z8&)]@ "GZOH6JZ,2>IU9.=/@ASK#-67!D+
MRRDB>E62HXT-*AVG3-[5BI/?-Q.'LEA,/LM^O\T^D;_/BZNE'):?1-$\OGXJ
M7WV<^A +/X8H]4.($?8@IW'J)8BF)-5R83I;&9LLM.@,M:";R6XAZ(T?QRJ@
M3XWVJZ]E>M=[+V^P\<[+WW;?]^X6!GG9M8QLWW2]+]OY )=,3FZ7TV:M]==9
M(<A4>1@WLQ=1+M2T]V?9R,=Y639S<!H&422R !+/E[X!$@DDD8@ACL(@3!(/
M10$Q\0U, 8Q-'-:(@0): C+C0,$5)9!#XN4+R:6Y4P&S>0'OR%3($9,NP)U@
MRR)?Y**\ -)N,,_ /?EFYF08]YV>\^&R1QS+T>7MU8V<Z*P-J/H$?*_ _G"Q
MS_QV[Y2R=R[ %U*HO<'^UF#.Y;57'\<8Q*"^CRU%NSZ1]7W,1+1:6U)WN9K/
M%M('$S/V^D4V.EN4E].I>!!\^GHSRPKU)_YYJ5JZ8V)&BGQ^_^=\0CP>\RR.
M8(8I@R@((Y@*^8_'XC!#G*>AWC3K/!AC$]0:H!+$Y]H&(.? T@P%_@*4#7"P
M^'-NL+)LWTD:*_:#4.]8.94-8,,(I8,U^RL[P,H0.615IER UAAP/U!W&&P!
M#-(M VT.N.P>L\V$LUGMW&:PO_MP&Q!G,["U-7'^W>P<_P\D+WXCTZ7X)$BY
M+(1ZB,O5A[_DHI"W?'QM9JN<)*%/: 83'@@Y5,4"4I0(&(N(9)B3.)&W-O#Z
MC5H?VPBE<((**%@AK=S^SY>_F7GP9IV@Y[X[H];Q"-3%JH.512N:>G7%S1 ,
MZH=;D;/KA-O=Q$[-I)=_,V/S)Z'D=((1HI%TGB$*?>E8(T^J5:2V,X@G!/&)
M]+G)9+$*R3GY2FW=W4B-CD07]>HOBP7(*W2 +!9%3I<+-:,%BSGX.9\*PLTD
M:9O)S/,3A F!@? "R20.($U2.45) X8\GN(XBTQTWY[)(68>+IG4$V]K?AR+
MLZ*F!M8LIH#+'8;J99/^]/D@$[WJ[W8+@^KK0>-V]?/PE^ST\=VRS&=">9I/
M-*]WB;X*-G^85:LB7/9<GN6DC8\I+]D_EGDA^.6,?Y0?Y]-JO4S^3<YU^,I;
M7;1_>U6KPED0>BG$.(RE3B $<90QB ,4<JD5(O6RR8LHZ%Q7*1PC-GFW-G$[
M]G]>*O]GG@&V@@RF+68S^7'=Y7J"-J)N="R1K:5@P]0+L#86;%I;!TS*V7MC
M;[UKL+88-"9?K"?]B]7?CS\(QBH[4/?TJMNN,0\Z$@S4 ;MCRU#-6JRG7\NF
M%J_K79H/OWV^N>0\5QC)]/99_?<+>56SB;^1_$7P29;@@/O"AXB'!*(HYC"E
M)($BYHQ2/V*,)=KKZ,;-C\V+78,%\PHMR(106Y&9;&+Q> '*_-OBL1(<H0ZU
MJ1]GN3H^1PIIK\$JKGE/:2RF.^7?\1!08]_:8?SP&_RLMB37G5*; !H;0&V$
M4]8-ULR=LC_06KF#7C!;(K<FL7-IW/RNPRV)6UN\M11N?Q>[2=$72;<HY+!6
MA=O>/<H9;'F[7*B#KNKL\(0C@3!C 8P\(B<UA*E0?99"PA/B)X$7"XY,%C].
MM#>V@60%MX[,OP#S-5;P?3X#967!#V;3DE.DZTTK>J32\9BP9O&N9K$&"S;0
M]N?.:]+2JSM^JLU!W6E- G;=8=W+['3F^NEY.G\5XJNH(E(V/.BK9:%6S28D
M]=.8X QFD<@@"M6"=>"K*%LL. Y((@7(1&E.MC@VK9'SD&<Q*^LP\LHU;2P
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M>RN@&0Y9;)0?]0PL8QM+6E.JV3E?&P.:/ 6&85GG])*>4SX0]XY'ERW:-^P
MC2&;V?I;6U0NB<::*M#E>#4O8Y>\!U)[]<C/P3.H0]X#<;O^>!^WM)/8-L&_
M;'GW1.ZA-4V?A<R+/ *S $40<2^#F+#J[&R8^8SAV.R,C5GS8Q/2GV]OW__M
MYN-'</GY/;CY?'_Y^>>;=Q^OP>7=W;7I4K-A1^@)ISMZ'6ME"[S2ROV, <[7
MC^V(ZU4/#2$,*H%V].RJGN5=+(\,*LO4\H::Q'S-RS^^B$)]0!Z$/T%IRH.
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M6#<V@-8(L&$%N.1_7];)H@W\31>]JN'ZOW%?.5_):*V#E7G[F=$N0&=7*IO
M]\JJ']0.>6OJYN=OW,<&DX\W[NN!9BEOVN=FLQJ''=(Y_7'1[G#S)(>L;4VH
M7+;C,+AXY:-S52-;Y9L0-&)RKB4']I23#"9I'/#0C[$(C>9:1JV/;<#6CX"U
MG$V9]8W>_,D9XXZ'W3[)=A-L['1.9(9@?*'&I^8]=C>QEKSG0CR*65E-L]C\
M27P6B]OLGGR3O]5IGK_,"R6[EXM%D=/EHBJ^,O\L"5'56>93>?<'*=Y"/N&+
MB<<H22(?J6T(*8I<_D.PB&"&6. CGE)!T&0Q7Y"IMBCVB<](-E<HG;[):_-
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M2ZLU:\:BJL%'KW+8U=Z@0J9A^*X$Z5QB)AY<Y)/KV4(*T=T3F4[;D/()$3S
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MC]"J)Z\]D.58*3=X4A!5@NNK$SR9G[+L9J'?,Y9'VAKVA&6WP7OG*T]\W2*
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MO899GL[I-+VEP*&ZPO%HO#9#+=,=D.FU+; R!GR_,@>T]O2@Q7W2VF^ZJ7,
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MTQ3##">FCSO+()$\@XH62D5I$8O$*22R3=C@.&PV?8!:T-,J,G)A] 7/]-6
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MP%3E>::_N;G0OE:&()54NUYQI@A*4T*455:>N^BAL7/Z<Y;^'U"K#];Z@\H
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MLC@GD&%6J#1/N. =MHK?5V=HG*>_MDF7/>,/IL..YOH#N6/JNZ"+_+=IP(R
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MA$>*,9H7.([#G>I[:#B\G84YM5U.YY).3%OZ#@_O?>;S\E/[CN?H[8_KVXO
MLLK2@=:"M9N&MZT(>T;'P9S.7P#PQ=5A+<5XG,?_YU(\&$?Q;O9*)XO7.^TW
M?M*P?..+&9-S%,7Y".<B+Y#*($>%,H4H!*0L03#&,DFX5*3(N/6!_'EY0_/^
M[I;3J0F0F-<:@[E6&9BO#FB4!D9KAR-F"\@MSNG# MDQRZZ4_0_0J ON>D#1
MX:0^+)H]'=5?C*K;4;T]1JUG]1;#]'=8;V_3SFF]PV-!<UFJ;+D321(BY4A%
M@D.DD("8I 22C&G"CIE@*,4Y(59[<G\5AL;<JTR6LC65)4CZ2MO$V![@=0EW
MUP=\N\DK3;')X>6N6*#91^I*FQI#R%RQ@,DR<<5F)/<3R4TTY/7#7%9?IIO9
M<JJ_3,]TOGC]JK^I3:IJ@A&7*!&0)%13880S2 7A,"]B7N"81R*WNH5PDCHT
M'MS6$A@U';.!W2 _?[39"9 =,YP'ADZGGLZ87'P8:B^QMS-29Q"VCT[='_9M
M%+C07XPQFS1U;G^9ZPWZQS_Y9"DT[?TRFXD_QI/)J$@D506)(2U2"G&F%"0T
M2B'#:2I%E(N"QBY=Q^W$.E%/#^W(*RW_^I<XB_X.;NA\_FIVTM=/9EY<V^99
MH6[G:X7'LF/VV2@,5BW-*YW!N[768*7VZ308CTY\+C@%[M%G);KG[GTN<!SV
M]7-ZVK,9LF2+#^.23V:F'.0Z)3)625&D(H+*!-;BB"M($ZFWBH@5^E^91,RI
M"\)Q,4/S>XR68*.F=RWK$Z#:<<WE4'7,+1XHN;<Y;@4A;(/CXZ+Z;6W<:NY!
M4^/V3_MZ*>LX?ZW>S6RZ&$^7FF>^/<NZ!WMSIU!_[I[^*347:<%:QGA*YZ]5
MT(B)#]-/:M.UI(=;XTO)<C%B/"N$0A%,><PAYGD&"8L3F"I4,!HC@9&C:].9
MKD/SAU97BQ-S>;BZ.ZR;@9J[8/=FPMW-LHQR3)*X@'$A8HCUG\9W19 G118I
M1"DMG.K[#F66>VFI_?_-+-LZS(.8N\Z][*U[__H:96,JV-BZFM'F\Y6Y=:3S
MQCRPLB^D-][Y) 1VX;O3MV>_OW/@#S<+W8N\L('%[?1YN2@_RQ<Y04UJ%*=8
M)"PGD$F&(28X@B1*$*01CQ-58$83IXZR+;*&1OF5;@!Y-J4X@J4=,0="J&-B
MW>Y 5BMZ!1K  N:3.6#237.)(_+>IIW$:<-/-I!H><3]?N8+_>=L?K,L%YJ;
MYF45\$R+B/%4$$BHU-0@\P*:GT!<X%RJ+(HRG-I>Q!P./S0V6"GG'"I^!+GS
M]RF7X='UQ8DE%$ZW):<MOOA:Y,C0O=U_G#9K^Z*CY5-^K_3?2OE-?2P7XR>Z
MD.6HD(@B00L8I7D",1,44D091'D4DR)%>9$JE[?X[O!#6ZH_Q@_3*J+2!"=P
M;FXFJG)(IG].E<&XUKPJS;&*_''<PNU!;/=R]P>NXS6M%3/!ZVO5^FDA=1R.
MH*_R/1&]OKV/F[?_PC[Q*<\HLW7;^(]T;H)<RU4E=M.,DU]/Q8?Q9+F0HNHD
MOVF11E,J5<&T=X^X*>T49Y"H-($HIE&6295P[G2=X*G'X*BD,:-*['B4X(9.
M^+(IXZ-_5-E2D4AC#5A9:]&^(.C\V=%/#[/2,4]M3\@AUE='9N3WRI9N^.M"
M/,,&IGGJTF]TVF6 '82H73C<A><E[U^K>]\;D\)1)]&B7!9QDL&L,+%I:8'U
MYB@GD,M8B11QI,G4Z[1D7]+0>++2#E3J.6V0SD/J>&AR"5 =4Y<#1OX')*?L
M[^9XY$#:VQR.G#+ZY-'(R0?<"$'(\:@IO?$:(W8_7DSDB.11$A,:0YECH?=:
M"$&2QS'$.$>BB%2A(JN]UK'!A[;L*Z7,JUA2_@BJ5#:[=7\4N?:E?BD>':_N
M-10Q>L=^6A7,>;U\B;?9?615EY+__#![^9M^K%K0_\;FK[#^:[6*CP[8R\)M
M,V6U5EL_X]OX;L:E%-6]RRJ!Y)NZJ4I.5T'N(QG%F##"8!SG9J7J-SB+A(*<
M\HAEI,ABUYYW9R0.;2&O%*ZO2,?K+)N]TMRN3>[.X6[W<@^*9L<TL ODNO&.
MQK'6M^YX%[*EG24V@;O9G9/:<R,[2Q .>]C9/NC'/'58Z$BP*$>I8) 7I("8
MHAQ2)37'4);I_R)-+X5+=%4][- "H>Z-#$ KW=R(HH')C@W<C>_#KP]87G_7
MP*#KMAFZU\6Y:\[^"MS[K=\R6]54N),3T[KB?K:IN?-#+K0#88[W1[',I*!)
M"K&2$<0<9Y!@%,&81(07*A-QFJX:;]S;O^NMA%M]77<;<-SW$>)@$@[FM>)@
M,0.3M>IN"]AN NS6=S@\^UG^6Z5CP-T&RJUZ6ANUPY&$$TI!.<1.<J\4XP3&
M/@.Y/>P>.5'WQ?PB%X\S<3M]D>5"RJW<RDPE3*8L@KF*-"LI44"2(@%))%.1
MT)BDRNK(\+RHH>TY:@V;-@A^*:QGL&TGG+"(=<PR[F Y15_8X7!Q),89,;U%
M9=B9NQVA8?F$G_^RM>&HRRY<+[6<N:DM-R)$\5Q("C/"&,3:58$T8U2CRG(6
M\3R-J5, 9HNLH1'$S=;)PQ6@:SW]&X2U 6WGG02"KV.VV#YK6/7_ AM-P[DA
M%G $=3[:Y/7J<E@8ON]HV#SB[E[\D%7PTB]R]C"GSX]C3B>K0ADR,@6$<EC$
M0F]Z4H8@DSF!L51<(A$511[;>A8GI0R-,[8U]' H3J-YWI<(@E'7FQ4G>)Q<
MB+/F7^P]G);0F^-PULAMG^'\A]VO&S\T=>CN]:.C(E8,F<L*$N6F( 6/(2ER
M"3-.1<*3O.!VG9SW!Q[:HE[I!HQR]A>,.UB=OUST1:#C)6MGO--UXC%+O:\2
M=P;K[1KQF G;5XA'?^_GG1_/N6IR>O(LT8L04TA3$S>9IPA2\Y(M"AKG1+!(
M<JM*JC;"AK8L7=,CW=&U\\E#8=;Q0CX!5P?I4C: !'7+6P7VZI?;F+[OF%L]
MX^Z9KYI_74_%#SE_&7-9-KXD%T*I&!'((I9 G,0FW(!)2.-82))16616P=:M
M4H;&%HVB56QNHZF'@WX:U/,.>A"H.B8)+Y2<_/2S*%SLIY^6T)N??M;(;3_]
M_(?#-^JX?J'CB0E*_C2;_Z#;';PVS5E/E(A?_[Y<-VI&/).R2/4N/XN8WNKS
M E)4Z$DIHIAI,DED[!2_U)OF0R.IO<8>IMI'-XT]PLZ_G9\TR%GMF$^_W=Q>
M@:H>UG8+P[6U4%L$C;W'6X!L=^KNN?E')Q/26UN0L-H/IF%()Y/BTDJD&P4\
MFHQ\G\N/?SY7Y<WTZ_/Y\75"_QR7S;9-X3PJ&,:0"TH@CDR\&T'F[10KE+$X
M4Y&T;B_2)FEHKP^M*UPI"[:T=6B"T0IL.\\'A:MS/_<X4CX-OELA<^@8$@JZ
MGGJ%.'_9W'J#V*#1VA6D=8#^^H'8V+'3"<3J 0_*U 8NR_?C6<G'T@37:U9O
MOJ,Q3WA.<0H3E0G3@0]#@F4&8YE+BF4:2V;EOK>+&1I95HHZ+//3^%G08A!4
M.N;$2D>PI:0IK<1_]J'$TU@Y\&$0S'HBPQ/8!>+"LTBT$N'II_MCP;,6[%#@
M^4_[U[*^G9:+>?656)VTFEY+57MC\5W.32,?^B!'.4ER[2UB2#'E$%.50Y8@
M"A4JLM2D66-5N-:WMA,]-)Y<7Q089=W+7%OB;7>$T V*7=^@FNW_1NLKL(/H
M%:A5!QO=PU;)=L,K>.5L2_&]5]-V@^58A6W'$2XMJ-.4DBJ_SA:R_#RC4W-@
M_&D\I5,^GC[H_;8<O^P691%5\W2N_;HBB_3N%R%(E5 P1BQE2*)4$JM610%T
M&1JI;==Q61D#-GK[%LUQGR,[WNL)^8Z)\!CHILIQ5>^KLJ6Z=UI;LS4A/971
M\4:WHU(Z[OJ\43D=;^!.E]3Q']+7.9SK 4T7QRHI<%VLXYM2^I_7ILEZN;B9
M34R:SIQ.JE-,K=N/)?NGY(O[V1=:ZE_H'YMJ?UM-">L"=A\G^D/5EB>B22)Q
M E$A)<1,2<@*I#?;(B>93#).4N*2C-N/VD[\W4.RK[DHJYL^@7>?Y0.=@-I>
MQX#\GN;<UKD=VDQV[ABO#*Y[4%V![;+.M=F@L1ML#->OC/I&5!L/&NM-RF-M
M/V@ V.T+VE217($0TL/N<](">^>]J-ZS9]_G=!SN"GJ5[AE/*A=;%WJ+Q7S,
MEHOJ13H[T=&#DJ3(9:Y?67F!(4YC#HE(&*0TBQF.\Q@5A4?FNK,B5M35?Q:[
M82,3J0'HE@V&D*:[$9=COP!5Y^FR>]MT@WY/H:QRL6J5TF2^7^]!WWGK%&_X
MP@:^.FO1;S2L+T@'(;+> _EQI!%3MTAYD%/^JK<B\R6=K-J-5IQ^LYS/354)
M1E(115C!.*8F@3Y)(<D+$X&?8Y7&>89SIYJ;]J*'=J;2J K4; [*=>F"[?H>
M;,P7\F%.7[27YUOKPV%J[(BP&\ [9L"J<LJ6UE>@T?L*-,J&HSIW@()RG(/X
M7LG-'99]5O,8P8_.WB_+\50:84]L/*T6W5JN]D>GY5@T3: ^CRD;ZZ7Y.LJ)
MHN9, B:H$! 7!8*TX IF)(W2C%.2R\B%USQT&!K!K16K*.[+_]R!7Y[8K^#=
M7_]2(!3]7?^@^EO\]Y\ 7YMF_KJQS8WK?.;-CO0ZGHV.V6^E/=A2_VI#A^:P
M8,N"*["V(1PI7@!@4';TT:-7FKP J'V^O&0HCX"I7V__L4K-^"!+/GMY;6)8
MI)()HR9 *BDDQ%DB("DP@BQ)BB@RO4R%51_35BE#([]&.8<@H)/XM5-4,%0Z
M)B&M(ECI:&+\*RU]@J5.XN00*Q4"KYY"I3QQ<XN8.H=':\#4R8?[BY<ZI_].
MN-39#_MYC7?R939YT>QZ,Y=BO/A$>46IJ\Z<A.*<Y#DD&<T@1I)#AI6$*L4"
MY7F.J70J#-4J;6ADN%86U-J"E;IN_ET[PG:>7##<.J;+DY!UD(!NA4E0-ZQ=
M8J\.EY7Q^ZZ5W4.^Y>6FBSGEB_\>+QY730;OI%I.Q=I-6YW8I#S+*%(81I')
MUR&1)A5"&"QXGLL\BJ1R*X1O+WIH#',]F<S^J&JW5\=I=")-I=S%<CYU+&[M
M@+X=X72#:<?LLU(:_*&U!BNUKT"M^&:#V,'QF3M>@4O668OON8*=*RR'!>V<
M1_#8!=X^/2VG>F@QYEMI#-K!01$N",RIB$Q'TP12E!20<!['.!$X(E8E-$Z+
M&!HA;2OIL+DY#I_%#O!B4#IFE&W]_!-ECL/CL/&[&*:>=GU'X%J=FV[_:G6
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MHAG+"8%)1C*(*8YA(=,,QK%D3"8B4IG3'M5"YM!(:DM/L%;TTL:K)P&WXZ3
M,'9,2%X(7M*6]1PF735H/2GWK5JUG@.BI6GKV4>] W)O:/GX?3Y[&0LIWK_^
M5DIQ._WV7%UF3A^N^6+\4A79&:%4()5+!3'A&&+,<ECD<:8=I4(1G&.&<>22
M/&(OVHF">DH X5IU\-SH#M@KF*WT!G2MN'.TK>U<V-%2-PAWS$X&7*,U^+X%
M[CNCN=Z$_036RH/K\S#[1-8Z(A8ZI-96?-^QM(ZP' FB=1TA?.')TW7!3!/,
MZV\WMTUIL6]J4UQL76@0*Q*A/"(PC87I1E,@J(DOA2D1&<IRJK>):I6)8,>
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M3"'C:55EQGH!%86H+'@ART)@(;WJ"_8IW=C(]&[S^,B6SS;-4Y-MQ%8HWK]
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MW71H7M_#=,$?YQ_GML3\8FG+$Q")BA(3,XR(E[9,A(3&C"]AF5.N*2]1DK&
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M+XQYNK*N8;N3^:R[*VQ,M$@R17 *,RIS6VLH@SRE]L)GDI<)$<:T]:HTYRO
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MU\^-A^NK>K)E2^8/=X:'-ZN)I&9#HS&&F$L)$39SD5".H"A5PG&FM1+8M8Q
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MJ%-H<T#?8R.*Y-)]^:T.P"KADYS ;TRZV20RTI$YQA/DH%00?FC[I(.(AOI
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M$DA4;DQ,E;!482J(6XB%9[]C(S#TY[2[\&LE/[ *^-A([N/@8G!&03<RBWD
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M*L[Q0_CSSA$=2DX4<P8YU-(E$S)X7C249+R)LB#VE4Y\AJIF?)[^H-694AH
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M2*K.1@1:FK[.TS2T>7'+I96H<C^-U#IFI)$V( <H7QD2 6TO@(W8E<2KL8C
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MIHDV&!+@34W>A]FVPO08"V8?P8E$PM3U#J/5]=0S(=?>:-;3Q,@^N!FVY/S
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M_27$Y/L]\[Y%3)-9ZK[-U:[*:,<^W=[T;QGA5;S^B/1&4@3:YYT$@:Z6](4
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MU&[GR")$7JO;67"^=FO+K*])G0>Q2B_'B_#QX[R6UY.2WI:KQZXD?P-SRU3
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MG]J -^6,3Q$],)="[3E0IT%Y!UF6DH51EIS<7J"X#97#8K$WJ-QOX="7WAK
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M"4P,?3[VK5Z95\<M4MK & 6Q3-6V<-8*<#PI2!J9#JEXH\.W'-XMGM<(]MI
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M"I_F-_9@7<?$I#+1"/2K'*2R,0@C8Y'1N0I:<^#!N<?K$H::';Z%HO8S'CL
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M<*=LUE;*;&I/..]-=-/VJ@]LML\XKZO(!OSUAQL6?Z#4YXN?-W4\J_-?^>(
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MH1\@K)Z9P: 9<[0D  -C"E5-'?'!:Y)8U-X( [329N;GZ=G7L/SZ4^_[>5P
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M[W$KH\#SN%)6&"H,B4:EM()1$IUN1-F@E))"@35Y[K&^*4Z_ >S.9Z_C53X
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M)1HE '8J:B"4XCI1>\7<?A>2]D+-WF+UXZ2ZL7R5VPR#G.V^3-V+'S6)VL"
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MQ&Q^D9Z?A/.*6B\;-S4F7L6>,=:=4<Y#A<8 ^=T8/QS /0WI$<;,>X2Y8\T
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MTVIJ7 G*&N-D"AR:#>_:@9_B&2W8'>FM1WCC=^(4V[/@X[O&?E?:G2TEWLQ
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ML<)QS,%<A9DU X@X&F8_:T*!Y1H88YP3JA0.GMKI'7\1^C[I'KU891) U55
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M]7 9].N=K O>$T=)J-;9Z^/BSO[GE_.?SJ^]'DRK[ZY@P3IH@*^W"GKCJZB
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MNV&<NFAW@NN!!=D6%#O.<[6R4IY(,<[2V<VXD79AH,K.B&%O#\*\$4TF8"O
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M@=A$TT6.JIV"4CH:'$,CG)I7$C_#N'40#@YBCOL8Y9%@V)0OZCX<U2R3=@_
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MN-ZP0:I+/BEYR4:UO$=KF6_1_]O[5OV_ZR A&O(TCC8H3P.47C9; VCIZZH
M,44VIF '?;!8'9B)OL3OJ4*M,I(99363),I"U8!%[)&<X\Q2:LC-&NV HI5&
MRN_1.I_]N8(2"C;#*(Z&J+Z+NU!";PL%8^T G?J/[7:X9$7 WMUP-J-!#5&5
MJXZOIL[XHQ)$R7(G3P05%U.ZELZ@-;G@]0FT,(]A/,LQ6Y+,0,GW2GE_.7>2
M,'LX9LCY F@T2M;C5N67'V\,I[_3O2S?^W???W=X\OKW,)FM&,'Z>FSEDPA
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MZ>"E:X3;CT)B+0G0!:6E_)C0AK90H&?78R 3AU0_2M&^G<_N8NL,>?F2YX1
M9Y12&H>W85S71>1=ZL<E4>H,WVU.G]X<$GV[-B2ZV&JI@#.N"_GZWE!/+;U+
MPBP?1U/*D17%[J:4BC%, 463BT/MAR<3C<HN]4V%8UY; )CY_0SG34)KW(G6
MIT/28??X)6Z$3XU+.WP"(\'N* 0[W,[T]+F@!&O!"E",$25=T8<.$9CJE#P/
M"SS,E]MZF&MTFKTN^^")X22-7GC-QI:E[/4L8@M?%ZM;O.?8/:QP!#DFEY(!
M^.T&F'N*;U#X:JC/! _*5VGV]"659(^IW9)@A8)%9G>),)R]@V#O")OG]73#
M@-[+@T/O%&[5.TR(NE.)4U4N<\(\M(Y)TN)2HOLL&6N3,A!;\9R+?O5O(N3@
M"UR%1(!WG,O&#>+Y;C;DA#TE$G&I3JO174&ZS9O&V5'MO*A,4_K3$?HP[BC6
M.[L=X1V(8KL VOI>;F]Y<1?&MZ&WT^OO[C%>OB !A5RHK%%4J9TS @M018!^
M&;>:X/:J!!="N@#FW7ZJ!^7SI .V[I]21H+/[;!2(?<YES PS%CX*<R&5HIS
M[=.[O'PB$^PS0_1*B]@YVO^;)JLB+0@-;#(@^^@VY19FZ1U7Q=;)L'16Z(YC
MUM!8N3.AIA;2O=8&2N07PO1A@&H[$YV=*E+UIQ0O39-P,@!RWG4&M)L:<*>?
M.G7Z$()7!%=Y-DINT_B6,*>9/!FG%ZU& 7HK)<J6B'/4M&/C,&;&L<BU8<_#
M3Q$WER.7PSB-J2R)1(\]6(=V B,SNIQ)I?2GV0U0XW]TU9 QG'6N+JZ02HA(
M/\'#CV7RWK<]W+<3ECC=^Z;0@3?5IED?HZ;WHKM_P":JN8:HZ[-EF.)'+$93
M0N2Q<.XLS<?@.<,95<20%N0.KPC:P7*0 1DF_K_2#//"G3>+@(:[MI^C$[-1
M!Z,9$%))N9+R#*GEO 9N41W)LA33B3(HR2BXC8*9'V.[K%05.NR<[BK(_# I
M3RA5"'B@)4 9#D-1UD"#2B/3\M2FP.M^LE]'T^0F0$G*4'L!S5AK*5!V[IAV
MU;:\%H&+"]A,/U^\AT&8#[-HP*IS&&,**BT15WR'\(/ $M3;79)*G78*YG7^
M%%WAH?1B,CI5KV.9UKHM8GU%+&C5AW2\L6I?*Y4B-5TDG*:UU'B/H2+A%,+L
M!I]=3D_JNSN0(VQ.Q)V*A?$<W-IZ$#@599 Q[ ZZJ,.18(:B?1GDFR"Q*K<-
M6TLKN]DG3)YXOH=V)Z%CYQ$81MF<KSA4X@'$=D<=)VP#1$P\RPZIVE010\-.
M5%M?V]!%4QV';+PB2-FN>R>FL(@_H5 -EIF0L2(%,.K&A+1>'6>A#=J^(*=+
MG5F3D@"\35W/NY*J6_RP^6PTH7ST"<A,=GG@5D\IN$#=':W IK^P(5/M R>E
M8ESFJ@4;@JO%NCYJP )\)#N=9KGNG%*>8EJ:TE;X*\_6QE]YTCU>$.B1LUX7
M+V5M>4,'I(8&V+9D$X<<I;\T%JW2Q=.(+M48L,71Q8XM_(IB1^ZY-VHHM)"&
MJ4S_<]9;P*HD&T7#!JE40!*Z_Q:0\\]K0\XON@<'B\BY#"+\9>:^7)'6.N4L
MV.CWY+H1D-62T&=_W*6X&LY83VBO5H)H'.I.+WS%8&+ 5I8JV27F4&X]9>K[
M4W\HEB1,2@"FPX[W5M0$OA'[ALQBY%50;F4\_#*JF0L_X38 0J,%#?PZ7&E;
MT9*!A=,C>RM3Y;1BKE>"&V3,<5B#H$[L*8"M%Z=@8F5JLW.SS8*UK=\G=?1J
M4Z*&DTCFY;.P.\:*&L<'63"5X)9D&MK U[/AJX\%-EXY\G*C5%RWATC;-^,*
M^I=#!7*)H5"DC%\F-M]H^^M*!)3/D>XT @(F700,=BMCM@J6 CK 7#!U65P#
M>+I+3\MV#=D ,?UN;<3TXBBIXOUU,3NHFXRZKY-!S^T.B0)IKN7PZ$XM=^YV
MROU^5"@!+14VARU/1Z@P]H61?6+)02HN_+LT^ZO<<D(G:\'Z$ZG,GX!P9A^)
M)>1!?&X!4?^R>42]4I#2<L)*NRYA^D/U8,G/;9"%YVM#-KU>=W\!LLO/?I1Y
M O#Y.R(P?K-]#*9AQN@IU2;HB6"HQ>$MZGA*Q'(R]U2D'&YC0Y*7#6_:$2M+
M?7\0!038"<8;)D_D[+;,0O3VH"$K86D:D5K9_WN6%@:DE%]Z]DD[UWRRO&PW
M)UD_&$[GI"[VR<TUHIN@H%K6GYXL![0H2SA SY5V(?(P(TZ-)22I5$^YM!-X
M)S9+-188KX<\/-7M<Q^B99LDLXZ>:XPN8K4.MZTLV9NM,[DS>VG9[JI'#%I\
MRMEE,\A3#,[$X+XI,-#U\^Z3K 8S"^\P5@JFT#33O/&4YH9!P;!<85RN11/A
M2O[ "5\5<,<NO'^DLRSQ5YO"F$IJ@P!F4<6U$J7NS1$O_E2($2T%T;\!9LP_
MUL>,V5]H_JK,H'4R?ZGLY,I$6+2>/N6F@#AGUFZ(GJL@;#DXF=)_MX&,_M_:
MD-'B2Q1'@]:%AK@5KXDH-"0Q[K)[SYLEA B?8*B50M[VPWDE14\[UY2%QTW3
M[0'%!U%Z<>,TTCLJQ+*,3_$T6(85QDTXRF'E[-6FVKFY70M2[JB]88SQ%'*M
M\0BX"8E^@^JW:6T)!5QQS;BN;>"U]VO#:XMC?]:E?UT8SL35.8U \A0U+"4U
M9&VLY]H& OIU;0CH<+&P+E4BK0D5=2J9NB17-4J[JI#"MJ:50D+.]\8>B""5
M@]D0DZAOL:&U$T&[P;HK.W="-P>N)E2 .%8CPH]V@IG50(TJO+ADEHJ^%/ I
M C!G 8VI]89;-HS?'^)H5_@O)FR?>SOX-4G>7R$YM9#.I6SJ.I&05#CL\ID1
MH#$WMC'1+5V1AYHM"S@YG#&"=5*06L_>;<B!4JLH6KM.FE#%XS@=JK:#- U&
M+)_%?J:H:"MR9"[61LPM89-62SC7*+ / F6/H#DE?5/Z0;.+LDXX4$+H\@*1
M,W%-1I\EG\2N:^+E4F%J SFC6F?1J<HPMD&-?]A,^M[[YPRVDZB'3W][5/K$
M_Q1-9A,OF6'J<DN7JRBIR:88 K>A/'=;E'%=-I"U88^',P&,BT#S1L<XZ 1#
M/\8GQ'_X(+.@ZWEGN&LMY\WSPX7F%3/;J8QBBYQG1]'KN-*#0G6U18NG-A:S
M#7S^<6WX?'%R')P[C(B"^RV6X6'+GU6R][Q\\8L2U04/V=@EIC"Y\3E97C6Q
ME'Q.[P:8932+*?_REK*:[7H.:@,=!M)70KM!"'UG/,_Q<S+'85>P%==DZD<9
M-Z;X-)7Z]U35<<+@0>@#MVECGSP\.LTHF&4Z2]NN5C$5*FCU2\3@4;*>J@<Z
M)RQPR64+:C*>[M7H<P,8\)]KPX"+%2T+6TJX*!=_K&= :%UN] YZA05880%9
M-*!7U->IK@2L8H5,LD9@%<<:JX)KF@2"Q*IJBI+Z*E_LBDQ7YUEV&U%&A4J;
MX\H=?@A/VX(X,  'JGQ:E>TL"TAP?TB!SCTQ!:256.Z2<WUQ?5-U_%->A,F+
M>/R^,YN0%[&,/%J5^/DRT TB.4 &S(HVWJ@9?H0I19)YI;L>+S_T%T;"6:FF
M6!]5<6 !X3P2L)&J]W*M!3(J",8-FXB#,#;UM?!^DGM6UK8F$4S.VU8B6!\J
MV%?( 93_>0L*,E2F0Y.E4&LE#&;%-V\E/ GB#>+!VS5B0;;92QA!3:7T5"'O
M0HTIMJK C:T/?\&DRK!83TPFB[8\P;Y7A+2CA.@EM_)TA$J9DC/TR;C-4O40
M-A+4O0&;-HJ!UX=_#[O[_2?PG2?PG<\ WWFTG(.5=X%0E=>F"P3N;HMK-A9'
M),8>Z#\Y=5C.;0 4=D$583;-0@G1T6Y*E:8T6';J!%I'M('\Z&$L(D+XG)QJ
M5160'[>>7I!3XE2DZA[/.WRYX3[3!!JDWT7M B;IK-K7 $%Y>)1=$REL*J&O
M0S@BP(Y,4D'O@%W=2BFW=E8OLSQ5&!]^&>J6T]CR -.\Z8^'^R]/0;\CQ%*<
MI]Z_>9MAYTS1?ED.-KF1*35<QUQJ Z]JU%X7Q]T[@-?O'.V"[#=HX)35@+67
M5J\$*N$O3X.=UBA6ZS&9/V,ZT8+Y,*K HJWQG<";X"&U7JT_9\KM<]Z.^N;+
MM8E>+<@5=BN'UR4L1,P,TDHPI("*KQQ ,?M&@:*'V:Z4U+]4[KZQ \KI^]PF
MI93:7Y/#S^^MQ^J0 @ ++X0%O<%(>?+O&__^X_=$VP3__MIX\^OA>A94L9@J
M#RI2L6^760A&4XY>.BR25L;OPDMM#9:><ZUNND9C3DBE$H5NL^PGW+J2E*NU
MT3&+4Y0NPT(RI==%Q5AB6OLP$&M.9_K4X R)5UGC?+NE\6,R:'/X#ZDORO8#
M:0\VU]$1*1,5B\@--Q2@F'9Z^[L>9OKF3<,*-)3]RN.C;2#AZ[4AX<5555><
MDXK40=6D7Q2'[@O0L[(Y/.PX!]3E>&CP_@AD1I$W3(7K>(9C*2W.5!D2BAJ]
MBU+-O$5H;9S\)L^C%M'/<K< <I)P*AOR!;N:\-8HQ>"Z1Y(UQT&:^*!)@M 8
M5A4\)<?08EPGA*D=:LTF'N=P&A(?\.7,1PVXB^_A##Q*+D247,%5\V4^"A $
MDU>,Q[:X@T<L[=:WM!ML0X:<J]>CIVX$1T8NV.KLQ:%$EV<'3#8<A@'_)<J*
M.1#/)V_GX%BG)NZH#<['"%&@:PF,M6K&1L0W.BL]"0=;;A=!:1D.MIQ\J.Z!
M9"EC_J+O-3 +>Q)R%^&/[O0NP%\J6'.@LZ7:26V%ZE8B1$P4Q/!\N&?V3DY(
M5E; OFQ?I'*XR0DIH"?O'48SU@KRR]T%F:':"^3_O')U:;P_J3_6&DN#60YB
M)J_$7-2O A"Y7/!E>2]![AWV#G<&NWR;&^Z:2UX0ZGVJ<Q=X!)5#T^E@W"(D
MD%:?:^RFTYC\<'J0WM'QP4YOMP.<*4,=N$.UD;9% [$=\G+ND[PQVF=%B^(]
MF8XSA*V4D]06P-&^$A>:M)4,G>6T9WF!@+4P4/G1%Y5'R4*?QKXXN6&/B.EY
M9-@.,C*4(9RK79$\N_)VH><&YC_<W>NW.6S:]RSS XYQ*<)",4J!A"RLIZ+R
MZ^R]'*[A7MYOMX"73QG8>.P6[XO$:!"<%9AY+*O"L%Q#S8C3%1;.E[JPMATB
M^F1AATKDBRY7BSVVP>3\;6U,SL5YY4IK<G'BFEB:#25;2U1JV40I*ZO4-NK2
MZKI:JOJZQU(=8\T%JJY@U_0%KU1S;V7AXN^;1/<.^-Z:T#V7QTW@/5@SZ$Z1
MZ?O"SP/_W]Z[.!UP]9'\=$6Q5X5T)T$]G."?:!6Z;]H&4OMC;4CMH'O\8@&I
M:;MX7<CL<;&)FN,;;8[=\I@$"&E]8;<!P&A;<8J^P6#,T5,P9JV$ZO^LC5!=
MK+_%D%H7B4K2@YJV:UR!@F>8>SO*Z/N0@!;7/=;O4KH5.SW7=[GC:3TD@&!J
MU.?DX%V7$M>6+?+_J!LS]:K5O>S J8$!V +3X<\-HO(_X.Q4WZMK_]/:8&IX
MV@-(66W8G\TK<'[>#OP6SVC"A* Y"F$Q?MPA;RK[V1"F*,:O[VJW6ZB\T*7$
M('FZ[F%WK#REU.LH@<L44CU8'OX<O6CXU8XW0M^V:NE6Y/PA?(-C#\PN,_9B
MBEGB?]I3B>=1$4[R776SHRQ-]-U'A93X#YC'5&_;DI/T^^\.3UZ+0:Y]JUR*
MG(@/A#B4>G3[G^CJFM($^*UR^M()L(2F#2Q*F6T&(D3!:W!WM$JX9JH^L]-+
MJ-M42T[4-VB:'#^Z:8*OB((?GD7^2>"_W!_T>_V7_<.C@]Z+?O_@Y8O#OM\?
M'OLOA@?_>W+X;$/LF9>NH/]*9U;??>#JS2]G;W][?^:=/T1'K73J'\\N?_YP
M^>OIQ9LS[]V'T_=7WNG%6\_^%'X^__#VRH,/O.M?SN#_+\_@WTOXXR]G5]Z'
MGYUO7_UR>@F?+K,/+VM5]9?;!WKCJPBN6=%PB9TYN[H^_>G]^=4OOYY=7.,R
MK\X^GEZ>7INU/WR1CCW"U:(K2RV_ALF&1:V%IP0ZQDT[=:9=JR'7X0(#8QG2
M.]%.Q;!4&0-+\IR7MU<5+)0$>TJ(6FPO#,EYBE!S&$$.=(C 6;+!JZ+X,.IH
MN.B;5];@Z.$CKO=ZN4J#-2?Y*MLSUS.]>Q\NSK:#Y,7Q31:8E3)0OO00#EK=
M'Q3AV*B7%N&Z'5[*0(?#%$S'B%(RRCXK;2KU]_M];Q3E:&_2LU\1&?6>-&.O
MN\HIZX"+NM3%<<TY\^KL\O?S+>=**W[FRE:KR5!C[ NN- %71>&7&YE1E:MI
MM_$__&2&62.]#C.=E14OU4%O0KBVC&!B]/:WP._;0%!ENX](RO[P=[!_SB_>
M;22IW7<OZF2^14)LF:Q2E%V/EX=H?IBBBA1V<U499>$PO3$EAW48XVKL=F5
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M$O')Q*HSL4Z:3:SG@S28PW_&Q23^\?\#4$L#!!0    ( $.#I%1#OE-\1E0
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MFQ>!C87>'?@73'X<WXODQQ;P^-W31='N'$2?#&WMITA/W7F'@5FQO,VA?<?
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M C=$9!FVH8=/G4'&&7D+VO,B2:TZ>\_U:'!FX:C%%6F6S(2@<D-)V<E*0;B
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MG.0".+K-B_>2.?<\&RD2@&G(A(%P#C8 0P \6V(7Q/IB,&*]WL 5R1Z,KNL
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MHVV*EJXU= 5YO\8723*,GO=;I]8]UQ\6B9?:I)QM0OD;\]B#*.#[IJM8+]S
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M0MRU=3N"EFA;,[*L$=GV]'V92* 21%F%*K@64NA??\^66RTDM- LPIR8:(M
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M_:7@(GD-N&*_?J$%;#17ESP&%_Q(B;"S8L=1  LEM_V&?(4JV/K^/-2MZ7:
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M,;RN.AI7MN[9-^QU7:JUA3I]QS.!6;:W?&V5\SIULE&FTM+#6;%.ELPPI8@
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M%R:(;0(Q_;_!$-/-CB_?/3DHV-ZL-N'VGGZ=C:"IZ?/Y5_*PGIR,!XJ+9\*
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MU,]M'T_R> 7_F5>+]+O_#U!+ P04    " !#@Z14[<UGL;T'  # 'P  '@
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MK.JYWKUDUYZ]\^YR]70WJ?9.]^A/4$L! A0#%     @ 0X.D5" 2A$]3WP(
M?I,C !$              ( !     &=I;&0M,C R,C S,S$N:'1M4$L! A0#
M%     @ 0X.D5.P6@_LZ%@  #_8  !$              ( !@M\" &=I;&0M
M,C R,C S,S$N>'-D4$L! A0#%     @ 0X.D5'BWL-#0*   VZ ! !4
M         ( !Z_4" &=I;&0M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M $.#I%1G;B1RR&8  .M@!  5              "  >X> P!G:6QD+3(P,C(P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " !#@Z146)25]88, 0"<$PL %0
M        @ 'IA0, 9VEL9"TR,#(R,#,S,5]L86(N>&UL4$L! A0#%     @
M0X.D5$!>FO!LH0  ICP' !4              ( !HI($ &=I;&0M,C R,C S
M,S%?<')E+GAM;%!+ 0(4 Q0    ( $.#I%0>5M "IU    I- @ >
M      "  4$T!0!G:6QD<3$R,#(R97@Q,#$X,C R,G!S=6%G<BYH=&U02P$"
M% ,4    " !#@Z14]-)>SI!1  #N80( '@              @ $DA04 9VEL
M9'$Q,C R,F5X,3 R,C(P,C)P<W5A9W(N:'1M4$L! A0#%     @ 0X.D5$.^
M4WQ&5   3R4" !X              ( !\-8% &=I;&1Q,3(P,C)E>#$P,C@R
M,#(R96UP;&]Y+FAT;5!+ 0(4 Q0    ( $.#I%19WTQ*UDH  $S[ 0 >
M          "  7(K!@!G:6QD<3$R,#(R97@Q,#@R,#(R96UP;&]Y92YH=&U0
M2P$"% ,4    " !#@Z14[<UGL;T'  # 'P  '@              @ &$=@8
M9VEL9'$Q,C R,F5X,S$Q8V5O8V5R=&EF:6,N:'1M4$L! A0#%     @ 0X.D
M5,][B(^;!P  Z1T  !X              ( !?7X& &=I;&1Q,3(P,C)E>#,Q
M,F-F;V-E<G1I9FEC+FAT;5!+ 0(4 Q0    ( $.#I%3E>EPUF 4  "X6   >
M              "  52&!@!G:6QD<3$R,#(R97@S,G-E8W1I;VXY,#9C92YH
8=&U02P4&      T #0"> P  *(P&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
